15882284
D001241_D007674 NONE aspirin_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|The|of (r_acl) risk_1\NN|was|was|to|and|, (r_nsubjpass) related_8\VBN|NONE (l_conj) was_20\VBD|was|risk|to|and|, (l_acomp) high_22\JJ|.|it|] (l_prep) among_23\IN|particularly (l_pobj) subset_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|as (l_pobj) nephropathy_30\NN|NONE
D001241_D007676 CID aspirin_11\NN|NONE (l_conj) drugs_20\NNS|and (l_appos) NSAIDs_22\NNPS|other|(|inflammatory|analgesic (l_conj) disease_29\NN|)|and
D001241_D007676 CID aspirin_11\NN|NONE (l_conj) drugs_20\NNS|and (l_appos) NSAIDs_22\NNPS|other|(|inflammatory|analgesic (l_conj) disease_29\NN|)|and (l_appos) ESRD_31\NNP|stage|)|(|renal
D001241_D007676 CID aspirin_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|The|of (r_acl) risk_1\NN|was|was|to|and|, (l_prep) of_2\IN|The|associated (l_pobj) ESRD_3\NNS|NONE
D001241_D007676 CID aspirin_6\NN|NONE (r_pobj) of_5\IN|chronic|the (r_prep) use_4\NN|However|risk|.|,|may (r_nsubj) increase_8\VB|NONE (l_dobj) risk_10\NN|However|.|,|may|use (l_prep) of_11\IN|the (l_pobj) ESRD_12\NNP|NONE
17159032
D006886_D014786 CID hydroxychloroquine_8\NN|NONE (r_dobj) taking_7\VBG|NONE (r_acl) patients_6\NNS|NONE (r_pobj) in_5\IN|field|paracentral|visual|. (r_prep) loss_4\NN|NONE
D006886_D014786 CID hydroxychloroquine_17\JJ|in (r_compound) treatment_18\NN|NONE (r_pobj) to_16\IN|were|which (r_prep) attributed_15\VBN|field|, (r_relcl) abnormalities_11\NNS|.|patients
7018927
D006220_D006966 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) hyperprolactinemia_12\NN|NONE
D006220_D006966 CID haloperidol_4\NN|NONE (r_amod) infusions_5\NNS|NONE (r_pobj) of_3\IN|the (r_prep) course_2\NN|NONE (r_pobj) During_0\IN|,|was|with|.|hyperprolactinemia|,|,|compared (r_prep) found_10\VBN|NONE (l_nsubjpass) hyperprolactinemia_8\NN|,|was|with|During|.|,|,|compared
6305660
2553470
D010862_D013226 CID pilocarpine_8\NN|of|the (r_compound) model_9\NN|MK (r_pobj) on_4\IN|.|in|actions (r_prep) epilepticus_12\NN|NONE
D010862_D013226 CID pilocarpine_14\NN|and (r_conj) lithium_12\NN|NONE (r_pobj) by_11\IN|by|prior (r_agent) induced_10\VBN|NONE (r_acl) seizures_9\NNS|to (r_dobj) block_8\VB|easy|it|although (r_xcomp) is_4\VBZ|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ|NONE (l_xcomp) ongoing_29\JJ|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN|NONE
D010862_D013226 CID pilocarpine_21\NN|NONE (r_pobj) to_20\IN|NONE (r_prep) prior_19\RB|by|by (r_advmod) induced_10\VBN|NONE (r_acl) seizures_9\NNS|to (r_dobj) block_8\VB|easy|it|although (r_xcomp) is_4\VBZ|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ|NONE (l_xcomp) ongoing_29\JJ|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN|NONE
D010862_D013226 CID pilocarpine_8\NN|NONE (r_pobj) after_7\IN| (r_prep) min_6\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|i.e.|gradually|.|,|,|enhanced|activity|,|during|and (r_nsubj) reduced_17\VBD|NONE (l_prep) during_12\IN|i.e.|gradually|.|,|Administration|,|enhanced|activity|,|and (l_pobj) epilepticus_14\NN|status
D010862_D013226 CID pilocarpine_22\NN|the (r_compound) model_23\NN|NONE (r_pobj) in_18\IN|status|epilepticus (r_prep) damage_17\NN|NONE (l_amod) epilepticus_14\NN|status|in
D010862_D013226 CID pilocarpine_13\NN|and (r_conj) NMDA_11\NNP|NONE (r_pobj) of_10\IN|that|nonconvulsive (r_prep) doses_9\NNS|NONE (r_dobj) showing_6\VBG|NONE (r_acl) results_5\NNS|NONE (r_pobj) by_4\IN|further|were|.|was|This (r_agent) supported_3\VBN|NONE (l_conj) were_14\VBD|by|further|.|was|This (l_advcl) resulting_17\VBG|synergistic|, (l_prep) in_18\IN|NONE (l_pobj) mortality_23\NN|NONE (l_amod) epilepticus_20\NN|status
D016291_D013226 NONE MK-801_3\NNP|model (r_punct) on_4\IN|.|in|actions (r_prep) epilepticus_12\NN|NONE
D016291_D013226 NONE MK-801_2\NNP||or (r_punct) 30_3\CD|after (r_nummod) min_6\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|i.e.|gradually|.|,|,|enhanced|activity|,|during|and (r_nsubj) reduced_17\VBD|NONE (l_prep) during_12\IN|i.e.|gradually|.|,|Administration|,|enhanced|activity|,|and (l_pobj) epilepticus_14\NN|status
D016202_D013226 NONE NMDA_6\NNP|NONE (r_compound) receptors_7\NNS|NONE (r_pobj) of_5\IN|NONE (r_prep) activation_4\NN|that|role (r_nsubj) plays_8\VBZ|.|results (l_dobj) role_11\NN|activation|that (l_prep) in_12\IN|important|an (l_pobj) damage_17\NN|NONE (l_amod) epilepticus_14\NN|status|in
D016202_D013226 NONE NMDA_11\NNP|NONE (r_pobj) of_10\IN|that|nonconvulsive (r_prep) doses_9\NNS|NONE (r_dobj) showing_6\VBG|NONE (r_acl) results_5\NNS|NONE (r_pobj) by_4\IN|further|were|.|was|This (r_agent) supported_3\VBN|NONE (l_conj) were_14\VBD|by|further|.|was|This (l_advcl) resulting_17\VBG|synergistic|, (l_prep) in_18\IN|NONE (l_pobj) mortality_23\NN|NONE (l_amod) epilepticus_20\NN|status
D010862_D001930 NONE pilocarpine_22\NN|the (r_compound) model_23\NN|NONE (r_pobj) in_18\IN|status|epilepticus (r_prep) damage_17\NN|NONE
D016202_D001930 NONE NMDA_6\NNP|NONE (r_compound) receptors_7\NNS|NONE (r_pobj) of_5\IN|NONE (r_prep) activation_4\NN|that|role (r_nsubj) plays_8\VBZ|.|results (l_dobj) role_11\NN|activation|that (l_prep) in_12\IN|important|an (l_pobj) damage_17\NN|NONE
D010862_D012640 NONE pilocarpine_33\NN|and (r_conj) lithium_31\NN|NONE (r_pobj) of_30\IN|and|administration (r_prep) coadministration_29\NN|two|seizure|,|of (r_conj) models_27\NNS|NONE (l_compound) seizure_26\NN|two|,|of|coadministration
D010862_D012640 NONE pilocarpine_41\NN|NONE (r_pobj) of_40\IN|a|high|alone (r_prep) dose_39\NN|NONE (r_pobj) of_36\IN|two|seizure|,|coadministration (r_prep) models_27\NNS|NONE (l_compound) seizure_26\NN|two|,|of|coadministration
D010862_D012640 NONE pilocarpine_18\NN|the (r_compound) model_19\NN|NONE (r_pobj) with_14\IN|an|anticonvulsant|effective (r_prep) action_13\NN|pretreatment|.|,|with|First|MK|,|suggesting|but (r_dobj) produced_5\VBD|NONE (l_advcl) suggesting_29\VBG|pretreatment|.|,|with|action|First|MK|,|but (l_dobj) seizures_35\NNS|NONE
D010862_D012640 NONE pilocarpine_26\NN|NONE (r_pobj) with_25\IN|alone (r_prep) treated_24\VBN|NONE (r_acl) rats_23\NNS|not (r_pobj) with_22\IN|pretreatment|.|,|action|First|MK|,|suggesting|but (r_conj) produced_5\VBD|NONE (l_advcl) suggesting_29\VBG|pretreatment|.|,|with|action|First|MK|,|but (l_dobj) seizures_35\NNS|NONE
D010862_D012640 NONE pilocarpine_11\NN|the (r_compound) model_12\NN|MK (r_pobj) in_7\IN|only|,|.|effect|after|Second (r_prep) occurred_14\VBD|NONE (l_prep) after_15\IN|only|,|.|effect|in|Second (l_pobj) periods_17\NNS|NONE (l_prep) of_18\IN|initial (l_pobj) activity_20\NN|NONE (l_compound) seizure_19\NN|NONE
D010862_D012640 NONE pilocarpine_14\NN|and (r_conj) lithium_12\NN|NONE (r_pobj) by_11\IN|by|prior (r_agent) induced_10\VBN|NONE (r_acl) seizures_9\NNS|to
D010862_D012640 NONE pilocarpine_14\NN|and (r_conj) lithium_12\NN|NONE (r_pobj) by_11\IN|by|prior (r_agent) induced_10\VBN|NONE (r_acl) seizures_9\NNS|to (r_dobj) block_8\VB|easy|it|although (r_xcomp) is_4\VBZ|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ|NONE (l_xcomp) ongoing_29\JJ|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN|NONE (l_conj) block_33\VB|and|status (l_dobj) lethality_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) seizures_38\NNS|NONE
D010862_D012640 NONE pilocarpine_21\NN|NONE (r_pobj) to_20\IN|NONE (r_prep) prior_19\RB|by|by (r_advmod) induced_10\VBN|NONE (r_acl) seizures_9\NNS|to
D010862_D012640 NONE pilocarpine_21\NN|NONE (r_pobj) to_20\IN|NONE (r_prep) prior_19\RB|by|by (r_advmod) induced_10\VBN|NONE (r_acl) seizures_9\NNS|to (r_dobj) block_8\VB|easy|it|although (r_xcomp) is_4\VBZ|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ|NONE (l_xcomp) ongoing_29\JJ|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN|NONE (l_conj) block_33\VB|and|status (l_dobj) lethality_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) seizures_38\NNS|NONE
D010862_D012640 NONE pilocarpine_8\NN|NONE (r_pobj) after_7\IN| (r_prep) min_6\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|i.e.|gradually|.|,|,|enhanced|activity|,|during|and (r_nsubj) reduced_17\VBD|NONE (l_dobj) activity_22\NN|i.e.|gradually|.|,|Administration|,|enhanced|,|during|and (l_compound) seizure_21\NN|NONE
D008094_D012640 NONE lithium_31\NN|NONE (r_pobj) of_30\IN|and|administration (r_prep) coadministration_29\NN|two|seizure|,|of (r_conj) models_27\NNS|NONE (l_compound) seizure_26\NN|two|,|of|coadministration
D008094_D012640 NONE lithium_16\NN| (r_compound) pilocarpine_18\NN|the (r_compound) model_19\NN|NONE (r_pobj) with_14\IN|an|anticonvulsant|effective (r_prep) action_13\NN|pretreatment|.|,|with|First|MK|,|suggesting|but (r_dobj) produced_5\VBD|NONE (l_advcl) suggesting_29\VBG|pretreatment|.|,|with|action|First|MK|,|but (l_dobj) seizures_35\NNS|NONE
D008094_D012640 NONE lithium_9\NN| (r_compound) pilocarpine_11\NN|the (r_compound) model_12\NN|MK (r_pobj) in_7\IN|only|,|.|effect|after|Second (r_prep) occurred_14\VBD|NONE (l_prep) after_15\IN|only|,|.|effect|in|Second (l_pobj) periods_17\NNS|NONE (l_prep) of_18\IN|initial (l_pobj) activity_20\NN|NONE (l_compound) seizure_19\NN|NONE
D008094_D012640 NONE lithium_12\NN|NONE (r_pobj) by_11\IN|by|prior (r_agent) induced_10\VBN|NONE (r_acl) seizures_9\NNS|to
D008094_D012640 NONE lithium_12\NN|NONE (r_pobj) by_11\IN|by|prior (r_agent) induced_10\VBN|NONE (r_acl) seizures_9\NNS|to (r_dobj) block_8\VB|easy|it|although (r_xcomp) is_4\VBZ|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ|NONE (l_xcomp) ongoing_29\JJ|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN|NONE (l_conj) block_33\VB|and|status (l_dobj) lethality_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) seizures_38\NNS|NONE
D008094_D013226 CID lithium_6\NN| (r_compound) pilocarpine_8\NN|of|the (r_compound) model_9\NN|MK (r_pobj) on_4\IN|.|in|actions (r_prep) epilepticus_12\NN|NONE
D008094_D013226 CID lithium_12\NN|NONE (r_pobj) by_11\IN|by|prior (r_agent) induced_10\VBN|NONE (r_acl) seizures_9\NNS|to (r_dobj) block_8\VB|easy|it|although (r_xcomp) is_4\VBZ|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ|NONE (l_xcomp) ongoing_29\JJ|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN|NONE
D008094_D013226 CID lithium_20\NN| (r_compound) pilocarpine_22\NN|the (r_compound) model_23\NN|NONE (r_pobj) in_18\IN|status|epilepticus (r_prep) damage_17\NN|NONE (l_amod) epilepticus_14\NN|status|in
D016291_D012640 NONE MK-801_0\NNP|,|was|.|for|antagonist (r_punct) tested_18\VBN|NONE (l_prep) for_19\IN|,|was|.|MK|antagonist (l_pobj) effects_21\NNS|NONE (l_acl) using_24\VBG|anticonvulsant|in (l_dobj) models_27\NNS|NONE (l_compound) seizure_26\NN|two|,|of|coadministration
D016291_D012640 NONE MK-801_4\NNP|pretreatment|.|,|with|action|First|,|suggesting|but (r_punct) produced_5\VBD|NONE (l_advcl) suggesting_29\VBG|pretreatment|.|,|with|action|First|MK|,|but (l_dobj) seizures_35\NNS|NONE
D016291_D012640 NONE MK-801_6\NNP|model (r_punct) in_7\IN|only|,|.|effect|after|Second (r_prep) occurred_14\VBD|NONE (l_prep) after_15\IN|only|,|.|effect|in|Second (l_pobj) periods_17\NNS|NONE (l_prep) of_18\IN|initial (l_pobj) activity_20\NN|NONE (l_compound) seizure_19\NN|NONE
D016291_D012640 NONE MK-801_2\NNP||or (r_punct) 30_3\CD|after (r_nummod) min_6\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|i.e.|gradually|.|,|,|enhanced|activity|,|during|and (r_nsubj) reduced_17\VBD|NONE (l_dobj) activity_22\NN|i.e.|gradually|.|,|Administration|,|enhanced|,|during|and (l_compound) seizure_21\NN|NONE
D008094_D001930 NONE lithium_20\NN| (r_compound) pilocarpine_22\NN|the (r_compound) model_23\NN|NONE (r_pobj) in_18\IN|status|epilepticus (r_prep) damage_17\NN|NONE
D016202_D012640 NONE aspartate_10\NNP|receptor|,|NMDA|a|)|(|noncompetitive (r_nmod) antagonist_15\NN|,|was|.|MK|for (r_nsubjpass) tested_18\VBN|NONE (l_prep) for_19\IN|,|was|.|MK|antagonist (l_pobj) effects_21\NNS|NONE (l_acl) using_24\VBG|anticonvulsant|in (l_dobj) models_27\NNS|NONE (l_compound) seizure_26\NN|two|,|of|coadministration
D016202_D012640 NONE NMDA_12\NNP|receptor|,|a|)|aspartate|(|noncompetitive (r_nmod) antagonist_15\NN|,|was|.|MK|for (r_nsubjpass) tested_18\VBN|NONE (l_prep) for_19\IN|,|was|.|MK|antagonist (l_pobj) effects_21\NNS|NONE (l_acl) using_24\VBG|anticonvulsant|in (l_dobj) models_27\NNS|NONE (l_compound) seizure_26\NN|two|,|of|coadministration
9132810
D008727_D054198 NONE methotrexate_34\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) treated_29\VBN|acute|lymphoblastic (r_acl) leukemia_28\NN|NONE
D008727_D056784 CID methotrexate_34\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) treated_29\VBN|acute|lymphoblastic (r_acl) leukemia_28\NN|NONE (r_pobj) from_25\IN|which (r_prep) developed_24\VBD|necrotizing|,|disseminated (r_relcl) leukoencephalopathy_21\JJ|NONE
10219427
12828076
D000082_D062787 NONE paracetamol_12\JJ|NONE (r_compound) overdose_13\NN|to
D000082_D062787 NONE paracetamol_12\JJ|(|median|mL|range|,|; (r_compound) overdose_13\NN|to|than
D000082_D017114 CID paracetamol_12\JJ|NONE (r_compound) overdose_13\NN|to (r_pobj) due_10\IN|Increased|in|Fas|. (r_prep) serum_1\NN|NONE (l_prep) in_4\IN|Increased|Fas|.|due (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|NONE (l_pobj) failure_9\NN|NONE
D000082_D017114 CID paracetamol_12\JJ|(|median|mL|range|,|; (r_compound) overdose_13\NN|to|than (r_pobj) due_10\IN|with (r_prep) patients_5\NNS|NONE (l_prep) with_6\IN|due (l_pobj) failure_9\NN|NONE
D000082_D056486 NONE paracetamol_12\JJ|(|median|mL|range|,|; (r_compound) overdose_13\NN|to|than (r_pobj) due_10\IN|with (r_prep) patients_5\NNS|NONE (r_pobj) in_4\IN|significantly (r_prep) greater_3\JJR|.|Levels|mL (r_acomp) were_1\VBD|NONE (l_npadvmod) mL_51\NN|.|Levels|greater (l_punct) ,_47\,|range|)|U|;|P|/ (l_punct) to_42\IN|A (l_pobj) hepatitis_44\NN|NONE
11229942
C066444_D002303 CID CE_1\NNP|NONE (r_compound) levels_2\NNS|with|decrease|were|. (r_nsubjpass) associated_4\VBN|NONE (l_conj) decrease_25\NN|with|were|.|levels (l_prep) in_26\IN|)|(|)|p|CI|.|)|(|(|,|)|%|. (l_pobj) output_28\NN|NONE
C066444_D000437 NONE cocaethylene_5\NN|,|and (l_prep) in_7\IN|cardiotoxity (l_pobj) model_10\NN|NONE (l_prep) of_11\IN|an|animal (l_pobj) cocaine_12\NN|NONE (l_conj) abuse_15\NN|and
D003042_D019970 NONE Cocaine_0\NN|NONE (l_appos) ethanol_2\NN|,|. (l_conj) cocaethylene_5\NN|,|and (l_prep) in_7\IN|cardiotoxity (l_pobj) model_10\NN|NONE (l_prep) of_11\IN|an|animal (l_pobj) cocaine_12\NN|NONE (l_conj) abuse_15\NN|and
C066444_D066126 NONE cocaethylene_5\NN|,|and (l_dobj) cardiotoxity_6\NN|in
C066444_D066126 NONE cocaethylene_22\NN|to (r_pobj) due_20\JJ|they|;|.|be|also|,|however|may (r_acomp) be_19\VB|NONE (l_ccomp) be_5\VB|they|;|.|also|,|however|due|may (l_nsubj) toxicity_3\NN|due|may
C066444_D066126 NONE CE_24\NNP|,|metabolite (r_appos) cocaethylene_22\NN|to (r_pobj) due_20\JJ|they|;|.|be|also|,|however|may (r_acomp) be_19\VB|NONE (l_ccomp) be_5\VB|they|;|.|also|,|however|due|may (l_nsubj) toxicity_3\NN|due|may
C066444_D066126 NONE CE_11\NNP|NONE (r_pobj) of_10\IN|the|in (r_prep) role_9\NN|to (l_prep) in_12\IN|the|of (l_pobj) cardiotoxicity_15\NN|NONE
C066444_D019970 NONE cocaethylene_5\NN|,|and (l_prep) in_7\IN|cardiotoxity (l_pobj) model_10\NN|NONE (l_prep) of_11\IN|an|animal (l_pobj) cocaine_12\NN|NONE (l_conj) abuse_15\NN|and
D003042_D000437 NONE Cocaine_0\NN|NONE (l_appos) ethanol_2\NN|,|. (l_conj) cocaethylene_5\NN|,|and (l_prep) in_7\IN|cardiotoxity (l_pobj) model_10\NN|NONE (l_prep) of_11\IN|an|animal (l_pobj) cocaine_12\NN|NONE (l_conj) abuse_15\NN|and
D000431_D000437 NONE ethanol_2\NN|,|. (l_conj) cocaethylene_5\NN|,|and (l_prep) in_7\IN|cardiotoxity (l_pobj) model_10\NN|NONE (l_prep) of_11\IN|an|animal (l_pobj) cocaine_12\NN|NONE (l_conj) abuse_15\NN|and
C066444_D009202 NONE cocaethylene_2\NN|serum|Peak (r_compound) concentrations_3\NNS|were|.|with (r_nsubjpass) associated_5\VBN|NONE (l_prep) with_6\IN|were|concentrations|. (l_pobj) depression_9\NN|NONE
D000431_D019970 NONE ethanol_2\NN|,|. (l_conj) cocaethylene_5\NN|,|and (l_prep) in_7\IN|cardiotoxity (l_pobj) model_10\NN|NONE (l_prep) of_11\IN|an|animal (l_pobj) cocaine_12\NN|NONE (l_conj) abuse_15\NN|and
D003042_D066126 NONE Cocaine_0\NN|NONE (l_appos) ethanol_2\NN|,|. (l_conj) cocaethylene_5\NN|,|and (l_dobj) cardiotoxity_6\NN|in
D003042_D066126 NONE cocaine_28\NN|a|formed (r_compound) metabolite_29\NN|,|CE (r_appos) cocaethylene_22\NN|to (r_pobj) due_20\JJ|they|;|.|be|also|,|however|may (r_acomp) be_19\VB|NONE (l_ccomp) be_5\VB|they|;|.|also|,|however|due|may (l_nsubj) toxicity_3\NN|due|may
D003042_D066126 NONE cocaine_17\NN|NONE (r_pobj) of_16\IN|combined|the|in (r_prep) cardiotoxicity_15\NN|NONE
D000431_D066126 NONE ethanol_2\NN|,|. (l_conj) cocaethylene_5\NN|,|and (l_dobj) cardiotoxity_6\NN|in
D000431_D066126 NONE ethanol_36\NN|NONE (r_pobj) of_35\IN|the (r_prep) presence_34\NN|only (r_pobj) in_32\IN|NONE (r_prep) formed_30\VBN|a|cocaine (r_acl) metabolite_29\NN|,|CE (r_appos) cocaethylene_22\NN|to (r_pobj) due_20\JJ|they|;|.|be|also|,|however|may (r_acomp) be_19\VB|NONE (l_ccomp) be_5\VB|they|;|.|also|,|however|due|may (l_nsubj) toxicity_3\NN|due|may
D000431_D066126 NONE ethanol_19\NN|and (r_conj) cocaine_17\NN|NONE (r_pobj) of_16\IN|combined|the|in (r_prep) cardiotoxicity_15\NN|NONE
12487093
C009591_D006973 NONE triphenyltetrazolium_15\NN|NONE (r_dobj) using_14\VBG|which|was (r_advcl) evaluated_13\VBN|,|the (r_relcl) BBB_9\NN|to (r_dobj) destroy_7\VB|was|hypertension (r_xcomp) used_5\VBN|NONE (l_nsubjpass) hypertension_3\NN|destroy|was
C009591_D006973 NONE TTC_17\NNP|staining|) (r_appos) triphenyltetrazolium_15\NN|NONE (r_dobj) using_14\VBG|which|was (r_advcl) evaluated_13\VBN|,|the (r_relcl) BBB_9\NN|to (r_dobj) destroy_7\VB|was|hypertension (r_xcomp) used_5\VBN|NONE (l_nsubjpass) hypertension_3\NN|destroy|was
D004837_D006973 CID Adrenaline_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) hypertension_3\NN|destroy|was
D004837_D006973 CID adrenaline_27\NN|for (r_dobj) giving_26\VBG|just (r_pcomp) after_25\IN|of (r_prep) staining_19\NN|TTC|) (r_appos) triphenyltetrazolium_15\NN|NONE (r_dobj) using_14\VBG|which|was (r_advcl) evaluated_13\VBN|,|the (r_relcl) BBB_9\NN|to (r_dobj) destroy_7\VB|was|hypertension (r_xcomp) used_5\VBN|NONE (l_nsubjpass) hypertension_3\NN|destroy|was
256433
D002228_D007239 NONE carbenicillin_5\NN|NONE (l_prep) for_6\IN|NONE (l_pobj) infections_7\NNS|NONE
D014031_D007239 NONE tobramycin_2\NN|NONE (l_acl) combined_3\VBN|Continuous|.|infusion (l_prep) with_4\IN|NONE (l_pobj) carbenicillin_5\NN|NONE (l_prep) for_6\IN|NONE (l_pobj) infections_7\NNS|NONE
D002228_D009503 NONE carbenicillin_18\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) combined_15\VBN|tobramycin|overcome|.|and|,|by|was (r_conj) given_10\VBN|NONE (l_advcl) overcome_1\VB|tobramycin|.|combined|and|,|by|was (l_dobj) effects_4\NNS|To (l_prep) of_5\IN|the|adverse (l_pobj) neutropenia_6\NN|NONE
D003404_D053099 NONE creatinine_4\NN|(|)|Major (r_appos) azotemia_1\NN|in|.
D014031_D053099 CID tobramycin_10\JJ|therapy (r_amod) concentration_11\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) duration_5\NN|NONE (r_pobj) to_4\IN|was|.|not|Azotemia (r_prep) related_3\VBN|NONE (l_nsubjpass) Azotemia_0\NNP|was|.|not|to
D002228_D009369 NONE carbenicillin_5\NN|NONE (l_prep) for_6\IN|NONE (l_pobj) infections_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) patients_10\NNS|NONE (l_compound) cancer_9\NN|NONE
D014031_D009503 NONE tobramycin_8\JJ|overcome|.|combined|and|,|by|was (r_nsubjpass) given_10\VBN|NONE (l_advcl) overcome_1\VB|tobramycin|.|combined|and|,|by|was (l_dobj) effects_4\NNS|To (l_prep) of_5\IN|the|adverse (l_pobj) neutropenia_6\NN|NONE
D014031_D009369 NONE tobramycin_2\NN|NONE (l_acl) combined_3\VBN|Continuous|.|infusion (l_prep) with_4\IN|NONE (l_pobj) carbenicillin_5\NN|NONE (l_prep) for_6\IN|NONE (l_pobj) infections_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) patients_10\NNS|NONE (l_compound) cancer_9\NN|NONE
612112
D005045_D009207 CID etomidate_5\NN|will|that|be (r_nsubj) prove_7\VB|is|It|.|unlikely (l_xcomp) be_9\VB|will|etomidate|that (l_prep) because_22\IN|to|hypnotic (l_pobj) incidence_26\NN|of (l_prep) of_27\IN|high|after|the (l_pobj) myoclonia_28\NN|NONE
12752472
D010862_D006985 NONE pilocarpine_11\NN||and|control (r_npadvmod) treated_13\VBN|NONE (r_amod) rats_16\NNS|NONE (r_pobj) in_10\IN|spontaneous (r_prep) ventilation_9\NN|NONE (r_pobj) in_7\IN|a (r_prep) decrease_6\NN|maneuver|.|: (r_dobj) caused_4\VBD|NONE (l_nsubj) maneuver_3\NN|.|:|decrease (l_compound) hyperventilation_2\NN|The
D010862_D004827 CID pilocarpine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) epilepsy_18\NN|NONE
15096374
D016559_D003872 NONE tacrolimus_11\NN|NONE (r_compound) ointment_12\NN|NONE (r_pobj) with_10\IN|facial|inflammatory (r_prep) dermatoses_9\NNS|NONE (r_pobj) of_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) during_4\IN|of|. (r_prep) Induction_0\NN|NONE (l_prep) of_1\IN|during|. (l_pobj) dermatitis_3\NN|NONE
D016559_D003872 NONE tacrolimus_11\NN|NONE (r_compound) ointment_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|NONE (r_pobj) of_8\IN|a (r_prep) complication_7\NN|NONE (r_pobj) as_5\IN|We|on|. (r_prep) report_1\VBP|NONE (l_prep) on_2\IN|We|.|as (l_pobj) dermatitis_4\NN|NONE
D016559_D003872 NONE tacrolimus_15\NN|NONE (r_compound) ointment_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|NONE (r_pobj) of_12\IN|a (r_prep) complication_11\NN|NONE (r_pobj) as_9\IN|of|the (r_prep) spectrum_5\NN|that|heterogeneous (l_prep) of_6\IN|as|the (l_pobj) dermatitis_8\NN|NONE
D016559_D005148 NONE tacrolimus_11\NN|NONE (r_compound) ointment_12\NN|NONE (r_pobj) with_10\IN|facial|inflammatory (r_prep) dermatoses_9\NNS|NONE
D016559_D005148 NONE tacrolimus_10\NN|NONE (r_compound) ointment_11\NN|NONE (r_pobj) with_9\IN|were|patients|because|. (r_prep) treated_8\VBN|NONE (l_nsubjpass) patients_2\NNS|with|were|because|. (l_prep) with_3\IN|adult|Six (l_pobj) dermatoses_6\NNS|NONE
D016559_D019557 NONE Tacrolimus_0\NNP|NONE (r_compound) ointment_1\NN|and|indicate|is|,|for|increasingly (r_nsubjpass) used_4\VBN|NONE (l_conj) indicate_21\VBP|and|is|,|for|increasingly|ointment (l_ccomp) is_25\VBZ|.|observations (l_acomp) effective_26\JJ|treatment|that (l_prep) in_27\IN|NONE (l_pobj) rosacea_31\NN|NONE (l_conj) dermatitis_34\NN|aggravated|and
D013256_D012393 NONE steroid_28\NN| (r_npadvmod) aggravated_30\VBN|dermatitis|and (r_amod) rosacea_31\NN|NONE
D013256_D019557 NONE steroid_28\NN| (r_npadvmod) aggravated_30\VBN|dermatitis|and (r_amod) rosacea_31\NN|NONE (l_conj) dermatitis_34\NN|aggravated|and
D016559_D012393 CID Tacrolimus_0\NNP|NONE (r_compound) ointment_1\NN|and|indicate|is|,|for|increasingly (r_nsubjpass) used_4\VBN|NONE (l_conj) indicate_21\VBP|and|is|,|for|increasingly|ointment (l_ccomp) is_25\VBZ|.|observations (l_acomp) effective_26\JJ|treatment|that (l_prep) in_27\IN|NONE (l_pobj) rosacea_31\NN|NONE
20495512
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|:|review|. (r_amod) thrombocytopenia_3\NN|NONE
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|HIT (r_amod) thrombocytopenia_3\NN|.|recognized
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|HIT (r_amod) thrombocytopenia_3\NN|.|recognized (l_appos) HIT_5\NN|induced
D006493_D013921 CID heparin_16\JJ|NONE (r_compound) exposure_17\NN|NONE (r_pobj) after_15\IN|whenever|thrombosis (r_prep) occurs_14\VBZ|NONE (r_ccomp) suspected_11\VBN|HIT|must|be|.|for|and (r_conj) acknowledged_3\VBN|NONE (l_nsubjpass) HIT_0\NNP|suspected|must|be|.|for|and
D006493_D013921 CID heparin_10\JJ|all|and|institution (r_compound) exposure_11\NN|NONE (r_pobj) of_8\IN|an|immediate (r_prep) cessation_7\NN|treatment|,|using|. (r_dobj) mandates_4\NNS|NONE (l_nsubj) treatment_1\NN|cessation|,|using|. (l_prep) of_2\IN|The (l_pobj) HIT_3\NNP|NONE
D006493_D013921 CID heparin_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) history_16\NN|NONE (l_prep) of_17\IN|need|,|a (l_pobj) HIT_18\NN|NONE
D006493_D013921 CID heparin_1\NN|one|with|today|As (r_nsubj) remains_2\VBZ|must|be|,|.|vigilance|initiated (l_prep) with_11\IN|one|heparin|today|As (l_pobj) potential_12\NN|NONE (l_prep) for_13\IN|with (l_pobj) HIT_14\NN|NONE
D006493_D013921 CID heparin_17\JJ|every (r_compound) exposure_18\NN|NONE (r_pobj) with_15\IN|for (r_prep) potential_12\NN|NONE (l_prep) for_13\IN|with (l_pobj) HIT_14\NN|NONE
D006493_D013921 CID heparin_30\JJ|is|whenever (r_nsubjpass) initiated_32\VBN|must|be|,|remains|.|vigilance (r_advcl) practiced_28\VBN|NONE (l_advcl) remains_2\VBZ|must|be|,|.|vigilance|initiated (l_prep) with_11\IN|one|heparin|today|As (l_pobj) potential_12\NN|NONE (l_prep) for_13\IN|with (l_pobj) HIT_14\NN|NONE
D006493_D013927 CID heparin_16\JJ|NONE (r_compound) exposure_17\NN|NONE (r_pobj) after_15\IN|whenever|thrombosis (r_prep) occurs_14\VBZ|NONE (r_ccomp) suspected_11\VBN|HIT|must|be|.|for|and (r_conj) acknowledged_3\VBN|NONE (l_prep) for_4\IN|suspected|HIT|must|be|.|and (l_pobj) predilection_7\NN|NONE (l_prep) for_8\IN|intense|its (l_pobj) thrombosis_9\NN|NONE
D006493_D013927 CID heparin_16\JJ|NONE (r_compound) exposure_17\NN|NONE (r_pobj) after_15\IN|whenever|thrombosis (r_prep) occurs_14\VBZ|NONE (l_nsubj) thrombosis_13\NN|whenever|after
D000991_D013921 NONE inhibitor_26\NN|commonly (r_dobj) using_22\VBG|cessation|treatment|,|. (r_advcl) mandates_4\NNS|NONE (l_nsubj) treatment_1\NN|cessation|,|using|. (l_prep) of_2\IN|The (l_pobj) HIT_3\NNP|NONE
D000991_D013921 NONE inhibitors_2\NNS|.|alternatives (r_nsubj) are_3\VBP|NONE (l_attr) alternatives_9\NNS|inhibitors|. (l_prep) to_10\IN|based|appropriate|, (l_pobj) heparin_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) history_16\NN|NONE (l_prep) of_17\IN|need|,|a (l_pobj) HIT_18\NN|NONE
8825380
D011692_D006130 NONE PAN_15\NNP|chronic (r_compound) nephropathy_16\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) rats_12\NNS|NONE (r_pobj) in_11\IN|growth (r_prep) failure_10\NN|NONE
D011692_D007674 CID aminonucleoside_15\JJ|in (r_amod) nephropathy_16\NN|on
D011692_D007674 CID aminonucleoside_15\NN|model|(|,|PAN (r_nmod) nephropathy_19\NN|puromycin
D011692_D007674 CID aminonucleoside_15\NN|model|(|,|PAN (r_nmod) nephropathy_19\NN|puromycin (l_appos) model_23\NN|(|aminonucleoside|,|PAN (l_prep) of_24\IN|experimental|an (l_pobj) disease_26\NN|NONE
D011692_D007674 CID PAN_17\NNP|model|(|aminonucleoside|, (r_nmod) nephropathy_19\NN|puromycin
D011692_D007674 CID PAN_17\NNP|model|(|aminonucleoside|, (r_nmod) nephropathy_19\NN|puromycin (l_appos) model_23\NN|(|aminonucleoside|,|PAN (l_prep) of_24\IN|experimental|an (l_pobj) disease_26\NN|NONE
D011692_D007674 CID PAN_15\NNP|chronic (r_compound) nephropathy_16\NN|NONE
D011692_D007674 CID PAN_9\NNP|NONE (r_pobj) of_8\IN|serial|seven (r_prep) injections_7\NNS|NONE (r_pobj) by_4\IN|glomerulopathy|.|was|over (r_agent) induced_3\VBN|NONE (l_nsubjpass) glomerulopathy_1\NN|.|by|was|over
D011692_D007674 CID PAN_6\NNP|chronic (r_compound) nephropathy_7\NN|NONE
D011692_D007674 CID PAN_33\NNP|NONE (r_compound) nephropathy_34\NN|untreated
D011692_D007674 CID PAN_3\NNP|administration|, (r_compound) nephropathy_4\NN|NONE
D011692_D007674 CID PAN_19\NNP|chronic (r_compound) nephropathy_20\NN|NONE
D008315_-1 NONE malondialdehyde_22\NN|renal (r_compound) content_23\NN|or|,|tubulointerstitial (r_conj) injury_17\NN|,|increased|segmental
D008315_D007674 NONE malondialdehyde_22\NN|renal (r_compound) content_23\NN|or|,|tubulointerstitial (r_conj) injury_17\NN|,|increased|segmental (r_conj) glomerulosclerosis_14\NN|glomerular|or|enhanced (r_conj) hypertrophy_10\NN|NONE
D008315_D007674 NONE malondialdehyde_35\NN|renal|damage|or|, (r_compound) content_36\NN|glomerular|,|planar (l_conj) damage_42\NN|renal|malondialdehyde|or|,
D008315_D005921 NONE malondialdehyde_22\NN|renal (r_compound) content_23\NN|or|,|tubulointerstitial (r_conj) injury_17\NN|,|increased|segmental (r_conj) glomerulosclerosis_14\NN|glomerular|or|enhanced
D008315_D011507 NONE malondialdehyde_35\NN|renal|damage|or|, (r_compound) content_36\NN|glomerular|,|planar (r_conj) area_31\NN|, (r_conj) GFR_27\NNP|, (r_conj) proteinuria_25\NN|blood|,
20192893
D003287_D064420 NONE CM_13\NNP|NONE (r_compound) toxicity_14\NN|NONE
D003287_D007674 CID medium_1\NN|.|Contrast|after (r_amod) nephrotoxicity_2\NN|NONE
D003287_D007674 CID medium_6\NN|iodinated|(|contrast (r_amod) CM_8\NNP|) (r_nmod) administration_10\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Renal (r_acl) dysfunction_1\NN|.|)|benefit|can
D003287_D007674 CID CM_8\NNP|) (r_nmod) administration_10\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Renal (r_acl) dysfunction_1\NN|.|)|benefit|can
D003287_D007674 CID CM_8\NNP|NONE (r_pobj) of_7\IN|nephrotoxic|in (r_prep) effect_6\NN|NONE (l_amod) nephrotoxic_5\JJ|in|of
D003287_D007674 CID CM_17\NNP|than (r_compound) administration_18\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|renal (r_acl) damage_14\NN|NONE
7739955
D002220_D004802 CID carbamazepine_10\NN| (r_npadvmod) induced_12\VBN|eosinophilic|a|acute (r_amod) myocarditis_15\NN|and|had|one|had|,|,
D002220_D009205 CID carbamazepine_10\NN| (r_npadvmod) induced_12\VBN|eosinophilic|a|acute (r_amod) myocarditis_15\NN|and|had|one|had|,|, (r_dobj) had_8\VBD|NONE (l_ccomp) had_2\VBD|and|one|had|myocarditis|,|, (l_dobj) myocarditis_5\NN|patients
D002220_D009205 CID carbamazepine_10\NN| (r_npadvmod) induced_12\VBN|eosinophilic|a|acute (r_amod) myocarditis_15\NN|and|had|one|had|,|,
D002220_D012770 NONE carbamazepine_10\NN| (r_npadvmod) induced_12\VBN|eosinophilic|a|acute (r_amod) myocarditis_15\NN|and|had|one|had|,|, (r_dobj) had_8\VBD|NONE (l_conj) had_19\VBD|and|had|one|myocarditis|,|, (l_dobj) hemosiderosis_21\NN|one|. (l_acl) resulting_22\VBG|cardiac (l_prep) in_23\IN|NONE (l_pobj) shock_26\NN|NONE
24653743
C042288_D016757 CID Pilsicainide_8\NNP| (r_npadvmod) Induced_10\VBN|de|Torsades (r_amod) Pointes_13\NNP|to (r_pobj) due_6\IN|of|A|. (r_amod) Case_1\NN|NONE (l_prep) of_2\IN|A|.|due (l_pobj) Death_5\NNP|NONE
C042288_D016757 CID pilsicainide_7\NN|male|convert (r_dobj) received_5\VBD|.|later|;|death|patient (r_ccomp) developed_32\VBD|NONE (l_dobj) death_35\NN|.|later|;|received|patient
C042288_D016171 CID Pilsicainide_8\NNP| (r_npadvmod) Induced_10\VBN|de|Torsades (r_amod) Pointes_13\NNP|to
C042288_D016171 CID pilsicainide_14\NN|NONE (r_pobj) of_13\IN|the (r_prep) dose_12\NN|low (r_nsubj) was_15\VBD|Although|and|not|impaired|function (r_conj) was_6\VBD|may|concentration|,|high|,|.|have|produce (r_advcl) been_25\VBN|NONE (l_advcl) produce_30\VB|may|concentration|,|high|,|.|have|was (l_dobj) pointes_33\FW|can|which
C042288_D016171 CID pilsicainide_22\NN|NONE (r_pobj) of_21\IN|the|plasma (r_prep) concentration_20\NN|may|,|high|,|.|have|was|produce (r_nsubj) been_25\VBN|NONE (l_advcl) produce_30\VB|may|concentration|,|high|,|.|have|was (l_dobj) pointes_33\FW|can|which
C042288_D001281 NONE pilsicainide_7\NN|male|convert (r_dobj) received_5\VBD|.|later|;|death|patient (l_advcl) convert_20\VB|pilsicainide|male (l_dobj) fibrillation_24\NN|to|to
C042288_D001281 NONE pilsicainide_10\NN|NONE (r_pobj) including_9\VBG|,|the|oral|of (r_prep) administration_3\NN|Although|effective|, (r_nsubj) is_12\VBZ|.|be|before|must|consideration|, (l_acomp) effective_13\JJ|Although|administration|, (l_xcomp) terminate_15\VB|NONE (l_dobj) fibrillation_17\NN|to
D012964_D001281 NONE sodium_11\NN|pure (r_compound) channel_12\NN|a|with (r_compound) blocker_13\NN|,|oral|, (r_appos) pilsicainide_7\NN|male|convert (r_dobj) received_5\VBD|.|later|;|death|patient (l_advcl) convert_20\VB|pilsicainide|male (l_dobj) fibrillation_24\NN|to|to
D012964_D016757 NONE sodium_11\NN|pure (r_compound) channel_12\NN|a|with (r_compound) blocker_13\NN|,|oral|, (r_appos) pilsicainide_7\NN|male|convert (r_dobj) received_5\VBD|.|later|;|death|patient (r_ccomp) developed_32\VBD|NONE (l_dobj) death_35\NN|.|later|;|received|patient
9071336
D017239_D064420 NONE Paclitaxel_0\NNP|fluorouracil|.|cytotoxicity (r_nsubj) have_3\VBP|NONE (l_dobj) cytotoxicity_5\NN|fluorouracil|Paclitaxel|.
D005472_D064420 NONE 5-fluorouracil_2\CD|Paclitaxel|.|cytotoxicity (r_punct) have_3\VBP|NONE (l_dobj) cytotoxicity_5\NN|fluorouracil|Paclitaxel|.
D017239_D001943 NONE Paclitaxel_0\NNP|.|trial (l_conj) acid_6\NN|,|and|, (l_prep) in_7\IN|folinic|: (l_pobj) cancer_10\NN|NONE
D017239_D001943 NONE paclitaxel_3\NN|and|folinic (r_conj) acid_1\NN|Taxol|therapies|. (r_nsubj) are_17\VBP|NONE (l_attr) therapies_20\NNS|acid|Taxol|. (l_prep) for_21\IN|salvage|effective (l_pobj) patients_25\NNS|NONE (l_compound) cancer_24\NN|metastatic
D017239_D001943 NONE Taxol_5\NNP|acid|therapies|. (r_nsubj) are_17\VBP|NONE (l_attr) therapies_20\NNS|acid|Taxol|. (l_prep) for_21\IN|salvage|effective (l_pobj) patients_25\NNS|NONE (l_compound) cancer_24\NN|metastatic
D017239_D001943 NONE paclitaxel_7\NN|NONE (r_pobj) of_6\IN|II (r_prep) trial_5\NN|We|m|phase|. (r_dobj) performed_1\VBD|NONE (l_dobj) phase_3\NN|trial|We|m|. (l_relcl) followed_18\VBD|a (l_agent) by_19\IN|I (l_pobj) acid_21\NN|NONE (l_prep) in_44\IN|folinic|before|days|on (l_pobj) women_45\NNS|NONE (l_prep) with_46\IN|NONE (l_pobj) cancer_49\NN|NONE
D016179_D009503 NONE factor_54\NN|reported|;|due|cycles (r_dobj) required_49\VBN|;|patient|.|transfusions (l_ccomp) reported_2\VBN|;|due|factor|cycles (l_ccomp) associated_32\VBN|is|Analysis|on (l_prep) with_33\IN|cycles|were (l_pobj) hospitalization_38\NN|NONE (l_det) neutropenia_36\NN|/|requiring
D016179_D009503 NONE factor_54\NN|reported|;|due|cycles (r_dobj) required_49\VBN|;|patient|.|transfusions (l_prep) due_55\JJ|reported|;|factor|cycles (l_pobj) neutropenia_57\NN|to
D002955_D001943 NONE acid_6\NN|,|and|, (l_prep) in_7\IN|folinic|: (l_pobj) cancer_10\NN|NONE
D002955_D001943 NONE acid_1\NN|Taxol|therapies|. (r_nsubj) are_17\VBP|NONE (l_attr) therapies_20\NNS|acid|Taxol|. (l_prep) for_21\IN|salvage|effective (l_pobj) patients_25\NNS|NONE (l_compound) cancer_24\NN|metastatic
D002955_D001943 NONE acid_21\NN|NONE (l_prep) in_44\IN|folinic|before|days|on (l_pobj) women_45\NNS|NONE (l_prep) with_46\IN|NONE (l_pobj) cancer_49\NN|NONE
D005472_D001943 NONE 5-fluorouracil_2\CD|NONE (r_punct) ,_3\,|acid|and|, (r_punct) Paclitaxel_0\NNP|.|trial (l_conj) acid_6\NN|,|and|, (l_prep) in_7\IN|folinic|: (l_pobj) cancer_10\NN|NONE
D005472_D001943 NONE 5-fluorouracil_28\CD|mg||/ (r_punct) m2_32\NN|hour (r_pobj) before_27\IN|folinic|days|in|on (r_prep) acid_21\NN|NONE (l_prep) in_44\IN|folinic|before|days|on (l_pobj) women_45\NNS|NONE (l_prep) with_46\IN|NONE (l_pobj) cancer_49\NN|NONE
19967075
D005839_D007674 CID Gentamicin_17\NNP| (r_npadvmod) induced_19\VBN|NONE (r_amod) Nephropathy_20\NNP|NONE
D005839_D007674 CID gentamicin_17\NN| (r_npadvmod) induced_19\VBN|NONE (r_amod) nephropathy_20\NN|NONE
D005839_D007674 CID Gentamicin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) nephropathy_3\NN|in|.|be|causally|with|may
D011188_D007674 NONE K_5\NNP|/||NHE|Na|in|, (r_compound) ATPase_7\NNP|NONE (l_prep) in_16\IN|/||NHE|Na|K|, (l_pobj) Nephropathy_20\NNP|NONE
D011188_D007674 NONE Na(+)/K(+)-ATPase_17\NNP|NONE (r_pobj) of_16\IN|a|decreased (r_prep) expression_15\NN|NONE (r_pobj) with_12\IN|nephropathy|in|.|be|causally|may (r_prep) related_11\VBN|NONE (l_nsubjpass) nephropathy_3\NN|in|.|be|causally|with|may
D012964_D007674 NONE Na_3\NNP|/||NHE|in|K|, (r_nmod) ATPase_7\NNP|NONE (l_prep) in_16\IN|/||NHE|Na|K|, (l_pobj) Nephropathy_20\NNP|NONE
D012964_D007674 NONE Na(+)/K(+)-ATPase_17\NNP|NONE (r_pobj) of_16\IN|a|decreased (r_prep) expression_15\NN|NONE (r_pobj) with_12\IN|nephropathy|in|.|be|causally|may (r_prep) related_11\VBN|NONE (l_nsubjpass) nephropathy_3\NN|in|.|be|causally|with|may
17879100
D001241_D005334 NONE aspirin_4\JJ|NONE (r_pobj) on_3\IN|.|following|was|took|He|and (r_prep) put_2\VBN|NONE (l_conj) took_8\VBD|.|following|was|He|and|on (l_prep) for_10\IN|for|ibuprofen (l_pobj) fever_11\NN|NONE
D007052_D005334 NONE ibuprofen_9\NN|for|for (r_dobj) took_8\VBD|.|following|was|He|and|on (l_prep) for_10\IN|for|ibuprofen (l_pobj) fever_11\NN|NONE
24999722
D005446_D007249 NONE acetonide_5\NN|(|mg|) (r_compound) implant_6\NN|that (r_dobj) fluocinolone_4\NN|helps|.|data (r_ccomp) suggest_2\VBP|NONE (l_ccomp) helps_11\VBZ|.|fluocinolone|data (l_xcomp) control_13\VB|NONE (l_dobj) inflammation_14\NN|to
D005446_C537630 NONE acetonide_5\NN|intravitreal|Safety|)|in|mg|(|. (r_compound) implant_7\NN|NONE (l_prep) in_12\IN|intravitreal|Safety|)|acetonide|mg|(|. (l_pobj) retinochoroidopathy_14\JJ|NONE
D005446_C537630 NONE acetonide_8\NN|)|mg|intravitreal|in|( (r_amod) implant_10\NN|.|To|outcomes (l_prep) in_15\IN|)|acetonide|mg|intravitreal|( (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) retinochoroidopathy_19\JJ|NONE
D005446_C537630 NONE acetonide_5\NN|(|mg|) (r_compound) implant_6\NN|that (r_dobj) fluocinolone_4\NN|helps|.|data (r_ccomp) suggest_2\VBP|NONE (l_ccomp) helps_11\VBZ|.|fluocinolone|data (l_xcomp) control_13\VB|NONE (l_dobj) inflammation_14\NN|to (l_prep) in_15\IN|NONE (l_pobj) cases_20\NNS|NONE (l_prep) of_21\IN|refractory|otherwise (l_pobj) retinochoroidopathy_23\JJ|NONE
9323412
D015742_D009325 NONE propofol_3\JJ|a|avoidance|of|and (r_amod) infusion_4\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Anaesthesia_0\NNP|without|.|course (r_nsubj) provided_10\VBD|NONE (l_dobj) course_16\NN|without|Anaesthesia|. (l_amod) free_14\JJ|a|postoperative (l_npadvmod) nausea_12\NN|
D015742_D003866 NONE propofol_3\JJ|a|avoidance|of|and (r_amod) infusion_4\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Anaesthesia_0\NNP|without|.|course (r_nsubj) provided_10\VBD|NONE (l_prep) without_17\IN|Anaesthesia|.|course (l_pobj) exacerbation_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) disorder_22\NN|NONE
D017294_D003866 NONE ondansetron_7\NN|NONE (r_pobj) following_3\VBG|Acute|severe|. (r_prep) depression_2\NN|NONE
D012701_D003865 NONE serotonin_20\NN|a (r_compound) antagonist_21\NN|NONE (r_pobj) of_18\IN|the (r_prep) use_17\NN|NONE (r_pobj) to_15\IN|possibly (r_prep) related_14\VBN|disorder|She|thereafter|had|,|. (r_advcl) developed_2\VBN|NONE (l_dobj) disorder_8\NN|She|related|thereafter|had|,|.
D012701_D003866 NONE serotonin_8\NN|NONE (r_compound) antagonists_9\NNS|NONE (r_pobj) of_7\IN|a|avoidance|propofol|and (r_prep) infusion_4\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Anaesthesia_0\NNP|without|.|course (r_nsubj) provided_10\VBD|NONE (l_prep) without_17\IN|Anaesthesia|.|course (l_pobj) exacerbation_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) disorder_22\NN|NONE
D017294_D020250 NONE ondansetron_25\NN|NONE (r_compound) prophylaxis_26\NN|had|been|where (r_nsubjpass) used_29\VBN|a|previous (r_relcl) anaesthetic_23\NN|months (r_pobj) after_20\IN|woman|.|for (r_prep) presented_14\VBN|NONE (l_nsubj) woman_4\NN|.|for|after (l_prep) with_5\IN|A|old (l_pobj) history_8\NN|NONE (l_prep) of_9\IN|a|strong (l_pobj) nausea_11\NN|NONE (l_conj) vomiting_13\NN|postoperative|and
D012701_D009325 NONE serotonin_8\NN|NONE (r_compound) antagonists_9\NNS|NONE (r_pobj) of_7\IN|a|avoidance|propofol|and (r_prep) infusion_4\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Anaesthesia_0\NNP|without|.|course (r_nsubj) provided_10\VBD|NONE (l_dobj) course_16\NN|without|Anaesthesia|. (l_amod) free_14\JJ|a|postoperative (l_npadvmod) nausea_12\NN|
2131034
D008727_D020258 CID methotrexate_8\NNP|NONE (r_pobj) with_5\IN|have|toxicities|been|. (r_prep) described_4\VBN|NONE (l_nsubjpass) toxicities_1\NNS|have|with|been|.
D008727_D020258 CID MTX_16\NNP|NONE (r_pobj) with_15\IN|its (r_prep) combination_14\NN|.|,|In|could|neurotoxicity (r_nsubj) cause_24\VB|NONE (l_dobj) neurotoxicity_26\NN|.|,|combination|In|could
D013852_D020258 CID thiotepa_19\NNS|NONE (r_pobj) including_18\VBG|intrathecal|combination|IT (r_prep) chemotherapy_17\NN|NONE (r_pobj) of_11\IN|the (r_prep) administration_10\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) related_7\VBN|neurologic|delayed|severe (r_acl) toxicity_6\NN|NONE
D013852_D020258 CID TSPA_21\NNS|NONE (r_appos) thiotepa_19\NNS|NONE (r_pobj) including_18\VBG|intrathecal|combination|IT (r_prep) chemotherapy_17\NN|NONE (r_pobj) of_11\IN|the (r_prep) administration_10\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) related_7\VBN|neurologic|delayed|severe (r_acl) toxicity_6\NN|NONE
D013852_D020258 CID TSPA_17\NNP|,|and|cytosine (r_conj) arabinoside_13\NN||IT (r_conj) methotrexate_8\NNP|NONE (r_pobj) with_5\IN|have|toxicities|been|. (r_prep) described_4\VBN|NONE (l_nsubjpass) toxicities_1\NNS|have|with|been|.
D013852_D020258 CID TSPA_6\NNP|agent|that (r_nsubj) is_7\VBZ|the (r_acl) fact_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) spite_1\NN|NONE (r_pobj) In_0\IN|.|,|combination|could|neurotoxicity (r_prep) cause_24\VB|NONE (l_dobj) neurotoxicity_26\NN|.|,|combination|In|could
D013852_D011115 CID thiotepa_7\NNS|NONE (r_compound) combination_8\NN|:|description (r_compound) chemotherapy_9\NN|NONE (r_pobj) after_5\IN|.|loss|and|Severe (r_prep) polyneuropathy_1\NN|NONE
D003561_D020258 CID arabinoside_13\NN||IT (r_conj) methotrexate_8\NNP|NONE (r_pobj) with_5\IN|have|toxicities|been|. (r_prep) described_4\VBN|NONE (l_nsubjpass) toxicities_1\NNS|have|with|been|.
D003561_D020258 CID C_20\NN|, (r_conj) MTX_16\NNP|NONE (r_pobj) with_15\IN|its (r_prep) combination_14\NN|.|,|In|could|neurotoxicity (r_nsubj) cause_24\VB|NONE (l_dobj) neurotoxicity_26\NN|.|,|combination|In|could
10672628
D009569_D002375 NONE oxide_7\NN|NONE (r_compound) synthesis_8\NN|NONE (r_pobj) of_4\IN|chronic (r_prep) inhibition_3\NN|.|catalepsy (r_nsubj) modifies_9\VBZ|NONE (l_dobj) catalepsy_13\NN|.|inhibition
D009569_D002375 NONE oxide_18\NN|)|NOS|( (r_compound) synthase_19\NN|NONE (r_pobj) of_15\IN|an (r_prep) inhibitor_14\NN|NOARG|nitro|,|L|,|| (r_appos) arginine_6\NN|.|in|catalepsy (r_nsubj) induces_24\VBZ|NONE (l_dobj) catalepsy_25\NN|arginine|.|in
D004298_D002375 NONE dopamine_8\NN|NONE (r_compound) receptors_9\NNS|which (r_dobj) block_7\VBP|,|, (r_relcl) haloperidol_4\NN|such (r_pobj) as_3\IN|Neuroleptic (r_prep) drugs_1\NNS|also|.|in|catalepsy (r_nsubj) cause_12\VBP|NONE (l_dobj) catalepsy_13\NN|also|.|in|drugs
D009249_D002375 NONE NADPH_18\NNP| (r_compound) diaphorase_20\NN|NONE (r_compound) neurons_21\NNS|NONE (r_pobj) of_17\IN|in|the (r_prep) number_16\NN|and|induced (r_conj) catalepsy_13\NN|.|inhibition
D006220_D002375 CID haloperidol_10\NN| (r_npadvmod) induced_12\VBN|and|number (r_amod) catalepsy_13\NN|.|inhibition
D006220_D002375 CID haloperidol_4\NN|such (r_pobj) as_3\IN|Neuroleptic (r_prep) drugs_1\NNS|also|.|in|catalepsy (r_nsubj) cause_12\VBP|NONE (l_dobj) catalepsy_13\NN|also|.|in|drugs
D006220_D002375 CID haloperidol_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) catalepsy_14\NN|NONE
D006220_D002375 CID haloperidol_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) catalepsy_19\NN|NONE
D019335_D002375 NONE arginine_6\NN|.|in|catalepsy (r_nsubj) induces_24\VBZ|NONE (l_dobj) catalepsy_25\NN|arginine|.|in
D019335_D002375 NONE NOARG_10\NNP|nitro|,|L|,|||inhibitor (r_appos) arginine_6\NN|.|in|catalepsy (r_nsubj) induces_24\VBZ|NONE (l_dobj) catalepsy_25\NN|arginine|.|in
D019335_D002375 NONE NOARG_8\NNP|number|and|in|subchronic (r_compound) treatment_9\NN|NONE (l_prep) in_10\IN|number|NOARG|and|subchronic (l_pobj) catalepsy_14\NN|NONE
D019335_D002375 NONE NOARG_3\NNP|chronic (r_nmod) administration_7\NN|tolerance|.|: (r_nsubj) produced_8\VBD|NONE (l_dobj) tolerance_9\NN|.|:|administration (l_prep) of_10\IN|NONE (l_conj) of_15\IN|and|NOARG (l_pobj) catalepsy_19\NN|NONE
D019335_D002375 NONE NOARG_13\NNP|and|of (r_pobj) of_10\IN|NONE (l_conj) of_15\IN|and|NOARG (l_pobj) catalepsy_19\NN|NONE
3711722
D003035_D009202 CID cobalt_4\NN|NONE (r_compound) cardiomyopathy_5\NN|,|In|in|was
D004317_D006333 CID doxorubicin_4\RB| (r_npadvmod) induced_6\VBN|heart (r_amod) failure_8\NN|NONE
19020118
11988250
D007052_D004374 NONE ibuprofen_8\NNP|NONE (r_compound) administration_9\NN|NONE (r_pobj) after_7\IN|We|during|.|cases (r_prep) report_1\VBP|NONE (l_prep) during_10\IN|We|after|.|cases (l_pobj) trial_14\NN|NONE (l_prep) of_15\IN|randomised|in|a|controlled (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|with|prophylactic (l_pobj) arteriosus_21\NN|NONE
D007052_D004374 NONE ibuprofen_23\NN|NONE (r_pobj) with_22\IN|of|prophylactic (r_prep) treatment_17\NN|NONE (l_prep) of_18\IN|with|prophylactic (l_pobj) arteriosus_21\NN|NONE
D007052_D006976 CID ibuprofen_3\NNP|in (r_compound) prophylaxis_4\NN|NONE (r_pobj) after_2\IN|.|Pulmonary (r_prep) hypertension_1\NN|NONE
D009569_D000860 NONE oxide_6\NN|nitric|inhaled (r_compound) therapy_7\NN|NONE (r_pobj) on_3\IN|Hypoxaemia|.|quickly (r_prep) resolved_1\VBD|NONE (l_nsubj) Hypoxaemia_0\NNP|.|quickly|on
D007052_D000860 CID ibuprofen_8\NNP|NONE (r_compound) administration_9\NN|NONE (r_pobj) after_7\IN|We|during|.|cases (r_prep) report_1\VBP|NONE (l_dobj) cases_3\NNS|We|after|during|. (l_prep) of_4\IN|three (l_pobj) hypoxaemia_6\JJ|NONE
D007052_D000860 CID ibuprofen_23\NN|NONE (r_pobj) with_22\IN|of|prophylactic (r_prep) treatment_17\NN|NONE (r_pobj) of_15\IN|randomised|in|a|controlled (r_prep) trial_14\NN|NONE (r_pobj) during_10\IN|We|after|.|cases (r_prep) report_1\VBP|NONE (l_dobj) cases_3\NNS|We|after|during|. (l_prep) of_4\IN|three (l_pobj) hypoxaemia_6\JJ|NONE
D007052_D000860 CID ibuprofen_21\NNP|NONE (r_pobj) of_20\IN|prophylactic (r_prep) administration_19\NN|NONE (r_pobj) after_17\IN|hypoxaemia|if (r_prep) occurs_16\VBZ|investigators|that|to|attention (l_nsubj) hypoxaemia_15\JJ|after|if
17351238
D001285_D007022 NONE sulphate_23\NN|NONE (r_pobj) by_21\IN|.|was|,|experienced|this (r_agent) rectified_20\VBN|NONE (l_advcl) experienced_7\VBD|by|.|was|,|this (l_dobj) drop_10\NN|after|GTN|minutes (l_prep) in_11\IN|sudden|a (l_pobj) pressure_13\NN|NONE
D005996_D007022 CID GTN_8\NNP|prehospital (r_compound) administration_9\NN|NONE (r_pobj) following_6\VBG|in|dramatic|.|A (r_prep) drop_2\NN|NONE (l_prep) in_3\IN|dramatic|.|A|following (l_pobj) pressure_5\NN|NONE
D005996_D007022 CID GTN_4\NNP|after|drop|minutes (r_nsubj) experienced_7\VBD|by|.|was|,|this (l_dobj) drop_10\NN|after|GTN|minutes (l_prep) in_11\IN|sudden|a (l_pobj) pressure_13\NN|NONE
17223814
D015251_D054537 CID epirubicin_11\NNS|NONE (r_pobj) with_10\IN|NONE (r_prep) chemotherapy_9\NN|NONE (r_pobj) of_8\IN|a (r_prep) result_7\NN|NONE (r_pobj) as_5\IN|.|atrioventricular|operative (r_prep) block_4\NN|NONE
D017239_D054537 CID paclitaxel_13\NN|and (r_conj) epirubicin_11\NNS|NONE (r_pobj) with_10\IN|NONE (r_prep) chemotherapy_9\NN|NONE (r_pobj) of_8\IN|a (r_prep) result_7\NN|NONE (r_pobj) as_5\IN|.|atrioventricular|operative (r_prep) block_4\NN|NONE
7457821
25031906
D017311_D012678 NONE amlodipine_14\NN|NONE (r_pobj) with_13\IN|drug (r_prep) treatment_12\NN|NONE (r_pobj) on_10\IN|essential (r_prep) hypertension_9\NN|NONE (r_pobj) with_7\IN|a (r_prep) female_6\NN|NONE (r_pobj) about_4\IN|a (r_prep) case_3\NN|We|.|loss (r_dobj) report_1\VBP|NONE (l_dobj) loss_16\NN|We|.|case (l_prep) of_17\IN|developed (l_pobj) sensation_19\NN|NONE
D017311_D006973 NONE amlodipine_14\NN|NONE (r_pobj) with_13\IN|drug (r_prep) treatment_12\NN|NONE (r_pobj) on_10\IN|essential (r_prep) hypertension_9\NN|NONE
D017311_D004408 CID Amlodipine_14\NNP|NONE (r_pobj) of_13\IN||Rare (r_prep) effect_12\NN|to (r_attr) be_4\VB|Is|?|Dysguesia (r_xcomp) Going_2\VBG|NONE (l_compound) Dysguesia_1\NNP|Is|?|be
D017311_D004408 CID amlodipine_7\NN|NONE (r_pobj) of_6\IN||rare|side|A (r_prep) effect_5\NN|dysguesia|. (r_nsubj) is_8\VBZ|NONE (l_acomp) dysguesia_9\JJ|effect|.
D017311_D004408 CID amlodipine_3\NN|that|can|dysguesia (r_nsubj) cause_5\VB|We|. (l_dobj) dysguesia_6\NN|that|amlodipine|can
D017311_D004408 CID amlodipine_13\NN|NONE (l_conj) dysguesia_15\NN|and
4082192
D000082_D007683 CID Acetaminophen_0\NNP|.|necrosis|in (r_nsubj) produces_4\VBZ|NONE (l_dobj) necrosis_7\NN|Acetaminophen|.|in
D000082_D007683 CID APAP_2\NNP|)|( (r_appos) Acetaminophen_0\NNP|.|necrosis|in (r_nsubj) produces_4\VBZ|NONE (l_dobj) necrosis_7\NN|Acetaminophen|.|in
D000082_D007683 CID APAP_18\NNP| (r_npadvmod) induced_20\VBN|renal|tubular (r_amod) necrosis_23\NN|NONE
C026729_D007683 CID PAP_4\NNP|NONE (r_compound) formation_5\NN|that|,|,|,|for|in|in|, (r_nsubj) accounts_10\NNS|It|is|. (l_prep) for_17\IN|that|formation|,|,|,|in|in|, (l_pobj) necrosis_23\NN|NONE
D000082_D007674 NONE acetaminophen_7\RB| (r_advmod) induced_9\VBN|NONE (r_amod) nephrotoxicity_10\NN|NONE
D000082_D007674 NONE acetaminophen_7\RB| (r_advmod) induced_9\VBN|NONE (r_amod) nephrotoxicity_10\NN|NONE (r_pobj) in_6\IN|effect|The|.|:|of (r_prep) role_1\NN|NONE (l_appos) effect_12\NN|in|The|.|:|of (l_prep) of_13\IN|NONE (l_pobj) phosphate_18\NN|NONE (l_conj) nephrotoxicity_25\NN|on|)|nitrophenyl|and
D000082_D007674 NONE acetaminophen_20\NN|NONE (r_pobj) on_19\IN|nephrotoxicity|)|nitrophenyl|and (r_prep) phosphate_18\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) effect_12\NN|in|The|.|:|of (r_appos) role_1\NN|NONE (l_prep) in_6\IN|effect|The|.|:|of (l_pobj) nephrotoxicity_10\NN|NONE
D000082_D007674 NONE acetaminophen_20\NN|NONE (r_pobj) on_19\IN|nephrotoxicity|)|nitrophenyl|and (r_prep) phosphate_18\NN|NONE (l_conj) nephrotoxicity_25\NN|on|)|nitrophenyl|and
D000082_D007674 NONE APAP_16\NNP| (r_npadvmod) induced_18\VBN|NONE (r_amod) nephrotoxicity_19\NN|NONE
D000082_D007674 NONE APAP_19\NNP|NONE (l_conj) nephrotoxicity_22\NN|and
D000082_D007674 NONE APAP_7\NNP|NONE (r_pobj) to_6\IN|NONE (r_prep) prior_5\RB|of (r_advmod) Pretreatment_0\NN|in|. (r_nsubj) resulted_11\VBD|NONE (l_prep) in_12\IN|.|Pretreatment (l_pobj) reduction_14\NN|NONE (l_appos) nephrotoxicity_25\NN|marked|of (l_nmod) nephrotoxicity_21\NN|not|PAP
D000082_D007674 NONE APAP_7\NNP|NONE (r_pobj) to_6\IN|NONE (r_prep) prior_5\RB|of (r_advmod) Pretreatment_0\NN|in|. (r_nsubj) resulted_11\VBD|NONE (l_prep) in_12\IN|.|Pretreatment (l_pobj) reduction_14\NN|NONE (l_appos) nephrotoxicity_25\NN|marked|of
D000082_D007674 NONE APAP_16\NNP|NONE (r_pobj) of_15\IN|marked|nephrotoxicity (r_prep) reduction_14\NN|NONE (l_appos) nephrotoxicity_25\NN|marked|of (l_nmod) nephrotoxicity_21\NN|not|PAP
D000082_D007674 NONE APAP_16\NNP|NONE (r_pobj) of_15\IN|marked|nephrotoxicity (r_prep) reduction_14\NN|NONE (l_appos) nephrotoxicity_25\NN|marked|of
D000082_D007674 NONE APAP_8\NNP| (r_npadvmod) induced_10\VBN|NONE (r_amod) nephrotoxicity_11\NN|NONE
D000082_D007674 NONE APAP_19\NNP|NONE (r_compound) deacetylation_20\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) inhibition_17\NN|to (r_pobj) due_15\JJ|to (r_acomp) be_14\VB|Therefore|,|reduction|. (r_xcomp) appears_12\VBZ|NONE (l_nsubj) reduction_6\NN|Therefore|,|be|. (l_prep) in_7\IN|the|induced (l_pobj) nephrotoxicity_11\NN|NONE
C026729_D007674 NONE aminophenol_5\NN|NONE (r_pobj) of_2\IN|in|effect|The|.|: (r_prep) role_1\NN|NONE (l_prep) in_6\IN|effect|The|.|:|of (l_pobj) nephrotoxicity_10\NN|NONE
C026729_D007674 NONE aminophenol_5\NN|NONE (r_pobj) of_2\IN|in|effect|The|.|: (r_prep) role_1\NN|NONE (l_appos) effect_12\NN|in|The|.|:|of (l_prep) of_13\IN|NONE (l_pobj) phosphate_18\NN|NONE (l_conj) nephrotoxicity_25\NN|on|)|nitrophenyl|and
C026729_D007674 NONE aminophenol_24\NN|metabolism|and|in (r_amod) nephrotoxicity_25\NN|on|)|nitrophenyl|and (r_conj) phosphate_18\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) effect_12\NN|in|The|.|:|of (r_appos) role_1\NN|NONE (l_prep) in_6\IN|effect|The|.|:|of (l_pobj) nephrotoxicity_10\NN|NONE
C026729_D007674 NONE aminophenol_24\NN|metabolism|and|in (r_amod) nephrotoxicity_25\NN|on|)|nitrophenyl|and
C026729_D007674 NONE PAP_9\NNP|NONE (r_compound) formation_10\NN|if|step (r_nsubj) is_11\VBZ|to (l_attr) step_14\NN|if|formation (l_prep) in_15\IN|requisite|a (l_pobj) nephrotoxicity_19\NN|NONE
C026729_D007674 NONE PAP_21\NNP|metabolism|and (r_compound) nephrotoxicity_22\NN|and
C026729_D007674 NONE PAP_9\NNP|NONE (r_compound) administration_10\NN|or (r_conj) APAP_7\NNP|NONE (r_pobj) to_6\IN|NONE (r_prep) prior_5\RB|of (r_advmod) Pretreatment_0\NN|in|. (r_nsubj) resulted_11\VBD|NONE (l_prep) in_12\IN|.|Pretreatment (l_pobj) reduction_14\NN|NONE (l_appos) nephrotoxicity_25\NN|marked|of (l_nmod) nephrotoxicity_21\NN|not|PAP
C026729_D007674 NONE PAP_9\NNP|NONE (r_compound) administration_10\NN|or (r_conj) APAP_7\NNP|NONE (r_pobj) to_6\IN|NONE (r_prep) prior_5\RB|of (r_advmod) Pretreatment_0\NN|in|. (r_nsubj) resulted_11\VBD|NONE (l_prep) in_12\IN|.|Pretreatment (l_pobj) reduction_14\NN|NONE (l_appos) nephrotoxicity_25\NN|marked|of
C026729_D007674 NONE PAP_24\NNP|not|nephrotoxicity (r_compound) nephrotoxicity_25\NN|marked|of (l_nmod) nephrotoxicity_21\NN|not|PAP
C026729_D007674 NONE PAP_24\NNP|not|nephrotoxicity (r_compound) nephrotoxicity_25\NN|marked|of
C002887_D007674 NONE phosphate_18\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) effect_12\NN|in|The|.|:|of (r_appos) role_1\NN|NONE (l_prep) in_6\IN|effect|The|.|:|of (l_pobj) nephrotoxicity_10\NN|NONE
C002887_D007674 NONE phosphate_18\NN|NONE (l_conj) nephrotoxicity_25\NN|on|)|nitrophenyl|and
C002887_D007674 NONE phosphate_9\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effect_3\NN|Therefore|.|,|was (l_prep) on_18\IN|of|the (l_pobj) APAP_19\NNP|NONE (l_conj) nephrotoxicity_22\NN|and
C002887_D007674 NONE BNPP_11\NNP|,|inhibitor|nitrophenyl|, (r_appos) phosphate_9\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effect_3\NN|Therefore|.|,|was (l_prep) on_18\IN|of|the (l_pobj) APAP_19\NNP|NONE (l_conj) nephrotoxicity_22\NN|and
C002887_D007674 NONE BNPP_4\NNP|NONE (r_pobj) with_3\IN|NONE (r_prep) animals_2\NNS|NONE (r_pobj) of_1\IN|prior (r_prep) Pretreatment_0\NN|in|. (r_nsubj) resulted_11\VBD|NONE (l_prep) in_12\IN|.|Pretreatment (l_pobj) reduction_14\NN|NONE (l_appos) nephrotoxicity_25\NN|marked|of (l_nmod) nephrotoxicity_21\NN|not|PAP
C002887_D007674 NONE BNPP_4\NNP|NONE (r_pobj) with_3\IN|NONE (r_prep) animals_2\NNS|NONE (r_pobj) of_1\IN|prior (r_prep) Pretreatment_0\NN|in|. (r_nsubj) resulted_11\VBD|NONE (l_prep) in_12\IN|.|Pretreatment (l_pobj) reduction_14\NN|NONE (l_appos) nephrotoxicity_25\NN|marked|of
C002887_D007674 NONE BNPP_3\NNP| (r_npadvmod) induced_5\VBN|in|the (r_amod) reduction_6\NN|Therefore|,|be|. (l_prep) in_7\IN|the|induced (l_pobj) nephrotoxicity_11\NN|NONE
6299641
D007545_D013610 CID isoproterenol_28\NN| (r_npadvmod) induced_30\VBN|NONE (r_amod) tachycardia_31\NN|both|in|and
D007545_D013610 CID isoproterenol_3\NN|NONE (r_compound) tachycardia_4\NNS|NONE
D007545_D013610 CID isoproterenol_29\NN||whereas|blocked|remains (r_nsubj) activates_30\VBZ|data|,|.|consistent (r_advcl) are_2\VBP|NONE (l_acomp) consistent_3\JJ|activates|data|,|. (l_prep) with_4\IN|NONE (l_pobj) hypothesis_6\NN|NONE (l_relcl) results_12\NNS|the (l_nsubj) tachycardia_11\NN|from|largely|that
D001262_D013610 NONE atenolol_10\NN|NONE (r_pobj) of_7\IN|single (r_prep) doses_6\NNS|NONE (r_pobj) of_4\IN|the (r_prep) effects_3\NNS|We (r_dobj) compared_1\VBD|mg|,|placebo|(|)|nonselective|and|.|, (r_ccomp) propranolol_17\NN|NONE (l_conj) placebo_23\NN|mg|,|(|)|nonselective|and|.|compared|, (l_prep) on_24\IN|NONE (l_pobj) exercise-_26\JJ|NONE (l_conj) tachycardia_31\NN|both|in|and
D011433_D013610 NONE propranolol_17\NN|NONE (l_conj) placebo_23\NN|mg|,|(|)|nonselective|and|.|compared|, (l_prep) on_24\IN|NONE (l_pobj) exercise-_26\JJ|NONE (l_conj) tachycardia_31\NN|both|in|and
D001285_D013610 NONE atropine_10\NN|NONE (r_pobj) after_9\IN|mg/kg (r_prep) IV_14\NNP|and (r_conj) before_7\RB|.|were|effects|) (r_prep) determined_6\VBN|NONE (l_nsubjpass) effects_1\NNS|.|before|were|) (l_prep) on_2\IN|The (l_pobj) tachycardia_4\NNS|NONE
24132704
D003976_D006949 CID diazinon_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) hyperlipemia_10\NN|ERK|and
D003976_D006949 CID diazinon_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hyperlipemia_13\NN|NONE
C029036_D006949 NONE Crocin_0\NNS|levels|.|inhibition|and (r_nsubj) reduced_1\VBD|NONE (l_dobj) inhibition_2\NN|levels|.|Crocin|and (l_prep) of_3\IN|NONE (l_pobj) activation_5\NN|NONE (l_conj) hyperlipemia_10\NN|ERK|and
C029036_D006949 NONE Crocin_0\NNS|may|through|.|as|be (r_nsubjpass) considered_3\VBN|NONE (l_prep) as_4\IN|may|through|.|be|Crocin (l_pobj) agent_8\NN|NONE (l_prep) in_9\IN|a|protective|novel (l_pobj) hyperlipemia_13\NN|NONE
6321816
D003900_D006973 CID DOCA_9\NNP| (r_compound) salt_11\NN|NONE (r_compound) hypertension_12\NN|NONE
D003900_D006973 CID DOCA_33\NNP| (r_compound) salt_35\NN|NONE (r_compound) treatment_36\NN|NONE (r_pobj) after_32\IN|not|elevation|substantial|since (r_prep) was_20\VBD|.|Vasopressin|role|,|in (r_advcl) plays_1\VBZ|NONE (l_prep) in_5\IN|.|Vasopressin|role|,|was (l_pobj) pathogenesis_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) hypertension_12\NN|NONE
D008094_D003919 CID lithium_27\NN| (r_npadvmod) treated_29\VBN|NONE (r_amod) diabetes_30\NN|NONE (r_compound) insipidus_31\NN|NONE
D008094_D006973 NONE lithium_27\NN| (r_npadvmod) treated_29\VBN|NONE (r_amod) diabetes_30\NN|NONE (r_compound) insipidus_31\NN|NONE (r_pobj) with_26\IN|the (r_prep) rats_25\NNS|NONE (r_pobj) in_23\IN|NONE (r_prep) substantial_22\JJ|after|not|elevation|since (r_acomp) was_20\VBD|.|Vasopressin|role|,|in (r_advcl) plays_1\VBZ|NONE (l_prep) in_5\IN|.|Vasopressin|role|,|was (l_pobj) pathogenesis_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) hypertension_12\NN|NONE
D014667_D003919 NONE Vasopressin_0\NNP|.|role|,|was|in (r_nsubj) plays_1\VBZ|NONE (l_advcl) was_20\VBD|.|Vasopressin|role|,|in (l_acomp) substantial_22\JJ|after|not|elevation|since (l_prep) in_23\IN|NONE (l_pobj) rats_25\NNS|NONE (l_prep) with_26\IN|the (l_pobj) insipidus_31\NN|NONE
D014667_D006973 NONE Vasopressin_0\NNP|NONE (l_prep) as_1\IN|. (l_pobj) contributor_4\NN|NONE (l_prep) to_5\IN|possible|a (l_pobj) hypertension_6\NN|NONE
D014667_D006973 NONE vasopressin_3\NN|NONE (r_pobj) of_2\IN|as|The (r_prep) role_1\NN|.|was (l_prep) as_4\IN|The|of (l_pobj) agent_7\NN|NONE (l_prep) to_8\IN|a|pressor (l_pobj) process_11\NN|NONE (l_amod) hypertensive_10\JJ|the
D014667_D006973 NONE Vasopressin_0\NNP|.|role|,|was|in (r_nsubj) plays_1\VBZ|NONE (l_prep) in_5\IN|.|Vasopressin|role|,|was (l_pobj) pathogenesis_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) hypertension_12\NN|NONE
D014667_D006973 NONE vasopressin_6\NN|NONE (r_pobj) of_5\IN|the|pressor (r_prep) action_4\NN|.|,|observed|,|be|Furthermore (r_nsubj) appears_7\VBZ|NONE (l_xcomp) be_9\VB|.|,|observed|action|,|Furthermore (l_prep) in_11\IN|important|to (l_pobj) development_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) model_16\NN|NONE (l_prep) of_17\IN|this (l_pobj) hypertension_18\NN|NONE
D014667_D006973 NONE vasopressin_6\NN|NONE (r_pobj) of_5\IN|the|pressor (r_prep) action_4\NN|.|,|observed|,|be|Furthermore (r_nsubj) appears_7\VBZ|NONE (l_advcl) observed_29\VBN|.|,|action|,|be|Furthermore (l_prep) in_30\IN|since|responsiveness|was (l_pobj) stage_33\NN|NONE (l_prep) of_34\IN|the|initial (l_pobj) hypertension_35\NN|NONE
D014667_D006973 NONE vasopressin_3\NN|NONE (r_pobj) of_2\IN|Increased|from (r_prep) secretion_1\NN|also|.|function (r_nsubj) promotes_7\VBZ|NONE (l_dobj) function_9\NN|also|.|secretion (l_prep) as_13\IN|of|the (l_pobj) factor_16\NN|NONE (l_prep) in_17\IN|a|pathogenetic (l_pobj) hypertension_18\NN|NONE
D014667_D006973 NONE vasopressin_5\NN|NONE (r_pobj) of_4\IN|the (r_prep) role_3\NN|However|,|.|determined (r_nsubj) remains_6\VBZ|NONE (l_xcomp) determined_9\VBN|However|,|role|. (l_prep) in_10\IN|to|be (l_pobj) hypertension_13\NN|NONE
D003900_D003919 NONE DOCA_9\NNP| (r_compound) salt_11\NN|NONE (r_compound) hypertension_12\NN|NONE (r_pobj) of_8\IN|the (r_prep) pathogenesis_7\NN|NONE (r_pobj) in_5\IN|.|Vasopressin|role|,|was (r_prep) plays_1\VBZ|NONE (l_advcl) was_20\VBD|.|Vasopressin|role|,|in (l_acomp) substantial_22\JJ|after|not|elevation|since (l_prep) in_23\IN|NONE (l_pobj) rats_25\NNS|NONE (l_prep) with_26\IN|the (l_pobj) insipidus_31\NN|NONE
D003900_D003919 NONE DOCA_33\NNP| (r_compound) salt_35\NN|NONE (r_compound) treatment_36\NN|NONE (r_pobj) after_32\IN|not|elevation|substantial|since (r_prep) was_20\VBD|.|Vasopressin|role|,|in (l_acomp) substantial_22\JJ|after|not|elevation|since (l_prep) in_23\IN|NONE (l_pobj) rats_25\NNS|NONE (l_prep) with_26\IN|the (l_pobj) insipidus_31\NN|NONE
6884395
D003276_D000784 CID contraceptives_19\NNS|and|, (r_conj) smoke_15\NN|, (r_conj) hypertension_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) association_11\NN|NONE (r_pobj) in_10\IN|basilar|the (r_prep) artery_9\NN|NONE (r_pobj) of_6\IN|dissecting (r_prep) aneurysm_5\NN|NONE
D003276_D011782 NONE contraceptives_19\NNS|and|, (r_conj) smoke_15\NN|, (r_conj) hypertension_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) association_11\NN|NONE (r_pobj) in_10\IN|basilar|the (r_prep) artery_9\NN|NONE (r_pobj) of_6\IN|dissecting (r_prep) aneurysm_5\NN|NONE (r_pobj) of_2\IN|A (r_prep) case_1\NN|in|.|is (r_nsubjpass) reported_21\VBN|NONE (l_prep) in_22\IN|.|is|case (l_pobj) patient_26\NN|NONE (l_prep) with_27\IN|young|a|female (l_pobj) syndrome_32\NN|NONE
D003276_D006973 NONE contraceptives_19\NNS|and|, (r_conj) smoke_15\NN|, (r_conj) hypertension_13\NN|NONE
24739405
D006220_D006948 NONE haloperidol_23\NN|used (r_nsubj) induced_29\VBD|climbing|and|, (r_conj) induced_19\VBN|sc|Amphetamine|)|.|locomotion (r_conj) induced_6\VBD|NONE (l_dobj) locomotion_8\NN|sc|Amphetamine|)|.|induced (l_amod) hyper_7\JJ|,|apomorphine
D001058_D002375 NONE apomorphine_10\NN|,|hyper (r_conj) locomotion_8\NN|sc|Amphetamine|)|.|induced (r_dobj) induced_6\VBD|NONE (l_conj) induced_19\VBN|sc|Amphetamine|)|.|locomotion (l_conj) induced_29\VBD|climbing|and|, (l_ccomp) used_33\VBN|haloperidol (l_nsubjpass) tests_31\NNS|as|were (l_compound) catalepsy_30\NN|NONE
D001058_D012559 CID apomorphine_10\NN|,|hyper (r_conj) locomotion_8\NN|sc|Amphetamine|)|.|induced (r_dobj) induced_6\VBD|NONE (l_conj) induced_19\VBN|sc|Amphetamine|)|.|locomotion (l_conj) induced_29\VBD|climbing|and|, (l_ccomp) used_33\VBN|haloperidol (l_prep) as_34\IN|tests|were (l_pobj) models_36\NNS|NONE (l_prep) of_37\IN|animal (l_pobj) schizophrenia_38\NN|NONE
D000661_D002375 NONE Amphetamine_0\NN|sc|)|.|locomotion|induced (r_nsubj) induced_6\VBD|NONE (l_conj) induced_19\VBN|sc|Amphetamine|)|.|locomotion (l_conj) induced_29\VBD|climbing|and|, (l_ccomp) used_33\VBN|haloperidol (l_nsubjpass) tests_31\NNS|as|were (l_compound) catalepsy_30\NN|NONE
D006220_D002375 CID haloperidol_23\NN|used (r_nsubj) induced_29\VBD|climbing|and|, (l_ccomp) used_33\VBN|haloperidol (l_nsubjpass) tests_31\NNS|as|were (l_compound) catalepsy_30\NN|NONE
D006220_D002375 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|the|)|p<.|(|catalepsy (r_amod) test_13\NN|NONE (l_compound) catalepsy_12\NN|the|)|p<.|(|induced
D000661_D006948 NONE Amphetamine_0\NN|sc|)|.|locomotion|induced (r_nsubj) induced_6\VBD|NONE (l_dobj) locomotion_8\NN|sc|Amphetamine|)|.|induced (l_amod) hyper_7\JJ|,|apomorphine
D001058_D006948 NONE apomorphine_10\NN|,|hyper (r_conj) locomotion_8\NN|sc|Amphetamine|)|.|induced (l_amod) hyper_7\JJ|,|apomorphine
D000661_D012559 CID amphetamine_4\NN| (r_npadvmod) induced_6\VBN|schizophrenia|in (r_amod) models_8\NNS|NONE (l_compound) schizophrenia_7\NN|induced|in
D000661_D012559 CID Amphetamine_0\NN|sc|)|.|locomotion|induced (r_nsubj) induced_6\VBD|NONE (l_conj) induced_19\VBN|sc|Amphetamine|)|.|locomotion (l_conj) induced_29\VBD|climbing|and|, (l_ccomp) used_33\VBN|haloperidol (l_prep) as_34\IN|tests|were (l_pobj) models_36\NNS|NONE (l_prep) of_37\IN|animal (l_pobj) schizophrenia_38\NN|NONE
D006220_D012559 CID haloperidol_23\NN|used (r_nsubj) induced_29\VBD|climbing|and|, (l_ccomp) used_33\VBN|haloperidol (l_prep) as_34\IN|tests|were (l_pobj) models_36\NNS|NONE (l_prep) of_37\IN|animal (l_pobj) schizophrenia_38\NN|NONE
D003687_D002375 NONE DHEA_3\NNP|catalepsy|and|reduced|locomotor (r_nsubj) activity_6\NN|We|.|had|,|that (l_conj) catalepsy_9\NN|and|reduced|DHEA|locomotor
D003687_D012559 NONE dehydroepiandrosterone_2\NN|NONE (l_prep) in_3\IN|NONE (l_pobj) models_8\NNS|NONE (l_compound) schizophrenia_7\NN|induced|in
D003687_D012559 NONE dehydroepiandrosterone_5\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effects_3\NNS|To|. (l_prep) on_9\IN|of|the (l_pobj) models_11\NNS|NONE (l_prep) of_12\IN|animal (l_pobj) schizophrenia_13\NN|NONE
D003687_D012559 NONE DHEA_7\NNP|NONE (r_appos) dehydroepiandrosterone_5\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effects_3\NNS|To|. (l_prep) on_9\IN|of|the (l_pobj) models_11\NNS|NONE (l_prep) of_12\IN|animal (l_pobj) schizophrenia_13\NN|NONE
D003687_D012559 NONE DHEA_3\NNP|,|effects|that|used|and (r_nsubj) displays_4\VBZ|We|. (l_conj) used_14\VBN|DHEA|,|effects|that|and (l_prep) in_15\IN|may|be (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) schizophrenia_19\NN|NONE
23871786
C006780_D001008 CID A_4\DT|NONE (r_pobj) to_2\IN|Pubertal (r_prep) exposure_1\NN|and|.|decreases|behavior (r_nsubj) increases_5\VBZ|NONE (l_dobj) behavior_9\NN|and|.|decreases|exposure (l_amod) like_8\JJ|NONE (l_npadvmod) anxiety_6\NN|
C006780_D001008 CID BPA_17\NNP|NONE (r_pobj) to_16\IN|NONE (r_prep) exposed_15\VBN|NONE (r_acl) mice_14\NNS|NONE (r_pobj) in_13\IN|was|behavior|that (r_prep) increased_12\VBN|Results|. (l_nsubjpass) behavior_10\NN|was|in|that (l_amod) like_9\JJ|NONE (l_npadvmod) anxiety_7\NN|
C006780_D001008 CID BPA_5\NNP|pubertal (r_compound) exposure_6\NN|that|behavior (r_nsubj) increased_7\VBN|findings|. (l_dobj) behavior_11\NN|that|exposure (l_amod) like_10\JJ|,|associated (l_npadvmod) anxiety_8\NN|NONE
12699527
D002712_-1 NONE chloride_14\NN|NONE (r_compound) channel_15\NN|muscle|the|, (r_compound) function_16\NN|NONE (r_pobj) in_10\IN|a|cause (r_prep) defect_9\NN|NONE (l_relcl) cause_20\VB|a|in (l_dobj) depolarisation_23\NN|may|which
D002712_D009224 NONE chloride_14\NN|NONE (r_compound) channel_15\NN|muscle|the|, (r_compound) function_16\NN|NONE (r_pobj) in_10\IN|a|cause (r_prep) defect_9\NN|NONE (r_pobj) by_7\IN|is|congenita|. (r_agent) caused_6\VBN|NONE (l_nsubjpass) congenita_1\NN|is|.|by
D002712_D009224 NONE chloride_14\NN|NONE (r_compound) channel_15\NN|muscle|the|, (r_compound) function_16\NN|NONE (r_pobj) in_10\IN|a|cause (r_prep) defect_9\NN|NONE (r_pobj) by_7\IN|is|congenita|. (r_agent) caused_6\VBN|NONE (l_nsubjpass) congenita_1\NN|is|.|by (l_appos) MC_3\NNP|(|)|Myotonia
D013390_D013035 CID suxamethonium_26\NN|NONE (r_pobj) of_25\IN|preoperative|a (r_prep) injection_24\NN|NONE (r_pobj) following_21\VBG|spasm|who (r_prep) developed_10\VBD|a|healthy|old (l_dobj) spasm_16\NN|following|who
7315949
D009638_D013035 CID norepinephrine_9\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|in|Medial|. (r_acl) changes_1\NNS|NONE (l_prep) in_2\IN|induced|Medial|. (l_pobj) spasm_4\NN|NONE
D009638_D006547 NONE norepinephrine_17\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|NONE (r_acl) vasoconstriction_12\NN|within|hernias|In|,|. (r_nsubj) produced_18\VBD|NONE (l_dobj) hernias_25\NNS|within|In|,|.|vasoconstriction
3439580
D007099_D009447 NONE imipramine_5\NN|NONE (r_pobj) by_4\IN|.|Hypertension (r_prep) induced_3\VBN|NONE (l_nsubj) Hypertension_0\NN|.|by (l_prep) in_1\IN|NONE (l_pobj) neuroblastoma_2\NN|NONE
D007099_D009447 NONE Imipramine_23\NNP|control|who|was (r_dobj) given_22\VBN|NONE (r_relcl) neuroblastoma_19\NN|NONE
D007099_D002653 NONE Imipramine_23\NNP|control|who|was (r_dobj) given_22\VBN|NONE (l_advcl) control_25\VB|who|was|Imipramine (l_dobj) disorder_28\NN|to
D007099_D006973 CID imipramine_5\NN|NONE (r_pobj) by_4\IN|.|Hypertension (r_prep) induced_3\VBN|NONE (l_nsubj) Hypertension_0\NN|.|by
D007099_D006973 CID Imipramine_23\NNP|control|who|was (r_dobj) given_22\VBN|NONE (r_relcl) neuroblastoma_19\NN|NONE (r_pobj) with_18\IN|old|a (r_prep) girl_17\NN|NONE (r_pobj) in_12\IN|/|)|blood|( (r_prep) pressure_9\NN|severe (r_appos) hypertension_6\NN|NONE
D007099_D006973 CID Imipramine_16\NNP|NONE (r_pobj) of_14\IN|NONE (r_prep) discontinuation_13\NN|NONE (r_dobj) following_12\VBG|)|was|( (r_acl) none_11\NN|pressure|and|at|no (r_conj) elevation_6\NN|she|Since (r_dobj) had_2\VBD|caused|,|.|we (r_advcl) believe_27\VBP|NONE (l_ccomp) caused_37\VBD|had|,|.|we (l_dobj) hypertension_39\NN|that|drug
17151160
D018967_D011618 NONE risperidone_58\NN|)|(|day|with|or|to (r_conj) treatment_46\NN|were|,|disorder|randomly (r_xcomp) assigned_44\VBN|)|with|years|subjects|. (l_nsubjpass) disorder_29\NN|were|treatment|,|randomly
D018967_D011618 NONE risperidone_58\NN|)|(|day|with|or|to (r_conj) treatment_46\NN|were|,|disorder|randomly (r_xcomp) assigned_44\VBN|)|with|years|subjects|. (l_nsubjpass) disorder_29\NN|were|treatment|,|randomly (l_conj) disorder_37\NN|%|schizophreniform|)|or|,|(
D018967_D015430 CID risperidone_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) than_7\IN|gain|was|:|with (r_prep) occurred_4\VBD|NONE (l_nsubj) gain_3\NN|was|:|with|than
D018967_D015430 CID risperidone_43\NN|NONE (r_pobj) with_42\IN|(|)|.|% (r_prep) %_35\NN|and (r_conj) olanzapine_32\NN|NONE (r_pobj) with_31\IN|.|%|( (r_prep) %_24\NN|increase|. (r_attr) was_22\VBD|gain|:|with|than (r_conj) occurred_4\VBD|NONE (l_nsubj) gain_3\NN|was|:|with|than
D018967_D001480 CID risperidone_28\NN|NONE (r_pobj) with_27\IN|.|.|differ|) (r_prep) were_18\VBD|NONE (l_ccomp) differ_11\VB|.|with|.|) (l_prep) between_12\IN|did|not|outcomes (l_pobj) scores_17\NNS|NONE (l_compound) symptom_15\NN|severity|Extrapyramidal
C076029_D012559 NONE olanzapine_3\NN|NONE (l_prep) versus_4\IN|NONE (l_pobj) risperidone_5\NN|NONE (l_prep) for_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) schizophrenia_13\NN|NONE
C076029_D012559 NONE olanzapine_9\NN|NONE (l_prep) versus_10\IN|NONE (l_pobj) risperidone_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) disorders_20\NNS|NONE (l_compound) schizophrenia_18\NN|episode|spectrum
C076029_D012559 NONE olanzapine_48\NN|NONE (r_pobj) with_47\IN|risperidone|)|(|day|or|to (r_prep) treatment_46\NN|were|,|disorder|randomly (r_xcomp) assigned_44\VBN|)|with|years|subjects|. (r_conj) mean_9\JJ|NONE (l_prep) with_18\IN|)|assigned|years|subjects|. (l_pobj) schizophrenia_22\NN|NONE
C076029_D001480 CID olanzapine_39\NN|NONE (r_pobj) with_38\IN|and|%|CI=.|) (r_prep) risperidone_28\NN|NONE (r_pobj) with_27\IN|.|.|differ|) (r_prep) were_18\VBD|NONE (l_ccomp) differ_11\VB|.|with|.|) (l_prep) between_12\IN|did|not|outcomes (l_pobj) scores_17\NNS|NONE (l_compound) symptom_15\NN|severity|Extrapyramidal
D018967_D012559 NONE risperidone_5\NN|NONE (l_prep) for_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) schizophrenia_13\NN|NONE
D018967_D012559 NONE risperidone_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) disorders_20\NNS|NONE (l_compound) schizophrenia_18\NN|episode|spectrum
D018967_D012559 NONE risperidone_58\NN|)|(|day|with|or|to (r_conj) treatment_46\NN|were|,|disorder|randomly (r_xcomp) assigned_44\VBN|)|with|years|subjects|. (r_conj) mean_9\JJ|NONE (l_prep) with_18\IN|)|assigned|years|subjects|. (l_pobj) schizophrenia_22\NN|NONE
C076029_D015430 CID olanzapine_6\NN|NONE (r_pobj) with_5\IN|gain|was|:|than (r_prep) occurred_4\VBD|NONE (l_nsubj) gain_3\NN|was|:|with|than
C076029_D015430 CID olanzapine_32\NN|NONE (r_pobj) with_31\IN|.|%|( (r_prep) %_24\NN|increase|. (r_attr) was_22\VBD|gain|:|with|than (r_conj) occurred_4\VBD|NONE (l_nsubj) gain_3\NN|was|:|with|than
C076029_D015430 CID olanzapine_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) greater_12\JJR|.|gain (r_acomp) was_11\VBD|medications|but|gain|, (r_conj) caused_2\VBD|NONE (l_dobj) gain_6\NN|medications|but|,|was
C076029_D015430 CID olanzapine_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) greater_12\JJR|.|gain (r_acomp) was_11\VBD|medications|but|gain|, (l_nsubj) gain_10\NN|.|greater
C076029_D011618 NONE olanzapine_48\NN|NONE (r_pobj) with_47\IN|risperidone|)|(|day|or|to (r_prep) treatment_46\NN|were|,|disorder|randomly (r_xcomp) assigned_44\VBN|)|with|years|subjects|. (l_nsubjpass) disorder_29\NN|were|treatment|,|randomly
C076029_D011618 NONE olanzapine_48\NN|NONE (r_pobj) with_47\IN|risperidone|)|(|day|or|to (r_prep) treatment_46\NN|were|,|disorder|randomly (r_xcomp) assigned_44\VBN|)|with|years|subjects|. (l_nsubjpass) disorder_29\NN|were|treatment|,|randomly (l_conj) disorder_37\NN|%|schizophreniform|)|or|,|(
C076029_D017109 NONE olanzapine_39\NN|NONE (r_pobj) with_38\IN|and|%|CI=.|) (r_prep) risperidone_28\NN|NONE (r_pobj) with_27\IN|.|.|differ|) (r_prep) were_18\VBD|NONE (l_ccomp) differ_11\VB|.|with|.|) (l_nsubj) outcomes_2\NNS|did|not|between (l_conj) akathisia_8\NN|and|symptom|measures|Negative|and
C076029_D010302 NONE olanzapine_39\NN|NONE (r_pobj) with_38\IN|and|%|CI=.|) (r_prep) risperidone_28\NN|NONE (r_pobj) with_27\IN|.|.|differ|) (r_prep) were_18\VBD|NONE (l_ccomp) differ_11\VB|.|with|.|) (l_nsubj) outcomes_2\NNS|did|not|between (l_conj) measures_4\NNS|and|akathisia|symptom|Negative|and (l_prep) of_5\IN|NONE (l_pobj) parkinsonism_6\NN|NONE
D018967_D017109 NONE risperidone_28\NN|NONE (r_pobj) with_27\IN|.|.|differ|) (r_prep) were_18\VBD|NONE (l_ccomp) differ_11\VB|.|with|.|) (l_nsubj) outcomes_2\NNS|did|not|between (l_conj) akathisia_8\NN|and|symptom|measures|Negative|and
D018967_D010302 NONE risperidone_28\NN|NONE (r_pobj) with_27\IN|.|.|differ|) (r_prep) were_18\VBD|NONE (l_ccomp) differ_11\VB|.|with|.|) (l_nsubj) outcomes_2\NNS|did|not|between (l_conj) measures_4\NNS|and|akathisia|symptom|Negative|and (l_prep) of_5\IN|NONE (l_pobj) parkinsonism_6\NN|NONE
439781
D012964_D007022 NONE sodium_4\NN|NONE (r_npadvmod) depleted_7\VBN|NONE (r_amod) rats_8\NNS|hypotension|Indomethacin|. (r_dobj) induced_1\VBD|NONE (l_dobj) hypotension_2\NN|Indomethacin|.|rats
D007213_D007022 CID Indomethacin_0\NNP|hypotension|.|rats (r_nsubj) induced_1\VBD|NONE (l_dobj) hypotension_2\NN|Indomethacin|.|rats
19419794
C005177_D004409 NONE DOPA+benserazide_4\NNP|NONE (r_pobj) with_1\IN|) (r_prep) Treatment_0\NN|.|in (r_nsubj) resulted_9\VBD|NONE (l_prep) in_10\IN|Treatment|. (l_pobj) dyskinesias_13\NNS|NONE
D016627_D004409 NONE 6-hydroxydopamine_3\CD|and|development (r_compound) lesion_4\NN|NONE (l_conj) development_7\NN|and|hydroxydopamine (l_prep) of_8\IN|reduced|in (l_pobj) dyskinesias_9\NNS|NONE
D007980_D004409 CID DOPA_24\NNP||L| (r_compound) induced_26\VBN|NONE (r_amod) dyskinesias_27\NNS|NONE
D007980_D004409 CID DOPA_19\NNP|L|| (r_compound) induced_21\VBN|NONE (r_amod) dyskinesias_22\NNS|NONE
D004298_D004409 NONE DA_17\NNP|NONE (r_compound) lesion_18\NN|motor|and (r_conj) impairment_15\NN|NONE (r_pobj) of_13\IN|the (r_prep) severity_12\NN|,|reduced|and|that|lack (r_dobj) increased_10\VBD|.|results (l_conj) reduced_21\VBN|,|and|severity|that|lack (l_dobj) dyskinesias_27\NNS|NONE
23864035
C400082_D009101 NONE Bortezomib_0\NNP|NONE (l_conj) dexamethasone_2\NN|.|and (l_prep) in_6\IN|as (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) myeloma_13\NN|NONE
C400082_D009101 NONE Bortezomib_0\NNP|.|therapy (r_nsubj) is_6\VBZ|NONE (l_attr) therapy_9\NN|.|Bortezomib (l_prep) for_10\IN|an|effective (l_pobj) R_17\NNP|NONE (l_appos) myeloma_20\NN|relapsed|)|/|R|(|refractory|/
C400082_D009101 NONE Bortezomib_0\NNP|.|therapy (r_nsubj) is_6\VBZ|NONE (l_attr) therapy_9\NN|.|Bortezomib (l_prep) for_10\IN|an|effective (l_pobj) R_17\NNP|NONE (l_appos) myeloma_20\NN|relapsed|)|/|R|(|refractory|/ (l_appos) MM_22\NNP|)|multiple
C400082_D009101 NONE bort)-dexamethasone_2\NNP|(|(|) (r_nmod) dex_4\NN|NONE (r_appos) Bortezomib_0\NNP|.|therapy (r_nsubj) is_6\VBZ|NONE (l_attr) therapy_9\NN|.|Bortezomib (l_prep) for_10\IN|an|effective (l_pobj) R_17\NNP|NONE (l_appos) myeloma_20\NN|relapsed|)|/|R|(|refractory|/
C400082_D009101 NONE bort)-dexamethasone_2\NNP|(|(|) (r_nmod) dex_4\NN|NONE (r_appos) Bortezomib_0\NNP|.|therapy (r_nsubj) is_6\VBZ|NONE (l_attr) therapy_9\NN|.|Bortezomib (l_prep) for_10\IN|an|effective (l_pobj) R_17\NNP|NONE (l_appos) myeloma_20\NN|relapsed|)|/|R|(|refractory|/ (l_appos) MM_22\NNP|)|multiple
C400082_D009101 NONE bort_7\NN|NONE (r_pobj) of_6\IN|m(|)|the|on|( (r_prep) combination_5\NN|and|)|.|after|dex|study (r_dobj) investigated_3\VBD|NONE (l_conj) dex_29\NN|combination|and|)|.|after|study (l_prep) as_43\IN|(|mg|)|day|and (l_pobj) treatment_45\NN|NONE (l_prep) in_46\IN|salvage (l_pobj) patients_48\NNS|NONE (l_prep) with_49\IN| (l_pobj) MM_53\NNP|NONE
C400082_D009101 NONE bort_41\NN|NONE (r_pobj) after_40\IN|the (r_prep) day_39\NN|(|mg|)|and|as (r_conj) dex_29\NN|combination|and|)|.|after|study (l_prep) as_43\IN|(|mg|)|day|and (l_pobj) treatment_45\NN|NONE (l_prep) in_46\IN|salvage (l_pobj) patients_48\NNS|NONE (l_prep) with_49\IN| (l_pobj) MM_53\NNP|NONE
C400082_D009101 NONE Bort_0\NNP| (r_compound) dex_2\NN|.|treatment (r_nsubj) was_3\VBD|NONE (l_attr) treatment_7\NN|dex|. (l_prep) for_8\IN|effective|an|for|salvage|, (l_pobj) patients_10\NNS|NONE (l_compound) MM_9\NNP|NONE
D003907_D009101 NONE dexamethasone_2\NN|.|and (l_prep) in_6\IN|as (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) myeloma_13\NN|NONE
D003907_D009101 NONE bort)-dexamethasone_2\NNP|(|(|) (r_nmod) dex_4\NN|NONE (r_appos) Bortezomib_0\NNP|.|therapy (r_nsubj) is_6\VBZ|NONE (l_attr) therapy_9\NN|.|Bortezomib (l_prep) for_10\IN|an|effective (l_pobj) R_17\NNP|NONE (l_appos) myeloma_20\NN|relapsed|)|/|R|(|refractory|/
D003907_D009101 NONE bort)-dexamethasone_2\NNP|(|(|) (r_nmod) dex_4\NN|NONE (r_appos) Bortezomib_0\NNP|.|therapy (r_nsubj) is_6\VBZ|NONE (l_attr) therapy_9\NN|.|Bortezomib (l_prep) for_10\IN|an|effective (l_pobj) R_17\NNP|NONE (l_appos) myeloma_20\NN|relapsed|)|/|R|(|refractory|/ (l_appos) MM_22\NNP|)|multiple
D003907_D009101 NONE dex_4\NN|NONE (r_appos) Bortezomib_0\NNP|.|therapy (r_nsubj) is_6\VBZ|NONE (l_attr) therapy_9\NN|.|Bortezomib (l_prep) for_10\IN|an|effective (l_pobj) R_17\NNP|NONE (l_appos) myeloma_20\NN|relapsed|)|/|R|(|refractory|/
D003907_D009101 NONE dex_4\NN|NONE (r_appos) Bortezomib_0\NNP|.|therapy (r_nsubj) is_6\VBZ|NONE (l_attr) therapy_9\NN|.|Bortezomib (l_prep) for_10\IN|an|effective (l_pobj) R_17\NNP|NONE (l_appos) myeloma_20\NN|relapsed|)|/|R|(|refractory|/ (l_appos) MM_22\NNP|)|multiple
D003907_D009101 NONE dex_29\NN|combination|and|)|.|after|study (l_prep) as_43\IN|(|mg|)|day|and (l_pobj) treatment_45\NN|NONE (l_prep) in_46\IN|salvage (l_pobj) patients_48\NNS|NONE (l_prep) with_49\IN| (l_pobj) MM_53\NNP|NONE
D003907_D009101 NONE dex_2\NN|.|treatment (r_nsubj) was_3\VBD|NONE (l_attr) treatment_7\NN|dex|. (l_prep) for_8\IN|effective|an|for|salvage|, (l_pobj) patients_10\NNS|NONE (l_compound) MM_9\NNP|NONE
7931490
D017829_D009325 NONE granisetron_4\NN|NONE (r_pobj) of_3\IN|and|in|antagonist|.|safety|,|, (r_prep) Efficacy_0\NN|NONE (l_prep) in_12\IN|of|and|antagonist|.|safety|,|, (l_pobj) prevention_14\NN|NONE (l_prep) of_15\IN|vomiting|induced|the|and (l_pobj) nausea_16\NN|NONE
D017829_D009325 NONE granisetron_13\NN|NONE (r_pobj) of_12\IN|Kytril|;|Pharmaceuticals|four|)|(|different (r_prep) doses_11\NNS|NONE (r_pobj) of_8\IN|safety (r_prep) profile_7\NN|the|and|antiemetic (r_conj) effects_4\NNS|.|administered|To (r_dobj) assess_1\VB|NONE (l_advcl) administered_26\VBN|effects|.|To (l_dobj) dose_34\NN|when|as (l_prep) for_35\IN|NONE (l_pobj) prophylaxis_36\NN|NONE (l_prep) of_37\IN|NONE (l_pobj) nausea_41\NN|NONE
D017829_D009325 NONE Kytril_15\NNP|;|Pharmaceuticals|of|four|)|(|different (r_appos) doses_11\NNS|NONE (r_pobj) of_8\IN|safety (r_prep) profile_7\NN|the|and|antiemetic (r_conj) effects_4\NNS|.|administered|To (r_dobj) assess_1\VB|NONE (l_advcl) administered_26\VBN|effects|.|To (l_dobj) dose_34\NN|when|as (l_prep) for_35\IN|NONE (l_pobj) prophylaxis_36\NN|NONE (l_prep) of_37\IN|NONE (l_pobj) nausea_41\NN|NONE
D002945_D009325 CID cisplatin_24\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|of|vomiting|the|and (r_acl) prevention_14\NN|NONE (l_prep) of_15\IN|vomiting|induced|the|and (l_pobj) nausea_16\NN|NONE
D002945_D009325 CID cisplatin_38\NN| (r_advmod) induced_40\VBN|and|vomiting (r_amod) nausea_41\NN|NONE
D012701_D014839 NONE 5-hydroxytryptamine-3_8\CD|a|receptor|selective (r_nummod) antagonist_10\NN|of|and|in|.|safety|,|, (r_appos) Efficacy_0\NN|NONE (l_prep) in_12\IN|of|and|antagonist|.|safety|,|, (l_pobj) prevention_14\NN|NONE (l_conj) vomiting_18\VBG|of|induced|the|and
D017829_D014839 NONE granisetron_4\NN|NONE (r_pobj) of_3\IN|and|in|antagonist|.|safety|,|, (r_prep) Efficacy_0\NN|NONE (l_prep) in_12\IN|of|and|antagonist|.|safety|,|, (l_pobj) prevention_14\NN|NONE (l_conj) vomiting_18\VBG|of|induced|the|and
D017829_D014839 NONE granisetron_13\NN|NONE (r_pobj) of_12\IN|Kytril|;|Pharmaceuticals|four|)|(|different (r_prep) doses_11\NNS|NONE (r_pobj) of_8\IN|safety (r_prep) profile_7\NN|the|and|antiemetic (r_conj) effects_4\NNS|.|administered|To (r_dobj) assess_1\VB|NONE (l_advcl) administered_26\VBN|effects|.|To (l_dobj) dose_34\NN|when|as (l_prep) for_35\IN|NONE (l_pobj) prophylaxis_36\NN|NONE (l_prep) of_37\IN|NONE (l_pobj) nausea_41\NN|NONE (l_conj) vomiting_43\NN|and|induced
D017829_D014839 NONE Kytril_15\NNP|;|Pharmaceuticals|of|four|)|(|different (r_appos) doses_11\NNS|NONE (r_pobj) of_8\IN|safety (r_prep) profile_7\NN|the|and|antiemetic (r_conj) effects_4\NNS|.|administered|To (r_dobj) assess_1\VB|NONE (l_advcl) administered_26\VBN|effects|.|To (l_dobj) dose_34\NN|when|as (l_prep) for_35\IN|NONE (l_pobj) prophylaxis_36\NN|NONE (l_prep) of_37\IN|NONE (l_pobj) nausea_41\NN|NONE (l_conj) vomiting_43\NN|and|induced
D017829_D014839 NONE granisetron_1\NN||of|, (r_compound) doses_2\NNS|NONE (l_appos) 10_6\CD|of|granisetron|, (l_conj) micrograms_12\NNS|,|and| (l_appos) response_18\NN||/|,|kg (l_acl) vomiting_24\NN|a|rescue|major|,|(|and
D017829_D014839 NONE granisetron_1\NN||of|, (r_compound) doses_2\NNS|NONE (r_pobj) After_0\IN|and|was|response|in|. (r_prep) recorded_35\VBN|NONE (l_conj) response_57\NN|and|was|After|in|. (l_appos) vomiting_60\NN|a|)|(|complete|in
D017829_D014839 NONE granisetron_10\NN|NONE (r_pobj) of_9\IN|kg (r_prep) dose_8\NN|,|or (r_conj) 20-_2\CD|, (r_conj) 10-_0\LS|.|effective (r_nsubj) was_11\VBD|NONE (l_acomp) effective_12\JJ|.| (l_prep) in_13\IN|NONE (l_pcomp) controlling_14\VBG|NONE (l_dobj) vomiting_15\NN|NONE
D017829_D014839 NONE granisetron_10\NN|NONE (r_pobj) of_9\IN|kg (r_prep) dose_8\NN|,|or (r_conj) 20-_2\CD|, (r_conj) 10-_0\LS|.|effective (r_nsubj) was_11\VBD|NONE (l_acomp) effective_12\JJ|.| (l_prep) in_13\IN|NONE (l_pcomp) controlling_14\VBG|NONE (l_dobj) vomiting_15\NN|NONE (l_prep) in_16\IN|NONE (l_pobj) %_21\NN|NONE (l_prep) of_22\IN| (l_pobj) patients_23\NNS|NONE (l_relcl) received_25\VBD|NONE (l_conj) prevented_37\VBN|who|cisplatin|at|and (l_dobj) vomiting_38\VBG|to|totally
D002945_D014839 CID cisplatin_24\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|of|vomiting|the|and (r_acl) prevention_14\NN|NONE (l_conj) vomiting_18\VBG|of|induced|the|and
D002945_D014839 CID cisplatin_38\NN| (r_advmod) induced_40\VBN|and|vomiting (r_amod) nausea_41\NN|NONE (l_conj) vomiting_43\NN|and|induced
D002945_D014839 CID cisplatin_26\NN|prevented|who|at|and (r_dobj) received_25\VBD|NONE (r_relcl) patients_23\NNS|NONE (r_pobj) of_22\IN| (r_prep) %_21\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) vomiting_15\NN|NONE
D002945_D014839 CID cisplatin_26\NN|prevented|who|at|and (r_dobj) received_25\VBD|NONE (l_conj) prevented_37\VBN|who|cisplatin|at|and (l_dobj) vomiting_38\VBG|to|totally
D012701_D009325 NONE 5-hydroxytryptamine-3_8\CD|a|receptor|selective (r_nummod) antagonist_10\NN|of|and|in|.|safety|,|, (r_appos) Efficacy_0\NN|NONE (l_prep) in_12\IN|of|and|antagonist|.|safety|,|, (l_pobj) prevention_14\NN|NONE (l_prep) of_15\IN|vomiting|induced|the|and (l_pobj) nausea_16\NN|NONE
931801
D000617_D003681 NONE aminoglycoside_11\NN|NONE (r_compound) antibiotics_12\NNS|NONE (r_pobj) of_10\IN|combined|single (r_prep) injection_9\NN|NONE (r_pobj) following_7\VBG|acute|renal (r_acl) failure_6\NN|.|regularly|rats (r_dobj) develop_3\VBP|NONE (l_nsubj) rats_1\NNS|failure|.|regularly (l_amod) Dehydrated_0\JJ|NONE
D009005_D007674 NONE monosaccharides_12\NNS|NONE (r_pobj) by_11\IN|when|from|were|they (r_agent) spared_7\VBN|urine|.|Rats (l_prep) from_8\IN|when|were|by|they (l_pobj) lesions_10\NNS|NONE
D007612_D051437 NONE kanamycin_21\NN| (r_compound) dextran_23\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|renal (r_acl) failure_18\NN|NONE
D000617_D007674 NONE aminoglycoside_16\NN|peptide|as (r_conj) antibiotics_11\NNS|NONE (r_pobj) by_9\IN|NONE (r_agent) induced_8\VBN|renal (r_acl) damage_7\NN|NONE
C038936_D051437 NONE 6,3-dilactone_13\CD||acetyl|| (r_appos) D_9\NNP|O|against|protected (r_nmod) rats_15\NNS|NONE (l_prep) against_16\IN|O|D|protected (l_pobj) failure_18\NN|NONE
D005937_D007674 NONE Glucarates_4\NNP|NONE (r_pobj) of_1\IN|on|. (r_prep) Effect_0\NN|NONE (l_prep) on_5\IN|of|. (l_pobj) damage_11\NN|NONE
D005937_D007674 NONE Glucarates_2\NNP|.|effective|antibitocis (r_nsubj) were_3\VBD|NONE (l_acomp) effective_4\JJ|Glucarates|.|antibitocis (l_prep) against_5\IN|NONE (l_pobj) damage_7\NN|NONE
D005937_D007674 NONE glucarate_4\NN|NONE (r_pobj) With_0\IN|.|,|against|degree|was (r_prep) obtained_19\VBN|NONE (l_prep) against_20\IN|With|.|,|degree|was (l_pobj) damages_22\NNS|NONE
D005937_D007674 NONE Glucarates_2\NNP|ability|but|cure|. (r_nsubj) had_3\VBD|NONE (l_dobj) ability_5\NN|Glucarates|but|cure|. (l_acl) prevent_7\VB|the (l_dobj) damage_9\NN|to
D005937_D007674 NONE glucarates_6\NNS|NONE (l_prep) against_7\IN||D (l_pobj) nephrotoxicity_8\NN|NONE
D000617_D058186 CID aminoglycoside_11\NN|NONE (r_compound) antibiotics_12\NNS|NONE (r_pobj) of_10\IN|combined|single (r_prep) injection_9\NN|NONE (r_pobj) following_7\VBG|acute|renal (r_acl) failure_6\NN|.|regularly|rats
7967231
D002118_D020195 NONE calcium_11\NN|type (r_compound) channel_12\NN|NONE (r_compound) antagonists_13\NNS|not|,|, (r_conj) S-312-l_6\NNP|S|,|but (r_conj) S-312-d_2\NNP|effects|and|were|; (r_nsubj) showed_15\VBD|NONE (l_dobj) effects_17\NNS|and|were|Sd|; (l_prep) on_18\IN|anticonvulsant (l_pobj) convulsions_22\NNS|NONE
D010852_D012640 CID picrotoxin_49\NN|D|,|methyl| (r_conj) aspartate_47\NNP|NONE (r_pobj) by_40\IN|in (r_agent) induced_39\VBN|NONE (r_acl) convulsions_38\NNS|NONE (r_pobj) in_37\IN|effects|mice|were|,|:|.|observed (r_prep) observed_36\VBN|NONE (l_advcl) observed_10\VBN|effects|mice|were|,|:|.|in (l_prep) against_11\IN|were|effects|Although (l_pobj) convulsions_14\NNS|NONE
D010852_D012640 CID picrotoxin_49\NN|D|,|methyl| (r_conj) aspartate_47\NNP|NONE (r_pobj) by_40\IN|in (r_agent) induced_39\VBN|NONE (r_acl) convulsions_38\NNS|NONE
C059447_D004827 NONE S-312-d_0\NN|may|.|in|useful (r_nsubj) be_2\VB|NONE (l_prep) in_4\IN|Sd|may|.|useful (l_pobj) therapy_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) types_9\NNS|NONE (l_prep) of_10\IN|certain (l_pobj) epilepsy_12\NN|NONE
-1_D020195 NONE S-312-l_6\NNP|S|,|but (r_conj) S-312-d_2\NNP|effects|and|were|; (r_nsubj) showed_15\VBD|NONE (l_dobj) effects_17\NNS|and|were|Sd|; (l_prep) on_18\IN|anticonvulsant (l_pobj) convulsions_22\NNS|NONE
D001534_D012640 CID bemegride_25\NN|mg/kg|or|)|( (r_conj) pentylenetetrazole_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|the|clonic (r_acl) convulsions_14\NNS|NONE
D001534_D012640 CID bemegride_25\NN|mg/kg|or|)|( (r_conj) pentylenetetrazole_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|the|clonic (r_acl) convulsions_14\NNS|NONE (r_pobj) against_11\IN|were|effects|Although (r_prep) observed_10\VBN|effects|mice|were|,|:|.|in (r_advcl) observed_36\VBN|NONE (l_prep) in_37\IN|effects|mice|were|,|:|.|observed (l_pobj) convulsions_38\NNS|NONE
C059447_D012640 NONE S-312-d_5\NN|NONE (r_pobj) of_4\IN|anticonvulsant|moderate (r_prep) effects_3\NNS|were|Although|against (r_nsubjpass) observed_10\VBN|effects|mice|were|,|:|.|in (l_prep) against_11\IN|were|effects|Although (l_pobj) convulsions_14\NNS|NONE
C059447_D012640 NONE S-312-d_5\NN|NONE (r_pobj) of_4\IN|anticonvulsant|moderate (r_prep) effects_3\NNS|were|Although|against (r_nsubjpass) observed_10\VBN|effects|mice|were|,|:|.|in (r_advcl) observed_36\VBN|NONE (l_prep) in_37\IN|effects|mice|were|,|:|.|observed (l_pobj) convulsions_38\NNS|NONE
D005444_D020195 NONE flunarizine_57\NN|NONE (r_pobj) of_56\IN|NONE (r_prep) that_55\DT|.|while (r_nsubj) was_58\VBD|mg/kg|p.o.|,|.|values (r_advcl) were_31\VBD|effects|and|Sd|; (r_conj) showed_15\VBD|NONE (l_dobj) effects_17\NNS|and|were|Sd|; (l_prep) on_18\IN|anticonvulsant (l_pobj) convulsions_22\NNS|NONE
C059447_D020195 NONE S-312_0\NNP|,|Sl|but (r_punct) S-312-d_2\NNP|effects|and|were|; (r_nsubj) showed_15\VBD|NONE (l_dobj) effects_17\NNS|and|were|Sd|; (l_prep) on_18\IN|anticonvulsant (l_pobj) convulsions_22\NNS|NONE
C059447_D020195 NONE S-312-d_2\NNP|effects|and|were|; (r_nsubj) showed_15\VBD|NONE (l_dobj) effects_17\NNS|and|were|Sd|; (l_prep) on_18\IN|anticonvulsant (l_pobj) convulsions_22\NNS|NONE
D010433_D012640 CID pentylenetetrazole_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|the|clonic (r_acl) convulsions_14\NNS|NONE
D010433_D012640 CID pentylenetetrazole_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|the|clonic (r_acl) convulsions_14\NNS|NONE (r_pobj) against_11\IN|were|effects|Although (r_prep) observed_10\VBN|effects|mice|were|,|:|.|in (r_advcl) observed_36\VBN|NONE (l_prep) in_37\IN|effects|mice|were|,|:|.|observed (l_pobj) convulsions_38\NNS|NONE
D016202_D012640 NONE aspartate_47\NNP|NONE (r_pobj) by_40\IN|in (r_agent) induced_39\VBN|NONE (r_acl) convulsions_38\NNS|NONE (r_pobj) in_37\IN|effects|mice|were|,|:|.|observed (r_prep) observed_36\VBN|NONE (l_advcl) observed_10\VBN|effects|mice|were|,|:|.|in (l_prep) against_11\IN|were|effects|Although (l_pobj) convulsions_14\NNS|NONE
D016202_D012640 NONE aspartate_47\NNP|NONE (r_pobj) by_40\IN|in (r_agent) induced_39\VBN|NONE (r_acl) convulsions_38\NNS|NONE
17828434
D008094_D012640 NONE lithium_15\NN|NONE (r_pobj) of_14\IN|the|in (r_prep) effects_13\NNS|NONE (l_prep) in_16\IN|of|the (l_pobj) model_24\NN|NONE (l_compound) seizures_23\NNS|sensitive|the
D007294_D012640 NONE inositol_18\JJ|NONE (r_npadvmod) sensitive_19\JJ|seizures|the (r_amod) model_24\NN|NONE (l_compound) seizures_23\NNS|sensitive|the
C002647_D012640 NONE MIP_4\NNP|synthase (r_compound) inhibition_6\NN|not|that|does|or|augment (r_nsubj) replicate_9\VB|.|study (l_conj) augment_11\VB|not|that|does|or|inhibition (l_dobj) effects_13\NNS|NONE (l_prep) in_16\IN|of|the (l_pobj) model_24\NN|NONE (l_compound) seizures_23\NNS|sensitive|the
D010862_D012640 CID pilocarpine_20\NN| (r_npadvmod) induced_22\VBN|NONE (r_amod) seizures_23\NNS|sensitive|the
20859899
D000450_D006947 NONE aldosterone_14\NN|an (r_compound) antagonist_15\NN|, (r_appos) spiranolactone_11\NN|NONE (r_pobj) of_10\IN|several (r_prep) doses_9\NNS|,|to|in (r_attr) be_7\VB|.|cause|was (r_xcomp) considered_5\VBN|NONE (l_nsubjpass) cause_1\NN|.|be|was (l_prep) of_2\IN|The (l_pobj) hyperkalemia_3\NN|NONE
D011188_D007674 NONE potassium_21\NN|sparing (r_compound) agents_23\NNS|NONE (r_pobj) with_20\IN|NONE (r_prep) combination_19\NN|NONE (r_pobj) in_18\IN|ARB (r_prep) using_14\VBG|elderly (r_acl) patients_13\NNS|especially|have|and (r_pobj) in_11\IN|Clinicians|.|alert|should|, (l_conj) have_26\VBP|patients|especially|and (l_dobj) disturbance_29\NN|who
D000809_D013575 NONE angiotensin_12\NN| (r_npadvmod) converting_14\VBG|enzyme|the|spironolactone|and (r_amod) inhibitor_16\NN|NONE (r_pobj) with_10\IN|a|combined (r_prep) therapy_9\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) use_5\NN|NONE (r_pobj) during_4\IN|by (r_prep) caused_1\VBD|. (r_acl) Syncope_0\NNP|NONE
D011188_D006947 NONE potassium_21\NN|sparing (r_compound) agents_23\NNS|NONE (r_pobj) with_20\IN|NONE (r_prep) combination_19\NN|NONE (r_pobj) in_18\IN|ARB (r_prep) using_14\VBG|elderly (r_acl) patients_13\NNS|especially|have|and (r_pobj) in_11\IN|Clinicians|.|alert|should|, (r_prep) be_2\VB|NONE (l_acomp) alert_3\JJ|Clinicians|.|in|should|, (l_prep) to_4\IN|NONE (l_pobj) possibility_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) hyperkalemia_8\NN|NONE
D013148_D006947 CID spironolactone_18\NN|converting|enzyme|the|and (r_conj) inhibitor_16\NN|NONE (r_pobj) with_10\IN|a|combined (r_prep) therapy_9\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) use_5\NN|NONE (r_pobj) during_4\IN|by (r_prep) caused_1\VBD|. (l_agent) by_2\IN|during (l_pobj) hyperkalemia_3\NN|NONE
D013148_D006947 CID spiranolactone_11\NN|NONE (r_pobj) of_10\IN|several (r_prep) doses_9\NNS|,|to|in (r_attr) be_7\VB|.|cause|was (r_xcomp) considered_5\VBN|NONE (l_nsubjpass) cause_1\NN|.|be|was (l_prep) of_2\IN|The (l_pobj) hyperkalemia_3\NN|NONE
D013148_D013575 NONE spironolactone_18\NN|converting|enzyme|the|and (r_conj) inhibitor_16\NN|NONE (r_pobj) with_10\IN|a|combined (r_prep) therapy_9\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) use_5\NN|NONE (r_pobj) during_4\IN|by (r_prep) caused_1\VBD|. (r_acl) Syncope_0\NNP|NONE
D017257_D006947 CID ramipril_26\NN|NONE (r_pobj) of_25\IN|,|term|inhibitor|the (r_prep) intake_24\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) addition_18\NN|NONE (r_pobj) in_17\IN|,|to|doses (r_prep) be_7\VB|.|cause|was (r_xcomp) considered_5\VBN|NONE (l_nsubjpass) cause_1\NN|.|be|was (l_prep) of_2\IN|The (l_pobj) hyperkalemia_3\NN|NONE
D000809_D006947 NONE angiotensin_12\NN| (r_npadvmod) converting_14\VBG|enzyme|the|spironolactone|and (r_amod) inhibitor_16\NN|NONE (r_pobj) with_10\IN|a|combined (r_prep) therapy_9\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) use_5\NN|NONE (r_pobj) during_4\IN|by (r_prep) caused_1\VBD|. (l_agent) by_2\IN|during (l_pobj) hyperkalemia_3\NN|NONE
26115410
D001152_D009369 CID iAs_14\NNP|to|in|, (r_compound) exposure_15\NN|that (l_prep) in_25\IN|to|iAs|, (l_pobj) relationship_26\NN|particularly (l_prep) to_27\IN|NONE (l_pobj) cancer_28\NN|NONE
D001152_D009369 CID iAs_25\NNP|NONE (r_compound) exposure_26\NN|NONE (r_pobj) with_21\IN|is|that (r_prep) associated_20\VBN|of|the|increased|in (r_relcl) risk_12\NN|that (l_prep) of_13\IN|associated|the|increased|in (l_pobj) development_15\NN|NONE (l_compound) cancer_14\NN|NONE
D001152_D009369 CID iAs_28\NNP|NONE (r_compound) exposure_29\NN|by|effects (r_nsubj) elicits_30\VBZ|underlying|plausible (r_relcl) mechanisms_22\NNS|,|reprogramming|development|. (r_attr) are_19\VBP|NONE (l_nsubj) development_11\NN|,|reprogramming|mechanisms|. (l_prep) of_12\IN|and|immunomodulation|the|, (l_pobj) cells_15\NNS|NONE (l_compound) cancer_13\NN|stem
D001152_D009369 CID iAs_8\NNP|and|development (r_compound) exposure_9\NN|later|that (l_conj) development_12\NN|iAs|and (l_compound) cancer_11\NN|NONE
1359137
D014150_D000568 CID neuroleptic_12\NN| (r_npadvmod) associated_14\VBN|and|galactorrhea (r_amod) hyperprolactinemia_15\NN|NONE (l_conj) galactorrhea_19\NN|and|associated (l_nmod) amenorrhea_17\NN|/
D001971_D005687 NONE bromocriptine_3\NN|should|be|as|that|further (r_nsubjpass) evaluated_7\VBN|.|This (l_prep) as_8\IN|should|be|that|bromocriptine|further (l_pobj) therapy_10\NN|NONE (l_prep) for_11\IN|potential (l_pobj) hyperprolactinemia_15\NN|NONE (l_conj) galactorrhea_19\NN|and|associated
D014150_D006966 CID Neuroleptic_0\RB| (r_npadvmod) associated_2\VBN|. (r_amod) hyperprolactinemia_3\NN|NONE
D014150_D006966 CID neuroleptic_12\NN| (r_npadvmod) associated_14\VBN|and|galactorrhea (r_amod) hyperprolactinemia_15\NN|NONE
D001971_D009839 NONE bromocriptine_9\NN|NONE (r_pobj) with_8\IN|were (r_prep) treated_7\VBN|oligomenorrhea|.|with (r_advcl) associated_1\VBN|NONE (l_nsubj) oligomenorrhea_0\NN|treated|.|with
D014150_D005687 NONE neuroleptic_12\NN| (r_npadvmod) associated_14\VBN|and|galactorrhea (r_amod) hyperprolactinemia_15\NN|NONE (l_conj) galactorrhea_19\NN|and|associated
D014150_D009839 CID medications_5\NNS|NONE (r_pobj) with_2\IN|oligomenorrhea|treated|. (r_prep) associated_1\VBN|NONE (l_nsubj) oligomenorrhea_0\NN|treated|.|with
D001971_D000568 NONE bromocriptine_3\NN|should|be|as|that|further (r_nsubjpass) evaluated_7\VBN|.|This (l_prep) as_8\IN|should|be|that|bromocriptine|further (l_pobj) therapy_10\NN|NONE (l_prep) for_11\IN|potential (l_pobj) hyperprolactinemia_15\NN|NONE (l_conj) galactorrhea_19\NN|and|associated (l_nmod) amenorrhea_17\NN|/
D001971_D011618 CID bromocriptine_11\NN|while (r_dobj) taking_10\VBG|,|discontinued|woman|however|,|and|symptoms|, (r_advcl) developed_5\VBN|NONE (l_dobj) symptoms_8\NNS|,|discontinued|woman|however|,|and|taking|,
D001971_D006966 NONE bromocriptine_3\NN|should|be|as|that|further (r_nsubjpass) evaluated_7\VBN|.|This (l_prep) as_8\IN|should|be|that|bromocriptine|further (l_pobj) therapy_10\NN|NONE (l_prep) for_11\IN|potential (l_pobj) hyperprolactinemia_15\NN|NONE
24067251
C418563_D007674 NONE fumarate_17\NN|NONE (r_pobj) to_14\IN|NONE (r_prep) exposed_13\VBN|positive (r_acl) persons_12\NNS|NONE (r_pobj) in_8\IN|kidney (r_prep) injury_7\NN|NONE
C418563_D007674 NONE TDF_12\NNP| (r_npadvmod) related_14\VBN|)|kidney|,|% (r_amod) disease_16\NN|NONE
C418563_D007674 NONE TDF_12\NNP| (r_npadvmod) related_14\VBN|)|kidney|,|% (r_amod) disease_16\NN|NONE (r_pobj) for_11\IN|satisfied|,| (r_prep) criteria_10\NNS|NONE (r_dobj) analysed_6\VBN|Card||the (r_acl) records_5\NNS|NONE (r_pobj) Of_0\IN|found|had|.|features (r_prep) had_25\VBD|NONE (l_dobj) features_26\NNS|found|had|.|Of (l_prep) of_27\IN|%|)|(||, (l_pobj) dysfunction_30\NN|NONE
C418563_D007674 NONE TDF_12\NNP| (r_npadvmod) related_14\VBN|)|kidney|,|% (r_amod) disease_16\NN|NONE (r_pobj) for_11\IN|satisfied|,| (r_prep) criteria_10\NNS|NONE (r_dobj) analysed_6\VBN|Card||the (r_acl) records_5\NNS|NONE (r_pobj) Of_0\IN|found|had|.|features (r_prep) had_25\VBD|NONE (l_conj) found_38\VBN|had|.|Of|features (l_advcl) have_40\VB|were (l_dobj) features_41\NNS|to (l_prep) of_42\IN|%|and (l_pobj) dysfunction_44\NN|NONE
C418563_D005198 CID TDF_12\NNP| (r_npadvmod) related_14\VBN|)|kidney|,|% (r_amod) disease_16\NN|NONE (r_pobj) for_11\IN|satisfied|,| (r_prep) criteria_10\NNS|NONE (r_dobj) analysed_6\VBN|Card||the (r_acl) records_5\NNS|NONE (r_pobj) Of_0\IN|found|had|.|features (r_prep) had_25\VBD|NONE (l_conj) had_51\VBD|found|.|Of|features (l_dobj) syndrome_53\NN|NONE
C418563_D005198 CID TDF_5\NNP|adverse|kidney (r_compound) effects_8\NNS|NONE (r_pobj) for_4\IN|NONE (r_prep) hospitalisation_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) incidence_1\NN|high|,|amongst|. (r_nsubj) was_9\VBD|NONE (l_prep) amongst_13\IN|high|,|incidence|. (l_pobj) patients_14\NNS|particularly (l_prep) with_15\IN|NONE (l_pobj) features_16\NNS|NONE (l_prep) of_17\IN|NONE (l_pobj) syndrome_19\NN|NONE
8659767
D002045_D009203 NONE bupivacaine_4\NN|dysrhythmogenicity|whether|in (r_nsubj) alters_5\VBZ|We|.|therefore (l_prep) in_13\IN|dysrhythmogenicity|whether|bupivacaine (l_conj) in_19\IN|and|dogs (l_pobj) dogs_21\NNS|NONE (l_prep) with_22\IN|anesthetized (l_pobj) infarction_24\NN|NONE
D002045_D017180 NONE Bupivacaine_0\NNP|dysrhythmogenicity|. (r_nsubj) antagonizes_1\VBZ|NONE (l_dobj) dysrhythmogenicity_3\NN|Bupivacaine|. (l_prep) in_4\IN|epinephrine (l_pobj) dogs_6\NNS|in|and (l_amod) susceptible_7\JJ|conscious (l_prep) to_8\IN|NONE (l_pobj) VT_9\NNP|NONE
D002045_D001145 NONE bupivacaine_1\NN|NONE (r_pobj) Since_0\IN|could|dysrhythmias|.|effects (r_prep) potentiate_15\VB|NONE (l_nsubj) dysrhythmias_7\NNS|could|.|Since|effects
D002045_D001145 NONE bupivacaine_10\NN|both|may|,|precipitate (r_appos) dysrhythmias_7\NNS|could|.|Since|effects
D002045_D001145 NONE Bupivacaine_0\NNP|dysrhythmogenicity|. (r_nsubj) antagonizes_1\VBZ|NONE (l_dobj) dysrhythmogenicity_3\NN|Bupivacaine|. (l_prep) in_4\IN|epinephrine (l_conj) in_11\IN|dogs|and (l_pobj) dogs_13\NNS|NONE (l_prep) with_14\IN|anesthetized (l_pobj) dysrhythmias_17\NNS|NONE
D004837_D001145 NONE epinephrine_3\NN|and (r_conj) bupivacaine_1\NN|NONE (r_pobj) Since_0\IN|could|dysrhythmias|.|effects (r_prep) potentiate_15\VB|NONE (l_nsubj) dysrhythmias_7\NNS|could|.|Since|effects
D004837_D001145 NONE epinephrine_19\NN|NONE (r_pobj) of_18\IN|dysrhythmogenic (r_prep) effects_17\NNS|could|dysrhythmias|.|Since (r_dobj) potentiate_15\VB|NONE (l_nsubj) dysrhythmias_7\NNS|could|.|Since|effects
D004837_D001145 NONE epinephrine_2\NN|in (r_amod) dysrhythmogenicity_3\NN|Bupivacaine|. (l_prep) in_4\IN|epinephrine (l_conj) in_11\IN|dogs|and (l_pobj) dogs_13\NNS|NONE (l_prep) with_14\IN|anesthetized (l_pobj) dysrhythmias_17\NNS|NONE
D006221_D017180 NONE halothane_9\NN| (r_npadvmod) anesthetized_11\VBN|additional|six (r_amod) dogs_12\NNS|.|appeared|after|,|epinephrine (r_nsubj) received_13\VBD|NONE (l_advcl) appeared_19\VBD|.|dogs|after|,|epinephrine (l_nsubj) VT_18\NNP|until
D004837_D009203 NONE epinephrine_12\NN|NONE (r_pobj) of_11\IN|subsequent (r_prep) administration_10\NN|NONE (r_pobj) of_8\IN|the (r_prep) dysrhythmogenicity_7\NN|whether|bupivacaine|in (r_dobj) alters_5\VBZ|We|.|therefore (l_prep) in_13\IN|dysrhythmogenicity|whether|bupivacaine (l_conj) in_19\IN|and|dogs (l_pobj) dogs_21\NNS|NONE (l_prep) with_22\IN|anesthetized (l_pobj) infarction_24\NN|NONE
D004837_D009203 NONE epinephrine_16\NN|.|appeared|dogs|after|, (r_dobj) received_13\VBD|NONE (l_prep) after_2\IN|.|appeared|dogs|,|epinephrine (l_pobj) infarction_5\NN|day
D006221_D009203 NONE halothane_9\NN| (r_npadvmod) anesthetized_11\VBN|additional|six (r_amod) dogs_12\NNS|.|appeared|after|,|epinephrine (r_nsubj) received_13\VBD|NONE (l_prep) after_2\IN|.|appeared|dogs|,|epinephrine (l_pobj) infarction_5\NN|day
D004837_D017180 CID epinephrine_16\NN|.|appeared|dogs|after|, (r_dobj) received_13\VBD|NONE (l_advcl) appeared_19\VBD|.|dogs|after|,|epinephrine (l_nsubj) VT_18\NNP|until
D004837_D017180 CID epinephrine_2\NN|in (r_amod) dysrhythmogenicity_3\NN|Bupivacaine|. (l_prep) in_4\IN|epinephrine (l_pobj) dogs_6\NNS|in|and (l_amod) susceptible_7\JJ|conscious (l_prep) to_8\IN|NONE (l_pobj) VT_9\NNP|NONE
12678199
D004077_D007008 NONE digoxin_19\JJ|NONE (r_compound) excess_20\NN|and (r_conj) hypokalemia_17\NN|NONE
D004077_D016171 NONE digoxin_19\JJ|NONE (r_compound) excess_20\NN|and (r_conj) hypokalemia_17\NN|NONE (r_pobj) including_16\VBG|multiple|exacerbating (r_prep) factors_15\NNS|NONE (r_pobj) of_12\IN|the (r_prep) context_11\NN|NONE (r_pobj) in_9\IN|case|.|Consistent (r_prep) occurred_8\VBD|NONE (l_nsubj) case_5\NN|.|in|Consistent (l_prep) of_6\IN|this (l_pobj) TdP_7\NNP|NONE
D000638_D016171 CID Amiodarone_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) torsade_3\NN|de|.|presentation|:|during (r_nmod) pointes_5\FW|NONE
D000638_D016171 CID amiodarone_23\NN|oral (r_compound) therapy_24\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) associated_20\VBN|torsade|de|TdP|)|( (r_acl) pointes_16\FW|NONE
D000638_D016171 CID amiodarone_23\NN|oral (r_compound) therapy_24\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) associated_20\VBN|torsade|de|TdP|)|( (r_acl) pointes_16\FW|NONE (l_appos) TdP_18\NN|torsade|associated|de|)|(
D000638_D016171 CID amiodarone_4\NN|NONE (r_compound) therapy_5\NN|NONE (r_pobj) of_3\IN|the (r_prep) absence_2\NN|NONE (r_pobj) In_0\IN|did|,|TdP|irrigation|despite|not|. (r_prep) induce_13\VB|NONE (l_dobj) TdP_14\NN|did|In|,|irrigation|despite|not|.
D000638_C537153 NONE amiodarone_4\NN|NONE (r_compound) therapy_5\NN|NONE (r_pobj) of_3\IN|the (r_prep) absence_2\NN|NONE (r_pobj) In_0\IN|did|,|TdP|irrigation|despite|not|. (r_prep) induce_13\VB|NONE (l_prep) despite_15\IN|did|In|,|TdP|irrigation|not|. (l_pobj) hypokalemia_16\NN|NONE (l_conj) hypomagnesemia_18\NN|and
D000638_D007008 NONE amiodarone_4\NN|NONE (r_compound) therapy_5\NN|NONE (r_pobj) of_3\IN|the (r_prep) absence_2\NN|NONE (r_pobj) In_0\IN|did|,|TdP|irrigation|despite|not|. (r_prep) induce_13\VB|NONE (l_prep) despite_15\IN|did|In|,|TdP|irrigation|not|. (l_pobj) hypokalemia_16\NN|NONE
D000638_-1 NONE amiodarone_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|the (r_prep) context_18\NN|NONE (r_pobj) in_16\IN|in|tone|that (r_prep) resulted_22\VBD|.|authors (l_prep) in_23\IN|tone|in|that (l_pobj) proarrhythmia_27\NN|NONE
D000638_-1 NONE amiodarone_24\NN| (r_npadvmod) induced_26\VBN|NONE (r_amod) proarrhythmia_27\NN|NONE
20828385
C401859_D009369 NONE temsirolimus_19\NN|NONE (r_compound) treatment_20\NN|months (r_pobj) after_18\IN|,|regression|who (r_prep) had_13\VBD|refractory (l_dobj) regression_15\NN|,|after|who (l_compound) tumor_14\NN|NONE
C401859_D009369 NONE temsirolimus_7\NN|but|induce|through|that|proliferation|, (r_nsubj) inhibited_8\JJ|Comparison|. (l_dobj) proliferation_11\NN|but|temsirolimus|induce|through|that|, (l_compound) cell_10\NN|NONE (l_compound) tumor_9\NN|NONE
C401859_D009369 NONE temsirolimus_7\NN|but|induce|through|that|proliferation|, (r_nsubj) inhibited_8\JJ|Comparison|. (l_conj) induce_20\VB|but|temsirolimus|through|that|proliferation|, (l_dobj) change_22\NN|did|not (l_prep) in_23\IN|any (l_pobj) number_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) cells_29\NNS|NONE (l_compound) tumor_28\NN|apoptotic
C401859_D009369 NONE temsirolimus_6\NNS|,|effect|Apart|. (r_nsubj) had_7\VBD|NONE (l_dobj) effect_10\NN|,|Apart|.|temsirolimus (l_prep) with_11\IN|an|antiangiogenic (l_pobj) decrease_12\NN|and|of (l_prep) of_13\IN|NONE (l_pobj) density_16\NN|NONE (l_compound) tumor_14\NN|microvessel
C401859_D009369 NONE temsirolimus_2\NNS|Thus|,|.|through|burden (r_nsubj) reduced_3\VBN|NONE (l_dobj) burden_5\NN|Thus|,|temsirolimus|.|through (l_compound) tumor_4\NN|NONE
C401859_D009369 NONE temsirolimus_4\NN|NONE (r_pobj) of_3\IN|dual|This|on (r_prep) effect_2\NN|to|.|could (l_prep) on_5\IN|dual|of|This (l_pobj) tissue_7\NN|NONE (l_compound) tumor_6\NN|NONE
C401859_D020522 NONE temsirolimus_7\NN|NONE (r_pobj) of_6\IN|Cytostatic|angiogenic|in|. (r_prep) effects_5\NNS|NONE (l_prep) in_8\IN|Cytostatic|angiogenic|.|of (l_pobj) lymphoma_12\NN|NONE
C401859_D020522 NONE temsirolimus_16\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treated_14\VBN|However|been|rate|recently|in|.|,|has (r_advcl) reported_10\VBN|NONE (l_prep) in_11\IN|However|been|rate|recently|.|,|treated|has (l_pobj) MCL_13\NN|NONE
C401859_D020522 NONE temsirolimus_19\NN|NONE (r_compound) treatment_20\NN|months (r_pobj) after_18\IN|,|regression|who (r_prep) had_13\VBD|refractory (r_relcl) MCL_11\NNP|NONE
C401859_D020522 NONE temsirolimus_4\NN|NONE (r_pobj) of_3\IN|dual|This|on (r_prep) effect_2\NN|to|.|could (r_nsubj) contribute_9\VB|NONE (l_prep) to_10\IN|.|could|effect (l_pobj) efficiency_14\NN|NONE (l_prep) in_15\IN|its|reported|resistant (l_pobj) MCL_17\NN|NONE
C401859_D009336 CID temsirolimus_23\NN|month (r_compound) therapy_24\NN|NONE (r_pobj) after_21\IN|areas|.|were|Moreover|,|, (r_prep) found_20\VBN|NONE (l_nsubjpass) areas_9\NNS|.|were|Moreover|after|,|, (l_amod) compatible_11\JJ|fibrotic|,|limited|numerous|,|patchy (l_prep) with_12\IN|NONE (l_pobj) repair_17\NN|NONE (l_amod) necrotic_15\JJ|tissue
15696449
D003404_D058186 NONE creatinine_31\NN|the|serum (r_compound) level_32\NN|NONE (r_pobj) in_28\IN|is|minimum|of|a (r_prep) increase_16\NN|NONE (r_pobj) by_13\IN|insufficiency|was|melphalan|.|after (r_agent) defined_12\VBN|NONE (l_nsubjpass) insufficiency_2\NN|was|melphalan|.|by|after
D003404_D058186 NONE creatinine_31\NN|the|serum (r_compound) level_32\NN|NONE (r_pobj) in_28\IN|is|minimum|of|a (r_prep) increase_16\NN|NONE (r_pobj) by_13\IN|insufficiency|was|melphalan|.|after (r_agent) defined_12\VBN|NONE (l_nsubjpass) insufficiency_2\NN|was|melphalan|.|by|after (l_appos) ARI_4\NNP|renal|(|Acute|)
D008558_C531616 NONE melphalan_7\NN|NONE (l_prep) in_8\IN|dose (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) amyloidosis_13\NN|NONE
D008558_D058186 CID melphalan_7\NN|NONE (r_pobj) after_3\IN|.|Acute|renal (r_prep) insufficiency_2\NN|NONE
D008558_D058186 CID melphalan_12\NN|NONE (r_compound) conditioning_13\NN|immediately (r_pobj) after_11\IN|the|of (r_prep) development_5\NN|have|.|authors (l_prep) of_6\IN|after|the (l_pobj) insufficiency_9\NN|NONE
D008558_D058186 CID melphalan_10\NN|insufficiency|was|.|by|after (r_nsubjpass) defined_12\VBN|NONE (l_nsubjpass) insufficiency_2\NN|was|melphalan|.|by|after
D008558_D058186 CID melphalan_10\NN|insufficiency|was|.|by|after (r_nsubjpass) defined_12\VBN|NONE (l_nsubjpass) insufficiency_2\NN|was|melphalan|.|by|after (l_appos) ARI_4\NNP|renal|(|Acute|)
D008558_D058186 CID melphalan_18\NN|NONE (r_pobj) after_14\IN|,|Of|.|ARI|in (r_prep) developed_7\VBD|NONE (l_nsubj) ARI_6\NNP|,|after|Of|.|in
D008558_D058186 CID melphalan_8\NN|P|often|dialysis|.|had|and|Patients|, (r_nsubj) underwent_9\VBD|NONE (l_nsubj) Patients_0\NNS|P|often|dialysis|.|melphalan|had|and|, (l_relcl) had_2\VBD|NONE (l_dobj) ARI_3\NNP|who|after
D008558_D058186 CID melphalan_7\NN|.|strongly|timing (r_dobj) suggests_6\VBZ|NONE (l_nsubj) timing_1\NN|.|strongly|melphalan (l_prep) of_2\IN|The (l_pobj) injury_4\NN|NONE
D008558_D058186 CID melphalan_11\NN|NONE (r_pobj) by_10\IN|renal (r_prep) injury_9\NN|NONE
D008558_-1 NONE melphalan_11\NN|NONE (r_pobj) by_10\IN|renal (r_prep) injury_9\NN|NONE (r_pobj) for_7\IN|a (r_prep) prerequisite_6\NN|may|evidenced|injury|. (r_attr) be_4\VB|NONE (l_nsubj) injury_2\NN|prerequisite|may|evidenced|.
19139825
D019772_D005910 NONE Topotecan_0\NNP|exhibits|option|. (r_nsubj) is_1\VBZ|NONE (l_advcl) exhibits_7\VBZ|option|.|Topotecan (l_dobj) inhibition_9\NN|as|it (l_prep) of_10\IN|growth (l_pobj) glioma_12\NN|NONE
D019772_D005909 NONE Topotecan_0\JJ|NONE (l_prep) in_1\IN|. (l_pobj) combination_2\NN|NONE (l_prep) with_3\IN|NONE (l_pobj) radiotherapy_4\NN|NONE (l_prep) in_5\IN|NONE (l_pobj) glioblastoma_7\NN|NONE
D019772_D005909 NONE topotecan_15\JJ|combination|study|. (l_prep) in_34\IN|m()/day (l_pobj) adults_36\NNS|NONE (l_prep) with_37\IN| (l_pobj) GBM_42\NNP|NONE
3383127
D002945_D015179 NONE cisplatin_18\NN|CDDP (r_pobj) with_17\IN|while|being (r_prep) treated_16\VBN|.|symptoms|in|FU (r_advcl) developed_6\VBN|NONE (l_prep) in_7\IN|treated|.|symptoms|FU (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|three (l_pobj) carcinoma_13\NN|NONE
D002945_D015179 NONE CDDP_20\NNP|cisplatin (r_pobj) with_17\IN|while|being (r_prep) treated_16\VBN|.|symptoms|in|FU (r_advcl) developed_6\VBN|NONE (l_prep) in_7\IN|treated|.|symptoms|FU (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|three (l_pobj) carcinoma_13\NN|NONE
D005472_D007022 CID 5-fluorouracil_12\CD|NONE (r_punct) ._13\.|as (r_punct) Hypotension_0\NN|NONE
D005472_D007022 CID 5-fluorouracil_23\CD|)|( (r_punct) 5-FU_25\CD|treated|.|symptoms|in (r_npadvmod) developed_6\VBN|NONE (l_nsubj) symptoms_1\NNS|treated|.|in|FU (l_prep) including_3\VBG|Cardiac|,|, (l_pobj) hypotension_4\NN|NONE
D005472_D007022 CID 5-FU_25\CD|treated|.|symptoms|in (r_npadvmod) developed_6\VBN|NONE (l_nsubj) symptoms_1\NNS|treated|.|in|FU (l_prep) including_3\VBG|Cardiac|,|, (l_pobj) hypotension_4\NN|NONE
D005472_D015179 NONE 5-fluorouracil_23\CD|)|( (r_punct) 5-FU_25\CD|treated|.|symptoms|in (r_npadvmod) developed_6\VBN|NONE (l_prep) in_7\IN|treated|.|symptoms|FU (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|three (l_pobj) carcinoma_13\NN|NONE
D005472_D015179 NONE 5-FU_25\CD|treated|.|symptoms|in (r_npadvmod) developed_6\VBN|NONE (l_prep) in_7\IN|treated|.|symptoms|FU (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|three (l_pobj) carcinoma_13\NN|NONE
D002945_D066126 NONE cisplatin_10\NN|NONE (r_dobj) receiving_9\VBG|three (r_acl) patients_8\NNS|NONE (r_pobj) in_6\IN|of|a (r_prep) manifestation_3\NN|NONE (l_prep) of_4\IN|a|in (l_pobj) cardiotoxicity_5\NN|NONE
D002945_D066126 NONE CDDP_27\NNP|NONE (r_pobj) by_26\IN|be|that|may (r_agent) influenced_25\VBN|new|of (r_relcl) manifestations_18\NNS|presentation|. (l_prep) of_19\IN|influenced|new (l_pobj) cardiotoxicity_21\NN|NONE
D005472_D066126 NONE 5-fluorouracil_12\CD|NONE (r_punct) ._13\.|as (r_punct) Hypotension_0\NN|NONE (l_prep) as_1\IN|. (l_pobj) manifestation_3\NN|NONE (l_prep) of_4\IN|a|in (l_pobj) cardiotoxicity_5\NN|NONE
D005472_D066126 NONE 5-FU_20\CD|NONE (r_compound) cardiotoxicity_21\NN|NONE
D002945_D007022 CID cisplatin_10\NN|NONE (r_dobj) receiving_9\VBG|three (r_acl) patients_8\NNS|NONE (r_pobj) in_6\IN|of|a (r_prep) manifestation_3\NN|NONE (r_pobj) as_1\IN|. (r_prep) Hypotension_0\NN|NONE
D002945_D007022 CID cisplatin_18\NN|CDDP (r_pobj) with_17\IN|while|being (r_prep) treated_16\VBN|.|symptoms|in|FU (r_advcl) developed_6\VBN|NONE (l_nsubj) symptoms_1\NNS|treated|.|in|FU (l_prep) including_3\VBG|Cardiac|,|, (l_pobj) hypotension_4\NN|NONE
D002945_D007022 CID CDDP_20\NNP|cisplatin (r_pobj) with_17\IN|while|being (r_prep) treated_16\VBN|.|symptoms|in|FU (r_advcl) developed_6\VBN|NONE (l_nsubj) symptoms_1\NNS|treated|.|in|FU (l_prep) including_3\VBG|Cardiac|,|, (l_pobj) hypotension_4\NN|NONE
20431083
D014859_-1 NONE warfarin_57\NN|(|)|difference=. (r_amod) users_58\NNS|NONE (r_pobj) in_56\IN|(|)|.|, (r_prep) range_50\NN|)|in|. (r_parataxis) 3.4_40\CD|(|,|. (r_appos) range_38\NN|NONE (r_pobj) to_35\IN|odds|(|;|range|in (r_prep) ratio_24\NN|. (r_pobj) from_20\IN|excess|. (r_prep) increased_19\VBD|,|but|vs|frequent|MB|in|, (r_conj) were_2\VBD|NONE (l_nsubj) MB_1\NNS|increased|,|but|vs|frequent|in|,
D014859_-1 NONE warfarin_8\JJ|vs (r_amod) users_9\NNS|NONE (r_pobj) in_7\IN|of|an (r_prep) excess_4\NN|also|There|but|.|none (l_prep) of_5\IN|in|an (l_pobj) MB_6\NN|NONE
D014859_-1 NONE warfarin_32\JJ|with (r_amod) users_33\NNS|NONE (r_pobj) in_31\IN|NONE (r_prep) none_30\NN|also|There|but|excess|. (r_attr) was_1\VBD|NONE (l_attr) excess_4\NN|also|There|but|.|none (l_prep) of_5\IN|in|an (l_pobj) MB_6\NN|NONE
D014859_-1 NONE warfarin_5\JJ|with (r_amod) users_6\NNS|NONE (r_pobj) in_4\IN|of|The|compared (r_prep) excess_1\NN|.|increase (l_prep) of_2\IN|The|in|compared (l_pobj) MB_3\NN|NONE
D014859_-1 NONE warfarin_5\JJ|with (r_amod) users_6\NNS|NONE (r_pobj) in_4\IN|of|The|compared (r_prep) excess_1\NN|.|increase (r_nsubj) suggests_13\VBZ|NONE (l_ccomp) increase_16\VBP|.|excess (l_nsubj) MB_15\NN|risk|that
D014859_-1 NONE warfarin_20\NN| (r_npadvmod) associated_22\VBN|NONE (r_amod) ICH_23\NNP|NONE (r_pobj) of_19\IN|the (r_prep) risk_18\NN|MB|that (r_dobj) increase_16\VBP|.|excess (r_ccomp) suggests_13\VBZ|NONE (l_nsubj) excess_1\NN|.|increase (l_prep) of_2\IN|The|in|compared (l_pobj) MB_3\NN|NONE
D014859_-1 NONE warfarin_20\NN| (r_npadvmod) associated_22\VBN|NONE (r_amod) ICH_23\NNP|NONE (r_pobj) of_19\IN|the (r_prep) risk_18\NN|MB|that (r_dobj) increase_16\VBP|.|excess (l_nsubj) MB_15\NN|risk|that
D014859_D002543 CID warfarin_57\NN|(|)|difference=. (r_amod) users_58\NNS|NONE (r_pobj) in_56\IN|(|)|.|, (r_prep) range_50\NN|)|in|. (r_parataxis) 3.4_40\CD|(|,|. (r_appos) range_38\NN|NONE (r_pobj) to_35\IN|odds|(|;|range|in (r_prep) ratio_24\NN|. (r_pobj) from_20\IN|excess|. (r_prep) increased_19\VBD|,|but|vs|frequent|MB|in|, (r_conj) were_2\VBD|NONE (l_prep) in_5\IN|increased|,|but|vs|frequent|MB|, (l_pobj) ICH_6\NNP|NONE
D014859_D002543 CID warfarin_8\JJ|vs (r_amod) users_9\NNS|NONE (l_prep) vs_10\IN|warfarin (l_pobj) nonusers_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) ICH_13\NNP|NONE
D014859_D002543 CID warfarin_32\JJ|with (r_amod) users_33\NNS|NONE (r_pobj) in_31\IN|NONE (r_prep) none_30\NN|also|There|but|excess|. (r_attr) was_1\VBD|NONE (l_attr) excess_4\NN|also|There|but|.|none (l_prep) in_7\IN|of|an (l_pobj) users_9\NNS|NONE (l_prep) vs_10\IN|warfarin (l_pobj) nonusers_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) ICH_13\NNP|NONE
D014859_D002543 CID warfarin_5\JJ|with (r_amod) users_6\NNS|NONE (l_prep) with_7\IN|warfarin (l_pobj) ICH_8\NNP|NONE
D014859_D002543 CID warfarin_5\JJ|with (r_amod) users_6\NNS|NONE (r_pobj) in_4\IN|of|The|compared (r_prep) excess_1\NN|.|increase (r_nsubj) suggests_13\VBZ|NONE (l_ccomp) increase_16\VBP|.|excess (l_dobj) risk_18\NN|MB|that (l_prep) of_19\IN|the (l_pobj) ICH_23\NNP|NONE
D014859_D002543 CID warfarin_20\NN| (r_npadvmod) associated_22\VBN|NONE (r_amod) ICH_23\NNP|NONE (r_pobj) of_19\IN|the (r_prep) risk_18\NN|MB|that (r_dobj) increase_16\VBP|.|excess (r_ccomp) suggests_13\VBZ|NONE (l_nsubj) excess_1\NN|.|increase (l_prep) in_4\IN|of|The|compared (l_pobj) users_6\NNS|NONE (l_prep) with_7\IN|warfarin (l_pobj) ICH_8\NNP|NONE
D014859_D002543 CID warfarin_20\NN| (r_npadvmod) associated_22\VBN|NONE (r_amod) ICH_23\NNP|NONE
D014859_D002544 NONE warfarin_57\NN|(|)|difference=. (r_amod) users_58\NNS|NONE (r_pobj) in_56\IN|(|)|.|, (r_prep) range_50\NN|)|in|. (r_parataxis) 3.4_40\CD|(|,|. (r_appos) range_38\NN|NONE (r_pobj) to_35\IN|odds|(|;|range|in (r_prep) ratio_24\NN|. (r_pobj) from_20\IN|excess|. (r_prep) increased_19\VBD|,|but|vs|frequent|MB|in|, (r_conj) were_2\VBD|NONE (l_prep) vs_7\IN|increased|,|but|frequent|MB|in|, (l_pobj) TIA_10\NNP|NONE (l_nmod) IS_8\NNP|in|/
D014859_D002544 NONE warfarin_8\JJ|vs (r_amod) users_9\NNS|NONE (r_pobj) in_7\IN|of|an (r_prep) excess_4\NN|also|There|but|.|none (r_attr) was_1\VBD|NONE (l_attr) none_30\NN|also|There|but|excess|. (l_prep) in_31\IN|NONE (l_pobj) users_33\NNS|NONE (l_prep) with_34\IN|warfarin (l_pobj) TIA_37\NNP|NONE (l_nmod) IS_35\NNP|/|OR|(|;|)|CI
D014859_D002544 NONE warfarin_32\JJ|with (r_amod) users_33\NNS|NONE (l_prep) with_34\IN|warfarin (l_pobj) TIA_37\NNP|NONE (l_nmod) IS_35\NNP|/|OR|(|;|)|CI
D014859_D002546 NONE warfarin_57\NN|(|)|difference=. (r_amod) users_58\NNS|NONE (r_pobj) in_56\IN|(|)|.|, (r_prep) range_50\NN|)|in|. (r_parataxis) 3.4_40\CD|(|,|. (r_appos) range_38\NN|NONE (r_pobj) to_35\IN|odds|(|;|range|in (r_prep) ratio_24\NN|. (r_pobj) from_20\IN|excess|. (r_prep) increased_19\VBD|,|but|vs|frequent|MB|in|, (r_conj) were_2\VBD|NONE (l_prep) vs_7\IN|increased|,|but|frequent|MB|in|, (l_pobj) TIA_10\NNP|NONE
D014859_D002546 NONE warfarin_8\JJ|vs (r_amod) users_9\NNS|NONE (r_pobj) in_7\IN|of|an (r_prep) excess_4\NN|also|There|but|.|none (r_attr) was_1\VBD|NONE (l_attr) none_30\NN|also|There|but|excess|. (l_prep) in_31\IN|NONE (l_pobj) users_33\NNS|NONE (l_prep) with_34\IN|warfarin (l_pobj) TIA_37\NNP|NONE
D014859_D002546 NONE warfarin_32\JJ|with (r_amod) users_33\NNS|NONE (l_prep) with_34\IN|warfarin (l_pobj) TIA_37\NNP|NONE
16920333
D010852_D012640 CID picrotoxin_17\NN|NONE (r_pobj) of_16\IN|in (r_prep) microperfusion_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|NONE (r_acl) seizures_12\NNS|NONE
D010852_D012640 CID picrotoxin_8\NN|NONE (r_pobj) of_7\IN|threshold (r_prep) doses_6\NNS|NONE (r_pobj) with_4\IN|NONE (r_prep) treated_3\VBN|the (r_acl) animals_2\NNS|NONE (r_pobj) In_0\IN|.+/.|,|number|,|was|and (r_prep) was_15\VBD|NONE (l_nsubj) number_12\NN|.+/.|,|,|was|In|and (l_prep) of_13\IN|average|the (l_pobj) seizures_14\NNS|NONE
D010852_D012640 CID picrotoxin_8\NN|NONE (r_pobj) of_7\IN|threshold (r_prep) doses_6\NNS|NONE (r_pobj) with_4\IN|NONE (r_prep) treated_3\VBN|the (r_acl) animals_2\NNS|NONE (r_pobj) In_0\IN|.+/.|,|number|,|was|and (r_prep) was_15\VBD|NONE (l_conj) was_22\VBD|.+/.|,|number|,|In|and (l_nsubj) duration_21\NN|.|.+/.s (l_compound) seizure_20\NN|average
D010852_D012640 CID picrotoxin_11\NN|NONE (r_compound) microperfusion_12\NN|before|seizures|treatment|in|. (r_nsubj) prevented_13\VBD|NONE (l_dobj) seizures_14\NNS|microperfusion|before|treatment|in|.
C416835_D012640 NONE acetate_4\NN|NONE (r_pobj) of_2\IN|Anticonvulsant|on|. (r_prep) effect_1\NN|NONE (l_prep) on_11\IN|Anticonvulsant|of|. (l_pobj) seizures_12\NNS|NONE
C416835_D012640 NONE 093_9\CD|eslicarbazepine (r_appos) acetate_4\NN|NONE (r_pobj) of_2\IN|Anticonvulsant|on|. (r_prep) effect_1\NN|NONE (l_prep) on_11\IN|Anticonvulsant|of|. (l_pobj) seizures_12\NNS|NONE
C416835_D012640 NONE acetate_10\NN|NONE (l_prep) on_11\IN|eslicarbazepine (l_pobj) model_16\NN|NONE (l_relcl) elicited_23\VBN|a|animal (l_nsubjpass) seizures_20\NNS|on|can|repeatedly|without|be|in
C416835_D012640 NONE acetate_10\NN|NONE (l_prep) on_11\IN|eslicarbazepine (l_pobj) model_16\NN|NONE (l_relcl) elicited_23\VBN|a|animal (l_prep) without_28\IN|on|can|repeatedly|seizures|be|in (l_pobj) changes_29\NNS|NONE (l_prep) in_30\IN|NONE (l_pobj) threshold_31\NN|NONE (l_conj) patterns_34\NNS|or (l_compound) seizure_33\NN|NONE
15482540
D012254_D000743 CID ribavirin_2\RB|and (r_conj) Interferon_0\NNP|for|combination (r_nmod) therapy_4\NN|.|anemia (r_nsubj) produces_9\VBZ|NONE (l_dobj) anemia_11\NN|.|therapy
D012254_D019698 NONE ribavirin_2\RB|and (r_conj) Interferon_0\NNP|for|combination (r_nmod) therapy_4\NN|.|anemia (l_prep) for_5\IN|Interferon|combination (l_pobj) C_8\NNP|NONE
D012254_D019698 NONE ribavirin_27\RB|NONE (r_pobj) with_26\IN|NONE (r_prep) combination_25\NN|NONE (r_pobj) in_24\IN|intramuscularly|for (r_prep) administered_19\VBN|a|of (r_acl) dose_15\NN|NONE (r_pobj) at_13\IN|alphab|who (r_prep) received_9\VBD|hepatitis|chronic (r_relcl) C_7\NNP|NONE
D016898_D019698 NONE Interferon_0\NNP|for|combination (r_nmod) therapy_4\NN|.|anemia (l_prep) for_5\IN|Interferon|combination (l_pobj) C_8\NNP|NONE
D016898_D019698 NONE alpha-2b_12\NN|at|who (r_dobj) received_9\VBD|hepatitis|chronic (r_relcl) C_7\NNP|NONE
D012254_D000740 NONE ribavirin_3\RB| (r_npadvmod) induced_5\VBN|NONE (r_amod) anemia_6\NN|NONE
D012254_D000740 NONE ribavirin_10\RB| (r_npadvmod) induced_12\VBN|NONE (r_amod) anemia_13\NN|NONE
D012254_D000740 NONE ribavirin_12\RB| (r_npadvmod) induced_14\VBN|NONE (r_amod) anemia_15\NN|NONE
D012254_D000740 NONE Ribavirin_0\RB| (r_npadvmod) induced_2\VBN|NONE (r_amod) anemia_3\NN|in|.|during
D016898_D000743 CID Interferon_0\NNP|for|combination (r_nmod) therapy_4\NN|.|anemia (r_nsubj) produces_9\VBZ|NONE (l_dobj) anemia_11\NN|.|therapy
19549709
D010984_D002289 NONE platinum_18\NN|based|)|or||chemotherapy|inhibitors|( (r_nmod) stratum_21\NN|two|chemotherapy|prior|,|, (r_appos) regimens_15\NNS|NONE (r_pobj) with_9\IN|IIIb|:|, (r_prep) METHODS_0\NNS|RAD|day|.|until (l_appos) IIIb_3\NNS|with|:|, (l_conj) patients_7\NNS|or|Stage (l_compound) NSCLC_6\NNP|IV
C107135_D064420 NONE RAD001_41\NNP|METHODS|day|.|until (r_dobj) received_40\VBD|NONE (l_prep) until_46\IN|METHODS|RAD|day|. (l_pobj) progression_47\NN|NONE (l_conj) toxicity_50\NN|or
D014443_D002289 NONE tyrosine_32\NN|)|stratum|(|kinase (r_compound) inhibitors_34\NNS|based|platinum|)|or||chemotherapy|( (r_conj) stratum_21\NN|two|chemotherapy|prior|,|, (r_appos) regimens_15\NNS|NONE (r_pobj) with_9\IN|IIIb|:|, (r_prep) METHODS_0\NNS|RAD|day|.|until (l_appos) IIIb_3\NNS|with|:|, (l_conj) patients_7\NNS|or|Stage (l_compound) NSCLC_6\NNP|IV
D020123_D002289 NONE rapamycin_10\NNS|)|( (r_nmod) mTOR_12\NNP|NONE (r_pobj) of_9\IN|mammalian|the (r_prep) target_8\NN|NONE (r_pobj) of_5\IN|an|oral (r_prep) inhibitor_4\NN|,|, (r_appos) RAD001_0\NNP|.|has|phase (r_nsubj) shown_16\VBN|NONE (l_dobj) phase_17\NN|.|has|RAD (l_prep) in_20\IN|efficacy|I (l_pobj) NSCLC_21\NNP|NONE
D014443_D064420 NONE tyrosine_32\NN|)|stratum|(|kinase (r_compound) inhibitors_34\NNS|based|platinum|)|or||chemotherapy|( (r_conj) stratum_21\NN|two|chemotherapy|prior|,|, (r_appos) regimens_15\NNS|NONE (r_pobj) with_9\IN|IIIb|:|, (r_prep) METHODS_0\NNS|RAD|day|.|until (r_nsubj) received_40\VBD|NONE (l_prep) until_46\IN|METHODS|RAD|day|. (l_pobj) progression_47\NN|NONE (l_conj) toxicity_50\NN|or
C107135_D002289 NONE everolimus_2\NN|NONE (r_pobj) of_1\IN|.|in (r_prep) Efficacy_0\NN|NONE (l_prep) in_6\IN|.|of (l_pobj) patients_7\NNS|or|with (l_prep) with_8\IN|treated (l_pobj) NSCLC_10\NNP|NONE
C107135_D002289 NONE RAD001_4\NNP|(|) (r_appos) everolimus_2\NN|NONE (r_pobj) of_1\IN|.|in (r_prep) Efficacy_0\NN|NONE (l_prep) in_6\IN|.|of (l_pobj) patients_7\NNS|or|with (l_prep) with_8\IN|treated (l_pobj) NSCLC_10\NNP|NONE
C107135_D002289 NONE RAD001_0\NNP|.|has|phase (r_nsubj) shown_16\VBN|NONE (l_dobj) phase_17\NN|.|has|RAD (l_prep) in_20\IN|efficacy|I (l_pobj) NSCLC_21\NNP|NONE
C107135_D002289 NONE RAD001_41\NNP|METHODS|day|.|until (r_dobj) received_40\VBD|NONE (l_nsubj) METHODS_0\NNS|RAD|day|.|until (l_appos) IIIb_3\NNS|with|:|, (l_conj) patients_7\NNS|or|Stage (l_compound) NSCLC_6\NNP|IV
C107135_D002289 NONE RAD001_2\NNP|NONE (r_pobj) of_1\IN|therapy|plus (r_prep) Evaluation_0\NN|.|NSCLC (r_nsubj) continues_9\VBZ|NONE (l_nsubj) NSCLC_8\NNP|Evaluation|.
D010984_D064420 NONE platinum_18\NN|based|)|or||chemotherapy|inhibitors|( (r_nmod) stratum_21\NN|two|chemotherapy|prior|,|, (r_appos) regimens_15\NNS|NONE (r_pobj) with_9\IN|IIIb|:|, (r_prep) METHODS_0\NNS|RAD|day|.|until (r_nsubj) received_40\VBD|NONE (l_prep) until_46\IN|METHODS|RAD|day|. (l_pobj) progression_47\NN|NONE (l_conj) toxicity_50\NN|or
7671401
D000806_D000799 CID inhibitor_19\NN|NONE (r_pobj) with_14\IN|term (r_prep) therapy_13\NN|NONE (r_pobj) to_9\IN|NONE (r_prep) related_8\VBN|angio| (r_acl) oedema_7\NN|NONE
D000806_D000799 CID inhibitors_6\NNS|NONE (r_pobj) of_4\IN|the (r_prep) introduction_3\NN|NONE (r_pobj) after_1\IN|in|.|bouts|Soon|were|, (r_prep) reported_15\VBN|NONE (l_nsubjpass) bouts_9\NNS|after|in|.|Soon|were|, (l_prep) of_10\IN|acute (l_pobj) oedema_13\NN|NONE
D000806_D000799 CID inhibitors_13\NNS|NONE (r_pobj) to_11\IN|adverse|after (r_prep) reactions_10\NNS|NONE (l_prep) after_14\IN|adverse|to (l_conj) in_20\IN|use|and (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|NONE (l_pobj) oedema_28\NN|NONE
D000806_D006973 NONE inhibitors_7\NNS|converting (l_acl) used_9\VBD|(|,|)|ACE|, (l_xcomp) treat_11\VB|NONE (l_dobj) hypertension_12\NN|to
D000806_D006333 NONE inhibitors_7\NNS|converting (l_acl) used_9\VBD|(|,|)|ACE|, (l_xcomp) treat_11\VB|NONE (l_dobj) hypertension_12\NN|to (l_conj) failure_16\NN|and
24464946
D015251_D008228 NONE epirubicin_13\NNS|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|five|with (r_acl) patients_5\NNS|: (l_prep) with_6\IN|five|treated (l_pobj) lymphoma_10\NN|NONE
D015251_D006331 NONE epirubicin_25\NNS|NONE (r_compound) exposure_26\NN|NONE (r_pobj) after_24\IN|dysfunction|alterations|could|whether (r_prep) predict_18\VB|.|To (l_dobj) dysfunction_21\NN|alterations|could|after|whether
D015251_D066126 CID epirubicine_22\NN| (r_npadvmod) based_24\VBN|NONE (r_amod) chemotherapy_25\NN|NONE (r_pobj) during_21\IN|prediction|early|and (r_prep) detection_16\NN|NONE (l_conj) prediction_18\NN|during|early|and (l_prep) of_19\IN|NONE (l_pobj) cardiotoxicity_20\NN|NONE
D015251_D009202 NONE epirubicin_25\NNS|NONE (r_compound) exposure_26\NN|NONE (r_pobj) after_24\IN|dysfunction|alterations|could|whether (r_prep) predict_18\VB|.|To (l_nsubj) alterations_3\NNS|dysfunction|could|after|whether (l_prep) of_4\IN|NONE (l_pobj) strain_6\NN|NONE
D018943_D006331 NONE anthracycline_20\NN| (r_advmod) based_22\VBN|NONE (r_amod) chemotherapy_23\NN|NONE (r_dobj) receiving_19\VBG|NONE (r_acl) patients_18\NNS|NONE (r_pobj) in_17\IN|cardiac (r_prep) dysfunction_16\NN|to
1756784
D010862_D013226 CID pilocarpine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) status_10\NN|NONE (r_pobj) during_6\IN|of (r_prep) Damage_0\NN|in|study|.|: (r_nsubj) epilepticus_11\NN|NONE
D010862_D013226 CID pilocarpine_12\NN|NONE (r_pobj) of_11\IN|systemic|in (r_prep) injection_10\NN|NONE (r_pobj) by_8\IN|In|epilepticus|,|.|was (r_agent) induced_7\VBN|NONE (l_nsubjpass) epilepticus_5\NN|by|In|,|.|was
D002118_D009422 NONE calcium_10\NN| (r_npadvmod) binding_12\VBG|the|specific|,|parvalbumin (r_amod) protein_13\NN|NONE (r_pobj) against_5\IN||Nissl|antibodies|and|, (r_prep) staining_2\VBG|.|detect (r_nsubj) served_17\VBD|NONE (l_xcomp) detect_19\VB|.|staining (l_dobj) damage_21\NN|to
D010862_D001930 CID pilocarpine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) status_10\NN|NONE (r_pobj) during_6\IN|of (r_prep) Damage_0\NN|in|study|.|: (l_prep) of_1\IN|during (l_pobj) reticulata_5\NNS|NONE
9570197
D003042_D002637 NONE hydrochloride_78\NN|)|control|or (r_conj) subjects_74\NNS|,|( (r_appos) n=10_71\NNP|fraction|and|LV|before (r_appos) volumes_50\NNS|referred|we|,|.|and|,|rate (r_conj) measured_28\VBD|NONE (l_ccomp) referred_16\VBD|we|,|.|and|,|rate|volumes (l_prep) for_17\IN|In|:|patients (l_pobj) catheterization_19\NN|NONE (l_prep) for_20\IN|cardiac (l_pobj) evaluation_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) pain_25\NN|NONE
D003042_D018487 CID cocaine_8\NN|NONE (r_pobj) of_6\IN|large|a (r_prep) amount_5\NN|.|In|,|deterioration (r_nsubj) causes_9\VBZ|NONE (l_dobj) deterioration_12\NN|.|amount|In|, (l_prep) of_13\IN|profound|and|a|increase (l_pobj) function_20\NN|NONE
D003042_D018487 CID cocaine_7\NN|NONE (r_pobj) of_6\IN|the|intracoronary|sufficient (r_prep) infusion_5\NN|deterioration|,|.|In (r_nsubj) causes_21\VBZ|NONE (l_dobj) deterioration_23\NN|,|.|infusion|In (l_prep) of_24\IN|a (l_pobj) performance_29\NN|NONE
24691439
C075773_D009798 NONE 4-phenylbutyrate_11\RB|NONE (r_pobj) with_9\IN|of (r_prep) reduction_2\NN|hypertension|,|.|Furthermore (r_nsubj) prevented_12\VBN|NONE (l_dobj) hypertension_17\NN|,|reduction|.|Furthermore
D003907_D009798 CID dexamethasone_2\NN| (r_npadvmod) induced_4\VBN|ocular (r_amod) hypertension_6\NN|was|with|,|Furthermore|.
D003907_D009798 CID Dexamethasone_0\NN|CHOP|,|in|and|reduced (r_nsubj) induced_1\VBD|NONE (l_conj) reduced_23\VBN|CHOP|,|in|and|Dexamethasone (l_conj) prevented_30\VBN|deletion|stress|in|.|and (l_dobj) hypertension_35\NN|NONE
D003907_D009798 CID dexamethasone_31\NN| (r_npadvmod) induced_33\VBN|ocular (r_amod) hypertension_35\NN|NONE
D003907_D009798 CID dexamethasone_13\NN| (r_npadvmod) induced_15\VBN|in|ocular (r_amod) hypertension_17\NN|,|reduction|.|Furthermore
D003907_D009410 CID dexamethasone_9\NN|NONE (r_pobj) with_4\IN|of (r_prep) Treatment_0\NN|to|,|.|resembling (r_nsubj) led_10\VBN|NONE (l_prep) to_11\IN|,|Treatment|.|resembling (l_pobj) elevation_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) pressure_15\NN|NONE (l_appos) loss_23\NN|(|intraocular|IOP (l_conj) degeneration_31\NN|functional|,|of|and
D003907_D012173 NONE dexamethasone_9\NN|NONE (r_pobj) with_4\IN|of (r_prep) Treatment_0\NN|to|,|.|resembling (r_nsubj) led_10\VBN|NONE (l_prep) to_11\IN|,|Treatment|.|resembling (l_pobj) elevation_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) pressure_15\NN|NONE (l_appos) loss_23\NN|(|intraocular|IOP (l_prep) of_24\IN|functional|degeneration|,|and (l_pobj) cells_27\NNS|NONE (l_compound) ganglion_26\NN|retinal
D003907_D005901 CID dexamethasone_9\NN|NONE (r_pobj) with_4\IN|of (r_prep) Treatment_0\NN|to|,|.|resembling (r_nsubj) led_10\VBN|NONE (l_advcl) resembling_33\VBG|to|,|Treatment|. (l_dobj) glaucoma_37\NN|NONE
24971338
D004801_D007674 NONE eosin_7\NN|,|and|Schiff (r_conj) hematoxylin_5\NN|NONE (r_pobj) in_4\IN|.|lesions|were (r_prep) analyzed_3\VBN|NONE (l_nsubjpass) lesions_1\NNS|.|in|were
D006416_D007674 NONE hematoxylin_5\NN|NONE (r_pobj) in_4\IN|.|lesions|were (r_prep) analyzed_3\VBN|NONE (l_nsubjpass) lesions_1\NNS|.|in|were
D020123_D011507 CID SRL_0\NN| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|as|.|proteinuria|) (r_nsubj) presented_4\VBD|NONE (l_dobj) proteinuria_5\NN|rats|as|.|)
D020123_D007674 NONE sirolimus_2\VB|NONE (r_relcl) Conversion_0\NN|in|nephropathy (r_nsubj) ameliorates_3\VBZ|.|:|on (l_dobj) nephropathy_7\NN|Conversion|in
D020123_D007674 NONE sirolimus_10\VB|NONE (r_pobj) to_9\TO|from (r_prep) conversion_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Protocols_0\NNS|after|SRL|,|(|)|have|in|been|widely|but|remain (r_nsubjpass) used_17\VBN|NONE (l_prep) after_20\IN|SRL|,|(|)|Protocols|have|in|been|widely|but|remain (l_pobj) transplantation_21\NN|NONE (l_relcl) prevent_23\VB|NONE (l_dobj) nephropathy_27\NN|to
D020123_D007674 NONE SRL_12\NN|after|,|(|)|Protocols|have|in|been|widely|but|remain (r_nsubjpass) used_17\VBN|NONE (l_prep) after_20\IN|SRL|,|(|)|Protocols|have|in|been|widely|but|remain (l_pobj) transplantation_21\NN|NONE (l_relcl) prevent_23\VB|NONE (l_dobj) nephropathy_27\NN|to
D020123_D007674 NONE SRL_0\NN| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|as|.|proteinuria|) (r_nsubj) presented_4\VBD|NONE (l_prep) as_13\IN|rats|.|proteinuria|) (l_pobj) markers_16\NNS|NONE (l_prep) of_17\IN|best|the (l_pobj) impairment_19\NN|NONE
D020123_D007674 NONE SRL_2\NNP|NONE (r_pobj) to_1\IN|NONE (r_prep) Conversion_0\NN|seems|.|evolution|, (r_nsubj) prevented_3\VBN|NONE (l_dobj) evolution_9\NN|Conversion|seems|.|, (l_compound) damage_8\NN|renal|induced|lesions
D020123_D007674 NONE SRL_35\NNP|NONE (r_pobj) to_34\IN|CsA (r_prep) replacement_33\NN|NONE (r_pobj) of_31\IN|feasible|a (r_prep) biomarker_30\NN|to (r_attr) be_27\VB|while|NGAL (r_xcomp) seems_25\VBZ|Conversion|.|evolution|, (r_advcl) prevented_3\VBN|NONE (l_dobj) evolution_9\NN|Conversion|seems|.|, (l_compound) damage_8\NN|renal|induced|lesions
D016572_D007674 CID cyclosporine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) nephropathy_7\NN|Conversion|in
D016572_D007674 CID A_5\NNP|NONE (r_pobj) from_3\IN|to (r_prep) conversion_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Protocols_0\NNS|after|SRL|,|(|)|have|in|been|widely|but|remain (r_nsubjpass) used_17\VBN|NONE (l_prep) after_20\IN|SRL|,|(|)|Protocols|have|in|been|widely|but|remain (l_pobj) transplantation_21\NN|NONE (l_relcl) prevent_23\VB|NONE (l_dobj) nephropathy_27\NN|to
D016572_D007674 CID CsA_7\NNP|cyclosporin (r_appos) A_5\NNP|NONE (r_pobj) from_3\IN|to (r_prep) conversion_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Protocols_0\NNS|after|SRL|,|(|)|have|in|been|widely|but|remain (r_nsubjpass) used_17\VBN|NONE (l_prep) after_20\IN|SRL|,|(|)|Protocols|have|in|been|widely|but|remain (l_pobj) transplantation_21\NN|NONE (l_relcl) prevent_23\VB|NONE (l_dobj) nephropathy_27\NN|to
D016572_D007674 CID CsA_24\NNP| (r_npadvmod) induced_26\VBN|NONE (r_amod) nephropathy_27\NN|to
D016572_D007674 CID CsA_1\NNP|Short (r_compound) treatment_2\NN|CTGF|.|KIM|and|lesions|, (r_nsubj) presented_3\VBD|NONE (l_dobj) lesions_9\NNS|CTGF|.|treatment|KIM|and|,
D016572_D007674 CID CsA_1\NNP|Prolonged (r_compound) exposure_2\NN|.|b|damage|,|without (r_nsubj) aggravated_3\VBD|NONE (l_dobj) damage_5\NN|.|exposure|b|,|without
D016572_D007674 CID CsA_4\NNP| (r_npadvmod) induced_6\VBN|renal|damage|lesions (r_amod) evolution_9\NN|Conversion|seems|.|, (l_compound) damage_8\NN|renal|induced|lesions
D016572_D007674 CID CsA_32\NNP|to (r_compound) replacement_33\NN|NONE (r_pobj) of_31\IN|feasible|a (r_prep) biomarker_30\NN|to (r_attr) be_27\VB|while|NGAL (r_xcomp) seems_25\VBZ|Conversion|.|evolution|, (r_advcl) prevented_3\VBN|NONE (l_dobj) evolution_9\NN|Conversion|seems|.|, (l_compound) damage_8\NN|renal|induced|lesions
24671324
D003907_D001424 NONE dexamethasone_5\NN| (r_npadvmod) containing_7\VBG|dose (r_amod) regimens_8\NNS|and (r_conj) Bortezomib_0\NNP|be|.|are (r_nsubjpass) considered_10\VBN|NONE (l_xcomp) be_12\VB|.|Bortezomib|are (l_acomp) tolerable_14\JJ|to (l_prep) with_15\IN|generally (l_pobj) infections_19\NNS|NONE
D003907_D001424 NONE dexamethasone_16\NN|NONE (r_pobj) to_10\IN|NONE (r_prep) related_9\VBN|bacterial|fatal (r_acl) infections_8\NNS|NONE
C400082_D008258 NONE bortezomib_3\NNS|in|containing (r_amod) regimen_8\NN|NONE (l_prep) in_9\IN|bortezomib|containing (l_pobj) patient_12\NN|NONE (l_prep) of_13\IN|elderly|an (l_pobj) macroglobulinaemia_15\NN|NONE
C400082_D008258 NONE bortezomib_24\NNS|,|and|dose|rituximab (r_amod) dexamethasone_29\NN|NONE (r_pobj) with_23\IN|combination|the (r_prep) treatment_22\NN|NONE (r_pobj) after_19\IN|who|fasciitis|without (r_prep) suffered_14\VBD|old|with|a (r_relcl) man_9\NN|NONE (l_prep) with_10\IN|old|suffered|a (l_pobj) macroglobulinaemia_12\NN|NONE
C400082_D009369 NONE Bortezomib_0\NNP|be|.|are (r_nsubjpass) considered_10\VBN|NONE (l_xcomp) be_12\VB|.|Bortezomib|are (l_acomp) tolerable_14\JJ|to (l_prep) with_15\IN|generally (l_pobj) infections_19\NNS|NONE (l_prep) in_20\IN|severe|bacterial|few (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|NONE (l_pobj) malignancies_26\NNS|NONE
D003907_D008258 NONE dexamethasone_5\NN| (r_npadvmod) containing_7\VBG|in|bortezomib (r_amod) regimen_8\NN|NONE (l_prep) in_9\IN|bortezomib|containing (l_pobj) patient_12\NN|NONE (l_prep) of_13\IN|elderly|an (l_pobj) macroglobulinaemia_15\NN|NONE
D003907_D008258 NONE dexamethasone_29\NN|NONE (r_pobj) with_23\IN|combination|the (r_prep) treatment_22\NN|NONE (r_pobj) after_19\IN|who|fasciitis|without (r_prep) suffered_14\VBD|old|with|a (r_relcl) man_9\NN|NONE (l_prep) with_10\IN|old|suffered|a (l_pobj) macroglobulinaemia_12\NN|NONE
D003907_D009503 NONE dexamethasone_29\NN|NONE (r_pobj) with_23\IN|combination|the (r_prep) treatment_22\NN|NONE (r_pobj) after_19\IN|who|fasciitis|without (r_prep) suffered_14\VBD|old|with|a (l_prep) without_17\IN|who|fasciitis|after (l_pobj) neutropenia_18\NN|NONE
C400082_D019115 CID bortezomib_3\NNS|in|containing (r_amod) regimen_8\NN|NONE (r_pobj) after_2\IN|.|Necrotising (r_prep) fasciitis_1\NN|NONE
C400082_D019115 CID bortezomib_24\NNS|,|and|dose|rituximab (r_amod) dexamethasone_29\NN|NONE (r_pobj) with_23\IN|combination|the (r_prep) treatment_22\NN|NONE (r_pobj) after_19\IN|who|fasciitis|without (r_prep) suffered_14\VBD|old|with|a (l_dobj) fasciitis_16\NN|who|without|after
C400082_D009503 NONE bortezomib_24\NNS|,|and|dose|rituximab (r_amod) dexamethasone_29\NN|NONE (r_pobj) with_23\IN|combination|the (r_prep) treatment_22\NN|NONE (r_pobj) after_19\IN|who|fasciitis|without (r_prep) suffered_14\VBD|old|with|a (l_prep) without_17\IN|who|fasciitis|after (l_pobj) neutropenia_18\NN|NONE
D003907_D009369 NONE dexamethasone_5\NN| (r_npadvmod) containing_7\VBG|dose (r_amod) regimens_8\NNS|and (r_conj) Bortezomib_0\NNP|be|.|are (r_nsubjpass) considered_10\VBN|NONE (l_xcomp) be_12\VB|.|Bortezomib|are (l_acomp) tolerable_14\JJ|to (l_prep) with_15\IN|generally (l_pobj) infections_19\NNS|NONE (l_prep) in_20\IN|severe|bacterial|few (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|NONE (l_pobj) malignancies_26\NNS|NONE
C400082_D001424 NONE Bortezomib_0\NNP|be|.|are (r_nsubjpass) considered_10\VBN|NONE (l_xcomp) be_12\VB|.|Bortezomib|are (l_acomp) tolerable_14\JJ|to (l_prep) with_15\IN|generally (l_pobj) infections_19\NNS|NONE
C400082_D001424 NONE bortezomib_11\NNS|dose|in (r_amod) dexamethasone_16\NN|NONE (r_pobj) to_10\IN|NONE (r_prep) related_9\VBN|bacterial|fatal (r_acl) infections_8\NNS|NONE
D003907_D019115 CID dexamethasone_5\NN| (r_npadvmod) containing_7\VBG|in|bortezomib (r_amod) regimen_8\NN|NONE (r_pobj) after_2\IN|.|Necrotising (r_prep) fasciitis_1\NN|NONE
D003907_D019115 CID dexamethasone_29\NN|NONE (r_pobj) with_23\IN|combination|the (r_prep) treatment_22\NN|NONE (r_pobj) after_19\IN|who|fasciitis|without (r_prep) suffered_14\VBD|old|with|a (l_dobj) fasciitis_16\NN|who|without|after
16801510
D008691_D016171 NONE methadone_8\NN|the (r_compound) group_9\NN|NONE (r_pobj) in_6\IN|%|)|(|Six (r_prep) patients_1\NNS|.|pointes (r_nsubj) presented_10\VBD|NONE (l_dobj) pointes_13\FW|.|patients
D008691_D007008 NONE methadone_12\NN|NONE (r_compound) dose_13\NN|NONE (r_pobj) to_11\IN|of (r_prep) attribution_4\NN|analysis|.|cytochrome (r_dobj) allowed_3\VBD|NONE (l_conj) cytochrome_15\NN|analysis|.|attribution (l_dobj) interactions_21\NNS|, (l_appos) hypokalemia_23\NN|drug|A|,
D011188_D008133 NONE potassium_3\NN|,|function|and (r_compound) level_4\NN|,|A (r_conj) inhibitors_1\NNS|.|to (r_nsubj) contribute_9\VBP|NONE (l_prep) to_10\IN|.|inhibitors (l_pobj) prolongation_12\NN|NONE
D008691_D008133 CID methadone_11\NN|NONE (r_dobj) receiving_10\VBG|drug (r_acl) users_9\NNS|NONE (r_pobj) in_6\IN|long|.|induced|QT (r_prep) syndrome_5\NN|NONE
D008691_D008133 CID methadone_12\NN|NONE (r_compound) treatment_13\NN|NONE (r_pobj) with_11\IN|interval|QT (r_prep) prolongation_10\NN|NONE
D008691_D008133 CID methadone_3\NN|NONE (r_compound) dose_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) addition_1\NN|NONE (r_pobj) In_0\IN|as|were|,|.|variables (r_prep) considered_15\VBN|NONE (l_prep) as_16\IN|were|In|,|.|variables (l_pobj) factors_19\NNS|NONE (l_prep) for_20\IN|potential|risk (l_pobj) prolongation_22\NN|NONE
D008691_D008133 CID methadone_4\NN|hospitalized|maintenance (r_compound) patients_6\NNS|NONE (r_pobj) in_3\IN|interval|QT (r_prep) prolongation_2\NN|finding|.
D008691_D008133 CID methadone_9\NN|NONE (r_pobj) of_8\IN|low (r_prep) doses_7\NNS|NONE (r_pobj) with_5\IN|syndrome|.|can (r_prep) occur_4\VB|NONE (l_nsubj) syndrome_2\NN|.|can|with
24158386
D002945_D064420 NONE cisplatin_2\NN|and (r_conj) Gemcitabine_0\NNP|.|,|and|delivered|activity (r_nsubj) have_3\VBP|NONE (l_dobj) activity_4\NN|.|,|and|delivered|Gemcitabine (l_prep) in_5\IN|NONE (l_pobj) toxicity_11\NN|NONE
C056507_D064420 NONE Gemcitabine_0\NNP|.|,|and|delivered|activity (r_nsubj) have_3\VBP|NONE (l_dobj) activity_4\NN|.|,|and|delivered|Gemcitabine (l_prep) in_5\IN|NONE (l_pobj) toxicity_11\NN|NONE
D002945_D006689 NONE cisplatin_2\NN|and (r_conj) Gemcitabine_0\NNP|.|,|and|delivered|activity (r_nsubj) have_3\VBP|NONE (l_dobj) activity_4\NN|.|,|and|delivered|Gemcitabine (l_prep) in_5\IN|NONE (l_pobj) toxicity_11\NN|NONE (l_amod) overlapping_10\VBG|with (l_npadvmod) HL_6\NNP|
D002945_D006689 NONE cisplatin_38\NN|.|were (r_nsubjpass) included_55\VBN|with|methylprednisolone|In|;|and|patients|, (r_conj) treated_14\VBN|NONE (l_nsubj) patients_8\NNS|with|methylprednisolone|In|;|included|and|, (l_prep) with_9\IN|NONE (l_pobj) HL_13\NN|NONE
D008775_D006689 NONE methylprednisolone_30\NN|with|In|;|included|and|patients|, (r_advcl) treated_14\VBN|NONE (l_nsubj) patients_8\NNS|with|methylprednisolone|In|;|included|and|, (l_prep) with_9\IN|NONE (l_pobj) HL_13\NN|NONE
C056507_D006689 NONE GEM_0\NN| (r_compound) P_2\NN|NONE (r_compound) chemotherapy_3\NN|active|. (r_nsubj) is_4\VBZ|NONE (l_acomp) active_5\JJ|chemotherapy|. (l_prep) in_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) lymphoma_12\NN|NONE
C056507_D006689 NONE Gemcitabine_0\NNP|.|,|and|delivered|activity (r_nsubj) have_3\VBP|NONE (l_dobj) activity_4\NN|.|,|and|delivered|Gemcitabine (l_prep) in_5\IN|NONE (l_pobj) toxicity_11\NN|NONE (l_amod) overlapping_10\VBG|with (l_npadvmod) HL_6\NNP|
C056507_D006689 NONE gemcitabine_16\NN|D)|(|)|; (r_amod) day_22\NN|NONE (r_pobj) with_15\IN|methylprednisolone|In|;|included|and|patients|, (r_prep) treated_14\VBN|NONE (l_nsubj) patients_8\NNS|with|methylprednisolone|In|;|included|and|, (l_prep) with_9\IN|NONE (l_pobj) HL_13\NN|NONE
C056507_D006689 NONE GEM_50\NNP| (r_compound) P_52\NNP|every||)|( (r_appos) days_48\NNS|,|)|m( (r_appos) D15_44\NNP|NONE (r_dobj) cisplatin_38\NN|.|were (r_nsubjpass) included_55\VBN|with|methylprednisolone|In|;|and|patients|, (r_conj) treated_14\VBN|NONE (l_nsubj) patients_8\NNS|with|methylprednisolone|In|;|included|and|, (l_prep) with_9\IN|NONE (l_pobj) HL_13\NN|NONE
C056507_D006689 NONE GEM_0\NN| (r_compound) P_2\NNP|in|.|leading|,|chemotherapy|, (r_nsubj) is_3\VBZ|NONE (l_prep) in_21\IN|P|.|leading|,|chemotherapy|, (l_pobj) treatment_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) HL_28\NN|NONE
2931989
D015474_C563492 NONE Isotretinoin_0\NNP|because|.|in|is (r_nsubjpass) contraindicated_2\VBN|NONE (l_prep) because_5\IN|Isotretinoin|.|in|is (l_pobj) abnormalities_11\NNS|of (l_prep) after_12\IN|congenital|reported|the|many (l_pobj) use_14\NN|NONE (l_prep) including_16\VBG|maternal|(|) (l_pobj) microphthalmos_17\NNS|NONE (l_conj) hypertelorism_20\NN|, (l_conj) hypoplasia_25\NN|orbital|,|and
D015474_D000013 NONE Isotretinoin_0\NNP|because|.|in|is (r_nsubjpass) contraindicated_2\VBN|NONE (l_prep) because_5\IN|Isotretinoin|.|in|is (l_pobj) abnormalities_11\NNS|of
D015474_D000152 NONE isotretinoin_13\JJ|who (r_dobj) received_12\VBD|drug||, (r_relcl) patients_10\NNS|NONE (l_appos) drug_18\NN||,|received (l_prep) in_19\IN|a|used (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) acne_25\NN|NONE
D015474_D006972 NONE Isotretinoin_0\NNP|because|.|in|is (r_nsubjpass) contraindicated_2\VBN|NONE (l_prep) because_5\IN|Isotretinoin|.|in|is (l_pobj) abnormalities_11\NNS|of (l_prep) after_12\IN|congenital|reported|the|many (l_pobj) use_14\NN|NONE (l_prep) including_16\VBG|maternal|(|) (l_pobj) microphthalmos_17\NNS|NONE (l_conj) hypertelorism_20\NN|,
D015474_D008850 NONE Isotretinoin_0\NNP|because|.|in|is (r_nsubjpass) contraindicated_2\VBN|NONE (l_prep) because_5\IN|Isotretinoin|.|in|is (l_pobj) abnormalities_11\NNS|of (l_prep) after_12\IN|congenital|reported|the|many (l_pobj) use_14\NN|NONE (l_prep) including_16\VBG|maternal|(|) (l_pobj) microphthalmos_17\NNS|NONE
18987260
D004317_D014511 CID ADR_9\NNP|advanced|in (r_compound) nephropathy_10\NN|NONE (r_pobj) in_7\IN|urea (r_prep) clearance_6\NN|NONE (r_dobj) increased_4\VBN|.|uraemia|Losartan|and (r_conj) reduced_1\VBD|NONE (l_dobj) uraemia_2\RB|.|Losartan|increased|and
D004317_D006973 NONE adriamycin_3\JJ|NONE (r_amod) nephropathy_4\NN|NONE (r_pobj) of_2\IN|Reduced|.|in (r_prep) progression_1\NN|NONE (l_prep) in_5\IN|Reduced|.|of (l_pobj) rats_8\NNS|NONE (l_amod) hypertensive_7\JJ|treated
D004317_D006973 NONE adriamycin_37\NNS|ADR|)|( (r_nmod) nephropathy_41\NN|NONE (r_pobj) with_36\IN|renal|disease|in (r_prep) progression_28\NN|down (l_prep) in_29\IN|with|renal|disease (l_pobj) rats_32\NNS|NONE (l_amod) hypertensive_31\JJ|SHR|)|(
D004317_D006973 NONE ADR_39\NNP|adriamycin|)|( (r_nmod) nephropathy_41\NN|NONE (r_pobj) with_36\IN|renal|disease|in (r_prep) progression_28\NN|down (l_prep) in_29\IN|with|renal|disease (l_pobj) rats_32\NNS|NONE (l_amod) hypertensive_31\JJ|SHR|)|(
D014508_D007674 NONE urea_5\NN|in (r_compound) clearance_6\NN|NONE (l_prep) in_7\IN|urea (l_pobj) nephropathy_10\NN|NONE
D004317_D007674 NONE adriamycin_3\JJ|NONE (r_amod) nephropathy_4\NN|NONE
D004317_D007674 NONE adriamycin_37\NNS|ADR|)|( (r_nmod) nephropathy_41\NN|NONE (r_pobj) with_36\IN|renal|disease|in (r_prep) progression_28\NN|down (l_compound) disease_27\NN|with|renal|in
D004317_D007674 NONE adriamycin_37\NNS|ADR|)|( (r_nmod) nephropathy_41\NN|NONE
D004317_D007674 NONE ADR_39\NNP|adriamycin|)|( (r_nmod) nephropathy_41\NN|NONE (r_pobj) with_36\IN|renal|disease|in (r_prep) progression_28\NN|down (l_compound) disease_27\NN|with|renal|in
D004317_D007674 NONE ADR_39\NNP|adriamycin|)|( (r_nmod) nephropathy_41\NN|NONE
D004317_D007674 NONE ADR_9\NNP|advanced|in (r_compound) nephropathy_10\NN|NONE
D004317_D007674 NONE ADR_15\NNP|NONE (r_compound) nephropathy_16\NN|NONE
D000804_D007674 NONE II_13\CD|losartan|receptor|,|type (r_compound) blocker_16\NN|NONE (l_conj) losartan_18\NN|receptor|II|,|type (l_conj) potential_22\NN|,|and (l_prep) in_23\IN|its (l_pcomp) slowing_24\VBG|NONE (l_dobj) progression_28\NN|down (l_compound) disease_27\NN|with|renal|in
D000804_D007674 NONE II_13\CD|losartan|receptor|,|type (r_compound) blocker_16\NN|NONE (l_conj) losartan_18\NN|receptor|II|,|type (l_conj) potential_22\NN|,|and (l_prep) in_23\IN|its (l_pcomp) slowing_24\VBG|NONE (l_dobj) progression_28\NN|down (l_prep) with_36\IN|renal|disease|in (l_pobj) nephropathy_41\NN|NONE
D019808_D011507 NONE losartan_4\NN|term (r_amod) treatment_5\NN|.|besides|,|,|:|rate (r_nsubj) improved_11\VBD|NONE (l_dobj) rate_14\NN|.|treatment|besides|,|,|: (l_acl) resulting_18\VBG|and|glomerulosclerosis|glomerular|filtration (l_prep) in_19\IN|NONE (l_pobj) proteinuria_21\NN|NONE
D019808_D011507 NONE losartan_3\NN|NONE (r_pobj) with_2\IN|Prolonged (r_prep) treatment_1\NN|preventing|.|reduction|, (r_nsubj) showed_4\VBD|NONE (l_advcl) preventing_21\VBG|treatment|.|reduction|, (l_dobj) proteinuria_23\NN|thus
D004317_D001284 NONE ADR_15\NNP|NONE (r_compound) nephropathy_16\NN|NONE (r_pobj) in_14\IN|infiltration|tubular|, (r_prep) atrophy_8\NN|that|losartan|could
D019808_D001284 NONE losartan_3\NN|NONE (r_pobj) with_2\IN|Prolonged (r_prep) treatment_1\NN|preventing|.|reduction|, (r_nsubj) showed_4\VBD|NONE (l_dobj) reduction_6\NN|preventing|treatment|.|, (l_prep) of_7\IN|further (l_pobj) glomerulosclerosis_8\NN|NONE (l_acl) associated_9\VBN|NONE (l_prep) with_10\IN|NONE (l_pobj) progression_12\NN|NONE (l_prep) of_13\IN|reduced (l_pobj) atrophy_15\NN|NONE
D019808_D001284 NONE losartan_4\NN|that|atrophy|could (r_nsubj) prevent_6\VB|examination|. (l_dobj) atrophy_8\NN|that|losartan|could
D019808_D007674 NONE losartan_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) treated_9\VBN|hypertensive (r_acl) rats_8\NNS|NONE (r_pobj) in_5\IN|Reduced|.|of (r_prep) progression_1\NN|NONE (l_prep) of_2\IN|Reduced|.|in (l_pobj) nephropathy_4\NN|NONE
D019808_D007674 NONE losartan_18\NN|receptor|II|,|type (l_conj) potential_22\NN|,|and (l_prep) in_23\IN|its (l_pcomp) slowing_24\VBG|NONE (l_dobj) progression_28\NN|down (l_compound) disease_27\NN|with|renal|in
D019808_D007674 NONE losartan_18\NN|receptor|II|,|type (l_conj) potential_22\NN|,|and (l_prep) in_23\IN|its (l_pcomp) slowing_24\VBG|NONE (l_dobj) progression_28\NN|down (l_prep) with_36\IN|renal|disease|in (l_pobj) nephropathy_41\NN|NONE
D019808_D007674 NONE Losartan_0\NNP|.|uraemia|increased|and (r_nsubj) reduced_1\VBD|NONE (l_conj) increased_4\VBN|.|uraemia|Losartan|and (l_dobj) clearance_6\NN|NONE (l_prep) in_7\IN|urea (l_pobj) nephropathy_10\NN|NONE
D019808_D007674 NONE losartan_4\NN|that|atrophy|could (r_nsubj) prevent_6\VB|examination|. (l_dobj) atrophy_8\NN|that|losartan|could (l_prep) in_14\IN|infiltration|tubular|, (l_pobj) nephropathy_16\NN|NONE
D019808_D005921 NONE losartan_4\NN|term (r_amod) treatment_5\NN|.|besides|,|,|:|rate (r_nsubj) improved_11\VBD|NONE (l_dobj) rate_14\NN|.|treatment|besides|,|,|: (l_conj) glomerulosclerosis_17\NN|and|resulting|glomerular|filtration
D019808_D005921 NONE losartan_3\NN|NONE (r_pobj) with_2\IN|Prolonged (r_prep) treatment_1\NN|preventing|.|reduction|, (r_nsubj) showed_4\VBD|NONE (l_dobj) reduction_6\NN|preventing|treatment|.|, (l_prep) of_7\IN|further (l_pobj) glomerulosclerosis_8\NN|NONE
D019808_D007676 NONE losartan_3\NN|NONE (r_pobj) with_2\IN|Prolonged (r_prep) treatment_1\NN|preventing|.|reduction|, (r_nsubj) showed_4\VBD|NONE (l_advcl) preventing_21\VBG|treatment|.|reduction|, (l_dobj) proteinuria_23\NN|thus (l_conj) failure_27\NN|heavy|and
D019808_D007676 NONE Losartan_0\NNP|to|.|rate (r_nsubj) reduces_1\VBZ|NONE (l_prep) to_13\IN|.|rate|Losartan (l_pobj) disease_18\NN|NONE
D019808_D014511 NONE Losartan_0\NNP|.|uraemia|increased|and (r_nsubj) reduced_1\VBD|NONE (l_dobj) uraemia_2\RB|.|Losartan|increased|and
D004317_D007676 NONE ADR_7\NNP| (r_npadvmod) induced_9\VBN|segmental|focal (r_amod) glomerulosclerosis_12\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) progression_5\NN|NONE (r_pobj) of_4\IN|the (r_prep) rate_3\NN|to|.|Losartan (r_dobj) reduces_1\VBZ|NONE (l_prep) to_13\IN|.|rate|Losartan (l_pobj) disease_18\NN|NONE
D019808_D006973 NONE losartan_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) treated_9\VBN|hypertensive (r_acl) rats_8\NNS|NONE (l_amod) hypertensive_7\JJ|treated
D019808_D006973 NONE losartan_18\NN|receptor|II|,|type (l_conj) potential_22\NN|,|and (l_prep) in_23\IN|its (l_pcomp) slowing_24\VBG|NONE (l_dobj) progression_28\NN|down (l_prep) in_29\IN|with|renal|disease (l_pobj) rats_32\NNS|NONE (l_amod) hypertensive_31\JJ|SHR|)|(
D004317_D005923 CID ADR_7\NNP| (r_npadvmod) induced_9\VBN|segmental|focal (r_amod) glomerulosclerosis_12\NN|NONE
D000804_D006973 NONE II_13\CD|losartan|receptor|,|type (r_compound) blocker_16\NN|NONE (l_conj) losartan_18\NN|receptor|II|,|type (l_conj) potential_22\NN|,|and (l_prep) in_23\IN|its (l_pcomp) slowing_24\VBG|NONE (l_dobj) progression_28\NN|down (l_prep) in_29\IN|with|renal|disease (l_pobj) rats_32\NNS|NONE (l_amod) hypertensive_31\JJ|SHR|)|(
D019808_D005355 NONE losartan_3\NN|NONE (r_pobj) with_2\IN|Prolonged (r_prep) treatment_1\NN|preventing|.|reduction|, (r_nsubj) showed_4\VBD|NONE (l_dobj) reduction_6\NN|preventing|treatment|.|, (l_prep) of_7\IN|further (l_pobj) glomerulosclerosis_8\NN|NONE (l_acl) associated_9\VBN|NONE (l_prep) with_10\IN|NONE (l_pobj) progression_12\NN|NONE (l_prep) of_13\IN|reduced (l_pobj) atrophy_15\NN|NONE (l_conj) fibrosis_18\NN|tubular|and
D019808_D005355 NONE losartan_4\NN|that|atrophy|could (r_nsubj) prevent_6\VB|examination|. (l_dobj) atrophy_8\NN|that|losartan|could (l_conj) infiltration_11\NN|tubular|in|, (l_conj) fibrosis_13\NN|and|interstitial
D019808_D005923 NONE Losartan_0\NNP|to|.|rate (r_nsubj) reduces_1\VBZ|NONE (l_dobj) rate_3\NN|to|.|Losartan (l_prep) of_4\IN|the (l_pobj) progression_5\NN|NONE (l_prep) of_6\IN|NONE (l_pobj) glomerulosclerosis_12\NN|NONE
D004317_D005355 NONE ADR_15\NNP|NONE (r_compound) nephropathy_16\NN|NONE (r_pobj) in_14\IN|infiltration|tubular|, (r_prep) atrophy_8\NN|that|losartan|could (l_conj) infiltration_11\NN|tubular|in|, (l_conj) fibrosis_13\NN|and|interstitial
D014508_D014511 NONE urea_5\NN|in (r_compound) clearance_6\NN|NONE (r_dobj) increased_4\VBN|.|uraemia|Losartan|and (r_conj) reduced_1\VBD|NONE (l_dobj) uraemia_2\RB|.|Losartan|increased|and
1522360
D012293_D006461 CID rifampin_8\NN|intermittent (r_amod) therapy_9\NN|NONE (r_dobj) following_6\VBG|failure|.|Intravascular|and (r_prep) hemolysis_1\NN|NONE
D012293_D006461 CID rifampin_8\NN|therapy|hemolysis|rare|. (r_advmod) is_10\VBZ|NONE (l_nsubj) hemolysis_1\NN|therapy|rifampin|rare|.
D012293_D006461 CID rifampin_12\NN|NONE (r_pobj) following_11\VBG|who|failure (r_prep) developed_5\VBD|with|Two (l_dobj) failure_10\NN|who|following (l_nmod) hemolysis_6\NN|renal|acute
D012293_D007918 NONE rifampin_12\NN|NONE (r_pobj) following_11\VBG|who|failure (r_prep) developed_5\VBD|with|Two (r_relcl) patients_1\NNS|are|. (l_prep) with_2\IN|developed|Two (l_pobj) leprosy_3\NN|NONE
D012293_D058186 CID rifampin_8\NN|intermittent (r_amod) therapy_9\NN|NONE (r_dobj) following_6\VBG|failure|.|Intravascular|and (r_prep) hemolysis_1\NN|NONE (l_conj) failure_5\NN|.|Intravascular|and|following
D012293_D058186 CID rifampin_8\NN|therapy|hemolysis|rare|. (r_advmod) is_10\VBZ|NONE (l_nsubj) hemolysis_1\NN|therapy|rifampin|rare|. (l_acl) leading_2\VBG|Intravascular (l_prep) to_3\IN|NONE (l_pobj) failure_6\NN|NONE
D012293_D058186 CID rifampin_12\NN|NONE (r_pobj) following_11\VBG|who|failure (r_prep) developed_5\VBD|with|Two (l_dobj) failure_10\NN|who|following
D012293_D051437 NONE rifampin_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|a|rare (r_acl) complication_5\NN|.|failure (r_attr) is_2\VBZ|NONE (l_nsubj) failure_1\NN|.|complication
24283660
D016559_D012640 CID Tacrolimus_0\NNP| (r_npadvmod) related_2\VBN|experience|.||after (r_amod) seizure_3\NN|NONE
D016559_D012640 CID TAC_41\NNP|NONE (r_compound) level_42\NN|NONE (r_pobj) trough_40\NN|and|,|after|total (r_conj) bilirubin_35\NN|showed|.|,|before|Pugh|, (r_conj) score_29\NN|NONE (l_ccomp) showed_2\VBD|bilirubin|.|,|before|Pugh|, (l_ccomp) included_13\VBD|analysis (l_nsubj) factors_6\NNS|after|LT|gender|that (l_acl) associated_7\VBN|risk|the (l_prep) with_8\IN|NONE (l_pobj) seizures_9\NNS|NONE
D016559_D012640 CID TAC_5\NNP|trough (r_compound) level_6\NN|that|factor (r_nsubj) was_7\VBD|.|analysis (l_attr) factor_12\NN|that|level (l_acl) associated_13\VBN|risk|the|independent|only (l_prep) with_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D016559_D012640 CID TAC_2\NNP|High|trough (r_compound) level_3\NN|.|factor (r_nsubj) was_4\VBD|NONE (l_attr) factor_7\NN|.|level (l_relcl) contributed_9\VBD|predominant|the (l_prep) to_10\IN|that (l_pobj) seizures_11\NNS|NONE
D016559_D012640 CID TAC_22\NNP| (r_npadvmod) related_24\VBN|NONE (r_amod) seizures_25\NNS|NONE
D001663_D012640 NONE bilirubin_35\NN|showed|.|,|before|Pugh|, (r_conj) score_29\NN|NONE (l_ccomp) showed_2\VBD|bilirubin|.|,|before|Pugh|, (l_ccomp) included_13\VBD|analysis (l_nsubj) factors_6\NNS|after|LT|gender|that (l_acl) associated_7\VBN|risk|the (l_prep) with_8\IN|NONE (l_pobj) seizures_9\NNS|NONE
D016559_D058625 NONE TAC_41\NNP|NONE (r_compound) level_42\NN|NONE (r_pobj) trough_40\NN|and|,|after|total (r_conj) bilirubin_35\NN|showed|.|,|before|Pugh|, (r_conj) score_29\NN|NONE (l_ccomp) showed_2\VBD|bilirubin|.|,|before|Pugh|, (l_ccomp) included_13\VBD|analysis (l_dobj) gender_14\NN|factors|after|LT|that (l_conj) score_22\NN|, (l_compound) disease_21\NN|before
D001663_D058625 NONE bilirubin_35\NN|showed|.|,|before|Pugh|, (r_conj) score_29\NN|NONE (l_ccomp) showed_2\VBD|bilirubin|.|,|before|Pugh|, (l_ccomp) included_13\VBD|analysis (l_dobj) gender_14\NN|factors|after|LT|that (l_conj) score_22\NN|, (l_compound) disease_21\NN|before
2453942
D005680_D012640 NONE GABA_21\NNP|NONE (r_pobj) of_20\IN|the (r_prep) concentration_19\NN|at|in (r_dobj) measuring_17\VBG|NONE (l_prep) at_31\IN|concentration|in (l_pobj) onset_33\NN|NONE (l_prep) of_34\IN|the (l_pobj) seizures_35\NNS|NONE
D001556_D012640 CID lindane_5\NN|NONE (r_pobj) of_4\IN|)|(|mg/kg|the|on (r_prep) effect_3\NN|We|by|. (r_dobj) studied_1\VBD|NONE (l_prep) by_16\IN|We|.|effect (l_pcomp) measuring_17\VBG|NONE (l_prep) at_31\IN|concentration|in (l_pobj) onset_33\NN|NONE (l_prep) of_34\IN|the (l_pobj) seizures_35\NNS|NONE
D001556_D012640 CID lindane_11\NN|NONE (r_compound) administration_12\NN|NONE (r_pobj) after_10\IN|+/|. (r_prep) min_9\NN|NONE (r_pobj) at_5\IN|convulsions|animals|. (r_prep) suffered_2\VBD|NONE (l_dobj) convulsions_4\NNS|at|animals|.
D001556_D020258 NONE Lindane_0\NN|.|insecticide (r_nsubj) is_6\VBZ|NONE (l_attr) insecticide_9\NN|.|Lindane (l_prep) with_10\IN|an|organochlorine (l_pobj) effects_13\NNS|NONE (l_amod) neurotoxic_12\JJ|known
D001556_D020258 NONE hexachlorocyclohexane_4\NN|(|) (r_appos) Lindane_0\NN|.|insecticide (r_nsubj) is_6\VBZ|NONE (l_attr) insecticide_9\NN|.|Lindane (l_prep) with_10\IN|an|organochlorine (l_pobj) effects_13\NNS|NONE (l_amod) neurotoxic_12\JJ|known
D004298_D012640 NONE dopamine_23\NN|, (r_conj) GABA_21\NNP|NONE (r_pobj) of_20\IN|the (r_prep) concentration_19\NN|at|in (r_dobj) measuring_17\VBG|NONE (l_prep) at_31\IN|concentration|in (l_pobj) onset_33\NN|NONE (l_prep) of_34\IN|the (l_pobj) seizures_35\NNS|NONE
20009434
D008727_D001656 NONE MTX_11\NNP|in (r_compound) therapy_12\NN|NONE (r_pobj) after_8\IN|We|case (r_prep) report_1\VBP|.|patient|,|boy (r_ccomp) was_21\VBD|NONE (l_attr) boy_26\NN|.|patient|,|report (l_relcl) received_29\VBN|old|a (l_dobj) transplantation_35\NN|who|had (l_prep) for_36\IN|related|liver|a (l_pobj) atresia_39\NN|NONE
D008727_D002051 NONE methotrexate_3\NN|treatment|,|.|cause|but (r_nsubj) is_9\VBZ|NONE (l_attr) treatment_12\NN|methotrexate|,|.|cause|but (l_prep) for_13\IN|important|an (l_pobj) lymphoma_15\NN|NONE
D008727_D002051 NONE MTX_7\NNP|)|dose (r_appos) methotrexate_3\NN|treatment|,|.|cause|but (r_nsubj) is_9\VBZ|NONE (l_attr) treatment_12\NN|methotrexate|,|.|cause|but (l_prep) for_13\IN|important|an (l_pobj) lymphoma_15\NN|NONE
D008727_D007674 NONE methotrexate_3\NN|treatment|,|.|cause|but (r_nsubj) is_9\VBZ|NONE (l_conj) cause_19\VB|methotrexate|treatment|,|.|but (l_dobj) toxicity_23\NN|can|delayed
D008727_D007674 NONE MTX_7\NNP|)|dose (r_appos) methotrexate_3\NN|treatment|,|.|cause|but (r_nsubj) is_9\VBZ|NONE (l_conj) cause_19\VB|methotrexate|treatment|,|.|but (l_dobj) toxicity_23\NN|can|delayed
D008727_D056486 NONE methotrexate_3\NN|treatment|,|.|cause|but (r_nsubj) is_9\VBZ|NONE (l_conj) cause_19\VB|methotrexate|treatment|,|.|but (l_dobj) toxicity_23\NN|can|delayed
D008727_D056486 NONE MTX_7\NNP|)|dose (r_appos) methotrexate_3\NN|treatment|,|.|cause|but (r_nsubj) is_9\VBZ|NONE (l_conj) cause_19\VB|methotrexate|treatment|,|.|but (l_dobj) toxicity_23\NN|can|delayed
D008727_D058186 CID methotrexate_7\NN|dose|in (r_compound) therapy_8\NN|NONE (r_pobj) after_3\IN|.|Acute|renal (r_prep) failure_2\NN|NONE
D008727_D058186 CID MTX_11\NNP|in (r_compound) therapy_12\NN|NONE (r_pobj) after_8\IN|We|case (r_prep) report_1\VBP|.|patient|,|boy (l_dobj) case_3\NN|We|after (l_prep) of_4\IN|a (l_pobj) failure_7\NN|NONE
D008727_D058186 CID MTX_3\NNP|Subsequent (r_compound) therapy_4\NN|failure|. (r_nsubj) caused_5\VBD|NONE (l_dobj) failure_8\NN|therapy|.
14616590
D015742_D010146 CID Disoprivan_32\NNP|NONE (r_pobj) with_31\IN|NONE (r_prep) than_30\IN|AM (r_prep) with_28\IN|Pain|frequently|. (r_prep) occurred_25\VBD|NONE (l_nsubj) Pain_0\NN|frequently|.|with
D015742_D013924 CID Disoprivan_32\NNP|NONE (r_pobj) with_31\IN|NONE (r_prep) than_30\IN|AM (r_prep) with_28\IN|Pain|frequently|. (r_prep) occurred_25\VBD|NONE (l_nsubj) Pain_0\NN|frequently|.|with (l_conj) thrombophlebitis_14\NN|and|,|(|)|on|%|.
23846525
C055162_D056486 CID clopidogrel_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBD|:|Acute|.|report (r_acl) hepatitis_1\NN|NONE
C055162_D056486 CID clopidogrel_5\RB| (r_npadvmod) related_7\VBN|acute (r_amod) hepatitis_9\NN|NONE
C055162_D056486 CID clopidogrel_7\NN|to (r_pobj) due_5\JJ|about (r_amod) Reports_0\NNS|.|,|after|are|in (l_prep) about_1\IN|due (l_pobj) cases_2\NNS|NONE (l_prep) of_3\IN|NONE (l_pobj) hepatotoxicity_4\NN|NONE
C055162_D056486 CID clopidogrel_19\JJ|is|when (r_nsubjpass) prescribed_21\VBN|should|carefully|that|physicians|risk (r_advcl) consider_9\VB|,|.|In|we (l_dobj) risk_11\NN|should|carefully|that|physicians|prescribed (l_prep) of_12\IN|the (l_pobj) injury_17\NN|NONE
1779253
D002211_D051474 NONE capsaicin_3\NN|NONE (l_prep) in_4\IN|:|%|.|efficacy|Topical (l_pobj) neuralgia_9\NN|NONE
D002211_D051474 NONE capsaicin_18\NN|NONE (r_pobj) to_16\IN|NONE (r_prep) response_15\NN|NONE (r_pobj) of_14\IN|predictors|and (r_prep) action_11\NN|NONE (r_pobj) of_10\IN|time| (r_prep) course_9\NN|,|duration||,|with (r_nmod) patients_21\NNS|were|.|In|,|,|for|with (l_prep) with_22\IN|course|,|duration||, (l_pobj) neuralgia_27\NN|NONE
D002211_D051474 NONE capsaicin_18\NN|NONE (r_pobj) to_16\IN|NONE (r_prep) response_15\NN|NONE (r_pobj) of_14\IN|predictors|and (r_prep) action_11\NN|NONE (r_pobj) of_10\IN|time| (r_prep) course_9\NN|,|duration||,|with (r_nmod) patients_21\NNS|were|.|In|,|,|for|with (l_prep) with_22\IN|course|,|duration||, (l_pobj) neuralgia_27\NN|NONE (l_appos) PHN_29\NNP|herpetic|(|)|chronic
D002211_D051474 NONE capsaicin_42\NN|% (r_compound) cream_43\NN|NONE (r_pobj) with_39\IN|were|.|In|,|patients|,|for (r_prep) treated_38\VBN|NONE (l_nsubjpass) patients_21\NNS|were|.|In|,|,|for|with (l_prep) with_22\IN|course|,|duration||, (l_pobj) neuralgia_27\NN|NONE
D002211_D051474 NONE capsaicin_42\NN|% (r_compound) cream_43\NN|NONE (r_pobj) with_39\IN|were|.|In|,|patients|,|for (r_prep) treated_38\VBN|NONE (l_nsubjpass) patients_21\NNS|were|.|In|,|,|for|with (l_prep) with_22\IN|course|,|duration||, (l_pobj) neuralgia_27\NN|NONE (l_appos) PHN_29\NNP|herpetic|(|)|chronic
D002211_D051474 NONE capsaicin_26\NN|NONE (l_prep) in_27\IN|NONE (l_pobj) PHN_28\NNP|NONE
D002211_D008413 CID capsaicin_28\NN| (r_npadvmod) induced_30\VBN|;|||(|intolerable|burning (r_amod) sensations_32\NNS|such (l_appos) 4_34\CD|;||(|induced|intolerable|burning (l_conj) mastitis_37\NN|)|or
573555
D011433_D006932 NONE propranolol_27\NN|chronic (r_amod) therapy_28\NN|NONE (r_pobj) with_25\IN|can|not|statistically|be (r_prep) correlated_24\VBN|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP|We|. (l_nsubj) hypoglycemia_5\NN|that|and|correlated|invariable|not (l_conj) hyperbilirubinemia_7\NN|,|reported
D011433_D001049 NONE propranolol_27\NN|chronic (r_amod) therapy_28\NN|NONE (r_pobj) with_25\IN|can|not|statistically|be (r_prep) correlated_24\VBN|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP|We|. (l_nsubj) hypoglycemia_5\NN|that|and|correlated|invariable|not (l_conj) hyperbilirubinemia_7\NN|,|reported (l_conj) polycythemia_9\NN|, (l_conj) apnea_12\NN|,
D011433_D007003 NONE propranolol_27\NN|chronic (r_amod) therapy_28\NN|NONE (r_pobj) with_25\IN|can|not|statistically|be (r_prep) correlated_24\VBN|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP|We|. (l_nsubj) hypoglycemia_5\NN|that|and|correlated|invariable|not
D011433_D001919 NONE propranolol_27\NN|chronic (r_amod) therapy_28\NN|NONE (r_pobj) with_25\IN|can|not|statistically|be (r_prep) correlated_24\VBN|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP|We|. (l_nsubj) hypoglycemia_5\NN|that|and|correlated|invariable|not (l_conj) hyperbilirubinemia_7\NN|,|reported (l_conj) polycythemia_9\NN|, (l_conj) apnea_12\NN|, (l_conj) bradycardia_15\NN|neonatal|and|,
D011433_D011086 NONE propranolol_27\NN|chronic (r_amod) therapy_28\NN|NONE (r_pobj) with_25\IN|can|not|statistically|be (r_prep) correlated_24\VBN|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP|We|. (l_nsubj) hypoglycemia_5\NN|that|and|correlated|invariable|not (l_conj) hyperbilirubinemia_7\NN|,|reported (l_conj) polycythemia_9\NN|,
7173007
D003287_D064420 NONE media_9\NNS|polyvidone|and|are|preferred|. (r_oprd) considered_5\VBN|NONE (l_conj) preferred_22\VBN|polyvidone|and|are|media|. (l_prep) because_14\IN|Hexabrix|be|should (l_pobj) toxicity_18\NN|perhaps|of
C025504_D004244 CID X_3\NNP|The (r_compound) group_4\NN|incidence|. (r_nsubj) had_5\VBD|NONE (l_dobj) incidence_8\NN|group|. (l_prep) of_9\IN|higher|a (l_pobj) nausea_10\NN|NONE (l_conj) dizziness_12\NN|and
C025504_D009325 CID X_3\NNP|The (r_compound) group_4\NN|incidence|. (r_nsubj) had_5\VBD|NONE (l_dobj) incidence_8\NN|group|. (l_prep) of_9\IN|higher|a (l_pobj) nausea_10\NN|NONE
D007485_D064420 NONE Hexabrix_0\NNP|NONE (r_nmod) polyvidone_3\NN|and|are|media|preferred|. (r_nsubjpass) considered_5\VBN|NONE (l_conj) preferred_22\VBN|polyvidone|and|are|media|. (l_prep) because_14\IN|Hexabrix|be|should (l_pobj) toxicity_18\NN|perhaps|of
D007485_D064420 NONE Hexabrix_19\NNP|because|be|should (r_nsubjpass) preferred_22\VBN|polyvidone|and|are|media|. (l_prep) because_14\IN|Hexabrix|be|should (l_pobj) toxicity_18\NN|perhaps|of
D000100_D064420 NONE polyvidone_3\NN|and|are|media|preferred|. (r_nsubjpass) considered_5\VBN|NONE (l_conj) preferred_22\VBN|polyvidone|and|are|media|. (l_prep) because_14\IN|Hexabrix|be|should (l_pobj) toxicity_18\NN|perhaps|of
C006753_D015746 CID Endografine_1\NNP|The (r_compound) group_2\NN|incidence|. (r_nsubj) had_3\VBD|NONE (l_dobj) incidence_6\NN|.|group (l_prep) of_7\IN|a|higher (l_pobj) pain_9\NN|NONE
1449452
D004077_D001281 NONE digoxin_5\NN|NONE (l_compound) fibrillation_4\NN|NONE
D004077_D009203 NONE digoxin_19\NN|mortality|that|may|after (r_nsubj) increase_21\VB|a (l_prep) after_23\IN|mortality|digoxin|that|may (l_pobj) infarction_25\NN|NONE
D004077_D009203 NONE digoxin_19\NN|mortality|that|may|after (r_nsubj) increase_21\VB|a (l_prep) after_23\IN|mortality|digoxin|that|may (l_pobj) infarction_25\NN|NONE (l_appos) MI_27\NNP|myocardial|(|)
D004077_D001145 CID digoxin_2\NN|,|effects|.|Also (r_nsubj) has_3\VBZ|NONE (l_dobj) effects_5\NNS|digoxin|,|.|Also (l_prep) as_7\IN|undesirable (l_pcomp) increasing_8\VBG|such (l_conj) causing_16\VBG|and|resistance|, (l_dobj) arrhythmias_17\NNS|NONE
9197951
D004053_D011681 NONE DEP_4\NNP|while (l_appos) changes_7\NNS|, (l_prep) in_8\IN|especially (l_pobj) power_11\NN|NONE (l_prep) of_12\IN|the|total (l_pobj) oscillation_14\NN|NONE
D004053_D001714 CID diethylpropion_23\NN|NONE (r_pobj) of_19\IN|anticraving|the (r_prep) efficacy_18\NN|NONE (r_dobj) evaluating_15\VBG|a (r_acl) study_14\NN|NONE (r_pobj) in_12\IN|a (r_prep) subject_11\NN|who (r_attr) was_9\VBD|A|dependent|old (r_relcl) man_7\NN|manic|during|. (r_nsubj) became_27\VBD|NONE (l_acomp) manic_28\JJ|during|.|man
D004053_D001714 CID DEP_25\NNP|stimulant|the|medication (r_appos) diethylpropion_23\NN|NONE (r_pobj) of_19\IN|anticraving|the (r_prep) efficacy_18\NN|NONE (r_dobj) evaluating_15\VBG|a (r_acl) study_14\NN|NONE (r_pobj) in_12\IN|a (r_prep) subject_11\NN|who (r_attr) was_9\VBD|A|dependent|old (r_relcl) man_7\NN|manic|during|. (r_nsubj) became_27\VBD|NONE (l_acomp) manic_28\JJ|during|.|man
D004053_D001714 CID DEP_4\NNP|while (r_pobj) on_3\IN|Pupillometric (r_prep) changes_1\NNS|,|different|. (r_nsubj) were_16\VBD|NONE (l_acomp) different_18\JJ|,|.|changes (l_prep) than_19\IN|dramatically (l_pobj) those_20\DT|NONE (l_acl) observed_21\VBN|NONE (l_prep) in_22\IN|NONE (l_pobj) subjects_27\NNS|NONE (l_relcl) become_31\VB|the|other|eight|study (l_acomp) manic_32\JJ|who|did|not
D003042_D001714 NONE cocaine_4\NN| (r_npadvmod) dependent_6\JJ|A|old|was (r_amod) man_7\NN|manic|during|. (r_nsubj) became_27\VBD|NONE (l_acomp) manic_28\JJ|during|.|man
25006961
D008094_D011141 CID lithium_20\NN| (r_npadvmod) induced_22\VBN|NONE (r_amod) polyuria_23\NN|NONE
D008094_D011141 CID lithium_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) NDI_21\NNP|NONE (r_pobj) in_17\IN|prevents|ablation|,|that|and|expression (r_prep) preserves_7\VBZ|.|data (l_conj) prevents_24\VBZ|ablation|,|that|and|expression|in (l_dobj) development_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) polyuria_30\NN|NONE
D008094_D011141 CID lithium_33\NN|NONE (r_compound) therapy_34\NN|NONE (r_pobj) with_32\IN|NONE (r_prep) associated_31\VBN|severe|the (r_acl) polyuria_30\NN|NONE
D008094_D018500 CID lithium_6\NN| (r_npadvmod) induced_8\VBN|diabetes (r_amod) insipidus_11\NN|Absence|.
D008094_D018500 CID Lithium_0\NN|.|in|insipidus (r_nsubj) induces_6\VBZ|NONE (l_dobj) insipidus_9\NN|.|Lithium|in
D008094_D018500 CID Lithium_0\NN|.|in|insipidus (r_nsubj) induces_6\VBZ|NONE (l_dobj) insipidus_9\NN|.|Lithium|in (l_appos) NDI_11\NNP|)|diabetes|(|nephrogenic
D008094_D018500 CID lithium_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) NDI_21\NNP|NONE
D008094_D018500 CID lithium_33\NN|NONE (r_compound) therapy_34\NN|NONE (r_pobj) with_32\IN|NONE (r_prep) associated_31\VBN|severe|the (r_acl) polyuria_30\NN|NONE (r_pobj) of_27\IN|the (r_prep) development_26\NN|NONE (r_dobj) prevents_24\VBZ|ablation|,|that|and|expression|in (r_conj) preserves_7\VBZ|.|data (l_prep) in_17\IN|prevents|ablation|,|that|and|expression (l_pobj) NDI_21\NNP|NONE
6316193
D010852_D012640 CID picrotoxin_12\NN| (r_npadvmod) induced_14\VBN|by (r_amod) seizures_15\NNS|NONE
D010852_D012640 CID picrotoxin_24\NN|NONE (r_pobj) by_23\IN|in (r_agent) induced_22\VBN|NONE (r_acl) seizures_21\NNS|NONE
D010852_D012640 CID picrotoxin_31\NN| (r_npadvmod) induced_33\VBN|mortality|and (r_amod) seizures_34\NNS|,|,|totally|mumol
D002766_D012640 NONE cholecystokinin_17\NN|NONE (r_pobj) by_16\IN|induced (r_prep) seizures_15\NNS|NONE
D002766_D012640 NONE cholecystokinin_23\NN|NONE (r_pobj) of_22\IN|NONE (r_prep) analogues_21\NNS|and (r_conj) fragments_19\NNS|,|in (r_conj) cholecystokinin_17\NN|NONE (r_pobj) by_16\IN|induced (r_prep) seizures_15\NNS|NONE
D003975_D012640 NONE diazepam_27\NN|NONE (r_preconj) ,_26\,|,|seizures|totally|mumol (r_punct) prevented_30\VBD|,|peptide|activity|. (l_dobj) seizures_34\NNS|,|,|totally|mumol
D012844_D012640 NONE octapeptide_4\JJ|sulphate (r_compound) ester_6\NN|NONE (r_appos) cholecystokinin_3\NN|NONE (r_pobj) of_2\IN|cholecystokinin|and|CCKSE|Intraperitoneal (r_prep) administration_1\NN|.|latency (r_nsubj) enhanced_17\VBD|NONE (l_dobj) latency_19\NN|administration|. (l_prep) of_20\IN|the (l_pobj) seizures_21\NNS|NONE
D012844_D012640 NONE CCK-8-SE_8\NNP|cholecystokinin|of|and|Intraperitoneal (r_parataxis) administration_1\NN|.|latency (r_nsubj) enhanced_17\VBD|NONE (l_dobj) latency_19\NN|administration|. (l_prep) of_20\IN|the (l_pobj) seizures_21\NNS|NONE
D012844_D012640 NONE octapeptide_13\RB|)|nonsulphated (r_appos) cholecystokinin_12\NN|of|and|CCKSE|Intraperitoneal (r_conj) administration_1\NN|.|latency (r_nsubj) enhanced_17\VBD|NONE (l_dobj) latency_19\NN|administration|. (l_prep) of_20\IN|the (l_pobj) seizures_21\NNS|NONE
D012844_D012640 NONE CCK-8-NS_15\NNP|NONE (r_appos) octapeptide_13\RB|)|nonsulphated (r_appos) cholecystokinin_12\NN|of|and|CCKSE|Intraperitoneal (r_conj) administration_1\NN|.|latency (r_nsubj) enhanced_17\VBD|NONE (l_dobj) latency_19\NN|administration|. (l_prep) of_20\IN|the (l_pobj) seizures_21\NNS|NONE
4631913
D014750_D007970 CID sulfate_11\NN|NONE (r_pobj) of_9\IN|NONE (r_prep) mg_8\NN|to|. (r_quantmod) 2.5_7\CD|NONE (r_pobj) of_4\IN|intratracheal (r_prep) inoculation_3\NN|or (r_conj) Intravenous_0\JJ|by|was|. (r_nsubjpass) followed_13\VBN|NONE (l_agent) by_14\IN|Intravenous|was|. (l_pobj) leukopenia_15\NN|NONE
D014750_D011552 CID sulfate_3\NN|NONE (l_prep) on_4\IN|vincristine (l_pobj) infections_6\NNS|NONE
19681452
D000431_D020520 NONE alcohol_10\NN|and (r_conj) cocaine_8\NN|NONE (r_nmod) intoxication_11\NN|NONE (r_pobj) after_7\IN|the|globus (r_prep) pallidus_6\NN|NONE
D003042_D020520 NONE cocaine_8\NN|NONE (r_nmod) intoxication_11\NN|NONE (r_pobj) after_7\IN|the|globus (r_prep) pallidus_6\NN|NONE
D003042_D020520 NONE cocaine_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) use_6\NN|NONE (r_pobj) after_4\IN|Bilateral|ganglia|basal|,|without|, (r_prep) infarcts_3\NNS|been|.|never|have
D003042_D001145 NONE cocaine_12\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) related_10\VBN|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN|causes|.|,|In
D000431_D002543 NONE alcohol_10\NN|and (r_conj) cocaine_8\NN|NONE (r_nmod) intoxication_11\NN|NONE (r_pobj) after_7\IN|the|globus (r_prep) pallidus_6\NN|NONE
D000431_D002545 NONE alcohol_19\NN|NONE (r_pobj) after_17\IN|of|the (r_prep) case_3\NN|We|. (l_prep) of_4\IN|the|after (l_pobj) man_9\NN|NONE (l_prep) with_10\IN|old|a (l_pobj) ischemia_12\NN|NONE (l_prep) of_13\IN|bilateral (l_pobj) pallidus_16\NN|NONE
D003042_D012131 NONE cocaine_12\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) related_10\VBN|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN|causes|.|,|In (l_conj) dysfunction_9\NN|or|cardiac|transient|related
D000431_D012131 NONE ethanol_14\NN|NONE (r_compound) use_15\NN|and/or (r_conj) cocaine_12\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) related_10\VBN|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN|causes|.|,|In (l_conj) dysfunction_9\NN|or|cardiac|transient|related
D003042_D002543 NONE cocaine_8\NN|NONE (r_nmod) intoxication_11\NN|NONE (r_pobj) after_7\IN|the|globus (r_prep) pallidus_6\NN|NONE
D000431_D001145 NONE ethanol_14\NN|NONE (r_compound) use_15\NN|and/or (r_conj) cocaine_12\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) related_10\VBN|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN|causes|.|,|In
D003042_D002545 CID cocaine_22\NN|intranasal (r_compound) use_23\NN|excessive|and (r_conj) alcohol_19\NN|NONE (r_pobj) after_17\IN|of|the (r_prep) case_3\NN|We|. (l_prep) of_4\IN|the|after (l_pobj) man_9\NN|NONE (l_prep) with_10\IN|old|a (l_pobj) ischemia_12\NN|NONE (l_prep) of_13\IN|bilateral (l_pobj) pallidus_16\NN|NONE
D000431_-1 NONE ethanol_14\NN|NONE (r_compound) use_15\NN|and/or (r_conj) cocaine_12\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) related_10\VBN|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN|causes|.|,|In (r_nsubj) were_16\VBD|NONE (l_attr) causes_20\NNS|.|arrhythmia|,|In (l_prep) of_21\IN|the|likely (l_pobj) hypoperfusion_23\NN|NONE
D003042_D002544 NONE Cocaine_0\NN|.|factor (r_nsubj) is_1\VBZ|NONE (l_attr) factor_4\NN|.|Cocaine (l_prep) for_5\IN|a|risk (l_pobj) stroke_10\NN|NONE
D003932_D020520 CID heroin_11\NN|NONE (r_pobj) with_10\IN|often|are|.|infarctions (r_prep) associated_9\VBN|NONE (l_nsubjpass) infarctions_5\NNS|with|often|are|.
D003932_D020520 CID heroin_12\NN|concurrent (r_compound) use_13\NN|NONE (r_pobj) without_10\IN|Bilateral|ganglia|after|basal|,|, (r_prep) infarcts_3\NNS|been|.|never|have
D003042_-1 NONE cocaine_12\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) related_10\VBN|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN|causes|.|,|In (r_nsubj) were_16\VBD|NONE (l_attr) causes_20\NNS|.|arrhythmia|,|In (l_prep) of_21\IN|the|likely (l_pobj) hypoperfusion_23\NN|NONE
D003042_D020521 NONE Cocaine_0\NN|.|factor (r_nsubj) is_1\VBZ|NONE (l_attr) factor_4\NN|.|Cocaine (l_prep) for_5\IN|a|risk (l_pobj) stroke_10\NN|NONE
2320485
D008750_D000743 CID Methyldopa_0\NNP|presenting||.|in|anemia (r_nsubj) induced_2\VBN|NONE (l_dobj) anemia_4\NN|presenting||.|Methyldopa|in
D008750_D000743 CID methyldopa_5\NN| (r_npadvmod) induced_7\VBN|hemolytic|in (r_amod) anemia_9\NN|NONE
D008750_D014947 NONE methyldopa_7\NN|NONE (r_pobj) with_5\IN|boy|been|during|.|had (r_prep) treated_4\VBN|NONE (l_prep) during_8\IN|boy|been|.|had|with (l_pobj) admission_11\NN|NONE (l_compound) trauma_10\NN|prior|a
D008750_D000744 NONE Methyldopa_0\NNP|.|anemia (r_nsubj) causes_1\VBZ|NONE (l_dobj) anemia_5\NN|.|Methyldopa
D008750_D013575 NONE Methyldopa_0\NNP|presenting||.|in|anemia (r_nsubj) induced_2\VBN|NONE (l_advcl) presenting_10\VBG||.|Methyldopa|in|anemia (l_prep) as_11\IN|NONE (l_pobj) syncope_14\NN|NONE
D008750_D013575 NONE methyldopa_5\NN| (r_npadvmod) induced_7\VBN|hemolytic|in (r_amod) anemia_9\NN|NONE (l_prep) in_10\IN|hemolytic|induced (l_pobj) boy_15\NN|NONE (l_relcl) presented_17\VBD|a|old (l_prep) with_22\IN|who|to (l_pobj) syncope_25\NN|NONE
D008750_D004630 NONE methyldopa_5\NN| (r_npadvmod) induced_7\VBN|hemolytic|in (r_amod) anemia_9\NN|NONE (l_prep) in_10\IN|hemolytic|induced (l_pobj) boy_15\NN|NONE (l_relcl) presented_17\VBD|a|old (l_prep) to_18\IN|who|with (l_pobj) department_21\NN|NONE
16092435
D004317_D066126 NONE adriamycin_10\NNS| (r_npadvmod) evoked_12\VBN|in (r_amod) cardiotoxicity_13\NN|NONE
D004317_D066126 NONE Adriamycin_0\NNP|in|.|toxicity (r_cc) evoked_8\VBN|NONE (l_dobj) toxicity_12\NN|Adriamycin|in|.
D004317_D066126 NONE ADR_13\NNP|NONE (r_compound) cardiotoxicity_14\NN|not|.|did|ribose
D004317_D009202 CID adriamycin_7\NNS| (r_npadvmod) induced_9\VBN|NONE (r_amod) myocardiopathy_10\NN|NONE
D012266_D009202 NONE ribose_5\NN|NONE (l_prep) on_6\IN||in|d (l_pobj) myocardiopathy_10\NN|NONE
D012266_D066126 NONE ribose_8\NN|NONE (l_prep) on_9\IN||d (l_pobj) cardiotoxicity_13\NN|NONE
D012266_D066126 NONE ribose_2\NN|not|.|cardiotoxicity|did (r_nsubj) influence_12\VB|NONE (l_dobj) cardiotoxicity_14\NN|not|.|did|ribose
2782734
D000420_D001249 NONE salbutamol_15\NN|Tachyphylaxis|in|. (r_dobj) inhaled_14\VBN|NONE (l_prep) in_16\IN|Tachyphylaxis|.|salbutamol (l_pobj) asthmatics_17\NNS|NONE
D000420_D001249 NONE salbutamol_4\NN|NONE (r_pobj) of_2\IN|High (r_prep) doses_1\NNS|and|,|.|improvements|associated (r_nsubj) produce_5\VB|NONE (l_dobj) improvements_7\NNS|doses|and|,|.|associated (l_prep) in_8\IN|substantial (l_pobj) response_10\NN|NONE (l_prep) in_11\IN|airway (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) asthma_14\NN|NONE
D000420_D001249 NONE salbutamol_34\NN|high (r_appos) dose_32\NN|NONE (r_pobj) with_30\IN|a|day (r_prep) treatment_29\NN|were|predicted|daily|.|salbutamol (r_dobj) given_26\VBN|NONE (l_nsubjpass) predicted_10\VBD|treatment|were|daily|.|salbutamol (l_nsubj) patients_2\NNS|requiring|,|,|)|% (l_amod) asthmatic_1\JJ|(|FEV|Twelve
D000420_D001249 NONE salbutamol_46\NN|treatment|were|predicted|daily|. (r_dobj) given_26\VBN|NONE (l_nsubjpass) predicted_10\VBD|treatment|were|daily|.|salbutamol (l_nsubj) patients_2\NNS|requiring|,|,|)|% (l_amod) asthmatic_1\JJ|(|FEV|Twelve
24675088
D004317_D066126 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|NONE (r_amod) cardiotoxicity_15\NN|NONE
D004317_D064420 NONE doxorubicin_12\NN|NONE (r_pobj) of_10\IN|a|rat (r_prep) model_9\NN|In|we|.|,|,|have|applying (r_dobj) utilized_6\VBN|NONE (l_advcl) applying_17\VBG|In|we|.|,|model|,|have (l_conj) provide_31\VB|,|approaches (l_dobj) characterization_35\NN|to (l_prep) to_36\IN|comprehensive|the (l_pobj) date_37\NN|NONE (l_prep) of_38\IN|NONE (l_pobj) timecourse_40\NN|NONE (l_prep) of_41\IN|the (l_pobj) events_48\NNS|NONE (l_acl) underlying_49\VBG|serological (l_dobj) toxicity_51\NN|NONE
D004317_D064420 NONE DOX)-induced_14\VBN|( (r_amod) cardiomyopathy_15\NN|progressive (r_appos) doxorubicin_12\NN|NONE (r_pobj) of_10\IN|a|rat (r_prep) model_9\NN|In|we|.|,|,|have|applying (r_dobj) utilized_6\VBN|NONE (l_advcl) applying_17\VBG|In|we|.|,|model|,|have (l_conj) provide_31\VB|,|approaches (l_dobj) characterization_35\NN|to (l_prep) to_36\IN|comprehensive|the (l_pobj) date_37\NN|NONE (l_prep) of_38\IN|NONE (l_pobj) timecourse_40\NN|NONE (l_prep) of_41\IN|the (l_pobj) events_48\NNS|NONE (l_acl) underlying_49\VBG|serological (l_dobj) toxicity_51\NN|NONE
D005682_D018754 NONE gadolinium_9\NN|,|grading|contrast (r_compound) enhancement_11\NN|NONE (l_conj) grading_14\NN|,|contrast|gadolinium (l_conj) dysfunction_18\NN|,|and|histopathological
D004317_D009202 CID doxorubicin_12\NN|NONE (l_appos) cardiomyopathy_15\NN|progressive
D004317_D009202 CID DOX)-induced_14\VBN|( (r_amod) cardiomyopathy_15\NN|progressive
24100055
D006493_D013921 CID heparin_2\NN| (r_npadvmod) induced_4\VBN|type|thrombocytopenia (r_amod) II_7\NNP|NONE
D006493_D013921 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|mediated|thrombocytopenia|)|(|II|type (r_amod) II_11\NNP|NONE
D006493_D013921 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|mediated|thrombocytopenia|)|(|II|type (r_amod) II_11\NNP|NONE (l_appos) II_15\NNP|mediated|thrombocytopenia|)|induced|(|type
D006493_D013921 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|mediated|thrombocytopenia|)|(|II|type (r_amod) II_11\NNP|NONE (r_pobj) of_2\IN|as|The (r_prep) impact_1\NN|is|,|yet|with|not|. (l_prep) as_17\IN|of|The (l_pobj) cause_19\NN|NONE (l_prep) of_20\IN|a (l_pobj) thrombocytopenia_21\NN|NONE
D006493_D013921 CID heparin_12\NN|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|For|performed|,|and|should|be (r_nsubjpass) avoided_15\VBN|NONE (l_prep) For_0\IN|performed|use|,|and|should|be (l_pobj) reduction_2\NN|NONE (l_prep) of_3\IN|further (l_pobj) II_6\NNP|NONE
D006493_D013921 CID heparin_29\NN|NONE (r_pobj) with_23\IN|after|.|anticoagulation|should|be (r_prep) performed_22\VBN|For|use|,|and|should|be (r_conj) avoided_15\VBN|NONE (l_prep) For_0\IN|performed|use|,|and|should|be (l_pobj) reduction_2\NN|NONE (l_prep) of_3\IN|further (l_pobj) II_6\NNP|NONE
1837756
D012701_D003866 NONE serotonin_37\NN|reuptake (r_compound) inhibitors_39\NNS|NONE (r_pobj) with_36\IN|NONE (r_prep) associated_35\VBN|paranoid (r_acl) exacerbations_34\NNS|NONE (r_pobj) to_32\IN|.|may|disorders|vulnerability (r_prep) present_29\VB|NONE (l_nsubj) disorders_2\NNS|.|may|vulnerability|to
D005473_D010259 CID fluoxetine_10\NN|Five|of (r_advmod) cases_1\NNS|are|here|. (l_prep) of_2\IN|fluoxetine|Five (l_pobj) exacerbation_4\NN|NONE (l_amod) paranoid_3\JJ|with
D004298_D010259 NONE dopamine_18\NN|mediated|HT (r_compound) release_19\NN|NONE (r_pobj) including_13\VBG|several|,|cryptic|, (r_prep) mechanisms_11\NNS|pharmacology|Although (r_attr) remain_7\VBP|downregulation|to|,|might|,|. (l_nsubj) pharmacology_2\NN|mechanisms|Although (l_prep) of_5\IN|neurobiology|the|and (l_pobj) paranoia_6\NN|NONE
D012701_D011605 NONE serotonin_37\NN|reuptake (r_compound) inhibitors_39\NNS|NONE (r_pobj) with_36\IN|NONE (r_prep) associated_35\VBN|paranoid (r_acl) exacerbations_34\NNS|NONE (r_pobj) to_32\IN|.|may|disorders|vulnerability (r_prep) present_29\VB|NONE (l_nsubj) disorders_2\NNS|.|may|vulnerability|to (l_prep) including_4\VBG|depressive|)|(|Complicated (l_pobj) atypicality_5\NN|in (l_conj) chronicity_11\NN|,|of (l_conj) psychosis_13\NN|,
D012701_D011605 NONE serotonin_37\NN|reuptake (r_compound) inhibitors_39\NNS|NONE (r_pobj) with_36\IN|NONE (r_prep) associated_35\VBN|paranoid (r_acl) exacerbations_34\NNS|NONE (r_pobj) to_32\IN|.|may|disorders|vulnerability (r_prep) present_29\VB|NONE (l_nsubj) disorders_2\NNS|.|may|vulnerability|to (l_prep) including_4\VBG|depressive|)|(|Complicated (l_prep) in_20\IN|atypicality (l_pobj) course_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) psychosis_26\NN|NONE
D012701_D010259 NONE Serotonin_0\NNP|.|reuptake|,|paranoia (r_compound) inhibitors_2\NNS|NONE (l_appos) paranoia_4\NN|.|reuptake|,|Serotonin
D012701_D010259 NONE serotonin_7\NN|reuptake|the (r_compound) inhibitors_9\NNS|NONE (r_pobj) with_5\IN|paranoid (r_prep) exacerbation_4\NN|NONE (l_amod) paranoid_3\JJ|with
D012701_D010259 NONE serotonin_37\NN|reuptake (r_compound) inhibitors_39\NNS|NONE (r_pobj) with_36\IN|NONE (r_prep) associated_35\VBN|paranoid (r_acl) exacerbations_34\NNS|NONE (l_amod) paranoid_33\JJ|associated
D012701_D010259 NONE serotonin_9\NN|reuptake (r_compound) blockers_11\NNS|NONE (r_pobj) with_8\IN|possible|paranoid|in (r_prep) exacerbations_7\NNS|NONE (l_amod) paranoid_6\JJ|with|possible|in
D012701_D010259 NONE serotonin_9\NN|reuptake (r_compound) blockers_11\NNS|NONE (r_pobj) with_8\IN|possible|paranoid|in (r_prep) exacerbations_7\NNS|NONE (r_pobj) to_4\IN|and|.|raise|cases|attention (r_prep) call_2\VBP|NONE (l_conj) raise_16\VB|and|.|to|cases|attention (l_dobj) considerations_18\NNS|NONE (l_acl) regarding_19\VBG|neurobiological (l_pobj) paranoia_20\NN|NONE
D000639_D010259 CID amitriptyline_12\NN|and (r_conj) fluoxetine_10\NN|Five|of (r_advmod) cases_1\NNS|are|here|. (l_prep) of_2\IN|fluoxetine|Five (l_pobj) exacerbation_4\NN|NONE (l_amod) paranoid_3\JJ|with
3297909
D013827_D007565 NONE thiabendazole_12\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) exposure_10\NN|wk (r_pobj) after_9\IN|jaundice|man|. (r_prep) developed_5\VBD|NONE (l_dobj) jaundice_6\NN|man|after|.
D013827_D001649 NONE thiabendazole_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) after_4\IN|duct|Progressive|. (r_prep) injury_3\NN|NONE
6106951
D005479_D012640 CID FZP_2\NNP|in (r_compound) toxocity_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Signs_0\NNS|retching|salivation|. (r_nsubj) included_6\VBD|NONE (l_advcl) retching_14\NN|salivation|.|Signs (l_dobj) tremors_17\NNS|, (l_conj) convulsions_19\NNS|and|muscle
D005479_D012640 CID FZP_6\NNP|first|.|against|As|, (r_nsubj) protected_8\VBD|NONE (l_prep) against_9\IN|first|.|FZP|As|, (l_pobj) convulsions_10\NNS|NONE
D005479_D012640 CID FZP_3\NNP|NONE (r_pobj) of_2\IN|These (r_prep) doses_1\NNS|cause|.|lower (r_nsubj) were_4\VBD|NONE (l_prep) cause_11\VB|doses|.|lower (l_dobj) convulsions_12\NNS|NONE
D005479_D014202 NONE FZP_2\NNP|in (r_compound) toxocity_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Signs_0\NNS|retching|salivation|. (r_nsubj) included_6\VBD|NONE (l_advcl) retching_14\NN|salivation|.|Signs (l_dobj) tremors_17\NNS|,
D005479_D012798 NONE FZP_2\NNP|in (r_compound) toxocity_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Signs_0\NNS|retching|salivation|. (r_nsubj) included_6\VBD|NONE (l_dobj) salivation_8\NN|retching|.|Signs
D005479_D064420 NONE FZP_2\NNP|in (r_compound) toxocity_3\NN|NONE
D005479_D004827 NONE FZP_9\NNP|NONE (r_pobj) of_8\IN|in|the (r_prep) use_7\NN|NONE (l_prep) in_10\IN|of|the (l_pobj) situations_12\NNS|NONE (l_relcl) is_16\VBZ|clinical (l_attr) excitability_19\NN|in|there (l_prep) as_22\IN|neural|,|increased (l_pobj) epilepsy_23\NN|such
44072
C024986_D001145 CID BaCl2_9\NN|with|,|, (r_pobj) with_8\IN|with|.||types|are (r_prep) used_6\VBN|NONE (l_nsubjpass) types_1\NNS|with|.||with|are (l_prep) of_2\IN|Four (l_pobj) arrhythmia_4\NN|NONE
C024986_D001145 CID BaCl2_32\NN|NONE (r_pobj) with_31\IN||and|) (r_conj) in_25\IN|inhibition|( (r_prep) causing_13\VBG|compound|.|,|activity (r_advcl) manifests_2\VBZ|NONE (l_dobj) activity_4\NN|compound|.|causing|, (l_prep) in_5\IN|antiarrhythmic|used (l_pobj) models_7\NNS|NONE (l_prep) of_8\IN|all (l_pobj) arrhythmia_10\NN|NONE
C024986_D001145 CID BaCl2_32\NN|NONE (r_pobj) with_31\IN||and|) (r_conj) in_25\IN|inhibition|( (r_prep) causing_13\VBG|compound|.|,|activity (l_dobj) inhibition_15\NN|(|in (l_prep) on_16\IN|greatest (l_pobj) arrhythmia_18\NN|NONE
D000157_D001145 CID aconitine_21\NN|NONE (r_pobj) with_20\IN|and|G (r_conj) with_16\IN|.||types|with|are (r_prep) used_6\VBN|NONE (l_nsubjpass) types_1\NNS|with|.||with|are (l_prep) of_2\IN|Four (l_pobj) arrhythmia_4\NN|NONE
D002725_D001145 CID chloroform_12\NN| (r_compound) adrenaline_14\NN|NONE (r_pobj) with_11\IN|,|BaCl|, (r_conj) with_8\IN|with|.||types|are (r_prep) used_6\VBN|NONE (l_nsubjpass) types_1\NNS|with|.||with|are (l_prep) of_2\IN|Four (l_pobj) arrhythmia_4\NN|NONE
D002725_D001145 CID chloroform_21\NN| (r_compound) adrenaline_23\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|the (r_acl) arrhythmia_18\NN|NONE (r_pobj) on_16\IN|greatest (r_prep) inhibition_15\NN|(|in (r_dobj) causing_13\VBG|compound|.|,|activity (r_advcl) manifests_2\VBZ|NONE (l_dobj) activity_4\NN|compound|.|causing|, (l_prep) in_5\IN|antiarrhythmic|used (l_pobj) models_7\NNS|NONE (l_prep) of_8\IN|all (l_pobj) arrhythmia_10\NN|NONE
D002725_D001145 CID chloroform_21\NN| (r_compound) adrenaline_23\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|the (r_acl) arrhythmia_18\NN|NONE
D010042_D001145 CID G_18\NN|with|and (r_pobj) with_16\IN|.||types|with|are (r_prep) used_6\VBN|NONE (l_nsubjpass) types_1\NNS|with|.||with|are (l_prep) of_2\IN|Four (l_pobj) arrhythmia_4\NN|NONE
D004837_D001145 CID adrenaline_14\NN|NONE (r_pobj) with_11\IN|,|BaCl|, (r_conj) with_8\IN|with|.||types|are (r_prep) used_6\VBN|NONE (l_nsubjpass) types_1\NNS|with|.||with|are (l_prep) of_2\IN|Four (l_pobj) arrhythmia_4\NN|NONE
D004837_D001145 CID adrenaline_23\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|the (r_acl) arrhythmia_18\NN|NONE (r_pobj) on_16\IN|greatest (r_prep) inhibition_15\NN|(|in (r_dobj) causing_13\VBG|compound|.|,|activity (r_advcl) manifests_2\VBZ|NONE (l_dobj) activity_4\NN|compound|.|causing|, (l_prep) in_5\IN|antiarrhythmic|used (l_pobj) models_7\NNS|NONE (l_prep) of_8\IN|all (l_pobj) arrhythmia_10\NN|NONE
D004837_D001145 CID adrenaline_23\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|the (r_acl) arrhythmia_18\NN|NONE
10087562
D004280_D006333 NONE dobutamine_9\NN|dose|intermittent|low|in (r_compound) treatment_10\NN|NONE (l_prep) in_11\IN|dose|dobutamine|intermittent|low (l_pobj) patient_13\NN|NONE (l_prep) with_14\IN|a (l_pobj) failure_20\NN|NONE
D004280_D006333 NONE dobutamine_52\NN|NONE (r_pobj) of_40\IN|one (r_prep) cycle_39\NN|NONE (r_pobj) during_37\IN|who|prolongation (r_prep) developed_28\VBD|significant|ventricular (r_relcl) arrhythmias_26\NNS|NONE (r_pobj) of_23\IN|NONE (r_prep) absence_22\NN|cardiomyopathy|and|to (r_conj) dilated_19\VBN|.|case|authors (r_xcomp) describe_2\VBP|NONE (l_dobj) case_4\NN|.|authors|dilated (l_prep) of_5\IN|the (l_pobj) woman_10\NN|NONE (l_prep) with_11\IN|old|a (l_pobj) failure_16\NN|NONE
D004280_D008133 NONE dobutamine_52\NN|NONE (r_pobj) of_40\IN|one (r_prep) cycle_39\NN|NONE (r_pobj) during_37\IN|who|prolongation (r_prep) developed_28\VBD|significant|ventricular (l_dobj) prolongation_30\NN|who|during
D004280_D001145 NONE dobutamine_52\NN|NONE (r_pobj) of_40\IN|one (r_prep) cycle_39\NN|NONE (r_pobj) during_37\IN|who|prolongation (r_prep) developed_28\VBD|significant|ventricular (r_relcl) arrhythmias_26\NNS|NONE
D004280_D001145 NONE dobutamine_10\NN|NONE (r_pobj) during_8\IN|of|This (r_prep) report_1\NN|.|hypothesis (r_nsubj) supports_11\VBZ|NONE (l_dobj) hypothesis_13\NN|report|. (l_acl) occur_19\VB|the (l_nsubj) arrhythmias_17\NNS|may|with|that
D004280_D016171 CID dobutamine_9\NN|dose|intermittent|low|in (r_compound) treatment_10\NN|NONE (r_pobj) during_5\IN|de|tachycardia|.|Torsade (r_prep) pointes_2\VBZ|NONE
D004280_D016171 CID dobutamine_52\NN|NONE (r_pobj) of_40\IN|one (r_prep) cycle_39\NN|NONE (r_pobj) during_37\IN|who|prolongation (r_prep) developed_28\VBD|significant|ventricular (l_dobj) prolongation_30\NN|who|during (l_conj) tachycardia_36\NN|QT|and (l_nmod) pointes_34\FW|ventricular
D004280_D016171 CID dobutamine_10\NN|NONE (r_pobj) during_8\IN|of|This (r_prep) report_1\NN|.|hypothesis (l_prep) of_2\IN|during|This (l_pobj) tachycardia_7\NN|NONE (l_nmod) pointes_5\FW|ventricular
D004280_D002311 NONE dobutamine_9\NN|dose|intermittent|low|in (r_compound) treatment_10\NN|NONE (l_prep) in_11\IN|dose|dobutamine|intermittent|low (l_pobj) patient_13\NN|NONE (l_prep) with_14\IN|a (l_pobj) failure_20\NN|NONE (l_amod) cardiomyopathy_16\NN|dilated|heart
D004280_D002311 NONE dobutamine_52\NN|NONE (r_pobj) of_40\IN|one (r_prep) cycle_39\NN|NONE (r_pobj) during_37\IN|who|prolongation (r_prep) developed_28\VBD|significant|ventricular (r_relcl) arrhythmias_26\NNS|NONE (r_pobj) of_23\IN|NONE (r_prep) absence_22\NN|cardiomyopathy|and|to (r_conj) dilated_19\VBN|.|case|authors (l_advmod) cardiomyopathy_20\NN|absence|and|to
D004280_D017180 NONE dobutamine_9\NN|dose|intermittent|low|in (r_compound) treatment_10\NN|NONE (r_pobj) during_5\IN|de|tachycardia|.|Torsade (r_prep) pointes_2\VBZ|NONE (l_appos) tachycardia_4\NN|de|during|.|Torsade
D004280_D017180 NONE dobutamine_52\NN|NONE (r_pobj) of_40\IN|one (r_prep) cycle_39\NN|NONE (r_pobj) during_37\IN|who|prolongation (r_prep) developed_28\VBD|significant|ventricular (l_dobj) prolongation_30\NN|who|during (l_conj) tachycardia_36\NN|QT|and
D004280_D017180 NONE dobutamine_10\NN|NONE (r_pobj) during_8\IN|of|This (r_prep) report_1\NN|.|hypothesis (l_prep) of_2\IN|during|This (l_pobj) tachycardia_7\NN|NONE
3083835
D010406_D000707 CID Penicillin_0\NNP|. (r_compound) anaphylaxis_1\NN|NONE
D010406_D000707 CID penicillin_4\NN|oral (r_compound) anaphylaxis_5\NN|NONE
D010406_D000707 CID penicillin_4\NN|oral (r_compound) anaphylaxis_5\NN|NONE (r_pobj) of_2\IN|A (r_prep) case_1\NN|,|and|reviewed|is (r_nsubjpass) described_7\VBN|NONE (l_conj) reviewed_27\VBN|,|and|case|is (l_nsubjpass) terminology_11\NN|.|are (l_conj) occurrence_13\NN|the|, (l_conj) manifestations_16\NNS|, (l_conj) pathogenesis_18\NN|,|clinical (l_conj) prevention_20\NN|, (l_conj) treatment_23\NN|and|, (l_prep) of_24\IN|NONE (l_pobj) anaphylaxis_25\NN|NONE
D010406_D000707 CID penicillin_7\NN|oral (r_compound) anaphylaxis_8\NN|NONE
2767010
D013327_D001145 CID strophanthidin_9\NN| (r_npadvmod) induced_11\VBN|in (r_amod) arrhythmias_12\NNS|NONE
C043114_D001145 NONE ACC-9653_4\NN|necessary|phenytoin (r_nmod) sodium_7\NN|NONE (l_amod) necessary_8\JJ|ACC|phenytoin (l_xcomp) convert_10\VB|NONE (l_dobj) arrhythmia_12\NN|to|to
C043114_D001145 NONE sodium_7\NN|NONE (l_amod) necessary_8\JJ|ACC|phenytoin (l_xcomp) convert_10\VB|NONE (l_dobj) arrhythmia_12\NN|to|to
C043114_D001145 NONE sodium_2\NN|.|in (r_nsubj) displayed_3\VBD|NONE (l_prep) in_4\IN|.|sodium (l_pobj) activity_7\NN|NONE (l_prep) against_8\IN|vitro|antiarrhythmic (l_pobj) arrhythmias_12\NNS|NONE
D010042_D017180 CID ouabain_7\NN| (r_npadvmod) induced_9\VBN|ventricular (r_amod) tachycardia_11\NN|NONE
C043114_D064420 NONE ACC-9653_4\NNP|phenytoin (r_nmod) sodium_7\NN|NONE (r_pobj) of_3\IN|toxicity|Acute (r_prep) studies_2\NNS|out|by|in|.|were (l_compound) toxicity_1\NN|Acute|of
C043114_D064420 NONE sodium_7\NN|NONE (r_pobj) of_3\IN|toxicity|Acute (r_prep) studies_2\NNS|out|by|in|.|were (l_compound) toxicity_1\NN|Acute|of
C043114_D017180 NONE sodium_1\NN|in|activity|. (r_nsubj) have_2\VBP|NONE (l_dobj) activity_5\NN|sodium|in|. (l_prep) against_6\IN|antiarrhythmic|similar (l_pobj) tachycardia_11\NN|NONE
C043114_D012640 NONE ACC-9653_0\NN|NONE (l_conj) have_4\VBP|and (l_dobj) activity_7\NN|.|sodium (l_prep) against_8\IN|anticonvulsant|equivalent (l_pobj) seizures_9\NNS|NONE
C043114_D012640 NONE sodium_3\NN|activity|. (r_nsubj) have_4\VBP|and (l_dobj) activity_7\NN|.|sodium (l_prep) against_8\IN|anticonvulsant|equivalent (l_pobj) seizures_9\NNS|NONE
9272404
D007052_D010146 CID ibuprofen_6\NNP|NONE (r_pobj) of_5\IN|NONE (r_prep) administration_4\NN|described|,|,|was|indicating|.|by (r_nsubjpass) followed_8\VBN|NONE (l_agent) by_9\IN|described|,|,|was|indicating|administration|. (l_pobj) decrease_11\NN|NONE (l_prep) in_12\IN|a|increase| (l_pobj) pain_14\NN|NONE
D007052_D010146 CID ibuprofen_6\NNP|NONE (r_pobj) of_5\IN|NONE (r_prep) administration_4\NN|described|,|,|was|indicating|.|by (r_nsubjpass) followed_8\VBN|NONE (l_agent) by_9\IN|described|,|,|was|indicating|administration|. (l_pobj) decrease_11\NN|NONE (l_appos) increase_22\NN|a||in (l_prep) in_23\IN|an (l_pobj) correlates_24\NNS|NONE (l_prep) of_25\IN|NONE (l_pobj) pain_27\NN|NONE
D007052_D010146 CID ibuprofen_6\NNP|NONE (r_pobj) of_5\IN|NONE (r_prep) administration_4\NN|described|,|,|was|indicating|.|by (r_nsubjpass) followed_8\VBN|NONE (l_advcl) indicating_29\VBG|described|,|,|was|administration|.|by (l_dobj) effect_32\NN|NONE (l_prep) on_35\IN|specific|a|of (l_pobj) interaction_37\NN|NONE (l_prep) between_38\IN|the (l_pobj) stimuli_41\NNS|NONE (l_compound) pain_40\NN|under|the
D007052_D010146 CID ibuprofen_34\NN|NONE (r_pobj) of_33\IN|on|specific|a (r_prep) effect_32\NN|NONE (r_dobj) indicating_29\VBG|described|,|,|was|administration|.|by (r_advcl) followed_8\VBN|NONE (l_agent) by_9\IN|described|,|,|was|indicating|administration|. (l_pobj) decrease_11\NN|NONE (l_prep) in_12\IN|a|increase| (l_pobj) pain_14\NN|NONE
D007052_D010146 CID ibuprofen_34\NN|NONE (r_pobj) of_33\IN|on|specific|a (r_prep) effect_32\NN|NONE (r_dobj) indicating_29\VBG|described|,|,|was|administration|.|by (r_advcl) followed_8\VBN|NONE (l_agent) by_9\IN|described|,|,|was|indicating|administration|. (l_pobj) decrease_11\NN|NONE (l_appos) increase_22\NN|a||in (l_prep) in_23\IN|an (l_pobj) correlates_24\NNS|NONE (l_prep) of_25\IN|NONE (l_pobj) pain_27\NN|NONE
D007052_D010146 CID ibuprofen_34\NN|NONE (r_pobj) of_33\IN|on|specific|a (r_prep) effect_32\NN|NONE (l_prep) on_35\IN|specific|a|of (l_pobj) interaction_37\NN|NONE (l_prep) between_38\IN|the (l_pobj) stimuli_41\NNS|NONE (l_compound) pain_40\NN|under|the
D002245_D010146 NONE CO2_10\NN|NONE (r_pobj) of_9\IN|short (r_prep) pulses_8\NNS|NONE (r_pobj) of_6\IN|NONE (r_prep) means_5\NNS|NONE (r_pobj) by_4\IN|was|duration|pain|to (r_agent) applied_3\VBN|NONE (l_nsubjpass) pain_1\NN|was|duration|by|to
D002245_D010146 NONE CO2_10\NN|NONE (r_pobj) of_9\IN|short (r_prep) pulses_8\NNS|NONE (r_pobj) of_6\IN|NONE (r_prep) means_5\NNS|NONE (r_pobj) by_4\IN|was|duration|pain|to (r_agent) applied_3\VBN|NONE (l_parataxis) duration_17\NN|was|by|pain|to (l_conj) induced_31\VBN|interval|,|,|ms|stimulus|and|( (l_nsubjpass) pain_29\NN|%|by|.|was|in|)
D002245_D010146 NONE CO2_17\NN|the (r_compound) stimuli_18\NNS|NONE (r_pobj) to_15\IN|NONE (r_prep) response_14\NN|NONE (r_pobj) in_13\IN|were|CSSEPs|. (r_prep) obtained_12\VBN|NONE (l_nsubjpass) CSSEPs_1\NNS|were|.|in (l_prep) as_6\IN|as|Both (l_pobj) correlates_8\NNS|NONE (l_prep) of_9\IN|peripheral (l_pobj) pain_10\NN|NONE
18340638
D010718_D000740 NONE phosphatidylserine_19\NN|NONE (r_pobj) of_18\IN|at (r_prep) exposure_17\NN|NONE (r_pobj) by_16\IN|which|is (r_agent) characterized_15\VBN|or|eryptosis|,|accelerated|suicidal|erythrocyte (r_relcl) death_9\NN|NONE (r_pobj) from_5\IN|,|Alternatively|anemia|.|could (r_prep) result_4\VB|NONE (l_nsubj) anemia_2\NN|from|,|Alternatively|.|could
D010718_D000740 NONE PS_21\NNP|NONE (r_appos) phosphatidylserine_19\NN|NONE (r_pobj) of_18\IN|at (r_prep) exposure_17\NN|NONE (r_pobj) by_16\IN|which|is (r_agent) characterized_15\VBN|or|eryptosis|,|accelerated|suicidal|erythrocyte (r_relcl) death_9\NN|NONE (r_pobj) from_5\IN|,|Alternatively|anemia|.|could (r_prep) result_4\VB|NONE (l_nsubj) anemia_2\NN|from|,|Alternatively|.|could
D001379_D000740 CID azathioprine_4\NN|NONE (r_pobj) of_3\IN|The|side (r_prep) effects_2\NNS|anemia|. (r_nsubj) include_5\VBP|NONE (l_dobj) anemia_6\NN|effects|.
D001379_D000740 CID Azathioprine_0\NN|.|,|death|effect (r_nsubj) triggers_1\VBZ|NONE (l_npadvmod) effect_7\NN|Azathioprine|.|,|death (l_acl) contributing_9\VBG|an (l_prep) to_10\IN|presumably (l_pobj) anemia_14\NN|NONE
D001379_D000740 CID azathioprine_11\RB| (r_advmod) induced_13\VBN|NONE (r_amod) anemia_14\NN|NONE
10726030
D006493_D013927 NONE heparin_3\NN| (r_npadvmod) induced_5\VBN|and|thrombosis (r_amod) thrombocytopenia_6\NN|NONE (l_conj) thrombosis_8\NN|induced|and
D006493_D013927 NONE heparin_14\JJ|NONE (r_compound) therapy_15\NN|NONE (r_pobj) of_13\IN|other|side (r_prep) effects_12\NNS|and (r_conj) thrombosis_8\NN|induced|and
D006493_D013927 NONE Heparin_0\NNP|prevent|first|, (r_nsubj) used_3\VBD|treat|,|.|clinically|has|been (r_ccomp) used_16\VBN|NONE (l_xcomp) treat_18\VB|,|.|clinically|used|has|been (l_dobj) thrombosis_19\NN|for|to
D006493_D013927 NONE heparin_9\NN|.|are|treat|anticoagulant|, (r_nsubj) remains_10\VBZ|NONE (l_xcomp) treat_16\VB|.|are|heparin|anticoagulant|, (l_dobj) episodes_19\NNS|to (l_amod) thrombotic_18\JJ|acute
D006493_D013927 NONE heparin_18\NN|NONE (r_pobj) of_17\IN|widespread|the (r_prep) use_16\NN|NONE (r_pobj) given_12\VBN|common|,|.|some (r_prep) are_21\VBP|effects|in|but|rare|, (l_acomp) common_23\JJ|given|,|.|some (l_conj) HITT_26\NNP|quite|,
D006493_D006994 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|, (l_conj) transaminasemia_33\NN|, (l_conj) hyperkalemia_35\NN|, (l_conj) hypoaldosteronism_37\NN|,
D006493_D006994 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|, (l_conj) transaminasemia_33\NN|, (l_conj) hyperkalemia_35\NN|, (l_conj) hypoaldosteronism_37\NN|,
D006493_D006994 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|, (l_conj) transaminasemia_33\NN|, (l_conj) hyperkalemia_35\NN|, (l_conj) hypoaldosteronism_37\NN|,
D006493_D000505 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|,
D006493_D000505 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|,
D006493_D000505 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|,
D006493_D006947 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|, (l_conj) transaminasemia_33\NN|, (l_conj) hyperkalemia_35\NN|,
D006493_D006947 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|, (l_conj) transaminasemia_33\NN|, (l_conj) hyperkalemia_35\NN|,
D006493_D006947 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|, (l_conj) transaminasemia_33\NN|, (l_conj) hyperkalemia_35\NN|,
D006493_D010024 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|,
D006493_D010024 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|,
D006493_D010024 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|,
D006493_D010024 CID heparin_18\NN|NONE (r_pobj) of_17\IN|widespread|the (r_prep) use_16\NN|NONE (r_pobj) given_12\VBN|common|,|.|some (r_prep) are_21\VBP|effects|in|but|rare|, (l_acomp) common_23\JJ|given|,|.|some (l_conj) HITT_26\NNP|quite|, (l_conj) osteoporosis_28\NN|and|particularly
D006493_D004802 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated
D006493_D004802 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated
D006493_D004802 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated
D006493_D013921 CID heparin_3\NN| (r_npadvmod) induced_5\VBN|and|thrombosis (r_amod) thrombocytopenia_6\NN|NONE
D006493_D013921 CID heparin_14\JJ|NONE (r_compound) therapy_15\NN|NONE (r_pobj) of_13\IN|other|side (r_prep) effects_12\NNS|and (r_conj) thrombosis_8\NN|induced|and (r_conj) thrombocytopenia_6\NN|NONE
D006493_D013921 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects
D006493_D013921 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE
D006493_D013921 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects
D006493_D013921 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE
D006493_D013921 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|, (r_conj) thrombocytopenia_13\NN|However|.|,|effects
D006493_D013921 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE
D006493_D013921 NONE heparin_18\NN|NONE (r_pobj) of_17\IN|widespread|the (r_prep) use_16\NN|NONE (r_pobj) given_12\VBN|common|,|.|some (r_prep) are_21\VBP|effects|in|but|rare|, (l_acomp) common_23\JJ|given|,|.|some (l_conj) HITT_26\NNP|quite|,
D006493_D004342 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|,
D006493_D004342 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|,
D006493_D004342 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|,
D006493_D012871 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|,
D006493_D012871 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|,
D006493_D012871 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|,
D006493_D006470 NONE heparin_7\NN|NONE (r_pobj) of_6\IN|untoward|primary|the (r_prep) effect_5\NN|.|Bleeding (r_attr) is_1\VBZ|NONE (l_nsubj) Bleeding_0\VBG|.|effect
D006493_D006470 NONE heparin_9\JJ|NONE (r_compound) therapy_10\NN|NONE (r_dobj) receiving_8\VBG|NONE (r_acl) patients_7\NNS|NONE (r_pobj) in_6\IN|primary (r_prep) concern_5\NN|NONE (r_pobj) of_3\IN|.|bleeding (r_prep) is_2\VBZ|NONE (l_nsubj) bleeding_1\NN|of|.
D006493_D011317 CID heparin_7\JJ|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|additional|important|untoward (r_prep) effects_5\NNS|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP|NONE (l_dobj) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|, (l_conj) transaminasemia_33\NN|, (l_conj) hyperkalemia_35\NN|, (l_conj) hypoaldosteronism_37\NN|, (l_conj) priapism_40\NN|,|and
D006493_D011317 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|osteoporosis|, (r_amod) thrombocytopenia_13\NN|However|.|,|effects (l_conj) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|, (l_conj) transaminasemia_33\NN|, (l_conj) hyperkalemia_35\NN|, (l_conj) hypoaldosteronism_37\NN|, (l_conj) priapism_40\NN|,|and
D006493_D011317 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|,|eosinophilia (r_amod) osteoporosis_18\NN|induced|, (l_conj) eosinophilia_20\NN|,|associated (l_conj) reactions_23\NNS|, (l_conj) reactions_26\NNS|skin|, (l_amod) other_27\JJ|allergic (l_prep) than_28\IN|NONE (l_pobj) thrombocytopenia_29\JJ|NONE (l_conj) alopecia_31\NN|, (l_conj) transaminasemia_33\NN|, (l_conj) hyperkalemia_35\NN|, (l_conj) hypoaldosteronism_37\NN|, (l_conj) priapism_40\NN|,|and
10427794
C065757_D056486 CID Meloxicam_0\NNP| (r_npadvmod) induced_2\VBN|.|liver (r_amod) toxicity_4\NN|NONE
C065757_D056486 CID meloxicam_18\NN|to (r_pobj) due_16\IN|hepatitis|who (r_prep) developed_12\VBD|rheumatoid (l_dobj) hepatitis_15\NN|due|who
C065757_D056486 CID meloxicam_7\NNP|NONE (r_compound) administration_8\NN|NONE (r_pobj) after_6\IN|rapidly|.|and|hepatitis|associated (r_prep) occurred_4\VBD|NONE (l_nsubj) hepatitis_3\NN|rapidly|.|after|and|associated
C065757_D056486 CID meloxicam_4\NNP|related|liver (r_nmod) toxicity_7\NN|NONE
C065757_D056486 CID meloxicam_4\NNP|related|liver (r_nmod) toxicity_7\NN|NONE (r_pobj) of_3\IN|first|This (r_prep) case_2\NN|induce|.|potential (r_nsubj) demonstrates_8\VBZ|NONE (l_xcomp) induce_15\VB|.|case|potential (l_dobj) damage_17\NN|to
C065757_D004342 CID meloxicam_7\NNP|NONE (r_compound) administration_8\NN|NONE (r_pobj) after_6\IN|rapidly|.|and|hepatitis|associated (r_prep) occurred_4\VBD|NONE (l_conj) associated_11\VBN|rapidly|.|after|and|hepatitis (l_advcl) suggesting_18\VBG|with|was (l_dobj) mechanism_21\NN|NONE (l_compound) hypersensitivity_20\NN|a
C065757_D001172 NONE meloxicam_18\NN|to (r_pobj) due_16\IN|hepatitis|who (r_prep) developed_12\VBD|rheumatoid (r_relcl) arthritis_10\NN|NONE
19184102
D014635_D009765 CID VPA_20\NNP|NONE (r_compound) treatment_21\NN|NONE (r_pobj) during_19\IN|who|obesity (r_prep) developed_17\VBD|a (l_dobj) obesity_18\NN|during|who
D014635_D009765 CID VPA_18\NNP|NONE (r_pobj) with_17\IN|term (r_prep) treatment_16\NN|,|insulin|and (r_conj) resistance_10\NN|, (r_conj) hyperinsulinemia_7\NN|, (r_conj) obesity_5\NN|with|all|be|that|may
D014635_D009765 CID VPA_35\NNP|NONE (r_compound) withdrawal_36\NN|NONE (r_pobj) after_34\IN|reversible|suggests|;|.|effect (r_prep) is_32\VBZ|NONE (l_ccomp) suggests_3\VBZ|reversible|;|after|.|effect (l_ccomp) associated_22\VBN|case (l_nsubjpass) obesity_5\NN|with|all|be|that|may
D014635_D006946 CID VPA_18\NNP|NONE (r_pobj) with_17\IN|term (r_prep) treatment_16\NN|,|insulin|and (r_conj) resistance_10\NN|, (r_conj) hyperinsulinemia_7\NN|,
D014635_D006946 CID VPA_35\NNP|NONE (r_compound) withdrawal_36\NN|NONE (r_pobj) after_34\IN|reversible|suggests|;|.|effect (r_prep) is_32\VBZ|NONE (l_ccomp) suggests_3\VBZ|reversible|;|after|.|effect (l_ccomp) associated_22\VBN|case (l_nsubjpass) obesity_5\NN|with|all|be|that|may (l_conj) hyperinsulinemia_7\NN|,
D014635_D007333 CID VPA_18\NNP|NONE (r_pobj) with_17\IN|term (r_prep) treatment_16\NN|,|insulin|and (r_conj) resistance_10\NN|,
D014635_D007333 CID VPA_35\NNP|NONE (r_compound) withdrawal_36\NN|NONE (r_pobj) after_34\IN|reversible|suggests|;|.|effect (r_prep) is_32\VBZ|NONE (l_ccomp) suggests_3\VBZ|reversible|;|after|.|effect (l_ccomp) associated_22\VBN|case (l_nsubjpass) obesity_5\NN|with|all|be|that|may (l_conj) hyperinsulinemia_7\NN|, (l_conj) resistance_10\NN|,
D014635_D065626 CID valproate_5\NN|NONE (r_amod) therapy_6\NN|NONE (r_pobj) during_4\IN|liver|Nonalcoholic|.|fatty (r_prep) disease_3\NN|NONE
D014635_D065626 CID VPA_20\NNP|NONE (r_compound) treatment_21\NN|NONE (r_pobj) during_19\IN|who|obesity (r_prep) developed_17\VBD|a (r_relcl) child_15\NN|NONE (r_pobj) in_13\IN|NONE (r_prep) arising_12\VBG|fatty|NAFLD|liver|)|nonalcoholic|( (r_acl) disease_8\NN|NONE
D014635_D065626 CID VPA_20\NNP|NONE (r_compound) treatment_21\NN|NONE (r_pobj) during_19\IN|who|obesity (r_prep) developed_17\VBD|a (r_relcl) child_15\NN|NONE (r_pobj) in_13\IN|NONE (r_prep) arising_12\VBG|fatty|NAFLD|liver|)|nonalcoholic|( (r_acl) disease_8\NN|NONE (l_appos) NAFLD_10\NNP|arising|fatty|liver|)|nonalcoholic|(
D014635_D065626 CID VPA_18\NNP|NONE (r_pobj) with_17\IN|term (r_prep) treatment_16\NN|,|insulin|and (r_conj) resistance_10\NN|, (r_conj) hyperinsulinemia_7\NN|, (r_conj) obesity_5\NN|with|all|be|that|may (r_nsubjpass) associated_22\VBN|case (l_prep) with_23\IN|obesity|all|be|that|may (l_pobj) development_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) NAFLD_27\NNP|NONE
D014635_D065626 CID VPA_35\NNP|NONE (r_compound) withdrawal_36\NN|NONE (r_pobj) after_34\IN|reversible|suggests|;|.|effect (r_prep) is_32\VBZ|NONE (l_ccomp) suggests_3\VBZ|reversible|;|after|.|effect (l_ccomp) associated_22\VBN|case (l_prep) with_23\IN|obesity|all|be|that|may (l_pobj) development_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) NAFLD_27\NNP|NONE
D014635_D004827 NONE acid_1\NN|associated|,|effective|but (r_nsubj) is_5\VBZ|NONE (l_acomp) effective_6\JJ|associated|,|acid|but (l_prep) for_7\IN|NONE (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) types_12\NNS|NONE (l_prep) of_13\IN|many (l_pobj) epilepsy_14\NN|NONE
D014635_D004827 NONE VPA_3\NNP|(|Valproic|) (r_appos) acid_1\NN|associated|,|effective|but (r_nsubj) is_5\VBZ|NONE (l_acomp) effective_6\JJ|associated|,|acid|but (l_prep) for_7\IN|NONE (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) types_12\NNS|NONE (l_prep) of_13\IN|many (l_pobj) epilepsy_14\NN|NONE
D014635_D015431 NONE VPA_4\NNP|NONE (r_compound) therapy_5\NN|NONE (r_pobj) of_3\IN|the (r_prep) withdrawal_2\NN|NONE (r_pobj) After_0\IN|patient|loss|, (r_prep) showed_9\VBD|normalization|measurements|moreover|;|.|, (l_dobj) loss_13\NN|patient|After|,
18399341
D004837_D007022 NONE epinephrine_24\NN|,|treat|P=|required|. (r_amod) infusion_25\NN||and|Four|in (l_relcl) treat_27\VB|,|P=|required|.|epinephrine (l_dobj) hypotension_28\NN|to
24742750
D015283_D016171 CID Citalopram_8\NNP|and (r_conj) Terfenadine_6\NNP|reported|IKr|,|Finally|,|.|, (r_appos) blockers_4\NNS|NONE (l_relcl) reported_12\VBN|IKr|,|Finally|,|.|Terfenadine|, (l_xcomp) cause_14\VB|are|which (l_ccomp) produced_25\VBD|to (l_nsubj) Pointes_17\NNP|)|EAD
D015283_D016171 CID Citalopram_8\NNP|and (r_conj) Terfenadine_6\NNP|reported|IKr|,|Finally|,|.|, (r_appos) blockers_4\NNS|NONE (l_relcl) reported_12\VBN|IKr|,|Finally|,|.|Terfenadine|, (l_xcomp) cause_14\VB|are|which (l_ccomp) produced_25\VBD|to (l_nsubj) Pointes_17\NNP|)|EAD (l_appos) TdP_19\NNP|Torsade|in|(|de|,|)
D016593_D016171 CID Terfenadine_6\NNP|reported|IKr|,|Finally|,|.|, (r_appos) blockers_4\NNS|NONE (l_relcl) reported_12\VBN|IKr|,|Finally|,|.|Terfenadine|, (l_xcomp) cause_14\VB|are|which (l_ccomp) produced_25\VBD|to (l_nsubj) Pointes_17\NNP|)|EAD
D016593_D016171 CID Terfenadine_6\NNP|reported|IKr|,|Finally|,|.|, (r_appos) blockers_4\NNS|NONE (l_relcl) reported_12\VBN|IKr|,|Finally|,|.|Terfenadine|, (l_xcomp) cause_14\VB|are|which (l_ccomp) produced_25\VBD|to (l_nsubj) Pointes_17\NNP|)|EAD (l_appos) TdP_19\NNP|Torsade|in|(|de|,|)
2358093
D003613_D054179 NONE danazol_6\NN|NONE (r_pobj) of_5\IN|term|in|with|The|. (r_prep) safety_4\NN|NONE (l_prep) with_9\IN|term|in|of|The|. (l_pobj) angioedema_11\NN|NONE
D003613_D054179 NONE danazol_9\NN|NONE (r_pobj) of_8\IN|term|the (r_prep) safety_7\NN|We|by|therefore|. (r_dobj) investigated_2\VBD|NONE (l_prep) by_10\IN|We|safety|therefore|. (l_pcomp) performing_11\VBG|NONE (l_dobj) review_15\NN|NONE (l_prep) of_16\IN|a|treated|chart|retrospective (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN||female (l_pobj) angioedema_22\NN|NONE
D003613_D054179 NONE danazol_25\NN|NONE (r_pobj) with_24\IN|for (r_prep) treated_23\VBN|a|of|chart|retrospective (r_acl) review_15\NN|NONE (l_prep) of_16\IN|a|treated|chart|retrospective (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN||female (l_pobj) angioedema_22\NN|NONE
15859361
C105934_D004342 NONE CE_5\NNP|NONE (r_pobj) to_4\IN|one|hypersensitivity (r_prep) reaction_3\NN|was|among|. (l_compound) hypersensitivity_2\NN|one|to
D000082_D004342 NONE P_7\NN|NONE (r_pobj) to_6\IN|with (r_prep) hypersensitivity_5\NN|NONE
D000082_D004342 NONE P_10\NN||intolerant|NSAIDs (r_nmod) patients_17\NNS|NONE (r_pobj) among_8\IN|was|.|reaction (r_prep) documented_7\VBN|NONE (l_nsubjpass) reaction_3\NN|was|among|. (l_compound) hypersensitivity_2\NN|one|to
D000082_D003875 CID acetaminophen_10\RB|NONE (r_pobj) to_9\IN|adverse|paracetamol|skin (r_prep) reactions_8\NNS|NONE
D000082_D003875 CID paracetamol_12\NNP|adverse|to|skin (r_appos) reactions_8\NNS|NONE
D000082_D003875 CID P_20\NN|NONE (r_pobj) to_19\IN|cutaneous|adverse|associated (r_prep) reactions_18\NNS|NONE
D000082_D003875 CID P_3\NN|skin (r_nmod) reactions_9\NNS|NONE
C012655_D004342 NONE N_9\NN|and (r_conj) P_7\NN|NONE (r_pobj) to_6\IN|with (r_prep) hypersensitivity_5\NN|NONE
C012655_D004342 NONE N_12\NN|and (r_conj) P_10\NN||intolerant|NSAIDs (r_nmod) patients_17\NNS|NONE (r_pobj) among_8\IN|was|.|reaction (r_prep) documented_7\VBN|NONE (l_nsubjpass) reaction_3\NN|was|among|. (l_compound) hypersensitivity_2\NN|one|to
C105934_D003875 NONE celecoxib_2\NN|NONE (r_pobj) of_1\IN|.|in (r_prep) Safety_0\NN|NONE (l_prep) in_3\IN|.|of (l_pobj) patients_4\NNS|NONE (l_prep) with_5\IN|NONE (l_pobj) reactions_8\NNS|NONE
C105934_D003875 NONE CE_6\NNP|NONE (r_pobj) of_5\IN|the (r_prep) tolerability_4\NN|.|We|:|in (r_dobj) evaluated_2\VBD|NONE (l_prep) in_7\IN|.|tolerability|We|: (l_pobj) group_9\NN|NONE (l_prep) of_10\IN|a (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) history_14\NN|NONE (l_prep) of_15\IN|documented (l_pobj) reactions_18\NNS|NONE
C012655_D003875 CID nimesulide_15\NN|and|(|) (r_conj) paracetamol_12\NNP|adverse|to|skin (r_appos) reactions_8\NNS|NONE
C012655_D003875 CID N_22\NNP|and (r_conj) P_20\NN|NONE (r_pobj) to_19\IN|cutaneous|adverse|associated (r_prep) reactions_18\NNS|NONE
C012655_D003875 CID N_5\NN| (r_npadvmod) induced_7\VBN|and (r_conj) P_3\NN|skin (r_nmod) reactions_9\NNS|NONE
3088653
D012601_D000647 CID scopolamine_2\NN| (r_npadvmod) induced_4\VBN|of (r_amod) amnesia_5\NN|NONE
D012601_D000647 CID Scopolamine_0\NNP|amnesia|measured|. (r_nsubj) induced_13\VBD|NONE (l_dobj) amnesia_15\NN|Scopolamine|measured|.
D012601_D000647 CID scopolamine_21\NN| (r_npadvmod) induced_23\VBN|the (r_amod) amnesia_24\NN|also|.|administration
D012601_D008569 NONE scopolamine_14\NN| (r_npadvmod) induced_16\VBN|a|retention (r_amod) deficit_18\NN|NONE
D012601_D008569 NONE scopolamine_38\NN| (r_npadvmod) induced_40\VBN|retention|the (r_amod) deficit_42\NN|NONE
D019832_D000647 NONE scopolamine_5\NN|,|but (r_conj) Scopolamine_0\NNP|amnesia|measured|. (r_nsubj) induced_13\VBD|NONE (l_dobj) amnesia_15\NN|Scopolamine|measured|.
D009270_D008569 NONE naloxone_11\NN|NONE (l_prep) on_12\IN|in (l_pobj) deficit_18\NN|NONE
D009270_D008569 NONE Naloxone_0\NN|prior|.|attenuated (r_nsubj) injected_12\VBD|NONE (l_advcl) attenuated_16\VBD|prior|.|Naloxone (l_dobj) deficit_19\NN|with|at
D009270_D008569 NONE naloxone_14\NN|pain (r_appos) sensitivity_9\NN|NONE (r_pobj) in_7\IN|nor|neither|an|state|) (r_prep) increase_6\NN|be|that (r_nsubj) appear_27\VBP|experiments|. (l_xcomp) be_29\VB|that|increase (l_acomp) responsible_30\JJ|to (l_prep) for_31\IN|NONE (l_pobj) influence_33\NN|NONE (l_prep) of_34\IN|the (l_pobj) naloxone_35\NN|NONE (l_prep) on_36\IN|NONE (l_pobj) deficit_42\NN|NONE
D009270_D008569 NONE naloxone_25\NN|)|induced|aversive|an (r_appos) state_20\NN|nor|neither|an|in|) (r_conj) increase_6\NN|be|that (r_nsubj) appear_27\VBP|experiments|. (l_xcomp) be_29\VB|that|increase (l_acomp) responsible_30\JJ|to (l_prep) for_31\IN|NONE (l_pobj) influence_33\NN|NONE (l_prep) of_34\IN|the (l_pobj) naloxone_35\NN|NONE (l_prep) on_36\IN|NONE (l_pobj) deficit_42\NN|NONE
D009270_D008569 NONE naloxone_35\NN|NONE (l_prep) on_36\IN|NONE (l_pobj) deficit_42\NN|NONE
D009270_D000647 NONE naloxone_15\NN|NONE (r_pobj) by_9\IN|passive (r_prep) avoidance_8\NN|NONE (r_pobj) of_6\IN|induced (r_prep) amnesia_5\NN|NONE
D009270_D000647 NONE naloxone_5\NN|NONE (r_pobj) of_4\IN|training|as (r_prep) administration_3\NN|also|.|amnesia (r_nsubj) attenuated_19\VBD|NONE (l_dobj) amnesia_24\NN|also|.|administration
D012601_D010146 NONE scopolamine_38\NN| (r_npadvmod) induced_40\VBN|retention|the (r_amod) deficit_42\NN|NONE (r_pobj) on_36\IN|NONE (r_prep) naloxone_35\NN|NONE (r_pobj) of_34\IN|the (r_prep) influence_33\NN|NONE (r_pobj) for_31\IN|NONE (r_prep) responsible_30\JJ|to (r_acomp) be_29\VB|that|increase (r_xcomp) appear_27\VBP|experiments|. (l_nsubj) increase_6\NN|be|that (l_prep) in_7\IN|nor|neither|an|state|) (l_pobj) sensitivity_9\NN|NONE (l_compound) pain_8\NN|naloxone
D009270_D010146 NONE naloxone_14\NN|pain (r_appos) sensitivity_9\NN|NONE (l_compound) pain_8\NN|naloxone
D009270_D010146 NONE naloxone_25\NN|)|induced|aversive|an (r_appos) state_20\NN|nor|neither|an|in|) (r_conj) increase_6\NN|be|that (l_prep) in_7\IN|nor|neither|an|state|) (l_pobj) sensitivity_9\NN|NONE (l_compound) pain_8\NN|naloxone
D009270_D010146 NONE naloxone_35\NN|NONE (r_pobj) of_34\IN|the (r_prep) influence_33\NN|NONE (r_pobj) for_31\IN|NONE (r_prep) responsible_30\JJ|to (r_acomp) be_29\VB|that|increase (r_xcomp) appear_27\VBP|experiments|. (l_nsubj) increase_6\NN|be|that (l_prep) in_7\IN|nor|neither|an|state|) (l_pobj) sensitivity_9\NN|NONE (l_compound) pain_8\NN|naloxone
8808730
D009569_D001745 NONE oxide_5\NN|nitric|neuronal|in (r_compound) synthase_6\NN|NONE (r_pobj) of_2\IN|Increased|.|following (r_prep) expression_1\NN|NONE (l_prep) following_11\VBG|Increased|.|of (l_pobj) irritation_14\NN|NONE
D000171_D003556 NONE acrolein_13\NN|NONE (r_pobj) to_12\IN|which|is (r_prep) metabolized_11\VBN|)|( (r_relcl) CYP_7\NNP|NONE (r_appos) cyclophosphamide_5\NN|NONE (r_pobj) by_4\IN|was|cystitis (r_agent) induced_3\VBN|.|,|irritant|in (l_nsubjpass) cystitis_1\NN|by|was
D003520_D003556 CID cyclophosphamide_5\NN|NONE (r_pobj) by_4\IN|was|cystitis (r_agent) induced_3\VBN|.|,|irritant|in (l_nsubjpass) cystitis_1\NN|by|was
D003520_D003556 CID CYP_7\NNP|NONE (r_appos) cyclophosphamide_5\NN|NONE (r_pobj) by_4\IN|was|cystitis (r_agent) induced_3\VBN|.|,|irritant|in (l_nsubjpass) cystitis_1\NN|by|was
D009569_D014570 NONE oxide_13\NN|in|neuronal|)|(|NOS|nitric (r_compound) synthase_14\NN|NONE (r_pobj) of_10\IN|the (r_prep) expression_9\NN|NONE (r_pobj) in_7\IN|following (r_prep) alterations_6\NNS|to (l_prep) following_21\VBG|in (l_pobj) irritation_25\NN|NONE (l_prep) of_26\IN|acute (l_pobj) tract_29\NN|NONE
24753331
C083440_D064420 NONE S-23121_2\NN|and (r_conj) S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) retardation_25\NN|phenylimide|teratogenicity|,|and|embryolethality|and|, (l_prep) in_26\IN|growth (l_pobj) rats_27\NNS|NONE (l_prep) in_28\IN|NONE (l_pobj) studies_33\NNS|NONE (l_compound) toxicity_32\NN|conventional|oral
C083440_D006345 CID S-23121_2\NN|and (r_conj) S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) teratogenicity_12\NN|phenylimide|retardation|,|and|embryolethality|and|, (l_conj) defects_17\NNS|)|(
C083440_D006345 CID S-23121_3\NN|NONE (r_pobj) of_2\IN|Dermal|at (r_prep) administration_1\NN|,|observed|but|in (r_nsubj) resulted_7\VBD|NONE (l_prep) in_8\IN|administration|,|observed|but (l_pobj) incidence_11\NN|NONE (l_prep) of_12\IN|increased|an (l_pobj) death_14\NN|NONE (l_conj) defect_18\NN|embryonic|and
C083440_D006345 CID S-23121_34\NN|NONE (r_pobj) to_33\IN|oral (r_prep) exposure_32\NN|it|was|as (r_dobj) following_30\VBG|was|not|.|growth (r_advcl) observed_26\VBN|administration|,|but|in (r_conj) resulted_7\VBD|NONE (l_prep) in_8\IN|administration|,|observed|but (l_pobj) incidence_11\NN|NONE (l_prep) of_12\IN|increased|an (l_pobj) death_14\NN|NONE (l_conj) defect_18\NN|embryonic|and
C106487_D064793 CID S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) teratogenicity_12\NN|phenylimide|retardation|,|and|embryolethality|and|,
C106487_D064793 CID S-53482_5\NNS|,|Based|teratogenic|administered|. (r_nsubj) were_8\VBD|NONE (l_acomp) teratogenic_9\JJ|,|S|Based|administered|.
C083440_D020964 CID S-23121_2\NN|and (r_conj) S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) embryolethality_10\NN|phenylimide|retardation|teratogenicity|,|and|and|,
C083440_D020964 CID S-23121_3\NN|NONE (r_pobj) of_2\IN|Dermal|at (r_prep) administration_1\NN|,|observed|but|in (r_nsubj) resulted_7\VBD|NONE (l_prep) in_8\IN|administration|,|observed|but (l_pobj) incidence_11\NN|NONE (l_prep) of_12\IN|increased|an (l_pobj) death_14\NN|NONE
C083440_D020964 CID S-23121_34\NN|NONE (r_pobj) to_33\IN|oral (r_prep) exposure_32\NN|it|was|as (r_dobj) following_30\VBG|was|not|.|growth (r_advcl) observed_26\VBN|administration|,|but|in (r_conj) resulted_7\VBD|NONE (l_prep) in_8\IN|administration|,|observed|but (l_pobj) incidence_11\NN|NONE (l_prep) of_12\IN|increased|an (l_pobj) death_14\NN|NONE
C106487_D006345 CID S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) teratogenicity_12\NN|phenylimide|retardation|,|and|embryolethality|and|, (l_conj) defects_17\NNS|)|(
C106487_D005317 CID S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) retardation_25\NN|phenylimide|teratogenicity|,|and|embryolethality|and|,
C106487_D020964 CID S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) embryolethality_10\NN|phenylimide|retardation|teratogenicity|,|and|and|,
C083440_D005317 CID S-23121_2\NN|and (r_conj) S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) retardation_25\NN|phenylimide|teratogenicity|,|and|embryolethality|and|,
C106487_D064420 NONE S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) retardation_25\NN|phenylimide|teratogenicity|,|and|embryolethality|and|, (l_prep) in_26\IN|growth (l_pobj) rats_27\NNS|NONE (l_prep) in_28\IN|NONE (l_pobj) studies_33\NNS|NONE (l_compound) toxicity_32\NN|conventional|oral
C106487_D064420 NONE S-53482_5\NNS|NONE (r_pobj) to_4\IN|Dermal|.|at|of (r_prep) exposure_1\NN|NONE (l_prep) at_6\IN|Dermal|.|to|of (l_pobj) patterns_10\NNS|NONE (l_prep) of_11\IN|produced|mg/kg (l_pobj) toxicity_13\NN|NONE
C083440_D064793 CID S-23121_2\NN|and (r_conj) S-53482_0\NNS|.|herbicides (r_nsubj) are_3\VBP|NONE (l_attr) herbicides_7\NNS|.|S (l_conj) teratogenicity_12\NN|phenylimide|retardation|,|and|embryolethality|and|,
C083440_D064793 CID S-23121_7\NN|and (r_conj) S-53482_5\NNS|,|Based|teratogenic|administered|. (r_nsubj) were_8\VBD|NONE (l_acomp) teratogenic_9\JJ|,|S|Based|administered|.
24209900
D007069_D008223 NONE Ifosfamide_0\NNP|.|agent (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Ifosfamide (l_amod) useful_5\JJ|an|alkylating (l_prep) in_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) range_12\NN|NONE (l_prep) of_13\IN|wide|a (l_pobj) cancers_14\NNS|NONE (l_prep) including_15\VBG|NONE (l_pobj) sarcomas_16\NNS|NONE (l_conj) cancers_23\NNS|, (l_nmod) lymphoma_18\NN|gynecologic
D007069_D009369 NONE Ifosfamide_0\NNP|.|agent (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Ifosfamide (l_amod) useful_5\JJ|an|alkylating (l_prep) in_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) range_12\NN|NONE (l_prep) of_13\IN|wide|a (l_pobj) cancers_14\NNS|NONE
D007069_D009369 NONE Ifosfamide_0\NNP|.|agent (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Ifosfamide (l_amod) useful_5\JJ|an|alkylating (l_prep) in_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) range_12\NN|NONE (l_prep) of_13\IN|wide|a (l_pobj) cancers_14\NNS|NONE (l_prep) including_15\VBG|NONE (l_pobj) sarcomas_16\NNS|NONE (l_conj) cancers_23\NNS|,
D007069_D009369 NONE ifosfamide_29\RB|NONE (r_advmod) related_30\VBN|acute (r_amod) encephalopathy_32\NN|who (r_dobj) developed_28\VBD|on|was|admitted|.|,|,|review (r_relcl) done_10\VBN|NONE (l_advcl) admitted_15\VBN|on|was|.|,|,|developed|review (l_prep) to_16\IN|between (l_pobj) Center_20\NNP|NONE (l_compound) Cancer_19\NNP|Anderson|MD
D007069_D012509 NONE Ifosfamide_0\NNP|.|agent (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Ifosfamide (l_amod) useful_5\JJ|an|alkylating (l_prep) in_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) range_12\NN|NONE (l_prep) of_13\IN|wide|a (l_pobj) cancers_14\NNS|NONE (l_prep) including_15\VBG|NONE (l_pobj) sarcomas_16\NNS|NONE
D007069_D001927 NONE Ifosfamide_0\IN|need|related|.|: (r_nmod) encephalopathy_2\NN|NONE
D007069_D001927 NONE ifosfamide_16\NN|NONE (r_dobj) receiving_11\VBG|NONE (r_acl) patients_10\NNS|NONE (r_pobj) of_9\IN| (r_prep) %_8\NN|NONE (r_pobj) in_4\IN|been|has|Encephalopathy|. (r_prep) reported_3\VBN|NONE (l_nsubjpass) Encephalopathy_0\NNP|in|been|has|.
D007069_D001927 NONE ifosfamide_16\JJ|NONE (r_advmod) related_17\VBN|NONE (r_amod) encephalopathy_18\NN|NONE
D007069_D001927 NONE ifosfamide_29\RB|NONE (r_advmod) related_30\VBN|acute (r_amod) encephalopathy_32\NN|who
D007069_D001927 NONE ifosfamide_17\RB|NONE (r_advmod) receiving_16\VBG|within|(|:|)|symptoms|patients|after|. (r_advcl) experienced_4\VBD|NONE (l_dobj) symptoms_5\NNS|within|(|:|)|receiving|patients|after|. (l_prep) of_6\IN|NONE (l_pobj) encephalopathy_7\JJ|NONE
D007069_D001927 NONE ifosfamide_2\JJ|NONE (r_advmod) related_3\JJ|NONE (r_amod) encephalopathy_4\JJ|NONE
D007069_D001927 NONE ifosfamide_9\RB|NONE (l_relcl) develop_11\VBP|NONE (l_dobj) features_12\NNS|who (l_prep) of_13\IN|NONE (l_pobj) encephalopathy_14\NN|NONE
24733133
C031942_D013921 NONE argatroban_2\NN|with|in (r_amod) thrombolysis_7\NN|NONE (l_prep) in_10\IN|with|argatroban (l_pobj) patient_13\NN|NONE (l_prep) with_14\IN|oncology|an (l_pobj) thrombocytopenia_18\NN|NONE
C031942_D013921 NONE argatroban_21\NN|(|CDT|directed|) (r_amod) thrombolysis_26\NN|NONE (r_pobj) with_20\IN|with|was (r_prep) treated_19\VBN|thrombocytopenia|who|and (r_conj) developed_7\VBD|oncology|an (l_dobj) thrombocytopenia_11\NN|treated|who|and
C031942_D013921 NONE argatroban_21\NN|(|CDT|directed|) (r_amod) thrombolysis_26\NN|NONE (r_pobj) with_20\IN|with|was (r_prep) treated_19\VBN|thrombocytopenia|who|and (r_conj) developed_7\VBD|oncology|an (l_dobj) thrombocytopenia_11\NN|treated|who|and (l_prep) with_12\IN|induced (l_pobj) thrombosis_13\NN|NONE (l_appos) HITT_15\NNP|NONE
C031942_D013921 NONE argatroban_18\NN|NONE (r_amod) with_17\IN|man|successfully|with|.|was (r_prep) treated_16\VBN|NONE (l_nsubjpass) man_4\NN|with|successfully|with|.|was (l_prep) to_12\IN|with|A|old (l_pobj) HITT_13\NNP|NONE
C031942_D004844 NONE argatroban_13\NN|NONE (r_amod) on_12\IN|.|was|patient (r_prep) restarted_11\VBN|,|epistaxis|day|and (r_conj) resolved_2\VBD|NONE (l_nsubj) epistaxis_1\NN|,|day|restarted|and
D006493_D013921 CID heparin_15\NN| (r_npadvmod) induced_17\VBN|with (r_amod) thrombocytopenia_18\NN|NONE
D006493_D013921 CID heparin_8\NN| (r_npadvmod) induced_10\VBN|with (r_amod) thrombocytopenia_11\NN|treated|who|and
D006493_D013921 CID heparin_38\NN| (r_npadvmod) induced_40\VBN|NONE (r_amod) thrombocytopenia_41\NN|NONE
D006493_D013921 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|with (r_amod) thrombocytopenia_11\NN|treated|who|and (l_prep) with_12\IN|induced (l_pobj) thrombosis_13\NN|NONE (l_appos) HITT_15\NNP|NONE
D006493_D011655 CID heparin_38\NN| (r_npadvmod) induced_40\VBN|NONE (r_amod) thrombocytopenia_41\NN|NONE (r_pobj) to_37\IN|NONE (r_prep) secondary_36\JJ|pulmonary (r_amod) embolism_35\NN|(|DVT|)|bilateral|extensive|extremity|and|venous
D006493_D013927 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|with (r_amod) thrombocytopenia_18\NN|NONE (l_prep) with_19\IN|induced (l_pobj) thrombosis_20\NN|NONE
D006493_D013927 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|with (r_amod) thrombocytopenia_11\NN|treated|who|and (l_prep) with_12\IN|induced (l_pobj) thrombosis_13\NN|NONE
D006493_D013927 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|with (r_amod) thrombocytopenia_11\NN|treated|who|and (l_prep) with_12\IN|induced (l_pobj) thrombosis_13\NN|NONE (l_appos) HITT_15\NNP|NONE
D006493_D000686 NONE heparin_38\NN| (r_npadvmod) induced_40\VBN|NONE (r_amod) thrombocytopenia_41\NN|NONE (r_pobj) to_37\IN|NONE (r_prep) secondary_36\JJ|pulmonary (r_amod) embolism_35\NN|(|DVT|)|bilateral|extensive|extremity|and|venous (r_conj) thrombosis_29\NN|man|. (r_dobj) developed_21\VBD|NONE (l_nsubj) man_5\NN|thrombosis|. (l_prep) with_6\IN|A|old|Caucasian (l_pobj) amyloidosis_8\NN|NONE
D006493_D055499 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|with (r_amod) thrombocytopenia_18\NN|NONE (r_pobj) with_14\IN|oncology|an (r_prep) patient_13\NN|NONE (r_pobj) in_10\IN|with|argatroban (r_prep) thrombolysis_7\NN|NONE
D006493_D055499 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|with (r_amod) thrombocytopenia_11\NN|treated|who|and (r_dobj) developed_7\VBD|oncology|an (l_conj) treated_19\VBN|thrombocytopenia|who|and (l_prep) with_20\IN|with|was (l_pobj) thrombolysis_26\NN|NONE
C031942_D055499 NONE argatroban_2\NN|with|in (r_amod) thrombolysis_7\NN|NONE
C031942_D055499 NONE argatroban_21\NN|(|CDT|directed|) (r_amod) thrombolysis_26\NN|NONE
D006493_D056824 NONE heparin_38\NN| (r_npadvmod) induced_40\VBN|NONE (r_amod) thrombocytopenia_41\NN|NONE (r_pobj) to_37\IN|NONE (r_prep) secondary_36\JJ|pulmonary (r_amod) embolism_35\NN|(|DVT|)|bilateral|extensive|extremity|and|venous (r_conj) thrombosis_29\NN|man|.
D006493_D020246 CID heparin_38\NN| (r_npadvmod) induced_40\VBN|NONE (r_amod) thrombocytopenia_41\NN|NONE (r_pobj) to_37\IN|NONE (r_prep) secondary_36\JJ|pulmonary (r_amod) embolism_35\NN|(|DVT|)|bilateral|extensive|extremity|and|venous (r_conj) thrombosis_29\NN|man|. (l_appos) DVT_31\NNP|(|)|bilateral|extensive|extremity|and|embolism|venous
C031942_D013479 NONE argatroban_18\NN|NONE (r_amod) with_17\IN|man|successfully|with|.|was (r_prep) treated_16\VBN|NONE (l_nsubjpass) man_4\NN|with|successfully|with|.|was (l_prep) with_5\IN|A|old|to (l_pobj) amyloidosis_7\NN|NONE (l_conj) syndrome_10\NN|renal|and
C031942_D000686 NONE argatroban_18\NN|NONE (r_amod) with_17\IN|man|successfully|with|.|was (r_prep) treated_16\VBN|NONE (l_nsubjpass) man_4\NN|with|successfully|with|.|was (l_prep) with_5\IN|A|old|to (l_pobj) amyloidosis_7\NN|NONE
C031942_D013927 NONE argatroban_2\NN|with|in (r_amod) thrombolysis_7\NN|NONE (l_prep) in_10\IN|with|argatroban (l_pobj) patient_13\NN|NONE (l_prep) with_14\IN|oncology|an (l_pobj) thrombocytopenia_18\NN|NONE (l_prep) with_19\IN|induced (l_pobj) thrombosis_20\NN|NONE
C031942_D013927 NONE argatroban_21\NN|(|CDT|directed|) (r_amod) thrombolysis_26\NN|NONE (r_pobj) with_20\IN|with|was (r_prep) treated_19\VBN|thrombocytopenia|who|and (r_conj) developed_7\VBD|oncology|an (l_dobj) thrombocytopenia_11\NN|treated|who|and (l_prep) with_12\IN|induced (l_pobj) thrombosis_13\NN|NONE
C031942_D013927 NONE argatroban_21\NN|(|CDT|directed|) (r_amod) thrombolysis_26\NN|NONE (r_pobj) with_20\IN|with|was (r_prep) treated_19\VBN|thrombocytopenia|who|and (r_conj) developed_7\VBD|oncology|an (l_dobj) thrombocytopenia_11\NN|treated|who|and (l_prep) with_12\IN|induced (l_pobj) thrombosis_13\NN|NONE (l_appos) HITT_15\NNP|NONE
C031942_D013927 NONE argatroban_18\NN|NONE (r_amod) with_17\IN|man|successfully|with|.|was (r_prep) treated_16\VBN|NONE (l_nsubjpass) man_4\NN|with|successfully|with|.|was (l_prep) to_12\IN|with|A|old (l_pobj) HITT_13\NNP|NONE
24928523
C400082_D009101 NONE bortezomib_2\NNS|NONE (r_pobj) of_1\IN|thalidomide|as|. (r_prep) Combination_0\NN|NONE (l_prep) as_11\IN|of|thalidomide|. (l_pobj) therapy_14\NN|NONE (l_prep) after_15\IN|a|consolidation (l_pobj) transplantation_19\NN|NONE (l_prep) for_20\IN|cell|autologous (l_pobj) myeloma_23\NN|NONE
C400082_D009101 NONE bortezomib_15\NNS|NONE (r_pobj) of_14\IN|combination (r_prep) regimen_13\NNS|NONE (r_pobj) of_11\IN|the|and|efficacy (r_prep) safety_8\NN|.|,|In|retrospectively|we|as (r_dobj) analyzed_6\VBD|NONE (l_prep) as_24\IN|.|,|In|retrospectively|safety|we (l_pobj) therapy_26\NN|NONE (l_prep) in_27\IN|consolidation (l_pobj) patients_30\NNS|NONE (l_prep) with_31\IN|Japanese| (l_pobj) MM_34\NNP|NONE
D013792_D009101 NONE thalidomide_4\NN|of|as|. (r_conj) Combination_0\NN|NONE (l_prep) as_11\IN|of|thalidomide|. (l_pobj) therapy_14\NN|NONE (l_prep) after_15\IN|a|consolidation (l_pobj) transplantation_19\NN|NONE (l_prep) for_20\IN|cell|autologous (l_pobj) myeloma_23\NN|NONE
D013792_D009101 NONE thalidomide_17\NN|, (r_conj) bortezomib_15\NNS|NONE (r_pobj) of_14\IN|combination (r_prep) regimen_13\NNS|NONE (r_pobj) of_11\IN|the|and|efficacy (r_prep) safety_8\NN|.|,|In|retrospectively|we|as (r_dobj) analyzed_6\VBD|NONE (l_prep) as_24\IN|.|,|In|retrospectively|safety|we (l_pobj) therapy_26\NN|NONE (l_prep) in_27\IN|consolidation (l_pobj) patients_30\NNS|NONE (l_prep) with_31\IN|Japanese| (l_pobj) MM_34\NNP|NONE
D003907_D009101 NONE dexamethasone_7\NN|and|, (r_conj) thalidomide_4\NN|of|as|. (r_conj) Combination_0\NN|NONE (l_prep) as_11\IN|of|thalidomide|. (l_pobj) therapy_14\NN|NONE (l_prep) after_15\IN|a|consolidation (l_pobj) transplantation_19\NN|NONE (l_prep) for_20\IN|cell|autologous (l_pobj) myeloma_23\NN|NONE
D003907_D009101 NONE dexamethasone_20\NN|,|and (r_conj) thalidomide_17\NN|, (r_conj) bortezomib_15\NNS|NONE (r_pobj) of_14\IN|combination (r_prep) regimen_13\NNS|NONE (r_pobj) of_11\IN|the|and|efficacy (r_prep) safety_8\NN|.|,|In|retrospectively|we|as (r_dobj) analyzed_6\VBD|NONE (l_prep) as_24\IN|.|,|In|retrospectively|safety|we (l_pobj) therapy_26\NN|NONE (l_prep) in_27\IN|consolidation (l_pobj) patients_30\NNS|NONE (l_prep) with_31\IN|Japanese| (l_pobj) MM_34\NNP|NONE
2904523
D004837_D006973 CID adrenaline_2\NN| (r_compound) hypertension_4\NN|NONE
D004837_D006973 CID adrenaline_14\NN|hours (r_compound) infusion_15\NN|NONE (r_pobj) after_11\IN|hour|pressor (r_prep) effect_10\NN|.|:|for (r_appos) Support_0\NN|NONE (l_prep) for_1\IN|effect|.|: (l_pobj) hypothesis_5\NN|NONE (l_compound) hypertension_4\NN|NONE
D004837_D006973 CID adrenaline_7\NN| (r_compound) hypertension_9\NN|the|in
24114426
D018817_D020920 CID ecstasy_26\NN|NONE (r_compound) users_27\NNS|NONE (r_pobj) of_25\IN|current|the (r_prep) generation_24\NN|NONE (r_pobj) for_21\IN|the (r_prep) prognosis_20\NN|,|cause|Given|. (r_nsubj) is_28\VBZ|NONE (l_prep) Given_0\VBN|prognosis|,|cause|. (l_pobj) record_2\NN|NONE (l_prep) of_3\IN|this (l_pobj) memory_5\NN|NONE (l_conj) levels_9\NNS|impaired|and (l_prep) of_10\IN|significant (l_pobj) depression_11\NN|NONE (l_conj) impulsiveness_13\NN|, (l_conj) disturbance_17\NN|and|,
D018817_D003866 CID 3,4-methylenedioxymethamphetamine_15\NNP|ecstasy (r_pobj) of_14\IN|)|polydrug (r_prep) users_13\NNS|and|in|.|impulsiveness|, (r_conj) Depression_0\NN|NONE
D018817_D003866 CID MDMA_17\NNP|NONE (r_nmod) ecstasy_19\NN|,methylenedioxymethamphetamine (r_pobj) of_14\IN|)|polydrug (r_prep) users_13\NNS|and|in|.|impulsiveness|, (r_conj) Depression_0\NN|NONE
D018817_D003866 CID ecstasy_19\NN|,methylenedioxymethamphetamine (r_pobj) of_14\IN|)|polydrug (r_prep) users_13\NNS|and|in|.|impulsiveness|, (r_conj) Depression_0\NN|NONE
D018817_D003866 CID ecstasy_26\NN|NONE (r_compound) users_27\NNS|NONE (r_pobj) of_25\IN|current|the (r_prep) generation_24\NN|NONE (r_pobj) for_21\IN|the (r_prep) prognosis_20\NN|,|cause|Given|. (r_nsubj) is_28\VBZ|NONE (l_prep) Given_0\VBN|prognosis|,|cause|. (l_pobj) record_2\NN|NONE (l_prep) of_3\IN|this (l_pobj) memory_5\NN|NONE (l_conj) levels_9\NNS|impaired|and (l_prep) of_10\IN|significant (l_pobj) depression_11\NN|NONE
D018817_D010554 CID 3,4-methylenedioxymethamphetamine_15\NNP|ecstasy (r_pobj) of_14\IN|)|polydrug (r_prep) users_13\NNS|and|in|.|impulsiveness|, (r_conj) Depression_0\NN|NONE (l_conj) impulsiveness_2\NN|and|users|in|.|,
D018817_D010554 CID MDMA_17\NNP|NONE (r_nmod) ecstasy_19\NN|,methylenedioxymethamphetamine (r_pobj) of_14\IN|)|polydrug (r_prep) users_13\NNS|and|in|.|impulsiveness|, (r_conj) Depression_0\NN|NONE (l_conj) impulsiveness_2\NN|and|users|in|.|,
D018817_D010554 CID ecstasy_19\NN|,methylenedioxymethamphetamine (r_pobj) of_14\IN|)|polydrug (r_prep) users_13\NNS|and|in|.|impulsiveness|, (r_conj) Depression_0\NN|NONE (l_conj) impulsiveness_2\NN|and|users|in|.|,
D018817_D010554 CID ecstasy_26\NN|NONE (r_compound) users_27\NNS|NONE (r_pobj) of_25\IN|current|the (r_prep) generation_24\NN|NONE (r_pobj) for_21\IN|the (r_prep) prognosis_20\NN|,|cause|Given|. (r_nsubj) is_28\VBZ|NONE (l_prep) Given_0\VBN|prognosis|,|cause|. (l_pobj) record_2\NN|NONE (l_prep) of_3\IN|this (l_pobj) memory_5\NN|NONE (l_conj) levels_9\NNS|impaired|and (l_prep) of_10\IN|significant (l_pobj) depression_11\NN|NONE (l_conj) impulsiveness_13\NN|,
D018817_D008569 NONE ecstasy_26\NN|NONE (r_compound) users_27\NNS|NONE (r_pobj) of_25\IN|current|the (r_prep) generation_24\NN|NONE (r_pobj) for_21\IN|the (r_prep) prognosis_20\NN|,|cause|Given|. (r_nsubj) is_28\VBZ|NONE (l_prep) Given_0\VBN|prognosis|,|cause|. (l_pobj) record_2\NN|NONE (l_prep) of_3\IN|this (l_pobj) memory_5\NN|NONE
978847
D006145_D006973 NONE guanethidine_13\NN|NONE (r_pobj) of_12\IN|the|(|i.v.|(|)|,|mg|)|hexamethonium|intravenous (r_prep) injection_11\NN|NONE (r_pobj) by_5\IN|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN|NONE (l_conj) potentiated_34\VBN|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_prep) of_54\IN|tachycardia|and|the (l_pobj) pressure_56\NN|NONE
D018738_D006973 NONE hexamethonium_19\NN|the|(|i.v.|(|)|of|,|mg|)|intravenous (r_conj) injection_11\NN|NONE (r_pobj) by_5\IN|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN|NONE (l_conj) potentiated_34\VBN|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_prep) of_54\IN|tachycardia|and|the (l_pobj) pressure_56\NN|NONE
D002217_D006973 CID carbachol_62\NN|NONE (r_dobj) following_60\VBG|the (r_acl) tachycardia_59\NNS|of|and|the (r_conj) enlargement_53\NN|selectively (l_prep) of_54\IN|tachycardia|and|the (l_pobj) pressure_56\NN|NONE
D011433_D013610 NONE propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_conj) tachycardia_59\NNS|of|and|the
D003891_D006973 CID desmethylimipramine_37\NN|NONE (r_pobj) by_35\IN|,|,|propranolol|conversely (r_agent) potentiated_34\VBN|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_prep) of_54\IN|tachycardia|and|the (l_pobj) pressure_56\NN|NONE
D010646_D006973 NONE phentolamine_25\NN|)|or|(|mg (r_conj) hexamethonium_19\NN|the|(|i.v.|(|)|of|,|mg|)|intravenous (r_conj) injection_11\NN|NONE (r_pobj) by_5\IN|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN|NONE (l_conj) potentiated_34\VBN|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_prep) of_54\IN|tachycardia|and|the (l_pobj) pressure_56\NN|NONE
D011433_D006973 NONE propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_prep) of_54\IN|tachycardia|and|the (l_pobj) pressure_56\NN|NONE
D018738_D013610 NONE hexamethonium_19\NN|the|(|i.v.|(|)|of|,|mg|)|intravenous (r_conj) injection_11\NN|NONE (r_pobj) by_5\IN|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN|NONE (l_conj) potentiated_34\VBN|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_conj) tachycardia_59\NNS|of|and|the
D003891_D013610 NONE desmethylimipramine_37\NN|NONE (r_pobj) by_35\IN|,|,|propranolol|conversely (r_agent) potentiated_34\VBN|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_conj) tachycardia_59\NNS|of|and|the
D006145_D013610 NONE guanethidine_13\NN|NONE (r_pobj) of_12\IN|the|(|i.v.|(|)|,|mg|)|hexamethonium|intravenous (r_prep) injection_11\NN|NONE (r_pobj) by_5\IN|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN|NONE (l_conj) potentiated_34\VBN|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_conj) tachycardia_59\NNS|of|and|the
D010646_D013610 NONE phentolamine_25\NN|)|or|(|mg (r_conj) hexamethonium_19\NN|the|(|i.v.|(|)|of|,|mg|)|intravenous (r_conj) injection_11\NN|NONE (r_pobj) by_5\IN|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN|NONE (l_conj) potentiated_34\VBN|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN|,|,|by|conversely (l_conj) inhibited_51\VBD|mg|i.v.|while (l_dobj) enlargement_53\NN|selectively (l_conj) tachycardia_59\NNS|of|and|the
D002217_D013610 CID carbachol_62\NN|NONE (r_dobj) following_60\VBG|the (r_acl) tachycardia_59\NNS|of|and|the
8392553
D004837_D007511 NONE epinephrine_3\NN|chronic|week (r_compound) infusion_4\NN|NONE (r_pobj) With_0\IN|rats|observed|,|within|,|and (r_prep) died_10\VBD|NONE (l_conj) observed_26\VBN|rats|With|,|within|,|and (l_nsubjpass) lesions_18\NNS|.|were
D004837_D007511 NONE epinephrine_4\RB| (r_npadvmod) induced_6\VBN|)|(|P (r_amod) death_7\NN|and|,|attenuated|Treatment|. (r_dobj) prevented_3\VBD|NONE (l_conj) attenuated_15\VBD|and|,|death|Treatment|. (l_dobj) lesions_19\NNS|,|in
C056595_D006331 NONE clentiazem_3\NN|NONE (l_prep) against_4\IN|NONE (l_pobj) injury_9\NN|NONE
C056595_D006331 NONE clentiazem_3\NN|In|.|injury|,|,|through (r_npadvmod) attenuated_4\VBD|NONE (l_dobj) injury_9\NN|In|.|clentiazem|,|,|through
D004837_D009202 CID epinephrine_13\NN| (r_npadvmod) induced_15\VBN|in (r_amod) cardiomyopathy_16\NN|NONE
C106746_D009202 NONE 1,5-benzothiazepine_8\CD|a|calcium (r_amod) antagonist_10\NN|on|of|,|,|the (r_appos) effects_3\NNS|We|. (l_prep) on_12\IN|of|,|antagonist|,|the (l_pobj) cardiomyopathy_16\NN|NONE
C056595_D007511 NONE clentiazem_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|and|,|attenuated|death|. (r_nsubj) prevented_3\VBD|NONE (l_conj) attenuated_15\VBD|and|,|death|Treatment|. (l_dobj) lesions_19\NNS|,|in
C056595_D005355 NONE clentiazem_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|and|,|attenuated|death|. (r_nsubj) prevented_3\VBD|NONE (l_conj) attenuated_15\VBD|and|,|death|Treatment|. (l_dobj) lesions_19\NNS|,|in (l_conj) fibrosis_21\NN|the|ischemic|and|ventricular
C056595_D009202 NONE clentiazem_5\NN|NONE (r_pobj) of_4\IN|on|,|antagonist|,|the (r_prep) effects_3\NNS|We|. (l_prep) on_12\IN|of|,|antagonist|,|the (l_pobj) cardiomyopathy_16\NN|NONE
D004837_D005355 NONE epinephrine_3\NN|chronic|week (r_compound) infusion_4\NN|NONE (r_pobj) With_0\IN|rats|observed|,|within|,|and (r_prep) died_10\VBD|NONE (l_conj) observed_26\VBN|rats|With|,|within|,|and (l_nsubjpass) lesions_18\NNS|.|were (l_conj) fibrosis_20\NN|severe|and|of|ischemic
D004837_D005355 NONE epinephrine_4\RB| (r_npadvmod) induced_6\VBN|)|(|P (r_amod) death_7\NN|and|,|attenuated|Treatment|. (r_dobj) prevented_3\VBD|NONE (l_conj) attenuated_15\VBD|and|,|death|Treatment|. (l_dobj) lesions_19\NNS|,|in (l_conj) fibrosis_21\NN|the|ischemic|and|ventricular
D004837_D006331 NONE epinephrine_5\NN| (r_npadvmod) induced_7\VBN|cardiac|in (r_amod) injury_9\NN|NONE
D004837_D006331 NONE epinephrine_5\NN| (r_npadvmod) induced_7\VBN|cardiac (r_amod) injury_9\NN|In|.|clentiazem|,|,|through
D002118_D009202 NONE calcium_9\NN|a|,benzothiazepine (r_compound) antagonist_10\NN|on|of|,|,|the (r_appos) effects_3\NNS|We|. (l_prep) on_12\IN|of|,|antagonist|,|the (l_pobj) cardiomyopathy_16\NN|NONE
7369302
D011803_D015845 CID sulfate_30\NN|NONE (r_pobj) of_28\IN|the (r_prep) use_27\NN|NONE (r_pobj) after_25\IN|in (r_prep) developed_18\VBN|abnormal|evoked (r_acl) potentials_17\NNS|denervation|and|, (r_conj) supersensitivity_10\NN|a|transient|,|pupillary|tonic (r_conj) response_7\NN|NONE (l_amod) pupillary_6\JJ|a|supersensitivity|transient|,|tonic
D011803_D015845 CID quinine_16\NN|NONE (r_compound) toxicity_17\NN|NONE (r_pobj) in_15\IN|evoked|abnormal (r_prep) potentials_14\NNS|,|denervation|and (r_conj) supersensitivity_7\NN|,|A|pupillary|tonic|transient|,|to (r_conj) response_4\NN|not|have|been|,|.|previously (l_amod) pupillary_3\JJ|,|A|tonic|transient|supersensitivity|,|to
D011803_D001766 CID sulfate_30\NN|NONE (r_pobj) of_28\IN|the (r_prep) use_27\NN|NONE (r_pobj) after_25\IN|in (r_prep) developed_18\VBN|abnormal|evoked (r_acl) potentials_17\NNS|denervation|and|, (r_conj) supersensitivity_10\NN|a|transient|,|pupillary|tonic (r_conj) response_7\NN|NONE (r_pobj) with_2\IN|.|Total (r_prep) blindness_1\NN|NONE
D011803_D000550 CID quinine_10\NN|NONE (r_compound) amblyopia_11\NN|NONE
D011803_D064420 NONE quinine_16\NN|NONE (r_compound) toxicity_17\NN|NONE
D011803_D009120 NONE sulfate_30\NN|NONE (l_prep) for_31\IN|quinine (l_pobj) cramps_33\NNS|NONE
3812624
D002220_D015835 CID carbamazepine_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) associated_7\VBN|Two|.|of (r_acl) cases_1\NNS|NONE (l_prep) of_2\IN|Two|.|associated (l_pobj) nystagmus_4\NN|NONE (l_conj) oscillopsia_6\NN|downbeat|and
D002220_D009759 NONE carbamazepine_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) associated_7\VBN|Two|.|of (r_acl) cases_1\NNS|NONE (l_prep) of_2\IN|Two|.|associated (l_pobj) nystagmus_4\NN|NONE
D002220_D009759 NONE carbamazepine_14\NN|NONE (r_compound) therapy_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|reversible|downbeat (r_amod) nystagmus_11\NN|NONE
D002220_D009759 NONE carbamazepine_11\NN|the (r_compound) levels_12\NNS|NONE (r_pobj) of_8\IN|NONE (r_prep) reduction_7\NN|NONE (r_pobj) after_6\IN|nystagmus|. (r_prep) resolved_5\VBN|NONE (l_nsubj) nystagmus_1\NN|after|.
3798047
D008775_D006331 NONE MP_3\NNP|.|be|may|in (r_nsubjpass) contraindicated_6\VBN|NONE (l_prep) in_7\IN|.|be|may|MP (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) disease_12\NN|NONE
D008775_D001172 NONE methylprednisolone_13\NN|daily|who|for|) (r_dobj) received_8\VBD|consecutive||with (r_relcl) patients_3\NNS|NONE (l_prep) with_4\IN|received|consecutive| (l_pobj) arthritis_6\NN|NONE
D008775_D001172 NONE MP_15\NNP|(|)|( (r_nmod) therapy_17\NN|intravenous|dose (r_appos) methylprednisolone_13\NN|daily|who|for|) (r_dobj) received_8\VBD|consecutive||with (r_relcl) patients_3\NNS|NONE (l_prep) with_4\IN|received|consecutive| (l_pobj) arthritis_6\NN|NONE
D008775_D001919 CID methylprednisolone_6\NN|dose|intravenous (r_compound) therapy_7\NN|NONE (r_pobj) after_1\IN|. (r_prep) Bradycardia_0\NNS|NONE
17721298
D016578_D003320 CID cocaine_6\NN|crack (r_compound) use_7\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|.|Corneal (r_acl) ulcers_1\NNS|NONE
D016578_D003320 CID cocaine_8\NN|crack (r_compound) use_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|corneal (r_acl) ulcers_4\NNS|NONE
D016578_D003320 CID cocaine_2\NN|crack (r_compound) use_3\NN|with|can|.|be (r_nsubjpass) associated_6\VBN|NONE (l_prep) with_7\IN|use|can|.|be (l_pobj) development_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) ulcers_12\NNS|NONE
1655018
D000728_D006528 CID androgen_8\JJ|NONE (r_pobj) with_7\IN|.|carcinoma (r_prep) treated_6\VBN|NONE (l_nsubj) carcinoma_1\NN|.|with
D000305_D006528 CID corticosteroid_10\NN|and (r_conj) androgen_8\JJ|NONE (r_pobj) with_7\IN|.|carcinoma (r_prep) treated_6\VBN|NONE (l_nsubj) carcinoma_1\NN|.|with
D000305_D010382 CID corticosteroid_22\NN| (r_npadvmod) treated_24\VBN|and (r_conj) androgen-_20\NN|Fanconi (r_amod) anemia_27\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) patients_18\NNS|NONE (r_pobj) in_17\IN|can|neoplasms|that (r_prep) develop_16\VB|the|previous (l_nsubj) neoplasms_12\NNS|can|in|that (l_conj) peliosis_14\NN|metastasizing|and|hepatic
D000728_D010382 CID androgen-_20\NN|Fanconi (r_amod) anemia_27\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) patients_18\NNS|NONE (r_pobj) in_17\IN|can|neoplasms|that (r_prep) develop_16\VB|the|previous (l_nsubj) neoplasms_12\NNS|can|in|that (l_conj) peliosis_14\NN|metastasizing|and|hepatic
D000305_D005199 NONE corticosteroid_10\NN|and (r_conj) androgen_8\JJ|NONE (r_pobj) with_7\IN|.|carcinoma (r_prep) treated_6\VBN|NONE (l_nsubj) carcinoma_1\NN|.|with (l_prep) in_2\IN|Hepatocellular (l_pobj) anemia_5\NN|NONE
D000305_D005199 NONE corticosteroids_27\NNS|, (r_conj) androgens_25\NNS|NONE (r_pobj) with_24\IN|was (r_prep) treated_23\VBN|who|and|was|have (r_conj) known_12\VBN|is|.|case (l_xcomp) have_14\VB|who|and|was|treated (l_dobj) anemia_17\NN|to
D000305_D005199 NONE corticosteroid_22\NN| (r_npadvmod) treated_24\VBN|and (r_conj) androgen-_20\NN|Fanconi (r_amod) anemia_27\NN|NONE
D000728_D008113 NONE androgen-_20\NN|Fanconi (r_amod) anemia_27\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) patients_18\NNS|NONE (r_pobj) in_17\IN|can|neoplasms|that (r_prep) develop_16\VB|the|previous (l_nsubj) neoplasms_12\NNS|can|in|that
D000305_D008113 NONE corticosteroid_22\NN| (r_npadvmod) treated_24\VBN|and (r_conj) androgen-_20\NN|Fanconi (r_amod) anemia_27\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) patients_18\NNS|NONE (r_pobj) in_17\IN|can|neoplasms|that (r_prep) develop_16\VB|the|previous (l_nsubj) neoplasms_12\NNS|can|in|that
D000728_D005199 NONE androgen_8\JJ|NONE (r_pobj) with_7\IN|.|carcinoma (r_prep) treated_6\VBN|NONE (l_nsubj) carcinoma_1\NN|.|with (l_prep) in_2\IN|Hepatocellular (l_pobj) anemia_5\NN|NONE
D000728_D005199 NONE androgens_25\NNS|NONE (r_pobj) with_24\IN|was (r_prep) treated_23\VBN|who|and|was|have (r_conj) known_12\VBN|is|.|case (l_xcomp) have_14\VB|who|and|was|treated (l_dobj) anemia_17\NN|to
D000728_D005199 NONE androgen-_20\NN|Fanconi (r_amod) anemia_27\NN|NONE
10975596
D007545_D013610 CID isoproterenol_20\NN| (r_npadvmod) induced_22\VBN|the (r_amod) tachycardia_23\NN|.|at|, (r_dobj) decreased_18\VBD|dronedarone|,|tachycardia|and|significantly (r_conj) reduced_5\VBD|NONE (l_dobj) tachycardia_10\NN|decreased|dronedarone|,|and|significantly
D007545_D013610 CID isoproterenol_20\NN| (r_npadvmod) induced_22\VBN|the (r_amod) tachycardia_23\NN|.|at|,
D000638_D009203 NONE amiodarone_7\NN|and (l_prep) with_10\IN|in (l_pobj) infarction_14\NN|NONE
D000638_D009203 NONE amiodarone_14\NN|NONE (r_pobj) to_13\IN|compound|structurally (r_prep) related_12\VBN|,|hemodynamic|,|The|of (r_amod) effects_4\NNS|were|with|. (r_nsubjpass) compared_17\VBN|NONE (l_prep) with_18\IN|effects|were|. (l_pobj) those_19\DT|NONE (l_prep) at_28\IN|of|,|after (l_conj) during_31\IN|and|both|rest (l_pobj) stimulation_33\NN|NONE (l_prep) in_34\IN|sympathetic (l_pobj) dogs_36\NNS|NONE (l_prep) with_37\IN|conscious (l_pobj) infarction_41\NN|NONE
D000638_D009203 NONE amiodarone_21\NN|NONE (r_pobj) of_20\IN|,|after|at (r_prep) those_19\DT|NONE (l_prep) at_28\IN|of|,|after (l_conj) during_31\IN|and|both|rest (l_pobj) stimulation_33\NN|NONE (l_prep) in_34\IN|sympathetic (l_pobj) dogs_36\NNS|NONE (l_prep) with_37\IN|conscious (l_pobj) infarction_41\NN|NONE
D000638_D013610 NONE amiodarone_3\NN|Both|and (r_conj) dronedarone_1\NN|decreased|,|tachycardia|and|significantly (r_nsubj) reduced_5\VBD|NONE (l_dobj) tachycardia_10\NN|decreased|dronedarone|,|and|significantly
D000638_D013610 NONE amiodarone_3\NN|Both|and (r_conj) dronedarone_1\NN|decreased|,|tachycardia|and|significantly (r_nsubj) reduced_5\VBD|NONE (l_conj) decreased_18\VBD|dronedarone|,|tachycardia|and|significantly (l_dobj) tachycardia_23\NN|.|at|,
C118667_D001145 NONE dronedarone_2\NN|,|.|might|without|Consequently|suitable|, (r_nsubj) be_4\VB|NONE (l_acomp) suitable_6\JJ|,|.|might|without|Consequently|dronedarone|, (l_prep) for_7\IN|particularly (l_pobj) treatment_9\NN|NONE (l_prep) of_12\IN|prevention|the|and (l_pobj) arrhythmias_15\NNS|NONE
C118667_D009203 NONE dronedarone_5\NN|NONE (l_conj) amiodarone_7\NN|and (l_prep) with_10\IN|in (l_pobj) infarction_14\NN|NONE
C118667_D009203 NONE dronedarone_6\NN|NONE (r_pobj) of_5\IN|,|hemodynamic|,|The|related (r_prep) effects_4\NNS|were|with|. (r_nsubjpass) compared_17\VBN|NONE (l_prep) with_18\IN|effects|were|. (l_pobj) those_19\DT|NONE (l_prep) at_28\IN|of|,|after (l_conj) during_31\IN|and|both|rest (l_pobj) stimulation_33\NN|NONE (l_prep) in_34\IN|sympathetic (l_pobj) dogs_36\NNS|NONE (l_prep) with_37\IN|conscious (l_pobj) infarction_41\NN|NONE
C118667_D013610 NONE dronedarone_1\NN|decreased|,|tachycardia|and|significantly (r_nsubj) reduced_5\VBD|NONE (l_dobj) tachycardia_10\NN|decreased|dronedarone|,|and|significantly
C118667_D013610 NONE dronedarone_1\NN|decreased|,|tachycardia|and|significantly (r_nsubj) reduced_5\VBD|NONE (l_conj) decreased_18\VBD|dronedarone|,|tachycardia|and|significantly (l_dobj) tachycardia_23\NN|.|at|,
24618873
C002752_D012640 CID norpethidine_35\NN|,|,|its|neurotoxic (r_appos) metabolite_33\NN|NONE (r_pobj) through_30\IN|system|(|CNS|)|resulting (r_prep) effects_29\NNS|,|may|.|In|pethidine (l_acl) resulting_37\VBG|system|(|CNS|)|through (l_prep) in_38\IN|NONE (l_pobj) irritability_39\NN|NONE (l_conj) attack_42\NN|and (l_compound) seizure_41\NN|NONE
D008614_D012640 NONE pethidine_19\NN|,|effects|may|.|In (r_nsubj) cause_21\VB|NONE (l_dobj) effects_29\NNS|,|may|.|In|pethidine (l_acl) resulting_37\VBG|system|(|CNS|)|through (l_prep) in_38\IN|NONE (l_pobj) irritability_39\NN|NONE (l_conj) attack_42\NN|and (l_compound) seizure_41\NN|NONE
D008614_D010146 NONE Pethidine_0\NNP|opioid|. (r_nsubj) is_1\VBZ|NONE (l_attr) opioid_3\NN|Pethidine|. (l_relcl) gains_5\VBZ|an (l_prep) for_8\IN|popularity|that|through (l_pobj) control_12\NN|NONE (l_compound) pain_11\NN|the|effective
D008614_D010146 NONE pethidine_19\NN|,|effects|may|.|In (r_nsubj) cause_21\VB|NONE (l_prep) In_0\IN|,|effects|may|.|pethidine (l_conj) those_10\DT|,|and|patients (l_relcl) need_12\VBP|NONE (l_dobj) control_17\NN|who (l_compound) pain_16\NN|term
C002752_D001523 NONE norpethidine_35\NN|,|,|its|neurotoxic (r_appos) metabolite_33\NN|NONE (r_pobj) through_30\IN|system|(|CNS|)|resulting (r_prep) effects_29\NNS|,|may|.|In|pethidine (l_acl) resulting_37\VBG|system|(|CNS|)|through (l_prep) in_38\IN|NONE (l_pobj) irritability_39\NN|NONE
D008614_D002526 NONE pethidine_9\NN|NONE (r_pobj) of_8\IN|rapid (r_prep) infusion_7\NN|NONE (r_pobj) by_5\IN|dysfunction|. (r_agent) induced_4\VBN|NONE (l_nsubj) dysfunction_3\NN|by|.
D008614_D020258 NONE pethidine_19\NN|,|effects|may|.|In (r_nsubj) cause_21\VB|NONE (l_dobj) effects_29\NNS|,|may|.|In|pethidine (l_prep) through_30\IN|system|(|CNS|)|resulting (l_pobj) metabolite_33\NN|NONE (l_amod) neurotoxic_32\JJ|norpethidine|,|,|its
C002752_D017093 NONE norpethidine_35\NN|,|,|its|neurotoxic (r_appos) metabolite_33\NN|NONE (r_pobj) through_30\IN|system|(|CNS|)|resulting (r_prep) effects_29\NNS|,|may|.|In|pethidine (r_dobj) cause_21\VB|NONE (l_prep) In_0\IN|,|effects|may|.|pethidine (l_pobj) patients_1\NNS|,|and|those (l_prep) with_2\IN|NONE (l_pobj) function_7\NN|NONE
D008614_D005128 NONE pethidine_9\NN|NONE (r_pobj) of_8\IN|rapid (r_prep) infusion_7\NN|NONE (r_pobj) by_5\IN|dysfunction|. (r_agent) induced_4\VBN|NONE (l_nsubj) dysfunction_3\NN|by|.
D008614_D051437 NONE pethidine_19\NN|,|effects|may|.|In (r_nsubj) cause_21\VB|NONE (l_prep) In_0\IN|,|effects|may|.|pethidine (l_pobj) patients_1\NNS|,|and|those (l_prep) with_2\IN|NONE (l_pobj) function_7\NN|NONE
D008614_D017093 NONE pethidine_19\NN|,|effects|may|.|In (r_nsubj) cause_21\VB|NONE (l_prep) In_0\IN|,|effects|may|.|pethidine (l_pobj) patients_1\NNS|,|and|those (l_prep) with_2\IN|NONE (l_pobj) function_7\NN|NONE
C002752_D020258 NONE norpethidine_35\NN|,|,|its|neurotoxic (r_appos) metabolite_33\NN|NONE (l_amod) neurotoxic_32\JJ|norpethidine|,|,|its
C002752_D051437 NONE norpethidine_35\NN|,|,|its|neurotoxic (r_appos) metabolite_33\NN|NONE (r_pobj) through_30\IN|system|(|CNS|)|resulting (r_prep) effects_29\NNS|,|may|.|In|pethidine (r_dobj) cause_21\VB|NONE (l_prep) In_0\IN|,|effects|may|.|pethidine (l_pobj) patients_1\NNS|,|and|those (l_prep) with_2\IN|NONE (l_pobj) function_7\NN|NONE
C002752_D010146 NONE norpethidine_35\NN|,|,|its|neurotoxic (r_appos) metabolite_33\NN|NONE (r_pobj) through_30\IN|system|(|CNS|)|resulting (r_prep) effects_29\NNS|,|may|.|In|pethidine (r_dobj) cause_21\VB|NONE (l_prep) In_0\IN|,|effects|may|.|pethidine (l_conj) those_10\DT|,|and|patients (l_relcl) need_12\VBP|NONE (l_dobj) control_17\NN|who (l_compound) pain_16\NN|term
D008614_D001523 NONE pethidine_19\NN|,|effects|may|.|In (r_nsubj) cause_21\VB|NONE (l_dobj) effects_29\NNS|,|may|.|In|pethidine (l_acl) resulting_37\VBG|system|(|CNS|)|through (l_prep) in_38\IN|NONE (l_pobj) irritability_39\NN|NONE
7411769
D007213_D015210 NONE Indomethacin_0\NNP| (r_npadvmod) induced_2\VBN|in|. (r_amod) hyperkalemia_3\NN|NONE (l_prep) in_4\IN|induced|. (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|three (l_pobj) arthritis_9\NN|NONE
D007213_D015210 NONE indomethacin_23\NN|NONE (r_pobj) with_22\IN|of (r_prep) treatment_17\NN|NONE (l_prep) of_18\IN|with (l_pobj) arthritis_21\NN|NONE
D007213_D051437 CID indomethacin_23\NN|NONE (r_pobj) with_22\IN|of (r_prep) treatment_17\NN|NONE (r_pobj) after_16\IN|NONE (r_prep) developed_15\VBD|three|hyperkalemia (r_acl) patients_3\NNS|We|. (l_appos) hyperkalemia_11\NN|developed|three (l_conj) insufficiency_14\NN|and|threatening|,|severe|in
D007213_D006947 CID Indomethacin_0\NNP| (r_npadvmod) induced_2\VBN|in|. (r_amod) hyperkalemia_3\NN|NONE
D007213_D006947 CID indomethacin_23\NN|NONE (r_pobj) with_22\IN|of (r_prep) treatment_17\NN|NONE (r_pobj) after_16\IN|NONE (r_prep) developed_15\VBD|three|hyperkalemia (r_acl) patients_3\NNS|We|. (l_appos) hyperkalemia_11\NN|developed|three
D011188_D007674 NONE potassium_6\NN|NONE (r_compound) balance_7\NN|renal|in|and (r_conj) function_4\NN|NONE (r_pobj) to_2\IN|Careful (r_prep) attention_1\NN|,|,|prevent|will|in|. (r_nsubj) help_33\VB|NONE (l_prep) in_21\IN|,|,|prevent|attention|will|. (l_pobj) patients_23\NNS|particularly (l_prep) with_24\IN|those (l_pobj) mellitus_26\NN|NONE (l_conj) disease_30\NN|diabetes|or
D007213_D007674 NONE indomethacin_11\NN|NONE (r_dobj) receiving_10\VBG|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|renal|balance|and (r_prep) function_4\NN|NONE (r_pobj) to_2\IN|Careful (r_prep) attention_1\NN|,|,|prevent|will|in|. (r_nsubj) help_33\VB|NONE (l_prep) in_21\IN|,|,|prevent|attention|will|. (l_pobj) patients_23\NNS|particularly (l_prep) with_24\IN|those (l_pobj) mellitus_26\NN|NONE (l_conj) disease_30\NN|diabetes|or
D011453_D006994 NONE prostaglandin_8\JJ|hypoaidosteronism|and (r_amod) synthesis_9\NN|NONE (l_conj) hypoaidosteronism_13\NN|prostaglandin|and
D011188_D003920 NONE potassium_6\NN|NONE (r_compound) balance_7\NN|renal|in|and (r_conj) function_4\NN|NONE (r_pobj) to_2\IN|Careful (r_prep) attention_1\NN|,|,|prevent|will|in|. (r_nsubj) help_33\VB|NONE (l_prep) in_21\IN|,|,|prevent|attention|will|. (l_pobj) patients_23\NNS|particularly (l_prep) with_24\IN|those (l_pobj) mellitus_26\NN|NONE
D007213_D003920 NONE indomethacin_11\NN|NONE (r_dobj) receiving_10\VBG|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|renal|balance|and (r_prep) function_4\NN|NONE (r_pobj) to_2\IN|Careful (r_prep) attention_1\NN|,|,|prevent|will|in|. (r_nsubj) help_33\VB|NONE (l_prep) in_21\IN|,|,|prevent|attention|will|. (l_pobj) patients_23\NNS|particularly (l_prep) with_24\IN|those (l_pobj) mellitus_26\NN|NONE
9061777
D016202_D001930 NONE NMDA_31\NNP|mediated|excitatory|an (r_compound) mechanism_35\NN|NONE (r_pobj) through_28\IN|brain (r_prep) damage_27\NN|elevation|,|may|indicate|.
D012601_D012640 NONE Scopolamine_0\NNP|but|development|mg/kg|) (r_nsubj) prevented_11\VBN|.|not| (l_dobj) development_12\NN|but|Scopolamine|mg/kg|) (l_prep) of_13\IN|NONE (l_pobj) seizure_18\NN|NONE
D012601_D012640 NONE Scopolamine_0\NNP|.|augmented|,|seizure (r_nsubj) blocked_3\VBD|NONE (l_dobj) seizure_9\NN|.|augmented|,|Scopolamine
D012601_D012640 NONE Scopolamine_0\NNP|.|augmented|,|seizure (r_nsubj) blocked_3\VBD|NONE (l_conj) augmented_13\VBD|.|,|Scopolamine|seizure (l_dobj) seizure_16\NN|treatment
D016202_D013226 NONE NMDA_31\NNP|mediated|excitatory|an (r_compound) mechanism_35\NN|NONE (r_pobj) through_28\IN|brain (r_prep) damage_27\NN|elevation|,|may|indicate|. (r_dobj) cause_25\VB|NONE (l_ccomp) indicate_2\VBP|damage|elevation|,|may|. (l_ccomp) initiated_10\VBN|results (l_nsubjpass) status_4\NN|is|that|by|and|propagated (l_acl) induced_6\VBN|NONE (l_advmod) epilepticus_5\NN|by
D010862_D001930 NONE pilocarpine_2\NN| (r_npadvmod) induced_4\VBN|electrographic (r_amod) seizure_6\NN|.|MK|protects|but (r_dobj) augments_1\VBZ|NONE (l_conj) protects_8\VBZ|.|MK|seizure|but (l_prep) against_9\IN|NONE (l_pobj) damage_11\NN|NONE
D010862_D001930 NONE pilocarpine_10\NN|NONE (r_pobj) by_9\IN|the|brain (r_prep) damage_8\NN|MK
D010862_D001930 NONE pilocarpine_8\NN|NONE (r_pobj) by_7\IN|epilepticus (r_agent) induced_6\VBN|NONE (r_acl) status_4\NN|is|that|by|and|propagated (r_nsubjpass) initiated_10\VBN|results (r_ccomp) indicate_2\VBP|damage|elevation|,|may|. (r_ccomp) cause_25\VB|NONE (l_dobj) damage_27\NN|elevation|,|may|indicate|.
D010424_D001930 NONE Pentobarbital_0\JJ|in|darker|.|,|though|cells|, (l_appos) scopolamine_2\NN|, (l_conj) protected_5\VBD|and (l_dobj) damage_8\NN|MK
D010862_D013226 CID pilocarpine_8\NN|NONE (r_pobj) by_7\IN|epilepticus (r_agent) induced_6\VBN|NONE (l_advmod) epilepticus_5\NN|by
D010424_D012640 NONE pentobarbital_6\NN|and|mg/kg (r_conj) Scopolamine_0\NNP|but|development|mg/kg|) (r_nsubj) prevented_11\VBN|.|not| (l_dobj) development_12\NN|but|Scopolamine|mg/kg|) (l_prep) of_13\IN|NONE (l_pobj) seizure_18\NN|NONE
D010424_D012640 NONE pentobarbital_2\NN|and (r_conj) Scopolamine_0\NNP|.|augmented|,|seizure (r_nsubj) blocked_3\VBD|NONE (l_dobj) seizure_9\NN|.|augmented|,|Scopolamine
D010424_D012640 NONE pentobarbital_2\NN|and (r_conj) Scopolamine_0\NNP|.|augmented|,|seizure (r_nsubj) blocked_3\VBD|NONE (l_conj) augmented_13\VBD|.|,|Scopolamine|seizure (l_dobj) seizure_16\NN|treatment
D010862_D009410 CID Pilocarpine_0\NNP|death|. (r_nsubj) produced_1\VBD|NONE (l_dobj) death_3\NN|.|Pilocarpine
D012601_D001930 NONE scopolamine_2\NN|, (l_conj) protected_5\VBD|and (l_dobj) damage_8\NN|MK
D010862_D012640 CID pilocarpine_2\NN| (r_npadvmod) induced_4\VBN|electrographic (r_amod) seizure_6\NN|.|MK|protects|but
D010862_D012640 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|seizure|the (r_amod) model_14\NN|MK (l_compound) seizure_13\NN|induced|the
D010862_D012640 CID pilocarpine_3\NN|NONE (r_pobj) of_2\IN|mg/kg|Intraperitoneal (r_prep) injection_1\NN|seizure|. (r_nsubj) induced_8\VBN|NONE (l_dobj) seizure_12\NN|.|injection
D010862_D012640 CID pilocarpine_14\NN| (r_npadvmod) induced_16\VBN|behavioral (r_amod) seizure_18\NN|NONE
D010862_D012640 CID pilocarpine_10\NN| (r_npadvmod) treated_12\VBN|the (r_amod) group_13\NN|NONE (r_pobj) in_8\IN|.|seizure (r_prep) appeared_7\VBD|NONE (l_nsubj) seizure_2\NN|in|.
D010862_D012640 CID pilocarpine_5\NN| (r_npadvmod) induced_7\VBN|the|electrographic (r_amod) seizure_9\NN|.|augmented|,|Scopolamine
D010862_D012640 CID pilocarpine_5\NN| (r_npadvmod) induced_7\VBN|the|electrographic (r_amod) seizure_9\NN|.|augmented|,|Scopolamine (r_dobj) blocked_3\VBD|NONE (l_conj) augmented_13\VBD|.|,|Scopolamine|seizure (l_dobj) seizure_16\NN|treatment
D010862_D012640 CID pilocarpine_19\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|electrographic|the (r_acl) seizure_16\NN|treatment (r_dobj) augmented_13\VBD|.|,|Scopolamine|seizure (r_conj) blocked_3\VBD|NONE (l_dobj) seizure_9\NN|.|augmented|,|Scopolamine
D010862_D012640 CID pilocarpine_19\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|electrographic|the (r_acl) seizure_16\NN|treatment
D016291_D001930 NONE MK-801_0\NNP|.|protects|seizure|but (r_punct) augments_1\VBZ|NONE (l_conj) protects_8\VBZ|.|MK|seizure|but (l_prep) against_9\IN|NONE (l_pobj) damage_11\NN|NONE
D016291_D001930 NONE MK-801_4\NNP|damage (r_punct) protected_5\VBD|and (l_dobj) damage_8\NN|MK
D016291_D001930 NONE MK-801-treated_15\JJ|the (r_amod) group_16\NN|NONE (r_pobj) in_13\IN|Pentobarbital|darker|.|,|though|cells|, (r_prep) appeared_23\VBD|NONE (l_nsubj) Pentobarbital_0\JJ|in|darker|.|,|though|cells|, (l_appos) scopolamine_2\NN|, (l_conj) protected_5\VBD|and (l_dobj) damage_8\NN|MK
D016291_D012640 CID MK-801_0\NNP|.|protects|seizure|but (r_punct) augments_1\VBZ|NONE (l_dobj) seizure_6\NN|.|MK|protects|but
D016291_D012640 CID MK-801_7\NNP|model (r_punct) on_8\IN|the|anticonvulsant|of (l_pobj) model_14\NN|MK (l_compound) seizure_13\NN|induced|the
D016291_D012640 CID MK-801_20\NNP|( (r_punct) 0.5_22\CD|NONE (r_nummod) mg/kg_23\NN|but|Scopolamine|development|) (r_conj) prevented_11\VBN|.|not| (l_dobj) development_12\NN|but|Scopolamine|mg/kg|) (l_prep) of_13\IN|NONE (l_pobj) seizure_18\NN|NONE
D016291_D012640 CID MK-801_11\NNP|NONE (r_punct) treatment_12\NN|seizure (r_nsubj) augmented_13\VBD|.|,|Scopolamine|seizure (r_conj) blocked_3\VBD|NONE (l_dobj) seizure_9\NN|.|augmented|,|Scopolamine
D016291_D012640 CID MK-801_11\NNP|NONE (r_punct) treatment_12\NN|seizure (r_nsubj) augmented_13\VBD|.|,|Scopolamine|seizure (l_dobj) seizure_16\NN|treatment
24881749
D063325_D006816 NONE tiapride_10\NN|and|in (r_conj) tetrabenazine_8\NN|NONE (l_prep) in_11\IN|and|tiapride (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a|Japanese (l_pobj) disease_18\NN|NONE
D063325_D006816 NONE tiapride_27\NN|NONE (r_pobj) with_26\IN|and|day|(|for|the|)|of|tetrabenazine (r_prep) initiation_22\NN|days (l_prep) for_42\IN|and|day|(|the|)|of|tetrabenazine|with (l_pobj) disease_45\NN|NONE
D063325_D001943 NONE tiapride_10\NN|and|in (r_conj) tetrabenazine_8\NN|NONE (l_prep) in_11\IN|and|tiapride (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a|Japanese (l_pobj) disease_18\NN|NONE (l_prep) at_19\IN|Huntington (l_pobj) stage_22\NN|NONE (l_prep) of_23\IN|the|terminal (l_pobj) cancer_26\NN|NONE
D013747_D006816 NONE tetrabenazine_8\NN|NONE (l_prep) in_11\IN|and|tiapride (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a|Japanese (l_pobj) disease_18\NN|NONE
D013747_D006816 NONE tetrabenazine_35\NN|and|day|(|for|the|)|of|with (r_conj) initiation_22\NN|days (l_prep) for_42\IN|and|day|(|the|)|of|tetrabenazine|with (l_pobj) disease_45\NN|NONE
D013747_D009459 CID tetrabenazine_8\NN|NONE (r_pobj) with_7\IN|.|syndrome|by (r_prep) induced_3\VBN|NONE (l_nsubj) syndrome_2\NN|with|.|by
D013747_D009459 CID tetrabenazine_35\NN|and|day|(|for|the|)|of|with (r_conj) initiation_22\NN|days (r_pobj) after_20\IN|that (r_prep) occurred_17\VBD|Japanese|with|an|old (r_relcl) woman_11\NN|NONE (l_prep) with_12\IN|Japanese|occurred|an|old (l_pobj) syndrome_15\NN|NONE
D013747_D009459 CID tetrabenazine_18\NN|NONE (r_pobj) with_17\IN|combination (r_prep) therapy_16\NN|to (r_pobj) due_13\IN|of|the (r_prep) occurrence_8\NN|not|previously|been|has|,|To|. (l_prep) of_9\IN|due|the (l_pobj) syndrome_12\NN|NONE
D013747_D001943 NONE tetrabenazine_8\NN|NONE (l_prep) in_11\IN|and|tiapride (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a|Japanese (l_pobj) disease_18\NN|NONE (l_prep) at_19\IN|Huntington (l_pobj) stage_22\NN|NONE (l_prep) of_23\IN|the|terminal (l_pobj) cancer_26\NN|NONE
D063325_D009459 CID tiapride_10\NN|and|in (r_conj) tetrabenazine_8\NN|NONE (r_pobj) with_7\IN|.|syndrome|by (r_prep) induced_3\VBN|NONE (l_nsubj) syndrome_2\NN|with|.|by
D063325_D009459 CID tiapride_27\NN|NONE (r_pobj) with_26\IN|and|day|(|for|the|)|of|tetrabenazine (r_prep) initiation_22\NN|days (r_pobj) after_20\IN|that (r_prep) occurred_17\VBD|Japanese|with|an|old (r_relcl) woman_11\NN|NONE (l_prep) with_12\IN|Japanese|occurred|an|old (l_pobj) syndrome_15\NN|NONE
D063325_D009459 CID tiapride_20\NN|and (r_conj) tetrabenazine_18\NN|NONE (r_pobj) with_17\IN|combination (r_prep) therapy_16\NN|to (r_pobj) due_13\IN|of|the (r_prep) occurrence_8\NN|not|previously|been|has|,|To|. (l_prep) of_9\IN|due|the (l_pobj) syndrome_12\NN|NONE
3155884
D013311_D003920 CID streptozotocin_13\JJ|diabetic (r_nmod) rats_15\NNS|NONE (l_amod) diabetic_14\JJ|streptozotocin
D013311_D003920 CID streptozotocin_13\JJ|against (r_compound) diabetes_14\NNS|NONE
D013311_D003920 CID streptozotocin_10\JJ|that|resistance (r_nsubj) causes_13\VBZ|the (l_dobj) resistance_16\NN|that|streptozotocin (l_conj) points_18\NNS|ISO|the|and (l_prep) towards_19\IN|NONE (l_pobj) effect_23\NN|NONE (l_prep) on_24\IN|insulin|a|direct (l_pobj) sensitivity_27\NN|NONE (l_prep) in_28\IN|myocardial|catecholamine (l_pobj) rats_30\NNS|NONE (l_amod) diabetic_29\JJ|NONE
D013311_D066126 NONE streptozotocin_13\JJ|diabetic (r_nmod) rats_15\NNS|NONE (r_pobj) in_12\IN|the|of|cardiotoxic (r_prep) effect_9\NN|NONE (l_amod) cardiotoxic_8\JJ|the|in|of
D013311_D066126 NONE streptozotocin_13\JJ|against (r_compound) diabetes_14\NNS|NONE (l_prep) against_15\IN|streptozotocin (l_pobj) effect_18\NN|NONE (l_amod) cardiotoxic_17\JJ|of|the
D002395_D003920 NONE catecholamines_4\NNS|NONE (r_pobj) of_3\IN|myocardial|The (r_prep) content_2\NN|was|in|. (r_nsubjpass) estimated_6\VBN|NONE (l_prep) in_7\IN|was|content|. (l_pobj) rats_12\NNS|NONE (l_amod) diabetic_11\JJ|these|day
D002395_D003920 NONE catecholamine_26\NN|myocardial|in (r_compound) sensitivity_27\NN|NONE (l_prep) in_28\IN|myocardial|catecholamine (l_pobj) rats_30\NNS|NONE (l_amod) diabetic_29\JJ|NONE
D005947_D005355 NONE glucose_52\NN|NONE (r_pobj) in_50\IN|the (r_prep) fall_49\NN|NONE (r_pobj) of_47\IN|the (r_prep) slope_46\NN|NONE (r_pobj) to_44\IN|a|significant|(|. (r_prep) correlation_33\NN|was|,|morphometrically|appeared|later (r_conj) analyzed_25\VBN|induced|after|ISO|subcutaneously|was|and|.|, (r_conj) given_13\VBN|NONE (l_conj) induced_18\VBD|after|ISO|analyzed|subcutaneously|was|and|.|, (l_dobj) fibrosis_19\NN|in|when|ISO
D007545_D005355 CID isoproterenol_4\NN|NONE (r_pobj) of_3\IN|morphometric|A (r_prep) study_2\NN|fibrosis|. (r_nsubj) induced_5\VBN|NONE (l_dobj) fibrosis_7\NN|study|.
D007545_D005355 CID ISO_11\NN|induced|after|analyzed|subcutaneously|was|and|.|, (r_nsubjpass) given_13\VBN|NONE (l_conj) induced_18\VBD|after|ISO|analyzed|subcutaneously|was|and|.|, (l_dobj) fibrosis_19\NN|in|when|ISO
D007545_D005355 CID ISO_17\NN|in|when|fibrosis (r_nsubj) induced_18\VBD|after|ISO|analyzed|subcutaneously|was|and|.|, (l_dobj) fibrosis_19\NN|in|when|ISO
D007545_D003920 NONE isoproterenol_11\NN|NONE (r_pobj) of_10\IN|the|in|cardiotoxic (r_prep) effect_9\NN|NONE (l_prep) in_12\IN|the|of|cardiotoxic (l_pobj) rats_15\NNS|NONE (l_amod) diabetic_14\JJ|streptozotocin
D007545_D003920 NONE isoproterenol_23\NN|NONE (r_pobj) of_22\IN|)|high|ISO|( (r_prep) doses_21\NNS|NONE (r_pobj) of_19\IN|cardiotoxic|the (r_prep) effect_18\NN|NONE (r_pobj) against_15\IN|streptozotocin (r_prep) diabetes_14\NNS|NONE
D007545_D003920 NONE ISO_25\NN|)|of|high|( (r_appos) doses_21\NNS|NONE (r_pobj) of_19\IN|cardiotoxic|the (r_prep) effect_18\NN|NONE (r_pobj) against_15\IN|streptozotocin (r_prep) diabetes_14\NNS|NONE
D007545_D003920 NONE ISO_15\NN|the|points|and (r_compound) resistance_16\NN|that|streptozotocin (l_conj) points_18\NNS|ISO|the|and (l_prep) towards_19\IN|NONE (l_pobj) effect_23\NN|NONE (l_prep) on_24\IN|insulin|a|direct (l_pobj) sensitivity_27\NN|NONE (l_prep) in_28\IN|myocardial|catecholamine (l_pobj) rats_30\NNS|NONE (l_amod) diabetic_29\JJ|NONE
D007545_D066126 NONE isoproterenol_11\NN|NONE (r_pobj) of_10\IN|the|in|cardiotoxic (r_prep) effect_9\NN|NONE (l_amod) cardiotoxic_8\JJ|the|in|of
D007545_D066126 NONE isoproterenol_23\NN|NONE (r_pobj) of_22\IN|)|high|ISO|( (r_prep) doses_21\NNS|NONE (r_pobj) of_19\IN|cardiotoxic|the (r_prep) effect_18\NN|NONE (l_amod) cardiotoxic_17\JJ|of|the
D007545_D066126 NONE ISO_25\NN|)|of|high|( (r_appos) doses_21\NNS|NONE (r_pobj) of_19\IN|cardiotoxic|the (r_prep) effect_18\NN|NONE (l_amod) cardiotoxic_17\JJ|of|the
25096313
D013256_D009422 NONE steroid_5\NN|at (r_compound) injection_6\NN|NONE (r_pobj) after_4\IN|cutaneous|.|antebrachial|Lateral (r_prep) neuropathy_3\NN|NONE
D013256_D009422 NONE steroid_19\NN|a|in (r_compound) injection_20\NN|NONE (r_pobj) after_17\IN|treat|that (r_prep) occurred_16\VBD|)|lateral|(|cutaneous|LACNP|antebrachial (r_relcl) neuropathy_11\NN|NONE
D013256_D010292 CID steroid_23\NN|before|in|a (r_compound) injection_24\NN|NONE (r_pobj) after_21\IN|paresthesia|.|presented|;|had (r_prep) occurred_20\VBN|NONE (l_ccomp) presented_5\VBN|paresthesia|.|after|;|had (l_prep) with_6\IN|woman (l_pobj) sensation_8\NN|NONE (l_conj) paresthesia_10\NN|over|and|decreased
D013256_D010292 CID steroid_23\NN|before|in|a (r_compound) injection_24\NN|NONE (r_pobj) after_21\IN|paresthesia|.|presented|;|had (r_prep) occurred_20\VBN|NONE (l_nsubj) paresthesia_18\NN|.|presented|after|;|had
D013256_D013716 NONE steroid_19\NN|a|in (r_compound) injection_20\NN|NONE (r_pobj) after_17\IN|treat|that (r_prep) occurred_16\VBD|)|lateral|(|cutaneous|LACNP|antebrachial (l_advcl) treat_26\VB|that|after (l_dobj) epicondylitis_28\NN|in|to
D013256_D013716 NONE steroid_14\NN|a|for (r_compound) injection_15\NN|NONE (l_prep) for_16\IN|steroid|a (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) epicondylitis_21\NN|NONE
24664478
C104457_D020258 NONE Nelarabine_0\JJ|:|with (r_compound) neurotoxicity_1\NN|NONE
C104457_D020258 NONE nelarabine_1\JJ|in|Severe (r_compound) neurotoxicity_2\NN|.|is
C104457_D020258 NONE nelarabine_16\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) caused_14\VBN|severe (r_acl) neurotoxicity_13\NN|NONE
24659727
D003520_D009503 CID CTX_22\NNP|NONE (r_pobj) of_19\IN|the|first (r_prep) treatment_18\NN|NONE (r_pobj) after_15\IN|frequency (r_prep) neutropenia_14\NN|effect|.|was|Neutropenia|and|, (r_conj) was_1\VBD|NONE (l_nsubj) Neutropenia_0\NNP|effect|.|neutropenia|was|and|,
D003520_D009503 CID CTX_22\NNP|NONE (r_pobj) of_19\IN|the|first (r_prep) treatment_18\NN|NONE (r_pobj) after_15\IN|frequency (r_prep) neutropenia_14\NN|effect|.|was|Neutropenia|and|,
D008130_D064420 NONE lomustine_10\NN|NONE (r_pobj) of_9\IN|in|a (r_prep) protocol_8\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|NONE (r_acl) toxicity_4\NN|.|study
D008130_D064420 NONE CCNU_12\NNP|cyclophosphamide|and|)|( (r_appos) lomustine_10\NN|NONE (r_pobj) of_9\IN|in|a (r_prep) protocol_8\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|NONE (r_acl) toxicity_4\NN|.|study
D008130_D009503 CID CCNU_20\NNP|/ (r_nmod) CTX_22\NNP|NONE (r_pobj) of_19\IN|the|first (r_prep) treatment_18\NN|NONE (r_pobj) after_15\IN|frequency (r_prep) neutropenia_14\NN|effect|.|was|Neutropenia|and|, (r_conj) was_1\VBD|NONE (l_nsubj) Neutropenia_0\NNP|effect|.|neutropenia|was|and|,
D008130_D009503 CID CCNU_20\NNP|/ (r_nmod) CTX_22\NNP|NONE (r_pobj) of_19\IN|the|first (r_prep) treatment_18\NN|NONE (r_pobj) after_15\IN|frequency (r_prep) neutropenia_14\NN|effect|.|was|Neutropenia|and|,
D008130_D008223 NONE lomustine_2\NN|NONE (l_prep) in_7\IN|in (l_pobj) dogs_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) lymphoma_10\NN|NONE
D008130_D008223 NONE lomustine_10\NN|NONE (r_pobj) of_9\IN|in|a (r_prep) protocol_8\NN|NONE (l_prep) in_19\IN|of|a (l_pobj) dogs_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) lymphoma_22\NN|NONE
D008130_D008223 NONE CCNU_12\NNP|cyclophosphamide|and|)|( (r_appos) lomustine_10\NN|NONE (r_pobj) of_9\IN|in|a (r_prep) protocol_8\NN|NONE (l_prep) in_19\IN|of|a (l_pobj) dogs_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) lymphoma_22\NN|NONE
D003520_D008223 NONE cyclophosphamide_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) combination_4\NN|NONE (r_pobj) in_3\IN|in (r_prep) lomustine_2\NN|NONE (l_prep) in_7\IN|in (l_pobj) dogs_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) lymphoma_10\NN|NONE
D003520_D008223 NONE cyclophosphamide_15\NN|and|CCNU|)|( (r_conj) lomustine_10\NN|NONE (r_pobj) of_9\IN|in|a (r_prep) protocol_8\NN|NONE (l_prep) in_19\IN|of|a (l_pobj) dogs_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) lymphoma_22\NN|NONE
D003520_D008223 NONE CTX_17\NNP|)|( (r_appos) cyclophosphamide_15\NN|and|CCNU|)|( (r_conj) lomustine_10\NN|NONE (r_pobj) of_9\IN|in|a (r_prep) protocol_8\NN|NONE (l_prep) in_19\IN|of|a (l_pobj) dogs_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) lymphoma_22\NN|NONE
D003520_D064420 NONE cyclophosphamide_15\NN|and|CCNU|)|( (r_conj) lomustine_10\NN|NONE (r_pobj) of_9\IN|in|a (r_prep) protocol_8\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|NONE (r_acl) toxicity_4\NN|.|study
D003520_D064420 NONE CTX_17\NNP|)|( (r_appos) cyclophosphamide_15\NN|and|CCNU|)|( (r_conj) lomustine_10\NN|NONE (r_pobj) of_9\IN|in|a (r_prep) protocol_8\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|NONE (r_acl) toxicity_4\NN|.|study
15991002
D010433_D001008 CID pentylenetetrazole_18\NN|another|anxiogenic|,|,|in (r_appos) drug_16\NN|and (r_conj) caffeine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|NONE (r_acl) anxiety_9\NN|NONE
D010433_D001008 CID pentylenetetrazole_11\NN||not (r_advmod) induced_13\VBN|NONE (r_amod) anxiety_14\NN|caffeine|Nicotine|but|.
D009538_D001008 NONE nicotine_7\NN|NONE (r_pobj) of_6\IN|the|on (r_prep) effects_5\NNS|study|. (l_prep) on_8\IN|the|of (l_pobj) anxiety_9\NN|NONE
D009538_D001008 NONE Nicotine_0\NNP|caffeine|but|anxiety|. (r_nsubj) blocked_6\VBD|NONE (l_conj) anxiety_14\NN|caffeine|Nicotine|but|.
D009538_D001008 NONE nicotine_8\NN|NONE (r_pobj) of_7\IN|on|the|antagonistic (r_prep) effect_6\NN|that|,|of|specific (l_prep) on_9\IN|the|of|antagonistic (l_pobj) anxiety_13\NN|NONE
D002110_D001008 CID caffeine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|NONE (r_acl) anxiety_9\NN|NONE
D002110_D001008 CID caffeine-_8\NN|Nicotine|but|anxiety|. (r_dobj) blocked_6\VBD|NONE (l_conj) anxiety_14\NN|caffeine|Nicotine|but|.
D002110_D001008 CID caffeine_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) anxiety_13\NN|NONE
D002110_D001008 CID caffeine_17\NN|NONE (r_pobj) to_16\IN|NONE (r_prep) specific_15\JJ|that|,|of|effect (r_acomp) is_14\VBZ|results|. (l_nsubj) effect_6\NN|that|,|of|specific (l_prep) on_9\IN|the|of|antagonistic (l_pobj) anxiety_13\NN|NONE
3987172
D010665_D006973 CID phenylpropanolamine_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) hypertension_6\NN|NONE
D010665_D006973 CID Phenylpropanolamine_0\NNP|PPA|)|( (r_nmod) overdose_4\NN|hypertension|can|. (r_nsubj) cause_6\VB|NONE (l_dobj) hypertension_8\NN|can|.|overdose
D010665_D006973 CID PPA_2\NNP|Phenylpropanolamine|)|( (r_nmod) overdose_4\NN|hypertension|can|. (r_nsubj) cause_6\VB|NONE (l_dobj) hypertension_8\NN|can|.|overdose
D010665_D006973 CID PPA_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) hypertension_15\NN|NONE
D010665_D062787 NONE Phenylpropanolamine_0\NNP|PPA|)|( (r_nmod) overdose_4\NN|hypertension|can|.
D010665_D062787 NONE PPA_2\NNP|Phenylpropanolamine|)|( (r_nmod) overdose_4\NN|hypertension|can|.
D011433_D006973 NONE Propranolol_0\NNP|.|of (r_compound) antagonism_1\NN|NONE (l_prep) of_2\IN|.|Propranolol (l_pobj) hypertension_6\NN|NONE
D011433_D006973 NONE propranolol_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) treatment_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) hypertension_15\NN|NONE
D010665_D002543 NONE Phenylpropanolamine_0\NNP|PPA|)|( (r_nmod) overdose_4\NN|hypertension|can|. (r_nsubj) cause_6\VB|NONE (l_dobj) hypertension_8\NN|can|.|overdose (l_conj) hemorrhage_11\NN|severe|,
D010665_D002543 NONE PPA_2\NNP|Phenylpropanolamine|)|( (r_nmod) overdose_4\NN|hypertension|can|. (r_nsubj) cause_6\VB|NONE (l_dobj) hypertension_8\NN|can|.|overdose (l_conj) hemorrhage_11\NN|severe|,
D010665_D020521 NONE PPA_10\NNP|)|%|from|that|ml|volume (r_nsubj) increased_11\VBD|fraction|assessed|.|, (l_dobj) volume_14\NN|)|%|PPA|from|that|ml (l_compound) stroke_13\NN|the
20408947
D000082_D056486 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hepatotoxicity_3\NN|.|cause
D000082_D008107 NONE acetaminophen_34\RB| (r_advmod) induced_36\VBN|n= (r_amod) ALF_37\NNP|NONE (l_appos) n=36_39\NNP|induced (l_prep) with_41\IN|(|) (l_pobj) patients_47\NNS|NONE (l_acl) undergoing_48\VBG|matched|age (l_dobj) LT_50\NN|NONE (l_prep) for_51\IN|emergent (l_pobj) ALF_57\NNP|NONE (l_conj) LT_63\NN|(|and|induced|)|n= (l_prep) for_64\IN|elective (l_pobj) disease_67\NN|NONE
D000082_D008107 NONE acetaminophen_34\RB| (r_advmod) induced_36\VBN|n= (r_amod) ALF_37\NNP|NONE (l_appos) n=36_39\NNP|induced (l_prep) with_41\IN|(|) (l_pobj) patients_47\NNS|NONE (l_acl) undergoing_48\VBG|matched|age (l_dobj) LT_50\NN|NONE (l_prep) for_51\IN|emergent (l_pobj) ALF_57\NNP|NONE (l_conj) LT_63\NN|(|and|induced|)|n= (l_prep) for_64\IN|elective (l_pobj) disease_67\NN|NONE (l_appos) CLD_69\NNP|)|chronic|liver|(
D000082_D008107 NONE acetaminophen_54\RB|||non (r_advmod) induced_56\VBN|(|and|LT|)|n= (r_amod) ALF_57\NNP|NONE (l_conj) LT_63\NN|(|and|induced|)|n= (l_prep) for_64\IN|elective (l_pobj) disease_67\NN|NONE
D000082_D008107 NONE acetaminophen_54\RB|||non (r_advmod) induced_56\VBN|(|and|LT|)|n= (r_amod) ALF_57\NNP|NONE (l_conj) LT_63\NN|(|and|induced|)|n= (l_prep) for_64\IN|elective (l_pobj) disease_67\NN|NONE (l_appos) CLD_69\NNP|)|chronic|liver|(
D000082_D008107 NONE acetaminophen_5\RB| (r_advmod) induced_7\VBN|Twenty|ALF|(|% (r_amod) patients_9\NNS|before|diagnosis (r_nsubj) had_10\VBD|P<.|;|.|attempt (l_prep) before_15\IN|patients|diagnosis (l_pobj) LT_16\NNP|NONE (l_appos) ALF=0/35_23\NNP|NONE (l_appos) CLD=2/34_25\NNP|induced|,|non
D000082_D008107 NONE acetaminophen_20\RB| (r_advmod) induced_22\VBN|CLD=/|,|non (r_amod) ALF=0/35_23\NNP|NONE (l_appos) CLD=2/34_25\NNP|induced|,|non
D000082_D008107 NONE acetaminophen_31\RB| (r_advmod) induced_33\VBN|year (r_amod) ALF_34\NNP|the|ALF|;|( (r_appos) groups_29\NNS|NONE (r_pobj) between_27\IN|survival|or|graft (r_prep) failure_24\NN|CLD|,|in|no|significant (r_conj) differences_14\NNS|.|During|,|)|:|rank|there (l_conj) CLD_57\NNP|,|in|failure|no|significant
D000082_D008107 NONE acetaminophen_47\RB| (r_advmod) induced_49\VBN| (r_acomp) non_45\AFX|%|; (r_nmod) ALF_50\NNP|the|ALF|;|( (r_appos) groups_29\NNS|NONE (r_pobj) between_27\IN|survival|or|graft (r_prep) failure_24\NN|CLD|,|in|no|significant (r_conj) differences_14\NNS|.|During|,|)|:|rank|there (l_conj) CLD_57\NNP|,|in|failure|no|significant
D000082_D008107 NONE acetaminophen_14\RB| (r_advmod) induced_16\VBN|NONE (r_amod) ALF_17\NNP|NONE (r_pobj) for_13\IN|emergently (r_prep) transplanted_11\VBN|NONE (r_acl) patients_10\NNS|NONE (r_pobj) for_9\IN|NONE (r_prep) outcomes_8\NNS|Despite|comparable|,|. (r_nsubj) were_18\VBD|NONE (l_acomp) comparable_19\JJ|Despite|outcomes|,|. (l_prep) to_20\IN|NONE (l_pobj) those_21\DT|NONE (l_acl) transplanted_22\VBN|NONE (l_prep) for_32\IN|for (l_pobj) CLD_33\NNP|electively
D000082_D008107 NONE acetaminophen_26\RB|non|| (r_advmod) induced_28\VBN|NONE (r_amod) ALF_29\NNP|and (r_pobj) for_23\IN|for (r_prep) transplanted_22\VBN|NONE (l_prep) for_32\IN|for (l_pobj) CLD_33\NNP|electively
D000082_D017114 CID acetaminophen_8\RB| (r_advmod) induced_10\VBN|liver|acute (r_amod) failure_13\NN|NONE
D000082_D017114 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hepatotoxicity_3\NN|.|cause (r_nsubj) is_4\VBZ|NONE (l_attr) cause_8\NN|.|hepatotoxicity (l_prep) of_9\IN|common|the (l_pobj) failure_12\NN|NONE
D000082_D017114 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hepatotoxicity_3\NN|.|cause (r_nsubj) is_4\VBZ|NONE (l_attr) cause_8\NN|.|hepatotoxicity (l_prep) of_9\IN|common|the (l_pobj) failure_12\NN|NONE (l_appos) ALF_14\NNP|liver|acute|(|in
D000082_D017114 CID acetaminophen_34\RB| (r_advmod) induced_36\VBN|n= (r_amod) ALF_37\NNP|NONE
D000082_D017114 CID acetaminophen_34\RB| (r_advmod) induced_36\VBN|n= (r_amod) ALF_37\NNP|NONE (l_appos) n=36_39\NNP|induced (l_prep) with_41\IN|(|) (l_pobj) patients_47\NNS|NONE (l_acl) undergoing_48\VBG|matched|age (l_dobj) LT_50\NN|NONE (l_prep) for_51\IN|emergent (l_pobj) ALF_57\NNP|NONE
D000082_D017114 CID acetaminophen_54\RB|||non (r_advmod) induced_56\VBN|(|and|LT|)|n= (r_amod) ALF_57\NNP|NONE (r_pobj) for_51\IN|emergent (r_prep) LT_50\NN|NONE (r_dobj) undergoing_48\VBG|matched|age (r_acl) patients_47\NNS|NONE (r_pobj) with_41\IN|(|) (r_prep) n=36_39\NNP|induced (r_appos) ALF_37\NNP|NONE
D000082_D017114 CID acetaminophen_54\RB|||non (r_advmod) induced_56\VBN|(|and|LT|)|n= (r_amod) ALF_57\NNP|NONE
D000082_D017114 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|ALF|undergoing (r_amod) patients_4\NNS|.|severity (l_compound) ALF_3\NNP|undergoing|induced
D000082_D017114 CID acetaminophen_5\RB| (r_advmod) induced_7\VBN|Twenty|ALF|(|% (r_amod) patients_9\NNS|before|diagnosis (l_compound) ALF_8\NNP|induced|Twenty|(|%
D000082_D017114 CID acetaminophen_5\RB| (r_advmod) induced_7\VBN|Twenty|ALF|(|% (r_amod) patients_9\NNS|before|diagnosis (r_nsubj) had_10\VBD|P<.|;|.|attempt (l_prep) before_15\IN|patients|diagnosis (l_pobj) LT_16\NNP|NONE (l_appos) ALF=0/35_23\NNP|NONE
D000082_D017114 CID acetaminophen_20\RB| (r_advmod) induced_22\VBN|CLD=/|,|non (r_amod) ALF=0/35_23\NNP|NONE (r_appos) LT_16\NNP|NONE (r_pobj) before_15\IN|patients|diagnosis (r_prep) had_10\VBD|P<.|;|.|attempt (l_nsubj) patients_9\NNS|before|diagnosis (l_compound) ALF_8\NNP|induced|Twenty|(|%
D000082_D017114 CID acetaminophen_20\RB| (r_advmod) induced_22\VBN|CLD=/|,|non (r_amod) ALF=0/35_23\NNP|NONE
D000082_D017114 CID acetaminophen_31\RB| (r_advmod) induced_33\VBN|year (r_amod) ALF_34\NNP|the|ALF|;|(
D000082_D017114 CID acetaminophen_31\RB| (r_advmod) induced_33\VBN|year (r_amod) ALF_34\NNP|the|ALF|;|( (r_appos) groups_29\NNS|NONE (l_appos) ALF_50\NNP|the|ALF|;|(
D000082_D017114 CID acetaminophen_47\RB| (r_advmod) induced_49\VBN| (r_acomp) non_45\AFX|%|; (r_nmod) ALF_50\NNP|the|ALF|;|( (r_appos) groups_29\NNS|NONE (l_appos) ALF_34\NNP|the|ALF|;|(
D000082_D017114 CID acetaminophen_47\RB| (r_advmod) induced_49\VBN| (r_acomp) non_45\AFX|%|; (r_nmod) ALF_50\NNP|the|ALF|;|(
D000082_D017114 CID acetaminophen_1\RB| (r_advmod) induced_3\VBN|Two|ALF (r_amod) patients_5\NNS|.|LT (l_compound) ALF_4\NNP|induced|Two
D000082_D017114 CID acetaminophen_14\RB| (r_advmod) induced_16\VBN|NONE (r_amod) ALF_17\NNP|NONE
D000082_D017114 CID acetaminophen_14\RB| (r_advmod) induced_16\VBN|NONE (r_amod) ALF_17\NNP|NONE (r_pobj) for_13\IN|emergently (r_prep) transplanted_11\VBN|NONE (r_acl) patients_10\NNS|NONE (r_pobj) for_9\IN|NONE (r_prep) outcomes_8\NNS|Despite|comparable|,|. (r_nsubj) were_18\VBD|NONE (l_acomp) comparable_19\JJ|Despite|outcomes|,|. (l_prep) to_20\IN|NONE (l_pobj) those_21\DT|NONE (l_acl) transplanted_22\VBN|NONE (l_prep) for_23\IN|for (l_pobj) ALF_29\NNP|and
D000082_D017114 CID acetaminophen_26\RB|non|| (r_advmod) induced_28\VBN|NONE (r_amod) ALF_29\NNP|and (r_pobj) for_23\IN|for (r_prep) transplanted_22\VBN|NONE (r_acl) those_21\DT|NONE (r_pobj) to_20\IN|NONE (r_prep) comparable_19\JJ|Despite|outcomes|,|. (r_acomp) were_18\VBD|NONE (l_nsubj) outcomes_8\NNS|Despite|comparable|,|. (l_prep) for_9\IN|NONE (l_pobj) patients_10\NNS|NONE (l_acl) transplanted_11\VBN|NONE (l_prep) for_13\IN|emergently (l_pobj) ALF_17\NNP|NONE
D000082_D017114 CID acetaminophen_26\RB|non|| (r_advmod) induced_28\VBN|NONE (r_amod) ALF_29\NNP|and
1423336
D010649_D007022 NONE Phenylalanine_0\NNP|with (r_nsubj) competing_10\VBG|effects|.|, (r_advcl) reduced_22\VBD|NONE (l_dobj) effects_27\NNS|.|competing|, (l_amod) hypotensive_24\JJ|of|the
D000596_D007022 NONE acid_6\NN|, (r_appos) Phenylalanine_0\NNP|with (r_nsubj) competing_10\VBG|effects|.|, (r_advcl) reduced_22\VBD|NONE (l_dobj) effects_27\NNS|.|competing|, (l_amod) hypotensive_24\JJ|of|the
D007980_D007022 CID levodopa_6\NN|NONE (r_pobj) of_5\IN|the|hypotensive (r_prep) effect_4\NN|NONE (l_amod) hypotensive_3\JJ|of|the
D007980_D007022 CID levodopa_7\NN|NONE (r_pobj) of_6\IN|hypotensive|the (r_prep) effect_5\NN|NONE (l_amod) hypotensive_4\JJ|of|the
D007980_D007022 CID levodopa_12\NN|NONE (r_pobj) with_11\IN|Phenylalanine (r_prep) competing_10\VBG|effects|.|, (r_advcl) reduced_22\VBD|NONE (l_dobj) effects_27\NNS|.|competing|, (l_amod) hypotensive_24\JJ|of|the
D007980_D007022 CID levodopa_29\NN|NONE (r_pobj) of_28\IN|hypotensive|the (r_prep) effects_27\NNS|.|competing|, (l_amod) hypotensive_24\JJ|of|the
D007980_D007022 CID levodopa_3\NN|that|action (r_nsubj) has_4\VBZ|We|. (l_dobj) action_8\NN|that|levodopa (l_amod) hypotensive_7\JJ|a|central|parallels
D007980_D010300 NONE levodopa_6\NN|NONE (l_prep) in_7\IN|NONE (l_pobj) patients_9\NNS|NONE (l_amod) parkinsonian_8\JJ|NONE
D007980_D010300 NONE levodopa_5\NN|NONE (r_pobj) of_3\IN|pressure (r_prep) effects_2\NNS|levodopa|were|in|. (r_nsubjpass) examined_7\VBN|NONE (l_prep) in_8\IN|levodopa|effects|were|. (l_pobj) patients_10\NNS|NONE (l_amod) parkinsonian_9\JJ|with
D007980_D010300 NONE levodopa_17\VB|effects|were|in|. (r_advcl) examined_7\VBN|NONE (l_prep) in_8\IN|levodopa|effects|were|. (l_pobj) patients_10\NNS|NONE (l_amod) parkinsonian_9\JJ|with
16906379
D008911_D011565 NONE minocycline_9\NN|been|with|who|for|had (r_dobj) taking_8\VBG|old|.|A (l_prep) for_10\IN|been|with|who|minocycline|had (l_pobj) fever_14\NN|NONE (l_nmod) pustulosis_12\NN|developed|,|,|myalgias
D008911_D005334 NONE minocycline_9\NN|been|with|who|for|had (r_dobj) taking_8\VBG|old|.|A (l_prep) for_10\IN|been|with|who|minocycline|had (l_pobj) fever_14\NN|NONE
D008911_D014657 NONE Minocycline_0\NNP| (r_npadvmod) induced_2\VBN|fulfilling|. (r_amod) vasculitis_3\NN|NONE
D008911_D014657 NONE minocycline_10\NN| (r_npadvmod) induced_12\VBN|satisfying (r_amod) vasculitis_13\NN|NONE
D008911_D011115 NONE minocycline_9\NN|been|with|who|for|had (r_dobj) taking_8\VBG|old|.|A (l_prep) for_10\IN|been|with|who|minocycline|had (l_pobj) fever_14\NN|NONE (l_conj) myalgias_16\NNS|developed|,|pustulosis|, (l_conj) polyneuropathy_18\VBP|,
D008911_D013733 NONE minocycline_9\NN|been|with|who|for|had (r_dobj) taking_8\VBG|old|.|A (l_prep) for_10\IN|been|with|who|minocycline|had (l_pobj) fever_14\NN|NONE (l_conj) myalgias_16\NNS|developed|,|pustulosis|, (l_conj) polyneuropathy_18\VBP|, (l_conj) pain_22\NN|and|,
D008911_D010488 CID Minocycline_0\NNP| (r_npadvmod) induced_2\VBN|fulfilling|. (r_amod) vasculitis_3\NN|NONE (l_acl) fulfilling_4\VBG|induced|. (l_dobj) criteria_6\NNS|NONE (l_prep) of_7\IN|the (l_pobj) nodosa_9\NN|NONE
D008911_D063806 NONE minocycline_9\NN|been|with|who|for|had (r_dobj) taking_8\VBG|old|.|A (l_prep) for_10\IN|been|with|who|minocycline|had (l_pobj) fever_14\NN|NONE (l_conj) myalgias_16\NNS|developed|,|pustulosis|,
12523489
D000661_D006948 NONE amphetamine_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) hyperactivity_15\NN|NONE (r_pobj) than_11\IN|more|hyperactivity|is|.|by (r_prep) influenced_6\VBN|NONE (l_nsubjpass) hyperactivity_3\NN|more|than|is|.|by
D000661_D006948 NONE amphetamine_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) hyperactivity_15\NN|NONE
D000661_D006948 NONE amphetamine_12\NN| (r_npadvmod) induced_14\VBN|and| (r_conj) cocaine_9\NN|NONE (r_nmod) hyperactivity_15\NN|NONE
D000661_D006948 NONE amphetamine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) hyperactivity_10\NN|but|.|,|Similarly|,|at|agonists
D000661_D006948 NONE amphetamine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) hyperactivity_10\NN|but|.|,|Similarly|,|at|agonists (r_dobj) decreased_6\VBD|NONE (l_conj) at_13\IN|but|.|,|Similarly|,|agonists|hyperactivity (l_pobj) doses_16\NNS|NONE (l_prep) than_17\IN|higher|the (l_pobj) those_18\DT|NONE (l_relcl) were_20\VBD|NONE (l_acomp) active_21\JJ|which (l_prep) in_22\IN|NONE (l_pobj) hyperactivity_26\NN|NONE
D000661_D006948 NONE amphetamine_17\NN| (r_npadvmod) induced_19\VBN|locomotor (r_amod) activity_21\NN|and|indicate|cocaine|and|agonists|that (r_dobj) reduce_14\VBP|results|have|. (l_conj) indicate_23\VBP|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN|NONE (l_nsubjpass) hyperactivity_28\NN|is|more|that|than|by
D000661_D006948 NONE amphetamine_17\NN| (r_npadvmod) induced_19\VBN|locomotor (r_amod) activity_21\NN|and|indicate|cocaine|and|agonists|that (r_dobj) reduce_14\VBP|results|have|. (l_conj) indicate_23\VBP|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN|NONE (l_prep) than_41\IN|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN|NONE
D000661_D006948 NONE amphetamine_42\NN| (r_npadvmod) induced_44\VBN|NONE (r_amod) hyperactivity_45\NN|NONE (r_pobj) than_41\IN|is|more|that|hyperactivity|by (r_prep) influenced_31\VBN|NONE (l_nsubjpass) hyperactivity_28\NN|is|more|that|than|by
D000661_D006948 NONE amphetamine_42\NN| (r_npadvmod) induced_44\VBN|NONE (r_amod) hyperactivity_45\NN|NONE
D003042_D006948 NONE Cocaine_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) hyperactivity_3\NN|more|than|is|.|by
D003042_D006948 NONE Cocaine_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) hyperactivity_3\NN|more|than|is|.|by (r_nsubjpass) influenced_6\VBN|NONE (l_prep) than_11\IN|more|hyperactivity|is|.|by (l_pobj) hyperactivity_15\NN|NONE
D003042_D006948 NONE cocaine_9\NN|NONE (r_nmod) hyperactivity_15\NN|NONE
D003042_D006948 NONE cocaine_23\NN| (r_npadvmod) induced_25\VBN|NONE (r_amod) hyperactivity_26\NN|NONE (r_pobj) in_22\IN|NONE (r_prep) active_21\JJ|which (r_acomp) were_20\VBD|NONE (r_relcl) those_18\DT|NONE (r_pobj) than_17\IN|higher|the (r_prep) doses_16\NNS|NONE (r_pobj) at_13\IN|but|.|,|Similarly|,|agonists|hyperactivity (r_conj) decreased_6\VBD|NONE (l_dobj) hyperactivity_10\NN|but|.|,|Similarly|,|at|agonists
D003042_D006948 NONE cocaine_23\NN| (r_npadvmod) induced_25\VBN|NONE (r_amod) hyperactivity_26\NN|NONE
D003042_D006948 NONE cocaine-_15\JJ|and|indicate|and|agonists|that|activity (r_dobj) reduce_14\VBP|results|have|. (l_conj) indicate_23\VBP|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN|NONE (l_nsubjpass) hyperactivity_28\NN|is|more|that|than|by
D003042_D006948 NONE cocaine-_15\JJ|and|indicate|and|agonists|that|activity (r_dobj) reduce_14\VBP|results|have|. (l_conj) indicate_23\VBP|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN|NONE (l_prep) than_41\IN|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN|NONE
D003042_D006948 NONE cocaine_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) hyperactivity_28\NN|is|more|that|than|by
D003042_D006948 NONE cocaine_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) hyperactivity_28\NN|is|more|that|than|by (r_nsubjpass) influenced_31\VBN|NONE (l_prep) than_41\IN|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN|NONE
D000241_D006948 NONE adenosine_8\NN|receptor (r_amod) agonists_10\NNS|NONE (r_pobj) by_7\IN|more|than|hyperactivity|is|. (r_agent) influenced_6\VBN|NONE (l_nsubjpass) hyperactivity_3\NN|more|than|is|.|by
D000241_D006948 NONE adenosine_8\NN|receptor (r_amod) agonists_10\NNS|NONE (r_pobj) by_7\IN|more|than|hyperactivity|is|. (r_agent) influenced_6\VBN|NONE (l_prep) than_11\IN|more|hyperactivity|is|.|by (l_pobj) hyperactivity_15\NN|NONE
D000241_D006948 NONE adenosine_3\NN|antagonists|and|receptor (r_amod) agonists_5\NNS|NONE (l_conj) antagonists_7\NNS|and|adenosine|receptor (l_prep) on_8\IN|NONE (l_pobj) hyperactivity_15\NN|NONE
D000241_D006948 NONE adenosine_3\NN|receptor|all (r_amod) agonists_5\NNS|but|.|,|Similarly|,|at|hyperactivity (r_nsubj) decreased_6\VBD|NONE (l_dobj) hyperactivity_10\NN|but|.|,|Similarly|,|at|agonists
D000241_D006948 NONE adenosine_3\NN|receptor|all (r_amod) agonists_5\NNS|but|.|,|Similarly|,|at|hyperactivity (r_nsubj) decreased_6\VBD|NONE (l_conj) at_13\IN|but|.|,|Similarly|,|agonists|hyperactivity (l_pobj) doses_16\NNS|NONE (l_prep) than_17\IN|higher|the (l_pobj) those_18\DT|NONE (l_relcl) were_20\VBD|NONE (l_acomp) active_21\JJ|which (l_prep) in_22\IN|NONE (l_pobj) hyperactivity_26\NN|NONE
D000241_D006948 NONE adenosine_6\NN|A|)|all|(|receptor (r_amod) agonists_8\NNS|and|indicate|cocaine|and|that|activity (r_nsubj) reduce_14\VBP|results|have|. (l_conj) indicate_23\VBP|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN|NONE (l_nsubjpass) hyperactivity_28\NN|is|more|that|than|by
D000241_D006948 NONE adenosine_6\NN|A|)|all|(|receptor (r_amod) agonists_8\NNS|and|indicate|cocaine|and|that|activity (r_nsubj) reduce_14\VBP|results|have|. (l_conj) indicate_23\VBP|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN|NONE (l_prep) than_41\IN|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN|NONE
D000241_D006948 NONE adenosine_33\NN|receptor|(|)|receptors (r_amod) agonists_35\NNS|NONE (r_pobj) by_32\IN|is|more|that|than|hyperactivity (r_agent) influenced_31\VBN|NONE (l_nsubjpass) hyperactivity_28\NN|is|more|that|than|by
D000241_D006948 NONE adenosine_33\NN|receptor|(|)|receptors (r_amod) agonists_35\NNS|NONE (r_pobj) by_32\IN|is|more|that|than|hyperactivity (r_agent) influenced_31\VBN|NONE (l_prep) than_41\IN|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN|NONE
D000241_D004409 NONE adenosine_1\NN|All|receptor (r_amod) agonists_3\NNS|were|and|,|activity|significantly (r_nsubj) decreased_5\VBD|NONE (l_dobj) activity_8\NN|agonists|were|and|,|significantly
6453500
D004221_D056486 CID disulfiram_4\NN|NONE (r_pobj) by_3\IN|in|.|hepatitis (r_prep) induced_2\VBN|NONE (l_nsubj) hepatitis_1\NN|in|by|.
D004221_D056486 CID disulfiram_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|alcoholic|a (r_acl) woman_12\NN|NONE (r_pobj) in_7\IN|.|was|damage (r_prep) observed_6\VBN|NONE (l_nsubjpass) damage_4\NN|.|in|was
146391
D010672_D003875 CID diphenylhydantoin_13\NN|NONE (r_dobj) taking_12\VBG|a (r_acl) patient_11\NN|NONE (r_pobj) in_9\IN|NONE (r_prep) lymphadenopathy_8\NN|and|toxic (r_conj) dermatitis_6\NN|.|cell|,|Pure
D010672_D012010 CID diphenylhydantoin_13\NN|NONE (r_dobj) taking_12\VBG|a (r_acl) patient_11\NN|NONE (r_pobj) in_9\IN|NONE (r_prep) lymphadenopathy_8\NN|and|toxic (r_conj) dermatitis_6\NN|.|cell|,|Pure (r_conj) aplasia_3\NN|NONE
D010672_D012010 CID diphenylhydantoin_3\NN|for (r_dobj) taking_2\VBG|A (r_acl) patient_1\NN|rash|. (r_nsubj) developed_7\VBD|NONE (l_dobj) rash_11\NN|patient|. (l_appos) aplasia_18\NN|,|generalized|a|skin
D010672_D012010 CID diphenylhydantoin_6\NN|NONE (r_compound) medication_7\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|cell|Pure (r_acl) aplasia_3\NN|.|has|in|been
D010672_D012010 CID diphenylhydantoin_10\NN|NONE (r_pobj) of_9\IN|the|and|occurrence (r_prep) ingestion_8\NN|NONE (l_conj) occurrence_13\NN|the|and|of (l_prep) of_14\IN|the (l_pobj) rash_17\NN|NONE (l_conj) lymphadenopathy_19\JJ|the|skin|, (l_conj) aplasia_24\NN|and
D010672_D005076 NONE diphenylhydantoin_3\NN|for (r_dobj) taking_2\VBG|A (r_acl) patient_1\NN|rash|. (r_nsubj) developed_7\VBD|NONE (l_dobj) rash_11\NN|patient|.
D010672_D005076 NONE diphenylhydantoin_9\NN|NONE (r_compound) treatment_10\NN|NONE (r_pobj) of_8\IN|a|known (r_prep) complication_7\NN|is|rash|. (r_attr) is_2\VBZ|NONE (l_nsubj) rash_1\NN|is|.|complication
D010672_D005076 NONE diphenylhydantoin_10\NN|NONE (r_pobj) of_9\IN|the|and|occurrence (r_prep) ingestion_8\NN|NONE (l_conj) occurrence_13\NN|the|and|of (l_prep) of_14\IN|the (l_pobj) rash_17\NN|NONE
D010672_D008206 CID diphenylhydantoin_13\NN|NONE (r_dobj) taking_12\VBG|a (r_acl) patient_11\NN|NONE (r_pobj) in_9\IN|NONE (r_prep) lymphadenopathy_8\NN|and|toxic
D010672_D008206 CID diphenylhydantoin_3\NN|for (r_dobj) taking_2\VBG|A (r_acl) patient_1\NN|rash|. (r_nsubj) developed_7\VBD|NONE (l_dobj) rash_11\NN|patient|. (l_appos) aplasia_18\NN|,|generalized|a|skin (l_amod) lymphadenopathy_13\JJ|cell|pure
D010672_D008206 CID diphenylhydantoin_9\NN|NONE (r_compound) treatment_10\NN|NONE (r_pobj) of_8\IN|a|known (r_prep) complication_7\NN|is|rash|. (r_attr) is_2\VBZ|NONE (l_advcl) is_12\VBZ|rash|.|complication (l_acomp) lymphadenopathy_16\NN|as
D010672_D008206 CID diphenylhydantoin_10\NN|NONE (r_pobj) of_9\IN|the|and|occurrence (r_prep) ingestion_8\NN|NONE (l_conj) occurrence_13\NN|the|and|of (l_prep) of_14\IN|the (l_pobj) rash_17\NN|NONE (l_conj) lymphadenopathy_19\JJ|the|skin|,
6673474
D009599_D007022 CID nitroprusside_14\NN|NONE (r_amod) sodium_13\NN|NONE (r_pobj) under_12\IN|NONE (r_prep) dogs_11\NNS|NONE (r_pobj) in_10\IN|were|flow|.|and|trimetaphan (r_prep) studied_9\VBN|NONE (l_conj) trimetaphan_19\NN|were|flow|.|and|in (l_pobj) hypotension_24\NN|NONE
D009599_D007022 CID SNP_16\NNP|NONE (r_appos) nitroprusside_14\NN|NONE (r_amod) sodium_13\NN|NONE (r_pobj) under_12\IN|NONE (r_prep) dogs_11\NNS|NONE (r_pobj) in_10\IN|were|flow|.|and|trimetaphan (r_prep) studied_9\VBN|NONE (l_conj) trimetaphan_19\NN|were|flow|.|and|in (l_pobj) hypotension_24\NN|NONE
D009599_D007022 CID nitroprusside_30\JJ|NONE (r_amod) hypotension_31\NN|that|be|decrease|safely|to|could (r_nsubjpass) used_35\VBN|could|Regarding|we|. (r_ccomp) confirm_28\VB|NONE (l_prep) Regarding_0\VBG|could|used|we|. (l_pobj) effects_2\NNS|NONE (l_prep) of_3\IN|the (l_pobj) hypotension_7\NN|NONE
D009599_D007022 CID nitroprusside_30\JJ|NONE (r_amod) hypotension_31\NN|that|be|decrease|safely|to|could
D009599_D007022 CID nitroprusside_30\JJ|NONE (r_amod) hypotension_31\NN|that|be|decrease|safely|to|could (r_nsubjpass) used_35\VBN|could|Regarding|we|. (l_advcl) decrease_42\NN|that|hypotension|be|safely|to|could (l_conj) decrease_54\NN|mean|pressure|,|from (l_dep) hypotension_47\NN|pressure|mean|trimetaphan
D009599_D007022 CID SNP_6\NNP|NONE (r_compound) hypotension_7\NN|NONE
D014294_D007022 CID trimetaphan_19\NN|were|flow|.|and|in (l_pobj) hypotension_24\NN|NONE
D014294_D007022 CID TMP_21\NNP|%|)|(|deliberate|(|decrease (r_nmod) hypotension_24\NN|NONE
D014294_D007022 CID trimetaphan_46\NN|hypotension|pressure|mean (r_mark) decrease_54\NN|mean|pressure|,|from (r_conj) decrease_42\NN|that|hypotension|be|safely|to|could (r_advcl) used_35\VBN|could|Regarding|we|. (r_ccomp) confirm_28\VB|NONE (l_prep) Regarding_0\VBG|could|used|we|. (l_pobj) effects_2\NNS|NONE (l_prep) of_3\IN|the (l_pobj) hypotension_7\NN|NONE
D014294_D007022 CID trimetaphan_46\NN|hypotension|pressure|mean (r_mark) decrease_54\NN|mean|pressure|,|from (r_conj) decrease_42\NN|that|hypotension|be|safely|to|could (r_advcl) used_35\VBN|could|Regarding|we|. (l_nsubjpass) hypotension_31\NN|that|be|decrease|safely|to|could
D014294_D007022 CID trimetaphan_46\NN|hypotension|pressure|mean (r_mark) decrease_54\NN|mean|pressure|,|from (l_dep) hypotension_47\NN|pressure|mean|trimetaphan
20046642
D002330_D008569 CID BCNU_1\NNP|resulted|after|data|.|then (r_nsubj) revealed_16\VBD|NONE (l_ccomp) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D002330_D008569 CID BCNU_18\NNP|NONE (r_compound) administration_19\NN|in|that|,|measured (r_nsubj) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D008315_D064420 NONE MDA_27\NNP|, (r_conj) TNFalpha_25\NNP|NONE (r_pobj) of_24\IN|the|increased (r_prep) levels_23\NNS|NONE (r_dobj) counteracted_20\VBD|inhibition|and|it|as (r_conj) prevented_13\VBD|induction|.|In|toxicity|, (r_advcl) halts_5\VBZ|NONE (l_dobj) toxicity_10\NN|induction|prevented|.|In|,
D005978_D064420 NONE GSH_17\NNP|NONE (r_compound) depletion_18\NN|and|GR (r_conj) inhibition_15\NN|counteracted|and|it|as (r_dobj) prevented_13\VBD|induction|.|In|toxicity|, (r_advcl) halts_5\VBZ|NONE (l_dobj) toxicity_10\NN|induction|prevented|.|In|,
D005978_D007859 NONE glutathione_47\NN|hippocampal|activity|decreased (r_compound) reductase_48\NN|NONE (r_pobj) with_44\IN|NONE (r_prep) accompanied_43\VBN|,|as|by (r_conj) measured_35\VBN|administration|in|that|, (r_advcl) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D005978_D007859 NONE glutathione_55\NN|GSH|( (r_nmod) content_59\NN|and|)|GR|( (r_conj) activity_52\NN|glutathione|hippocampal|decreased (r_appos) reductase_48\NN|NONE (r_pobj) with_44\IN|NONE (r_prep) accompanied_43\VBN|,|as|by (r_conj) measured_35\VBN|administration|in|that|, (r_advcl) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D005978_D007859 NONE GSH_57\NNP|glutathione|( (r_nmod) content_59\NN|and|)|GR|( (r_conj) activity_52\NN|glutathione|hippocampal|decreased (r_appos) reductase_48\NN|NONE (r_pobj) with_44\IN|NONE (r_prep) accompanied_43\VBN|,|as|by (r_conj) measured_35\VBN|administration|in|that|, (r_advcl) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D002330_D009336 NONE BCNU_2\NNP|NONE (r_compound) administration_3\NN|,|Also|.|contents (r_nsubj) increased_4\VBD|NONE (l_dobj) contents_22\NNS|,|Also|administration|. (l_nmod) factor_8\NN|activity|as|MDA|)|( (l_compound) necrosis_7\NN||alpha
D008315_D009369 NONE malondialdehyde_18\NN|and|hippocampal (r_conj) MT_16\NNP|,|TNFalpha (r_appos) alpha_10\NN||necrosis (r_appos) factor_8\NN|activity|as|MDA|)|( (l_compound) necrosis_7\NN||alpha (l_compound) tumor_6\NN|NONE
D008315_D009369 NONE MDA_20\NNP|activity|as|)|(|factor (r_nmod) contents_22\NNS|,|Also|administration|. (l_nmod) factor_8\NN|activity|as|MDA|)|( (l_compound) necrosis_7\NN||alpha (l_compound) tumor_6\NN|NONE
D008315_D009336 NONE malondialdehyde_18\NN|and|hippocampal (r_conj) MT_16\NNP|,|TNFalpha (r_appos) alpha_10\NN||necrosis (r_appos) factor_8\NN|activity|as|MDA|)|( (l_compound) necrosis_7\NN||alpha
D008315_D009336 NONE MDA_20\NNP|activity|as|)|(|factor (r_nmod) contents_22\NNS|,|Also|administration|. (l_nmod) factor_8\NN|activity|as|MDA|)|( (l_compound) necrosis_7\NN||alpha
D002330_D007859 CID BCNU_1\NNP|resulted|after|data|.|then (r_nsubj) revealed_16\VBD|NONE (l_ccomp) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D002330_D007859 CID BCNU_18\NNP|NONE (r_compound) administration_19\NN|in|that|,|measured (r_nsubj) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D008668_D003072 NONE MT_9\NNP|on (r_compound) induction_10\NN|NONE (l_prep) on_11\IN|MT (l_pobj) carmustine_12\NN|NONE (l_appos) dysfunction_17\NN|NONE
D008668_D064420 NONE MT_3\NNP|NONE (r_compound) induction_4\NN|prevented|.|In|toxicity|, (r_nsubj) halts_5\VBZ|NONE (l_dobj) toxicity_10\NN|induction|prevented|.|In|,
D008668_D009369 NONE MT_16\NNP|,|TNFalpha (r_appos) alpha_10\NN||necrosis (r_appos) factor_8\NN|activity|as|MDA|)|( (l_compound) necrosis_7\NN||alpha (l_compound) tumor_6\NN|NONE
D002330_D009369 NONE BCNU_2\NNP|NONE (r_compound) administration_3\NN|,|Also|.|contents (r_nsubj) increased_4\VBD|NONE (l_dobj) contents_22\NNS|,|Also|administration|. (l_nmod) factor_8\NN|activity|as|MDA|)|( (l_compound) necrosis_7\NN||alpha (l_compound) tumor_6\NN|NONE
D008668_D009336 NONE MT_16\NNP|,|TNFalpha (r_appos) alpha_10\NN||necrosis (r_appos) factor_8\NN|activity|as|MDA|)|( (l_compound) necrosis_7\NN||alpha
D002330_D064420 NONE BCNU_6\NNP| (r_npadvmod) induced_8\VBN|hippocampal (r_amod) toxicity_10\NN|induction|prevented|.|In|,
D005978_D008569 NONE glutathione_47\NN|hippocampal|activity|decreased (r_compound) reductase_48\NN|NONE (r_pobj) with_44\IN|NONE (r_prep) accompanied_43\VBN|,|as|by (r_conj) measured_35\VBN|administration|in|that|, (r_advcl) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D005978_D008569 NONE glutathione_55\NN|GSH|( (r_nmod) content_59\NN|and|)|GR|( (r_conj) activity_52\NN|glutathione|hippocampal|decreased (r_appos) reductase_48\NN|NONE (r_pobj) with_44\IN|NONE (r_prep) accompanied_43\VBN|,|as|by (r_conj) measured_35\VBN|administration|in|that|, (r_advcl) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D005978_D008569 NONE GSH_57\NNP|glutathione|( (r_nmod) content_59\NN|and|)|GR|( (r_conj) activity_52\NN|glutathione|hippocampal|decreased (r_appos) reductase_48\NN|NONE (r_pobj) with_44\IN|NONE (r_prep) accompanied_43\VBN|,|as|by (r_conj) measured_35\VBN|administration|in|that|, (r_advcl) resulted_20\VBD|BCNU|after|data|.|then (l_prep) in_21\IN|administration|that|,|measured (l_pobj) deterioration_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) learning_24\NN|NONE (l_conj) memory_29\NN|and
D002330_D003072 CID carmustine_12\NN|NONE (l_appos) dysfunction_17\NN|NONE
D002330_D003072 CID BCNU)-induced_14\VBN|(|in|hippocampal|cognitive (r_amod) dysfunction_17\NN|NONE
24438483
D015742_D066126 NONE propofol_19\NN|NONE (r_pobj) of_18\IN|lipid|the (r_prep) content_17\NN|cardiotoxicity|may|. (r_nsubj) alleviate_21\VB|been|has|and|increase|treatment|, (l_dobj) cardiotoxicity_25\NN|may|.|content
D015742_D066126 NONE propofol_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) intralipid_13\NN|NONE (l_conj) emulsions_16\NNS|or (l_prep) on_17\IN|medialipid (l_pobj) cardiotoxicity_21\NN|NONE
D015742_D066126 NONE propofol_7\NN|.|We|induced|delayed (r_dobj) conclude_1\VBP|NONE (l_conj) induced_25\VBN|.|We|propofol|delayed (l_dobj) effects_27\NNS| (l_amod) cardiotoxic_26\JJ|levels|as
D015742_D066126 NONE propofol_13\NN|NONE (r_pcomp) with_12\IN|NONE (r_prep) compared_11\VBN|that|with|in|, (r_prep) propofol_7\NN|.|We|induced|delayed (r_dobj) conclude_1\VBP|NONE (l_conj) induced_25\VBN|.|We|propofol|delayed (l_dobj) effects_27\NNS| (l_amod) cardiotoxic_26\JJ|levels|as
D002045_D066126 CID bupivacaine_12\NN|NONE (r_pobj) of_11\IN|lethal (r_prep) doses_10\NNS|to (r_dobj) increase_8\VB|alleviate|been|has|and|treatment|, (r_xcomp) shown_6\VBN|NONE (l_conj) alleviate_21\VB|been|has|and|increase|treatment|, (l_dobj) cardiotoxicity_25\NN|may|.|content
D002045_D066126 CID bupivacaine_22\NN| (r_npadvmod) induced_24\VBN|NONE (r_amod) cardiotoxicity_25\NN|may|.|content
D002045_D066126 CID bupivacaine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_compound) cardiotoxicity_21\NN|NONE
D002045_D066126 CID bupivacaine_23\NN|NONE (r_pobj) of_22\IN|the (r_prep) onset_21\NN|, (r_dobj) delayed_19\VBD|.|We|induced|propofol (r_conj) conclude_1\VBP|NONE (l_conj) induced_25\VBN|.|We|propofol|delayed (l_dobj) effects_27\NNS| (l_amod) cardiotoxic_26\JJ|levels|as
D002045_D066126 CID bupivacaine_33\NN|NONE (r_compound) levels_34\NNS|as|cardiotoxic (r_conj) effects_27\NNS| (l_amod) cardiotoxic_26\JJ|levels|as
D002045_D002318 NONE bupivacaine_4\NN| (r_npadvmod) induced_6\VBN|cardiovascular (r_amod) depression_8\NN|NONE
D002045_D001145 NONE bupivacaine_37\NN|NONE (r_compound) consumption_38\NN|NONE (r_pobj) of_36\IN|total (r_prep) amount_35\NN|asystole (r_conj) time_30\NN|and|mean|arterial|, (r_conj) pressure_27\NN|respective|and|to (r_conj) times_9\NNS|We|,|to|time|. (r_npadvmod) recorded_1\VBD|NONE (l_prep) to_3\IN|We|,|times|time|. (l_pobj) occurrence_6\NN|NONE (l_amod) dysrhythmia_5\NN|first
D002045_D006323 CID bupivacaine_37\NN|NONE (r_compound) consumption_38\NN|NONE (r_pobj) of_36\IN|total (r_prep) amount_35\NN|asystole (r_conj) time_30\NN|and|mean|arterial|, (l_relcl) asystole_32\NN|amount
D015742_D002318 NONE propofol_14\NN|NONE (r_pobj) of_13\IN|different|lipid (r_prep) formulations_12\NNS|treatment|. (r_dobj) using_9\VBG|NONE (l_nsubj) treatment_2\NN|formulations|. (l_prep) of_3\IN||Pre (l_pobj) depression_8\NN|NONE
6695685
D014700_D002637 NONE verapamil_8\NN|suppressed|neither|.|frequency|In|nor|, (r_nsubj) increased_10\VBD|NONE (l_prep) In_0\IN|suppressed|neither|.|verapamil|frequency|nor|, (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) syndromes_6\NNS|NONE (l_compound) pain_5\NN|chest|various
D014700_D001145 CID verapamil_5\NN|oral (r_compound) therapy_6\NN|NONE (r_pobj) during_3\IN|Accelerated|.|junctional (r_prep) rhythms_2\NNS|NONE
D014700_D001145 CID verapamil_20\NN|NONE (r_dobj) receiving_18\VBG| (r_acl) patients_17\NNS|NONE (r_pobj) in_15\IN|rhythms (r_prep) accelerated_12\VBD|frequency|and|study|. (l_dobj) rhythms_14\NNS|in
7176945
D013390_D010146 CID suxamethonium_2\NN|in|. (r_compound) pains_3\NNS|NONE
D013390_D010146 CID scoline_8\JJ|NONE (r_amod) pain_9\NN|Contrary|in|,|.
D013390_D010146 CID scoline_9\JJ|NONE (r_amod) pain_10\NN|%|compared|.
D013390_D010146 CID scoline_20\JJ|NONE (r_amod) pain_21\NN|NONE
D013390_D010146 CID suxamethonium_16\NN|NONE (r_pobj) of_15\IN|salt|the (r_prep) preparation_14\NN|the|nor|of|Neither|, (r_conj) type_2\NN|.|incidence (r_nsubj) affected_24\VBD|NONE (l_dobj) incidence_26\NN|type|. (l_prep) of_27\IN|the (l_pobj) pain_29\NN|NONE
D013390_D010146 CID scoline_28\JJ|NONE (r_amod) pain_29\NN|NONE
D000530_D010146 NONE Althesin_7\NNP|induction|(|) (r_appos) agent_5\NN|NONE (r_pobj) of_3\IN|the|nor|Neither|,|preparation (r_prep) type_2\NN|.|incidence (r_nsubj) affected_24\VBD|NONE (l_dobj) incidence_26\NN|type|. (l_prep) of_27\IN|the (l_pobj) pain_29\NN|NONE
D013390_D005207 CID scoline_20\JJ|NONE (r_amod) pain_21\NN|NONE (r_pobj) of_19\IN|the (r_prep) occurrence_18\NN|did|not|abolition|. (r_dobj) influence_16\VB|NONE (l_nsubj) abolition_1\NN|did|not|occurrence|. (l_prep) of_2\IN|dose|The (l_pobj) fasciculations_4\NNS|NONE
C084773_D005207 NONE Fazadinium_12\NNP|NONE (r_pobj) of_11\IN|(|by|)|kg (r_prep) dose_10\NN|The|of (r_appos) abolition_1\NN|did|not|occurrence|. (l_prep) of_2\IN|dose|The (l_pobj) fasciculations_4\NNS|NONE
D002712_D010146 NONE chloride_19\NN|NONE (r_oprd) used_17\VBN|NONE (r_acl) suxamethonium_16\NN|NONE (r_pobj) of_15\IN|salt|the (r_prep) preparation_14\NN|the|nor|of|Neither|, (r_conj) type_2\NN|.|incidence (r_nsubj) affected_24\VBD|NONE (l_dobj) incidence_26\NN|type|. (l_prep) of_27\IN|the (l_pobj) pain_29\NN|NONE
C084773_D010146 NONE Fazadinium_12\NNP|NONE (r_pobj) of_11\IN|(|by|)|kg (r_prep) dose_10\NN|The|of (r_appos) abolition_1\NN|did|not|occurrence|. (r_nsubj) influence_16\VB|NONE (l_dobj) occurrence_18\NN|did|not|abolition|. (l_prep) of_19\IN|the (l_pobj) pain_21\NN|NONE
D001965_D010146 NONE bromide_21\NN|or|(|) (r_conj) chloride_19\NN|NONE (r_oprd) used_17\VBN|NONE (r_acl) suxamethonium_16\NN|NONE (r_pobj) of_15\IN|salt|the (r_prep) preparation_14\NN|the|nor|of|Neither|, (r_conj) type_2\NN|.|incidence (r_nsubj) affected_24\VBD|NONE (l_dobj) incidence_26\NN|type|. (l_prep) of_27\IN|the (l_pobj) pain_29\NN|NONE
D013874_D010146 NONE Thiopentone_9\NNP|or (r_conj) Althesin_7\NNP|induction|(|) (r_appos) agent_5\NN|NONE (r_pobj) of_3\IN|the|nor|Neither|,|preparation (r_prep) type_2\NN|.|incidence (r_nsubj) affected_24\VBD|NONE (l_dobj) incidence_26\NN|type|. (l_prep) of_27\IN|the (l_pobj) pain_29\NN|NONE
26033014
C051786_D008113 CID Metolachlor_0\NNP|as|.|by|based|is (r_nsubjpass) classified_8\VBN|NONE (l_prep) based_20\VBN|as|.|by|is|Metolachlor (l_prep) on_21\IN|NONE (l_pobj) neoplasms_24\NNS|NONE
C051786_D008113 CID metolachlor_6\NN|among|liver (r_nmod) cancer_9\NN|NONE
C051786_D008113 CID metolachlor_6\NN|among|liver (r_nmod) cancer_9\NN|NONE (r_pobj) between_5\IN|an (r_prep) association_4\NN|NONE (r_pobj) of_2\IN|This (r_prep) suggestion_1\NN|finding|. (r_nsubj) is_13\VBZ|NONE (l_attr) finding_16\NN|suggestion|. (l_conj) echoes_18\VBZ|a|and|novel (l_dobj) observation_19\NN|in (l_prep) of_20\IN|NONE (l_pobj) neoplasms_23\NNS|NONE
C051786_D008113 CID metolachlor_21\JJ|from (r_amod) use_22\NN|NONE (r_pobj) of_20\IN|differentiate (r_prep) effects_19\NNS|NONE (r_pobj) to_16\TO|follow||warrant (r_prep) up_15\NN|both|liver|and (r_conj) cancer_7\NN|NONE
C051786_D009369 NONE metolachlor_3\JJ|in (r_amod) use_4\NN|Cancer|and (r_conj) incidence_1\NN|An|:|. (l_compound) Cancer_0\NN|use|and
C051786_D009369 NONE metolachlor_22\NN|ever (r_dobj) using_21\VBG|% (r_xcomp) reported_19\VBD|We|for|through|incidence|. (r_advcl) evaluated_1\VBD|NONE (l_dobj) incidence_3\NN|We|for|through|.|reported (l_compound) cancer_2\NN|NONE
C051786_D009369 NONE metolachlor_11\JJ|NONE (r_amod) use_12\NN|NONE (r_pobj) of_10\IN|days|incidence|(|)|two|and (r_prep) metrics_9\NNS|NONE (l_conj) incidence_25\NN|days|of|(|)|two|and (l_compound) cancer_24\NN|NONE
C051786_D009369 NONE metolachlor_5\JJ|and|incidence|, (r_amod) use_6\NN|NONE (l_conj) incidence_8\NN|and|metolachlor|, (l_prep) of_9\IN|NONE (l_pobj) cancers_11\NNS|NONE
C051786_D009369 NONE metolachlor_5\JJ|and|incidence|, (r_amod) use_6\NN|NONE (r_pobj) between_4\IN|no|with (r_prep) association_3\NN|We|. (l_prep) with_17\IN|no|between (l_pobj) lag_20\NN|NONE (l_conj) cancers_27\NNS|year|a|)|or
C051786_D008175 NONE metolachlor_12\JJ|in (r_amod) use_13\NN|NONE (r_pobj) of_11\IN|high (r_prep) levels_10\NNS|NONE (r_pobj) at_8\IN|cancer|increased (r_prep) risk_7\NN|NONE (l_compound) cancer_6\NN|at|increased
C051786_D008223 NONE metolachlor_21\JJ|from (r_amod) use_22\NN|NONE (r_pobj) of_20\IN|differentiate (r_prep) effects_19\NNS|NONE (r_pobj) to_16\TO|follow||warrant (r_prep) up_15\NN|both|liver|and (l_compound) warrant_12\NN|follow||to (l_compound) lymphoma_11\NN|NONE
3895875
D008012_D009203 NONE lidocaine_1\NN|NONE (l_prep) in_2\IN|Prophylactic|. (l_pobj) phase_5\NN|NONE (l_prep) of_6\IN|early|the (l_pobj) infarction_9\NN|NONE
D008012_D009203 NONE lidocaine_25\NN|NONE (r_pobj) of_24\IN|blind|randomized|a (r_prep) trial_23\NN|.|patients (r_dobj) entered_17\VBD|NONE (l_nsubj) patients_3\NNS|trial|. (l_prep) with_4\IN|two (l_pobj) infarction_7\NN|NONE
D008012_D009203 NONE lidocaine_3\NN|average|The|after (r_compound) level_4\NN|for|.|higher (l_prep) after_7\IN|average|The|lidocaine (l_pobj) administration_8\NN|minutes (l_prep) for_9\IN|NONE (l_pobj) patients_10\NNS|NONE (l_prep) without_11\IN|NONE (l_pobj) infarction_14\NN|NONE
D008012_D009203 NONE lidocaine_7\NN|NONE (r_pobj) of_6\IN|the (r_prep) administration_5\NN|We|not|in|.|prophylactically|can (r_dobj) advocate_3\VB|NONE (l_prep) in_9\IN|We|not|.|administration|prophylactically|can (l_pobj) hours_12\NNS|NONE (l_prep) of_13\IN|early|the (l_pobj) infarction_16\NN|NONE
D008012_D007238 NONE lidocaine_3\NN|average|The|after (r_compound) level_4\NN|for|.|higher (r_nsubj) was_15\VBD|NONE (l_prep) for_20\IN|.|higher|level (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|NONE (l_pobj) infarction_25\NN|NONE
D008012_D006323 NONE lidocaine_19\NN|the (r_compound) group_20\NN|NONE (r_pobj) in_17\IN|significantly (r_prep) greater_16\JJR|During|,|incidence (r_acomp) was_14\VBD|,|died|in|hypotension|and|, (r_ccomp) occurred_23\VBD|NONE (l_conj) died_38\VBD|was|,|in|hypotension|and|, (l_prep) from_39\IN|,|patients|had|. (l_pobj) asystole_40\NN|NONE
D008012_D006323 NONE lidocaine_33\NN|had|nine (r_dobj) received_32\VBN||, (r_relcl) patients_26\NNS|NONE (r_pobj) in_24\IN|was|,|died|hypotension|and|, (r_prep) occurred_23\VBD|NONE (l_conj) died_38\VBD|was|,|in|hypotension|and|, (l_prep) from_39\IN|,|patients|had|. (l_pobj) asystole_40\NN|NONE
D008012_D006323 NONE lidocaine_47\NN|had|three (r_dobj) had_46\VBN|,|from|patients|. (r_conj) died_38\VBD|was|,|in|hypotension|and|, (l_prep) from_39\IN|,|patients|had|. (l_pobj) asystole_40\NN|NONE
D008012_D017180 NONE Lidocaine_0\NN|,|.|not|,|,|)|tachycardia|given|did|was (r_nsubj) prevent_17\VB|NONE (l_dobj) tachycardia_20\NN|,|.|not|,|,|Lidocaine|)|given|did|was
D008012_D017180 NONE lidocaine_45\NN|NONE (r_pobj) of_44\IN|the|. (r_prep) administration_43\NN|minutes (r_pobj) after_41\IN|although|reduction|there (r_prep) was_24\VBD|,|.|not|,|,|Lidocaine|)|tachycardia|given|did (r_advcl) prevent_17\VB|NONE (l_dobj) tachycardia_20\NN|,|.|not|,|,|Lidocaine|)|given|did|was
D008012_D001145 NONE Lidocaine_0\NN|,|.|not|,|,|)|tachycardia|given|did|was (r_nsubj) prevent_17\VB|NONE (l_advcl) was_24\VBD|,|.|not|,|,|Lidocaine|)|tachycardia|given|did (l_attr) reduction_27\NN|although|after|there (l_prep) in_28\IN|a|significant (l_pobj) number_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN|NONE (l_pcomp) warning_34\VBG|NONE (l_dobj) arrhythmias_35\NNS|NONE
D008012_D001145 NONE lidocaine_45\NN|NONE (r_pobj) of_44\IN|the|. (r_prep) administration_43\NN|minutes (r_pobj) after_41\IN|although|reduction|there (r_prep) was_24\VBD|,|.|not|,|,|Lidocaine|)|tachycardia|given|did (l_attr) reduction_27\NN|although|after|there (l_prep) in_28\IN|a|significant (l_pobj) number_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN|NONE (l_pcomp) warning_34\VBG|NONE (l_dobj) arrhythmias_35\NNS|NONE
D008012_D007022 CID lidocaine_19\NN|the (r_compound) group_20\NN|NONE (r_pobj) in_17\IN|significantly (r_prep) greater_16\JJR|During|,|incidence (r_acomp) was_14\VBD|,|died|in|hypotension|and|, (r_ccomp) occurred_23\VBD|NONE (l_nsubj) hypotension_22\NN|was|,|died|in|and|,
D008012_D007022 CID lidocaine_33\NN|had|nine (r_dobj) received_32\VBN||, (r_relcl) patients_26\NNS|NONE (r_pobj) in_24\IN|was|,|died|hypotension|and|, (r_prep) occurred_23\VBD|NONE (l_nsubj) hypotension_22\NN|was|,|died|in|and|,
D008012_D007022 CID lidocaine_47\NN|had|three (r_dobj) had_46\VBN|,|from|patients|. (r_conj) died_38\VBD|was|,|in|hypotension|and|, (r_conj) occurred_23\VBD|NONE (l_nsubj) hypotension_22\NN|was|,|died|in|and|,
16880771
D004298_D020521 NONE dopamine_3\NN|NONE (r_compound) precursor_4\NN|the (r_compound) levodopa_5\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|learning|. (r_nsubj) enhances_6\VBZ|NONE (l_dobj) learning_7\VBG|Administration|. (l_prep) in_8\IN|NONE (l_pobj) subjects_10\NNS|NONE (l_conj) patients_13\NNS|healthy|and (l_compound) stroke_12\NN|NONE
D004298_D020521 NONE dopamine_12\NN|by|learning (r_nsubj) enhances_13\VBZ|critical|the (l_dobj) learning_15\NN|by|dopamine (l_prep) in_16\IN|associative (l_pobj) subjects_18\NNS|NONE (l_conj) patients_21\NNS|and|healthy (l_compound) stroke_20\NN|NONE
D007980_D020521 NONE levodopa_5\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|learning|. (r_nsubj) enhances_6\VBZ|NONE (l_dobj) learning_7\VBG|Administration|. (l_prep) in_8\IN|NONE (l_pobj) subjects_10\NNS|NONE (l_conj) patients_13\NNS|healthy|and (l_compound) stroke_12\NN|NONE
D004298_D007859 NONE dopamine_1\NN|The (r_compound) agonist_2\NN|significantly (r_nsubj) impaired_4\JJ|compared|.|word (r_amod) learning_7\NN|NONE
7248895
D003520_D006869 NONE cyclophosphamide_23\NN|NONE (r_pobj) wtih_22\IN|being|for|for (r_prep) treated_18\VBN|NONE (r_pcomp) after_16\IN|woman|.|hematuria (r_prep) had_13\VBD|NONE (l_nsubj) woman_4\NN|.|after|hematuria (l_prep) with_5\IN|A|old (l_pobj) hydroureteronephrosis_7\NN|NONE
D003520_D006869 NONE cyclophosphamide_21\NN|NONE (r_pobj) to_20\IN|tract|urinary|upper (r_prep) epithelium_19\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) exposure_14\NN|NONE (r_dobj) intensified_13\VBN|that|and|stasis (r_conj) prolonged_11\VBN|.|association (r_ccomp) suggests_8\VBZ|NONE (l_nsubj) association_1\NN|.|prolonged (l_prep) with_5\IN|The|of (l_pobj) hydroureteronephrosis_7\NN|NONE
D003520_D006417 CID cyclophosphamide_23\NN|NONE (r_pobj) wtih_22\IN|being|for|for (r_prep) treated_18\VBN|NONE (r_pcomp) after_16\IN|woman|.|hematuria (r_prep) had_13\VBD|NONE (l_dobj) hematuria_15\NN|woman|.|after
D003520_D020293 NONE cyclophosphamide_23\NN|NONE (r_pobj) wtih_22\IN|being|for|for (r_prep) treated_18\VBN|NONE (l_prep) for_24\IN|being|for|wtih (l_pobj) vasculitis_26\NN|NONE
D003520_D014571 NONE cyclophosphamide_4\NN|NONE (r_pobj) of_3\IN|cause|the (r_prep) ability_2\NN|Although|known (r_nsubj) is_18\VBZ|,|it (r_advcl) is_23\VBZ|widely|.|associated (r_auxpass) appreciated_26\VBN|NONE (l_ccomp) associated_31\VBN|widely|.|is (l_prep) with_32\IN|also|is|it|that (l_pobj) carcinoma_33\NN|NONE (l_prep) of_34\IN|NONE (l_pobj) tract_37\NN|NONE
D003520_D014571 NONE cyclophosphamide_11\JJ|for (r_compound) treatment_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) association_9\NN|NONE (r_pobj) in_8\IN|NONE (r_prep) reported_7\VBN|urinary|tract|third|the (r_acl) cancer_6\NN|It|.
D003520_-1 NONE cyclophosphamide_8\NN|term (r_compound) treatment_9\NN|NONE (r_pobj) for_4\IN|NONE (r_prep) candidates_3\NNS|who (r_attr) are_2\VBP|NONE (r_relcl) Patients_0\NNS|be|routinely|for|should|. (r_nsubjpass) evaluated_13\VBN|NONE (l_prep) for_14\IN|be|routinely|should|Patients|. (l_pobj) uropathy_16\NN|NONE
D003520_D010386 NONE cyclophosphamide_7\NN|NONE (r_compound) therapy_8\NN|for (r_dobj) following_6\VBG|renal|the (r_prep) pelvis_5\NN|NONE
D003520_D010386 NONE cyclophosphamide_15\NN|NONE (r_compound) treatment_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) association_13\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) reported_11\VBD|renal|the (r_acl) pelvis_10\NN|NONE
D003520_D006470 NONE cyclophosphamide_4\NN|NONE (r_pobj) of_3\IN|cause|the (r_prep) ability_2\NN|Although|known (l_acl) cause_6\VB|of|the (l_dobj) cystitis_8\NN|to|and|urine
D003520_D002277 CID cyclophosphamide_4\NN|NONE (r_pobj) of_3\IN|cause|the (r_prep) ability_2\NN|Although|known (l_acl) cause_6\VB|of|the (l_conj) urine_10\NN|cystitis|to|and (l_dobj) abnormalities_12\NNS|NONE (l_amod) indistinguishable_13\JJ|cytologic (l_prep) from_14\IN|NONE (l_pobj) carcinoma_17\NN|NONE
D003520_D003556 NONE cyclophosphamide_4\NN|NONE (r_pobj) of_3\IN|cause|the (r_prep) ability_2\NN|Although|known (l_acl) cause_6\VB|of|the (l_dobj) cystitis_8\NN|to|and|urine
D003520_D009369 NONE cyclophosphamide_21\NN|NONE (r_pobj) to_20\IN|tract|urinary|upper (r_prep) epithelium_19\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) exposure_14\NN|NONE (r_dobj) intensified_13\VBN|that|and|stasis (r_conj) prolonged_11\VBN|.|association (r_ccomp) suggests_8\VBZ|NONE (l_nsubj) association_1\NN|.|prolonged (l_prep) of_2\IN|The|with (l_pobj) tumor_4\NN|NONE
24345882
D008727_D054198 NONE methotrexate_20\JJ|a (r_compound) consequence_21\NN|P|protocols|and|standard|:|)|( (r_appos) risk_3\NN|? (l_appos) protocols_14\NNS|P|consequence|and|standard|:|)|( (l_compound) leukemia_13\NN|ACCL|lymphoblastic|(|acute|)
D008727_D054198 NONE methotrexate_5\NN|in|MTX (r_nmod) neurotoxicity_9\NN|NONE (r_pobj) about_1\IN|NONE (r_prep) Concerns_0\NNS|to|. (r_nsubj) led_13\VBD|NONE (l_prep) to_14\IN|Concerns|. (l_pobj) modifications_15\NNS|NONE (l_prep) in_16\IN|NONE (l_pobj) therapy_21\NN|NONE (l_conj) rescue_24\NN|(|,|IT|intrathecal|) (l_conj) frequency_27\NN|,|leucovorin|and (l_prep) in_32\IN|of (l_pobj) children_33\NNS|NONE (l_prep) with_34\IN|NONE (l_pobj) leukemia_37\NN|NONE
D008727_D054198 NONE MTX_7\NNP|in|methotrexate (r_nmod) neurotoxicity_9\NN|NONE (r_pobj) about_1\IN|NONE (r_prep) Concerns_0\NNS|to|. (r_nsubj) led_13\VBD|NONE (l_prep) to_14\IN|Concerns|. (l_pobj) modifications_15\NNS|NONE (l_prep) in_16\IN|NONE (l_pobj) therapy_21\NN|NONE (l_conj) rescue_24\NN|(|,|IT|intrathecal|) (l_conj) frequency_27\NN|,|leucovorin|and (l_prep) in_32\IN|of (l_pobj) children_33\NNS|NONE (l_prep) with_34\IN|NONE (l_pobj) leukemia_37\NN|NONE
D008727_D054198 NONE MTX_30\NNP|systemic (r_compound) administration_31\NN|NONE (r_pobj) of_28\IN|in (r_prep) frequency_27\NN|,|leucovorin|and (l_prep) in_32\IN|of (l_pobj) children_33\NNS|NONE (l_prep) with_34\IN|NONE (l_pobj) leukemia_37\NN|NONE
D008727_D020258 NONE methotrexate_5\NN|in|MTX (r_nmod) neurotoxicity_9\NN|NONE
D008727_D020258 NONE MTX_7\NNP|in|methotrexate (r_nmod) neurotoxicity_9\NN|NONE
D008727_D020258 NONE MTX_30\NNP|systemic (r_compound) administration_31\NN|NONE (r_pobj) of_28\IN|in (r_prep) frequency_27\NN|,|leucovorin|and (r_conj) rescue_24\NN|(|,|IT|intrathecal|) (r_conj) therapy_21\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) modifications_15\NNS|NONE (r_pobj) to_14\IN|Concerns|. (r_prep) led_13\VBD|NONE (l_nsubj) Concerns_0\NNS|to|. (l_prep) about_1\IN|NONE (l_pobj) neurotoxicity_9\NN|NONE
18945509
D005913_D003324 NONE glipizide_36\NN|NONE (r_pobj) with_35\IN|.|was|P=.|and|;|)|.fold|, (r_prep) 2-fold_27\JJ|associated|of|The|.|; (r_appos) hazard_1\NN|NONE (l_prep) of_2\IN|fold|associated|The|.|; (l_pcomp) developing_3\VBG|NONE (l_dobj) CAD_4\NNP|NONE
D005913_D003324 NONE glipizide_9\NN|or (r_conj) glibenclamide_7\NN|NONE (r_pobj) with_6\IN| (r_prep) diabetes_5\NNS|treatment (r_dobj) Initiating_0\VBG|.|with|is (r_csubjpass) associated_11\VBN|NONE (l_prep) with_12\IN|.|is|Initiating (l_pobj) risk_14\NN|NONE (l_prep) of_15\IN|increased|in (l_pobj) CAD_16\NNP|NONE
D005907_D003324 NONE gliclazide_20\VB|NONE (r_pobj) to_19\TO|NONE (r_prep) comparison_18\NN|NONE (r_pobj) in_17\IN|of|increased (r_prep) risk_14\NN|NONE (l_prep) of_15\IN|increased|in (l_pobj) CAD_16\NNP|NONE
-1_D003924 NONE sulphonylurea_8\JJ|of|initial (r_compound) treatment_9\NN|NONE (l_prep) of_10\IN|initial|sulphonylurea (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) diabetes_15\NNS|NONE
-1_D003924 NONE sulphonylureas_25\NNS|NONE (r_pobj) with_23\IN| (r_prep) diabetes_22\NNS|disease
C057619_D003924 NONE glimepiride_22\NN|or (r_conj) gliclazide_20\VB|NONE (r_pobj) to_19\TO|NONE (r_prep) comparison_18\NN|NONE (r_pobj) in_17\IN|of|increased (r_prep) risk_14\NN|NONE (r_pobj) with_12\IN|.|is|Initiating (r_prep) associated_11\VBN|NONE (l_csubjpass) Initiating_0\VBG|.|with|is (l_dobj) diabetes_5\NNS|treatment
D005907_D003924 NONE gliclazide_20\VB|NONE (r_pobj) to_19\TO|NONE (r_prep) comparison_18\NN|NONE (r_pobj) in_17\IN|of|increased (r_prep) risk_14\NN|NONE (r_pobj) with_12\IN|.|is|Initiating (r_prep) associated_11\VBN|NONE (l_csubjpass) Initiating_0\VBG|.|with|is (l_dobj) diabetes_5\NNS|treatment
-1_D003324 NONE sulphonylurea_8\JJ|of|initial (r_compound) treatment_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|artery|coronary (r_acl) disease_4\NN|NONE
-1_D003324 NONE sulphonylureas_25\NNS|NONE (r_pobj) with_23\IN| (r_prep) diabetes_22\NNS|disease (r_dobj) developing_8\VBG|NONE (l_dobj) disease_11\NN|diabetes
-1_D003324 NONE sulphonylureas_25\NNS|NONE (r_pobj) with_23\IN| (r_prep) diabetes_22\NNS|disease (r_dobj) developing_8\VBG|NONE (l_dobj) disease_11\NN|diabetes (l_appos) CAD_13\NNP|artery|)|(|coronary|associated
D005905_D003324 CID glibenclamide_25\NN|NONE (r_pobj) with_24\IN|by (r_prep) increased_14\VBN|initial (r_acl) treatment_13\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBN|fold|of|The|.|; (r_acl) hazard_1\NN|NONE (l_prep) of_2\IN|fold|associated|The|.|; (l_pcomp) developing_3\VBG|NONE (l_dobj) CAD_4\NNP|NONE
D005905_D003324 CID glibenclamide_7\NN|NONE (r_pobj) with_6\IN| (r_prep) diabetes_5\NNS|treatment (r_dobj) Initiating_0\VBG|.|with|is (r_csubjpass) associated_11\VBN|NONE (l_prep) with_12\IN|.|is|Initiating (l_pobj) risk_14\NN|NONE (l_prep) of_15\IN|increased|in (l_pobj) CAD_16\NNP|NONE
C057619_D003324 NONE glimepiride_22\NN|or (r_conj) gliclazide_20\VB|NONE (r_pobj) to_19\TO|NONE (r_prep) comparison_18\NN|NONE (r_pobj) in_17\IN|of|increased (r_prep) risk_14\NN|NONE (l_prep) of_15\IN|increased|in (l_pobj) CAD_16\NNP|NONE
D005913_D003924 NONE glipizide_9\NN|or (r_conj) glibenclamide_7\NN|NONE (r_pobj) with_6\IN| (r_prep) diabetes_5\NNS|treatment
D005905_D003924 NONE glibenclamide_7\NN|NONE (r_pobj) with_6\IN| (r_prep) diabetes_5\NNS|treatment
D008687_D003324 NONE metformin_53\NN|NONE (r_pobj) with_52\IN|NONE (r_prep) unchanged_51\JJ|NONE (r_acomp) was_50\VBD|.|P=.|and|;|)|.fold|,|with (r_conj) 2-fold_27\JJ|associated|of|The|.|; (r_appos) hazard_1\NN|NONE (l_prep) of_2\IN|fold|associated|The|.|; (l_pcomp) developing_3\VBG|NONE (l_dobj) CAD_4\NNP|NONE
15627798
D005839_D005355 NONE gentamicin_3\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) treated_1\VBN|NONE (r_acl) Animals_0\NNS|.|can|areas (r_nsubj) show_5\VB|NONE (l_dobj) areas_7\NNS|.|can|Animals (l_prep) of_8\IN|residual|in (l_pobj) fibrosis_10\NN|NONE
D005839_D009395 CID gentamicin_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|tubulointerstitial (r_acl) nephritis_9\NN|.|Inhibition
D005839_D009395 CID gentamicin_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|that|nephritis|inhibition (r_advcl) attenuates_10\VBZ|.|data (l_dobj) nephritis_12\NN|induced|that|inhibition
16731636
D007545_D006332 CID isoproterenol_1\NN| (r_npadvmod) induced_3\VBN|.|Enhanced|in|cardiac (r_amod) hypertrophy_5\NN|NONE
D007545_D006332 CID Iso_4\NNP|NONE (r_compound) treatment_5\NN|NONE (r_pobj) by_3\IN|hypertrophy (r_agent) induced_2\VBN|NONE (l_nsubj) hypertrophy_1\NN|by
6985498
D008733_D041881 NONE methoxyflurane_10\NN|developed (r_compound) anesthesia_11\NN|NONE (r_pobj) under_9\IN|for (r_prep) operated_5\VBN|A|old|. (l_prep) for_6\IN|under (l_pobj) cholecystitis_8\NN|NONE
D008733_D056486 CID methoxyflurane_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) anesthesia_6\NN|NONE (r_pobj) after_5\IN|tubular|renal (r_prep) acidosis_4\NN|and|. (r_conj) Hepatitis_0\NNP|NONE
D008733_D000141 CID methoxyflurane_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) anesthesia_6\NN|NONE (r_pobj) after_5\IN|tubular|renal (r_prep) acidosis_4\NN|and|.
D008733_D000141 CID methoxyflurane_10\NN|developed (r_compound) anesthesia_11\NN|NONE (l_acl) developed_12\VBD|methoxyflurane (l_dobj) syndrome_17\NN|postoperatively (l_conj) acidosis_21\NN|a|insufficiency|and
D008733_D048550 NONE methoxyflurane_10\NN|developed (r_compound) anesthesia_11\NN|NONE (l_acl) developed_12\VBD|methoxyflurane (l_dobj) syndrome_17\NN|postoperatively
8819482
C082828_D023921 NONE CD-832_7\NNP|NONE (r_punct) ,_8\,|on|of|. (r_punct) Effects_0\NNS|NONE (l_prep) on_9\IN|of|,|. (l_pobj) ischemia_14\NN|NONE (l_prep) in_15\IN|induced|myocardial (l_pobj) dogs_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) stenosis_20\NN|NONE
C082828_D023921 NONE CD-832_2\NNP|NONE (r_pobj) of_1\IN|on (r_prep) Effects_0\NNS|ischemia|.|compared|in|were (r_nsubjpass) studied_10\VBN|NONE (l_prep) in_11\IN|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) stenosis_16\NN|NONE
D007545_D017202 CID isoproterenol_10\NN| (r_npadvmod) induced_12\VBN|in|myocardial (r_amod) ischemia_14\NN|NONE
D007545_D017202 CID isoproterenol_4\NN|NONE (r_pobj) on_3\IN|of (r_prep) Effects_0\NNS|ischemia|.|compared|in|were (r_nsubjpass) studied_10\VBN|NONE (l_nsubjpass) ischemia_8\NN|Effects|.|compared|in|were
D007545_D017202 CID ISO)-induced_6\VBN|myocardial (r_nmod) ischemia_8\NN|Effects|.|compared|in|were
D007545_D017202 CID ISO_9\NN|with (r_compound) infusion_10\NN|NONE (r_pobj) during_8\IN|CD|that|and|ischemia|suggest (r_prep) improves_5\VBZ|data|. (l_dobj) ischemia_7\NN|CD|that|during|and|suggest
D007545_D023921 NONE isoproterenol_10\NN| (r_npadvmod) induced_12\VBN|in|myocardial (r_amod) ischemia_14\NN|NONE (l_prep) in_15\IN|induced|myocardial (l_pobj) dogs_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) stenosis_20\NN|NONE
D007545_D023921 NONE isoproterenol_4\NN|NONE (r_pobj) on_3\IN|of (r_prep) Effects_0\NNS|ischemia|.|compared|in|were (r_nsubjpass) studied_10\VBN|NONE (l_prep) in_11\IN|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) stenosis_16\NN|NONE
D007545_D023921 NONE ISO)-induced_6\VBN|myocardial (r_nmod) ischemia_8\NN|Effects|.|compared|in|were (r_nsubjpass) studied_10\VBN|NONE (l_prep) in_11\IN|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) stenosis_16\NN|NONE
D007545_D023921 NONE ISO_12\NNP|intracoronary (r_compound) infusion_13\NN|NONE (r_pobj) of_10\IN|min|min (r_prep) periods_9\NNS|rate|In|,|. (r_nsubj) increased_22\VBN|NONE (l_prep) In_0\IN|rate|periods|,|. (l_pobj) presence_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) stenosis_6\NN|NONE
D007545_D003251 NONE ISO_3\NN|with (r_compound) infusion_4\NN|,|After|CD|doses|was (l_prep) with_5\IN|ISO (l_pobj) stenosis_6\NN|NONE
D007545_D003251 NONE ISO_64\NN|with (r_compound) infusion_65\NN|NONE (l_prep) with_66\IN|ISO (l_pobj) stenosis_67\NN|NONE
D007545_D003251 NONE ISO_60\NN|with (r_compound) infusion_61\NN|NONE (l_prep) with_62\IN|ISO (l_pobj) stenosis_63\NN|NONE
D007545_D003251 NONE ISO_9\NN|with (r_compound) infusion_10\NN|NONE (l_prep) with_11\IN|ISO (l_pobj) stenosis_12\NN|NONE
D004110_D003251 NONE Diltiazem_0\NNP|to|decrease|.|and|(|elevation|micrograms|also (r_nsubj) prevented_10\VBD|NONE (l_conj) elevation_40\NN|to|decrease|.|and|Diltiazem|(|micrograms|also (l_prep) from_41\IN|segment (l_prep) at_56\IN|mV|to (l_pobj) min_58\NN|NONE (l_prep) after_59\IN| (l_pobj) infusion_61\NN|NONE (l_prep) with_62\IN|ISO (l_pobj) stenosis_63\NN|NONE
D009543_D023921 NONE nifedipine_30\NN|NONE (r_pobj) for_29\IN|NONE (r_prep) those_28\DT|NONE (r_pobj) with_27\IN|were (r_prep) compared_26\VBN|Effects|ischemia|.|in|were (r_prep) studied_10\VBN|NONE (l_prep) in_11\IN|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) stenosis_16\NN|NONE
C082828_D017202 NONE CD-832_7\NNP|NONE (r_punct) ,_8\,|on|of|. (r_punct) Effects_0\NNS|NONE (l_prep) on_9\IN|of|,|. (l_pobj) ischemia_14\NN|NONE
C082828_D017202 NONE CD-832_2\NNP|NONE (r_pobj) of_1\IN|on (r_prep) Effects_0\NNS|ischemia|.|compared|in|were (r_nsubjpass) studied_10\VBN|NONE (l_nsubjpass) ischemia_8\NN|Effects|.|compared|in|were
C082828_D017202 NONE CD-832_4\NNP|that|during|and|ischemia|suggest (r_nsubj) improves_5\VBZ|data|. (l_dobj) ischemia_7\NN|CD|that|during|and|suggest
C082828_D017202 NONE CD-832_21\NNP|property|in|role|that (r_punct) plays_22\VBZ|NONE (r_ccomp) suggest_14\VBP|CD|that|during|and|ischemia (r_conj) improves_5\VBZ|data|. (l_dobj) ischemia_7\NN|CD|that|during|and|suggest
C082828_D017202 NONE CD-832_31\NNP|NONE (r_pobj) of_30\IN|the|beneficial (r_prep) effects_29\NNS|NONE (r_pobj) in_26\IN|CD|property|role|that (r_prep) plays_22\VBZ|NONE (r_ccomp) suggest_14\VBP|CD|that|during|and|ischemia (r_conj) improves_5\VBZ|data|. (l_dobj) ischemia_7\NN|CD|that|during|and|suggest
D009543_D017202 NONE nifedipine_30\NN|NONE (r_pobj) for_29\IN|NONE (r_prep) those_28\DT|NONE (r_pobj) with_27\IN|were (r_prep) compared_26\VBN|Effects|ischemia|.|in|were (r_prep) studied_10\VBN|NONE (l_nsubjpass) ischemia_8\NN|Effects|.|compared|in|were
C082828_D003251 NONE CD-832_13\NNP|,|After|doses|was|infusion (r_punct) performed_8\VBN|NONE (l_nsubjpass) infusion_4\NN|,|After|CD|doses|was (l_prep) with_5\IN|ISO (l_pobj) stenosis_6\NN|NONE
C082828_D003251 NONE CD-832_5\NNP|and|decrease|In|elevation|.|, (r_nsubj) prevented_14\VBD|NONE (l_conj) elevation_44\NN|and|decrease|In|CD|.|, (l_prep) at_60\IN|from|to|segment (l_pobj) min_62\NN|NONE (l_prep) after_63\IN| (l_pobj) infusion_65\NN|NONE (l_prep) with_66\IN|ISO (l_pobj) stenosis_67\NN|NONE
C082828_D003251 NONE CD-832_4\NNP|that|during|and|ischemia|suggest (r_nsubj) improves_5\VBZ|data|. (l_prep) during_8\IN|CD|that|and|ischemia|suggest (l_pobj) infusion_10\NN|NONE (l_prep) with_11\IN|ISO (l_pobj) stenosis_12\NN|NONE
C082828_D003251 NONE CD-832_21\NNP|property|in|role|that (r_punct) plays_22\VBZ|NONE (r_ccomp) suggest_14\VBP|CD|that|during|and|ischemia (r_conj) improves_5\VBZ|data|. (l_prep) during_8\IN|CD|that|and|ischemia|suggest (l_pobj) infusion_10\NN|NONE (l_prep) with_11\IN|ISO (l_pobj) stenosis_12\NN|NONE
C082828_D003251 NONE CD-832_31\NNP|NONE (r_pobj) of_30\IN|the|beneficial (r_prep) effects_29\NNS|NONE (r_pobj) in_26\IN|CD|property|role|that (r_prep) plays_22\VBZ|NONE (r_ccomp) suggest_14\VBP|CD|that|during|and|ischemia (r_conj) improves_5\VBZ|data|. (l_prep) during_8\IN|CD|that|and|ischemia|suggest (l_pobj) infusion_10\NN|NONE (l_prep) with_11\IN|ISO (l_pobj) stenosis_12\NN|NONE
D004110_D017202 NONE diltiazem_32\NN|or (r_conj) nifedipine_30\NN|NONE (r_pobj) for_29\IN|NONE (r_prep) those_28\DT|NONE (r_pobj) with_27\IN|were (r_prep) compared_26\VBN|Effects|ischemia|.|in|were (r_prep) studied_10\VBN|NONE (l_nsubjpass) ischemia_8\NN|Effects|.|compared|in|were
D009543_D003251 NONE nifedipine_3\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) contrast_1\NN|NONE (r_pobj) In_0\IN|and|decrease|CD|elevation|.|, (r_prep) prevented_14\VBD|NONE (l_conj) elevation_44\NN|and|decrease|In|CD|.|, (l_prep) at_60\IN|from|to|segment (l_pobj) min_62\NN|NONE (l_prep) after_63\IN| (l_pobj) infusion_65\NN|NONE (l_prep) with_66\IN|ISO (l_pobj) stenosis_67\NN|NONE
D002118_D023921 NONE calcium_4\NN|a|new|, (r_compound) antagonist_5\NN|NONE (r_pobj) of_1\IN|on|,|. (r_prep) Effects_0\NNS|NONE (l_prep) on_9\IN|of|,|. (l_pobj) ischemia_14\NN|NONE (l_prep) in_15\IN|induced|myocardial (l_pobj) dogs_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) stenosis_20\NN|NONE
D004110_D023921 NONE diltiazem_32\NN|or (r_conj) nifedipine_30\NN|NONE (r_pobj) for_29\IN|NONE (r_prep) those_28\DT|NONE (r_pobj) with_27\IN|were (r_prep) compared_26\VBN|Effects|ischemia|.|in|were (r_prep) studied_10\VBN|NONE (l_prep) in_11\IN|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) stenosis_16\NN|NONE
D002118_D017202 NONE calcium_4\NN|a|new|, (r_compound) antagonist_5\NN|NONE (r_pobj) of_1\IN|on|,|. (r_prep) Effects_0\NNS|NONE (l_prep) on_9\IN|of|,|. (l_pobj) ischemia_14\NN|NONE
12165618
D019469_D015658 NONE indinavir_18\NNS|NONE (r_pobj) with_17\IN|NONE (r_prep) treated_16\VBN|infected (r_acl) children_15\NNS|.|leukocyturia|with|is (l_amod) 1-infected_14\VBN|treated
D019469_D015658 NONE indinavir_5\NNS| (r_npadvmod) related_7\VBN|NONE (r_amod) nephrotoxicity_8\NN|in|to (r_dobj) monitor_4\VB|A|.|prospective (l_prep) in_9\IN|nephrotoxicity|to (l_pobj) cohort_11\NN|NONE (l_prep) of_12\IN|a (l_pobj) children_19\NNS|NONE (l_amod) 1-infected_18\VBN|treated|type
D019469_D015658 NONE indinavir_22\NNS|NONE (r_pobj) with_21\IN|NONE (r_prep) treated_20\VBN|type|infected (r_acl) children_19\NNS|NONE (l_amod) 1-infected_18\VBN|treated|type
D019469_-1 NONE indinavir_18\NNS|NONE (r_pobj) with_17\IN|NONE (r_prep) treated_16\VBN|infected (r_acl) children_15\NNS|.|leukocyturia|with|is (r_dobj) associated_4\VBN|NONE (l_nsubjpass) leukocyturia_2\NN|.|with|children|is
D019469_-1 NONE indinavir_30\NNS|NONE (r_pobj) of_29\IN|a|serum|peak (r_prep) level_28\NN|/||mg|x|or|h (r_conj) L_21\NN|NONE (r_appos) >_17\XX|was|incidence|in (r_meta) found_8\VBN|NONE (l_nsubjpass) incidence_3\NN|was|in|> (l_prep) of_4\IN|higher|A|cumulative (l_pobj) leukocyturia_6\NN|NONE
D019469_-1 NONE indinavir_3\NNS|NONE (r_pobj) with_2\IN|Children (r_prep) treated_1\VBN|incidence|. (r_csubj) have_4\VBP|NONE (l_dobj) incidence_8\NN|treated|. (l_prep) of_9\IN|a|high|cumulative (l_pobj) leukocyturia_12\NN|NONE
D019469_-1 NONE Indinavir_0\NNP| (r_npadvmod) associated_2\VBN|NONE (r_amod) nephrotoxicity_3\NN|in|be|,|closely|age|must (r_nsubjpass) monitored_6\VBN|NONE (l_prep) in_10\IN|be|,|nephrotoxicity|closely|age|must (l_pobj) children_11\NNS|especially (l_prep) with_12\IN|NONE (l_pobj) factors_14\NNS|NONE (l_prep) as_16\IN|risk (l_pobj) leukocyturia_19\NN|such
D019469_-1 NONE indinavir_32\NNS|NONE (r_pobj) of_31\IN|the (r_prep) curve_30\NN|NONE (r_pobj) under_28\IN|an (r_prep) area_27\NN|years|<|, (r_appos) age_21\NN|in|be|,|nephrotoxicity|closely|must (r_appos) monitored_6\VBN|NONE (l_prep) in_10\IN|be|,|nephrotoxicity|closely|age|must (l_pobj) children_11\NNS|especially (l_prep) with_12\IN|NONE (l_pobj) factors_14\NNS|NONE (l_prep) as_16\IN|risk (l_pobj) leukocyturia_19\NN|such
D003404_-1 NONE creatinine_15\NN|albumin (r_compound) ratio_16\NN|the (r_appos) urine_12\NN|by|and (r_pobj) in_10\IN|a|mild (r_prep) increase_9\NN|NONE (r_pobj) with_6\IN|frequently|.|was|leukocyturia (r_prep) associated_5\VBN|NONE (l_nsubjpass) leukocyturia_2\NN|with|frequently|.|was
D003404_-1 NONE creatinine_9\JJ|serum|of (r_compound) levels_10\NNS|without|Children|.|frequently (r_dobj) had_7\VBD|NONE (l_nsubj) Children_0\NNS|without|levels|.|frequently (l_prep) with_1\IN|NONE (l_pobj) leukocyturia_4\NN|NONE
D003404_-1 NONE creatinine_9\JJ|serum|of (r_compound) levels_10\NNS|without|Children|.|frequently (r_dobj) had_7\VBD|NONE (l_prep) without_19\IN|levels|Children|.|frequently (l_pobj) leukocyturia_22\NN|NONE
D003404_-1 NONE creatinine_4\NN|serum|the (r_compound) levels_5\NNS|Subsequently|,|,|returned (r_nsubj) decreased_6\VBD|NONE (l_conj) returned_14\VBD|Subsequently|levels|,|, (l_conj) disappeared_21\VBD|,|to|ratios|and (l_nsubj) leukocyturia_20\NN|.|within
D003404_-1 NONE creatinine_12\NN|albumin|urine (r_compound) ratios_13\NNS|,|to|and|disappeared (r_nsubj) returned_14\VBD|Subsequently|levels|,|, (l_conj) disappeared_21\VBD|,|to|ratios|and (l_nsubj) leukocyturia_20\NN|.|within
D003404_-1 NONE creatinine_12\NN|serum|of (r_compound) levels_13\NNS|NONE (r_pobj) in_10\IN|above|an (r_prep) increase_9\NN|frequently|Children|. (r_dobj) had_7\VBD|NONE (l_nsubj) Children_0\NNS|frequently|.|increase (l_prep) with_1\IN|NONE (l_pobj) leukocyturia_4\NN|NONE
D003404_D006417 NONE creatinine_15\NN|albumin (r_compound) ratio_16\NN|the (r_appos) urine_12\NN|by|and (r_pobj) in_10\IN|a|mild (l_conj) by_18\IN|and|urine (l_pobj) hematuria_20\NN|NONE
D019469_D007674 CID indinavir_18\NNS|NONE (r_pobj) with_17\IN|NONE (r_prep) treated_16\VBN|infected (r_acl) children_15\NNS|.|leukocyturia|with|is (r_dobj) associated_4\VBN|NONE (l_prep) with_5\IN|.|leukocyturia|children|is (l_pobj) function_8\NN|NONE
D019469_D007674 CID indinavir_5\NNS| (r_npadvmod) related_7\VBN|NONE (r_amod) nephrotoxicity_8\NN|in|to
D019469_D007674 CID indinavir_22\NNS|NONE (r_pobj) with_21\IN|NONE (r_prep) treated_20\VBN|type|infected (r_acl) children_19\NNS|NONE (r_pobj) of_12\IN|a (r_prep) cohort_11\NN|NONE (r_pobj) in_9\IN|nephrotoxicity|to (r_prep) monitor_4\VB|A|.|prospective (l_dobj) nephrotoxicity_8\NN|in|to
D019469_D007674 CID indinavir_4\NNS|was|In|.|of|, (r_nsubjpass) discontinued_6\VBN|NONE (l_prep) of_8\IN|was|In|.|,|indinavir (l_pobj) nephrotoxicity_9\NN|because
D019469_D007674 CID Indinavir_0\NNP| (r_npadvmod) associated_2\VBN|NONE (r_amod) nephrotoxicity_3\NN|in|be|,|closely|age|must
D019469_D007674 CID indinavir_32\NNS|NONE (r_pobj) of_31\IN|the (r_prep) curve_30\NN|NONE (r_pobj) under_28\IN|an (r_prep) area_27\NN|years|<|, (r_appos) age_21\NN|in|be|,|nephrotoxicity|closely|must (r_appos) monitored_6\VBN|NONE (l_nsubjpass) nephrotoxicity_3\NN|in|be|,|closely|age|must
16083708
D019980_D056486 CID clavulanate_2\NNP|out|.|as (r_nsubj) stands_3\VBZ|NONE (l_prep) as_5\IN|out|.|clavulanate (l_pobj) drug_9\NN|NONE (l_acl) related_10\VBN|the|common (l_prep) to_11\IN|NONE (l_pobj) DILI_12\NNP|NONE
D001663_D017114 NONE bilirubin_54\NN|CI|higher|plasma (r_compound) value_55\NN|)|,|P|and|< (r_conj) .009_47\CD|.|.|;|Factors|sex (r_appos) were_9\VBD|NONE (l_nsubj) Factors_0\NNS|.|.|.|;|sex (l_acl) associated_1\VBN|NONE (l_prep) with_2\IN|NONE (l_pobj) development_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) failure_8\NN|NONE
23872883
D007545_D066126 CID isoproterenol_18\NN| (r_npadvmod) induced_20\VBN|in (r_amod) cardiotoxicity_21\NN|NONE
3833372
D013999_D006973 NONE maleate_23\NN|NONE (r_pobj) of_21\IN|mg||and (r_prep) mg_20\NN|NONE (r_dobj) containing_18\VBG|ratio|a|administered|, (r_acl) combination_17\NN|NONE (l_acl) administered_30\VBN|ratio|a|containing|, (l_prep) to_36\IN|daily|for (l_pobj) patients_38\NNS|NONE (l_amod) hypertensive_37\JJ|NONE
D006852_D006973 NONE hydrochlorothiazide_28\NN|NONE (r_pobj) of_27\IN| (r_prep) mg_26\NN|of||and (r_conj) mg_20\NN|NONE (r_dobj) containing_18\VBG|ratio|a|administered|, (r_acl) combination_17\NN|NONE (l_acl) administered_30\VBN|ratio|a|containing|, (l_prep) to_36\IN|daily|for (l_pobj) patients_38\NNS|NONE (l_amod) hypertensive_37\JJ|NONE
25041770
D017291_D012206 CID clarithromycin_9\NN|NONE (r_pobj) in_8\IN|simvastatin (r_prep) increment_7\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) association_2\NN|NONE (r_pobj) in_1\IN|. (r_prep) Rhabdomyolysis_0\NNP|NONE
D017291_D012206 CID clarithromycin_17\NN|NONE (r_pobj) of_16\IN|the (r_prep) dose_15\NN|NONE (r_pobj) in_13\IN|an (r_prep) increase_12\NN|NONE (r_pobj) after_10\IN|only (r_prep) occurred_9\VBD|of|case|. (r_advcl) is_3\VBZ|NONE (l_prep) of_4\IN|occurred|case|. (l_pobj) interest_5\NN|NONE (l_prep) as_6\IN|NONE (l_pobj) rhabdomyolysis_7\NN|NONE
D019821_D012206 CID simvastatin_4\NN|in (r_nmod) increment_7\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) association_2\NN|NONE (r_pobj) in_1\IN|. (r_prep) Rhabdomyolysis_0\NNP|NONE
D019821_D012206 CID statin_10\NN|NONE (r_pobj) with_9\IN|could|,|that|induced|be|warrant|elevation (r_prep) associated_8\VBN|.|case (l_conj) induced_11\VBN|could|,|that|be|warrant|elevation|with (l_dobj) rhabdomyolysis_12\NN|NONE
11835460
D007980_D015835 CID Levodopa_0\NNP|.||dyskinesias (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesias_4\NNS|.|Levodopa|
D007980_D015835 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|ocular (r_amod) dyskinesias_4\NNS|.|uncommon
D007980_D015835 CID levodopa_17\NN|NONE (r_pobj) of_16\IN|the|peak (r_prep) effect_15\NN|NONE (r_pobj) during_12\IN|We|,|and|on|hypothesize|. (r_prep) report_1\VBP|NONE (l_conj) hypothesize_20\VB|We|,|during|and|on|. (l_ccomp) needed_31\VBN|NONE (l_prep) for_32\IN|that|denervation|is (l_pobj) appearance_34\NN|NONE (l_prep) of_35\IN|the (l_pobj) dyskinesias_41\NNS|NONE
D007980_D015835 CID levodopa_37\NN| (r_npadvmod) induce_39\VB|ocular|these (r_amod) dyskinesias_41\NNS|NONE
D007980_D010300 NONE Levodopa_0\NNP|.||dyskinesias (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesias_4\NNS|.|Levodopa| (l_prep) in_5\IN|ocular (l_pobj) disease_8\NN|NONE
9759693
D018170_D017091 CID sumatriptan_3\JJ|NONE (r_amod) use_4\NN|Ischemic|.|and (r_conj) colitis_1\NN|NONE
D018170_D017091 CID sumatriptan_18\NNP|NONE (r_pobj) with_17\IN|NONE (r_prep) treated_16\VBN|NONE (r_acl) migraine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) in_12\IN|the|of (r_prep) development_4\NN|NONE (l_prep) of_5\IN|the|in (l_pobj) cases_8\NNS|NONE (l_prep) of_9\IN|serious| (l_pobj) colitis_11\NN|NONE
D018170_D017202 NONE sumatriptan_16\JJ|NONE (r_compound) use_17\NN|NONE (r_pobj) after_15\IN|NONE (r_prep) occurring_14\VBG|myocardial (r_acl) infarction_13\NN|myocardial|,|and (r_conj) ischemia_9\NN|coronary|,
D018170_D009203 NONE sumatriptan_16\JJ|NONE (r_compound) use_17\NN|NONE (r_pobj) after_15\IN|NONE (r_prep) occurring_14\VBG|myocardial (r_acl) infarction_13\NN|myocardial|,|and
D018170_D008881 NONE sumatriptan_18\NNP|NONE (r_pobj) with_17\IN|NONE (r_prep) treated_16\VBN|NONE (r_acl) migraine_15\NN|NONE
D018170_D003329 NONE sumatriptan_16\JJ|NONE (r_compound) use_17\NN|NONE (r_pobj) after_15\IN|NONE (r_prep) occurring_14\VBG|myocardial (r_acl) infarction_13\NN|myocardial|,|and (r_conj) ischemia_9\NN|coronary|, (r_conj) vasospasm_6\NN|NONE
9382023
D004280_D006973 CID dobutamine_3\NN|NONE (r_compound) stress_4\NN|NONE (r_compound) echocardiography_5\RB|NONE (r_pobj) during_2\IN|Hypertensive|. (r_prep) response_1\NN|NONE (l_amod) Hypertensive_0\JJ|during|.
D004280_D006973 CID dobutamine_2\NN|NONE (r_compound) stress_3\NN|NONE (r_compound) echocardiographic_4\JJ|, (r_amod) studies_5\NNS|NONE (r_pobj) Among_0\IN|,|or|a|,|hypertensive|defined (r_prep) response_9\NN|NONE (l_amod) hypertensive_8\JJ|,|or|a|,|Among|defined
D004280_D006973 CID dobutamine_20\NN|NONE (r_compound) infusion_21\NN|NONE (r_pobj) before_19\IN|BP (r_prep) had_12\VBD|.|often|history|Patients|and (r_conj) had_6\VBD|NONE (l_dobj) history_8\NN|.|had|often|Patients|and (l_prep) of_9\IN|a (l_pobj) hypertension_10\NN|NONE
9125676
D013015_D002311 NONE sotalol_32\NN|patients|prevent|. (r_dobj) received_26\VBD|NONE (l_nsubj) patients_4\NNS|prevent|.|sotalol (l_appos) 54_6\CD|with|consecutive|(|one (l_conj) 20_13\CD|and|,|with (l_prep) with_14\IN|) (l_pobj) cardiomyopathy_16\NN|NONE
D013015_D016171 CID sotalol_32\NN|d (r_pobj) with_27\IN|NONE (r_prep) treated_26\VBN|NONE (r_acl) patients_25\NNS|NONE (r_pobj) in_24\IN|torsades|de (r_prep) pointes_23\FW|NONE (r_pobj) for_20\IN|risk|the|presumable (r_prep) factors_19\NNS|the|of|and|, (r_conj) incidence_9\NN|clinical|the|, (l_prep) of_10\IN|the|and|,|factors (l_pobj) pointes_13\FW|NONE
D013015_D016171 CID sotalol_32\NN|d (r_pobj) with_27\IN|NONE (r_prep) treated_26\VBN|NONE (r_acl) patients_25\NNS|NONE (r_pobj) in_24\IN|torsades|de (r_prep) pointes_23\FW|NONE
D013015_D016171 CID sotalol_21\NN|NONE (r_pobj) with_16\IN|initial|the|oral (r_prep) treatment_15\NN|NONE (r_pobj) during_11\IN|patients|from|. (r_prep) had_6\VBD|NONE (l_prep) from_7\IN|patients|.|during (l_pobj) pointes_10\FW|NONE
D013015_D016171 CID sotalol_10\NN|However|,|dose|,|.|lower|in (r_nsubj) was_11\VBD|NONE (l_prep) in_14\IN|However|sotalol|,|dose|,|.|lower (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) pointes_19\FW|NONE
D013015_D016171 CID sotalol_23\NN|NONE (r_pobj) with_18\IN|successful (r_prep) treatment_17\NN|NONE (r_pobj) of_15\IN| (r_prep) years_14\NNS|NONE (r_pobj) after_12\IN|.|pointes|patient (r_prep) had_7\VBD|NONE (l_dobj) pointes_11\NNS|.|patient|after
D013015_D016171 CID sotalol_17\NN|NONE (r_pobj) of_11\IN|low (r_prep) doses_10\NNS|even (r_pobj) with_8\IN|NONE (r_prep) treatment_6\NN|NONE (r_pobj) during_5\IN|pointes|.|early (r_prep) occurred_3\VBD|NONE (l_nsubj) pointes_2\NNS|during|.|early
D013015_D016171 CID sotalol_26\NN|d|.|might|subgroup|Pronounced|, (r_nsubj) identify_28\VB|NONE (l_dobj) subgroup_30\NN|sotalol|d|.|might|Pronounced|, (l_prep) of_31\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN|NONE (l_pobj) risk_36\NN|NONE (l_prep) for_37\IN|an|increased (l_pobj) pointes_40\FW|NONE
D013015_D016171 CID sotalol_11\NN|,|not|.|patients|did|parameters|at (r_nsubj) identify_14\VB|NONE (l_prep) at_16\IN|,|not|.|sotalol|patients|did|parameters (l_pobj) risk_18\NN|NONE (l_prep) for_19\IN|increased (l_pobj) pointes_22\FW|NONE
D013015_D014693 NONE sotalol_32\NN|patients|prevent|. (r_dobj) received_26\VBD|NONE (l_nsubj) patients_4\NNS|prevent|.|sotalol (l_prep) with_18\IN|consecutive|(|one| (l_pobj) tachycardia_22\NN|NONE (l_conj) fibrillation_25\NN|ventricular|or|sustained|inducible
D013015_D014693 NONE sotalol_8\NN|induction|in|, (r_nsubj) prevented_9\VBN|Those (l_dobj) induction_10\NN|in|,|sotalol (l_prep) of_11\IN|NONE (l_pobj) tachycardia_13\NN|NONE (l_conj) fibrillation_16\NN|ventricular|or
D013015_-1 NONE sotalol_11\NN|d (r_pobj) of_6\IN|the (r_prep) use_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) proarrhythmia_2\NN|and|.
D013015_D006331 NONE sotalol_23\NN|NONE (r_pobj) with_18\IN|successful (r_prep) treatment_17\NN|NONE (r_pobj) of_15\IN| (r_prep) years_14\NNS|NONE (r_pobj) after_12\IN|.|pointes|patient (r_prep) had_7\VBD|NONE (l_nsubj) patient_2\NN|.|pointes|after (l_prep) with_3\IN|One|female (l_pobj) disease_6\NN|NONE
D013015_D003324 NONE sotalol_32\NN|patients|prevent|. (r_dobj) received_26\VBD|NONE (l_nsubj) patients_4\NNS|prevent|.|sotalol (l_appos) 54_6\CD|with|consecutive|(|one (l_prep) with_7\IN|and|,| (l_pobj) disease_10\NN|NONE
D013015_D017180 NONE sotalol_11\NN|d (l_prep) for_12\IN||,|l (l_pobj) tachyarrhythmias_15\NNS|NONE
D013015_D017180 NONE sotalol_32\NN|d (l_prep) for_33\IN||l|, (l_pobj) tachyarrhythmias_36\NNS|NONE
D013015_D017180 NONE sotalol_32\NN|patients|prevent|. (r_dobj) received_26\VBD|NONE (l_nsubj) patients_4\NNS|prevent|.|sotalol (l_prep) with_18\IN|consecutive|(|one| (l_pobj) tachycardia_22\NN|NONE
D013015_D017180 NONE sotalol_32\NN|patients|prevent|. (r_dobj) received_26\VBD|NONE (l_advcl) prevent_34\VB|patients|.|sotalol (l_dobj) induction_35\NN|to (l_prep) of_36\IN|NONE (l_pobj) tachyarrhythmia_39\NN|NONE
D013015_D017180 NONE sotalol_8\NN|induction|in|, (r_nsubj) prevented_9\VBN|Those (l_dobj) induction_10\NN|in|,|sotalol (l_prep) of_11\IN|NONE (l_pobj) tachycardia_13\NN|NONE
D013015_D017180 NONE sotalol_13\NN|,|in|inducible|d|;|tachyarrhythmia (r_dep) remained_25\VBD|;|by|Induction|was|and|tolerate (r_conj) prevented_6\VBN|NONE (l_nsubjpass) Induction_0\NN|;|by|remained|was|and|tolerate (l_prep) of_1\IN|NONE (l_pobj) tachyarrhythmia_4\NN|NONE
D013015_D017180 NONE sotalol_13\NN|,|in|inducible|d|;|tachyarrhythmia (r_dep) remained_25\VBD|;|by|Induction|was|and|tolerate (l_nsubj) tachyarrhythmia_24\NN|,|sotalol|in|inducible|d|;
D013015_D017180 NONE sotalol_53\NN|d (r_pobj) of_48\IN| (r_prep) mg_47\NN|not|patients|did|daily|. (r_dobj) tolerate_44\VB|;|by|Induction|remained|was|and (r_conj) prevented_6\VBN|NONE (l_nsubjpass) Induction_0\NN|;|by|remained|was|and|tolerate (l_prep) of_1\IN|NONE (l_pobj) tachyarrhythmia_4\NN|NONE
D013015_D017180 NONE sotalol_53\NN|d (r_pobj) of_48\IN| (r_prep) mg_47\NN|not|patients|did|daily|. (r_dobj) tolerate_44\VB|;|by|Induction|remained|was|and (r_conj) prevented_6\VBN|NONE (l_conj) remained_25\VBD|;|by|Induction|was|and|tolerate (l_nsubj) tachyarrhythmia_24\NN|,|sotalol|in|inducible|d|;
1735570
D014294_D007022 CID trimethaphan_1\RB| (r_npadvmod) induced_3\VBN|The (r_amod) hypotension_4\NN|was|.|by
D014294_D001919 NONE trimethaphan_1\RB| (r_npadvmod) induced_3\VBN|The (r_amod) hypotension_4\NN|was|.|by (r_nsubjpass) accompanied_6\VBN|NONE (l_agent) by_7\IN|was|.|hypotension (l_pobj) bradycardia_10\NN|NONE
D014294_D013610 CID trimethaphan_1\RB| (r_npadvmod) induced_3\VBN|The (r_amod) hypotension_4\NN|was|.|by (r_nsubjpass) accompanied_6\VBN|NONE (l_agent) by_7\IN|was|.|hypotension (l_pobj) bradycardia_10\NN|NONE (l_prep) in_11\IN|a|significant (l_pobj) rats_13\NNS|NONE (l_appos) beats_18\NNS|(||lesioned (l_conj) tachycardia_24\NN|per|+/||but|)
20169779
D007980_D001523 NONE levodopa_1\RB| (r_npadvmod) treated_3\VBN|The|lesioned (r_amod) marmoset_7\NN|as|.|was (r_nsubjpass) used_9\VBN|NONE (l_prep) as_10\IN|.|marmoset|was (l_pobj) model_12\NN|NONE (l_prep) of_13\IN|a (l_pobj) symptoms_15\NNS|NONE
D007980_D001523 NONE levodopa_7\NN| (r_npadvmod) induced_9\VBN|behaviors|motor|and (r_amod) fluctuations_11\NNS|NONE (l_conj) behaviors_16\NNS|motor|induced|and
D007980_D001523 NONE levodopa_27\VB|NONE (r_pobj) to_26\IN|and|on|)|( (r_prep) prior_25\RB|analysis|,|blind (r_advmod) hoc_45\FW|for|were|Animals|on|. (r_prep) evaluated_2\VBN|NONE (l_prep) for_3\IN|hoc|were|Animals|on|. (l_pobj) disability_5\NN|NONE (l_conj) dyskinesia_7\JJ|,|parkinsonian (l_conj) behaviors_20\NNS|(|on|fluctuations|and|and|)
D007980_D001523 NONE levodopa_3\RB| (r_npadvmod) induced_5\VBN|like (r_amod) behaviors_9\NNS|and|present|,|In|correlate
D007980_D001523 NONE levodopa_16\JJ|NONE (r_compound) treatment_17\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) 1_14\CD|NONE (r_nummod) Day_13\NN|NONE (r_pobj) on_12\IN|NONE (r_prep) present_11\JJ|and|,|In|behaviors|correlate (r_acomp) were_10\VBD|NONE (l_nsubj) behaviors_9\NNS|and|present|,|In|correlate
D007980_D001523 NONE levodopa_14\NN|NONE (r_pobj) between_13\IN|than|an (r_prep) interaction_12\NN|likely|that|therapy|disorders (r_attr) are_8\VBP|data|. (l_nsubj) disorders_5\NNS|likely|that|interaction|therapy
D015632_D001523 NONE MPTP_4\NNP| (r_npadvmod) lesioned_6\VBN|The|treated (r_amod) marmoset_7\NN|as|.|was (r_nsubjpass) used_9\VBN|NONE (l_prep) as_10\IN|.|marmoset|was (l_pobj) model_12\NN|NONE (l_prep) of_13\IN|a (l_pobj) symptoms_15\NNS|NONE
D015632_D010302 NONE MPTP_4\NNP|the|of|marmoset (r_nmod) model_6\NN|NONE (l_prep) of_7\IN|MPTP|the|marmoset (l_pobj) disease_10\NN|NONE
D015632_D010302 NONE MPTP_4\NNP| (r_npadvmod) lesioned_6\VBN|The|treated (r_amod) marmoset_7\NN|as|.|was (r_nsubjpass) used_9\VBN|NONE (l_prep) as_10\IN|.|marmoset|was (l_pobj) model_12\NN|NONE (l_prep) of_13\IN|a (l_pobj) symptoms_15\NNS|NONE (l_prep) in_16\IN|neuropsychiatric (l_pobj) patients_18\NNS|NONE (l_compound) PD_17\NNP|NONE
D015632_D010302 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_3\CD|)|were|for|.|Marmosets|s.c.|resulting|, (r_oprd) administered_2\VBN|NONE (l_advcl) resulting_13\VBG|)|were|methylphenyl,,,tetrahydropyridine|for|.|Marmosets|s.c.|, (l_prep) in_14\IN|NONE (l_pobj) parkinsonism_16\NN|NONE
D007980_D020734 NONE levodopa_27\VB|NONE (r_pobj) to_26\IN|and|on|)|( (r_prep) prior_25\RB|analysis|,|blind (r_advmod) hoc_45\FW|for|were|Animals|on|. (r_prep) evaluated_2\VBN|NONE (l_prep) for_3\IN|hoc|were|Animals|on|. (l_pobj) disability_5\NN|NONE
D007980_D004409 CID levodopa_27\VB|NONE (r_pobj) to_26\IN|and|on|)|( (r_prep) prior_25\RB|analysis|,|blind (r_advmod) hoc_45\FW|for|were|Animals|on|. (r_prep) evaluated_2\VBN|NONE (l_prep) for_3\IN|hoc|were|Animals|on|. (l_pobj) disability_5\NN|NONE (l_conj) dyskinesia_7\JJ|,|parkinsonian
D007980_D004409 CID levodopa_9\NN| (r_npadvmod) induced_11\VBN|dyskinesia|,|motor (r_amod) fluctuations_13\NNS|NONE (l_conj) dyskinesia_15\JJ|induced|,|motor
D007980_D004409 CID levodopa_27\NN|NONE (r_compound) therapy_28\NN|NONE (r_pobj) of_26\IN|the (r_prep) duration_25\NN|NONE (r_pobj) with_23\IN|that (r_prep) correlated_22\VBD|in|a|progressive (r_relcl) increase_7\NN|anticipated|,|.|,|animals (l_prep) in_8\IN|correlated|a|progressive (l_pobj) fluctuations_13\NNS|NONE (l_conj) dyskinesia_15\JJ|induced|,|motor
D007980_D010302 NONE levodopa_1\RB| (r_npadvmod) treated_3\VBN|The|lesioned (r_amod) marmoset_7\NN|as|.|was (r_nsubjpass) used_9\VBN|NONE (l_prep) as_10\IN|.|marmoset|was (l_pobj) model_12\NN|NONE (l_prep) of_13\IN|a (l_pobj) symptoms_15\NNS|NONE (l_prep) in_16\IN|neuropsychiatric (l_pobj) patients_18\NNS|NONE (l_compound) PD_17\NNP|NONE
D007980_D010302 NONE levodopa_14\NN|NONE (r_pobj) between_13\IN|than|an (r_prep) interaction_12\NN|likely|that|therapy|disorders (r_attr) are_8\VBP|data|. (l_nsubj) disorders_5\NNS|likely|that|interaction|therapy (l_prep) in_6\IN|neuropsychiatric (l_pobj) PD_7\NNP|NONE
24641119
D007654_-1 NONE ketoconazole_4\NN|NONE (r_pobj) by_3\IN|.|syndrome (r_prep) induced_2\VBN|NONE (l_nsubj) syndrome_1\NN|.|by
D007654_-1 NONE ketoconazole_21\NN|NONE (r_pobj) to_19\IN|prior (r_prep) sensitivity_18\NN|which (r_dobj) included_16\VBD|,|his (r_relcl) history_13\NN|NONE (r_pobj) on_11\IN|NONE (r_prep) based_10\VBN|baboon|induced (r_acl) syndrome_9\NN|NONE
D007654_-1 NONE ketoconazole_14\RB| (r_npadvmod) induced_16\VBN|in|baboon (r_amod) syndrome_18\NN|NONE
D007654_D003875 CID ketoconazole_20\RB|NONE (r_dobj) using_18\VBG|NONE (r_pcomp) after_17\IN|.|patient|with (r_prep) presented_6\VBN|NONE (l_prep) with_7\IN|after|.|patient (l_pobj) eruption_10\NN|NONE
24840785
D002118_D011041 NONE Ca(2_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) role_8\NN|NONE (r_pobj) on_6\IN|NONE (r_prep) available_5\JJ|However|)|in|reports|.|+|, (r_acomp) are_4\VBP|NONE (l_prep) in_13\IN|However|)|available|reports|.|+|, (l_pobj) poisoning_15\NN|NONE
D002118_D011041 NONE Ca(2_10\NNP|NONE (r_pobj) of_8\IN|the (r_prep) importance_7\NN|,|.|signaling|In|we|) (r_dobj) explored_5\VBD|NONE (l_advcl) signaling_13\NN|,|.|importance|In|we|) (l_prep) in_14\IN|in (l_pobj) poisoning_16\NN|NONE
D000157_D011041 CID aconitine_14\NN|NONE (r_compound) poisoning_15\NN|NONE
D000157_D011041 CID aconitine_15\NN|NONE (r_compound) poisoning_16\NN|NONE
D012964_D066126 NONE Na(+_7\NN|voltage| (r_cc) dependent_6\JJ|) (r_nmod) channels_9\NNS|that|in|roles (r_nsubj) have_10\VBP|evidence|. (l_prep) in_13\IN|channels|that|roles (l_pobj) cardiotoxicity_15\NN|NONE
D000157_D064420 NONE aconitine_4\NN|NONE (r_pobj) of_3\IN|on (r_prep) effects_2\NNS|To (r_dobj) investigate_1\VB|assay|.|we|, (r_advcl) performed_10\VBD|NONE (l_dobj) assay_12\NN|.|we|investigate|, (l_compound) cytotoxicity_11\NN|level|as|in|,
D002118_D001145 NONE Ca2_3\NN|and|apoptosis|arrhythmia|. (r_nsubj) causes_6\NNS|NONE (l_dobj) arrhythmia_7\NN|Ca|and|apoptosis|.
D002118_D001145 NONE Ca(2_3\NNP|accelerated|caused|that|and (r_nsubj) lead_7\NN|.|We (l_conj) caused_18\VBD|accelerated|Ca(|that|and (l_dobj) arrhythmia_19\NN|in
D002118_D001145 NONE Ca(2_9\NNP|causes|)|and (r_nmod) overload_12\NN|and|significantly|aconitine|promotes (l_conj) causes_14\VBZ|)|and|Ca( (l_dobj) arrhythmia_15\NN|NONE
D019344_D064420 NONE lactate_26\NN|NONE (r_compound) dehydrogenase_27\NN|measured|in (r_compound) level_28\NN|as|in|cytotoxicity|, (r_conj) assay_12\NN|.|we|investigate|, (l_compound) cytotoxicity_11\NN|level|as|in|,
D019344_D009202 NONE lactate_26\NN|NONE (r_compound) dehydrogenase_27\NN|measured|in (r_compound) level_28\NN|as|in|cytotoxicity|, (r_conj) assay_12\NN|.|we|investigate|, (r_dobj) performed_10\VBD|NONE (l_advcl) investigate_1\VB|assay|.|we|, (l_dobj) effects_2\NNS|To (l_prep) on_5\IN|of (l_pobj) injury_7\NN|NONE
D000157_D001145 CID Aconitine_0\NNP| (r_npadvmod) induced_2\VBN|+|overload (r_amod) Ca2_3\NN|and|apoptosis|arrhythmia|. (r_nsubj) causes_6\NNS|NONE (l_dobj) arrhythmia_7\NN|Ca|and|apoptosis|.
D000157_D001145 CID aconitine_6\NN|and|significantly|promotes|overload (r_nsubj) aggravates_8\VBZ|Hence|,|results|. (l_dobj) overload_12\NN|and|significantly|aconitine|promotes (l_conj) causes_14\VBZ|)|and|Ca( (l_dobj) arrhythmia_15\NN|NONE
D000157_D066126 CID aconitine_17\NN|NONE (r_pobj) of_16\IN|the (r_prep) cardiotoxicity_15\NN|NONE
D000157_D009202 NONE aconitine_4\NN|NONE (r_pobj) of_3\IN|on (r_prep) effects_2\NNS|To (l_prep) on_5\IN|of (l_pobj) injury_7\NN|NONE
D000157_D009202 NONE aconitine_4\NN|that|and|in|reduced (r_nsubj) resulted_5\VBD|.|results (l_prep) in_6\IN|that|aconitine|and|reduced (l_pobj) injury_8\NN|NONE
24975837
D014508_D058186 NONE urea_33\NN|and (r_conj) creatinine_31\NN|NONE (r_pobj) of_30\IN|serum (r_prep) levels_29\NNS|increase|, (r_dobj) augment_27\VBP|,|drug|however|adopted|;|injury|can|,|.|due (r_conj) induce_14\VB|NONE (l_dobj) injury_17\NN|,|drug|however|adopted|;|augment|can|,|.|due
D002945_D007674 NONE cisplatin_15\NN|NONE (r_amod) therapy_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|NONE (r_acl) nephrotoxicity_12\NN|NONE
D003404_D007683 NONE creatinine_31\NN|NONE (r_pobj) of_30\IN|serum (r_prep) levels_29\NNS|increase|, (r_dobj) augment_27\VBP|,|drug|however|adopted|;|injury|can|,|.|due (l_conj) increase_35\VB|levels|, (l_dobj) score_40\NN|NONE (l_compound) necrosis_39\NN|and|acute|tubular|the|cytokines
D003404_D058186 NONE creatinine_31\NN|NONE (r_pobj) of_30\IN|serum (r_prep) levels_29\NNS|increase|, (r_dobj) augment_27\VBP|,|drug|however|adopted|;|injury|can|,|.|due (r_conj) induce_14\VB|NONE (l_dobj) injury_17\NN|,|drug|however|adopted|;|augment|can|,|.|due
D002945_D058186 CID cisplatin_7\RB| (r_npadvmod) induced_9\VBN|acute|renal (r_amod) injury_12\NN|deletion|.
D002945_D058186 CID Cisplatin_0\NNP|NONE (r_compound) treatment_1\NN|has|in|been (r_nsubjpass) adopted_4\VBN|,|drug|however|;|augment|injury|can|,|.|due (r_ccomp) induce_14\VB|NONE (l_dobj) injury_17\NN|,|drug|however|adopted|;|augment|can|,|.|due
D002945_D058186 CID cisplatin_10\NN| (r_advmod) induced_12\VBN|acute|kidney (r_amod) injury_15\NN|NONE
D002945_D058186 CID cisplatin_25\NN|NONE (r_pobj) with_24\IN|examine|were|.|mice (r_prep) challenged_23\VBN|NONE (l_advcl) examine_1\VB|with|were|.|mice (l_dobj) role_3\NN|To (l_prep) of_4\IN|the (l_pobj) kinin_6\NN|NONE (l_appos) receptor_8\NN|kinin|the|, (l_prep) in_9\IN|B (l_pobj) injury_15\NN|NONE
D002945_D058186 CID cisplatin_13\NN| (r_advmod) induced_15\VBN|kidney|acute (r_amod) injury_18\NN|NONE
D002945_D007683 CID Cisplatin_0\NNP|NONE (r_compound) treatment_1\NN|has|in|been (r_nsubjpass) adopted_4\VBN|,|drug|however|;|augment|injury|can|,|.|due (r_ccomp) induce_14\VB|NONE (l_conj) augment_27\VBP|,|drug|however|adopted|;|injury|can|,|.|due (l_conj) increase_35\VB|levels|, (l_dobj) score_40\NN|NONE (l_compound) necrosis_39\NN|and|acute|tubular|the|cytokines
D014508_D007683 NONE urea_33\NN|and (r_conj) creatinine_31\NN|NONE (r_pobj) of_30\IN|serum (r_prep) levels_29\NNS|increase|, (r_dobj) augment_27\VBP|,|drug|however|adopted|;|injury|can|,|.|due (l_conj) increase_35\VB|levels|, (l_dobj) score_40\NN|NONE (l_compound) necrosis_39\NN|and|acute|tubular|the|cytokines
D002945_D009336 NONE cisplatin_13\NN| (r_advmod) induced_15\VBN|kidney|acute (r_amod) injury_18\NN|NONE (r_pobj) in_12\IN|kinin|is|by|that (r_prep) involved_11\VBN|Thus|data|,|. (l_prep) by_19\IN|kinin|is|in|that (l_pcomp) mediating_20\VBG|NONE (l_dobj) process_23\NN|resulting|, (l_amod) necrotic_22\JJ|expression|and|the
1556529
D015215_D056486 CID Zidovudine_0\RB| (r_npadvmod) induced_2\VBN|. (r_amod) hepatitis_3\NN|NONE
D015215_D056486 CID zidovudine_7\NNP|NONE (r_pobj) by_6\IN|in (r_agent) induced_5\VBN|of|A (r_acl) case_1\NN|.|is (l_prep) of_2\IN|induced|A (l_pobj) hepatitis_4\NN|NONE
D015215_D000163 NONE zidovudine_7\NNP|NONE (r_pobj) by_6\IN|in (r_agent) induced_5\VBN|of|A (l_prep) in_8\IN|by (l_pobj) patient_13\NN|NONE (l_prep) with_14\IN|old|a (l_pobj) AIDS_15\NNP|NONE
8667442
D009853_D051437 NONE omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (r_pobj) with_1\IN|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN|.|hallmark|triad (r_ccomp) remains_37\VBZ|NONE (l_nsubj) triad_28\NN|.|hallmark|decreased (l_prep) of_29\IN|the|classic (l_pobj) hypercalcemia_30\NN|NONE (l_conj) alkalosis_32\NN|, (l_conj) impairment_36\NN|and|,
D002118_D010437 NONE calcium_24\NN|NONE (r_pobj) of_23\IN|large (r_prep) amounts_22\NNS|NONE (r_pobj) with_20\IN|of|the (r_prep) treatment_15\NN|NONE (l_prep) of_16\IN|the|with (l_pobj) disease_19\NN|NONE
D013392_D014456 NONE sucralfate_12\JJ|and|, (r_conj) omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (l_compound) ulcer_3\NN|blockers|H|current|(
D002118_D006934 CID calcium_24\NN|NONE (r_pobj) of_23\IN|large (r_prep) amounts_22\NNS|NONE (r_pobj) with_20\IN|of|the (r_prep) treatment_15\NN|NONE (r_pobj) of_13\IN|the (r_prep) context_12\NN|NONE (r_pobj) in_10\IN|was|syndrome|ago|first|. (r_prep) described_6\VBN|NONE (l_nsubjpass) syndrome_3\NN|was|ago|first|.|in
D009853_D000471 NONE omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (r_pobj) with_1\IN|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN|.|hallmark|triad (r_ccomp) remains_37\VBZ|NONE (l_nsubj) triad_28\NN|.|hallmark|decreased (l_prep) of_29\IN|the|classic (l_pobj) hypercalcemia_30\NN|NONE (l_conj) alkalosis_32\NN|,
D013392_D000471 NONE sucralfate_12\JJ|and|, (r_conj) omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (r_pobj) with_1\IN|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN|.|hallmark|triad (r_ccomp) remains_37\VBZ|NONE (l_nsubj) triad_28\NN|.|hallmark|decreased (l_prep) of_29\IN|the|classic (l_pobj) hypercalcemia_30\NN|NONE (l_conj) alkalosis_32\NN|,
D002119_D007011 NONE carbonate_12\NN|NONE (r_pobj) with_10\IN|resulting|was|who (r_prep) treated_9\VBN|NONE (r_relcl) hypoparathyroidism_6\NN|NONE
D009853_D006934 NONE omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (r_pobj) with_1\IN|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN|.|hallmark|triad (l_nsubj) frequency_16\NN|has|significantly|,|with|, (l_prep) of_17\IN|the (l_pobj) syndrome_21\NN|NONE
D009853_D006934 NONE omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (r_pobj) with_1\IN|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN|.|hallmark|triad (r_ccomp) remains_37\VBZ|NONE (l_nsubj) triad_28\NN|.|hallmark|decreased (l_prep) of_29\IN|the|classic (l_pobj) hypercalcemia_30\NN|NONE
C019248_D006934 NONE pamidronate_3\NN|.|This (l_advcl) presents_14\VBZ|as|intravenous (l_nsubj) syndrome_13\NN|as|when
C019248_D006934 NONE pamidronate_3\NN|.|This (l_advcl) presents_14\VBZ|as|intravenous (l_prep) as_15\IN|when|syndrome (l_pobj) emergency_17\NN|NONE
D002119_D006934 CID carbonate_12\NN|NONE (r_pobj) with_10\IN|resulting|was|who (r_prep) treated_9\VBN|NONE (l_advcl) resulting_15\VBG|was|with|who (l_prep) in_16\IN|NONE (l_pobj) admissions_18\NNS|NONE (l_prep) for_22\IN|to|two (l_pobj) syndrome_26\NN|NONE
D002117_D006934 CID 1,25(OH)2D_6\CD|NONE (r_pobj) by_5\IN|in (r_agent) induced_4\VBN|alkali|. (r_acl) syndrome_3\NN|NONE
D002117_D006934 CID calcitriol_14\NN|calcium|and (r_conj) carbonate_12\NN|NONE (r_pobj) with_10\IN|resulting|was|who (r_prep) treated_9\VBN|NONE (l_advcl) resulting_15\VBG|was|with|who (l_prep) in_16\IN|NONE (l_pobj) admissions_18\NNS|NONE (l_prep) for_22\IN|to|two (l_pobj) syndrome_26\NN|NONE
D000468_D006934 CID alkali_26\NN|and (r_conj) calcium_24\NN|NONE (r_pobj) of_23\IN|large (r_prep) amounts_22\NNS|NONE (r_pobj) with_20\IN|of|the (r_prep) treatment_15\NN|NONE (r_pobj) of_13\IN|the (r_prep) context_12\NN|NONE (r_pobj) in_10\IN|was|syndrome|ago|first|. (r_prep) described_6\VBN|NONE (l_nsubjpass) syndrome_3\NN|was|ago|first|.|in
D013392_D006934 NONE sucralfate_12\JJ|and|, (r_conj) omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (r_pobj) with_1\IN|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN|.|hallmark|triad (l_nsubj) frequency_16\NN|has|significantly|,|with|, (l_prep) of_17\IN|the (l_pobj) syndrome_21\NN|NONE
D013392_D006934 NONE sucralfate_12\JJ|and|, (r_conj) omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (r_pobj) with_1\IN|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN|.|hallmark|triad (r_ccomp) remains_37\VBZ|NONE (l_nsubj) triad_28\NN|.|hallmark|decreased (l_prep) of_29\IN|the|classic (l_pobj) hypercalcemia_30\NN|NONE
D009853_D014456 NONE omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (l_compound) ulcer_3\NN|blockers|H|current|(
D002117_D007011 NONE 1,25(OH)2D_6\CD|NONE (r_pobj) by_5\IN|in (r_agent) induced_4\VBN|alkali|. (l_prep) in_7\IN|by (l_pobj) patient_9\NN|NONE (l_prep) with_10\IN|a (l_pobj) hypoparathyroidism_11\NN|NONE
D002117_D007011 NONE calcitriol_14\NN|calcium|and (r_conj) carbonate_12\NN|NONE (r_pobj) with_10\IN|resulting|was|who (r_prep) treated_9\VBN|NONE (r_relcl) hypoparathyroidism_6\NN|NONE
D013392_D051437 NONE sucralfate_12\JJ|and|, (r_conj) omeprazole_9\NN|)|, (r_conj) blockers_7\NNS|H|current|ulcer|( (r_conj) therapy_4\NN|Although (r_pobj) with_1\IN|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN|.|hallmark|triad (r_ccomp) remains_37\VBZ|NONE (l_nsubj) triad_28\NN|.|hallmark|decreased (l_prep) of_29\IN|the|classic (l_pobj) hypercalcemia_30\NN|NONE (l_conj) alkalosis_32\NN|, (l_conj) impairment_36\NN|and|,
D000468_D010437 NONE alkali_26\NN|and (r_conj) calcium_24\NN|NONE (r_pobj) of_23\IN|large (r_prep) amounts_22\NNS|NONE (r_pobj) with_20\IN|of|the (r_prep) treatment_15\NN|NONE (l_prep) of_16\IN|the|with (l_pobj) disease_19\NN|NONE
10986547
C076029_D015430 CID olanzapine_2\RB| (r_npadvmod) treated_4\VBN|NONE (r_amod) patients_5\NNS|However|,|.|mean (r_nsubj) had_6\VBD|NONE (l_dobj) mean_11\JJ|However|patients|,|. (l_appos) gain_17\NN|significant|a|greater|(
C076029_D001714 NONE olanzapine_2\NN|NONE (r_pobj) of_1\IN|.|in|study|: (r_prep) Efficacy_0\NN|NONE (l_prep) in_3\IN|.|study|:|of (l_pobj) mania_6\NN|NONE
C076029_D001714 NONE olanzapine_7\NN|NONE (r_pobj) of_6\IN|for|the|safety|and (r_prep) efficacy_3\NN|We|. (l_prep) for_10\IN|the|safety|of|and (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) mania_16\NN|NONE
C076029_D001714 NONE olanzapine_22\NN|,|total|.|were (r_xcomp) randomized_20\VBN|NONE (l_nsubjpass) total_1\NN|,|.|were|olanzapine (l_prep) of_2\IN|A (l_pobj) patients_4\NNS|NONE (l_prep) with_5\IN| (l_pobj) diagnosis_10\NN|NONE (l_prep) of_11\IN|IV|a (l_pobj) disorder_13\NN|NONE
C076029_D001714 NONE olanzapine_22\NN|,|total|.|were (r_xcomp) randomized_20\VBN|NONE (l_nsubjpass) total_1\NN|,|.|were|olanzapine (l_prep) of_2\IN|A (l_pobj) patients_4\NNS|NONE (l_prep) with_5\IN| (l_pobj) diagnosis_10\NN|NONE (l_prep) of_11\IN|IV|a (l_pobj) disorder_13\NN|NONE (l_amod) manic_15\JJ|,|bipolar
C076029_D001714 NONE Olanzapine_0\NNP|efficacy|.|tolerated|and (r_nsubj) demonstrated_1\VBD|NONE (l_dobj) efficacy_3\NN|Olanzapine|.|tolerated|and (l_prep) than_4\IN|greater (l_pobj) placebo_5\NN|NONE (l_prep) in_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) mania_12\NN|NONE
C076029_D006970 CID olanzapine_2\RB| (r_npadvmod) treated_4\VBN|NONE (r_amod) patients_5\NNS|However|,|.|mean (r_nsubj) had_6\VBD|NONE (l_dobj) mean_11\JJ|However|patients|,|. (l_appos) gain_17\NN|significant|a|greater|( (l_conj) experienced_37\VBD|SD|and|+/|weight|)|than (l_dobj) somnolence_42\NN|also
17356399
D003561_D006212 CID cytarabine_35\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) after_30\IN|diffuse|on|cerebral (r_prep) vasospasm_25\NN|NONE (r_pobj) with_22\IN|sided (r_prep) weakness_21\NN|visual|,|and (r_conj) hallucinations_15\NNS|,
C042705_D054198 NONE asparaginase_11\NN|NONE (r_pobj) including_8\VBG|NONE (r_prep) chemotherapy_7\NN|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ|NONE (l_prep) for_15\IN|.|after|chemotherapy|encephalopathy (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) leukemia_21\NN|NONE
C042705_D020803 NONE asparaginase_11\NN|NONE (r_pobj) including_8\VBG|NONE (r_prep) chemotherapy_7\NN|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ|NONE (l_nsubj) encephalopathy_1\JJ|for|.|after|chemotherapy
C042705_D020301 CID asparaginase_11\NN|NONE (r_pobj) including_8\VBG|NONE (r_prep) chemotherapy_7\NN|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ|NONE (l_nsubj) encephalopathy_1\JJ|for|.|after|chemotherapy (l_conj) vasospasm_4\NN|Acute|and
D003561_D018908 CID cytarabine_35\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) after_30\IN|diffuse|on|cerebral (r_prep) vasospasm_25\NN|NONE (r_pobj) with_22\IN|sided (r_prep) weakness_21\NN|visual|,|and
D003561_D001037 CID cytarabine_35\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) after_30\IN|diffuse|on|cerebral (r_prep) vasospasm_25\NN|NONE (r_pobj) with_22\IN|sided (r_prep) weakness_21\NN|visual|,|and (r_conj) hallucinations_15\NNS|, (r_conj) incontinence_12\NN|, (r_conj) aphasia_10\NN|behavioral|,
D003561_D020803 NONE cytarabine_14\NN|PEG||and (r_conj) asparaginase_11\NN|NONE (r_pobj) including_8\VBG|NONE (r_prep) chemotherapy_7\NN|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ|NONE (l_nsubj) encephalopathy_1\JJ|for|.|after|chemotherapy
D003561_D020803 NONE cytarabine_35\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) after_30\IN|diffuse|on|cerebral (r_prep) vasospasm_25\NN|NONE (r_pobj) with_22\IN|sided (r_prep) weakness_21\NN|visual|,|and (r_conj) hallucinations_15\NNS|, (r_conj) incontinence_12\NN|, (r_conj) aphasia_10\NN|behavioral|, (r_conj) changes_8\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) evidenced_5\VBN|acute (r_acl) encephalopathy_4\NN|.|patient
D003561_D014549 CID cytarabine_35\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) after_30\IN|diffuse|on|cerebral (r_prep) vasospasm_25\NN|NONE (r_pobj) with_22\IN|sided (r_prep) weakness_21\NN|visual|,|and (r_conj) hallucinations_15\NNS|, (r_conj) incontinence_12\NN|,
D003561_D020301 CID cytarabine_14\NN|PEG||and (r_conj) asparaginase_11\NN|NONE (r_pobj) including_8\VBG|NONE (r_prep) chemotherapy_7\NN|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ|NONE (l_nsubj) encephalopathy_1\JJ|for|.|after|chemotherapy (l_conj) vasospasm_4\NN|Acute|and
D003561_D020301 CID cytarabine_35\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) after_30\IN|diffuse|on|cerebral (r_prep) vasospasm_25\NN|NONE
D003561_D054198 NONE cytarabine_14\NN|PEG||and (r_conj) asparaginase_11\NN|NONE (r_pobj) including_8\VBG|NONE (r_prep) chemotherapy_7\NN|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ|NONE (l_prep) for_15\IN|.|after|chemotherapy|encephalopathy (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) leukemia_21\NN|NONE
3533179
D003520_D007153 NONE CYA_4\NNP|the (r_compound) cardiotoxicity_5\NN|,|prepared|that|and|with|calculated (r_nsubj) correlates_6\VBZ|.|We (l_conj) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS|be|for|that|can|effectively (l_prep) with_20\IN|NONE (l_pobj) anemia_22\NN|NONE (l_conj) immunodeficiencies_24\NNS|aplastic|and
D003520_D007153 NONE CYA_8\NNP|NONE (r_compound) dosage_9\NN|NONE (r_pobj) with_7\IN|,|prepared|that|and|cardiotoxicity|calculated (r_prep) correlates_6\VBZ|.|We (l_conj) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS|be|for|that|can|effectively (l_prep) with_20\IN|NONE (l_pobj) anemia_22\NN|NONE (l_conj) immunodeficiencies_24\NNS|aplastic|and
D003520_D007153 NONE CYA_35\NNP|a|of (r_compound) dose_36\NN|NONE (r_pobj) at_33\IN|marrow|with (r_prep) grafting_32\VBG|NONE (r_pobj) for_29\IN|be|patients|that|can|effectively (r_prep) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS|be|for|that|can|effectively (l_prep) with_20\IN|NONE (l_pobj) anemia_22\NN|NONE (l_conj) immunodeficiencies_24\NNS|aplastic|and
D003520_D007153 NONE CYA_54\NNP|whose (r_compound) dosage_55\NN|based|is (r_nsubjpass) calculated_57\VBN|NONE (r_relcl) patients_52\NNS|NONE (r_pobj) than_51\IN|NONE (r_prep) cardiotoxicity_50\NN|NONE (r_pobj) of_49\IN|a|lower (r_prep) incidence_48\NN|NONE (r_pobj) with_45\IN|marrow|at (r_prep) grafting_32\VBG|NONE (r_pobj) for_29\IN|be|patients|that|can|effectively (r_prep) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS|be|for|that|can|effectively (l_prep) with_20\IN|NONE (l_pobj) anemia_22\NN|NONE (l_conj) immunodeficiencies_24\NNS|aplastic|and
D003520_D014923 NONE CYA_6\NNP|to (r_dobj) receive_5\VB|who (r_xcomp) were_3\VBD|Eighty (r_relcl) patients_1\NNS|total|for|.|syndrome|,|d (r_nsubj) underwent_21\VBD|NONE (l_conj) syndrome_34\NN|total|for|.|patients|,|d
D003520_D016511 NONE CYA_6\NNP|to (r_dobj) receive_5\VB|who (r_xcomp) were_3\VBD|Eighty (r_relcl) patients_1\NNS|total|for|.|syndrome|,|d (r_nsubj) underwent_21\VBD|NONE (l_conj) syndrome_34\NN|total|for|.|patients|,|d (l_conj) syndrome_40\NN|,|Aldrich|or
D003520_D000741 NONE CYA_6\NNP|to (r_dobj) receive_5\VB|who (r_xcomp) were_3\VBD|Eighty (r_relcl) patients_1\NNS|total|for|.|syndrome|,|d (r_nsubj) underwent_21\VBD|NONE (l_dobj) total_23\NN|for|.|syndrome|patients|,|d (l_prep) of_24\IN|a (l_pobj) transplants_26\NNS|NONE (l_prep) for_27\IN| (l_pobj) anemia_29\NN|NONE
D003520_D000741 NONE CYA_4\NNP|the (r_compound) cardiotoxicity_5\NN|,|prepared|that|and|with|calculated (r_nsubj) correlates_6\VBZ|.|We (l_conj) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS|be|for|that|can|effectively (l_prep) with_20\IN|NONE (l_pobj) anemia_22\NN|NONE
D003520_D000741 NONE CYA_8\NNP|NONE (r_compound) dosage_9\NN|NONE (r_pobj) with_7\IN|,|prepared|that|and|cardiotoxicity|calculated (r_prep) correlates_6\VBZ|.|We (l_conj) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS|be|for|that|can|effectively (l_prep) with_20\IN|NONE (l_pobj) anemia_22\NN|NONE
D003520_D000741 NONE CYA_35\NNP|a|of (r_compound) dose_36\NN|NONE (r_pobj) at_33\IN|marrow|with (r_prep) grafting_32\VBG|NONE (r_pobj) for_29\IN|be|patients|that|can|effectively (r_prep) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS|be|for|that|can|effectively (l_prep) with_20\IN|NONE (l_pobj) anemia_22\NN|NONE
D003520_D000741 NONE CYA_54\NNP|whose (r_compound) dosage_55\NN|based|is (r_nsubjpass) calculated_57\VBN|NONE (r_relcl) patients_52\NNS|NONE (r_pobj) than_51\IN|NONE (r_prep) cardiotoxicity_50\NN|NONE (r_pobj) of_49\IN|a|lower (r_prep) incidence_48\NN|NONE (r_pobj) with_45\IN|marrow|at (r_prep) grafting_32\VBG|NONE (r_pobj) for_29\IN|be|patients|that|can|effectively (r_prep) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS|be|for|that|can|effectively (l_prep) with_20\IN|NONE (l_pobj) anemia_22\NN|NONE
D003520_D064420 NONE CYA_19\NNP|NONE (r_pobj) of_18\IN|in|the (r_prep) dose_17\NN|.|determine|correlates|we|retrospectively|, (r_dobj) calculated_15\VBD|NONE (l_advcl) correlates_5\VBZ|.|dose|determine|we|retrospectively|, (l_nsubj) toxicity_3\NN|with|Since|generally
D003520_D064420 NONE CYA_32\NNP|NONE (r_compound) cardiotoxicity_33\NN|NONE (r_pobj) of_31\IN|the (r_prep) incidence_30\NN|with|whether (r_nsubj) correlated_34\VBN|to (r_ccomp) determine_27\VB|.|dose|correlates|we|retrospectively|, (r_advcl) calculated_15\VBD|NONE (l_advcl) correlates_5\VBZ|.|dose|determine|we|retrospectively|, (l_nsubj) toxicity_3\NN|with|Since|generally
D003520_D066126 NONE Cyclophosphamide_0\NNP|:|analysis|. (r_compound) cardiotoxicity_1\NN|NONE
D003520_D066126 NONE CYA_5\NNP|NONE (r_pobj) of_4\IN|these|high (r_prep) doses_3\NNS|NONE (r_pobj) At_0\IN|may|cardiotoxicity|,|described|but|, (r_prep) occur_10\VB|NONE (l_nsubj) cardiotoxicity_8\NN|may|At|,|described|but|,
D003520_D066126 NONE CYA_5\NNP|NONE (r_pobj) of_4\IN|these|high (r_prep) doses_3\NNS|NONE (r_pobj) At_0\IN|may|cardiotoxicity|,|described|but|, (r_prep) occur_10\VB|NONE (l_conj) described_25\VBN|may|cardiotoxicity|At|,|but|, (l_nsubjpass) factors_15\NNS|not|been|have|. (l_prep) for_16\IN|definitive|risk (l_pobj) development_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) cardiotoxicity_21\NN|NONE
D003520_D066126 NONE CYA_19\NNP|NONE (r_pobj) of_18\IN|in|the (r_prep) dose_17\NN|.|determine|correlates|we|retrospectively|, (r_dobj) calculated_15\VBD|NONE (l_advcl) determine_27\VB|.|dose|correlates|we|retrospectively|, (l_ccomp) correlated_34\VBN|to (l_nsubj) incidence_30\NN|with|whether (l_prep) of_31\IN|the (l_pobj) cardiotoxicity_33\NN|NONE
D003520_D066126 NONE CYA_32\NNP|NONE (r_compound) cardiotoxicity_33\NN|NONE
D003520_D066126 NONE CYA_14\NNP|NONE (r_compound) cardiotoxicity_15\NN|NONE
D003520_D066126 NONE CYA_26\NNP|NONE (r_pobj) of_25\IN| (r_prep) doses_24\NNS|NONE (r_dobj) receiving_20\VBG|NONE (r_pcomp) of_19\IN|ten (r_prep) days_18\NNS|NONE (r_pobj) within_16\IN|symptoms|patients|. (r_prep) had_8\VBD|NONE (l_dobj) symptoms_9\NNS|within|patients|. (l_amod) consistent_12\JJ|and|signs (l_prep) with_13\IN|NONE (l_pobj) cardiotoxicity_15\NN|NONE
D003520_D066126 NONE CYA_8\NNP|NONE (r_pobj) to_7\IN|be|to (r_prep) related_6\VBN|that|was (r_xcomp) thought_3\VBN|NONE (r_relcl) Cardiotoxicity_0\NN|.|in
D003520_D066126 NONE CYA_4\NNP|the (r_compound) cardiotoxicity_5\NN|,|prepared|that|and|with|calculated
D003520_D066126 NONE CYA_4\NNP|the (r_compound) cardiotoxicity_5\NN|,|prepared|that|and|with|calculated (r_nsubj) correlates_6\VBZ|.|We (l_conj) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_prep) for_29\IN|be|patients|that|can|effectively (l_pobj) grafting_32\VBG|NONE (l_prep) with_45\IN|marrow|at (l_pobj) incidence_48\NN|NONE (l_prep) of_49\IN|a|lower (l_pobj) cardiotoxicity_50\NN|NONE
D003520_D066126 NONE CYA_8\NNP|NONE (r_compound) dosage_9\NN|NONE (r_pobj) with_7\IN|,|prepared|that|and|cardiotoxicity|calculated (r_prep) correlates_6\VBZ|.|We (l_nsubj) cardiotoxicity_5\NN|,|prepared|that|and|with|calculated
D003520_D066126 NONE CYA_8\NNP|NONE (r_compound) dosage_9\NN|NONE (r_pobj) with_7\IN|,|prepared|that|and|cardiotoxicity|calculated (r_prep) correlates_6\VBZ|.|We (l_conj) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (l_prep) for_29\IN|be|patients|that|can|effectively (l_pobj) grafting_32\VBG|NONE (l_prep) with_45\IN|marrow|at (l_pobj) incidence_48\NN|NONE (l_prep) of_49\IN|a|lower (l_pobj) cardiotoxicity_50\NN|NONE
D003520_D066126 NONE CYA_35\NNP|a|of (r_compound) dose_36\NN|NONE (r_pobj) at_33\IN|marrow|with (r_prep) grafting_32\VBG|NONE (r_pobj) for_29\IN|be|patients|that|can|effectively (r_prep) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (r_conj) correlates_6\VBZ|.|We (l_nsubj) cardiotoxicity_5\NN|,|prepared|that|and|with|calculated
D003520_D066126 NONE CYA_35\NNP|a|of (r_compound) dose_36\NN|NONE (r_pobj) at_33\IN|marrow|with (r_prep) grafting_32\VBG|NONE (l_prep) with_45\IN|marrow|at (l_pobj) incidence_48\NN|NONE (l_prep) of_49\IN|a|lower (l_pobj) cardiotoxicity_50\NN|NONE
D003520_D066126 NONE CYA_54\NNP|whose (r_compound) dosage_55\NN|based|is (r_nsubjpass) calculated_57\VBN|NONE (r_relcl) patients_52\NNS|NONE (r_pobj) than_51\IN|NONE (r_prep) cardiotoxicity_50\NN|NONE (r_pobj) of_49\IN|a|lower (r_prep) incidence_48\NN|NONE (r_pobj) with_45\IN|marrow|at (r_prep) grafting_32\VBG|NONE (r_pobj) for_29\IN|be|patients|that|can|effectively (r_prep) prepared_28\VBN|,|that|and|with|cardiotoxicity|calculated (r_conj) correlates_6\VBZ|.|We (l_nsubj) cardiotoxicity_5\NN|,|prepared|that|and|with|calculated
D003520_D066126 NONE CYA_54\NNP|whose (r_compound) dosage_55\NN|based|is (r_nsubjpass) calculated_57\VBN|NONE (r_relcl) patients_52\NNS|NONE (r_pobj) than_51\IN|NONE (r_prep) cardiotoxicity_50\NN|NONE
20589632
D014295_D000743 CID Trimethoprim_0\NNP| (r_npadvmod) induced_2\VBN|.|in|immune|hemolytic (r_amod) anemia_5\NN|NONE
15018178
D015662_D000743 CID sulfomethoxazole_24\NN|NONE (r_pobj) by_21\IN|NONE (r_agent) induced_20\VBN|anemia|installing|a|hemolytic (r_acl) crisis_19\NN|who (l_compound) anemia_18\NN|induced|installing|a|hemolytic
D015662_D002534 NONE sulfomethoxazole_24\NN|NONE (r_pobj) by_21\IN|NONE (r_agent) induced_20\VBN|anemia|installing|a|hemolytic (r_acl) crisis_19\NN|who (r_dobj) had_13\VBD|a|old (r_relcl) girl_11\NN|NONE (r_pobj) of_6\IN|imaging (r_prep) findings_5\NNS|We|resulting|.|, (r_dobj) present_1\VBP|NONE (l_advcl) resulting_26\VBG|We|findings|.|, (l_prep) in_27\IN|NONE (l_pobj) anoxia_29\NN|NONE
23666265
D003520_D010146 CID CYP_7\NNP|NONE (r_pobj) of_6\IN|the (r_prep) administration_5\NN|NONE (r_pobj) following_3\VBG|pain|Spontaneous (r_prep) behaviors_2\NNS|.|were (l_compound) pain_1\NN|following|Spontaneous
D003520_D010146 CID Cyclophosphamide_0\NNP|NONE (r_compound) treatment_1\NN|.|scores (r_nsubj) increased_2\VBD|NONE (l_dobj) scores_7\NNS|.|treatment (l_compound) behaviors_6\NNS|NONE (l_compound) pain_5\NN|spontaneous|the
D003520_D003556 CID cyclophosphamide_10\NN| (r_npadvmod) induced_12\VBN|in (r_amod) cystitis_13\NN|NONE
D003520_D003556 CID cyclophosphamide_17\NN|NONE (r_pobj) on_16\IN|PX|cystitis|( (r_prep) antagonists_15\NNS|NONE (l_appos) cystitis_20\NN|PX|(|on
D003520_D003556 CID CYP)-induced_19\VBN|in (r_amod) cystitis_20\NN|PX|(|on
D003520_D003556 CID CYP_1\NNP| (r_npadvmod) induced_3\VBN|expression|,|increased (r_amod) cystitis_4\NN|.
9578276
15366550
D008094_D018500 CID Lithium_0\NN|changed|is|,|and|in (r_nsubjpass) implicated_2\VBN|NONE (l_prep) in_3\IN|changed|Lithium|is|,|and (l_pobj) DI_8\NNP|NONE
D008094_D018500 CID Lithium_0\NN|changed|is|,|and|in (r_nsubjpass) implicated_2\VBN|NONE (l_conj) changed_27\VBD|Lithium|is|,|and|in (l_advcl) focus_29\VB|,|treatment|.|received (l_prep) on_30\IN|to (l_pobj) DI_32\NNP|NONE
D008094_D018500 CID lithium_17\NN|because|patient|had|not|since (r_dobj) received_16\VBN|focus|,|treatment|. (r_advcl) changed_27\VBD|Lithium|is|,|and|in (r_conj) implicated_2\VBN|NONE (l_prep) in_3\IN|changed|Lithium|is|,|and (l_pobj) DI_8\NNP|NONE
D008094_D018500 CID lithium_17\NN|because|patient|had|not|since (r_dobj) received_16\VBN|focus|,|treatment|. (r_advcl) changed_27\VBD|Lithium|is|,|and|in (l_advcl) focus_29\VB|,|treatment|.|received (l_prep) on_30\IN|to (l_pobj) DI_32\NNP|NONE
D008094_D018500 CID lithium_32\NN| (r_npadvmod) induced_34\VBN|nephrogenic|his (r_amod) DI_36\NNP||developed|self|and|been
D008094_D018500 CID lithium_32\NN| (r_npadvmod) induced_34\VBN|nephrogenic|his (r_amod) DI_36\NNP||developed|self|and|been (r_dobj) treating_30\VBG|team|By|,|. (l_conj) developed_38\VBN||DI|self|and|been (l_dobj) DI_40\NNP|brain
D008094_D001930 NONE lithium_32\NN| (r_npadvmod) induced_34\VBN|nephrogenic|his (r_amod) DI_36\NNP||developed|self|and|been (r_dobj) treating_30\VBG|team|By|,|. (l_conj) developed_38\VBN||DI|self|and|been (l_advcl) brain_43\NN|DI (l_dobj) trauma_44\NN|to
D008094_D059606 NONE lithium_24\NN|standing (r_compound) use_25\NN|and (r_conj) polydipsia_19\NN|NONE
10713017
D005277_D006976 CID fenfluramines_9\NNS|However|.|association|,|of|,|compared (r_nsubj) had_10\VBD|NONE (l_dobj) association_14\NN|However|.|,|of|,|fenfluramines|compared (l_prep) with_15\IN|significant|preferential|a (l_pobj) PPH_16\NNP|NONE
D005277_D006976 CID fenfluramines_22\NNS|NONE (r_pobj) for_21\IN|the (r_prep) specificity_20\NN|and|with|the (r_conj) association_4\NN|NONE (l_prep) with_5\IN|and|specificity|the (l_pobj) PPH_6\NNP|NONE
D005277_D006976 CID fenfluramines_22\NNS|NONE (r_pobj) for_21\IN|the (r_prep) specificity_20\NN|and|with|the (r_conj) association_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) magnitude_1\NN|consistent|. (r_nsubj) are_23\VBP|NONE (l_acomp) consistent_24\JJ|magnitude|. (l_prep) with_25\IN|NONE (l_pobj) studies_27\NNS|NONE (l_acl) indicating_28\VBG|previous (l_ccomp) related_33\VBN|NONE (l_prep) to_34\IN|causally|fenfluramines|are|that (l_pobj) PPH_35\NNP|NONE
D005277_D006976 CID fenfluramines_30\NNS|to|causally|are|that (r_nsubjpass) related_33\VBN|NONE (r_ccomp) indicating_28\VBG|previous (r_acl) studies_27\NNS|NONE (r_pobj) with_25\IN|NONE (r_prep) consistent_24\JJ|magnitude|. (r_acomp) are_23\VBP|NONE (l_nsubj) magnitude_1\NN|consistent|. (l_prep) of_2\IN|The (l_pobj) association_4\NN|NONE (l_prep) with_5\IN|and|specificity|the (l_pobj) PPH_6\NNP|NONE
D005277_D006976 CID fenfluramines_30\NNS|to|causally|are|that (r_nsubjpass) related_33\VBN|NONE (l_prep) to_34\IN|causally|fenfluramines|are|that (l_pobj) PPH_35\NNP|NONE
2818777
D010672_D056486 NONE Phenytoin_0\NNP|.|injury (r_nsubj) induced_1\VBD|NONE (l_dobj) injury_4\NN|.|Phenytoin
D010672_D017093 CID phenytoin_10\NN|NONE (r_compound) administration_11\NN|NONE (r_pobj) after_9\IN|.|A|developed|old|female|fatal|hepatic (r_prep) failure_8\NN|NONE
25986755
D003404_D005355 NONE creatinine_26\NN|NONE (r_nmod) protein_29\NN|NONE (r_pobj) of_24\IN|elevated (r_prep) levels_23\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) accompanied_20\VBN|kidneys|glomerulosclerosis|that (r_advcl) exhibited_12\VBD|results|. (l_dobj) glomerulosclerosis_13\NN|kidneys|accompanied|that (l_conj) fibrosis_18\NN|as
D003404_D005921 NONE creatinine_26\NN|NONE (r_nmod) protein_29\NN|NONE (r_pobj) of_24\IN|elevated (r_prep) levels_23\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) accompanied_20\VBN|kidneys|glomerulosclerosis|that (r_advcl) exhibited_12\VBD|results|. (l_dobj) glomerulosclerosis_13\NN|kidneys|accompanied|that
D002110_D005317 CID caffeine_7\NN|PCE (r_compound) exposure_8\NN|that|could|retardation (r_nsubj) induce_13\VB|.|has|study (l_dobj) retardation_16\NN|that|could|exposure
D002110_D005317 CID caffeine_7\NN|PCE (r_compound) exposure_8\NN|that|could|retardation (r_nsubj) induce_13\VB|.|has|study (l_dobj) retardation_16\NN|that|could|exposure (l_appos) IUGR_18\NNP|intrauterine|growth
D002110_D005921 NONE caffeine_18\NN|NONE (r_compound) exposure_19\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|adult (r_acl) offspring_14\NN|NONE (r_pobj) in_12\IN|.|origin|programming (r_prep) mediates_6\VBZ|NONE (l_dobj) origin_9\NN|.|programming|in (l_prep) of_10\IN|the|developmental (l_pobj) glomerulosclerosis_11\NN|NONE
2217015
D008528_D051437 CID acid_1\NN|neutropenia||. (r_npadvmod) induced_3\VBN|NONE (l_dobj) neutropenia_4\NN|acid||. (l_conj) failure_7\NN|and|with|in
D008528_D051437 CID acid_3\NN| (r_npadvmod) induced_5\VBN|occurring|oliguric|and|renal|mefenamic (r_amod) failure_10\NN|We|.
D008528_D009503 CID acid_1\NN|neutropenia||. (r_npadvmod) induced_3\VBN|NONE (l_dobj) neutropenia_4\NN|acid||.
D008528_D009503 CID acid_3\NN| (r_npadvmod) induced_5\VBN|occurring|oliguric|and|renal|mefenamic (r_amod) failure_10\NN|We|. (l_conj) occurring_14\VBG|oliguric|and|induced|renal|mefenamic (l_compound) neutropenia_13\NN|simultaneously|in
D008528_D007037 NONE acid_1\NN|neutropenia||. (r_npadvmod) induced_3\VBN|NONE (l_dobj) neutropenia_4\NN|acid||. (l_prep) with_11\IN|and|failure|in (l_pobj) hypothyroidism_12\NN|NONE
D008528_D007037 NONE acid_10\NN|in|to|corrected|not (r_dobj) use_8\VB|However|prudent|,|it|.|would (l_prep) in_11\IN|acid|to|corrected|not (l_pobj) patients_13\NNS|NONE (l_amod) hypothyroid_12\JJ|NONE
D008528_D007037 NONE acid_10\NN|in|to|corrected|not (r_dobj) use_8\VB|However|prudent|,|it|.|would (l_advcl) corrected_19\VBN|acid|in|to|not (l_nsubjpass) hypothyroidism_16\NN|has|been|until
15609701
D013015_D002311 NONE Sotalol_0\NNP||spasm|.|in (r_npadvmod) induced_2\VBN|NONE (l_prep) in_5\IN||Sotalol|spasm|. (l_pobj) patient_7\NN|NONE (l_prep) with_8\IN|a (l_pobj) cardiomyopathy_10\NN|NONE
C076259_D017180 NONE hydrochloride_5\NN|NONE (r_pobj) of_3\IN|the (r_prep) administration_2\NN|.|After|was|,|VT (r_nsubjpass) terminated_10\VBN|NONE (l_nsubjpass) VT_8\NNP|.|After|was|administration|,
D013015_D003329 CID Sotalol_0\NNP||spasm|.|in (r_npadvmod) induced_2\VBN|NONE (l_dobj) spasm_4\NN||Sotalol|.|in
D013015_D003329 CID sotalol_15\NN|NONE (r_pobj) of_14\IN|blocking|the|selective (r_prep) properties_13\NNS|NONE (r_pobj) by_5\IN|vasospasm|may|be|. (r_agent) induced_4\VBN|NONE (l_nsubjpass) vasospasm_1\NN|may|be|.|by
D013015_D017180 NONE Sotalol_0\NNP||spasm|.|in (r_npadvmod) induced_2\VBN|NONE (l_prep) in_5\IN||Sotalol|spasm|. (l_pobj) patient_7\NN|NONE (l_prep) with_8\IN|a (l_pobj) cardiomyopathy_10\NN|NONE (l_acl) associated_11\VBN|dilated (l_prep) with_12\IN|NONE (l_pobj) tachycardia_15\NN|NONE
D013015_D017180 NONE sotalol_6\NN|An|class|,|III|alternate (r_appos) agent_4\NN|,|effective|.|also (r_nsubj) was_8\VBD|NONE (l_acomp) effective_10\JJ|,|agent|.|also (l_prep) for_11\IN|NONE (l_pobj) prevention_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) VT_15\NNP|NONE
23433219
D008694_D000987 CID methamphetamine_39\NN|heavy (r_compound) uses_40\NNS|personality|(|and|antisocial|OR=. (r_conj) disorder_28\NN|major|,|(|,|disorder|depressive|OR=.|morbid
D008694_D000987 CID methamphetamine_46\NN| (r_npadvmod) induced_48\VBN|lifetime (r_amod) psychosis_49\NN|NONE (r_pobj) with_44\IN|were|significantly|adjusted|disorder|. (r_prep) associated_43\VBN|NONE (l_nsubjpass) disorder_5\NN|were|significantly|adjusted|with|. (l_appos) disorder_28\NN|major|,|(|,|disorder|depressive|OR=.|morbid
D008694_D000987 CID methamphetamine_15\NN|heavy (r_compound) use_16\NN|antisocial|,|and (r_conj) personality_11\NN|affective|,|morbid
D008694_D019964 NONE methamphetamine_15\NN|heavy (r_compound) use_16\NN|antisocial|,|and (r_conj) personality_11\NN|affective|,|morbid (r_conj) disorder_8\NN|NONE
D008694_D011605 CID methamphetamine_6\NN|in (r_compound) psychosis_7\NN|NONE
D008694_D011605 CID methamphetamine_9\NN| (r_npadvmod) dependent_11\JJ|in (r_amod) patients_12\NNS|NONE (r_pobj) in_8\IN|methamphetamine (r_prep) psychosis_7\NN|NONE
D008694_D011605 CID methamphetamine_14\NN| (r_npadvmod) induced_16\VBN|current (r_amod) psychosis_17\NN|and|in
D008694_D011605 CID methamphetamine_21\NN|NONE (r_compound) dependence_22\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) patients_19\NNS|NONE (r_pobj) in_18\IN|and|psychosis (r_prep) lifetime_11\NN|NONE (l_conj) psychosis_17\NN|and|in
D008694_D011605 CID methamphetamine_8\NN|NONE (r_punct) -_9\HYPH|morbidity (r_punct) induced_10\VBN|NONE (r_amod) psychosis_11\NN|NONE
D008694_D011605 CID methamphetamine_5\NN|NONE (r_pobj) of_4\IN|the (r_prep) diagnosis_3\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Patients_0\NNS|using|were (r_nsubjpass) interviewed_12\VBN|NONE (l_advcl) using_13\VBG|Patients|were (l_prep) for_22\IN|Interview (l_pobj) psychosis_26\NN|NONE
D008694_D011605 CID methamphetamine_23\NN| (r_npadvmod) induced_25\VBN|and|Axis (r_amod) psychosis_26\NN|NONE
D008694_D011605 CID methamphetamine_39\NN|heavy (r_compound) uses_40\NNS|personality|(|and|antisocial|OR=. (r_conj) disorder_28\NN|major|,|(|,|disorder|depressive|OR=.|morbid (r_appos) disorder_5\NN|were|significantly|adjusted|with|. (r_nsubjpass) associated_43\VBN|NONE (l_prep) with_44\IN|were|significantly|adjusted|disorder|. (l_pobj) psychosis_49\NN|NONE
D008694_D011605 CID methamphetamine_46\NN| (r_npadvmod) induced_48\VBN|lifetime (r_amod) psychosis_49\NN|NONE
D008694_D011605 CID methamphetamine_10\NN|NONE (r_compound) dependence_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) patients_8\NNS|NONE (r_pobj) in_7\IN|of|a|high (r_prep) risk_4\NN|There|. (l_prep) of_5\IN|a|high|in (l_pobj) psychosis_6\NN|NONE
D008694_D011605 CID methamphetamine_7\NN|NONE (r_compound) dependence_8\NN|NONE (r_pobj) of_6\IN|all (r_prep) cases_5\NNS|that|be|should|for (r_nsubjpass) screened_11\VBN|.|It|is (l_prep) for_12\IN|cases|that|be|should (l_pobj) symptoms_14\NNS|NONE
D008694_D003866 NONE methamphetamine_39\NN|heavy (r_compound) uses_40\NNS|personality|(|and|antisocial|OR=. (r_conj) disorder_28\NN|major|,|(|,|disorder|depressive|OR=.|morbid (r_appos) disorder_5\NN|were|significantly|adjusted|with|.
D008694_D003866 NONE methamphetamine_46\NN| (r_npadvmod) induced_48\VBN|lifetime (r_amod) psychosis_49\NN|NONE (r_pobj) with_44\IN|were|significantly|adjusted|disorder|. (r_prep) associated_43\VBN|NONE (l_nsubjpass) disorder_5\NN|were|significantly|adjusted|with|.
D008694_D001714 CID methamphetamine_39\NN|heavy (r_compound) uses_40\NNS|personality|(|and|antisocial|OR=. (r_conj) disorder_28\NN|major|,|(|,|disorder|depressive|OR=.|morbid (r_appos) disorder_5\NN|were|significantly|adjusted|with|. (l_appos) disorder_16\NN|major|,|(|,|depressive|OR=.|disorder|morbid
D008694_D001714 CID methamphetamine_46\NN| (r_npadvmod) induced_48\VBN|lifetime (r_amod) psychosis_49\NN|NONE (r_pobj) with_44\IN|were|significantly|adjusted|disorder|. (r_prep) associated_43\VBN|NONE (l_nsubjpass) disorder_5\NN|were|significantly|adjusted|with|. (l_appos) disorder_16\NN|major|,|(|,|depressive|OR=.|disorder|morbid
16112787
C048498_-1 NONE erdosteine_33\NN|the (r_amod) groups_34\NNS|and|the (r_conj) control_30\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) those_27\DT|NONE (r_pobj) than_26\IN|NONE (r_prep) more_25\JJR|a|significant|,|vacuolization|of (r_amod) dilatation_4\NN|There|. (l_conj) vacuolization_12\NN|a|significant|,|of|more (l_conj) atrophy_14\NN|cell|in|epithelial|extensive|, (l_conj) desquamation_16\NN|,
D014640_D009336 NONE VCM_21\NNP| (r_npadvmod) treated_23\VBN|NONE (r_amod) rats_24\NNS|NONE (r_pobj) in_20\IN|cell|epithelial|atrophy|extensive|, (r_prep) vacuolization_12\NN|a|significant|,|of|more (l_conj) atrophy_14\NN|cell|in|epithelial|extensive|, (l_conj) desquamation_16\NN|, (l_conj) necrosis_19\NN|,|and
D014640_D007674 CID vancomycin_12\NNP| (r_npadvmod) induced_14\VBN|protection|: (r_amod) nephrotoxicity_15\NN|NONE
D014640_D007674 CID vancomycin_8\NNP|oxidative|(|promotes|and|VCM)induced (r_det) stress_12\NN|to|investigate (r_dobj) examine_7\VB|.|aims (l_advcl) investigate_25\VB|stress|to (l_dobj) role_27\NN|to (l_appos) agent_33\NN|,|of|the (l_prep) on_41\IN|an|,|expectorant|,|has (l_pobj) tissue_43\NN|NONE (l_prep) against_44\IN|kidney (l_pobj) impairment_51\NN|NONE
D014640_D007674 CID VCM)-induced_10\VBN|oxidative|(|promotes|and|vancomycin (r_amod) stress_12\NN|to|investigate (r_dobj) examine_7\VB|.|aims (l_advcl) investigate_25\VB|stress|to (l_dobj) role_27\NN|to (l_appos) agent_33\NN|,|of|the (l_prep) on_41\IN|an|,|expectorant|,|has (l_pobj) tissue_43\NN|NONE (l_prep) against_44\IN|kidney (l_pobj) impairment_51\NN|NONE
D014640_D007674 CID VCM_47\NN| (r_npadvmod) induced_49\VBN|possible|in|the|renal (r_amod) impairment_51\NN|NONE
D014640_D007674 CID VCM_0\NN|NONE (r_compound) administration_1\NN|decreased|.|but|rats|to|malondialdehyde (r_nsubj) control_3\VB|NONE (l_dobj) malondialdehyde_8\NN|decreased|.|but|administration|rats|to (l_appos) excretion_33\NN|(|increased|renal|MDA (l_nmod) glucosaminidase_22\NN|NONE (l_appos) NAG_24\NN|beta|d||(||urinary|) (l_appos) marker_27\NN|, (l_prep) of_28\IN|a (l_pobj) injury_31\NN|NONE
D014640_D007674 CID VCM_5\NNP| (r_npadvmod) induced_7\VBN|NONE (r_amod) nephrotoxicity_8\NN|NONE
D014640_D007674 CID VCM_13\NNP| (r_npadvmod) induced_15\VBN|the (r_amod) nephrotoxicity_16\NN|NONE
D014640_D007674 CID VCM_13\NNP| (r_npadvmod) induced_15\VBN|the (r_amod) nephrotoxicity_16\NN|NONE (r_pobj) in_11\IN|an|and|modulation|important (r_prep) role_10\NN|damage|that (r_dobj) plays_7\VBZ|reduces|It|is|. (r_ccomp) concluded_2\VBN|NONE (l_conj) reduces_25\VBZ|It|is|plays|. (l_dobj) damage_31\NN|NONE
D014640_D007674 CID VCM_27\NNP| (r_npadvmod) induced_29\VBN|the|kidney|at (r_amod) damage_31\NN|NONE (r_dobj) reduces_25\VBZ|It|is|plays|. (r_conj) concluded_2\VBN|NONE (l_ccomp) plays_7\VBZ|reduces|It|is|. (l_dobj) role_10\NN|damage|that (l_prep) in_11\IN|an|and|modulation|important (l_pobj) nephrotoxicity_16\NN|NONE
D014640_D007674 CID VCM_27\NNP| (r_npadvmod) induced_29\VBN|the|kidney|at (r_amod) damage_31\NN|NONE
C048498_D007674 NONE erdosteine_19\NN|NONE (r_pobj) by_18\IN|NONE (r_prep) protection_17\NN|induced|: (r_appos) nephrotoxicity_15\NN|NONE
C048498_D007674 NONE erdosteine_29\NN|NONE (r_pobj) of_28\IN|,|agent|the (r_prep) role_27\NN|to (l_appos) agent_33\NN|,|of|the (l_prep) on_41\IN|an|,|expectorant|,|has (l_pobj) tissue_43\NN|NONE (l_prep) against_44\IN|kidney (l_pobj) impairment_51\NN|NONE
C048498_D007674 NONE Erdosteine_0\NNP|.|protection (r_nsubj) showed_1\VBD|NONE (l_dobj) protection_3\NN|Erdosteine|. (l_prep) against_4\IN|histopathological (l_pobj) nephrotoxicity_8\NN|NONE
C048498_D007674 NONE erdosteine_24\NN|NONE (r_pobj) with_23\IN|of|the (r_prep) modulation_19\NN|an|in|and|important (r_conj) role_10\NN|damage|that (l_prep) in_11\IN|an|and|modulation|important (l_pobj) nephrotoxicity_16\NN|NONE
C048498_D007674 NONE erdosteine_24\NN|NONE (r_pobj) with_23\IN|of|the (r_prep) modulation_19\NN|an|in|and|important (r_conj) role_10\NN|damage|that (r_dobj) plays_7\VBZ|reduces|It|is|. (r_ccomp) concluded_2\VBN|NONE (l_conj) reduces_25\VBZ|It|is|plays|. (l_dobj) damage_31\NN|NONE
C048498_D009336 NONE erdosteine_33\NN|the (r_amod) groups_34\NNS|and|the (r_conj) control_30\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) those_27\DT|NONE (r_pobj) than_26\IN|NONE (r_prep) more_25\JJR|a|significant|,|vacuolization|of (r_amod) dilatation_4\NN|There|. (l_conj) vacuolization_12\NN|a|significant|,|of|more (l_conj) atrophy_14\NN|cell|in|epithelial|extensive|, (l_conj) desquamation_16\NN|, (l_conj) necrosis_19\NN|,|and
D014640_-1 NONE VCM_21\NNP| (r_npadvmod) treated_23\VBN|NONE (r_amod) rats_24\NNS|NONE (r_pobj) in_20\IN|cell|epithelial|atrophy|extensive|, (r_prep) vacuolization_12\NN|a|significant|,|of|more (l_conj) atrophy_14\NN|cell|in|epithelial|extensive|, (l_conj) desquamation_16\NN|,
D010100_D007674 NONE oxygen_18\NN|ROS|)|(|reactive (r_compound) species_19\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) production_15\NN|that (r_dobj) promotes_14\VBZ|oxidative|(|and|VCM)induced|vancomycin (r_relcl) stress_12\NN|to|investigate (r_dobj) examine_7\VB|.|aims (l_advcl) investigate_25\VB|stress|to (l_dobj) role_27\NN|to (l_appos) agent_33\NN|,|of|the (l_prep) on_41\IN|an|,|expectorant|,|has (l_pobj) tissue_43\NN|NONE (l_prep) against_44\IN|kidney (l_pobj) impairment_51\NN|NONE
D008315_D007674 NONE malondialdehyde_8\NN|decreased|.|but|administration|rats|to (l_appos) excretion_33\NN|(|increased|renal|MDA (l_nmod) glucosaminidase_22\NN|NONE (l_appos) NAG_24\NN|beta|d||(||urinary|) (l_appos) marker_27\NN|, (l_prep) of_28\IN|a (l_pobj) injury_31\NN|NONE
D008315_D007674 NONE MDA_10\NNP|(|excretion|increased|renal (r_appos) malondialdehyde_8\NN|decreased|.|but|administration|rats|to (l_appos) excretion_33\NN|(|increased|renal|MDA (l_nmod) glucosaminidase_22\NN|NONE (l_appos) NAG_24\NN|beta|d||(||urinary|) (l_appos) marker_27\NN|, (l_prep) of_28\IN|a (l_pobj) injury_31\NN|NONE
D013481_D007674 NONE superoxide_36\NN|and|activities|SOD|(|) (r_amod) dismutase_37\NN|NONE (r_dobj) decreased_35\VBD|.|but|administration|rats|to|malondialdehyde (r_conj) control_3\VB|NONE (l_dobj) malondialdehyde_8\NN|decreased|.|but|administration|rats|to (l_appos) excretion_33\NN|(|increased|renal|MDA (l_nmod) glucosaminidase_22\NN|NONE (l_appos) NAG_24\NN|beta|d||(||urinary|) (l_appos) marker_27\NN|, (l_prep) of_28\IN|a (l_pobj) injury_31\NN|NONE
D014640_D001284 NONE VCM_21\NNP| (r_npadvmod) treated_23\VBN|NONE (r_amod) rats_24\NNS|NONE (r_pobj) in_20\IN|cell|epithelial|atrophy|extensive|, (r_prep) vacuolization_12\NN|a|significant|,|of|more (l_conj) atrophy_14\NN|cell|in|epithelial|extensive|,
C048498_D001284 NONE erdosteine_33\NN|the (r_amod) groups_34\NNS|and|the (r_conj) control_30\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) those_27\DT|NONE (r_pobj) than_26\IN|NONE (r_prep) more_25\JJR|a|significant|,|vacuolization|of (r_amod) dilatation_4\NN|There|. (l_conj) vacuolization_12\NN|a|significant|,|of|more (l_conj) atrophy_14\NN|cell|in|epithelial|extensive|,
11439380
D013792_D011471 NONE Thalidomide_0\NNP|.|in (r_compound) neuropathy_1\NN|NONE (l_prep) in_2\IN|Thalidomide|. (l_pobj) patients_3\NNS|NONE (l_acl) treated_4\VBN|NONE (l_prep) for_5\IN|NONE (l_pobj) cancer_8\NN|NONE
D013792_D011471 NONE thalidomide_19\NN|NONE (r_pobj) of_17\IN|an|label (r_prep) trial_16\NN|NONE (r_pobj) in_11\IN|with|seven (r_prep) men_3\NNS|.|to|examinations (l_prep) with_4\IN|in|seven (l_pobj) cancer_10\NN|NONE
D013792_D009422 NONE Thalidomide_0\NNP|.|in (r_compound) neuropathy_1\NN|NONE
D013792_D009422 NONE thalidomide_3\NN| (r_npadvmod) induced_5\VBN|using (r_amod) neuropathy_6\NN|We|.|prospectively
D013792_D009422 NONE thalidomide_8\NN|NONE (r_pobj) of_7\IN|a|common|in (r_prep) complication_6\NN|thus|may|.|Neuropathy (r_attr) be_3\VB|NONE (l_nsubj) Neuropathy_0\NNP|thus|may|.|complication
D000728_D011471 NONE androgen_6\JJ| (r_npadvmod) independent_8\JJ|metastatic|prostate (r_amod) cancer_10\NN|NONE
24842192
D000667_D009203 NONE AMP_20\NNP| (r_npadvmod) activated_22\VBN|AMPK|protein (r_amod) kinase_24\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) activation_18\NN|to (r_pobj) due_16\JJ|.|effect|treatment (r_prep) has_4\VBZ|NONE (l_dobj) effect_7\NN|due|.|treatment (l_prep) in_8\IN|a|by|protective (l_pobj) infarction_10\NN|NONE
D007545_D009369 NONE isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|in (r_amod) elevation_6\NN|.|,|myeloid|markedly|Metfromin (r_dobj) lowered_2\VBD|NONE (l_advcl) myeloid_14\NN|.|,|elevation|markedly|Metfromin (l_dobj) protein_16\NN|in (l_appos) factor_24\NN|MyD||,|differentiation|) (l_compound) necrosis_23\NN|interleukin||alpha|,|and (l_compound) tumor_22\NN|NONE
D007545_D009203 CID Isoproterenol_0\NNP|was|.|subcutaneously|induce|on (r_nsubjpass) injected_7\VBN|NONE (l_advcl) induce_16\VB|was|.|subcutaneously|Isoproterenol|on (l_dobj) infarction_19\NN|to
D008687_D018487 NONE metformin_3\NN|NONE (r_pobj) with_2\IN|Chronic (r_prep) treatment_1\NN|and|left|.|attenuates|receptor (r_nsubj) suppresses_4\VBZ|NONE (l_conj) left_13\VBN|treatment|and|.|attenuates|receptor (l_dobj) dysfunction_15\NN|NONE
D008687_D018487 NONE metformin_18\NN|NONE (r_pobj) of_17\IN|/| (r_prep) kg_16\NNS|NONE (r_pobj) with_11\IN|NONE (r_prep) treated_10\VBN|the (r_acl) groups_9\NNS|NONE (r_pobj) in_7\IN|dysfunction|lower|. (r_prep) was_4\VBD|NONE (l_nsubj) dysfunction_3\NN|in|lower|.
D008687_D006331 NONE metformin_13\NN|TLR|following|)|( (l_prep) on_14\IN|with|,|In|effect (l_pobj) dysfunction_16\NN|NONE
D008687_D009203 NONE metformin_3\NN|NONE (r_pobj) with_2\IN|Chronic (r_prep) treatment_1\NN|and|left|.|attenuates|receptor (r_nsubj) suppresses_4\VBZ|NONE (l_conj) left_13\VBN|treatment|and|.|attenuates|receptor (l_dobj) dysfunction_15\NN|NONE (l_prep) following_16\VBG|ventricular (l_pobj) infarction_18\NN|NONE
D008687_D009203 NONE metformin_3\NN|NONE (r_pobj) with_2\IN|Acute (r_prep) treatment_1\NN|due|.|effect (r_nsubj) has_4\VBZ|NONE (l_dobj) effect_7\NN|due|.|treatment (l_prep) in_8\IN|a|by|protective (l_pobj) infarction_10\NN|NONE
D008687_D009203 NONE metformin_13\NN|TLR|following|)|( (r_nmod) activities_26\NNS|.|were (l_acl) following_27\VBG|TLR|metformin|)|( (l_pobj) infarction_29\NN|NONE
D008687_D009203 NONE metformin_5\NN|suppresses|.|and|dysfunction (r_nsubj) reduces_6\VBZ|NONE (l_dobj) dysfunction_12\NN|suppresses|.|and|metformin (l_nmod) infarction_10\NN|myocardial|cardiac
D007545_D009336 NONE isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|in (r_amod) elevation_6\NN|.|,|myeloid|markedly|Metfromin (r_dobj) lowered_2\VBD|NONE (l_advcl) myeloid_14\NN|.|,|elevation|markedly|Metfromin (l_dobj) protein_16\NN|in (l_appos) factor_24\NN|MyD||,|differentiation|) (l_compound) necrosis_23\NN|interleukin||alpha|,|and
9646784
D006493_D013923 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|.|thromboembolism|, (r_amod) thrombocytopenia_3\NN|NONE (l_conj) thromboembolism_6\NN|.|induced|,
D006493_D013923 CID heparin_13\JJ|NONE (r_compound) therapy_14\NN|NONE (r_pobj) of_12\IN|other|side (r_prep) effects_11\NNS|,|and|paradoxical (r_conj) thromboembolism_6\NN|.|induced|,
D006493_D000505 CID heparin_4\JJ|including (r_compound) therapy_5\NN|NONE (l_prep) including_6\VBG|heparin (l_pobj) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|, (l_conj) reactions_23\NNS|skin|, (l_amod) other_24\JJ|allergic (l_prep) than_25\IN|NONE (l_pobj) thrombocytopenia_26\JJ|NONE (l_conj) alopecia_28\NN|and
D006493_D000505 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|osteoporosis|, (r_amod) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|, (l_conj) reactions_23\NNS|skin|, (l_amod) other_24\JJ|allergic (l_prep) than_25\IN|NONE (l_pobj) thrombocytopenia_26\JJ|NONE (l_conj) alopecia_28\NN|and
D006493_D000505 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|eosinophilia|, (r_amod) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|, (l_conj) reactions_23\NNS|skin|, (l_amod) other_24\JJ|allergic (l_prep) than_25\IN|NONE (l_pobj) thrombocytopenia_26\JJ|NONE (l_conj) alopecia_28\NN|and
D006493_D010024 CID heparin_4\JJ|including (r_compound) therapy_5\NN|NONE (l_prep) including_6\VBG|heparin (l_pobj) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|,
D006493_D010024 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|osteoporosis|, (r_amod) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|,
D006493_D010024 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|eosinophilia|, (r_amod) osteoporosis_15\NN|induced|,
D006493_D012871 CID heparin_4\JJ|including (r_compound) therapy_5\NN|NONE (l_prep) including_6\VBG|heparin (l_pobj) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|,
D006493_D012871 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|osteoporosis|, (r_amod) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|,
D006493_D012871 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|eosinophilia|, (r_amod) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|,
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|.|thromboembolism|, (r_amod) thrombocytopenia_3\NN|NONE
D006493_D013921 CID heparin_13\JJ|NONE (r_compound) therapy_14\NN|NONE (r_pobj) of_12\IN|other|side (r_prep) effects_11\NNS|,|and|paradoxical (r_conj) thromboembolism_6\NN|.|induced|, (r_conj) thrombocytopenia_3\NN|NONE
D006493_D013921 CID heparin_4\JJ|including (r_compound) therapy_5\NN|NONE (l_prep) including_6\VBG|heparin (l_pobj) thrombocytopenia_10\NN|NONE
D006493_D013921 CID heparin_4\JJ|including (r_compound) therapy_5\NN|NONE (l_prep) including_6\VBG|heparin (l_pobj) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|, (l_conj) reactions_23\NNS|skin|, (l_amod) other_24\JJ|allergic (l_prep) than_25\IN|NONE (l_pobj) thrombocytopenia_26\JJ|NONE
D006493_D013921 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|osteoporosis|, (r_amod) thrombocytopenia_10\NN|NONE
D006493_D013921 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|osteoporosis|, (r_amod) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|, (l_conj) reactions_23\NNS|skin|, (l_amod) other_24\JJ|allergic (l_prep) than_25\IN|NONE (l_pobj) thrombocytopenia_26\JJ|NONE
D006493_D013921 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|eosinophilia|, (r_amod) osteoporosis_15\NN|induced|, (r_conj) thrombocytopenia_10\NN|NONE
D006493_D013921 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|eosinophilia|, (r_amod) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|, (l_conj) reactions_23\NNS|skin|, (l_amod) other_24\JJ|allergic (l_prep) than_25\IN|NONE (l_pobj) thrombocytopenia_26\JJ|NONE
D006493_D004342 CID heparin_4\JJ|including (r_compound) therapy_5\NN|NONE (l_prep) including_6\VBG|heparin (l_pobj) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|, (l_conj) reactions_23\NNS|skin|,
D006493_D004342 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|osteoporosis|, (r_amod) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|, (l_conj) reactions_23\NNS|skin|,
D006493_D004342 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|eosinophilia|, (r_amod) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|, (l_conj) reactions_20\NNS|, (l_conj) reactions_23\NNS|skin|,
D006493_D004802 CID heparin_4\JJ|including (r_compound) therapy_5\NN|NONE (l_prep) including_6\VBG|heparin (l_pobj) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|,
D006493_D004802 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|osteoporosis|, (r_amod) thrombocytopenia_10\NN|NONE (l_conj) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|,
D006493_D004802 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|eosinophilia|, (r_amod) osteoporosis_15\NN|induced|, (l_conj) eosinophilia_17\NN|associated|,
24582773
C069541_D011595 CID quetiapine_11\NN|high|add||in (r_amod) doses_10\NNS|NONE (r_pobj) by_4\IN|agitation|. (r_prep) induced_3\VBN|NONE (l_nsubj) agitation_2\NN|.|by
C069541_D011595 CID quetiapine_9\NN|NONE (r_pobj) of_8\IN|the|)|(|gradual|day (r_prep) introduction_7\NN|NONE (r_pobj) following_4\VBG|the| (r_prep) h_3\NN|NONE (r_pobj) Within_0\IN|,|patient|contrasting|,|agitation|without|. (r_prep) presented_21\VBD|NONE (l_dobj) agitation_23\NN|,|patient|Within|contrasting|,|without|.
C069541_D011595 CID quetiapine_7\NN|NONE (r_pobj) of_6\IN|later|,|the|gradual|,|led (r_prep) reintroduction_5\NN|The|and (l_relcl) led_13\VBD|of|later|,|the|gradual|, (l_prep) to_14\IN|which (l_pobj) agitation_17\NN|NONE
C069541_D011595 CID quetiapine_7\NN|NONE (r_pobj) of_6\IN|later|,|the|gradual|,|led (r_prep) reintroduction_5\NN|The|and (r_conj) withdrawal_1\NN|us|attribute|. (r_nsubj) enabled_19\VBD|NONE (l_xcomp) attribute_22\VB|withdrawal|us|. (l_dobj) agitation_24\NN|to|to
C069541_D011595 CID quetiapine_27\NN|specifically (r_pobj) to_26\IN|to|agitation (r_prep) attribute_22\VB|withdrawal|us|. (r_xcomp) enabled_19\VBD|NONE (l_nsubj) withdrawal_1\NN|us|attribute|. (l_conj) reintroduction_5\NN|The|and (l_relcl) led_13\VBD|of|later|,|the|gradual|, (l_prep) to_14\IN|which (l_pobj) agitation_17\NN|NONE
C069541_D011595 CID quetiapine_27\NN|specifically (r_pobj) to_26\IN|to|agitation (r_prep) attribute_22\VB|withdrawal|us|. (l_dobj) agitation_24\NN|to|to
D008094_D011618 NONE lithium_41\NN|day|and (r_conj) zuclopenthixol_33\NN|,|generation (r_appos) antipsychotics_31\NNS|NONE (r_pobj) of_27\IN|a (r_prep) combination_26\NN|NONE (r_pobj) by_24\IN|serum (r_agent) treated_23\VBN|of|,|the|since (r_acl) case_3\NN|We|. (l_prep) of_4\IN|,|treated|the|since (l_pobj) suffering_10\NN|NONE (l_prep) from_11\IN|a|old|patient (l_pobj) disorder_15\NN|NONE
D008094_D011618 NONE lithium=0.85_50\NN|)|l|( (r_punct) serum_49\NN|by (r_parataxis) treated_23\VBN|of|,|the|since (r_acl) case_3\NN|We|. (l_prep) of_4\IN|,|treated|the|since (l_pobj) suffering_10\NN|NONE (l_prep) from_11\IN|a|old|patient (l_pobj) disorder_15\NN|NONE
C069541_D010554 NONE quetiapine_9\NN|NONE (r_pobj) of_8\IN|the|)|(|gradual|day (r_prep) introduction_7\NN|NONE (r_pobj) following_4\VBG|the| (r_prep) h_3\NN|NONE (r_pobj) Within_0\IN|,|patient|contrasting|,|agitation|without|. (r_prep) presented_21\VBD|NONE (l_advcl) contrasting_29\VBG|,|patient|Within|,|agitation|without|. (l_prep) with_30\IN|NONE (l_pobj) absence_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) history_35\NN|NONE (l_prep) of_36\IN|a (l_pobj) aggressiveness_37\NN|NONE
C069541_D010554 NONE quetiapine_9\NN|NONE (r_pobj) of_8\IN|the|)|(|gradual|day (r_prep) introduction_7\NN|NONE (r_pobj) following_4\VBG|the| (r_prep) h_3\NN|NONE (r_pobj) Within_0\IN|,|patient|contrasting|,|agitation|without|. (r_prep) presented_21\VBD|NONE (l_advcl) contrasting_29\VBG|,|patient|Within|,|agitation|without|. (l_prep) with_30\IN|NONE (l_pobj) absence_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) history_35\NN|NONE (l_prep) of_36\IN|a (l_pobj) aggressiveness_37\NN|NONE (l_conj) disorder_40\NN|or
C069541_D011618 NONE quetiapine_11\NN|high|add||in (r_amod) doses_10\NNS|NONE (l_prep) in_12\IN|high|add||quetiapine (l_pobj) disorder_16\NN|NONE
D003006_D011618 NONE zuclopenthixol_33\NN|,|generation (r_appos) antipsychotics_31\NNS|NONE (r_pobj) of_27\IN|a (r_prep) combination_26\NN|NONE (r_pobj) by_24\IN|serum (r_agent) treated_23\VBN|of|,|the|since (r_acl) case_3\NN|We|. (l_prep) of_4\IN|,|treated|the|since (l_pobj) suffering_10\NN|NONE (l_prep) from_11\IN|a|old|patient (l_pobj) disorder_15\NN|NONE
24459006
D015725_D013921 CID Fluconazole_0\NNP|.|agranulocytosis (r_nsubj) associated_1\VBD|NONE (l_dobj) agranulocytosis_2\NN|Fluconazole|. (l_conj) thrombocytopenia_4\NN|and
D015725_D013921 CID fluconazole_6\NN|NONE (r_pobj) of_5\IN|a|second (r_prep) case_4\NN|We|agranulocytosis|. (r_dobj) describe_1\VBP|NONE (l_dobj) agranulocytosis_8\NN|We|case|. (l_prep) with_9\IN|associated (l_pobj) thrombocytopenia_10\NN|NONE
D015725_D013921 CID fluconazole_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) therapy_19\NN|NONE (r_pobj) of_18\IN|a (r_prep) result_17\NN|NONE (r_pobj) as_15\IN|agranulocytosis|that (r_prep) occurred_14\VBD|the (l_nsubj) agranulocytosis_11\NN|as|that (l_conj) thrombocytopenia_13\NN|patient|and
D015725_D001855 NONE fluconazole_13\NN|NONE (r_pobj) of_12\IN|and|the|abatement (r_prep) initiation_11\NN|NONE (r_pobj) to_9\IN|temporal|of|the (r_prep) relationship_4\NN|particular|. (l_prep) of_5\IN|to|temporal|the (l_pobj) suppression_8\NN|NONE
D015725_D000380 CID Fluconazole_0\NNP|.|agranulocytosis (r_nsubj) associated_1\VBD|NONE (l_dobj) agranulocytosis_2\NN|Fluconazole|.
D015725_D000380 CID fluconazole_6\NN|NONE (r_pobj) of_5\IN|a|second (r_prep) case_4\NN|We|agranulocytosis|. (r_dobj) describe_1\VBP|NONE (l_dobj) agranulocytosis_8\NN|We|case|.
D015725_D000380 CID fluconazole_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) therapy_19\NN|NONE (r_pobj) of_18\IN|a (r_prep) result_17\NN|NONE (r_pobj) as_15\IN|agranulocytosis|that (r_prep) occurred_14\VBD|the (l_nsubj) agranulocytosis_11\NN|as|that
24234943
C086816_D001008 CID desvenlafaxine_3\NN|included|and|medications|, (r_dobj) included_2\VBD|NONE (l_conj) included_7\VBD|and|medications|,|desvenlafaxine (l_dobj) nausea_8\NN|symptoms|. (l_conj) anxiety_10\NN|,
C086816_D007177 CID desvenlafaxine_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|hormone|antidiuretic|inappropriate (r_acl) secretion_5\NN|NONE (l_compound) hormone_4\NN|antidiuretic|associated|inappropriate
C086816_D007177 CID desvenlafaxine_18\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) associated_16\VBN|)|hormone|inappropriate|SIADH|( (r_acl) secretion_15\NN|NONE (l_nmod) hormone_11\NN|)|inappropriate|SIADH|(|associated
C086816_D007177 CID desvenlafaxine_18\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) associated_16\VBN|)|hormone|inappropriate|SIADH|( (r_acl) secretion_15\NN|NONE (l_nmod) SIADH_13\NNP|)|hormone|inappropriate|(|associated
C086816_D009325 CID desvenlafaxine_3\NN|included|and|medications|, (r_dobj) included_2\VBD|NONE (l_conj) included_7\VBD|and|medications|,|desvenlafaxine (l_dobj) nausea_8\NN|symptoms|.
C086816_D003221 CID desvenlafaxine_3\NN|included|and|medications|, (r_dobj) included_2\VBD|NONE (l_conj) included_7\VBD|and|medications|,|desvenlafaxine (l_dobj) nausea_8\NN|symptoms|. (l_conj) anxiety_10\NN|, (l_conj) confusion_12\NN|and
C086816_D007010 CID desvenlafaxine_5\NN|might|hyponatremia|that (r_nsubj) cause_7\VB|report|. (l_dobj) hyponatremia_10\NN|might|desvenlafaxine|that
D012964_D007177 NONE sodium_2\NN|L (r_nsubj) was_6\VBD|osmolality|mosmol|.|, (r_ccomp) was_14\VBD|NONE (l_attr) mosmol_16\NN|osmolality|was|.|, (l_amod) consistent_34\JJ|,|,|/|kg|osmolality| (l_prep) with_35\IN|NONE (l_pobj) diagnosis_37\NN|NONE (l_prep) of_38\IN|a (l_pobj) SIADH_39\NNP|NONE
D012964_D007177 NONE sodium_28\NN|and|L|/|mosmol (r_conj) kg_25\NNS|urine (r_appos) osmolality_21\NN|,|,|/|kg|consistent| (r_appos) mosmol_16\NN|osmolality|was|.|, (l_amod) consistent_34\JJ|,|,|/|kg|osmolality| (l_prep) with_35\IN|NONE (l_pobj) diagnosis_37\NN|NONE (l_prep) of_38\IN|a (l_pobj) SIADH_39\NNP|NONE
8829135
D001058_D000647 CID apomorphine_5\NN| (r_npadvmod) induced_7\VBN|of (r_amod) amnesia_8\NN|Nefiracetam
D001058_D000647 CID apomorphine_2\NN|NONE (r_pobj) Given_0\VBN|retention|given (r_prep) inhibits_3\VBZ|,|.|ability|we (r_ccomp) evaluated_24\VBD|NONE (l_dobj) ability_26\NN|,|.|inhibits|we (l_acl) attenuate_30\VB|the|of (l_dobj) amnesia_31\NN|to
D001058_D000647 CID apomorphine_13\NN|NONE (r_pobj) by_12\IN|at (r_agent) induced_11\VBN|the (r_acl) amnesia_10\NN|However|was|administration|,|completely|and
D011760_D007859 NONE pyrrolidone_4\NN|a|attenuates|novel (r_compound) derivative_5\NN|.|Nefiracetam (l_relcl) attenuates_7\VBZ|a|novel|pyrrolidone (l_dobj) learning_11\NN|which (l_conj) deficits_17\NNS|induced|and
C058876_D007859 NONE Nefiracetam_0\NNP|.|derivative (r_nsubj) is_1\VBZ|NONE (l_attr) derivative_5\NN|.|Nefiracetam (l_relcl) attenuates_7\VBZ|a|novel|pyrrolidone (l_dobj) learning_11\NN|which (l_conj) deficits_17\NNS|induced|and
D012601_D007859 CID scopolamine_8\NN| (r_npadvmod) induced_10\VBN|deficits|and (r_amod) learning_11\NN|which (l_conj) deficits_17\NNS|induced|and
C058876_D000647 NONE Nefiracetam_0\NNP|amnesia (r_nsubj) reverses_4\VBZ|emergence|.|: (l_dobj) amnesia_8\NN|Nefiracetam
C058876_D000647 NONE DM-9384_2\NNP|(|) (r_appos) Nefiracetam_0\NNP|amnesia (r_nsubj) reverses_4\VBZ|emergence|.|: (l_dobj) amnesia_8\NN|Nefiracetam
C058876_D000647 NONE nefiracetam_28\NN|NONE (r_pobj) of_27\IN|attenuate|the (r_prep) ability_26\NN|,|.|inhibits|we (l_acl) attenuate_30\VB|the|of (l_dobj) amnesia_31\NN|to
C058876_D000647 NONE nefiracetam_4\NN|NONE (r_pobj) of_3\IN|during (r_prep) administration_2\NN|However|was|amnesia|,|completely|and (r_nsubj) reversed_8\VBD|NONE (l_dobj) amnesia_10\NN|However|was|administration|,|completely|and
24709919
C035054_D006930 NONE ginsenosides_15\NNS|NONE (l_prep) on_23\IN|components|,|,|Re (l_pobj) OIH_24\NNP|NONE
C035054_D006930 NONE ginsenosides_6\NNS|However|prevent|,|. (r_nsubj) failed_7\VBD|NONE (l_xcomp) prevent_9\VB|However|ginsenosides|,|. (l_dobj) OIH_10\NNP|in|to
C035054_D006930 NONE Rg1_2\NNP|tendency|.|,|Furthermore (r_nsubj) showed_3\VBD|NONE (l_dobj) tendency_5\NN|.|,|Rg|Furthermore (l_acl) aggravate_7\VB|a (l_dobj) OIH_8\NNP|in|to
C035054_D006930 NONE Rg1_10\NN|the|but|Re (r_conj) ginsenoside_5\NN|that|,|toward|may (r_nsubj) contribute_15\VB|data|. (l_prep) toward_16\IN|ginsenoside|that|,|may (l_pobj) reversal_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) OIH_19\NNP|NONE
D009020_D006930 CID morphine_9\NN|NONE (r_pobj) of_8\IN|subcutaneous (r_prep) administration_7\NN|NONE (r_pobj) after_5\IN|was|OIH|in|for|. (r_prep) achieved_2\VBN|NONE (l_nsubjpass) OIH_0\NNP|was|in|after|for|.
D036145_D006930 NONE ginsenosides_2\NNS|NONE (l_prep) on_3\IN|NONE (l_pobj) hyperalgesia_7\NN|NONE
C049864_D006930 NONE ginsenosides_15\NNS|NONE (l_prep) on_23\IN|components|,|,|Re (l_pobj) OIH_24\NNP|NONE
C049864_D006930 NONE Re_0\IN|NONE (l_appos) mg/kg_3\NNS|.|( (l_dobj) OIH_6\NNP||in
C049864_D006930 NONE Re_6\IN|the|but|Rg (r_prep) ginsenoside_5\NN|that|,|toward|may (r_nsubj) contribute_15\VB|data|. (l_prep) toward_16\IN|ginsenoside|that|,|may (l_pobj) reversal_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) OIH_19\NNP|NONE
D019342_D006930 NONE acid_16\NN||writhing (r_npadvmod) induced_18\VBN|the (r_advcl) acetic_15\JJ|the|sensitivity|both|and (r_conj) test_12\NN|NONE (r_pobj) in_7\IN||OIH (r_prep) mg/kg_3\NNS|.|( (l_dobj) OIH_6\NNP||in
D019342_D006930 NONE acid_12\NN|the||acetic (r_npadvmod) induced_14\VBN|NONE (r_amod) writhing_15\VBG|NONE (r_compound) test_16\NN|NONE (r_pobj) in_9\IN|OIH|to (r_prep) aggravate_7\VB|a (l_dobj) OIH_8\NNP|in|to
C442759_D006930 NONE ginsenosides_15\NNS|NONE (l_prep) on_23\IN|components|,|,|Re (l_pobj) OIH_24\NNP|NONE
C442759_D006930 NONE ginsenosides_6\NNS|However|prevent|,|. (r_nsubj) failed_7\VBD|NONE (l_xcomp) prevent_9\VB|However|ginsenosides|,|. (l_dobj) OIH_10\NNP|in|to
C442759_D006930 NONE Rb1_12\NN|not|or (r_conj) Rg1_10\NN|the|but|Re (r_conj) ginsenoside_5\NN|that|,|toward|may (r_nsubj) contribute_15\VB|data|. (l_prep) toward_16\IN|ginsenoside|that|,|may (l_pobj) reversal_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) OIH_19\NNP|NONE
689020
D005280_D014202 CID hydrobromide_6\NN|NONE (r_compound) infusion_7\NN|NONE (r_pobj) of_3\IN|the (r_prep) end_2\NN|NONE (r_pobj) After_0\IN|.|amplitudes|,|faster (r_prep) decreased_11\VBD|NONE (l_nsubj) amplitudes_10\NNS|.|After|,|faster (l_compound) tremor_9\NN|NONE
D012312_D014202 CID HCl_19\NN|NONE (r_compound) infusion_20\NN|NONE (r_pobj) following_16\VBG|NONE (r_acl) those_15\DT|NONE (r_pobj) than_14\IN|significantly (r_prep) faster_13\RBR|.|After|amplitudes|, (r_advmod) decreased_11\VBD|NONE (l_nsubj) amplitudes_10\NNS|.|After|,|faster (l_compound) tremor_9\NN|NONE
19392810
D003932_D012206 CID heroin_7\NN| (r_npadvmod) dependent_9\JJ|a (r_amod) male_10\NN|NONE (r_pobj) in_5\IN|.|Rhabdomyolysis|under|ischemic (r_prep) stroke_4\NN|NONE (l_nmod) Rhabdomyolysis_0\NNP|.|under|in|ischemic
D003932_D012206 CID heroin_14\NN|NONE (r_pobj) after_12\IN|with|man|. (r_prep) presented_5\VBN|NONE (l_prep) with_6\IN|man|.|after (l_pobj) rhabdomyolysis_7\NN|NONE
D003932_D012206 CID heroin_4\NN|and (r_conj) methadone_2\NN|simultaneously (r_dobj) using_1\VBG|NONE (r_acl) Those_0\DT|.|risk|may (r_nsubj) increase_7\VB|NONE (l_dobj) risk_8\NN|.|Those|may (l_prep) of_9\IN|NONE (l_pobj) rhabdomyolysis_10\NN|NONE
D003932_D012206 CID heroin_2\NN| (r_npadvmod) related_4\VBN|stroke|and (r_amod) rhabdomyolysis_5\NN|NONE
D003932_D012206 CID heroin_9\NN|NONE (r_compound) abusers_10\NNS|NONE (r_pobj) in_8\IN|NONE (r_prep) stroke_7\NN|and|related (r_conj) rhabdomyolysis_5\NN|NONE
D003932_D002544 NONE heroin_7\NN| (r_npadvmod) dependent_9\JJ|a (r_amod) male_10\NN|NONE (r_pobj) in_5\IN|.|Rhabdomyolysis|under|ischemic (r_prep) stroke_4\NN|NONE
D003932_D002544 NONE heroin_14\NN|NONE (r_pobj) after_12\IN|with|man|. (r_prep) presented_5\VBN|NONE (l_prep) with_6\IN|man|.|after (l_pobj) rhabdomyolysis_7\NN|NONE (l_conj) stroke_11\NN|and
D003932_D002544 NONE heroin_4\NN|and (r_conj) methadone_2\NN|simultaneously (r_dobj) using_1\VBG|NONE (r_acl) Those_0\DT|.|risk|may (r_nsubj) increase_7\VB|NONE (l_dobj) risk_8\NN|.|Those|may (l_prep) of_9\IN|NONE (l_pobj) rhabdomyolysis_10\NN|NONE (l_conj) stroke_13\NN|and
D008691_D012206 CID methadone_12\NN|maintenance (r_compound) therapy_14\NN|NONE (r_pobj) under_11\IN|.|Rhabdomyolysis|in|ischemic (r_prep) stroke_4\NN|NONE (l_nmod) Rhabdomyolysis_0\NNP|.|under|in|ischemic
D008691_D012206 CID methadone_2\NN|simultaneously (r_dobj) using_1\VBG|NONE (r_acl) Those_0\DT|.|risk|may (r_nsubj) increase_7\VB|NONE (l_dobj) risk_8\NN|.|Those|may (l_prep) of_9\IN|NONE (l_pobj) rhabdomyolysis_10\NN|NONE
D003932_D020521 CID heroin_2\NN| (r_npadvmod) related_4\VBN|stroke|and (r_amod) rhabdomyolysis_5\NN|NONE (l_conj) stroke_7\NN|and|related
D003932_D020521 CID heroin_9\NN|NONE (r_compound) abusers_10\NNS|NONE (r_pobj) in_8\IN|NONE (r_prep) stroke_7\NN|and|related
D008691_D002544 NONE methadone_12\NN|maintenance (r_compound) therapy_14\NN|NONE (r_pobj) under_11\IN|.|Rhabdomyolysis|in|ischemic (r_prep) stroke_4\NN|NONE
D008691_D002544 NONE methadone_2\NN|simultaneously (r_dobj) using_1\VBG|NONE (r_acl) Those_0\DT|.|risk|may (r_nsubj) increase_7\VB|NONE (l_dobj) risk_8\NN|.|Those|may (l_prep) of_9\IN|NONE (l_pobj) rhabdomyolysis_10\NN|NONE (l_conj) stroke_13\NN|and
24451297
C065180_D056486 CID Fluvastatin_10\NNP|NONE (r_compound) Therapy_11\NNP|NONE (r_pobj) After_9\IN| (r_prep) Hours_8\NNS|NONE (r_pobj) Within_6\IN|Liver|.|Induced|Acute (r_prep) Injury_5\NN|NONE
C065180_D056486 CID fluvastatin_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treatment_17\NN|NONE (r_dobj) beginning_16\VBG|hours (r_pcomp) after_15\IN|which (r_prep) appeared_12\VBD|,|liver (r_relcl) damage_9\NN|NONE
D019161_D056486 NONE statins_1\NNS|Although|generally|drugs (r_nsubj) are_2\VBP|been|cases|have|.|, (r_advcl) reported_23\VBN|NONE (l_nsubjpass) cases_10\NNS|been|are|have|.|, (l_prep) of_11\IN|associated|recent (l_pobj) injury_16\NN|NONE
15229250
D008694_D006984 NONE MA_3\NNP|NONE (r_compound) abusers_4\NNS|.|On|.|volumes|, (r_nsubj) had_5\VBD|NONE (l_dobj) 0.05_29\CD|.|On|abusers|volumes|, (l_conj) hypertrophy_36\NN|.|;|)|,|;|right|and|<|p
D008694_D008659 NONE MA_7\NNP|have|who (r_dobj) used_6\VBN|human (r_relcl) subjects_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Studies_0\NNS|.|deficits|have|chronically (r_nsubj) revealed_10\VBN|NONE (l_dobj) deficits_11\NNS|.|have|chronically|Studies (l_prep) in_12\IN|NONE (l_pobj) systems_16\NNS|NONE (l_conj) abnormalities_20\NNS|dopaminergic|and
D008694_D008569 CID methamphetamine_7\NN|chronic (r_compound) abuse_8\NN|pattern|that (r_nsubj) causes_9\VBZ|maps|. (l_dobj) pattern_12\NN|abuse|that (l_prep) of_13\IN|selective|a (l_pobj) deterioration_15\NN|NONE (l_relcl) contributes_17\VBZ|cerebral (l_prep) to_18\IN|that (l_pobj) performance_21\NN|NONE
D008694_D003072 NONE MA_26\NNP|in|chronic (r_compound) abuse_27\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) associated_23\VBN|structural|brain (r_acl) alterations_22\NNS|NONE (r_pobj) of_19\IN|the (r_prep) pattern_18\NN|related|we|and|.|,|Using (r_dobj) determined_16\VBD|NONE (l_conj) related_32\VBD|we|and|.|,|pattern|Using (l_prep) to_35\IN|deficits (l_pobj) impairment_37\NN|NONE
D008694_D001930 CID methamphetamine_20\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|human|the (r_acl) brain_16\NN|NONE
D008694_D001930 CID MA_22\NNP|(|) (r_nmod) abuse_24\NN|chronic (r_appos) methamphetamine_20\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|human|the (r_acl) brain_16\NN|NONE
D008694_D001930 CID MA_34\NNP|who (r_dobj) used_33\VBD|human| (r_relcl) subjects_31\NNS|NONE (r_pobj) in_28\IN|NONE (r_prep) ventricles_27\NNS|and|white|,
D008694_D001930 CID MA_10\NNP|NONE (r_compound) abuse_11\NN|NONE (r_pobj) of_9\IN|the (r_prep) symptoms_8\NNS|NONE (r_pobj) for_6\IN|NONE (r_prep) account_5\VB|.|providing|,|may|substrates (r_xcomp) help_4\VB|NONE (l_advcl) providing_13\VBG|.|,|account|may|substrates (l_dobj) targets_15\NNS|NONE (l_prep) for_16\IN|therapeutic (l_pobj) injury_21\NN|NONE
16867246
D002746_D012559 NONE chlorpromazine_5\NN| (r_npadvmod) induced_7\VBN|and|DRD (r_conj) polymorphisms_3\NNS|in|extrapyramidal (r_nmod) syndrome_9\NN|NONE (l_prep) in_10\IN|polymorphisms|extrapyramidal (l_pobj) patients_13\NNS|NONE (l_amod) schizophrenic_12\JJ|Chinese
D002746_D012559 NONE chlorpromazine_11\NN| (r_npadvmod) induced_13\VBN|in (r_amod) EPS_14\NNP|NONE (l_prep) in_15\IN|induced (l_pobj) patients_17\NNS|NONE (l_amod) schizophrenic_16\JJ|NONE
D002746_D012559 NONE chlorpromazine_38\NN|NONE (r_pobj) with_37\IN|,|after|TaqIB|.|rs (r_prep) treated_36\VBN|NONE (l_nsubj) rs6275_6\ADD|,|after|TaqIB|.|with (l_prep) in_12\IN|rs|SerCys|)|,|, (l_pobj) gene_15\NN|NONE (l_prep) in_16\IN|DRD|the (l_pobj) inpatients_19\NNS|NONE (l_amod) schizophrenic_18\JJ|(|according||
D002746_D012559 NONE chlorpromazine_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|the|variable|adverse (r_acl) effect_27\NN|NONE (r_pobj) in_22\IN|variation|that|in|,|role (r_prep) plays_18\VBZ|the (l_prep) in_34\IN|variation|in|that|,|role (l_pobj) patients_36\NNS|least (l_prep) with_37\IN|Chinese (l_pobj) schizophrenia_38\NN|NONE
D002746_D001480 CID chlorpromazine_5\NN| (r_npadvmod) induced_7\VBN|and|DRD (r_conj) polymorphisms_3\NNS|in|extrapyramidal (r_nmod) syndrome_9\NN|NONE
D002746_D001480 CID chlorpromazine_11\NN| (r_npadvmod) induced_13\VBN|in (r_amod) EPS_14\NNP|NONE
D002746_D001480 CID chlorpromazine_38\NN|NONE (r_pobj) with_37\IN|,|after|TaqIB|.|rs (r_prep) treated_36\VBN|NONE (l_nsubj) rs6275_6\ADD|,|after|TaqIB|.|with (l_prep) in_12\IN|rs|SerCys|)|,|, (l_pobj) gene_15\NN|NONE (l_prep) in_16\IN|DRD|the (l_pobj) inpatients_19\NNS|NONE (l_appos) 59_21\CD|schizophrenic|(|according| (l_prep) with_22\IN||and (l_pobj) EPS_23\NNP|NONE
D002746_D001480 CID chlorpromazine_38\NN|NONE (r_pobj) with_37\IN|,|after|TaqIB|.|rs (r_prep) treated_36\VBN|NONE (l_nsubj) rs6275_6\ADD|,|after|TaqIB|.|with (l_prep) in_12\IN|rs|SerCys|)|,|, (l_pobj) gene_15\NN|NONE (l_prep) in_16\IN|DRD|the (l_pobj) inpatients_19\NNS|NONE (l_appos) 59_21\CD|schizophrenic|(|according| (l_conj) 87_25\CD|and|with (l_prep) without_26\IN|NONE (l_pobj) EPS_27\NNP|NONE
611664
D009638_D004342 NONE norepinephrine_27\NN|NONE (r_pobj) of_25\IN|the|pressor (r_prep) effects_24\NNS|NONE (r_pobj) to_21\IN|NONE (r_prep) hypersensitivity_20\NN|had
D002395_D004342 NONE catecholamines_6\NNS|They|marked|.|and (r_dobj) exhibited_2\VBD|NONE (l_conj) marked_19\VBN|They|catecholamines|.|and (l_dobj) hypersensitivity_20\NN|had
D011433_D006973 CID propranolol_9\NN|NONE (r_pobj) by_8\IN|hypertension|,|In|and|was|had (r_agent) induced_7\VBN|NONE (l_nsubjpass) hypertension_5\NN|,|by|In|and|was|had
D011433_C544351 NONE propranolol_2\NN|NONE (l_prep) in_3\IN|NONE (l_pobj) treatment_5\NN|NONE (l_prep) of_6\IN|the (l_pobj) hypotension_9\NN|NONE
D011433_C544351 NONE propranolol_4\NN|that|drug (r_nsubj) is_5\VBZ|.|studies (l_attr) drug_8\NN|that|propranolol (l_prep) in_9\IN|useful|a (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|selected (l_pobj) hypotension_16\NN|NONE
20513036
C542870_D010243 NONE botox_3\JJ|for (r_compound) injection_4\NN|NONE (r_pobj) after_2\IN|.|Abductor (r_prep) paralysis_1\NN|NONE
C542870_D010243 NONE Botox_10\NNP|complication|,|for (r_compound) injections_11\NNS|NONE (r_pobj) following_9\VBG|.|cases|Here|we (r_prep) report_2\VBP|NONE (l_dobj) cases_4\NNS|.|following|Here|we (l_prep) of_5\IN|multiple (l_pobj) paralysis_8\NN|NONE
C542870_D010243 NONE Botox_12\NNP|dose|paralytic|, (r_compound) dose_13\NN|, (r_conj) sex_9\NN|, (r_conj) age_7\NN|bilateral|,|abductor (r_conj) paralysis_5\NN|NONE
C542870_D010243 NONE Botox_12\NNP|dose|paralytic|, (r_compound) dose_13\NN|, (l_conj) dose_17\NN|paralytic|Botox|, (l_conj) paralysis_22\NN|and|prior|course|,|Botox
C542870_D010243 NONE Botox_16\NNP|and|prior|course|,|paralysis (r_compound) dose_17\NN|paralytic|Botox|, (r_conj) dose_13\NN|, (r_conj) sex_9\NN|, (r_conj) age_7\NN|bilateral|,|abductor (r_conj) paralysis_5\NN|NONE
C542870_D010243 NONE Botox_16\NNP|and|prior|course|,|paralysis (r_compound) dose_17\NN|paralytic|Botox|, (l_conj) paralysis_22\NN|and|prior|course|,|Botox
C542870_D010243 NONE Botox_6\NNP|for (r_compound) injection_7\NN|NONE (r_pobj) after_5\IN|of|The (r_prep) incidence_1\NN|%|. (l_prep) of_2\IN|after|The (l_pobj) paralysis_4\NN|NONE
C542870_D010243 NONE Botox_8\NNP|for (r_compound) injections_9\NNS|NONE (r_pobj) of_7\IN|a|rare (r_prep) complication_6\NN|paralysis|causing|.|, (r_attr) is_3\VBZ|NONE (l_nsubj) paralysis_2\NN|complication|causing|.|,
C542870_D010243 NONE Botox_8\NNP|NONE (r_pobj) of_7\IN|around (r_prep) diffusion_6\NN|.|mechanism (r_attr) is_5\VBZ|NONE (l_nsubj) mechanism_2\NN|diffusion|. (l_prep) of_3\IN|likely|The (l_pobj) paralysis_4\NN|NONE
C542870_D055154 NONE Botox_5\NNP|NONE (r_compound) injections_6\NNS|that|for (r_dobj) received_4\VBD|NONE (l_prep) for_7\IN|injections|that (l_pobj) dysphonia_9\NN|NONE
C542870_D014826 CID botox_3\JJ|for (r_compound) injection_4\NN|NONE (l_prep) for_5\IN|botox (l_pobj) dysphonia_8\NN|NONE
C542870_D014826 CID Botox_3\NNP|Botulinum|(|injections|) (r_appos) toxin_1\NN|.|standard (r_nsubj) are_10\VBP|NONE (l_attr) standard_13\NN|.|toxin (l_prep) for_16\IN|of|the|current (l_pobj) dysphonia_19\NN|NONE
C542870_D014826 CID Botox_3\NNP|Botulinum|(|injections|) (r_appos) toxin_1\NN|.|standard (r_nsubj) are_10\VBP|NONE (l_attr) standard_13\NN|.|toxin (l_prep) for_16\IN|of|the|current (l_pobj) dysphonia_19\NN|NONE (l_appos) ADSD_21\NNP|adductor|spasmodic|)|(
C542870_D014826 CID Botox_10\NNP|complication|,|for (r_compound) injections_11\NNS|NONE (l_prep) for_12\IN|complication|Botox|, (l_pobj) ADSD_13\NNP|NONE
C542870_D014826 CID Botox_7\NNP|NONE (r_dobj) receiving_6\VBG| (r_acl) patients_5\NNS|NONE (r_pobj) of_3\IN|a (r_prep) database_2\NN|NONE (r_pobj) From_0\IN|been|patients|with|had|,|. (r_prep) diagnosed_13\VBN|NONE (l_prep) with_14\IN|been|patients|had|,|.|From (l_pobj) ADSD_15\NNP|NONE
C542870_D014826 CID Botox_6\NNP|for (r_compound) injection_7\NN|NONE (l_prep) for_8\IN|Botox (l_pobj) ADSD_9\NNP|NONE
C542870_D014826 CID Botox_8\NNP|for (r_compound) injections_9\NNS|NONE (l_prep) for_10\IN|Botox (l_pobj) ADSD_11\NNP|NONE
2614930
D009543_D009422 NONE Nifedipine_0\NNP|.|bradycardia|in (r_nsubj) induced_1\VBD|NONE (l_prep) in_3\IN|.|bradycardia|Nifedipine (l_pobj) patient_5\NN|NONE (l_prep) with_6\IN|a (l_pobj) neuropathy_8\NN|NONE
D009543_D013610 CID nifedipine_10\NN|in|that|tachycardia (r_nsubj) induces_11\VBZ|established|the (l_dobj) tachycardia_12\VBG|nifedipine|in|that
D009543_D001919 CID Nifedipine_0\NNP|.|bradycardia|in (r_nsubj) induced_1\VBD|NONE (l_dobj) bradycardia_2\NNP|.|Nifedipine|in
D009543_D001282 NONE nifedipine_21\NN|to|down|which (r_advcl) slowed_14\VBD|of|ventricular|a (r_relcl) rate_10\NN|NONE (r_pobj) at_7\IN|to|flutter (r_prep) have_4\VB|was|He|. (l_dobj) flutter_6\NN|at|to
24614773
D014635_D020325 NONE valproate_25\NN|on|been|had (l_prep) for_26\IN|NONE (l_pobj) migraine_29\NN|NONE
D014635_D010291 NONE valproate_25\NN|on|been|had (r_conj) started_23\VBN|patient|,|and|In|,|.|number (r_conj) had_7\VBD|NONE (l_dobj) number_9\NN|patient|,|and|started|In|,|. (l_prep) of_10\IN|a (l_pobj) admissions_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) hemiparesis_15\NN|NONE
D014635_D001927 NONE valproate_4\VBP|Normoammonemic|:|? (r_acl) encephalopathy_1\NN|NONE
D014635_D001927 NONE valproate_4\NN| (r_npadvmod) induced_6\VBN|and|encephalitis (r_amod) encephalopathy_7\JJ|NONE
D016202_D004660 NONE NMDA_9\NNP|associated (r_nmod) encephalitis_13\NN|and|induced
D016202_D001927 NONE aspartate_20\NNP|receptor|titre|low (r_nmod) antibodies_25\NNS|and|, (r_conj) encephalopathy_9\JJ|NONE
D016202_D001927 NONE NMDA_22\NNP|)|( (r_nmod) receptor_24\NN|aspartate|titre|low (r_compound) antibodies_25\NNS|and|, (r_conj) encephalopathy_9\JJ|NONE
D016202_D001927 NONE NMDA_9\NNP|associated (r_nmod) encephalitis_13\NN|and|induced (r_conj) encephalopathy_7\JJ|NONE
D014635_D004660 NONE valproate_4\NN| (r_npadvmod) induced_6\VBN|and|encephalitis (r_amod) encephalopathy_7\JJ|NONE (l_conj) encephalitis_13\NN|and|induced
17042797
D010862_D013226 CID pilocarpine_14\NN| (r_npadvmod) induced_16\VBN|epilepticus (r_amod) status_17\NN|NONE (l_acl) epilepticus_18\NN|induced
D010862_D013226 CID pilocarpine_22\NN| (r_npadvmod) induced_24\VBN|NONE (r_amod) status_25\NN|NONE (r_nsubj) epilepticus_26\NN|NONE
D010862_D004833 CID pilocarpine_16\NN|of|the (r_amod) model_17\NN|NONE (l_prep) of_18\IN|pilocarpine|the (l_pobj) epilepsy_21\NN|NONE
7378868
D010197_D014313 NONE pancuronium_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) pretreatment_19\NN|NONE (r_pobj) despite_18\IN|in (r_prep) suxamethonium_12\NN|NONE (r_pobj) after_11\IN|that|rigidity|may (r_prep) occur_10\VB|.|case (l_nsubj) rigidity_6\NN|that|after|may
D013390_D063806 CID Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|myalgia|associated|jaw|and (r_amod) stiffness_4\NN|.|case|: (l_conj) myalgia_6\NN|associated|jaw|induced|and
D013390_D063806 CID suxamethonium_12\NN|NONE (r_pobj) after_11\IN|that|rigidity|may (r_prep) occur_10\VB|.|case (l_nsubj) rigidity_6\NN|that|after|may (l_conj) myalgia_8\NN|prolonged|and|jaw
D013390_D014313 CID Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|myalgia|associated|jaw|and (r_amod) stiffness_4\NN|.|case|:
D013390_D014313 CID suxamethonium_12\NN|NONE (r_pobj) after_11\IN|that|rigidity|may (r_prep) occur_10\VB|.|case (l_nsubj) rigidity_6\NN|that|after|may
D010197_D063806 NONE pancuronium_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) pretreatment_19\NN|NONE (r_pobj) despite_18\IN|in (r_prep) suxamethonium_12\NN|NONE (r_pobj) after_11\IN|that|rigidity|may (r_prep) occur_10\VB|.|case (l_nsubj) rigidity_6\NN|that|after|may (l_conj) myalgia_8\NN|prolonged|and|jaw
9869655
D004997_D002780 CID ethinylestradiol_6\NNP|with|is|that (l_appos) cholestasis_10\NN||alpha
D004997_D002780 CID EE)-induced_8\VBN|in|intrahepatic|( (r_nmod) cholestasis_10\NN||alpha
D001647_D002780 NONE salt_24\NN|BS (r_nmod) synthesis_28\NN|NONE (r_pobj) of_22\IN|the|neutral (r_prep) pathway_21\NN|NONE (r_pobj) of_18\IN|selective (r_prep) inhibition_17\NN|NONE (r_pobj) with_15\IN|is|that|ethinylestradiol (r_prep) associated_14\VBN|.|study (l_nsubjpass) ethinylestradiol_6\NNP|with|is|that (l_appos) cholestasis_10\NN||alpha
D001647_D002780 NONE BS_26\NN|salt (r_nmod) synthesis_28\NN|NONE (r_pobj) of_22\IN|the|neutral (r_prep) pathway_21\NN|NONE (r_pobj) of_18\IN|selective (r_prep) inhibition_17\NN|NONE (r_pobj) with_15\IN|is|that|ethinylestradiol (r_prep) associated_14\VBN|.|study (l_nsubjpass) ethinylestradiol_6\NNP|with|is|that (l_appos) cholestasis_10\NN||alpha
11366874
D019888_D001145 NONE Viracept_0\NNP|heartbeat|. (r_amod) warning_4\NN|NONE (l_compound) heartbeat_3\NN|.|Viracept
D019888_D001145 NONE Viracept_11\NNP|that|may|beat (r_nsubj) cause_13\VB|.|group (l_ccomp) beat_17\VBD|that|may|Viracept
D019888_D001919 CID Viracept_11\NNP|that|may|beat (r_nsubj) cause_13\VB|.|group (l_ccomp) beat_17\VBD|that|may|Viracept (l_advcl) known_19\VBN|,|,|in|heart (l_prep) as_20\IN|NONE (l_pobj) bradycardia_21\NNP|NONE
D019888_D001919 CID Viracept_11\NNP|who (r_attr) was_10\VBD|male|a|old (r_relcl) patient_8\NN|NONE (r_pobj) in_2\IN|.|Bradycardia (r_prep) occurred_1\VBD|NONE (l_nsubj) Bradycardia_0\NNS|.|in
11423811
D003042_D002637 CID cocaine_17\NN| (r_npadvmod) associated_19\VBN|chest (r_amod) pain_21\NN|NONE
D003042_D002637 CID cocaine_9\NN|NONE (r_compound) use_10\NN|NONE (r_pobj) of_8\IN|the (r_prep) setting_7\NN|NONE (r_pobj) in_5\IN|Chest (r_prep) pain_4\NN|dilemma
D003042_D002637 CID cocaine_13\NN|NONE (r_compound) use_14\NN|NONE (r_pobj) of_12\IN|the (r_prep) setting_11\NN|NONE (r_pobj) in_9\IN|NONE (r_prep) dobutamine_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) administration_6\NN|NONE (r_pobj) regarding_5\VBG|theoretical|the (r_prep) concern_4\NN|of (r_pobj) Because_0\IN|,|.|we|study (r_prep) conducted_17\VBD|NONE (l_dobj) study_20\NN|Because|,|.|we (l_relcl) assess_22\VB|pilot|a (l_dobj) safety_24\NN|to (l_prep) in_27\IN|the|of (l_pobj) patients_30\NNS|NONE (l_prep) with_31\IN|department (l_pobj) pain_36\NN|NONE
D003042_D002637 CID cocaine_32\NN| (r_npadvmod) associated_34\VBN|chest (r_amod) pain_36\NN|NONE
D003042_D002637 CID cocaine_9\NN|within|if|had|they|preceding|had|and (r_dobj) used_8\VBN|eligible|.|Patients (l_advcl) preceding_13\VBG|within|if|had|they|had|cocaine|and (l_dobj) onset_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) pain_18\NN|NONE
D003042_D002637 CID cocaine_13\NN| (r_npadvmod) related_15\VBN|chest (r_amod) pain_17\NN|NONE
D004280_D002637 NONE dobutamine_8\NN|echocardiography (r_compound) stress_9\NN|NONE (l_dobj) echocardiography_10\RB|dobutamine (l_prep) in_11\IN|NONE (l_pobj) evaluation_15\NN|NONE (l_prep) of_16\IN|department|the (l_pobj) pain_21\NN|NONE
D004280_D002637 NONE dobutamine_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) administration_6\NN|NONE (r_pobj) regarding_5\VBG|theoretical|the (r_prep) concern_4\NN|of (r_pobj) Because_0\IN|,|.|we|study (r_prep) conducted_17\VBD|NONE (l_dobj) study_20\NN|Because|,|.|we (l_relcl) assess_22\VB|pilot|a (l_dobj) safety_24\NN|to (l_prep) in_27\IN|the|of (l_pobj) patients_30\NNS|NONE (l_prep) with_31\IN|department (l_pobj) pain_36\NN|NONE
D004280_D002637 NONE dobutamine_7\NN|to|when|was (r_nsubjpass) administered_9\VBN|response|was|. (l_prep) to_10\IN|when|was|dobutamine (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) pain_17\NN|NONE
D004280_D007511 NONE Dobutamine_0\NNP|echocardiography (r_nsubj) stress_1\NN|test|. (r_nsubj) is_6\VBZ|NONE (l_attr) test_12\NN|stress|. (l_prep) for_13\IN|a|available (l_pcomp) evaluating_14\VBG|NONE (l_dobj) ischemia_16\NN|NONE
D003042_D064420 NONE cocaine_5\NN|continuing (r_compound) toxicity_6\NN|NONE
17255138
D000082_D006471 NONE acetaminophen_24\RB|NS||and (r_conj) NSAIDs_22\NNPS|COX|, (r_conj) inhibitors_18\NNS|NONE (r_dobj) using_16\VBG|elderly (r_acl) patients_15\NNS|NONE (r_pobj) among_13\IN|NONE (r_prep) bleeding_12\VBG|the|of
D009288_D006471 CID naproxen_7\NN|,|carry|Among|. (r_nsubj) seemed_8\VBD|NONE (l_xcomp) carry_10\VB|,|Among|naproxen|. (l_dobj) risk_13\NN|to (l_prep) for_14\IN|the|highest (l_pobj) bleeding_18\NN|NONE
C105934_D064420 NONE celecoxib_6\NN|NONE (r_pobj) of_5\IN|The|GI (r_prep) toxicity_4\NN|seemed|.|and|similar
D007052_D009203 NONE ibuprofen_66\NNP|.|and (r_conj) diclofenac_58\NN|.|, (r_conj) naproxen_50\NN|,|.|,|(|)|celecoxib|. (r_appos) rofecoxib_34\XX|:|group|Among|,|. (r_nsubj) were_32\VBD|NONE (l_nsubj) group_31\NN|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS|NONE (l_appos) interval_15\NN|the|adjusted|hazard|) (l_prep) of_17\IN|)|(|%|confidence (l_pobj) hospitalization_18\NN|NONE (l_prep) for_19\IN|NONE (l_pobj) GI_22\NNP|NONE (l_nmod) AMI_20\NNP|with|vs|/
D052246_D006471 NONE inhibitors_18\NNS|NONE (r_dobj) using_16\VBG|elderly (r_acl) patients_15\NNS|NONE (r_pobj) among_13\IN|NONE (r_prep) bleeding_12\VBG|the|of
D000082_D064420 NONE acetaminophen_12\RB|NONE (r_pobj) of_11\IN|NONE (r_prep) that_10\DT|NONE (r_pobj) to_9\IN|NONE (r_prep) similar_8\JJ|seemed|.|and|toxicity (r_acomp) was_7\VBD|NONE (l_nsubj) toxicity_4\NN|seemed|.|and|similar
D001241_D006471 NONE aspirin_5\NN|NONE (r_pobj) of_4\IN|non| (r_prep) users_3\NNS|NONE (r_punct) ,_6\,|carry|Among|naproxen|. (r_punct) seemed_8\VBD|NONE (l_xcomp) carry_10\VB|,|Among|naproxen|. (l_dobj) risk_13\NN|to (l_prep) for_14\IN|the|highest (l_pobj) bleeding_18\NN|NONE
D001241_D009203 NONE aspirin_5\NN|NONE (r_pobj) of_4\IN|non| (r_prep) users_3\NNS|NONE (r_punct) ,_6\,|:|rofecoxib|group|Among|. (r_punct) were_32\VBD|NONE (l_nsubj) group_31\NN|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS|NONE (l_appos) interval_15\NN|the|adjusted|hazard|) (l_prep) of_17\IN|)|(|%|confidence (l_pobj) hospitalization_18\NN|NONE (l_prep) for_19\IN|NONE (l_pobj) GI_22\NNP|NONE (l_nmod) AMI_20\NNP|with|vs|/
D001241_D009203 NONE aspirin_29\NN|( (r_pobj) with_27\IN|AMI|vs|/ (r_parataxis) GI_22\NNP|NONE (l_nmod) AMI_20\NNP|with|vs|/
D001241_D009203 NONE aspirin_5\NN|NONE (r_pobj) of_4\IN|non| (r_prep) users_3\NNS|NONE (r_punct) ,_6\,|carry|Among|naproxen|. (r_punct) seemed_8\VBD|NONE (l_xcomp) carry_10\VB|,|Among|naproxen|. (l_dobj) risk_13\NN|to (l_prep) for_14\IN|the|highest (l_pobj) bleeding_18\NN|NONE (l_compound) GI_17\NNP|NONE (l_nmod) AMI_15\NNP|/
C116926_D009203 CID rofecoxib_34\XX|:|group|Among|,|. (r_nsubj) were_32\VBD|NONE (l_nsubj) group_31\NN|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS|NONE (l_appos) interval_15\NN|the|adjusted|hazard|) (l_prep) of_17\IN|)|(|%|confidence (l_pobj) hospitalization_18\NN|NONE (l_prep) for_19\IN|NONE (l_pobj) GI_22\NNP|NONE (l_nmod) AMI_20\NNP|with|vs|/
C116926_D009203 CID rofecoxib_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) those_19\DT|NONE (r_pobj) than_18\IN|NONE (r_prep) better_17\JJR|to (r_acomp) be_16\VB|NONE (r_xcomp) seemed_14\VBD|.|and|similar|toxicity (r_conj) was_7\VBD|NONE (l_nsubj) toxicity_4\NN|seemed|.|and|similar (l_compound) GI_3\NNP|of|The (l_nmod) AMI_1\NNP|/
D009288_D009203 CID naproxen_50\NN|,|.|,|(|)|celecoxib|. (r_appos) rofecoxib_34\XX|:|group|Among|,|. (r_nsubj) were_32\VBD|NONE (l_nsubj) group_31\NN|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS|NONE (l_appos) interval_15\NN|the|adjusted|hazard|) (l_prep) of_17\IN|)|(|%|confidence (l_pobj) hospitalization_18\NN|NONE (l_prep) for_19\IN|NONE (l_pobj) GI_22\NNP|NONE (l_nmod) AMI_20\NNP|with|vs|/
D009288_D009203 CID naproxen_7\NN|,|carry|Among|. (r_nsubj) seemed_8\VBD|NONE (l_xcomp) carry_10\VB|,|Among|naproxen|. (l_dobj) risk_13\NN|to (l_prep) for_14\IN|the|highest (l_pobj) bleeding_18\NN|NONE (l_compound) GI_17\NNP|NONE (l_nmod) AMI_15\NNP|/
C116926_D064420 NONE rofecoxib_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) those_19\DT|NONE (r_pobj) than_18\IN|NONE (r_prep) better_17\JJR|to (r_acomp) be_16\VB|NONE (r_xcomp) seemed_14\VBD|.|and|similar|toxicity (r_conj) was_7\VBD|NONE (l_nsubj) toxicity_4\NN|seemed|.|and|similar
C105934_D009203 NONE celecoxib_42\NN|,|.|,|(|)|naproxen|. (r_conj) rofecoxib_34\XX|:|group|Among|,|. (r_nsubj) were_32\VBD|NONE (l_nsubj) group_31\NN|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS|NONE (l_appos) interval_15\NN|the|adjusted|hazard|) (l_prep) of_17\IN|)|(|%|confidence (l_pobj) hospitalization_18\NN|NONE (l_prep) for_19\IN|NONE (l_pobj) GI_22\NNP|NONE (l_nmod) AMI_20\NNP|with|vs|/
C105934_D009203 NONE celecoxib_6\NN|NONE (r_pobj) of_5\IN|The|GI (r_prep) toxicity_4\NN|seemed|.|and|similar (l_compound) GI_3\NNP|of|The (l_nmod) AMI_1\NNP|/
D000082_D009203 NONE acetaminophen_24\RB|NS||and (r_conj) NSAIDs_22\NNPS|COX|, (r_conj) inhibitors_18\NNS|NONE (r_dobj) using_16\VBG|elderly (r_acl) patients_15\NNS|NONE (r_pobj) among_13\IN|NONE (r_prep) bleeding_12\VBG|the|of (r_acl) risks_5\NNS|to (l_prep) of_6\IN|the|bleeding (l_pobj) hospitalization_7\NN|NONE (l_prep) for_8\IN|NONE (l_pobj) AMI_9\NNP|NONE
D000082_D009203 NONE acetaminophen_25\NN|NONE (r_pobj) vs_23\IN|with|AMI|/ (r_prep) GI_22\NNP|NONE (l_nmod) AMI_20\NNP|with|vs|/
D000082_D009203 NONE acetaminophen_12\RB|NONE (r_pobj) of_11\IN|NONE (r_prep) that_10\DT|NONE (r_pobj) to_9\IN|NONE (r_prep) similar_8\JJ|seemed|.|and|toxicity (r_acomp) was_7\VBD|NONE (l_nsubj) toxicity_4\NN|seemed|.|and|similar (l_compound) GI_3\NNP|of|The (l_nmod) AMI_1\NNP|/
D052246_D009203 CID inhibitors_11\NNS|NONE (r_pobj) with_9\IN|(|acute|)|AMI|myocardial (r_prep) infarction_5\NN|NONE
D052246_D009203 CID inhibitors_11\NNS|NONE (r_pobj) with_9\IN|(|acute|)|AMI|myocardial (r_prep) infarction_5\NN|NONE (l_appos) AMI_7\NNP|(|acute|)|myocardial|with
D052246_D009203 CID inhibitors_18\NNS|NONE (r_dobj) using_16\VBG|elderly (r_acl) patients_15\NNS|NONE (r_pobj) among_13\IN|NONE (r_prep) bleeding_12\VBG|the|of (r_acl) risks_5\NNS|to (l_prep) of_6\IN|the|bleeding (l_pobj) hospitalization_7\NN|NONE (l_prep) for_8\IN|NONE (l_pobj) AMI_9\NNP|NONE
D000894_D009203 CID drugs_34\NNS|NONE (r_pobj) with_21\IN|NONE (r_prep) compared_20\VBN|risk|.|benefit|may (r_prep) offset_13\VB|NONE (l_nsubj) risk_1\NN|compared|.|benefit|may (l_prep) of_2\IN|The (l_pobj) infarction_5\NN|NONE
D000894_D009203 CID drugs_34\NNS|NONE (r_pobj) with_21\IN|NONE (r_prep) compared_20\VBN|risk|.|benefit|may (r_prep) offset_13\VB|NONE (l_nsubj) risk_1\NN|compared|.|benefit|may (l_prep) of_2\IN|The (l_pobj) infarction_5\NN|NONE (l_appos) AMI_7\NNP|(|acute|)|myocardial|with
D004008_D009203 NONE diclofenac_58\NN|.|, (r_conj) naproxen_50\NN|,|.|,|(|)|celecoxib|. (r_appos) rofecoxib_34\XX|:|group|Among|,|. (r_nsubj) were_32\VBD|NONE (l_nsubj) group_31\NN|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS|NONE (l_appos) interval_15\NN|the|adjusted|hazard|) (l_prep) of_17\IN|)|(|%|confidence (l_pobj) hospitalization_18\NN|NONE (l_prep) for_19\IN|NONE (l_pobj) GI_22\NNP|NONE (l_nmod) AMI_20\NNP|with|vs|/
15953230
C012052_D062787 NONE amisulpride_3\JJ|NONE (r_amod) overdose_4\NN|NONE
C012052_D011041 NONE amisulpride_14\NN|NONE (r_pobj) of_13\IN|,|respectively|. (r_prep) g_12\NN||and|deliberate|with|self (r_conj) poisoning_6\NN|NONE
D002125_D008133 NONE gluconate_11\VBN|NONE (r_pobj) of_8\IN|NONE (r_prep) administration_7\NN|NONE (r_pobj) to_6\IN|to (r_prep) respond_5\VB|.|prolongation (r_xcomp) appeared_3\VBD|NONE (l_nsubj) prolongation_2\NN|.|respond
C012052_D008133 CID amisulpride_3\JJ|NONE (r_amod) overdose_4\NN|NONE (r_pobj) of_2\IN|:|.|Two|cause (r_prep) cases_1\NNS|NONE (l_appos) cause_7\NN|:|of|.|Two (l_prep) for_8\IN|a (l_pobj) syndrome_11\NN|NONE
12498738
C043211_D009202 NONE Carvedilol_0\NNP|against|. (r_nsubj) protects_1\VBZ|NONE (l_prep) against_2\IN|.|Carvedilol (l_pobj) cardiomyopathy_7\NN|NONE
C043211_D009202 NONE carvedilol_7\NN|NONE (r_pobj) by_6\IN|this (r_prep) protection_5\NN|that|in|advantage|may (r_nsubj) afford_18\VB|It|is|. (l_prep) in_22\IN|that|advantage|protection|may (l_pcomp) minimizing_23\VBG|NONE (l_dobj) dysfunction_29\NN|NONE (l_conj) cardiomyopathy_31\NN|the|limiting|mitochondrial|and|accompanies
C043211_D028361 NONE carvedilol_7\NN|NONE (r_pobj) by_6\IN|this (r_prep) protection_5\NN|that|in|advantage|may (r_nsubj) afford_18\VB|It|is|. (l_prep) in_22\IN|that|advantage|protection|may (l_pcomp) minimizing_23\VBG|NONE (l_dobj) dysfunction_29\NN|NONE
D004317_D028361 NONE doxorubicin_37\NN|term (r_compound) therapy_38\NN|in|that (r_dobj) accompanies_33\VBZ|the|limiting|mitochondrial|and|cardiomyopathy (r_relcl) dysfunction_29\NN|NONE
D004317_D064420 NONE doxorubicin_37\JJ|subchronic (r_compound) toxicity_38\NN|NONE
D004317_D009202 CID doxorubicin_3\RB| (r_npadvmod) induced_5\VBN|mitochondrial (r_amod) cardiomyopathy_7\NN|NONE
D004317_D009202 CID doxorubicin_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) caused_16\VBN|cumulative|the|limiting (r_acl) cardiomyopathy_15\NN|to
D004317_D009202 CID doxorubicin_37\NN|term (r_compound) therapy_38\NN|in|that (r_dobj) accompanies_33\VBZ|the|limiting|mitochondrial|and|cardiomyopathy (r_relcl) dysfunction_29\NN|NONE (l_conj) cardiomyopathy_31\NN|the|limiting|mitochondrial|and|accompanies
C043211_D009369 NONE carvedilol_7\NN|NONE (r_pobj) by_6\IN|this (r_prep) protection_5\NN|that|in|advantage|may (r_nsubj) afford_18\VB|It|is|. (l_prep) in_22\IN|that|advantage|protection|may (l_pcomp) minimizing_23\VBG|NONE (l_dobj) dysfunction_29\NN|NONE (l_relcl) accompanies_33\VBZ|the|limiting|mitochondrial|and|cardiomyopathy (l_prep) in_39\IN|therapy|that (l_pobj) patients_41\NNS|NONE (l_compound) cancer_40\NN|NONE
D004317_D009369 NONE doxorubicin_37\NN|term (r_compound) therapy_38\NN|in|that (r_dobj) accompanies_33\VBZ|the|limiting|mitochondrial|and|cardiomyopathy (l_prep) in_39\IN|therapy|that (l_pobj) patients_41\NNS|NONE (l_compound) cancer_40\NN|NONE
C043211_D064420 NONE carvedilol_11\NN|against (r_nsubj) protects_25\VBZ|the (l_prep) against_26\IN|carvedilol (l_pobj) dysfunction_33\NN|NONE (l_acl) associated_34\VBN|the|cardiac|bioenergetic|mitochondrial (l_prep) with_35\IN|NONE (l_pobj) toxicity_38\NN|NONE
19515070
D019343_D064420 NONE citrate_6\NN|unsafe|regional|in (r_compound) anticoagulation_7\NN|carries|.|anticoagulation (r_attr) is_2\VBZ|NONE (l_conj) carries_15\VBZ|.|anticoagulation|anticoagulation (l_dobj) risk_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) toxicity_20\NN|NONE
D019343_D064420 NONE citrate_19\JJ|NONE (r_compound) toxicity_20\NN|NONE
D019343_D064420 NONE citrate_10\JJ|NONE (r_compound) toxicity_11\NN|NONE
D000082_D017114 CID acetaminophen_11\RB| (r_advmod) induced_13\VBN|with|fulminant|liver (r_amod) failure_16\NN|NONE
D019343_D017114 NONE citrate_30\NN|NONE (r_compound) dialysate_31\NN|NONE (r_pobj) with_29\IN|during (r_prep) anticoagulated_28\VBN|liver (r_acl) transplantation_27\NN|NONE (r_pobj) during_25\IN|support|who (r_prep) underwent_21\VBD|associated (r_relcl) AKI_19\NNP|NONE (r_pobj) with_17\IN|induced|fulminant|liver (r_prep) failure_16\NN|NONE
D019343_D017114 NONE Citrate_0\NNP|NONE (r_compound) dialysate_1\NN|.|alternative (r_nsubj) is_2\VBZ|NONE (l_attr) alternative_5\NN|.|dialysate (l_prep) for_6\IN|a|safe (l_pobj) support_8\NN|NONE (l_prep) in_12\IN|of|intradialytic (l_pobj) failure_15\NN|NONE
D000082_D058186 CID acetaminophen_11\RB| (r_advmod) induced_13\VBN|with|fulminant|liver (r_amod) failure_16\NN|NONE (l_prep) with_17\IN|induced|fulminant|liver (l_pobj) AKI_19\NNP|NONE
D019343_D058186 NONE citrate_30\NN|NONE (r_compound) dialysate_31\NN|NONE (r_pobj) with_29\IN|during (r_prep) anticoagulated_28\VBN|liver (r_acl) transplantation_27\NN|NONE (r_pobj) during_25\IN|support|who (r_prep) underwent_21\VBD|associated (r_relcl) AKI_19\NNP|NONE
9889429
D009543_D005885 CID nifedipine_10\NN|and|cyclosporin (r_conj) A_8\NN|NONE (r_pobj) with_6\IN|combined (r_prep) therapy_5\NN|NONE (r_pobj) during_3\IN|The|adverse (r_prep) events_2\NNS|increase|. (r_nsubj) included_11\VBD|NONE (l_dobj) increase_13\NN|events|. (l_prep) in_19\IN|an|in|in (l_pobj) 9_20\CD|NONE (l_prep) of_21\IN|NONE (l_pobj) patients_24\NNS|NONE (l_prep) of_27\IN||the|development|and (l_pobj) hyperplasia_29\NN|NONE
D009543_D005885 CID nifedipine_7\NN|for|useful|but|,|monitored (r_nsubj) is_8\VBZ|findings|. (l_conj) monitored_29\VBN|for|nifedipine|useful|but|, (l_prep) for_30\IN|should|patients|be|that (l_pobj) hyperplasia_32\NN|NONE
D016572_D011565 NONE A_15\NNP| (r_npadvmod) induced_17\VBN|in (r_amod) hypertension_18\NN|NONE (l_prep) in_19\IN|induced (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) psoriasis_22\NN|NONE
D016572_D011565 NONE A_10\NNP|NONE (r_det) therapy_11\NN|cyclosporin (r_pobj) of_8\IN|the (r_prep) course_7\NN|NONE (r_pobj) during_5\IN|with|psoriatic|Thirteen (r_prep) patients_2\NNS|study|with|.|were|for|nifedipine|,|, (l_amod) psoriatic_1\JJ|with|Thirteen|during
D016572_D011565 NONE A_21\NN|NONE (r_pobj) with_19\IN|term (r_prep) treatment_18\NN|NONE (r_pobj) under_14\IN|hypertensive|psoriatic (r_prep) patients_13\NNS|NONE (l_amod) psoriatic_12\JJ|under|hypertensive
D016572_D006973 CID A_15\NNP| (r_npadvmod) induced_17\VBN|in (r_amod) hypertension_18\NN|NONE
D016572_D006973 CID A_10\NNP|NONE (r_det) therapy_11\NN|cyclosporin (r_pobj) of_8\IN|the (r_prep) course_7\NN|NONE (r_pobj) during_5\IN|with|psoriatic|Thirteen (r_prep) patients_2\NNS|study|with|.|were|for|nifedipine|,|, (l_prep) with_3\IN|psoriatic|Thirteen|during (l_pobj) hypertension_4\NN|NONE
D016572_D006973 CID A_13\NNP|NONE (r_det) therapy_14\NN|NONE (r_dobj) cyclosporin_12\NN|NONE (r_pcomp) before_11\IN|.|state|Seven|had (r_prep) exhibited_6\VBN|NONE (l_dobj) state_10\NN|.|Seven|before|had (l_amod) hypertensive_9\JJ|a|subclinical
D016572_D006973 CID A_21\NN|NONE (r_pobj) with_19\IN|term (r_prep) treatment_18\NN|NONE (r_pobj) under_14\IN|hypertensive|psoriatic (r_prep) patients_13\NNS|NONE (l_amod) hypertensive_11\JJ|under|psoriatic
D001806_D005885 NONE nitrogen_17\NN|urea (r_compound) levels_18\NNS|NONE (r_pobj) in_14\IN|in|an|in (r_prep) increase_13\NN|events|. (l_prep) in_19\IN|an|in|in (l_pobj) 9_20\CD|NONE (l_prep) of_21\IN|NONE (l_pobj) patients_24\NNS|NONE (l_prep) of_27\IN||the|development|and (l_pobj) hyperplasia_29\NN|NONE
D002118_D011565 NONE calcium_19\NN|NONE (r_compound) channel_20\NN|a (r_compound) blocker_21\NN|NONE (r_pobj) with_17\IN|study|patients|.|were|for|nifedipine|,|, (r_prep) treated_13\VBN|NONE (l_nsubjpass) patients_2\NNS|study|with|.|were|for|nifedipine|,|, (l_amod) psoriatic_1\JJ|with|Thirteen|during
D009543_D011565 NONE nifedipine_8\JJ|for|release (r_amod) tablets_12\NNS|NONE (l_prep) for_13\IN|release|nifedipine (l_pobj) cyclosporin_14\NN|NONE (l_dobj) hypertension_18\NN|NONE (l_prep) in_19\IN|induced (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) psoriasis_22\NN|NONE
D009543_D011565 NONE nifedipine_26\NN|study|patients|with|.|were|for|,|, (r_dobj) treated_13\VBN|NONE (l_nsubjpass) patients_2\NNS|study|with|.|were|for|nifedipine|,|, (l_amod) psoriatic_1\JJ|with|Thirteen|during
D009543_D011565 NONE nifedipine_7\NN|for|useful|but|,|monitored (r_nsubj) is_8\VBZ|findings|. (l_prep) for_10\IN|nifedipine|useful|but|,|monitored (l_pobj) patients_13\NNS|NONE (l_amod) psoriatic_12\JJ|under|hypertensive
D009543_D006973 NONE nifedipine_8\JJ|for|release (r_amod) tablets_12\NNS|NONE (l_prep) for_13\IN|release|nifedipine (l_pobj) cyclosporin_14\NN|NONE (l_dobj) hypertension_18\NN|NONE
D009543_D006973 NONE nifedipine_26\NN|study|patients|with|.|were|for|,|, (r_dobj) treated_13\VBN|NONE (l_nsubjpass) patients_2\NNS|study|with|.|were|for|nifedipine|,|, (l_prep) with_3\IN|psoriatic|Thirteen|during (l_pobj) hypertension_4\NN|NONE
D009543_D006973 NONE nifedipine_7\NN|for|useful|but|,|monitored (r_nsubj) is_8\VBZ|findings|. (l_prep) for_10\IN|nifedipine|useful|but|,|monitored (l_pobj) patients_13\NNS|NONE (l_amod) hypertensive_11\JJ|under|psoriatic
D002118_D006973 NONE calcium_19\NN|NONE (r_compound) channel_20\NN|a (r_compound) blocker_21\NN|NONE (r_pobj) with_17\IN|study|patients|.|were|for|nifedipine|,|, (r_prep) treated_13\VBN|NONE (l_nsubjpass) patients_2\NNS|study|with|.|were|for|nifedipine|,|, (l_prep) with_3\IN|psoriatic|Thirteen|during (l_pobj) hypertension_4\NN|NONE
D016572_D005885 CID A_8\NN|NONE (r_pobj) with_6\IN|combined (r_prep) therapy_5\NN|NONE (r_pobj) during_3\IN|The|adverse (r_prep) events_2\NNS|increase|. (r_nsubj) included_11\VBD|NONE (l_dobj) increase_13\NN|events|. (l_prep) in_19\IN|an|in|in (l_pobj) 9_20\CD|NONE (l_prep) of_21\IN|NONE (l_pobj) patients_24\NNS|NONE (l_prep) of_27\IN||the|development|and (l_pobj) hyperplasia_29\NN|NONE
D016572_D005885 CID A_21\NN|NONE (r_pobj) with_19\IN|term (r_prep) treatment_18\NN|NONE (r_pobj) under_14\IN|hypertensive|psoriatic (r_prep) patients_13\NNS|NONE (r_pobj) for_10\IN|nifedipine|useful|but|,|monitored (r_prep) is_8\VBZ|findings|. (l_conj) monitored_29\VBN|for|nifedipine|useful|but|, (l_prep) for_30\IN|should|patients|be|that (l_pobj) hyperplasia_32\NN|NONE
17554526
D003042_D001925 CID cocaine_6\NN|regular (r_compound) users_7\NNS|NONE (r_pobj) in_3\IN|Impaired|fear|. (r_prep) recognition_2\NN|NONE
D003042_D001925 CID cocaine_21\NN|NONE (r_pobj) of_20\IN|the|subacute (r_prep) effects_19\NNS|NONE (r_pobj) by_16\IN|deficit|were|.|can|,|be|not (r_agent) explained_15\VBN|NONE (l_nsubjpass) deficit_2\NN|were|.|can|,|be|not|by (l_prep) in_3\IN|selective|The (l_pobj) accuracy_6\NN|fear (l_compound) recognition_5\NN|manifested
D018817_D001925 NONE ecstasy_24\NN|,|or (r_conj) cocaine_21\NN|NONE (r_pobj) of_20\IN|the|subacute (r_prep) effects_19\NNS|NONE (r_pobj) by_16\IN|deficit|were|.|can|,|be|not (r_agent) explained_15\VBN|NONE (l_nsubjpass) deficit_2\NN|were|.|can|,|be|not|by (l_prep) in_3\IN|selective|The (l_pobj) accuracy_6\NN|fear (l_compound) recognition_5\NN|manifested
920167
D014859_-1 NONE warfarin_3\RB| (r_npadvmod) induced_5\VBN|with (r_amod) embryopathy_6\JJ|.|baby (l_prep) with_7\IN|induced (l_pobj) hypoplasia_9\NN|NONE
D014859_-1 NONE warfarin_19\NN|NONE (r_pobj) with_18\IN|during (r_prep) treated_17\VBN|NONE (r_acl) mothers_16\NNS|NONE (r_pobj) to_15\IN|NONE (r_prep) born_14\VBN| (r_acl) infants_13\NNS|NONE (r_pobj) in_11\IN|hypoplasia|now|is|been|has|,|and (r_prep) reported_10\VBN|NONE (l_nsubjpass) hypoplasia_1\NN|in|now|is|been|has|,|and
D014859_D005315 NONE warfarin_3\RB| (r_npadvmod) induced_5\VBN|with (r_amod) embryopathy_6\JJ|.|baby
D014859_D002806 CID warfarin_3\RB| (r_npadvmod) induced_5\VBN|with (r_amod) embryopathy_6\JJ|.|baby (l_prep) with_7\IN|induced (l_pobj) hypoplasia_9\NN|NONE (l_conj) epiphyses_12\NNS|and|nasal
D014859_D002806 CID warfarin_3\RB| (r_npadvmod) induced_5\VBN|with (r_amod) embryopathy_6\JJ|.|baby (l_prep) with_7\IN|induced (l_pobj) hypoplasia_9\NN|NONE (l_conj) epiphyses_12\NNS|and|nasal (l_appos) punctata_15\NN|)|(|stippled
D014859_D002806 CID warfarin_19\NN|NONE (r_pobj) with_18\IN|during (r_prep) treated_17\VBN|NONE (r_acl) mothers_16\NNS|NONE (r_pobj) to_15\IN|NONE (r_prep) born_14\VBN| (r_acl) infants_13\NNS|NONE (r_pobj) in_11\IN|hypoplasia|now|is|been|has|,|and (r_prep) reported_10\VBN|NONE (l_nsubjpass) hypoplasia_1\NN|in|now|is|been|has|,|and (l_prep) with_2\IN|Nasal (l_conj) without_4\IN|or (l_pobj) epiphyses_6\NNS|NONE
25054547
C049430_C537417 CID mivacurium_16\NN|or (r_conj) suxamethonium_14\NN|)|(|muscle (r_appos) relaxants_12\NNS|NONE (r_pobj) of_10\IN|the|in (r_prep) use_9\NN|NONE (r_pobj) after_7\IN|by|is|.|deficiency (r_prep) characterized_3\VBN|NONE (l_nsubjpass) deficiency_1\NN|after|by|is|.
D013390_C537417 CID suxamethonium_14\NN|)|(|muscle (r_appos) relaxants_12\NNS|NONE (r_pobj) of_10\IN|the|in (r_prep) use_9\NN|NONE (r_pobj) after_7\IN|by|is|.|deficiency (r_prep) characterized_3\VBN|NONE (l_nsubjpass) deficiency_1\NN|after|by|is|.
D013390_D001049 CID suxamethonium_25\NN|NONE (r_pobj) with_24\IN|prolonged (r_prep) apnea_23\NN|of|and
D013390_D001049 CID suxamethonium_14\NN|)|(|muscle (r_appos) relaxants_12\NNS|NONE (r_pobj) of_10\IN|the|in (r_prep) use_9\NN|NONE (r_pobj) after_7\IN|by|is|.|deficiency (r_prep) characterized_3\VBN|NONE (l_agent) by_4\IN|after|is|.|deficiency (l_pobj) apnea_6\NN|NONE
C049430_D001049 CID mivacurium_16\NN|or (r_conj) suxamethonium_14\NN|)|(|muscle (r_appos) relaxants_12\NNS|NONE (r_pobj) of_10\IN|the|in (r_prep) use_9\NN|NONE (r_pobj) after_7\IN|by|is|.|deficiency (r_prep) characterized_3\VBN|NONE (l_agent) by_4\IN|after|is|.|deficiency (l_pobj) apnea_6\NN|NONE
10677406
D004280_D017202 NONE dobutamine_13\NN|NONE (r_pobj) after_11\IN|ischaemia (r_mark) induced_16\VBN|in|.|dysfunction (l_dobj) ischaemia_18\NN|after
D004280_D003324 NONE dobutamine_13\NN|NONE (r_pobj) after_11\IN|ischaemia (r_mark) induced_16\VBN|in|.|dysfunction (r_advcl) occurs_4\VBZ|NONE (l_prep) in_5\IN|induced|.|dysfunction (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) disease_10\NN|NONE
D004280_D003324 NONE dobutamine_7\NN|in|,|results|.|In|,|presumed (r_nsubj) induced_8\VBN|NONE (l_prep) In_0\IN|in|,|results|.|,|presumed|dobutamine (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) disease_5\NN|NONE
D004280_D003324 NONE Dobutamine_0\NNP|ischaemia (r_nsubj) induced_1\VBD|therefore|could|.|be|study (r_csubjpass) used_6\VBN|NONE (l_xcomp) study_8\VB|therefore|could|.|be|induced (l_prep) in_15\IN|pathophysiology|to|further (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) disease_20\NN|NONE
D004280_D007511 NONE dobutamine_17\NN|and (r_conj) exercise_15\NN|NONE (r_pobj) after_14\IN|randomised|crossover|of|A (r_prep) study_3\NN|.|ischaemia (r_nsubj) induced_18\VBN|NONE (l_dobj) ischaemia_19\NN|.|study
D004280_D007511 NONE dobutamine_7\NN|in|,|results|.|In|,|presumed (r_nsubj) induced_8\VBN|NONE (l_dobj) results_10\NNS|in|,|.|In|,|presumed|dobutamine (l_compound) ischaemia_9\NN|NONE
D004280_D007511 NONE Dobutamine_0\NNP|ischaemia (r_nsubj) induced_1\VBD|therefore|could|.|be|study (l_dobj) ischaemia_2\NN|Dobutamine
D004280_D018487 CID dobutamine_13\NN|NONE (r_pobj) after_11\IN|ischaemia (r_mark) induced_16\VBN|in|.|dysfunction (r_advcl) occurs_4\VBZ|NONE (l_nsubj) dysfunction_3\NN|induced|in|.
D004280_D018487 CID dobutamine_7\NN|in|,|results|.|In|,|presumed (r_nsubj) induced_8\VBN|NONE (l_prep) in_11\IN|,|results|.|In|,|presumed|dobutamine (l_pobj) dysfunction_16\NN|NONE
D004280_D017682 CID dobutamine_7\NN|in|,|results|.|In|,|presumed (r_nsubj) induced_8\VBN|NONE (l_conj) presumed_18\VBN|in|,|results|.|In|,|dobutamine (l_xcomp) be_20\VB|NONE (l_acomp) similar_24\JJ|to (l_amod) stunning_22\JJ|to|myocardial
1361574
D007538_D012640 CID isoniazid_22\NN|NONE (r_pobj) by_21\IN|NONE (r_agent) induced_20\VBN|the (r_acl) convulsions_19\NNS|.|mg/kg|increase|Moreover|and|,|markedly
D002243_D012640 NONE carboline_8\NN|NONE (r_pobj) of_4\IN|. (r_prep) mg/kg_3\NNS|convulsions|.|increase|Moreover|and|,|markedly (r_nsubj) reduced_9\VBD|NONE (l_conj) convulsions_19\NNS|.|mg/kg|increase|Moreover|and|,|markedly
C037476_D012640 NONE 35S]TBPS_15\NNP|[ (r_nummod) binding_16\NN|NONE (r_pobj) of_13\IN|the (r_prep) increase_12\NN|convulsions|.|mg/kg|Moreover|and|,|markedly (r_dobj) reduced_9\VBD|NONE (l_conj) convulsions_19\NNS|.|mg/kg|increase|Moreover|and|,|markedly
6687006
D000661_D020258 NONE amphetamine_3\NN|NONE (r_compound) hyperactivity_4\NN|NONE (r_pobj) of_2\IN|The|induced (r_prep) reduction_1\NN|by|.|was (r_nsubjpass) blocked_9\VBN|NONE (l_agent) by_10\IN|.|reduction|was (l_pobj) pretreatment_11\NN|NONE (l_prep) with_12\IN|NONE (l_pobj) agent_18\NN|NONE (l_relcl) prevents_23\VBZ|,|desipramine|the|uptake|,|blocking (l_dobj) action_26\NN|which (l_amod) neurotoxic_25\JJ|of|the
D003913_D006948 CID amphetamine_6\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The|) (r_acl) hyperactivity_1\NN|.|was|by|significantly
C012102_D019956 NONE DSP4_17\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) pretreatment_15\NN|NONE (r_pobj) by_14\IN|However|,|not|rearings|.|were (r_agent) blocked_13\VBN|NONE (l_nsubjpass) rearings_4\NNS|However|,|not|by|.|were (l_conj) stereotypies_10\NNS|the|and|increased
D009638_D020258 NONE noradrenaline_14\NN| (r_amod) uptake_16\NN|,|desipramine|the|,|prevents|blocking (r_compound) agent_18\NN|NONE (l_relcl) prevents_23\VBZ|,|desipramine|the|uptake|,|blocking (l_dobj) action_26\NN|which (l_amod) neurotoxic_25\JJ|of|the
D000661_D006948 NONE amphetamine_3\NN|NONE (r_compound) hyperactivity_4\NN|NONE
C012102_D020258 NONE DSP4_7\NNP|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|of|The (r_acl) reduction_1\NN|by|.|was (r_nsubjpass) blocked_9\VBN|NONE (l_agent) by_10\IN|.|reduction|was (l_pobj) pretreatment_11\NN|NONE (l_prep) with_12\IN|NONE (l_pobj) agent_18\NN|NONE (l_relcl) prevents_23\VBZ|,|desipramine|the|uptake|,|blocking (l_dobj) action_26\NN|which (l_amod) neurotoxic_25\JJ|of|the
C012102_D020258 NONE DSP4_28\NNP|NONE (r_pobj) of_27\IN|the|neurotoxic (r_prep) action_26\NN|which (l_amod) neurotoxic_25\JJ|of|the
D003891_D006948 NONE desipramine_20\NN|,|the|uptake|,|prevents|blocking (r_appos) agent_18\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) pretreatment_11\NN|NONE (r_pobj) by_10\IN|.|reduction|was (r_agent) blocked_9\VBN|NONE (l_nsubjpass) reduction_1\NN|by|.|was (l_prep) of_2\IN|The|induced (l_pobj) hyperactivity_4\NN|NONE
D003891_D020258 NONE desipramine_20\NN|,|the|uptake|,|prevents|blocking (r_appos) agent_18\NN|NONE (l_relcl) prevents_23\VBZ|,|desipramine|the|uptake|,|blocking (l_dobj) action_26\NN|which (l_amod) neurotoxic_25\JJ|of|the
C012102_D006948 NONE DSP4_17\NNP|NONE (r_compound) pretreatment_18\NN|NONE (r_pobj) by_16\IN|.|was|hyperactivity|significantly (r_agent) reduced_15\VBN|NONE (l_nsubjpass) hyperactivity_1\NN|.|was|by|significantly
C012102_D006948 NONE DSP4_7\NNP|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|of|The (r_acl) reduction_1\NN|by|.|was (l_prep) of_2\IN|The|induced (l_pobj) hyperactivity_4\NN|NONE
C012102_D006948 NONE DSP4_28\NNP|NONE (r_pobj) of_27\IN|the|neurotoxic (r_prep) action_26\NN|which (r_dobj) prevents_23\VBZ|,|desipramine|the|uptake|,|blocking (r_relcl) agent_18\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) pretreatment_11\NN|NONE (r_pobj) by_10\IN|.|reduction|was (r_agent) blocked_9\VBN|NONE (l_nsubjpass) reduction_1\NN|by|.|was (l_prep) of_2\IN|The|induced (l_pobj) hyperactivity_4\NN|NONE
D009638_D006948 NONE noradrenaline_14\NN| (r_amod) uptake_16\NN|,|desipramine|the|,|prevents|blocking (r_compound) agent_18\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) pretreatment_11\NN|NONE (r_pobj) by_10\IN|.|reduction|was (r_agent) blocked_9\VBN|NONE (l_nsubjpass) reduction_1\NN|by|.|was (l_prep) of_2\IN|The|induced (l_pobj) hyperactivity_4\NN|NONE
D000661_D019956 NONE amphetamine_7\NN| (r_npadvmod) induced_9\VBN|the (r_amod) stereotypies_10\NNS|the|and|increased
10770468
D008094_D001714 NONE lithium_8\NN|developed (r_compound) therapy_9\NN|NONE (r_dobj) receiving_6\VBG|a|bipolar (r_acl) patient_5\NN|NONE (l_amod) bipolar_4\JJ|a|receiving
D008094_D001714 NONE lithium_8\NN|developed (r_compound) therapy_9\NN|NONE (r_dobj) receiving_6\VBG|a|bipolar (r_acl) patient_5\NN|NONE (r_pobj) in_2\IN|Recent (r_prep) findings_1\NNS|authors|conduct|. (r_nsubj) prompted_16\VBD|NONE (l_xcomp) conduct_20\VB|authors|findings|. (l_dobj) study_23\NN|to (l_prep) of_24\IN|a|retrospective|with (l_pobj) patients_26\NNS|NONE (l_amod) bipolar_25\JJ|NONE
D008094_D001714 NONE lithium_28\NN| (r_npadvmod) associated_30\VBN|NONE (r_amod) hypercalcemia_31\NN|NONE (r_pobj) with_27\IN|a|retrospective|of (r_prep) study_23\NN|to (r_dobj) conduct_20\VB|authors|findings|. (r_xcomp) prompted_16\VBD|NONE (l_nsubj) findings_1\NNS|authors|conduct|. (l_prep) in_2\IN|Recent (l_pobj) patient_5\NN|NONE (l_amod) bipolar_4\JJ|a|receiving
D008094_D001714 NONE lithium_28\NN| (r_npadvmod) associated_30\VBN|NONE (r_amod) hypercalcemia_31\NN|NONE (r_pobj) with_27\IN|a|retrospective|of (r_prep) study_23\NN|to (l_prep) of_24\IN|a|retrospective|with (l_pobj) patients_26\NNS|NONE (l_amod) bipolar_25\JJ|NONE
D008094_D001714 NONE lithium_18\NN| (r_npadvmod) treated_20\VBN|normocalcemic|bipolar|comparable|age (r_amod) patients_23\NNS|which (l_amod) bipolar_21\JJ|normocalcemic|comparable|treated|age
D008094_D001714 NONE lithium_18\NN| (r_npadvmod) treated_20\VBN|normocalcemic|bipolar|comparable|age (r_amod) patients_23\NNS|which (r_dobj) included_12\VBD|,|,|C|:|group|and (r_relcl) C1_9\NN|Thus|,|groups|were|. (l_conj) C2_27\NNP|,|,|included|:|group|and (l_relcl) included_30\VBD|,|group (l_dobj) patients_33\NNS|which (l_amod) bipolar_31\JJ|treated|normocalcemic
D008094_D001714 NONE lithium_11\NN| (r_npadvmod) associated_13\VBN|NONE (r_amod) hypercalcemia_14\NN|NONE (r_pobj) with_10\IN|medical|and|patients (r_prep) diseases_6\NNS|NONE (l_conj) patients_9\NNS|medical|with|and (l_amod) bipolar_8\JJ|NONE
D008094_D006934 CID lithium_8\NN|developed (r_compound) therapy_9\NN|NONE (l_relcl) developed_11\VBD|lithium (l_dobj) hypercalcemia_12\NN|who
D008094_D006934 CID lithium_8\NN|developed (r_compound) therapy_9\NN|NONE (r_dobj) receiving_6\VBG|a|bipolar (r_acl) patient_5\NN|NONE (r_pobj) in_2\IN|Recent (r_prep) findings_1\NNS|authors|conduct|. (r_nsubj) prompted_16\VBD|NONE (l_xcomp) conduct_20\VB|authors|findings|. (l_dobj) study_23\NN|to (l_prep) with_27\IN|a|retrospective|of (l_pobj) hypercalcemia_31\NN|NONE
D008094_D006934 CID lithium_28\NN| (r_npadvmod) associated_30\VBN|NONE (r_amod) hypercalcemia_31\NN|NONE (r_pobj) with_27\IN|a|retrospective|of (r_prep) study_23\NN|to (r_dobj) conduct_20\VB|authors|findings|. (r_xcomp) prompted_16\VBD|NONE (l_nsubj) findings_1\NNS|authors|conduct|. (l_prep) in_2\IN|Recent (l_pobj) patient_5\NN|NONE (l_acl) receiving_6\VBG|a|bipolar (l_dobj) therapy_9\NN|NONE (l_relcl) developed_11\VBD|lithium (l_dobj) hypercalcemia_12\NN|who
D008094_D006934 CID lithium_28\NN| (r_npadvmod) associated_30\VBN|NONE (r_amod) hypercalcemia_31\NN|NONE
D008094_D006934 CID lithium_17\NN| (r_npadvmod) treated_19\VBN||with|and|patients (r_amod) patients_20\NNS|authors|After|.|, (r_dobj) identified_13\VBD|NONE (l_prep) After_0\IN|patients|authors|.|, (l_pcomp) eliminating_1\VBG|NONE (l_dobj) hypercalcemias_3\NNS|NONE
D008094_D006934 CID lithium_17\NN| (r_npadvmod) treated_19\VBN||with|and|patients (r_amod) patients_20\NNS|authors|After|.|, (l_prep) with_21\IN||treated|and|patients (l_pobj) hypercalcemias_22\NNS|NONE
D008094_D006934 CID lithium_17\NN| (r_npadvmod) treated_19\VBN||with|and|patients (r_amod) patients_20\NNS|authors|After|.|, (l_conj) patients_36\NNS||treated|with|and (l_prep) with_37\IN| (l_pobj) hypercalcemia_41\NN|NONE
D008094_D006934 CID lithium_38\NN| (r_npadvmod) associated_40\VBN|(|)|B (r_amod) hypercalcemia_41\NN|NONE (r_pobj) with_37\IN| (r_prep) patients_36\NNS||treated|with|and (r_conj) patients_20\NNS|authors|After|.|, (r_dobj) identified_13\VBD|NONE (l_prep) After_0\IN|patients|authors|.|, (l_pcomp) eliminating_1\VBG|NONE (l_dobj) hypercalcemias_3\NNS|NONE
D008094_D006934 CID lithium_38\NN| (r_npadvmod) associated_40\VBN|(|)|B (r_amod) hypercalcemia_41\NN|NONE (r_pobj) with_37\IN| (r_prep) patients_36\NNS||treated|with|and (r_conj) patients_20\NNS|authors|After|.|, (l_prep) with_21\IN||treated|and|patients (l_pobj) hypercalcemias_22\NNS|NONE
D008094_D006934 CID lithium_38\NN| (r_npadvmod) associated_40\VBN|(|)|B (r_amod) hypercalcemia_41\NN|NONE
D008094_D006934 CID lithium_11\NN| (r_npadvmod) associated_13\VBN|NONE (r_amod) hypercalcemia_14\NN|NONE (r_pobj) with_10\IN|medical|and|patients (r_prep) diseases_6\NNS|NONE (r_pobj) from_4\IN|NONE (r_prep) resulting_3\VBG|NONE (r_acl) hypercalcemia_2\NN|NONE
D008094_D006934 CID lithium_11\NN| (r_npadvmod) associated_13\VBN|NONE (r_amod) hypercalcemia_14\NN|NONE
D008094_D001919 NONE lithium_8\NN|developed (r_compound) therapy_9\NN|NONE (l_relcl) developed_11\VBD|lithium (l_dobj) hypercalcemia_12\NN|who (l_conj) bradyarrhythmia_15\NN|and
D008094_D001919 NONE lithium_28\NN| (r_npadvmod) associated_30\VBN|NONE (r_amod) hypercalcemia_31\NN|NONE (r_pobj) with_27\IN|a|retrospective|of (r_prep) study_23\NN|to (r_dobj) conduct_20\VB|authors|findings|. (r_xcomp) prompted_16\VBD|NONE (l_nsubj) findings_1\NNS|authors|conduct|. (l_prep) in_2\IN|Recent (l_pobj) patient_5\NN|NONE (l_acl) receiving_6\VBG|a|bipolar (l_dobj) therapy_9\NN|NONE (l_relcl) developed_11\VBD|lithium (l_dobj) hypercalcemia_12\NN|who (l_conj) bradyarrhythmia_15\NN|and
D008094_D009369 NONE lithium_17\NN| (r_npadvmod) treated_19\VBN||with|and|patients (r_amod) patients_20\NNS|authors|After|.|, (l_prep) with_21\IN||treated|and|patients (l_pobj) hypercalcemias_22\NNS|NONE (l_acl) related_23\VBN|NONE (l_prep) to_24\IN|NONE (l_pobj) malignancies_25\NNS|NONE
D008094_D009369 NONE lithium_38\NN| (r_npadvmod) associated_40\VBN|(|)|B (r_amod) hypercalcemia_41\NN|NONE (r_pobj) with_37\IN| (r_prep) patients_36\NNS||treated|with|and (r_conj) patients_20\NNS|authors|After|.|, (l_prep) with_21\IN||treated|and|patients (l_pobj) hypercalcemias_22\NNS|NONE (l_acl) related_23\VBN|NONE (l_prep) to_24\IN|NONE (l_pobj) malignancies_25\NNS|NONE
18025637
D005473_D012170 CID fluoxetine_5\NN|.|Branch|and|vein (r_conj) occlusion_3\NN|NONE
D005473_D012170 CID fluoxetine_9\NN| (r_advmod) induced_11\VBN|secondary (r_amod) hypertension_13\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) associated_7\VBN|branch|vein (r_acl) occlusion_6\NN|NONE
D005473_D006973 CID fluoxetine_9\NN| (r_advmod) induced_11\VBN|secondary (r_amod) hypertension_13\NN|NONE
D012701_D006973 NONE serotonin_6\NN|reuptake|inhibitor|selective (r_compound) therapy_9\NN|NONE (r_pobj) of_4\IN|infrequent|an (r_prep) complication_3\NN|NONE (r_pobj) Although_0\IN|important|.|are|,|it (r_prep) is_12\VBZ|NONE (l_ccomp) are_16\VBP|Although|important|.|,|it (l_acomp) aware_17\JJ|ophthalmologists|that (l_ccomp) cause_22\VB|NONE (l_dobj) hypertension_23\NN|that|can|agents|prescribed
16309808
D004298_D012148 NONE dopamine_14\NN|levodopa (r_compound) agonists_15\NNS|NONE (r_pobj) by_11\IN|For|,|,|be|.|dramatically|can|symptoms|induce (r_agent) improved_10\VBN|NONE (l_nsubjpass) symptoms_4\NNS|For|,|,|be|.|dramatically|can|by|induce (l_prep) of_5\IN|the (l_pobj) RLS_6\NNP|NONE
D004298_D012148 NONE dopamine_14\NN|levodopa (r_compound) agonists_15\NNS|NONE (r_pobj) by_11\IN|For|,|,|be|.|dramatically|can|symptoms|induce (r_agent) improved_10\VBN|NONE (l_advcl) induce_24\VB|For|,|,|be|.|dramatically|can|symptoms|by (l_conj) aggravate_26\VB|or|antagonists|whereas|can (l_dobj) symptoms_28\NNS|NONE (l_compound) RLS_27\NNP|NONE
D004298_D012148 NONE dopamine_19\NN|receptor (r_compound) antagonists_22\NNS|or|aggravate|whereas|can (r_nsubj) induce_24\VB|For|,|,|be|.|dramatically|can|symptoms|by (r_advcl) improved_10\VBN|NONE (l_nsubjpass) symptoms_4\NNS|For|,|,|be|.|dramatically|can|by|induce (l_prep) of_5\IN|the (l_pobj) RLS_6\NNP|NONE
D004298_D012148 NONE dopamine_19\NN|receptor (r_compound) antagonists_22\NNS|or|aggravate|whereas|can (r_nsubj) induce_24\VB|For|,|,|be|.|dramatically|can|symptoms|by (l_conj) aggravate_26\VB|or|antagonists|whereas|can (l_dobj) symptoms_28\NNS|NONE (l_compound) RLS_27\NNP|NONE
D004298_D012148 NONE dopamine_15\NN|receptor|D|a (r_compound) antagonist_18\NN|, (r_appos) domperidone_11\NN|aggravate|also|can|whether|or|, (r_nsubj) induce_22\VB|NONE (l_conj) aggravate_24\VBP|domperidone|also|can|whether|or|, (l_dobj) symptoms_25\NNS|NONE (l_prep) of_26\IN|NONE (l_pobj) RLS_27\NNP|NONE
D004298_D012148 NONE dopamine_24\NN|receptor|concomitant (r_compound) antagonists_27\NNS|NONE (r_dobj) receiving_22\VBG|especially (r_acl) those_21\DT|the|associated|, (r_appos) possibility_8\NN|NONE (l_acl) associated_13\VBN|the|those|, (l_prep) with_14\IN|that|can|mirtazapine|be|in (l_pobj) RLS_15\NNP|NONE
D007980_D012148 NONE levodopa_12\NN|dopamine (r_nmod) agonists_15\NNS|NONE (r_pobj) by_11\IN|For|,|,|be|.|dramatically|can|symptoms|induce (r_agent) improved_10\VBN|NONE (l_nsubjpass) symptoms_4\NNS|For|,|,|be|.|dramatically|can|by|induce (l_prep) of_5\IN|the (l_pobj) RLS_6\NNP|NONE
D007980_D012148 NONE levodopa_12\NN|dopamine (r_nmod) agonists_15\NNS|NONE (r_pobj) by_11\IN|For|,|,|be|.|dramatically|can|symptoms|induce (r_agent) improved_10\VBN|NONE (l_advcl) induce_24\VB|For|,|,|be|.|dramatically|can|symptoms|by (l_conj) aggravate_26\VB|or|antagonists|whereas|can (l_dobj) symptoms_28\NNS|NONE (l_compound) RLS_27\NNP|NONE
D004294_D012148 NONE domperidone_1\NN|?|Does|syndrome (r_nsubj) potentiate_2\VB|NONE (l_dobj) syndrome_8\NN|?|domperidone|Does
D004294_D012148 NONE domperidone_11\NN|aggravate|also|can|whether|or|, (r_nsubj) induce_22\VB|NONE (l_conj) aggravate_24\VBP|domperidone|also|can|whether|or|, (l_dobj) symptoms_25\NNS|NONE (l_prep) of_26\IN|NONE (l_pobj) RLS_27\NNP|NONE
D004294_D012148 NONE domperidone_21\NN|his (r_compound) therapy_22\NN|NONE (r_pobj) to_19\IN|been|had (r_prep) added_18\VBN|comorbid|.|here|authors (r_ccomp) report_2\VBP|NONE (l_dobj) comorbid_7\JJ|added|.|here|authors (l_prep) with_8\IN|a|depressed|patient (l_pobj) dyspepsia_10\NN|NONE (l_relcl) developed_12\VBD|postprandial (l_dobj) RLS_13\NNP|who|after
D004294_D012148 NONE domperione_24\NN|NONE (r_pobj) of_23\IN|a|potentiating (r_prep) effect_22\NN|did|relationship|not|. (r_dobj) support_19\VB|NONE (l_nsubj) relationship_3\NN|did|not|.|effect (l_prep) between_4\IN|temporal|Such|a (l_pobj) use_6\NN|NONE (l_conj) symptoms_11\NNS|the|and|of (l_prep) of_12\IN|in|the (l_pobj) RLS_13\NNP|NONE
D004294_D012148 NONE domperione_24\NN|NONE (l_prep) on_25\IN|NONE (l_pobj) RLS_29\NNP|NONE
D004294_D004415 NONE domperidone_21\NN|his (r_compound) therapy_22\NN|NONE (r_pobj) to_19\IN|been|had (r_prep) added_18\VBN|comorbid|.|here|authors (r_ccomp) report_2\VBP|NONE (l_dobj) comorbid_7\JJ|added|.|here|authors (l_prep) with_8\IN|a|depressed|patient (l_pobj) dyspepsia_10\NN|NONE
C035133_D004415 NONE mirtazapine_15\RB|NONE (r_pobj) after_14\IN|who|RLS (r_prep) developed_12\VBD|postprandial (r_relcl) dyspepsia_10\NN|NONE
C035133_D012148 CID mirtazapine_3\RB| (r_advmod) associated_5\VBN|legs (r_amod) syndrome_8\NN|?|domperidone|Does
C035133_D012148 CID Mirtazapine_0\NNP|with|.|been|in|has (r_nsubjpass) associated_15\VBN|NONE (l_prep) with_16\IN|Mirtazapine|.|been|in|has (l_pobj) RLS_17\NNP|NONE
C035133_D012148 CID mirtazapine_15\RB|NONE (r_pobj) after_14\IN|who|RLS (r_prep) developed_12\VBD|postprandial (l_dobj) RLS_13\NNP|who|after
C035133_D012148 CID mirtazapine_15\NN|NONE (r_pobj) with_14\IN|had|only|been|he|after (r_prep) treated_13\VBN|symptoms|to (r_advcl) have_4\VB|and|patient|resolved|, (l_dobj) symptoms_5\NNS|treated|to (l_prep) of_6\IN|NONE (l_pobj) RLS_7\NNP|NONE
C035133_D012148 CID mirtazapine_15\NN|NONE (r_pobj) with_14\IN|had|only|been|he|after (r_prep) treated_13\VBN|symptoms|to (r_advcl) have_4\VB|and|patient|resolved|, (r_xcomp) started_2\VBD|NONE (l_conj) resolved_21\VBD|and|patient|,|have (l_nsubj) symptoms_20\NNS|.|completely|upon (l_compound) RLS_19\NNP|his
C035133_D012148 CID mirtazapine_27\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) discontinuation_24\NN|NONE (r_pobj) upon_23\IN|.|symptoms|completely (r_prep) resolved_21\VBD|and|patient|,|have (r_conj) started_2\VBD|NONE (l_xcomp) have_4\VB|and|patient|resolved|, (l_dobj) symptoms_5\NNS|treated|to (l_prep) of_6\IN|NONE (l_pobj) RLS_7\NNP|NONE
C035133_D012148 CID mirtazapine_27\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) discontinuation_24\NN|NONE (r_pobj) upon_23\IN|.|symptoms|completely (r_prep) resolved_21\VBD|and|patient|,|have (l_nsubj) symptoms_20\NNS|.|completely|upon (l_compound) RLS_19\NNP|his
C035133_D012148 CID mirtazapine_8\NN|NONE (r_pobj) of_7\IN|the|and|symptoms (r_prep) use_6\NN|NONE (l_conj) symptoms_11\NNS|the|and|of (l_prep) of_12\IN|in|the (l_pobj) RLS_13\NNP|NONE
C035133_D012148 CID mirtazapine_8\NN|NONE (r_pobj) of_7\IN|the|and|symptoms (r_prep) use_6\NN|NONE (r_pobj) between_4\IN|temporal|Such|a (r_prep) relationship_3\NN|did|not|.|effect (r_nsubj) support_19\VB|NONE (l_dobj) effect_22\NN|did|relationship|not|. (l_prep) of_23\IN|a|potentiating (l_pobj) domperione_24\NN|NONE (l_prep) on_25\IN|NONE (l_pobj) RLS_29\NNP|NONE
C035133_D012148 CID mirtazapine_26\RB| (r_npadvmod) associated_28\VBN|NONE (r_amod) RLS_29\NNP|NONE (r_pobj) on_25\IN|NONE (r_prep) domperione_24\NN|NONE (r_pobj) of_23\IN|a|potentiating (r_prep) effect_22\NN|did|relationship|not|. (r_dobj) support_19\VB|NONE (l_nsubj) relationship_3\NN|did|not|.|effect (l_prep) between_4\IN|temporal|Such|a (l_pobj) use_6\NN|NONE (l_conj) symptoms_11\NNS|the|and|of (l_prep) of_12\IN|in|the (l_pobj) RLS_13\NNP|NONE
C035133_D012148 CID mirtazapine_26\RB| (r_npadvmod) associated_28\VBN|NONE (r_amod) RLS_29\NNP|NONE
C035133_D012148 CID mirtazapine_10\NN|that|can|with|be|in (r_nsubjpass) associated_13\VBN|the|those|, (l_prep) with_14\IN|that|can|mirtazapine|be|in (l_pobj) RLS_15\NNP|NONE
3832950
D002998_D013036 NONE clonazepam_23\NN|NONE (r_pobj) with_22\IN|patients|.|were (r_prep) treated_21\VBN|NONE (l_nsubjpass) patients_1\NNS|.|were|with (l_prep) with_12\IN|(|Sixty|)|range (l_pobj) types_14\NNS|NONE (l_prep) than_17\IN|of|other (l_pobj) spasms_19\NNS|NONE
D002998_D004827 NONE Clonazepam_0\NNP|.|for|in (r_compound) monotherapy_1\NN|NONE (l_prep) for_2\IN|Clonazepam|.|in (l_pobj) epilepsy_3\NN|NONE
D002998_D004827 NONE clonazepam_23\NN|NONE (r_pobj) with_22\IN|patients|.|were (r_prep) treated_21\VBN|NONE (l_nsubjpass) patients_1\NNS|.|were|with (l_prep) with_12\IN|(|Sixty|)|range (l_pobj) types_14\NNS|NONE (l_prep) of_15\IN|than|other (l_pobj) epilepsy_16\NN|NONE
4010471
D004229_D012640 NONE dithiothreitol_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|NONE (r_pobj) by_12\IN|.|sites|were|equally (r_agent) affected_11\VBN|NONE (l_nsubjpass) sites_2\NNS|.|by|were|equally (l_prep) from_3\IN|binding|The (l_pobj) mice_8\NNS|NONE (l_amod) sensitive_5\JJ|NONE (l_npadvmod) seizure_4\NN|and|resistant
D009538_D012640 CID nicotine_2\NN| (r_npadvmod) induced_4\VBN|receptors|and (r_amod) seizures_5\NNS|NONE
D009538_D012640 CID nicotine_15\NN| (r_npadvmod) induced_17\VBN|concentration|and (r_amod) seizures_18\NNS|NONE
D009538_D012640 CID nicotine_7\NN|NONE (r_pobj) of_6\IN|convulsant|the (r_prep) effects_5\NNS|NONE (r_pobj) to_2\IN|NONE (r_prep) sensitive_1\JJ|NONE (r_amod) Mice_0\NNS|.|binding (r_nsubj) had_8\VBD|NONE (l_dobj) binding_13\NN|Mice|. (l_prep) than_17\IN|bungarotoxin|in|greater (l_pobj) mice_20\NNS|NONE (l_nmod) seizure_18\NN|insensitive
7644931
D017239_D006402 CID paclitaxel_14\NN|/ (r_nmod) carboplatin_16\NN|the (r_compound) combination_17\NN|be|could|.|weeks (r_nsubjpass) dosed_20\VBN|and|,|not|did|add|Carboplatin (r_conj) appear_3\VB|NONE (l_xcomp) add_5\VB|and|,|dosed|not|did|Carboplatin (l_prep) to_6\IN|to (l_pobj) toxicities_9\NNS|NONE
D017239_D064420 NONE paclitaxel_14\NN|NONE (r_pobj) of_13\IN|alone|I (r_prep) trial_12\NN|Toxicities|.|were|with (r_dobj) compared_2\VBN|NONE (l_nsubjpass) Toxicities_0\NNS|trial|.|were|with
D017239_D002289 NONE Paclitaxel_0\NNP|was|with|.|in (r_nsubjpass) combined_18\VBN|NONE (l_prep) in_21\IN|Paclitaxel|was|with|. (l_pobj) phase_23\NN|NONE (l_acl) directed_28\VBN|a (l_prep) to_29\IN|study (l_pobj) patients_30\NNS|NONE (l_prep) with_31\IN|NONE (l_pobj) cancer_37\NN|NONE
D017239_D002289 NONE Taxol_2\NNP|Company (r_appos) Paclitaxel_0\NNP|was|with|.|in (r_nsubjpass) combined_18\VBN|NONE (l_prep) in_21\IN|Paclitaxel|was|with|. (l_pobj) phase_23\NN|NONE (l_acl) directed_28\VBN|a (l_prep) to_29\IN|study (l_pobj) patients_30\NNS|NONE (l_prep) with_31\IN|NONE (l_pobj) cancer_37\NN|NONE
D016190_D002289 NONE carboplatin_20\NN|NONE (r_pobj) with_19\IN|Paclitaxel|was|.|in (r_prep) combined_18\VBN|NONE (l_prep) in_21\IN|Paclitaxel|was|with|. (l_pobj) phase_23\NN|NONE (l_acl) directed_28\VBN|a (l_prep) to_29\IN|study (l_pobj) patients_30\NNS|NONE (l_prep) with_31\IN|NONE (l_pobj) cancer_37\NN|NONE
D016190_D006402 NONE Carboplatin_0\NNP|and|,|dosed|not|did|add (r_nsubj) appear_3\VB|NONE (l_xcomp) add_5\VB|and|,|dosed|not|did|Carboplatin (l_prep) to_6\IN|to (l_pobj) toxicities_9\NNS|NONE
D016190_D006402 NONE carboplatin_16\NN|the (r_compound) combination_17\NN|be|could|.|weeks (r_nsubjpass) dosed_20\VBN|and|,|not|did|add|Carboplatin (r_conj) appear_3\VB|NONE (l_xcomp) add_5\VB|and|,|dosed|not|did|Carboplatin (l_prep) to_6\IN|to (l_pobj) toxicities_9\NNS|NONE
1280054
D014750_D007049 CID Vincristine_0\NNP|.|,|intrathecally|to|was|accidentally|producing (r_nsubjpass) given_3\VBN|NONE (l_advcl) producing_11\VBG|.|,|intrathecally|to|was|accidentally|Vincristine (l_dobj) dysfunction_15\NN|NONE
D014750_D001927 CID vincristine_5\NN|intrathecal (r_compound) administration_6\NN|to (r_pobj) due_2\IN|.|Fatal (r_prep) myeloencephalopathy_1\NN|NONE
D014750_D001927 CID Vincristine_0\NNP|.|,|intrathecally|to|was|accidentally|producing (r_nsubjpass) given_3\VBN|NONE (l_advcl) producing_11\VBG|.|,|intrathecally|to|was|accidentally|Vincristine (l_dobj) dysfunction_15\NN|NONE (l_acl) followed_16\VBN|sensory (l_agent) by_17\IN|NONE (l_pobj) encephalopathy_18\JJ|NONE
D014750_D007938 NONE Vincristine_0\NNP|.|,|intrathecally|to|was|accidentally|producing (r_nsubjpass) given_3\VBN|NONE (l_dative) to_5\IN|.|,|intrathecally|was|accidentally|Vincristine|producing (l_pobj) child_7\NN|NONE (l_prep) with_8\IN|a (l_pobj) leukaemia_9\NN|NONE
895432
D007545_D009203 CID isoproterenol_7\NN| (r_npadvmod) induced_9\VBN|myocardial (r_amod) infarction_11\NN|NONE
D007545_D009203 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|myocardial (r_amod) infarction_12\NN|NONE
D007545_D007238 NONE isoproterenol_16\NN|NONE (r_pobj) of_15\IN|large (r_prep) dosages_14\NNS|NONE (r_pobj) of_12\IN|the (r_prep) effects_11\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|the (r_acl) mortality_7\NN|but|exercise|had|that (r_dobj) reduced_5\VBD|.|results (l_conj) had_18\VBD|but|exercise|mortality|that (l_prep) on_20\IN|little (l_pobj) severity_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) infarction_25\NN|NONE
19815465
D020888_D014786 CID vigabatrin_8\NN|NONE (r_pobj) to_7\TO|NONE (r_prep) specific_6\JJ|not|.|defects (r_acomp) are_4\VBP|NONE (l_nsubj) defects_3\NNS|not|.|specific
D020888_D014786 CID vigabatrin_11\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|visual|the (r_acl) defects_5\NNS|.|study
D020888_D014786 CID VGB_13\NNP|the|(|antiepileptic|drug|) (r_appos) vigabatrin_11\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|visual|the (r_acl) defects_5\NNS|.|study
D020888_D004827 NONE VGB_24\NNP|NONE (r_pobj) to_23\IN|no|current (r_prep) exposure_22\NN|)|(|antiepileptic|drug (r_appos) therapy_14\NN|NONE (r_pobj) of_11\IN|the (r_prep) basis_10\NN|NONE (r_pobj) on_8\IN|people|.|were (r_prep) grouped_7\VBN|NONE (l_nsubjpass) people_3\NNS|.|were|on (l_prep) with_4\IN|four (l_pobj) epilepsy_5\NN|NONE
D020888_D012164 CID VGB_19\NNP|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|retinal (r_acl) toxicity_16\NN|reliably|to
16565833
C522803_D066126 NONE monoHER_7\NN|NONE (r_pobj) between_6\IN|time|the (r_prep) interval_5\NN|NONE (r_pobj) of_2\IN|and|.|The|administration (r_prep) influence_1\NN|NONE (l_conj) administration_10\NN|and|.|of|The (l_prep) on_11\IN|doxorubicin (l_pobj) protection_13\NN|NONE (l_prep) against_14\IN|the (l_pobj) cardiotoxicity_18\NN|NONE
C522803_D066126 NONE monohydroxyethylrutoside_3\NN|.|cardioprotection (r_nsubj) showed_7\VBD|NONE (l_dobj) cardioprotection_8\NN|.|monohydroxyethylrutoside (l_prep) against_9\IN|NONE (l_pobj) cardiotoxicity_13\NN|NONE
C522803_D066126 NONE monoHER_5\NN|flavonoid|semisynthetic|The|)|( (r_appos) monohydroxyethylrutoside_3\NN|.|cardioprotection (r_nsubj) showed_7\VBD|NONE (l_dobj) cardioprotection_8\NN|.|monohydroxyethylrutoside (l_prep) against_9\IN|NONE (l_pobj) cardiotoxicity_13\NN|NONE
D004317_D066126 NONE doxorubicin_9\NN|on (r_compound) administration_10\NN|and|.|of|The (l_prep) on_11\IN|doxorubicin (l_pobj) protection_13\NN|NONE (l_prep) against_14\IN|the (l_pobj) cardiotoxicity_18\NN|NONE
D004317_D066126 NONE doxorubicin_15\NN| (r_npadvmod) induced_17\VBN|in (r_amod) cardiotoxicity_18\NN|NONE
D004317_D066126 NONE doxorubicin_9\NN|.|be (l_prep) Despite_0\IN|anthracyclin|DOX|, (l_pobj) cardiotoxicity_5\NN|NONE
D004317_D066126 NONE DOX_11\NNP|anthracyclin|Despite|, (r_appos) doxorubicin_9\NN|.|be (l_prep) Despite_0\IN|anthracyclin|DOX|, (l_pobj) cardiotoxicity_5\NN|NONE
D004317_D066126 NONE DOX_10\NNP| (r_npadvmod) induced_12\VBN|through (r_amod) cardiotoxicity_13\NN|NONE
D007501_D066126 NONE iron_19\NN|NONE (r_compound) chelating_20\VBG|scavenging (r_compound) properties_21\NNS|NONE (r_pobj) through_14\IN|induced (r_prep) cardiotoxicity_13\NN|NONE
D004317_D006331 NONE DOX_0\NNP| (r_npadvmod) induced_2\VBN|cardiac (r_amod) damage_4\NN|from|presumably|.
D004317_D006331 NONE DOX_14\NNP|NONE (r_pobj) by_13\IN|free (r_prep) radicals_12\NNS|NONE (r_pobj) of_10\IN|the (r_prep) formation_9\NN|NONE (r_pobj) from_7\IN|presumably|damage|. (r_prep) results_6\VBZ|NONE (l_nsubj) damage_4\NN|from|presumably|.
D004317_D006331 NONE DOX_6\NNP|NONE (r_pobj) with_5\IN|alone (r_prep) treatment_4\NN|that|damage (r_nsubj) induced_8\VBD|.|evaluation (l_dobj) damage_11\NN|that|treatment
D005419_D066126 NONE flavonoid_2\NN|semisynthetic|monoHER|The|)|( (r_compound) monohydroxyethylrutoside_3\NN|.|cardioprotection (r_nsubj) showed_7\VBD|NONE (l_dobj) cardioprotection_8\NN|.|monohydroxyethylrutoside (l_prep) against_9\IN|NONE (l_pobj) cardiotoxicity_13\NN|NONE
20682692
D013311_D003920 NONE streptozotocin_28\JJ|(|STZ)induced (r_nmod) diabetes_31\NNS|NONE
D013311_D003920 NONE STZ)-induced_30\VBN|(|streptozotocin (r_amod) diabetes_31\NNS|NONE
D013311_D003928 CID streptozotocin_15\NNS| (r_npadvmod) induced_17\VBN|diabetic (r_amod) nephropathy_19\NN|NONE
D013311_D003928 CID STZ_22\NNP| (r_npadvmod) induced_24\VBN|in|diabetic (r_amod) nephropathy_26\NN|NONE
D013311_D003928 CID STZ_20\NNP| (r_npadvmod) induced_22\VBN|diabetic (r_amod) nephropathy_24\NN|NONE
D000804_D003928 NONE angiotensin_13\NN|the (r_compound) system_14\NN|NONE (r_pobj) of_9\IN|in|early (r_prep) blockade_8\NN|that|,|not|did|suggesting|progression (r_nsubj) retard_25\VB|trial|. (l_advcl) suggesting_31\VBG|that|blockade|,|not|did|progression (l_ccomp) involved_37\VBN|NONE (l_prep) in_38\IN|)|mechanism(s|are|that (l_pobj) pathogenesis_40\NN|NONE (l_prep) of_41\IN|the (l_pobj) nephropathy_44\NN|NONE
D000804_D003928 NONE angiotensin_13\NN|the (r_compound) system_14\NN|NONE (r_pobj) of_9\IN|in|early (r_prep) blockade_8\NN|that|,|not|did|suggesting|progression (r_nsubj) retard_25\VB|trial|. (l_advcl) suggesting_31\VBG|that|blockade|,|not|did|progression (l_ccomp) involved_37\VBN|NONE (l_prep) in_38\IN|)|mechanism(s|are|that (l_pobj) pathogenesis_40\NN|NONE (l_prep) of_41\IN|the (l_pobj) nephropathy_44\NN|NONE (l_appos) nephropathy_47\NN|early|(|diabetic|)
D013311_D005355 NONE streptozotocin_28\JJ|(|STZ)induced (r_nmod) diabetes_31\NNS|NONE (r_pobj) with_27\IN|NONE (r_prep) mice_26\NNS|NONE (r_pobj) in_25\IN|early|the|of|of (r_prep) development_17\NN|NONE (l_prep) of_18\IN|in|early|the|of (l_pobj) fibrosis_21\NN|NONE
D013311_D005355 NONE STZ)-induced_30\VBN|(|streptozotocin (r_amod) diabetes_31\NNS|NONE (r_pobj) with_27\IN|NONE (r_prep) mice_26\NNS|NONE (r_pobj) in_25\IN|early|the|of|of (r_prep) development_17\NN|NONE (l_prep) of_18\IN|in|early|the|of (l_pobj) fibrosis_21\NN|NONE
D000804_D007674 NONE angiotensin_13\NN|the (r_compound) system_14\NN|NONE (r_pobj) of_9\IN|in|early (r_prep) blockade_8\NN|that|,|not|did|suggesting|progression (r_nsubj) retard_25\VB|trial|. (l_dobj) progression_27\NN|that|blockade|,|not|did|suggesting (l_prep) of_28\IN|the (l_pobj) nephropathy_29\NN|NONE
D000804_D003922 NONE angiotensin_13\NN|the (r_compound) system_14\NN|NONE (r_pobj) of_9\IN|in|early (r_prep) blockade_8\NN|that|,|not|did|suggesting|progression (l_prep) in_15\IN|of|early (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) diabetes_20\NNS|NONE
18189308
D014443_D003556 NONE tyrosine_9\NN|(|)|Trks|kinase (r_det) receptors_11\NNS|NONE (r_pobj) of_8\IN|the|regulation|and (r_prep) expression_5\NN|studies|in|.|have (r_dobj) examined_3\VBN|NONE (l_prep) in_15\IN|studies|expression|.|have (l_pobj) reflexes_17\NNS|NONE (l_prep) with_18\IN|micturition (l_pobj) inflammation_21\NN|NONE
D003520_D003556 CID cyclophosphamide_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) cystitis_15\NN|NONE
D003520_D003556 CID cyclophosphamide_27\NN|NONE (r_pobj) by_26\IN|NONE (r_agent) induced_25\VBN|various|of (r_acl) durations_21\NNS|NONE (l_prep) of_22\IN|various|induced (l_pobj) inflammation_24\NN|NONE
D003520_D003556 CID CYP_29\NNP|NONE (r_appos) cyclophosphamide_27\NN|NONE (r_pobj) by_26\IN|NONE (r_agent) induced_25\VBN|various|of (r_acl) durations_21\NNS|NONE (l_prep) of_22\IN|various|induced (l_pobj) inflammation_24\NN|NONE
D003520_D003556 CID CYP_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) cystitis_3\NN|(|expression|.
D003520_D003556 CID CYP_27\NNP| (r_npadvmod) induced_29\VBN|)|acute|( (r_amod) cystitis_30\NN|NONE
D003520_D003556 CID CYP_7\NNP||intermediate (r_npadvmod) induced_9\VBN|NONE (r_amod) cystitis_10\NN|NONE
9428298
D000420_D001249 NONE albuterol_2\NN|NONE (l_prep) in_3\IN|nebulized|:|.|study (l_pobj) exacerbations_5\NNS|NONE (l_prep) of_6\IN|severe|in (l_pobj) asthma_7\NN|NONE
D000420_D001249 NONE albuterol_25\NN|(|)|nebulized (r_nmod) CNA_27\NNP|who|versus (r_dobj) received_22\VBD|severe|of (r_relcl) exacerbations_18\NNS|NONE (l_prep) of_19\IN|severe|received (l_pobj) asthma_20\NN|NONE
D000420_D001249 NONE albuterol_31\NN|(|intermittent|INA|) (r_nmod) treatments_35\NNS|NONE (r_pobj) versus_29\IN|who|CNA (r_prep) received_22\VBD|severe|of (r_relcl) exacerbations_18\NNS|NONE (l_prep) of_19\IN|severe|received (l_pobj) asthma_20\NN|NONE
16369751
C032348_D002637 NONE FBAL_34\NNP|serum|of (r_compound) concentration_35\NN|NONE (r_pobj) with_30\IN|concomitantly|pain|during (r_prep) occurred_28\VBD|intravenous|,|a|of|continuous (l_nsubj) pain_22\NN|concomitantly|with|during
C032348_D002037 NONE FBAL_34\NNP|serum|of (r_compound) concentration_35\NN|NONE (r_pobj) with_30\IN|concomitantly|pain|during (r_prep) occurred_28\VBD|intravenous|,|a|of|continuous (l_nsubj) pain_22\NN|concomitantly|with|during (l_prep) with_23\IN|precordial (l_pobj) block_27\NN|NONE
C032348_D066126 NONE alanine_10\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|.|Fluorouracil (r_acl) cardiotoxicity_1\NN|NONE
C032348_D066126 NONE alanine_30\NN|NONE (r_pobj) of_23\IN|serum|a|high (r_prep) level_22\NN|)|in|(|was (r_nsubjpass) observed_35\VBN|induced|, (r_relcl) cardiotoxicity_15\NN|NONE
C032348_D066126 NONE FBAL_32\NNP|NONE (r_preconj) (_31\-LRB-|)|in|level|was (r_punct) observed_35\VBN|induced|, (r_relcl) cardiotoxicity_15\NN|NONE
C032348_D066126 NONE FBAL_16\NNP|to|that|is (r_nsubjpass) related_18\VBN|.|,|experience (l_prep) to_19\IN|FBAL|that|is (l_pobj) cardiotoxicity_23\NN|NONE
D005472_D002037 CID 5-FU_11\CD|NONE (r_pobj) of_10\IN|intravenous|,|occurred|a|continuous (r_prep) infusion_9\NN|,|After|.|patient (l_relcl) occurred_28\VBD|intravenous|,|a|of|continuous (l_nsubj) pain_22\NN|concomitantly|with|during (l_prep) with_23\IN|precordial (l_pobj) block_27\NN|NONE
D005472_D009369 NONE 5-FU_1\CD|)|(|for|. (r_nummod) treatment_3\NN|NONE (l_prep) for_4\IN|)|(|.|FU (l_pobj) malignancies_5\NNS|NONE
D005472_D066126 NONE 5-Fluorouracil_0\CD|.|induced (r_punct) cardiotoxicity_1\NN|NONE
D005472_D066126 NONE 5-fluorouracil_7\CD|complication|Cardiotoxicity (r_punct) is_1\VBZ|NONE (l_nsubj) Cardiotoxicity_0\NNP|complication|fluorouracil
D005472_D066126 NONE 5-FU_12\CD| (r_npadvmod) induced_14\VBN|observed|, (r_amod) cardiotoxicity_15\NN|NONE
D005472_D066126 NONE 5-FU_14\CD| (r_npadvmod) induced_16\VBN|NONE (r_compound) cardiotoxicity_17\NN|NONE
D005472_D066126 NONE 5-FU_22\CD|NONE (r_pobj) of_21\IN|the (r_prep) administration_20\NN|,|considered|was|. (r_nsubjpass) abandoned_24\VBN|NONE (l_advcl) considered_8\VBN|,|administration|was|. (l_xcomp) been_11\VBN|As|pain|was (l_acomp) due_12\JJ|have|to (l_prep) to_13\IN|NONE (l_pobj) cardiotoxicity_17\NN|NONE
D005472_D066126 NONE 5-FU_20\CD| (r_npadvmod) induced_22\VBN|NONE (r_compound) cardiotoxicity_23\NN|NONE
D005472_D066126 NONE 5-FU_8\CD| (r_npadvmod) induced_10\VBN|NONE (r_amod) cardiotoxicity_11\NN|NONE
D005472_D002637 CID 5-FU_11\CD|NONE (r_pobj) of_10\IN|intravenous|,|occurred|a|continuous (r_prep) infusion_9\NN|,|After|.|patient (l_relcl) occurred_28\VBD|intravenous|,|a|of|continuous (l_nsubj) pain_22\NN|concomitantly|with|during
D005472_D002637 CID 5-FU_14\CD|NONE (r_pobj) of_13\IN|the (r_prep) discontinuation_12\NN|NONE (r_pobj) after_10\IN|.|spontaneously|pain (r_prep) disappeared_8\VBD|NONE (l_nsubj) pain_3\NN|after|.|spontaneously
D005472_D002637 CID 5-FU_14\CD| (r_npadvmod) induced_16\VBN|NONE (r_compound) cardiotoxicity_17\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) due_12\JJ|have|to (r_acomp) been_11\VBN|As|pain|was (r_xcomp) considered_8\VBN|,|administration|was|. (l_nsubjpass) pain_3\NN|As|was|been
D005472_D002637 CID 5-FU_22\CD|NONE (r_pobj) of_21\IN|the (r_prep) administration_20\NN|,|considered|was|. (r_nsubjpass) abandoned_24\VBN|NONE (l_advcl) considered_8\VBN|,|administration|was|. (l_nsubjpass) pain_3\NN|As|was|been
3708328
D005680_D012640 NONE acid_16\NN|NONE (r_pobj) of_11\IN|the (r_prep) activity_10\NN|NONE (r_dobj) manipulating_8\VBG|NONE (r_pcomp) of_7\IN|the|inhibition (r_prep) effects_6\NNS|,|were|In|.|, (l_appos) inhibition_20\NN|of|the (l_prep) on_25\IN|(|within|GABA)mediated|synaptic (l_pobj) seizures_26\NNS|NONE
D005680_D012640 NONE GABA)-mediated_18\VBN|(|within|on|synaptic (r_amod) inhibition_20\NN|of|the (l_prep) on_25\IN|(|within|GABA)mediated|synaptic (l_pobj) seizures_26\NNS|NONE
D005680_D012640 NONE GABA_17\NNP| (r_npadvmod) synthesizing_19\VBG|decarboxylase|,|,|into|the (r_amod) enzyme_20\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) activity_14\NN|NONE (r_pobj) of_13\IN|an (r_prep) inhibitor_12\NN|,| (r_appos) micrograms_9\NNS|,|of (r_conj) microinjections_4\NNS|NONE (r_pobj) with_3\IN|NONE (r_prep) pretreated_2\VBN|NONE (r_acl) animals_1\NNS|NONE (r_pobj) In_0\IN|.|doses|in (r_prep) resulted_52\VBD|NONE (l_prep) in_53\IN|.|doses|In (l_pobj) seizures_57\NNS|NONE
D005680_D012640 NONE GABA_20\NNP| (r_npadvmod) mediated_22\VBN|synaptic|the|within (r_amod) inhibition_24\NN|NONE (r_pobj) of_18\IN|the (r_prep) regulation_17\NN|NONE (r_pobj) to_15\IN|is|that|threshold (r_prep) subjected_14\VBN|.|results (l_nsubjpass) threshold_5\NN|to|is|that (l_prep) for_6\IN|the (l_pobj) seizures_10\NNS|NONE
D007538_D013226 NONE isoniazid_6\NN|NONE (r_pobj) of_5\IN|micrograms|, (r_prep) microinjections_4\NNS|NONE (r_pobj) with_3\IN|NONE (r_prep) pretreated_2\VBN|NONE (r_acl) animals_1\NNS|NONE (r_pobj) In_0\IN|.|doses|in (r_prep) resulted_52\VBD|NONE (l_prep) in_53\IN|.|doses|In (l_pobj) seizures_57\NNS|NONE (l_conj) epilepticus_60\NN|motor|severe|limbic|and
D010862_D013226 NONE pilocarpine_45\NN|NONE (r_pobj) of_44\IN|,|mg/kg|,||convulsant (r_prep) doses_43\NNS|.|In|in (r_nsubj) resulted_52\VBD|NONE (l_prep) in_53\IN|.|doses|In (l_pobj) seizures_57\NNS|NONE (l_conj) epilepticus_60\NN|motor|severe|limbic|and
D020888_D012640 NONE GABA_17\NNP|or (r_conj) isoniazid_11\NN|NONE (r_pobj) of_10\IN|into (r_prep) microinjection_9\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) rats_7\NNS|NONE (r_pobj) in_6\IN|by (r_prep) produced_3\VBN|NONE (r_acl) seizures_2\NNS|NONE
D020888_D012640 NONE acid_6\NN|,|,|into|,|micrograms (r_appos) D_1\NNP|mg/kg|,|.|(|,|bilaterally|,|appearance (r_nsubj) suppressed_18\VBD|NONE (l_dobj) appearance_20\NN|mg/kg|,|.|(|,|bilaterally|D|, (l_prep) of_21\IN|the (l_pobj) seizures_25\NNS|NONE
D020888_D012640 NONE GABA_6\NNP|NONE (r_pobj) of_1\IN|into (r_prep) Microinjections_0\NNS|.|prevent|,|mg/kg|bilaterally|,|, (r_nsubj) failed_18\VBD|NONE (l_xcomp) prevent_20\VB|.|,|mg/kg|bilaterally|Microinjections|,|, (l_dobj) development_22\NN|to (l_prep) of_23\IN|the (l_pobj) convulsions_24\NNS|NONE
D018698_D012640 NONE acid_25\NN|glutamic (r_compound) decarboxylase_26\NN|,|synthesizing|,|into|the (r_appos) enzyme_20\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) activity_14\NN|NONE (r_pobj) of_13\IN|an (r_prep) inhibitor_12\NN|,| (r_appos) micrograms_9\NNS|,|of (r_conj) microinjections_4\NNS|NONE (r_pobj) with_3\IN|NONE (r_prep) pretreated_2\VBN|NONE (r_acl) animals_1\NNS|NONE (r_pobj) In_0\IN|.|doses|in (r_prep) resulted_52\VBD|NONE (l_prep) in_53\IN|.|doses|In (l_pobj) seizures_57\NNS|NONE
D010862_D012640 CID pilocarpine_5\NN|NONE (r_pobj) by_4\IN|in (r_agent) produced_3\VBN|NONE (r_acl) seizures_2\NNS|NONE
D010862_D012640 CID Pilocarpine_0\NNP|and|,|.|provides|sequelae|,|given (r_nsubj) reproduces_7\VBZ|NONE (l_conj) provides_16\VBZ|and|,|Pilocarpine|.|sequelae|,|given (l_dobj) model_20\NN|NONE (l_prep) for_21\IN|relevant|a|animal (l_pcomp) studying_22\VBG|NONE (l_dobj) mechanisms_23\NNS|NONE (l_prep) of_24\IN|NONE (l_pobj) buildup_25\NN|NONE (l_prep) of_26\IN|NONE (l_pobj) activity_28\NN|NONE (l_amod) convulsive_27\JJ|pathways|and|operative
D010862_D012640 CID Pilocarpine_0\NNP|and|,|.|provides|sequelae|,|given (r_nsubj) reproduces_7\VBZ|NONE (l_conj) provides_16\VBZ|and|,|Pilocarpine|.|sequelae|,|given (l_dobj) model_20\NN|NONE (l_prep) for_21\IN|relevant|a|animal (l_pcomp) studying_22\VBG|NONE (l_dobj) mechanisms_23\NNS|NONE (l_prep) of_24\IN|NONE (l_pobj) buildup_25\NN|NONE (l_prep) of_26\IN|NONE (l_pobj) activity_28\NN|NONE (l_amod) operative_31\JJ|pathways|and|convulsive (l_prep) in_32\IN|NONE (l_pobj) generalization_34\NN|NONE (l_prep) of_37\IN|the|propagation|and (l_pobj) seizures_38\NNS|NONE
D010862_D012640 CID pilocarpine_29\NN|NONE (r_pobj) by_28\IN|in (r_agent) produced_27\VBN|NONE (r_acl) seizures_26\NNS|NONE
D010862_D012640 CID pilocarpine_45\NN|NONE (r_pobj) of_44\IN|,|mg/kg|,||convulsant (r_prep) doses_43\NNS|.|In|in (r_nsubj) resulted_52\VBD|NONE (l_prep) in_53\IN|.|doses|In (l_pobj) seizures_57\NNS|NONE
D010862_D012640 CID pilocarpine_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) convulsions_15\NNS|NONE
D010862_D012640 CID pilocarpine_36\NN|NONE (r_pobj) with_35\IN|in|which|typically|is (r_prep) observed_34\VBN|hippocampal|,|,|the|thalamus (r_relcl) formation_17\NN|NONE (r_pobj) to_14\IN|related (r_prep) damage_13\NN|analysis|. (l_amod) related_12\VBN|to (l_npadvmod) seizure_10\NN|
D010862_D012640 CID pilocarpine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) produced_9\VBN|,|mg/kg (r_acl) seizures_8\NNS|.|not|did|injections
D010862_D012640 CID pilocarpine_28\NN|NONE (r_pobj) by_27\IN|NONE (r_agent) produced_26\VBN|electrographic (r_acl) seizures_25\NNS|NONE
D010862_D012640 CID pilocarpine_27\NN|NONE (r_pobj) by_26\IN|NONE (r_agent) produced_25\VBN|NONE (r_acl) convulsions_24\NNS|NONE
D010862_D012640 CID pilocarpine_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) seizures_10\NNS|NONE
D010862_D004833 NONE Pilocarpine_0\NNP|and|,|.|provides|sequelae|,|given (r_nsubj) reproduces_7\VBZ|NONE (l_dobj) sequelae_10\NNS|and|,|Pilocarpine|.|provides|,|given (l_prep) of_11\IN|the|neuropathological (l_pobj) epilepsy_14\NN|NONE
D007538_D012640 NONE isoniazid_11\NN|NONE (r_pobj) of_10\IN|into (r_prep) microinjection_9\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) rats_7\NNS|NONE (r_pobj) in_6\IN|by (r_prep) produced_3\VBN|NONE (r_acl) seizures_2\NNS|NONE
D007538_D012640 NONE isoniazid_6\NN|NONE (r_pobj) of_5\IN|micrograms|, (r_prep) microinjections_4\NNS|NONE (r_pobj) with_3\IN|NONE (r_prep) pretreated_2\VBN|NONE (r_acl) animals_1\NNS|NONE (r_pobj) In_0\IN|.|doses|in (r_prep) resulted_52\VBD|NONE (l_prep) in_53\IN|.|doses|In (l_pobj) seizures_57\NNS|NONE
D007538_D012640 NONE isoniazid_4\NN|NONE (r_pobj) of_3\IN|Bilateral|intrastriatal (r_prep) injections_2\NNS|.|not|did|seizures (r_nsubj) augment_7\VB|NONE (l_dobj) seizures_8\NNS|.|not|did|injections
D018698_D013226 NONE acid_25\NN|glutamic (r_compound) decarboxylase_26\NN|,|synthesizing|,|into|the (r_appos) enzyme_20\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) activity_14\NN|NONE (r_pobj) of_13\IN|an (r_prep) inhibitor_12\NN|,| (r_appos) micrograms_9\NNS|,|of (r_conj) microinjections_4\NNS|NONE (r_pobj) with_3\IN|NONE (r_prep) pretreated_2\VBN|NONE (r_acl) animals_1\NNS|NONE (r_pobj) In_0\IN|.|doses|in (r_prep) resulted_52\VBD|NONE (l_prep) in_53\IN|.|doses|In (l_pobj) seizures_57\NNS|NONE (l_conj) epilepticus_60\NN|motor|severe|limbic|and
D005680_D013226 NONE GABA_17\NNP| (r_npadvmod) synthesizing_19\VBG|decarboxylase|,|,|into|the (r_amod) enzyme_20\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) activity_14\NN|NONE (r_pobj) of_13\IN|an (r_prep) inhibitor_12\NN|,| (r_appos) micrograms_9\NNS|,|of (r_conj) microinjections_4\NNS|NONE (r_pobj) with_3\IN|NONE (r_prep) pretreated_2\VBN|NONE (r_acl) animals_1\NNS|NONE (r_pobj) In_0\IN|.|doses|in (r_prep) resulted_52\VBD|NONE (l_prep) in_53\IN|.|doses|In (l_pobj) seizures_57\NNS|NONE (l_conj) epilepticus_60\NN|motor|severe|limbic|and
4082466
D009020_D012640 CID Morphine_0\NNP| (r_npadvmod) induced_2\VBN|.|in (r_amod) seizures_3\NNS|NONE
D009020_D012640 CID sulfate_12\NN|NONE (r_pobj) of_9\IN|the (r_prep) course_8\NN|NONE (r_pobj) during_6\IN|neonates|.|from (r_prep) suffered_2\VBD|NONE (l_prep) from_3\IN|neonates|.|during (l_pobj) seizures_5\NNS|NONE
D009020_D012640 CID morphine_18\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) cessation_16\NN|hours (r_pobj) after_15\IN|reoccur|convulsions|and|. (r_prep) stopped_11\VBD|reasons|and|were|out (r_conj) ruled_6\VBN|NONE (l_nsubjpass) reasons_2\NNS|and|were|stopped|out (l_prep) for_3\IN|Other|known (l_pobj) seizures_4\NNS|NONE
D009020_D012640 CID morphine_18\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) cessation_16\NN|hours (r_pobj) after_15\IN|reoccur|convulsions|and|. (r_prep) stopped_11\VBD|reasons|and|were|out (l_nsubj) convulsions_10\NNS|after|reoccur|and|.
2933998
D017265_D014202 CID procaterol_8\NN|NONE (r_pobj) of_7\IN|Both|asthmatic (r_prep) effects_6\NNS|related|. (l_amod) asthmatic_3\JJ|of|Both (l_conj) tremorgenic_5\JJ||and
D013726_D001249 NONE terbutaline_2\NN|and|. (l_prep) in_3\IN|NONE (l_pobj) asthma_5\NN|NONE
D017265_D001249 NONE Procaterol_0\NNP|NONE (l_conj) terbutaline_2\NN|and|. (l_prep) in_3\IN|NONE (l_pobj) asthma_5\NN|NONE
D017265_D001249 NONE Procaterol_0\NNP|in|was|. (r_nsubjpass) studied_9\VBN|NONE (l_prep) in_10\IN|was|.|Procaterol (l_pobj) trial_23\NN|NONE (l_prep) in_24\IN|controlled|blind|,|cross|a|, (l_pobj) patients_25\NNS|NONE (l_prep) with_26\IN|NONE (l_pobj) asthma_28\NN|NONE
D017265_D001249 NONE procaterol_8\NN|NONE (r_pobj) of_7\IN|Both|asthmatic (r_prep) effects_6\NNS|related|. (l_amod) asthmatic_3\JJ|of|Both
24778426
D008353_D007674 NONE mannitol_22\NN|NONE (r_pobj) without_21\IN|and (r_conj) with_19\IN|NONE (r_prep) cisplatin_18\NN|agent (r_dobj) receiving_14\VBG|cancer (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|induced (r_prep) nephrotoxicity_10\NN|NONE
D008353_D007674 NONE mannitol_5\NN|not|who|did (r_dobj) receive_4\VB|NONE (r_relcl) Patients_0\NNS|.|likely|ratio (r_nsubj) were_6\VBD|NONE (l_acomp) likely_8\JJ|.|Patients|ratio (l_xcomp) develop_10\VB|more (l_dobj) nephrotoxicity_11\NN|to
D008353_D007674 NONE mannitol_4\NNS|NONE (r_pobj) of_3\IN|limited (r_prep) quantities_2\NNS|When|available (r_nsubj) are_5\VBP|should|.|to|,|preferentially|it|be (r_advcl) given_12\VBN|NONE (l_dative) to_13\IN|should|.|,|preferentially|it|be|are (l_pobj) patients_14\NNS|NONE (l_prep) at_15\IN|NONE (l_pobj) risk_18\NN|NONE (l_prep) of_19\IN|high (l_pobj) nephrotoxicity_20\NN|NONE
D008353_D007674 NONE mannitol_38\NN|NONE (r_pobj) of_37\IN|the (r_prep) addition_36\NN|NONE (r_pobj) from_34\IN|would (r_prep) benefit_33\VB|weeks|and|at (r_conj) are_24\VBP|that|patients (l_prep) at_25\IN|weeks|and|benefit (l_pobj) risk_28\NN|NONE (l_prep) of_29\IN|the|greatest (l_pobj) nephrotoxicity_30\NN|NONE
D002945_D007674 NONE cisplatin_6\JJ|NONE (r_amod) use_7\NN|NONE (r_pobj) of_5\IN|the|major (r_prep) complications_4\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) One_0\CD|nephrotoxicity|. (r_nsubj) is_8\VBZ|NONE (l_attr) nephrotoxicity_12\NN|One|.
D002945_D007674 NONE cisplatin_7\NN| (r_advmod) induced_9\VBN|in (r_amod) nephrotoxicity_10\NN|NONE
D002945_D007674 NONE cisplatin_18\NN|agent (r_dobj) receiving_14\VBG|cancer (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|induced (r_prep) nephrotoxicity_10\NN|NONE
D002945_D007674 NONE cisplatin_16\NN|analysis|. (l_advcl) are_24\VBP|that|patients (l_prep) at_25\IN|weeks|and|benefit (l_pobj) risk_28\NN|NONE (l_prep) of_29\IN|the|greatest (l_pobj) nephrotoxicity_30\NN|NONE
D008353_D064420 NONE mannitol_13\NN|NONE (r_pobj) of_12\IN|as|the (r_prep) use_11\NN|NONE (r_pobj) including_9\VBG|,|to|toxicity (r_prep) prevent_5\VB|many (l_dobj) toxicity_7\NN|,|to|including
D002945_D009369 NONE cisplatin_7\NN| (r_advmod) induced_9\VBN|in (r_amod) nephrotoxicity_10\NN|NONE (l_prep) in_11\IN|induced (l_pobj) patients_13\NNS|NONE (l_compound) cancer_12\NN|receiving
D002945_D009369 NONE cisplatin_18\NN|agent (r_dobj) receiving_14\VBG|cancer (r_acl) patients_13\NNS|NONE (l_compound) cancer_12\NN|receiving
D002945_D009369 NONE cisplatin_11\NN|as (r_dobj) receiving_7\VBG|cancer (r_acl) patients_6\NNS|NONE (l_compound) cancer_5\NN|receiving
D002945_D009369 NONE cisplatin_10\NN|who (r_dobj) received_6\VBD| (r_relcl) patients_4\NNS|:|We (r_dobj) evaluated_2\VBD|.|as|%|;|cancer (r_ccomp) had_16\VBD|NONE (l_prep) as_21\IN|.|evaluated|%|;|cancer (l_pobj) malignancy_24\NN|NONE
D002945_D006973 NONE cisplatin_16\NN|analysis|. (l_advcl) are_24\VBP|that|patients (l_nsubj) weeks_19\NNS|and|benefit|at (l_conj) those_21\DT|every|and| (l_prep) with_22\IN|NONE (l_pobj) hypertension_23\NN|NONE
D002945_D006258 NONE cisplatin_10\NN|who (r_dobj) received_6\VBD| (r_relcl) patients_4\NNS|:|We (r_dobj) evaluated_2\VBD|.|as|%|;|cancer (r_ccomp) had_16\VBD|NONE (l_dobj) cancer_20\NN|.|as|evaluated|%|;
D008353_D009369 NONE mannitol_22\NN|NONE (r_pobj) without_21\IN|and (r_conj) with_19\IN|NONE (r_prep) cisplatin_18\NN|agent (r_dobj) receiving_14\VBG|cancer (r_acl) patients_13\NNS|NONE (l_compound) cancer_12\NN|receiving
D008353_D006973 NONE mannitol_38\NN|NONE (r_pobj) of_37\IN|the (r_prep) addition_36\NN|NONE (r_pobj) from_34\IN|would (r_prep) benefit_33\VB|weeks|and|at (r_conj) are_24\VBP|that|patients (l_nsubj) weeks_19\NNS|and|benefit|at (l_conj) those_21\DT|every|and| (l_prep) with_22\IN|NONE (l_pobj) hypertension_23\NN|NONE
20447294
C401121_D003929 NONE CNSB002_9\NNP|and (r_conj) morphine_7\NN|NONE (r_pobj) of_6\IN|nonsedating (r_prep) doses_5\NNS|NONE (r_pobj) for_3\IN|response|given (r_prep) curves_2\VBZ|were|for (r_nsubjpass) constructed_18\VBN|induced|paw|and|:|.|streptozotocin|neuropathy (r_ccomp) inflammation_38\NN|NONE (l_appos) neuropathy_44\NN|induced|paw|and|:|.|streptozotocin|constructed
C401121_D007249 NONE CNSB002_9\NNP|and (r_conj) morphine_7\NN|NONE (r_pobj) of_6\IN|nonsedating (r_prep) doses_5\NNS|NONE (r_pobj) for_3\IN|response|given (r_prep) curves_2\VBZ|were|for (r_nsubjpass) constructed_18\VBN|induced|paw|and|:|.|streptozotocin|neuropathy (r_ccomp) inflammation_38\NN|NONE
D013311_D007249 NONE streptozotocin_40\JJ|induced|paw|and|:|.|neuropathy|constructed (r_conj) inflammation_38\NN|NONE
D013311_D007249 NONE STZ)-induced_42\VBN|(|diabetic (r_amod) neuropathy_44\NN|induced|paw|and|:|.|streptozotocin|constructed (r_appos) inflammation_38\NN|NONE
C401121_D006930 NONE CNSB002_45\NNP|NONE (r_pobj) for_44\IN|neuropathy|the|induced (r_prep) model_43\NN|NONE (r_pobj) in_37\IN|,|)|SEM|.|(|.|and|) (r_prep) 7.54_14\CD|doses|. (r_attr) were_13\VBD|NONE (l_nsubj) doses_1\NNS|.|. (l_acl) calculated_2\VBN|(|)|ED|The (l_advcl) cause_4\VB|NONE (l_dobj) reversal_7\NN|to (l_prep) of_8\IN|% (l_pobj) hyperalgesia_9\NN|NONE
C401121_D006930 NONE CNSB002_15\NNP|administration (r_pobj) with_14\IN|to|.|reversal|and (r_punct) from_16\IN|was|antinociception|. (l_conj) reversal_26\NN|to|.|and|with (l_prep) of_27\IN|respectively|%|,|P|(|in (l_pobj) hyperalgesia_28\NN|NONE
C401121_D010146 NONE CNSB002_9\NNP|and (r_conj) morphine_7\NN|NONE (r_pobj) of_6\IN|nonsedating (r_prep) doses_5\NNS|NONE (r_pobj) for_3\IN|response|given (r_prep) curves_2\VBZ|were|for (r_nsubjpass) constructed_18\VBN|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN|were|curves (l_pobj) effect_21\NN|NONE (l_acl) using_22\VBG|antihyperalgesic (l_prep) in_28\IN|withdrawal (l_pobj) models_32\NNS|NONE (l_compound) pain_31\NN|rat|two
C401121_D009437 NONE CNSB002_12\NNP|novel|a|,|channel (r_appos) blocker_10\NN|and (r_conj) morphine_4\NN|NONE (r_pobj) between_3\IN|NONE (r_prep) synergy_2\NN|NONE (r_pobj) of_1\IN|.|in|, (r_prep) Studies_0\NNS|NONE (l_prep) in_14\IN|.|of|, (l_pobj) models_16\NNS|NONE (l_prep) of_17\IN|rat (l_pobj) pain_21\NN|NONE
C401121_D009437 NONE CNSB002_9\NNP|NONE (l_appos) blocker_14\NN|, (l_prep) with_15\IN|channel|a (l_conj) in_21\IN|properties|and (l_pobj) combinations_22\NNS|NONE (l_prep) in_25\IN|with (l_pobj) models_27\NNS|NONE (l_prep) of_28\IN|rat (l_pobj) pain_32\NN|NONE
D002351_D010146 NONE carrageenan_34\NN| (r_npadvmod) induced_36\VBN|paw|and|:|.|streptozotocin|neuropathy|constructed (r_amod) inflammation_38\NN|NONE (l_ccomp) constructed_18\VBN|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN|were|curves (l_pobj) effect_21\NN|NONE (l_acl) using_22\VBG|antihyperalgesic (l_prep) in_28\IN|withdrawal (l_pobj) models_32\NNS|NONE (l_compound) pain_31\NN|rat|two
D013311_D009422 NONE STZ_39\NNP| (r_npadvmod) induced_41\VBN|neuropathy|for|the (r_amod) model_43\NN|NONE (l_compound) neuropathy_42\NN|for|the|induced
D009020_D010146 NONE morphine_7\NN|NONE (r_pobj) of_6\IN|nonsedating (r_prep) doses_5\NNS|NONE (r_pobj) for_3\IN|response|given (r_prep) curves_2\VBZ|were|for (r_nsubjpass) constructed_18\VBN|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN|were|curves (l_pobj) effect_21\NN|NONE (l_acl) using_22\VBG|antihyperalgesic (l_prep) in_28\IN|withdrawal (l_pobj) models_32\NNS|NONE (l_compound) pain_31\NN|rat|two
D002351_D006930 CID carrageenan_25\NN|the (r_compound) model_26\NN|NONE (r_pobj) in_23\IN|.|.|.|.|and|and (r_prep) 4.83_19\CD|,|)|SEM|.|(|in|and|) (r_conj) 7.54_14\CD|doses|. (r_attr) were_13\VBD|NONE (l_nsubj) doses_1\NNS|.|. (l_acl) calculated_2\VBN|(|)|ED|The (l_advcl) cause_4\VB|NONE (l_dobj) reversal_7\NN|to (l_prep) of_8\IN|% (l_pobj) hyperalgesia_9\NN|NONE
D009020_D009437 NONE morphine_4\NN|NONE (r_pobj) between_3\IN|NONE (r_prep) synergy_2\NN|NONE (r_pobj) of_1\IN|.|in|, (r_prep) Studies_0\NNS|NONE (l_prep) in_14\IN|.|of|, (l_pobj) models_16\NNS|NONE (l_prep) of_17\IN|rat (l_pobj) pain_21\NN|NONE
D009020_D009437 NONE morphine_24\NN|NONE (r_pobj) with_23\IN|in (r_prep) combinations_22\NNS|NONE (l_prep) in_25\IN|with (l_pobj) models_27\NNS|NONE (l_prep) of_28\IN|rat (l_pobj) pain_32\NN|NONE
D002351_D003929 NONE carrageenan_34\NN| (r_npadvmod) induced_36\VBN|paw|and|:|.|streptozotocin|neuropathy|constructed (r_amod) inflammation_38\NN|NONE (l_appos) neuropathy_44\NN|induced|paw|and|:|.|streptozotocin|constructed
D013311_D006930 CID STZ_39\NNP| (r_npadvmod) induced_41\VBN|neuropathy|for|the (r_amod) model_43\NN|NONE (r_pobj) in_37\IN|,|)|SEM|.|(|.|and|) (r_prep) 7.54_14\CD|doses|. (r_attr) were_13\VBD|NONE (l_nsubj) doses_1\NNS|.|. (l_acl) calculated_2\VBN|(|)|ED|The (l_advcl) cause_4\VB|NONE (l_dobj) reversal_7\NN|to (l_prep) of_8\IN|% (l_pobj) hyperalgesia_9\NN|NONE
D002351_D009422 NONE carrageenan_25\NN|the (r_compound) model_26\NN|NONE (r_pobj) in_23\IN|.|.|.|.|and|and (r_prep) 4.83_19\CD|,|)|SEM|.|(|in|and|) (r_conj) 7.54_14\CD|doses|. (l_prep) in_37\IN|,|)|SEM|.|(|.|and|) (l_pobj) model_43\NN|NONE (l_compound) neuropathy_42\NN|for|the|induced
D002351_D009422 NONE carrageenan_29\NN|the (r_compound) model_30\NN|NONE (r_pobj) in_27\IN|.|nonsedating|maximum|the (r_prep) dose_21\NN|NONE (r_pobj) than_17\IN|and|. (r_prep) less_16\JJR|.|values (l_conj) 1.37_32\CD|than|and (l_prep) in_36\IN|. (l_pobj) model_39\NN|SEM (l_compound) neuropathy_38\NN|the
C401121_D009422 NONE CNSB002_45\NNP|NONE (r_pobj) for_44\IN|neuropathy|the|induced (r_prep) model_43\NN|NONE (l_compound) neuropathy_42\NN|for|the|induced
C401121_D009422 NONE CNSB002_10\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) combination_8\NN|NONE (r_pobj) in_7\IN|when|mg/kg (r_prep) given_6\VBN|for|ED|The (r_advcl) values_2\NNS|.|less (r_nsubj) were_15\VBD|NONE (l_acomp) less_16\JJR|.|values (l_conj) 1.37_32\CD|than|and (l_prep) in_36\IN|. (l_pobj) model_39\NN|SEM (l_compound) neuropathy_38\NN|the
C401121_D009422 NONE CNSB002_15\NNP|administration (r_pobj) with_14\IN|to|.|reversal|and (r_punct) from_16\IN|was|antinociception|. (l_conj) reversal_26\NN|to|.|and|with (l_prep) in_29\IN|respectively|%|,|P|(|of (l_pobj) models_34\NNS|NONE (l_amod) inflammatory_31\JJ|the (l_conj) neuropathic_33\JJ|and
D013311_D003929 CID streptozotocin_40\JJ|induced|paw|and|:|.|neuropathy|constructed (r_conj) inflammation_38\NN|NONE (l_appos) neuropathy_44\NN|induced|paw|and|:|.|streptozotocin|constructed
D013311_D003929 CID STZ)-induced_42\VBN|(|diabetic (r_amod) neuropathy_44\NN|induced|paw|and|:|.|streptozotocin|constructed
D009020_D006930 NONE morphine_47\NN|and (r_conj) CNSB002_45\NNP|NONE (r_pobj) for_44\IN|neuropathy|the|induced (r_prep) model_43\NN|NONE (r_pobj) in_37\IN|,|)|SEM|.|(|.|and|) (r_prep) 7.54_14\CD|doses|. (r_attr) were_13\VBD|NONE (l_nsubj) doses_1\NNS|.|. (l_acl) calculated_2\VBN|(|)|ED|The (l_advcl) cause_4\VB|NONE (l_dobj) reversal_7\NN|to (l_prep) of_8\IN|% (l_pobj) hyperalgesia_9\NN|NONE
D009020_D006930 NONE morphine_3\NN|NONE (r_pobj) after_2\IN|mg/kg|The|(|) (r_prep) antinociception_1\NN|was|from|. (r_nsubjpass) increased_9\VBN|NONE (l_prep) from_16\IN|was|antinociception|. (l_conj) reversal_26\NN|to|.|and|with (l_prep) of_27\IN|respectively|%|,|P|(|in (l_pobj) hyperalgesia_28\NN|NONE
D013311_D010146 NONE streptozotocin_40\JJ|induced|paw|and|:|.|neuropathy|constructed (r_conj) inflammation_38\NN|NONE (l_ccomp) constructed_18\VBN|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN|were|curves (l_pobj) effect_21\NN|NONE (l_acl) using_22\VBG|antihyperalgesic (l_prep) in_28\IN|withdrawal (l_pobj) models_32\NNS|NONE (l_compound) pain_31\NN|rat|two
D013311_D010146 NONE STZ)-induced_42\VBN|(|diabetic (r_amod) neuropathy_44\NN|induced|paw|and|:|.|streptozotocin|constructed (r_appos) inflammation_38\NN|NONE (l_ccomp) constructed_18\VBN|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN|were|curves (l_pobj) effect_21\NN|NONE (l_acl) using_22\VBG|antihyperalgesic (l_prep) in_28\IN|withdrawal (l_pobj) models_32\NNS|NONE (l_compound) pain_31\NN|rat|two
D012964_D009437 NONE sodium_8\NN|NONE (r_compound) channel_9\NN|novel|a|CNSB|, (r_compound) blocker_10\NN|and (r_conj) morphine_4\NN|NONE (r_pobj) between_3\IN|NONE (r_prep) synergy_2\NN|NONE (r_pobj) of_1\IN|.|in|, (r_prep) Studies_0\NNS|NONE (l_prep) in_14\IN|.|of|, (l_pobj) models_16\NNS|NONE (l_prep) of_17\IN|rat (l_pobj) pain_21\NN|NONE
D012964_D009437 NONE sodium_12\NN|NONE (r_compound) channel_13\NN|a|with (r_compound) blocker_14\NN|, (l_prep) with_15\IN|channel|a (l_conj) in_21\IN|properties|and (l_pobj) combinations_22\NNS|NONE (l_prep) in_25\IN|with (l_pobj) models_27\NNS|NONE (l_prep) of_28\IN|rat (l_pobj) pain_32\NN|NONE
D009020_D009422 NONE morphine_47\NN|and (r_conj) CNSB002_45\NNP|NONE (r_pobj) for_44\IN|neuropathy|the|induced (r_prep) model_43\NN|NONE (l_compound) neuropathy_42\NN|for|the|induced
D009020_D009422 NONE morphine_4\NN|NONE (r_pobj) for_3\IN|given|ED|The (r_prep) values_2\NNS|.|less (r_nsubj) were_15\VBD|NONE (l_acomp) less_16\JJR|.|values (l_conj) 1.37_32\CD|than|and (l_prep) in_36\IN|. (l_pobj) model_39\NN|SEM (l_compound) neuropathy_38\NN|the
D009020_D009422 NONE morphine_3\NN|NONE (r_pobj) after_2\IN|mg/kg|The|(|) (r_prep) antinociception_1\NN|was|from|. (r_nsubjpass) increased_9\VBN|NONE (l_prep) from_16\IN|was|antinociception|. (l_conj) reversal_26\NN|to|.|and|with (l_prep) in_29\IN|respectively|%|,|P|(|of (l_pobj) models_34\NNS|NONE (l_amod) inflammatory_31\JJ|the (l_conj) neuropathic_33\JJ|and
D009020_D007249 NONE morphine_7\NN|NONE (r_pobj) of_6\IN|nonsedating (r_prep) doses_5\NNS|NONE (r_pobj) for_3\IN|response|given (r_prep) curves_2\VBZ|were|for (r_nsubjpass) constructed_18\VBN|induced|paw|and|:|.|streptozotocin|neuropathy (r_ccomp) inflammation_38\NN|NONE
D009020_D003929 NONE morphine_7\NN|NONE (r_pobj) of_6\IN|nonsedating (r_prep) doses_5\NNS|NONE (r_pobj) for_3\IN|response|given (r_prep) curves_2\VBZ|were|for (r_nsubjpass) constructed_18\VBN|induced|paw|and|:|.|streptozotocin|neuropathy (r_ccomp) inflammation_38\NN|NONE (l_appos) neuropathy_44\NN|induced|paw|and|:|.|streptozotocin|constructed
D002351_D007249 CID carrageenan_34\NN| (r_npadvmod) induced_36\VBN|paw|and|:|.|streptozotocin|neuropathy|constructed (r_amod) inflammation_38\NN|NONE
22836123
D016559_D012595 CID tacrolimus_13\NN|in (r_compound) use_14\NN|NONE (l_prep) in_15\IN|tacrolimus (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) SSc_18\NNS|NONE
D016572_D012595 NONE cyclosporine_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) SSc_15\NNS|NONE
D000305_D007674 NONE corticosteroid_4\NN|high|dose (r_compound) use_5\NN|NONE (r_pobj) to_1\IN|NONE (r_prep) Moderate_0\JJ|is|.|as (r_nsubjpass) recognized_7\VBN|NONE (l_prep) as_8\IN|is|Moderate|. (l_pobj) factor_12\NN|NONE (l_prep) for_13\IN|risk|major|a (l_pobj) SRC_14\NNP|NONE
D000305_D007674 NONE corticosteroids_14\NNS|and (r_conj) tacrolimus_12\NNS|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|with|a (r_acl) patient_7\NN|In|,|we|. (l_prep) with_8\IN|induced|a (l_pobj) SRC_9\NNP|NONE
D016572_D057049 CID cyclosporine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) precipitated_9\VBN|thrombotic (r_acl) microangiopathy_8\NN|NONE
D011239_D007674 NONE prednisolone_10\NN|and (r_conj) tacrolimus_8\NN|NONE (r_pobj) by_7\IN|crisis (r_agent) induced_6\VBN|.|case|a|: (l_nsubj) crisis_5\NN|by
D016559_D007674 NONE tacrolimus_8\NN|NONE (r_pobj) by_7\IN|crisis (r_agent) induced_6\VBN|.|case|a|: (l_nsubj) crisis_5\NN|by
D016559_D007674 NONE tacrolimus_12\NNS|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|with|a (r_acl) patient_7\NN|In|,|we|. (l_prep) with_8\IN|induced|a (l_pobj) SRC_9\NNP|NONE
12559315
D007213_D008415 CID Indomethacin_0\NNP|.|in (r_nsubj) resulted_1\VBD|NONE (l_prep) in_2\IN|.|Indomethacin (l_pobj) findings_4\NNS|NONE (l_amod) typical_5\JJ|histopathologic (l_prep) of_6\IN|NONE (l_pobj) cystitis_8\NN|NONE (l_prep) as_11\IN|,|interstitial (l_pobj) epithelium_14\NN|such (l_conj) mastocytosis_17\NN|leaky|bladder|and
D007213_D018856 CID Indomethacin_0\NNP|.|in (r_nsubj) resulted_1\VBD|NONE (l_prep) in_2\IN|.|Indomethacin (l_pobj) findings_4\NNS|NONE (l_amod) typical_5\JJ|histopathologic (l_prep) of_6\IN|NONE (l_pobj) cystitis_8\NN|NONE
753803
D008696_D009135 NONE Dianabol_29\NNP|(|)|anabolizing|one (r_appos) agent_27\NN|NONE (r_pobj) of_24\IN|the|at|beneficial (r_prep) effects_23\NNS|to (r_dobj) investigate_20\VB|results|authors|have|E. (r_xcomp) encouraged_16\VBN|NONE (l_nsubj) results_2\NNS|investigate|authors|have|E. (l_acl) obtained_3\VBN|The|encouraging (l_prep) in_4\IN|by (l_pobj) departments_7\NNS|NONE (l_prep) in_8\IN|various|authoratative (l_pobj) patients_10\NNS|NONE (l_amod) myopathic_9\JJ|NONE
D008696_D009135 NONE Dianabol_29\NNP|(|)|anabolizing|one (r_appos) agent_27\NN|NONE (r_pobj) of_24\IN|the|at|beneficial (r_prep) effects_23\NNS|to (l_prep) at_33\IN|the|of|beneficial (l_pobj) doses_35\NNS|NONE (l_prep) in_36\IN|high (l_pobj) rats_37\NNS|NONE (l_acl) rendered_38\VBN|NONE (l_oprd) myopathic_39\JJ|by
D014810_D009136 CID E._15\NNP|NONE (r_pobj) in_13\IN|NONE (r_prep) lacking_12\VBG|a (r_acl) diet_11\NN|it (r_dobj) giving_8\VBG|NONE (r_pcomp) by_7\IN|myodystrophy|authors (r_prep) induced_2\VBD|NONE (l_dobj) myodystrophy_3\NN|by|authors
-1_D009135 NONE CIBA_31\NNP|, (r_appos) Dianabol_29\NNP|(|)|anabolizing|one (r_appos) agent_27\NN|NONE (r_pobj) of_24\IN|the|at|beneficial (r_prep) effects_23\NNS|to (r_dobj) investigate_20\VB|results|authors|have|E. (r_xcomp) encouraged_16\VBN|NONE (l_nsubj) results_2\NNS|investigate|authors|have|E. (l_acl) obtained_3\VBN|The|encouraging (l_prep) in_4\IN|by (l_pobj) departments_7\NNS|NONE (l_prep) in_8\IN|various|authoratative (l_pobj) patients_10\NNS|NONE (l_amod) myopathic_9\JJ|NONE
-1_D009135 NONE CIBA_31\NNP|, (r_appos) Dianabol_29\NNP|(|)|anabolizing|one (r_appos) agent_27\NN|NONE (r_pobj) of_24\IN|the|at|beneficial (r_prep) effects_23\NNS|to (l_prep) at_33\IN|the|of|beneficial (l_pobj) doses_35\NNS|NONE (l_prep) in_36\IN|high (l_pobj) rats_37\NNS|NONE (l_acl) rendered_38\VBN|NONE (l_oprd) myopathic_39\JJ|by
D013256_D009135 NONE steroids_14\NNS|NONE (r_dobj) using_12\VBG|NONE (r_pcomp) by_11\IN|in (r_prep) obtained_3\VBN|The|encouraging (l_prep) in_4\IN|by (l_pobj) departments_7\NNS|NONE (l_prep) in_8\IN|various|authoratative (l_pobj) patients_10\NNS|NONE (l_amod) myopathic_9\JJ|NONE
D013256_D009135 NONE steroids_14\NNS|NONE (r_dobj) using_12\VBG|NONE (r_pcomp) by_11\IN|in (r_prep) obtained_3\VBN|The|encouraging (r_acl) results_2\NNS|investigate|authors|have|E. (r_nsubj) encouraged_16\VBN|NONE (l_xcomp) investigate_20\VB|results|authors|have|E. (l_dobj) effects_23\NNS|to (l_prep) at_33\IN|the|of|beneficial (l_pobj) doses_35\NNS|NONE (l_prep) in_36\IN|high (l_pobj) rats_37\NNS|NONE (l_acl) rendered_38\VBN|NONE (l_oprd) myopathic_39\JJ|by
D013256_D009135 NONE steroids_11\NNS|NONE (r_pobj) of_8\IN|in|undoubted|the (r_prep) efficacy_7\NN|NONE (l_prep) in_12\IN|undoubted|the|of (l_pobj) disease_15\NN|NONE
D014810_D009135 NONE E_6\NNS|NONE (r_pobj) of_4\IN|induced (r_prep) lack_3\NN|to (r_pobj) due_1\IN|NONE (r_amod) Myopathy_0\NNP|with|much|.|anatomically
D014810_D009135 NONE E_6\NNS|NONE (l_conj) myopathy_8\NNS|and|vitamin
D014810_D009135 NONE E._46\NNP|results|investigate|authors|have (r_punct) encouraged_16\VBN|NONE (l_nsubj) results_2\NNS|investigate|authors|have|E. (l_acl) obtained_3\VBN|The|encouraging (l_prep) in_4\IN|by (l_pobj) departments_7\NNS|NONE (l_prep) in_8\IN|various|authoratative (l_pobj) patients_10\NNS|NONE (l_amod) myopathic_9\JJ|NONE
D014810_D009135 NONE E._46\NNP|results|investigate|authors|have (r_punct) encouraged_16\VBN|NONE (l_xcomp) investigate_20\VB|results|authors|have|E. (l_dobj) effects_23\NNS|to (l_prep) at_33\IN|the|of|beneficial (l_pobj) doses_35\NNS|NONE (l_prep) in_36\IN|high (l_pobj) rats_37\NNS|NONE (l_acl) rendered_38\VBN|NONE (l_oprd) myopathic_39\JJ|by
D014810_D009135 NONE E_91\NN|NONE (r_pobj) of_89\IN|but|the|something (r_prep) lack_88\NN|because|finally|agent|certainly|not (r_attr) is_84\VBZ|often|;|and|because|at|injury (r_conj) occurs_58\VBZ|reservations|.|;|they (r_advcl) have_19\VBP|by|,|but|authors (r_conj) conclude_2\VBP|NONE (l_prep) by_3\IN|have|,|but|authors (l_pcomp) affirming_4\VBG|NONE (l_dobj) efficacy_7\NN|NONE (l_prep) in_12\IN|undoubted|the|of (l_pobj) disease_15\NN|NONE
1760851
D004317_D066126 CID doxorubicin_3\NN|NONE (r_pobj) of_2\IN|Reduced|and|.|:|study (r_prep) cardiotoxicity_1\NN|NONE
D004317_D066126 CID doxorubicin_18\NN|NONE (r_pobj) of_15\IN|the|late (r_prep) cardiotoxicity_14\NN|acute|and|general|the
D004317_D066126 CID DOX_20\NNP|mg/kg (r_appos) doxorubicin_18\NN|NONE (r_pobj) of_15\IN|the|late (r_prep) cardiotoxicity_14\NN|acute|and|general|the
D004317_D066126 CID DOX_21\NNP|that (r_dobj) received_18\VBD|NONE (r_relcl) animals_16\NNS|only (r_pobj) in_15\IN|deaths|Throughout|,|were (r_prep) observed_13\VBN|in|investigations|.|,|changes|; (l_nsubjpass) deaths_8\NNS|in|Throughout|,|were (l_acl) related_9\VBN|NONE (l_prep) to_10\IN|NONE (l_pobj) cardiotoxicity_11\NN|NONE
D004317_D066126 CID DOX_21\NNP|that (r_dobj) received_18\VBD|NONE (r_relcl) animals_16\NNS|only (r_pobj) in_15\IN|deaths|Throughout|,|were (r_prep) observed_13\VBN|in|investigations|.|,|changes|; (r_ccomp) revealed_38\VBD|NONE (l_dobj) changes_40\NNS|in|investigations|.|,|;|observed (l_relcl) were_45\VBD|marked|in (l_acomp) consistent_46\JJ|that (l_prep) with_47\IN|NONE (l_pobj) cardiotoxicity_51\NN|NONE
D004317_D066126 CID DOX_30\NNP|HPMA|and (r_conj) copolymer_27\NN|NONE (r_pobj) of_25\IN|the (r_prep) mixture_24\NN|free|or (r_conj) DOX_21\NNP|that (r_dobj) received_18\VBD|NONE (r_relcl) animals_16\NNS|only (r_pobj) in_15\IN|deaths|Throughout|,|were (r_prep) observed_13\VBN|in|investigations|.|,|changes|; (l_nsubjpass) deaths_8\NNS|in|Throughout|,|were (l_acl) related_9\VBN|NONE (l_prep) to_10\IN|NONE (l_pobj) cardiotoxicity_11\NN|NONE
D004317_D066126 CID DOX_30\NNP|HPMA|and (r_conj) copolymer_27\NN|NONE (r_pobj) of_25\IN|the (r_prep) mixture_24\NN|free|or (r_conj) DOX_21\NNP|that (r_dobj) received_18\VBD|NONE (r_relcl) animals_16\NNS|only (r_pobj) in_15\IN|deaths|Throughout|,|were (r_prep) observed_13\VBN|in|investigations|.|,|changes|; (r_ccomp) revealed_38\VBD|NONE (l_dobj) changes_40\NNS|in|investigations|.|,|;|observed (l_relcl) were_45\VBD|marked|in (l_acomp) consistent_46\JJ|that (l_prep) with_47\IN|NONE (l_pobj) cardiotoxicity_51\NN|NONE
D004317_D066126 CID DOX_48\NNP| (r_npadvmod) induced_50\VBN|NONE (r_amod) cardiotoxicity_51\NN|NONE (r_pobj) with_47\IN|NONE (r_prep) consistent_46\JJ|that (r_acomp) were_45\VBD|marked|in (r_relcl) changes_40\NNS|in|investigations|.|,|;|observed (r_dobj) revealed_38\VBD|NONE (l_ccomp) observed_13\VBN|in|investigations|.|,|changes|; (l_nsubjpass) deaths_8\NNS|in|Throughout|,|were (l_acl) related_9\VBN|NONE (l_prep) to_10\IN|NONE (l_pobj) cardiotoxicity_11\NN|NONE
D004317_D066126 CID DOX_48\NNP| (r_npadvmod) induced_50\VBN|NONE (r_amod) cardiotoxicity_51\NN|NONE
C032976_D064420 NONE N-(2-hydroxypropyl)methacrylamide_33\NN|copolymer|three (r_nmod) conjugates_38\NNS|NONE (r_pobj) of_31\IN|the (r_prep) form_30\NN|NONE (r_pobj) in_28\IN|or|drug|either (r_conj) as_24\IN|NONE (r_prep) given_22\VBN|was|evaluate|model|. (r_prep) used_4\VBN|NONE (l_xcomp) evaluate_6\VB|was|model|.|given (l_dobj) toxicity_10\NN|to
C032976_D064420 NONE HPMA_35\NNP|)|( (r_nmod) copolymer_37\NN|N(hydroxypropyl)methacrylamide|three (r_compound) conjugates_38\NNS|NONE (r_pobj) of_31\IN|the (r_prep) form_30\NN|NONE (r_pobj) in_28\IN|or|drug|either (r_conj) as_24\IN|NONE (r_prep) given_22\VBN|was|evaluate|model|. (r_prep) used_4\VBN|NONE (l_xcomp) evaluate_6\VB|was|model|.|given (l_dobj) toxicity_10\NN|to
D004317_D064420 NONE doxorubicin_18\NN|NONE (r_pobj) of_15\IN|the|late (r_prep) cardiotoxicity_14\NN|acute|and|general|the (r_conj) toxicity_10\NN|to
D004317_D064420 NONE DOX_20\NNP|mg/kg (r_appos) doxorubicin_18\NN|NONE (r_pobj) of_15\IN|the|late (r_prep) cardiotoxicity_14\NN|acute|and|general|the (r_conj) toxicity_10\NN|to
C032976_D066126 NONE N-(2-hydroxypropyl)methacrylamide_9\JJ|NONE (r_compound) conjugates_10\NNS|NONE (r_pobj) of_8\IN|the (r_prep) form_7\NN|NONE (r_pobj) in_5\IN|NONE (r_prep) given_4\VBN|NONE (r_acl) doxorubicin_3\NN|NONE (r_pobj) of_2\IN|Reduced|and|.|:|study (r_prep) cardiotoxicity_1\NN|NONE
C032976_D066126 NONE N-(2-hydroxypropyl)methacrylamide_33\NN|copolymer|three (r_nmod) conjugates_38\NNS|NONE (r_pobj) of_31\IN|the (r_prep) form_30\NN|NONE (r_pobj) in_28\IN|or|drug|either (r_conj) as_24\IN|NONE (r_prep) given_22\VBN|was|evaluate|model|. (r_prep) used_4\VBN|NONE (l_xcomp) evaluate_6\VB|was|model|.|given (l_dobj) toxicity_10\NN|to (l_conj) cardiotoxicity_14\NN|acute|and|general|the
C032976_D066126 NONE HPMA_35\NNP|)|( (r_nmod) copolymer_37\NN|N(hydroxypropyl)methacrylamide|three (r_compound) conjugates_38\NNS|NONE (r_pobj) of_31\IN|the (r_prep) form_30\NN|NONE (r_pobj) in_28\IN|or|drug|either (r_conj) as_24\IN|NONE (r_prep) given_22\VBN|was|evaluate|model|. (r_prep) used_4\VBN|NONE (l_xcomp) evaluate_6\VB|was|model|.|given (l_dobj) toxicity_10\NN|to (l_conj) cardiotoxicity_14\NN|acute|and|general|the
C032976_D066126 NONE HPMA_26\NNP|DOX|and (r_compound) copolymer_27\NN|NONE (r_pobj) of_25\IN|the (r_prep) mixture_24\NN|free|or (r_conj) DOX_21\NNP|that (r_dobj) received_18\VBD|NONE (r_relcl) animals_16\NNS|only (r_pobj) in_15\IN|deaths|Throughout|,|were (r_prep) observed_13\VBN|in|investigations|.|,|changes|; (l_nsubjpass) deaths_8\NNS|in|Throughout|,|were (l_acl) related_9\VBN|NONE (l_prep) to_10\IN|NONE (l_pobj) cardiotoxicity_11\NN|NONE
C032976_D066126 NONE HPMA_26\NNP|DOX|and (r_compound) copolymer_27\NN|NONE (r_pobj) of_25\IN|the (r_prep) mixture_24\NN|free|or (r_conj) DOX_21\NNP|that (r_dobj) received_18\VBD|NONE (r_relcl) animals_16\NNS|only (r_pobj) in_15\IN|deaths|Throughout|,|were (r_prep) observed_13\VBN|in|investigations|.|,|changes|; (r_ccomp) revealed_38\VBD|NONE (l_dobj) changes_40\NNS|in|investigations|.|,|;|observed (l_relcl) were_45\VBD|marked|in (l_acomp) consistent_46\JJ|that (l_prep) with_47\IN|NONE (l_pobj) cardiotoxicity_51\NN|NONE
17879217
D012293_D014376 NONE rifampicin_9\NNS|NONE (r_compound) therapy_10\NN|NONE (r_pobj) of_8\IN|in (r_prep) complication_7\NN|NONE (l_prep) in_11\IN|of (l_pobj) patients_12\NNS|NONE (l_acl) receiving_13\VBG|NONE (l_dobj) treatment_14\NN|NONE (l_prep) for_15\IN|NONE (l_pobj) tuberculosis_16\NN|NONE
D012293_D058186 CID rifampicin_25\NNS|NONE (r_pobj) with_24\IN|while|being (r_prep) treated_23\VBN|,|and|failure|who|review (r_advcl) developed_11\VBD|Staphylococcal (l_dobj) failure_14\NN|,|and|treated|who|review
D012293_D058186 CID rifampicin_35\NNS|NONE (r_compound) therapy_36\NN|NONE (r_pobj) of_34\IN|this (r_prep) complication_33\NN|NONE (r_pobj) regarding_31\VBG|literature (r_prep) review_28\VB|,|and|treated|failure|who (r_conj) developed_11\VBD|Staphylococcal (l_dobj) failure_14\NN|,|and|treated|who|review
D012293_D013203 NONE Rifampicin_0\NNS| (r_npadvmod) associated_2\VBN|necrotizing|in|. (r_amod) glomerulonephritis_5\NN|NONE (l_prep) in_6\IN|necrotizing|associated|. (l_pobj) endocarditis_8\NN|NONE
D012293_D013203 NONE rifampicin_20\NNS|NONE (l_prep) for_21\IN|NONE (l_pobj) infections_23\NNS|NONE
D012293_D013203 NONE rifampicin_25\NNS|NONE (r_pobj) with_24\IN|while|being (r_prep) treated_23\VBN|,|and|failure|who|review (r_advcl) developed_11\VBD|Staphylococcal (r_relcl) IE_9\NNP|NONE
D012293_D013203 NONE rifampicin_35\NNS|NONE (r_compound) therapy_36\NN|NONE (r_pobj) of_34\IN|this (r_prep) complication_33\NN|NONE (r_pobj) regarding_31\VBG|literature (r_prep) review_28\VB|,|and|treated|failure|who (r_conj) developed_11\VBD|Staphylococcal (r_relcl) IE_9\NNP|NONE
D012293_D005921 CID Rifampicin_0\NNS| (r_npadvmod) associated_2\VBN|necrotizing|in|. (r_amod) glomerulonephritis_5\NN|NONE
D012293_D005921 CID rifampicin_9\NNS|NONE (r_compound) therapy_10\NN|NONE (r_pobj) of_8\IN|in (r_prep) complication_7\NN|NONE (r_pobj) as_6\IN|.|been|has|glomerulonephritis (r_prep) reported_5\VBN|NONE (l_nsubjpass) glomerulonephritis_2\NN|.|as|been|has
D012293_D005921 CID rifampicin_25\NNS|NONE (r_pobj) with_24\IN|while|being (r_prep) treated_23\VBN|,|and|failure|who|review (r_advcl) developed_11\VBD|Staphylococcal (l_dobj) failure_14\NN|,|and|treated|who|review (l_amod) secondary_15\JJ|renal|acute (l_prep) to_16\IN|NONE (l_pobj) glomerulonephritis_20\NN|NONE
D012293_D005921 CID rifampicin_35\NNS|NONE (r_compound) therapy_36\NN|NONE (r_pobj) of_34\IN|this (r_prep) complication_33\NN|NONE (r_pobj) regarding_31\VBG|literature (r_prep) review_28\VB|,|and|treated|failure|who (r_conj) developed_11\VBD|Staphylococcal (l_dobj) failure_14\NN|,|and|treated|who|review (l_amod) secondary_15\JJ|renal|acute (l_prep) to_16\IN|NONE (l_pobj) glomerulonephritis_20\NN|NONE
D012293_D007239 NONE rifampicin_20\NNS|NONE (r_pobj) of_19\IN|the (r_prep) use_18\NN|NONE (r_pobj) in_16\IN|an (r_prep) increase_15\NN|NONE (r_pobj) to_13\IN|Changing|.|has (r_prep) led_12\VBN|NONE (l_csubj) Changing_0\VBG|.|has|to (l_dobj) epidemiology_1\NN|NONE (l_prep) of_2\IN|NONE (l_pobj) infections_3\NNS|NONE
D012293_D004696 NONE Rifampicin_0\NNS| (r_npadvmod) associated_2\VBN|necrotizing|in|. (r_amod) glomerulonephritis_5\NN|NONE (l_prep) in_6\IN|necrotizing|associated|. (l_pobj) endocarditis_8\NN|NONE
D012293_D004696 NONE rifampicin_20\NNS|NONE (r_pobj) of_19\IN|the (r_prep) use_18\NN|NONE (r_pobj) in_16\IN|an (r_prep) increase_15\NN|NONE (r_pobj) to_13\IN|Changing|.|has (r_prep) led_12\VBN|NONE (l_csubj) Changing_0\VBG|.|has|to (l_dobj) epidemiology_1\NN|NONE (l_prep) of_2\IN|NONE (l_pobj) infections_3\NNS|NONE (l_prep) as_5\IN|NONE (l_pobj) endocarditis_7\NN|such
D012293_D004696 NONE rifampicin_20\NNS|NONE (r_pobj) of_19\IN|the (r_prep) use_18\NN|NONE (r_pobj) in_16\IN|an (r_prep) increase_15\NN|NONE (r_pobj) to_13\IN|Changing|.|has (r_prep) led_12\VBN|NONE (l_csubj) Changing_0\VBG|.|has|to (l_dobj) epidemiology_1\NN|NONE (l_prep) of_2\IN|NONE (l_pobj) infections_3\NNS|NONE (l_prep) as_5\IN|NONE (l_pobj) endocarditis_7\NN|such (l_appos) IE_9\NNP|infective|)|(
D012293_D004696 NONE rifampicin_25\NNS|NONE (r_pobj) with_24\IN|while|being (r_prep) treated_23\VBN|,|and|failure|who|review (r_advcl) developed_11\VBD|Staphylococcal (r_relcl) IE_9\NNP|NONE
D012293_D004696 NONE rifampicin_35\NNS|NONE (r_compound) therapy_36\NN|NONE (r_pobj) of_34\IN|this (r_prep) complication_33\NN|NONE (r_pobj) regarding_31\VBG|literature (r_prep) review_28\VB|,|and|treated|failure|who (r_conj) developed_11\VBD|Staphylococcal (r_relcl) IE_9\NNP|NONE
8957205
D000324_D006935 NONE corticotropin_1\NN| (r_npadvmod) releasing_3\VBG|Human|and (r_amod) hormone_4\NN|releasing (r_nmod) hormone_9\NN|.|response (r_nsubj) modulate_10\VBP|NONE (l_dobj) response_14\NN|.|hormone (l_amod) hypercapnic_12\JJ|the|ventilatory|in
D013972_D006935 NONE thyrotropin_6\NN| (r_npadvmod) releasing_8\VBG|hormone (r_amod) hormone_9\NN|.|response (r_nsubj) modulate_10\VBP|NONE (l_dobj) response_14\NN|.|hormone (l_amod) hypercapnic_12\JJ|the|ventilatory|in
24816962
D008795_D001927 CID Metronidazole_0\NNP| (r_npadvmod) induced_2\VBN|.|:|scenario (r_amod) encephalopathy_3\NN|NONE
D008795_D001927 CID metronidazole_13\NN|prolonged (r_compound) intake_14\NN|NONE (r_pobj) following_11\VBG|of|patient|where|a|developed (r_prep) features_8\NNS|a (l_prep) of_9\IN|following|patient|where|a|developed (l_pobj) encephalopathy_10\JJ|NONE
D008795_D064420 NONE metronidazole_3\JJ|NONE (r_amod) toxicity_4\NN|NONE
12950111
D006024_D006261 CID glycopyrrolate_17\NN||)|( (r_appos) patients_13\NNS|NONE (r_pobj) in_11\IN|a|sore (r_prep) throat_10\NN|,|dry|a|headache|and (r_conj) mouth_6\NN|.|effects (l_appos) headache_22\NN|,|dry|a|throat|and
D006024_D006261 CID glycopyrrolate_29\NN|a|light|in (r_parataxis) headache_22\NN|,|dry|a|throat|and
D006024_D010612 CID glycopyrrolate_17\NN||)|( (r_appos) patients_13\NNS|NONE (r_pobj) in_11\IN|a|sore (r_prep) throat_10\NN|,|dry|a|headache|and
D006024_D010612 CID glycopyrrolate_29\NN|a|light|in (r_parataxis) headache_22\NN|,|dry|a|throat|and (r_appos) mouth_6\NN|.|effects (l_conj) throat_10\NN|,|dry|a|headache|and
D006024_D014987 NONE glycopyrrolate_17\NN||)|( (r_appos) patients_13\NNS|NONE (r_pobj) in_11\IN|a|sore (r_prep) throat_10\NN|,|dry|a|headache|and (r_conj) mouth_6\NN|.|effects
D006024_D014987 NONE glycopyrrolate_29\NN|a|light|in (r_parataxis) headache_22\NN|,|dry|a|throat|and (r_appos) mouth_6\NN|.|effects
D006024_D013547 NONE glycopyrrolate_7\NN|NONE (r_pobj) with_5\IN|gustatory|compensatory (r_prep) hyperhidrosis_4\NN|NONE
D006024_D013547 NONE glycopyrrolate_3\NN|NONE (r_dobj) applying_1\VBG|NONE (r_pcomp) After_0\IN|,|excellent|.|sweating|effect (r_prep) was_8\VBD|NONE (l_parataxis) sweating_12\NN|,|excellent|.|After|effect
D006024_D013547 NONE glycopyrrolate_3\NN|NONE (r_dobj) applying_1\VBG|NONE (r_pcomp) After_0\IN|,|excellent|.|sweating|effect (r_prep) was_8\VBD|NONE (l_parataxis) sweating_12\NN|,|excellent|.|After|effect (l_conj) sweating_32\NN|no|in|(|and|after|)|,
D006024_D013547 NONE glycopyrrolate_5\JJ|a (r_compound) pad_6\NN|NONE (r_pobj) of_3\IN|topical|The|method (r_prep) application_2\NN|tolerated|.|be (l_appos) method_20\NN|of|topical|The (l_prep) to_25\TO|,|convenient|of|in|a|with (l_pobj) symptoms_27\NNS|NONE (l_prep) of_28\IN|severe (l_pobj) hyperhidrosis_30\NN|NONE
20024739
D000431_D003866 CID alcohol_5\NN|and|depression (r_compound) consumption_6\NN|NONE (l_conj) depression_8\NN|and|alcohol
D000431_D003866 CID alcohol_39\NN|NONE (r_compound) use_40\NN|at|and|,|semiannually|. (r_compound) assessment_41\NN|participants|examination|using|and|,|( (r_conj) had_2\VBD|NONE (l_dobj) examination_4\NN|participants|using|assessment|and|,|( (l_appos) measurement_19\NN|extraction|physical|, (l_prep) of_20\IN|NONE (l_pobj) symptoms_22\NNS|NONE (l_compound) depression_21\NN|NONE
D000431_D003866 CID alcohol_39\NN|NONE (r_compound) use_40\NN|at|and|,|semiannually|. (r_compound) assessment_41\NN|participants|examination|using|and|,|( (r_conj) had_2\VBD|NONE (l_advcl) using_24\VBG|participants|examination|assessment|and|,|( (l_dobj) Center_29\NNP|) (l_prep) for_30\IN|report|the (l_pobj) Scale_35\NNP|NONE (l_compound) Depression_34\NNP|Epidemiological
D000431_D003866 CID alcohol_3\NN|depression|and (r_compound) consumption_4\NN|NONE (l_conj) depression_6\NN|and|alcohol
D000431_D003866 CID alcohol_4\NN|NONE (r_compound) consumption_5\NN|that|association (r_nsubj) has_6\VBZ|.|findings (l_dobj) association_9\NN|consumption|that (l_prep) with_10\IN|direct|a (l_pobj) depression_11\NN|NONE
D000431_D015658 NONE alcohol_3\NN|with (r_compound) use_4\NN|NONE (l_prep) with_5\IN|alcohol (l_pobj) progression_8\NN|NONE (l_compound) disease_7\NN|health|and
D000431_D015658 NONE alcohol_5\NN|and|depression (r_compound) consumption_6\NN|NONE (r_pobj) of_4\IN|the (r_prep) association_3\NN|We|,|.|and|effects (r_dobj) evaluated_1\VBD|NONE (l_conj) effects_12\NNS|We|,|.|association|and (l_prep) on_13\IN|their (l_pobj) progression_16\NN|NONE (l_compound) disease_15\NN|among
24717468
D015742_D007022 CID propofol_16\NN|who|dexmedetomidine|or (r_conj) receive_13\VBP|neurocritical|care (r_relcl) patients_11\NNS|NONE (r_pobj) in_8\IN|similar (r_prep) prevalence_7\NN|NONE (r_pobj) at_5\IN|.|hypotension (r_prep) occur_4\VBP|NONE (l_nsubj) hypotension_1\NN|.|at
D020927_D001919 CID dexmedetomidine_14\NN|who|propofol|or (r_dobj) receive_13\VBP|neurocritical|care (r_relcl) patients_11\NNS|NONE (r_pobj) in_8\IN|similar (r_prep) prevalence_7\NN|NONE (r_pobj) at_5\IN|.|hypotension (r_prep) occur_4\VBP|NONE (l_nsubj) hypotension_1\NN|.|at (l_conj) bradycardia_3\NN|and|Severe
D015742_D001919 CID propofol_16\NN|who|dexmedetomidine|or (r_conj) receive_13\VBP|neurocritical|care (r_relcl) patients_11\NNS|NONE (r_pobj) in_8\IN|similar (r_prep) prevalence_7\NN|NONE (r_pobj) at_5\IN|.|hypotension (r_prep) occur_4\VBP|NONE (l_nsubj) hypotension_1\NN|.|at (l_conj) bradycardia_3\NN|and|Severe
D020927_D007022 CID dexmedetomidine_14\NN|who|propofol|or (r_dobj) receive_13\VBP|neurocritical|care (r_relcl) patients_11\NNS|NONE (r_pobj) in_8\IN|similar (r_prep) prevalence_7\NN|NONE (r_pobj) at_5\IN|.|hypotension (r_prep) occur_4\VBP|NONE (l_nsubj) hypotension_1\NN|.|at
8985298
D019259_D006509 NONE Lamivudine_0\NNP|effective|. (r_nsubj) is_1\VBZ|NONE (l_acomp) effective_2\JJ|Lamivudine|. (l_prep) in_3\IN|NONE (l_pcomp) suppressing_4\VBG|NONE (l_dobj) DNA_8\NN|NONE (l_compound) virus_7\NN|in|:|trial (l_compound) B_6\NNP|NONE
D019259_D006509 NONE Lamivudine_0\NNP|analogue|. (r_nsubj) is_1\VBZ|NONE (l_attr) analogue_6\NN|Lamivudine|. (l_relcl) has_8\VBZ|novel|a|','dideoxy|cytosine (l_dobj) effects_11\NNS|that|in (l_prep) on_12\IN|potent|inhibitory (l_pobj) replication_16\NN|NONE (l_compound) virus_15\NN|NONE (l_compound) B_14\NN|NONE
D019259_D006509 NONE cytosine_5\NN|novel|a|','dideoxy|has (r_compound) analogue_6\NN|Lamivudine|. (l_relcl) has_8\VBZ|novel|a|','dideoxy|cytosine (l_dobj) effects_11\NNS|that|in (l_prep) on_12\IN|potent|inhibitory (l_pobj) replication_16\NN|NONE (l_compound) virus_15\NN|NONE (l_compound) B_14\NN|NONE
D019259_D006509 NONE lamivudine_4\NN|NONE (r_dobj) receiving_3\VBG|All| (r_acl) patients_2\NNS|)|.|decrease|compared (r_nsubj) had_5\VBD|NONE (l_dobj) decrease_7\NN|)|patients|.|compared (l_prep) in_8\IN|a (l_pobj) virus_11\NN|NONE (l_compound) B_10\NN|P|values|(|(
D006514_D006509 CID antigen_14\NN|B|Chinese (r_compound) carriers_15\NNS|NONE (r_pobj) in_9\IN|:|trial|virus (r_prep) DNA_8\NN|NONE (l_compound) virus_7\NN|in|:|trial (l_compound) B_6\NNP|NONE
24927617
D019821_D012206 CID simvastatin_12\NN|and|with (r_conj) treated_8\VBN|infected (r_acl) patient_7\NN|.|in (r_appos) Rhabdomyolysis_0\NNP|NONE
D019821_D009135 CID Simvastatin_0\NNP|NONE (r_compound) plasma_1\NN|NONE (r_compound) concentration_2\NN|times|in|induced|. (r_nsubj) increased_3\VBD|NONE (l_advcl) induced_11\VBD|times|in|concentration|. (l_ccomp) related_15\VBN|NONE (l_nsubjpass) toxicity_13\NN|is|to
D019821_D009135 CID statin_10\NN|this|and (r_conj) patient_8\NN|NONE (r_pobj) in_6\IN|times|concentration|induced|. (r_prep) increased_3\VBD|NONE (l_advcl) induced_11\VBD|times|in|concentration|. (l_ccomp) related_15\VBN|NONE (l_nsubjpass) toxicity_13\NN|is|to
D019821_D009135 CID statin_21\NN|NONE (r_pobj) of_19\IN|the (r_prep) concentration_18\NN|NONE (r_pobj) to_16\IN|toxicity|is (r_prep) related_15\VBN|NONE (l_nsubjpass) toxicity_13\NN|is|to
D019821_D064420 NONE simvastatin_2\NN|admission (l_conj) discontinued_8\VBN|and (l_advcl) suspected_19\VBN|were|.|drugs (l_nsubjpass) toxicity_10\NN|was|because
D019821_D006526 NONE simvastatin_12\NN|and|with (r_conj) treated_8\VBN|infected (r_acl) patient_7\NN|.|in (l_amod) infected_6\VBN|treated
C486464_D012206 CID telaprevir_10\NNS|NONE (r_pobj) with_9\IN|and|simvastatin (r_prep) treated_8\VBN|infected (r_acl) patient_7\NN|.|in (r_appos) Rhabdomyolysis_0\NNP|NONE
C417083_D006526 NONE interferon_18\NN|NONE (r_dobj) pegylated_17\VBN|with|man|.|therapy|, (r_conj) received_11\VBD|NONE (l_nsubj) man_3\NN|with|.|pegylated|therapy|, (l_prep) with_4\IN|year|old|A (l_pobj) infection_10\NN|NONE
D012254_D006526 NONE ribavirin_15\RB|NONE (r_pobj) with_14\IN|man|.|pegylated|therapy|, (r_prep) received_11\VBD|NONE (l_nsubj) man_3\NN|with|.|pegylated|therapy|, (l_prep) with_4\IN|year|old|A (l_pobj) infection_10\NN|NONE
C486464_D006526 NONE telaprevir_10\NNS|NONE (r_pobj) with_9\IN|and|simvastatin (r_prep) treated_8\VBN|infected (r_acl) patient_7\NN|.|in (l_amod) infected_6\VBN|treated
C486464_D006526 NONE telaprevir_20\NNS|and (r_conj) interferon_18\NN|NONE (r_dobj) pegylated_17\VBN|with|man|.|therapy|, (r_conj) received_11\VBD|NONE (l_nsubj) man_3\NN|with|.|pegylated|therapy|, (l_prep) with_4\IN|year|old|A (l_pobj) infection_10\NN|NONE
11474137
D000617_D006311 NONE aminoglycoside_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) ototoxicity_10\NN|NONE
D000617_D006311 NONE aminoglycoside_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) ototoxicity_10\NN|NONE (r_pobj) in_6\IN|reactive|oxygen (r_prep) species_5\NNS|NONE (r_pobj) of_2\IN|The (r_prep) participation_1\NN|has|.|been|from (r_nsubjpass) deduced_13\VBN|NONE (l_prep) from_14\IN|has|.|participation|been (l_pobj) observations_15\NNS|NONE (l_acl) catalyze_21\VBP|NONE (l_conj) attenuate_32\VBP|complexes|that|and|formation (l_dobj) ototoxicity_33\NN|antioxidants|that
D000617_D006311 NONE aminoglycoside_17\NN| (r_compound) iron_19\NN|NONE (r_compound) complexes_20\NNS|attenuate|that|and|formation (r_nsubj) catalyze_21\VBP|NONE (r_acl) observations_15\NNS|NONE (r_pobj) from_14\IN|has|.|participation|been (r_prep) deduced_13\VBN|NONE (l_nsubjpass) participation_1\NN|has|.|been|from (l_prep) of_2\IN|The (l_pobj) species_5\NNS|NONE (l_prep) in_6\IN|reactive|oxygen (l_pobj) ototoxicity_10\NN|NONE
D000617_D006311 NONE aminoglycoside_17\NN| (r_compound) iron_19\NN|NONE (r_compound) complexes_20\NNS|attenuate|that|and|formation (r_nsubj) catalyze_21\VBP|NONE (l_conj) attenuate_32\VBP|complexes|that|and|formation (l_dobj) ototoxicity_33\NN|antioxidants|that
D000617_D006311 NONE aminoglycoside_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) ototoxicity_21\NN|NONE
D003300_D034381 NONE copper_2\NN|/||zinc (r_npadvmod) superoxide_6\NN|NONE (r_amod) dismutase_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Overexpression_0\NN|from|. (r_nsubj) protects_8\VBZ|NONE (l_prep) from_9\IN|Overexpression|. (l_pobj) loss_14\NN|NONE
D007612_D034381 CID kanamycin_10\NN| (r_npadvmod) induced_12\VBN|hearing (r_amod) loss_14\NN|NONE
D015032_D006311 NONE Zn_8\NNP| (r_compound) superoxide_10\NN|)|Cu|/|SOD|( (r_amod) dismutase_11\NN|NONE (r_pobj) of_5\IN|that (r_prep) overexpression_4\NN|from|should|mice (r_nsubj) protect_18\VB|We|.|therefore (l_prep) from_21\IN|should|overexpression|mice (l_pobj) ototoxicity_22\NN|NONE
D003300_D006311 NONE Cu_6\NNP|superoxide|)|/|SOD|( (r_nmod) dismutase_11\NN|NONE (r_pobj) of_5\IN|that (r_prep) overexpression_4\NN|from|should|mice (r_nsubj) protect_18\VB|We|.|therefore (l_prep) from_21\IN|should|overexpression|mice (l_pobj) ototoxicity_22\NN|NONE
D013481_D034381 NONE superoxide_6\NN|NONE (r_amod) dismutase_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Overexpression_0\NN|from|. (r_nsubj) protects_8\VBZ|NONE (l_prep) from_9\IN|Overexpression|. (l_pobj) loss_14\NN|NONE
D015032_D034381 NONE zinc_4\NN|copper|/| (r_npadvmod) superoxide_6\NN|NONE (r_amod) dismutase_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Overexpression_0\NN|from|. (r_nsubj) protects_8\VBZ|NONE (l_prep) from_9\IN|Overexpression|. (l_pobj) loss_14\NN|NONE
D010100_D006311 NONE oxygen_4\NN|reactive|in (r_compound) species_5\NNS|NONE (l_prep) in_6\IN|reactive|oxygen (l_pobj) ototoxicity_10\NN|NONE
D010100_D006311 NONE oxygen_4\NN|reactive|in (r_compound) species_5\NNS|NONE (r_pobj) of_2\IN|The (r_prep) participation_1\NN|has|.|been|from (r_nsubjpass) deduced_13\VBN|NONE (l_prep) from_14\IN|has|.|participation|been (l_pobj) observations_15\NNS|NONE (l_acl) catalyze_21\VBP|NONE (l_conj) attenuate_32\VBP|complexes|that|and|formation (l_dobj) ototoxicity_33\NN|antioxidants|that
D013481_D006311 NONE superoxide_25\JJ|in (r_amod) radicals_26\NNS|NONE (r_pobj) of_24\IN|the (r_prep) formation_23\NN|complexes|attenuate|that|and (r_dobj) catalyze_21\VBP|NONE (r_acl) observations_15\NNS|NONE (r_pobj) from_14\IN|has|.|participation|been (r_prep) deduced_13\VBN|NONE (l_nsubjpass) participation_1\NN|has|.|been|from (l_prep) of_2\IN|The (l_pobj) species_5\NNS|NONE (l_prep) in_6\IN|reactive|oxygen (l_pobj) ototoxicity_10\NN|NONE
D013481_D006311 NONE superoxide_25\JJ|in (r_amod) radicals_26\NNS|NONE (r_pobj) of_24\IN|the (r_prep) formation_23\NN|complexes|attenuate|that|and (r_dobj) catalyze_21\VBP|NONE (l_conj) attenuate_32\VBP|complexes|that|and|formation (l_dobj) ototoxicity_33\NN|antioxidants|that
D013481_D006311 NONE superoxide_10\NN|)|Cu|/|SOD|( (r_amod) dismutase_11\NN|NONE (r_pobj) of_5\IN|that (r_prep) overexpression_4\NN|from|should|mice (r_nsubj) protect_18\VB|We|.|therefore (l_prep) from_21\IN|should|overexpression|mice (l_pobj) ototoxicity_22\NN|NONE
D013481_D006311 NONE superoxide_5\NN|NONE (r_amod) dismutase_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) overexpression_3\NN|NONE (r_pobj) by_2\IN|The (r_prep) protection_1\NN|.|hypothesis (r_nsubj) supports_7\VBZ|NONE (l_dobj) hypothesis_9\NN|.|protection (l_acl) plays_13\VBZ|the (l_dobj) role_16\NN|that|stress (l_prep) in_17\IN|significant|a (l_pobj) ototoxicity_21\NN|NONE
D007501_D006311 NONE iron_19\NN|NONE (r_compound) complexes_20\NNS|attenuate|that|and|formation (r_nsubj) catalyze_21\VBP|NONE (r_acl) observations_15\NNS|NONE (r_pobj) from_14\IN|has|.|participation|been (r_prep) deduced_13\VBN|NONE (l_nsubjpass) participation_1\NN|has|.|been|from (l_prep) of_2\IN|The (l_pobj) species_5\NNS|NONE (l_prep) in_6\IN|reactive|oxygen (l_pobj) ototoxicity_10\NN|NONE
D007501_D006311 NONE iron_19\NN|NONE (r_compound) complexes_20\NNS|attenuate|that|and|formation (r_nsubj) catalyze_21\VBP|NONE (l_conj) attenuate_32\VBP|complexes|that|and|formation (l_dobj) ototoxicity_33\NN|antioxidants|that
24897009
D004977_D011115 CID Ethambutol_0\NNP|is|cause|and|polyneuropathy (r_nsubjpass) known_2\VBN|NONE (l_conj) polyneuropathy_13\NN|Ethambutol|is|cause|and
D004977_D064420 NONE ethambutol_15\VB|.|case|vulnerability (l_dobj) toxicity_16\NN|to
D004977_D009901 CID Ethambutol_0\NNP|is|cause|and|polyneuropathy (r_nsubjpass) known_2\VBN|NONE (l_xcomp) cause_4\VB|Ethambutol|is|and|polyneuropathy (l_dobj) neuropathy_6\NN|to
D004977_D010292 CID ethambutol_32\NN|NONE (r_pobj) of_31\IN|a|supratherapeutic (r_prep) dose_30\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) exposure_26\NN|NONE (r_pobj) of_25\IN| (r_prep) weeks_24\NNS|NONE (r_pobj) after_22\IN|who|loss (r_prep) developed_17\VBD|old|a (l_dobj) loss_19\NN|after|who (l_conj) paresthesias_21\NNS|visual|and
D004977_D014786 CID ethambutol_32\NN|NONE (r_pobj) of_31\IN|a|supratherapeutic (r_prep) dose_30\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) exposure_26\NN|NONE (r_pobj) of_25\IN| (r_prep) weeks_24\NNS|NONE (r_pobj) after_22\IN|who|loss (r_prep) developed_17\VBD|old|a (l_dobj) loss_19\NN|after|who
D004977_D010523 NONE ethambutol_6\NN|NONE (r_amod) overtreatment_7\NN|to (r_pobj) due_4\IN|and|neuropathy|. (r_prep) Optochiasmatic_0\JJ|NONE (l_conj) neuropathy_3\NN|and|.|due
25071004
C039726_D000740 NONE artesunate_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) treatment_3\NN|NONE (r_pobj) after_2\IN|issue|:|.|anemia (r_prep) Delayed_0\JJ|NONE (l_dobj) anemia_1\NN|issue|:|after|.
C039726_D008288 NONE artesunate_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|NONE (r_pobj) after_8\IN|been|Organization|have|,|Cases (r_prep) described_7\VBN|NONE (l_appos) Organization_18\NNP|been|have|,|after|Cases (l_parataxis) WHO)-recommended_20\VBN|current|Health|the|World (l_dobj) drug_24\NN|.|( (l_prep) for_25\IN|line (l_pobj) treatment_27\NN|NONE (l_prep) of_28\IN|the (l_pobj) malaria_30\NN|NONE
C039726_D008288 NONE artesunate_36\NN|NONE (l_prep) for_37\IN|injectable (l_pobj) malaria_39\NN|NONE
C039726_D000743 CID artesunate_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|NONE (r_pobj) after_8\IN|been|Organization|have|,|Cases (r_prep) described_7\VBN|NONE (l_nsubjpass) Cases_0\NNS|been|Organization|have|,|after (l_prep) of_1\IN|NONE (l_pobj) anemia_4\NN|NONE
19914299
D005473_D008569 NONE Fluoxetine_0\NNP|.|deficits|fluorouracil (r_nsubj) improves_1\VBZ|NONE (l_dobj) deficits_4\NNS|Fluoxetine|.|fluorouracil
D005472_D008569 CID 5-fluorouracil_10\CD|Fluoxetine|.|deficits (r_punct) improves_1\VBZ|NONE (l_dobj) deficits_4\NNS|Fluoxetine|.|fluorouracil
11745287
D004317_D002294 NONE doxorubicin_7\NN|in (r_dobj) liposomal_6\JJ|.|II|and|of (l_prep) in_8\IN|doxorubicin (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) carcinoma_14\NN|NONE (l_prep) of_15\IN|cell|recurrent (l_pobj) cervix_17\NN|NONE
D004317_D002294 NONE doxorubicin_18\NN|combination|; (r_dobj) liposomal_17\JJ|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN|NONE (l_prep) to_37\IN|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS|NONE (l_prep) with_40\IN| (l_pobj) carcinoma_45\NN|NONE
D004317_D002294 NONE Doxil_20\NNS|NONE (r_appos) doxorubicin_18\NN|combination|; (r_dobj) liposomal_17\JJ|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN|NONE (l_prep) to_37\IN|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS|NONE (l_prep) with_40\IN| (l_pobj) carcinoma_45\NN|NONE
D004317_D064420 NONE doxorubicin_18\NN|combination|; (r_dobj) liposomal_17\JJ|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN|NONE (l_advcl) determine_47\VB|was|days|intravenously|.|to|dose|liposomal (l_dobj) activity_49\NN|to (l_conj) profile_52\NN|antitumor|and (l_compound) toxicity_51\NN|NONE
D004317_D064420 NONE Doxil_20\NNS|NONE (r_appos) doxorubicin_18\NN|combination|; (r_dobj) liposomal_17\JJ|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN|NONE (l_advcl) determine_47\VB|was|days|intravenously|.|to|dose|liposomal (l_dobj) activity_49\NN|to (l_conj) profile_52\NN|antitumor|and (l_compound) toxicity_51\NN|NONE
D016190_D064420 NONE carboplatin_3\NN|(|under (r_nmod) area_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) combination_1\NN|doxorubicin|; (r_nsubj) liposomal_17\JJ|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN|NONE (l_advcl) determine_47\VB|was|days|intravenously|.|to|dose|liposomal (l_dobj) activity_49\NN|to (l_conj) profile_52\NN|antitumor|and (l_compound) toxicity_51\NN|NONE
D016190_D002294 NONE carboplatin_4\NN|NONE (r_pobj) of_3\IN|liposomal|.|II|and (r_prep) study_2\NN|NONE (l_conj) liposomal_6\JJ|.|II|and|of (l_prep) in_8\IN|doxorubicin (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) carcinoma_14\NN|NONE (l_prep) of_15\IN|cell|recurrent (l_pobj) cervix_17\NN|NONE
D016190_D002294 NONE carboplatin_3\NN|(|under (r_nmod) area_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) combination_1\NN|doxorubicin|; (r_nsubj) liposomal_17\JJ|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN|NONE (l_prep) to_37\IN|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS|NONE (l_prep) with_40\IN| (l_pobj) carcinoma_45\NN|NONE
D016190_D002583 NONE carboplatin_4\NN|NONE (r_pobj) of_3\IN|liposomal|.|II|and (r_prep) study_2\NN|NONE (l_conj) liposomal_6\JJ|.|II|and|of (l_prep) in_8\IN|doxorubicin (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) carcinoma_14\NN|NONE (l_prep) of_15\IN|cell|recurrent (l_pobj) cervix_17\NN|NONE
D016190_D002583 NONE carboplatin_6\NN|NONE (r_pobj) of_5\IN|the (r_prep) combination_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) activity_1\NN|was|.|in (r_nsubjpass) tested_11\VBN|NONE (l_prep) in_12\IN|was|.|activity (l_pobj) study_16\NN|NONE (l_prep) of_17\IN|II|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) carcinoma_22\NN|NONE
D016190_D002583 NONE carboplatin_3\NN|(|under (r_nmod) area_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) combination_1\NN|doxorubicin|; (r_nsubj) liposomal_17\JJ|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN|NONE (l_prep) to_37\IN|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS|NONE (l_prep) with_40\IN| (l_pobj) carcinoma_45\NN|NONE
D016190_D002583 NONE carboplatin_3\NN|doxorubicin (r_pobj) of_2\IN|The (r_prep) combination_1\NN|activity|. (r_nsubj) has_7\VBZ|NONE (l_dobj) activity_9\NN|combination|. (l_prep) in_10\IN|modest (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) carcinoma_15\NN|NONE
D004317_D002583 NONE doxorubicin_7\NN|in (r_dobj) liposomal_6\JJ|.|II|and|of (l_prep) in_8\IN|doxorubicin (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) carcinoma_14\NN|NONE (l_prep) of_15\IN|cell|recurrent (l_pobj) cervix_17\NN|NONE
D004317_D002583 NONE doxorubicin_9\NN|and (r_conj) carboplatin_6\NN|NONE (r_pobj) of_5\IN|the (r_prep) combination_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) activity_1\NN|was|.|in (r_nsubjpass) tested_11\VBN|NONE (l_prep) in_12\IN|was|.|activity (l_pobj) study_16\NN|NONE (l_prep) of_17\IN|II|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) carcinoma_22\NN|NONE
D004317_D002583 NONE doxorubicin_18\NN|combination|; (r_dobj) liposomal_17\JJ|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN|NONE (l_prep) to_37\IN|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS|NONE (l_prep) with_40\IN| (l_pobj) carcinoma_45\NN|NONE
D004317_D002583 NONE Doxil_20\NNS|NONE (r_appos) doxorubicin_18\NN|combination|; (r_dobj) liposomal_17\JJ|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN|NONE (l_prep) to_37\IN|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS|NONE (l_prep) with_40\IN| (l_pobj) carcinoma_45\NN|NONE
D004317_D002583 NONE doxorubicin_6\NN|carboplatin (r_pobj) of_2\IN|The (r_prep) combination_1\NN|activity|. (r_nsubj) has_7\VBZ|NONE (l_dobj) activity_9\NN|combination|. (l_prep) in_10\IN|modest (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) carcinoma_15\NN|NONE
10510854
D006220_D002375 CID haloperidol_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|high|a|of|indicating (r_acl) reversal_4\NN|e|. (l_prep) of_5\IN|high|a|induced|indicating (l_pobj) catalepsy_6\NN|NONE
1943082
D005978_D015427 NONE glutathione_8\NN|NONE (r_pobj) in_4\IN|following|no (r_prep) change_3\NN|.|There (l_prep) following_9\VBG|in|no (l_pobj) injury_14\NN|NONE
D005978_D007511 NONE glutathione_8\NN|NONE (r_pobj) in_4\IN|following|no (r_prep) change_3\NN|.|There (l_prep) following_9\VBG|in|no (l_pobj) injury_14\NN|NONE (l_compound) reperfusion_13\NN|intestinal (l_compound) ischemia_11\NN|
3074291
C017590_D014839 NONE oxitropium_6\NN|NONE (r_pobj) of_5\IN|side (r_prep) effects_4\NNS|compared|.|subject|, (r_dobj) reported_2\VBN|NONE (l_advcl) compared_9\VBN|.|effects|subject|, (l_prep) to_10\IN|as (l_pobj) subjects_12\NNS|NONE (l_acl) reporting_13\VBG|three (l_dobj) nausea_14\NN|after (l_conj) vomiting_16\VBG|,
D013806_D009325 CID theophylline_20\NN|NONE (r_pobj) after_19\IN|nausea (r_prep) reporting_13\VBG|three (l_dobj) nausea_14\NN|after
C017590_D009325 NONE oxitropium_6\NN|NONE (r_pobj) of_5\IN|side (r_prep) effects_4\NNS|compared|.|subject|, (r_dobj) reported_2\VBN|NONE (l_advcl) compared_9\VBN|.|effects|subject|, (l_prep) to_10\IN|as (l_pobj) subjects_12\NNS|NONE (l_acl) reporting_13\VBG|three (l_dobj) nausea_14\NN|after
D013806_D001249 NONE theophylline_12\NN|NONE (l_prep) on_13\IN|release (l_pobj) asthma_15\NN|NONE
D013806_D001249 NONE theophylline_18\NN|upon|a|release (r_amod) preparation_19\NN|NONE (l_prep) upon_20\IN|a|theophylline|release (l_pobj) asthma_22\NN|NONE
D013806_D001249 NONE theophylline_8\NN|NONE (r_pobj) to_7\IN|in|valuable|a (r_prep) alternative_6\NN|to (l_prep) in_9\IN|to|valuable|a (l_pobj) asthma_11\NN|NONE
C017590_D001249 NONE bromide_6\NN|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|NONE (r_pobj) of_1\IN|.|and|of (r_prep) Comparison_0\NN|NONE (l_conj) of_8\IN|.|and|of (l_pobj) theophylline_12\NN|NONE (l_prep) on_13\IN|release (l_pobj) asthma_15\NN|NONE
C017590_D001249 NONE bromide_10\NN|a|,|inhaled|antimuscarinic|new (r_appos) drug_7\NN|and|of (r_pobj) of_2\IN|The (l_conj) of_13\IN|and|drug (l_pobj) preparation_19\NN|NONE (l_prep) upon_20\IN|a|theophylline|release (l_pobj) asthma_22\NN|NONE
C017590_D001249 NONE Oxitropium_0\NNP|is|be|.|, (r_nsubj) proves_1\VBZ|NONE (l_xcomp) be_3\VB|is|.|Oxitropium|, (l_attr) alternative_6\NN|to (l_prep) in_9\IN|to|valuable|a (l_pobj) asthma_11\NN|NONE
D013806_D014202 CID theophylline_20\NN|NONE (r_pobj) after_19\IN|nausea (r_prep) reporting_13\VBG|three (l_dobj) nausea_14\NN|after (l_conj) vomiting_16\VBG|, (l_conj) tremors_18\NNS|and
C017590_D014202 NONE oxitropium_6\NN|NONE (r_pobj) of_5\IN|side (r_prep) effects_4\NNS|compared|.|subject|, (r_dobj) reported_2\VBN|NONE (l_advcl) compared_9\VBN|.|effects|subject|, (l_prep) to_10\IN|as (l_pobj) subjects_12\NNS|NONE (l_acl) reporting_13\VBG|three (l_dobj) nausea_14\NN|after (l_conj) vomiting_16\VBG|, (l_conj) tremors_18\NNS|and
D013806_D014839 CID theophylline_20\NN|NONE (r_pobj) after_19\IN|nausea (r_prep) reporting_13\VBG|three (l_dobj) nausea_14\NN|after (l_conj) vomiting_16\VBG|,
19263707
D002231_D014657 NONE carbimazole_12\NN|who (r_dobj) developed_9\VBD|Graves (r_relcl) disease_7\NN|NONE (r_pobj) with_4\IN|a (r_prep) patient_3\NN|vasculitis (r_nsubj) induced_13\VBD|We|. (l_dobj) vasculitis_14\NN|patient
D002231_D014657 NONE carbimazole_12\NN|this|.|To (l_acl) induced_13\VBD|first|the|ANCA|positive (l_dobj) case_15\NN|NONE (l_compound) vasculitis_14\JJ|reported
D002231_D006980 NONE carbimazole_6\NN|NONE (r_pobj) like_5\IN|,|thyroid (r_prep) drugs_3\NNS|are|commonly|.|for (r_nsubjpass) prescribed_14\VBN|NONE (l_prep) for_15\IN|drugs|are|commonly|. (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) hyperthyroidism_19\NN|NONE
D013956_D006980 NONE drugs_3\NNS|are|commonly|.|for (r_nsubjpass) prescribed_14\VBN|NONE (l_prep) for_15\IN|drugs|are|commonly|. (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) hyperthyroidism_19\NN|NONE
D002231_D056648 CID Carbimazole_0\NNS|.|vasculitis (r_nsubj) induced_1\VBD|NONE (l_dobj) vasculitis_4\NN|Carbimazole|.
D002231_D006111 NONE carbimazole_12\NN|who (r_dobj) developed_9\VBD|Graves (r_relcl) disease_7\NN|NONE
D013956_D056648 CID antithyroidmedications_15\NNS|NONE (r_pobj) of_14\IN|threatening|adverse|a (r_prep) effect_13\NN|.|antibody (r_attr) is_6\VBZ|NONE (l_nsubj) antibody_2\NN|.|effect (l_appos) vasculitis_5\NN|cytoplasmic|Antineutrophil
D011441_D006980 NONE propylthiouracil_8\NN|PTU|and (r_conj) carbimazole_6\NN|NONE (r_pobj) like_5\IN|,|thyroid (r_prep) drugs_3\NNS|are|commonly|.|for (r_nsubjpass) prescribed_14\VBN|NONE (l_prep) for_15\IN|drugs|are|commonly|. (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) hyperthyroidism_19\NN|NONE
D011441_D006980 NONE PTU_10\NNP|propylthiouracil|and (r_appos) carbimazole_6\NN|NONE (r_pobj) like_5\IN|,|thyroid (r_prep) drugs_3\NNS|are|commonly|.|for (r_nsubjpass) prescribed_14\VBN|NONE (l_prep) for_15\IN|drugs|are|commonly|. (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) hyperthyroidism_19\NN|NONE
816141
D002512_D007674 NONE cephalothin_13\JJ|NONE (r_compound) therapy_14\NN|while (r_dobj) receiving_12\VBG|anemia|patient|. (r_advcl) developed_5\VBD|NONE (l_nsubj) patient_1\NN|anemia|receiving|. (l_prep) with_2\IN|A (l_pobj) disease_4\NN|NONE
D002512_D000743 CID Cephalothin_0\NNP| (r_npadvmod) induced_2\VBN|immune|.|hemolytic (r_amod) anemia_5\NN|NONE
D002512_D000743 CID cephalothin_13\JJ|NONE (r_compound) therapy_14\NN|while (r_dobj) receiving_12\VBG|anemia|patient|. (r_advcl) developed_5\VBD|NONE (l_dobj) anemia_10\NN|patient|receiving|.
10960401
D009020_D009759 CID morphine_10\NN|NONE (r_pobj) of_9\IN|intravenous|controlled (r_prep) administration_8\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|.|Downbeat (r_acl) nystagmus_1\NN|NONE
D009020_D009759 CID morphine_23\NN|NONE (r_pobj) of_17\IN|large|a (r_prep) dose_16\NN|while (r_dobj) receiving_12\VBG|who|dizziness|with (r_advcl) developed_6\VBD|a (l_prep) with_8\IN|who|receiving|dizziness (l_pobj) nystagmus_10\NN|NONE
D009020_D004244 CID morphine_23\NN|NONE (r_pobj) of_17\IN|large|a (r_prep) dose_16\NN|while (r_dobj) receiving_12\VBG|who|dizziness|with (r_advcl) developed_6\VBD|a (l_dobj) dizziness_7\NN|who|receiving|with
891494
D010672_D012640 NONE phenytoin_3\NNP|)|with|DPH|( (r_nmod) encephalopathy_7\JJ|NONE (l_prep) with_8\IN|phenytoin|)|DPH|( (l_pobj) seizures_10\NNS|NONE
D010672_D012640 NONE DPH_5\NNP|phenytoin|)|with|( (r_nmod) encephalopathy_7\JJ|NONE (l_prep) with_8\IN|phenytoin|)|DPH|( (l_pobj) seizures_10\NNS|NONE
D010672_D012640 NONE DPH_8\NNP|NONE (r_compound) treatment_9\NN|NONE (r_dobj) starting_7\VBG|a (r_acl) patient_6\NN|increase (r_pobj) in_4\IN|should|to|physician|are|that|,|, (l_pobj) increase_12\NN|patient (l_prep) in_13\IN|an|with|,|unexpected (l_pobj) seizures_14\NNS|NONE
D010672_D012640 NONE DPH_34\NNP|from (r_dobj) eliminating_33\VBG|NONE (r_pcomp) for_32\IN|possible|the (r_prep) need_31\NN|NONE (r_pobj) to_28\IN|should|physician|are|that|in|,|, (r_prep) alert_25\VB|.|authors (l_prep) in_4\IN|should|to|physician|are|that|,|, (l_pobj) increase_12\NN|patient (l_prep) in_13\IN|an|with|,|unexpected (l_pobj) seizures_14\NNS|NONE
D010672_D005076 NONE DPH_6\NNP|NONE (r_pobj) of_4\IN|the (r_prep) concentration_3\NN|In|normal (r_nsubj) was_7\VBD|patient|,|during|rash (r_ccomp) presented_12\VBD|protidogram|,|normal|had|and|, (l_dobj) rash_16\JJ|patient|,|during|was
D010672_D005076 NONE DPH_18\NNP|NONE (r_compound) treatment_19\NN|NONE (r_pobj) during_17\IN|patient|,|was|rash (r_prep) presented_12\VBD|protidogram|,|normal|had|and|, (l_dobj) rash_16\JJ|patient|,|during|was
D010672_D005076 NONE DPH_29\NNP|an|intradermic (r_compound) injection_30\NN|effect|. (r_nsubj) had_31\VBD|protidogram|,|normal|and|presented|, (r_conj) was_23\VBD|NONE (l_ccomp) presented_12\VBD|protidogram|,|normal|had|and|, (l_dobj) rash_16\JJ|patient|,|during|was
D010672_D001927 CID Phenytoin_0\NNP|as|report|:|. (r_compound) encephalopathy_1\NNP|NONE
D010672_D001927 CID phenytoin_3\NNP|)|with|DPH|( (r_nmod) encephalopathy_7\JJ|NONE
D010672_D001927 CID DPH_5\NNP|phenytoin|)|with|( (r_nmod) encephalopathy_7\JJ|NONE
11915580
D009569_D004412 NONE NO_19\JJ|an (r_det) donor_20\NN|glyceryl|,|,|(|GTN|) (r_appos) trinitrate_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) efficacy_10\NN|to|in (r_dobj) determine_8\VB|.|aim (l_prep) in_22\IN|to|efficacy (l_pobj) resolution_24\NN|NONE (l_prep) of_25\IN|the|in (l_pobj) dysmenorrhea_27\NN|NONE
D005996_D006261 CID GTN_5\NNP|not|but (r_pobj) by_4\IN|.|was|significantly|by|Headache (r_agent) increased_3\VBN|NONE (l_nsubjpass) Headache_0\NNP|.|was|significantly|by|by
D005996_D006261 CID GTN_4\NNP|NONE (r_dobj) using_3\VBG|became|patients|. (r_xcomp) stopped_2\VBD|NONE (l_advcl) became_13\VBD|patients|using|. (l_nsubj) headache_6\NN|intolerable|because
D004008_D006261 NONE DCF_9\NNP|NONE (r_pobj) by_8\IN|.|was|significantly|Headache|by (r_prep) increased_3\VBN|NONE (l_nsubjpass) Headache_0\NNP|.|was|significantly|by|by
D004008_D004412 NONE diclofenac_6\NN|NONE (r_pobj) with_5\IN|for|glyceryl (r_prep) trinitrate_4\NN|NONE (l_prep) for_7\IN|glyceryl|with (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) dysmenorrhea_12\NN|NONE
D004008_D004412 NONE diclofenac_31\NNP|NONE (r_pobj) with_30\IN|NONE (r_prep) comparison_29\NN|NONE (r_pobj) in_28\IN|of|the (r_prep) resolution_24\NN|NONE (l_prep) of_25\IN|the|in (l_pobj) dysmenorrhea_27\NN|NONE
D004008_D004412 NONE DCF_33\NNP|NONE (r_appos) diclofenac_31\NNP|NONE (r_pobj) with_30\IN|NONE (r_prep) comparison_29\NN|NONE (r_pobj) in_28\IN|of|the (r_prep) resolution_24\NN|NONE (l_prep) of_25\IN|the|in (l_pobj) dysmenorrhea_27\NN|NONE
D004008_D004412 NONE DCF_14\NNP|NONE (r_pobj) with_13\IN|in (r_prep) comparison_12\NN|NONE (l_prep) in_15\IN|with (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) dysmenorrhea_20\NN|NONE
D005996_D004412 NONE trinitrate_4\NN|NONE (l_prep) for_7\IN|glyceryl|with (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) dysmenorrhea_12\NN|NONE
D005996_D004412 NONE trinitrate_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) efficacy_10\NN|to|in (r_dobj) determine_8\VB|.|aim (l_prep) in_22\IN|to|efficacy (l_pobj) resolution_24\NN|NONE (l_prep) of_25\IN|the|in (l_pobj) dysmenorrhea_27\NN|NONE
D005996_D004412 NONE GTN_15\NNP|glyceryl|donor|,|,|(|) (r_appos) trinitrate_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) efficacy_10\NN|to|in (r_dobj) determine_8\VB|.|aim (l_prep) in_22\IN|to|efficacy (l_pobj) resolution_24\NN|NONE (l_prep) of_25\IN|the|in (l_pobj) dysmenorrhea_27\NN|NONE
D005996_D004412 NONE GTN_4\NNP|that|efficacy|by (r_nsubj) has_5\VBZ|findings|. (l_prep) by_11\IN|GTN|that|efficacy (l_pobj) comparison_12\NN|NONE (l_prep) in_15\IN|with (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) dysmenorrhea_20\NN|NONE
D011453_D004412 NONE prostaglandins_16\NNS|NONE (r_pobj) of_14\IN|a (r_prep) hypersecretion_13\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) caused_10\VBN|uterine|painful (r_acl) contractility_9\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) characterized_5\VBN|a (r_acl) syndrome_4\NN|dysmenorrhea|.|are (r_attr) is_2\VBZ|NONE (l_nsubj) dysmenorrhea_1\NN|.|syndrome|are
D004008_D017699 NONE DCF_2\NNP|However|,|remained|.|,|be (r_nsubj) continued_3\VBD|NONE (l_xcomp) be_5\VB|However|,|DCF|remained|.|, (l_acomp) effective_6\JJ|to (l_prep) in_7\IN|NONE (l_pcomp) reducing_8\VBG|NONE (l_dobj) pain_10\NN|for
D005996_D017699 NONE GTN_16\NNP|NONE (r_compound) scores_17\NNS|(|:|whereas|stable|GTN|after|and|higher|after (r_nsubj) remained_18\VBD|However|,|DCF|.|,|be (r_advcl) continued_3\VBD|NONE (l_xcomp) be_5\VB|However|,|DCF|remained|.|, (l_acomp) effective_6\JJ|to (l_prep) in_7\IN|NONE (l_pcomp) reducing_8\VBG|NONE (l_dobj) pain_10\NN|for
D005996_D017699 NONE GTN_38\NNP|(|:|whereas|stable|after|scores|and|higher|after (r_npadvmod) remained_18\VBD|However|,|DCF|.|,|be (r_advcl) continued_3\VBD|NONE (l_xcomp) be_5\VB|However|,|DCF|remained|.|, (l_acomp) effective_6\JJ|to (l_prep) in_7\IN|NONE (l_pcomp) reducing_8\VBG|NONE (l_dobj) pain_10\NN|for
D005996_D017699 NONE GTN_54\NNP|.|,|after|;|;|.|.|.|DFC|DFC|:|+/|. (r_appos) GTN_38\NNP|(|:|whereas|stable|after|scores|and|higher|after (r_npadvmod) remained_18\VBD|However|,|DCF|.|,|be (r_advcl) continued_3\VBD|NONE (l_xcomp) be_5\VB|However|,|DCF|remained|.|, (l_acomp) effective_6\JJ|to (l_prep) in_7\IN|NONE (l_pcomp) reducing_8\VBG|NONE (l_dobj) pain_10\NN|for
24190587
D018817_D008107 NONE Ecstasy_0\NNP|.|drug (r_nsubj) is_4\VBZ|NONE (l_attr) drug_7\NN|.|Ecstasy (l_relcl) associated_11\VBN|psychostimulant|a (l_prep) with_12\IN|is|increasingly|which (l_pobj) dysfunction_14\NN|NONE
D018817_D008107 NONE MDMA_2\NNP|NONE (r_appos) Ecstasy_0\NNP|.|drug (r_nsubj) is_4\VBZ|NONE (l_attr) drug_7\NN|.|Ecstasy (l_relcl) associated_11\VBN|psychostimulant|a (l_prep) with_12\IN|is|increasingly|which (l_pobj) dysfunction_14\NN|NONE
D018817_D003866 CID ecstasy_14\NN| (r_npadvmod) polydrug_16\NN|recreational (r_compound) users_17\NNS|NONE (r_pobj) in_12\IN|previous (r_prep) observations_11\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) line_8\NN|NONE (r_pobj) in_7\IN|.|increases (r_prep) are_6\VBP|NONE (l_nsubj) increases_1\NNS|.|in (l_prep) in_2\IN|The (l_pobj) anxiety_3\NN|NONE (l_conj) depression_5\NN|and
D018817_D001008 NONE ecstasy_14\NN| (r_npadvmod) polydrug_16\NN|recreational (r_compound) users_17\NNS|NONE (r_pobj) in_12\IN|previous (r_prep) observations_11\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) line_8\NN|NONE (r_pobj) in_7\IN|.|increases (r_prep) are_6\VBP|NONE (l_nsubj) increases_1\NNS|.|in (l_prep) in_2\IN|The (l_pobj) anxiety_3\NN|NONE
35781
D010423_D002375 NONE pentazocine_18\NN|and (r_conj) fentanyl_16\NN|, (r_conj) codeine_14\NN|, (r_conj) morphine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|NONE (r_acl) analgesia_9\NN|NONE (r_pobj) on_8\IN|NONE (r_prep) xylometazoline_7\NN|and|, (r_conj) naphazoline_5\NN|, (r_conj) clonidine_3\NN|on|and (r_pobj) of_2\IN|The (l_conj) on_21\IN|clonidine|and (l_pobj) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
D003000_D002375 CID clonidine_3\NN|on|and (r_pobj) of_2\IN|The (l_conj) on_21\IN|clonidine|and (l_pobj) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
D003000_D002375 CID clonidine_5\NN|NONE (r_pobj) by_4\IN|and|decreased|catalepsy|was|. (r_agent) increased_3\VBN|NONE (l_nsubjpass) catalepsy_1\NN|and|decreased|by|was|.
D009638_D002375 NONE NA_8\NNP|central (r_compound) receptors_9\NNS|NONE (r_dobj) stimulating_6\VBG|three (r_acl) drugs_5\NNS|that|enhanced|affect|and (r_nsubj) failed_10\VBD|was|It|. (l_conj) enhanced_22\VBD|that|affect|drugs|and (l_dobj) catalepsy_23\NN|they
D003061_D002375 CID codeine_14\NN|, (r_conj) morphine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|NONE (r_acl) analgesia_9\NN|NONE (r_pobj) on_8\IN|NONE (r_prep) xylometazoline_7\NN|and|, (r_conj) naphazoline_5\NN|, (r_conj) clonidine_3\NN|on|and (r_pobj) of_2\IN|The (l_conj) on_21\IN|clonidine|and (l_pobj) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
D003061_D002375 CID codine_27\NN|, (r_conj) morphine_25\NN|NONE (r_pobj) of_24\IN|cataleptic (r_prep) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
D003061_D002375 CID Codeine_0\NNP|NONE (r_compound) catalepsy_1\NN|and|decreased|by|was|.
C009695_D002375 CID xylometazoline_7\NN|and|, (r_conj) naphazoline_5\NN|, (r_conj) clonidine_3\NN|on|and (r_pobj) of_2\IN|The (l_conj) on_21\IN|clonidine|and (l_pobj) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
C009695_D002375 CID xylometazoline_11\NN|and (r_conj) naphazoline_9\NN|NONE (r_pobj) by_8\IN|NONE (r_prep) decreased_7\VBD|and|catalepsy|by|was|. (r_conj) increased_3\VBN|NONE (l_nsubjpass) catalepsy_1\NN|and|decreased|by|was|.
D009020_D002375 CID morphine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|NONE (r_acl) analgesia_9\NN|NONE (r_pobj) on_8\IN|NONE (r_prep) xylometazoline_7\NN|and|, (r_conj) naphazoline_5\NN|, (r_conj) clonidine_3\NN|on|and (r_pobj) of_2\IN|The (l_conj) on_21\IN|clonidine|and (l_pobj) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
D009020_D002375 CID morphine_25\NN|NONE (r_pobj) of_24\IN|cataleptic (r_prep) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
D009020_D002375 CID morphine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_agent) induced_24\VBN|NONE (r_acl) catalepsy_23\NN|they
D009278_D002375 CID naphazoline_5\NN|, (r_conj) clonidine_3\NN|on|and (r_pobj) of_2\IN|The (l_conj) on_21\IN|clonidine|and (l_pobj) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
D009278_D002375 CID naphazoline_9\NN|NONE (r_pobj) by_8\IN|NONE (r_prep) decreased_7\VBD|and|catalepsy|by|was|. (r_conj) increased_3\VBN|NONE (l_nsubjpass) catalepsy_1\NN|and|decreased|by|was|.
D005283_D002375 CID fentanyl_16\NN|, (r_conj) codeine_14\NN|, (r_conj) morphine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|NONE (r_acl) analgesia_9\NN|NONE (r_pobj) on_8\IN|NONE (r_prep) xylometazoline_7\NN|and|, (r_conj) naphazoline_5\NN|, (r_conj) clonidine_3\NN|on|and (r_pobj) of_2\IN|The (l_conj) on_21\IN|clonidine|and (l_pobj) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
D005283_D002375 CID fentanyl_29\NN|and (r_conj) codine_27\NN|, (r_conj) morphine_25\NN|NONE (r_pobj) of_24\IN|cataleptic (r_prep) effect_23\NN|NONE (l_amod) cataleptic_22\JJ|of
D005283_D002375 CID fentanyl_28\NN|and (r_conj) morphine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_agent) induced_24\VBN|NONE (r_acl) catalepsy_23\NN|they
6310832
D016572_D016470 NONE cyclosporine_3\NN|NONE (r_pobj) on_2\IN|Renal (r_prep) patients_1\NNS|.|bacteremias (r_nsubj) had_4\VBD|NONE (l_dobj) bacteremias_7\NNS|.|patients
D001379_D013203 NONE Aza_0\NNP|NONE (r_compound) patients_1\NNS|occurred|and|infections|, (r_nsubj) had_2\VBD|NONE (l_dobj) infections_6\NNS|occurred|patients|and|,
D016572_D003586 NONE cyclosporine_2\JJ|the (r_compound) patients_3\NNS|NONE (r_pobj) Of_0\IN| (r_prep) %_6\NN|,|symptoms|. (r_nsubj) had_7\VBD|NONE (l_dobj) symptoms_8\NNS|,|%|. (l_acl) related_9\VBN|NONE (l_prep) to_10\IN|NONE (l_pobj) infection_12\NN|NONE
D016572_D007239 CID cyclosporine_12\NN|NONE (r_pobj) on_11\IN|transplant (r_prep) recipients_10\NNS|and|, (r_conj) heart_5\NN|, (r_conj) kidney_3\NN|NONE (r_pobj) in_2\IN|Early|. (r_prep) infections_1\NNS|NONE
D016572_D007239 CID cyclosporine_27\NN|the|randomized (r_compound) patients_28\NNS|NONE (r_pobj) than_24\IN|patients|.|infections (r_prep) had_4\VBD|NONE (l_dobj) infections_7\NNS|patients|.|than
D016572_D007239 CID cyclosporine_27\NN|the|randomized (r_compound) patients_28\NNS|NONE (r_pobj) than_24\IN|patients|.|infections (r_prep) had_4\VBD|NONE (l_dobj) infections_7\NNS|patients|.|than (l_appos) P_9\NN|(|(|overall|)|P (l_conj) infections_17\NNS|)|.|and
D016572_D007239 CID cyclosporine_8\JJ|renal (r_nmod) patients_10\NNS|NONE (r_pobj) than_7\IN|infections|more|but (r_prep) infections_6\NNS|patients|.
D016572_D007239 CID cyclosporine_8\JJ|renal (r_nmod) patients_10\NNS|NONE (r_pobj) than_7\IN|infections|more|but (r_prep) infections_6\NNS|patients|. (l_conj) infections_13\NNS|than|more|but
D016572_D007239 CID cyclosporine_10\NN|NONE (r_pobj) on_9\IN|transplant|renal (r_prep) patients_8\NNS|NONE (r_pobj) in_5\IN|infectious|no (r_prep) deaths_4\NNS|There|played|but|, (r_attr) were_1\VBD|NONE (l_conj) played_16\VBD|There|but|deaths|, (l_nsubj) infection_15\NN|out|.|in|role|out
D016572_D007239 CID cyclosporine_6\NN| (r_npadvmod) treated_8\VBN|renal (r_amod) patients_10\NNS|NONE (r_pobj) in_5\IN|infections|than|common|. (r_prep) were_2\VBD|NONE (l_nsubj) infections_1\NNS|than|in|common|.
D016572_D020031 NONE cyclosporine_14\NN|studied| (r_compound) patients_15\NNS|NONE (r_pobj) of_12\IN| (r_prep) %_11\NN|NONE (r_pobj) in_9\IN|was|.|evidence (r_prep) found_8\VBN|NONE (l_nsubjpass) evidence_1\NN|was|.|in (l_prep) for_2\IN|Serological (l_pobj) infection_6\NN|NONE
D001379_D009181 NONE Aza_0\NNP|NONE (r_compound) patients_1\NNS|occurred|and|infections|, (r_nsubj) had_2\VBD|NONE (l_conj) occurred_23\VBD|patients|and|infections|, (l_nsubj) infections_22\NNS|in|.
D001379_D007239 CID Aza_2\NNP|The|randomized (r_compound) patients_3\NNS|.|infections|than (r_nsubj) had_4\VBD|NONE (l_dobj) infections_7\NNS|patients|.|than
D001379_D007239 CID Aza_2\NNP|The|randomized (r_compound) patients_3\NNS|.|infections|than (r_nsubj) had_4\VBD|NONE (l_dobj) infections_7\NNS|patients|.|than (l_appos) P_9\NN|(|(|overall|)|P (l_conj) infections_17\NNS|)|.|and
D001379_D007239 CID Aza_16\NNP|the|renal (r_nmod) patients_18\NNS|NONE (r_pobj) than_14\IN|fewer (r_prep) infections_13\NNS|than|more|but (r_conj) infections_6\NNS|patients|.
D001379_D007239 CID Aza_16\NNP|the|renal (r_nmod) patients_18\NNS|NONE (r_pobj) than_14\IN|fewer (r_prep) infections_13\NNS|than|more|but
D001379_D007239 CID Aza_12\NNP|or (r_conj) cyclosporine_10\NN|NONE (r_pobj) on_9\IN|transplant|renal (r_prep) patients_8\NNS|NONE (r_pobj) in_5\IN|infectious|no (r_prep) deaths_4\NNS|There|played|but|, (r_attr) were_1\VBD|NONE (l_conj) played_16\VBD|There|but|deaths|, (l_nsubj) infection_15\NN|out|.|in|role|out
D001379_D007239 CID Aza_13\NNP| (r_npadvmod) treated_15\VBN|(|)|P (r_amod) patients_16\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) than_11\IN|infections|in|common|. (r_prep) were_2\VBD|NONE (l_nsubj) infections_1\NNS|than|in|common|.
8096565
D018170_D003027 NONE sumatriptan_15\NNP|NONE (r_pobj) of_14\IN|NONE (r_prep) administration_13\NN|NONE (r_pobj) after_12\IN|acute|subcutaneously|myocardial|an|for (r_prep) infarction_11\NN|NONE (l_prep) for_19\IN|acute|subcutaneously|myocardial|an|after (l_pobj) headache_21\NN|NONE
D018170_D009203 CID sumatriptan_4\NNP|NONE (r_pobj) with_3\IN|Transmural|myocardial|. (r_prep) infarction_2\NN|NONE
D018170_D009203 CID sumatriptan_15\NNP|NONE (r_pobj) of_14\IN|NONE (r_prep) administration_13\NN|NONE (r_pobj) after_12\IN|acute|subcutaneously|myocardial|an|for (r_prep) infarction_11\NN|NONE
16876986
D010862_D012640 CID pilocarpine_6\NN| (r_npadvmod) induced_8\VBN|in|subsequent (r_amod) seizures_9\NNS|NONE
D010862_D012640 CID pilocarpine_6\NN|in (r_amod) injections_7\NNS|NONE (r_pobj) by_5\IN|were|.|,|Thereafter|seizures (r_agent) induced_4\VBN|NONE (l_nsubjpass) seizures_2\NNS|were|.|,|by|Thereafter
946593
D008727_D002493 NONE methothexate_34\NN|cerebrospinal|elevated|;|related|presence (r_compound) concentration_35\NN|,|cerebrospinal|abnormal|and|related|leakage|; (r_appos) dynamics_15\NNS|The|following (l_acl) related_16\VBN|,|cerebrospinal|abnormal|and|leakage|;|concentration (l_prep) to_17\IN|NONE (l_pobj) presence_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) leukemia_24\NN|NONE
D008727_D002493 NONE methotrexate_46\NN|high|based (r_compound) doses_47\NNS|NONE (r_pobj) to_43\TO|and|to (r_conj) related_36\VBN|cerebrospinal|elevated|methothexate|;|presence (r_acl) concentration_35\NN|,|cerebrospinal|abnormal|and|related|leakage|; (r_appos) dynamics_15\NNS|The|following (l_acl) related_16\VBN|,|cerebrospinal|abnormal|and|leakage|;|concentration (l_prep) to_17\IN|NONE (l_pobj) presence_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) leukemia_24\NN|NONE
D008727_D002493 NONE methotrexate_68\NN|diluents|available|and (r_compound) preparations_69\NNS|NONE (r_pobj) in_65\IN|of|and|;|the|use (r_prep) presence_61\NN|cerebrospinal|elevated|methothexate|;|related (r_conj) concentration_35\NN|,|cerebrospinal|abnormal|and|related|leakage|; (r_appos) dynamics_15\NNS|The|following (l_acl) related_16\VBN|,|cerebrospinal|abnormal|and|leakage|;|concentration (l_prep) to_17\IN|NONE (l_pobj) presence_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) leukemia_24\NN|NONE
D008727_D002493 NONE methotrexate_77\NN|of (r_compound) diluents_78\NNS|NONE (r_pobj) of_76\IN|the (r_prep) use_75\NN|in|of|and|;|the (r_conj) presence_61\NN|cerebrospinal|elevated|methothexate|;|related (r_conj) concentration_35\NN|,|cerebrospinal|abnormal|and|related|leakage|; (r_appos) dynamics_15\NNS|The|following (l_acl) related_16\VBN|,|cerebrospinal|abnormal|and|leakage|;|concentration (l_prep) to_17\IN|NONE (l_pobj) presence_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) leukemia_24\NN|NONE
D008727_D002493 NONE methotrexate_12\NNP|NONE (r_pobj) of_11\IN|lower (r_prep) doses_10\NNS|in|in|, (r_dobj) employing_8\VBG|NONE (l_prep) in_13\IN|doses|in|, (l_pobj) presence_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) leukemia_20\NN|NONE
D008727_D020258 NONE methothexate_34\NN|cerebrospinal|elevated|;|related|presence (r_compound) concentration_35\NN|,|cerebrospinal|abnormal|and|related|leakage|; (l_conj) presence_61\NN|cerebrospinal|elevated|methothexate|;|related (l_prep) of_62\IN|in|and|;|the|use (l_pobj) preservatives_64\NNS|NONE (l_amod) neurotoxic_63\JJ|NONE
D008727_D020258 NONE methotrexate_46\NN|high|based (r_compound) doses_47\NNS|NONE (r_pobj) to_43\TO|and|to (r_conj) related_36\VBN|cerebrospinal|elevated|methothexate|;|presence (r_acl) concentration_35\NN|,|cerebrospinal|abnormal|and|related|leakage|; (l_conj) presence_61\NN|cerebrospinal|elevated|methothexate|;|related (l_prep) of_62\IN|in|and|;|the|use (l_pobj) preservatives_64\NNS|NONE (l_amod) neurotoxic_63\JJ|NONE
D008727_D020258 NONE methotrexate_68\NN|diluents|available|and (r_compound) preparations_69\NNS|NONE (r_pobj) in_65\IN|of|and|;|the|use (r_prep) presence_61\NN|cerebrospinal|elevated|methothexate|;|related (l_prep) of_62\IN|in|and|;|the|use (l_pobj) preservatives_64\NNS|NONE (l_amod) neurotoxic_63\JJ|NONE
D008727_D020258 NONE methotrexate_77\NN|of (r_compound) diluents_78\NNS|NONE (r_pobj) of_76\IN|the (r_prep) use_75\NN|in|of|and|;|the (r_conj) presence_61\NN|cerebrospinal|elevated|methothexate|;|related (l_prep) of_62\IN|in|and|;|the|use (l_pobj) preservatives_64\NNS|NONE (l_amod) neurotoxic_63\JJ|NONE
D008727_D020258 NONE methotrexate_12\NNP|NONE (r_pobj) of_11\IN|lower (r_prep) doses_10\NNS|in|in|, (r_dobj) employing_8\VBG|NONE (r_pcomp) by_7\IN|incidence|be|.|may (r_prep) reduced_6\VBN|NONE (l_nsubjpass) incidence_1\NN|by|be|.|may (l_prep) of_2\IN|The (l_pobj) neurotoxicity_3\NN|NONE
D008727_D020258 NONE methotrexate_5\NNP|cerebruspinal (r_compound) levels_6\NNS|NONE (r_pobj) of_2\IN|Periodic (r_prep) monitoring_1\NN|may|.|predictive (r_nsubj) be_8\VB|NONE (l_acomp) predictive_9\JJ|monitoring|may|. (l_prep) of_10\IN|NONE (l_pobj) development_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) neurotoxicity_15\NN|NONE
D008727_D064420 NONE methotrexate_3\NNP|deficiency|, (r_compound) contaminants_4\NNS|NONE (r_pobj) of_2\IN|in|The (r_prep) role_1\NN|.|unclear (l_prep) in_13\IN|The|of (l_pobj) pathogenesis_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) toxicity_19\NN|NONE
D008727_D064420 NONE methotrexate_18\NNP|intrathecal (r_compound) toxicity_19\NN|NONE
D008727_D010264 CID methotrexate_3\NN|NONE (r_dobj) following_1\VBG|report (r_prep) Paraplegia_0\NNP|NONE
D008727_D010264 CID methotrexate_10\NNP|NONE (r_pobj) of_9\IN|the|intrathecal (r_prep) instillation_8\NN|NONE (r_pobj) following_5\VBG|paraplegia|who (r_prep) developed_3\VBD|A (l_dobj) paraplegia_4\NNS|following|who
D008727_C536409 NONE methotrexate_3\NNP|deficiency|, (r_compound) contaminants_4\NNS|NONE (l_conj) deficiency_8\NN|,|methotrexate
D008727_C536409 NONE methotrexate_18\NNP|intrathecal (r_compound) toxicity_19\NN|NONE (r_pobj) of_16\IN|the (r_prep) pathogenesis_15\NN|NONE (r_pobj) in_13\IN|The|of (r_prep) role_1\NN|.|unclear (l_prep) of_2\IN|in|The (l_pobj) contaminants_4\NNS|NONE (l_conj) deficiency_8\NN|,|methotrexate
16034922
D004967_D020521 CID oestrogen_3\NN|term (r_compound) HT_6\NNP|risk|significantly|also|. (r_nsubj) increased_9\VBD|NONE (l_dobj) risk_11\NN|significantly|HT|also|. (l_prep) of_12\IN|the (l_pobj) disease_16\NN|NONE (l_nmod) stroke_13\NN|NONE
D004967_D005705 CID oestrogen_3\NN|term (r_compound) HT_6\NNP|risk|significantly|also|. (r_nsubj) increased_9\VBD|NONE (l_dobj) risk_11\NN|significantly|HT|also|. (l_prep) of_12\IN|the (l_pobj) disease_16\NN|NONE
17445520
D002110_D003865 NONE caffeine_51\NN|NONE (r_compound) challenge_52\NN|oral|an (r_compound) test_53\NN|NONE (r_pobj) by_48\IN|panic (r_prep) attacks_47\NNS|NONE (r_pobj) of_45\IN|the (r_prep) induction_44\NN|NONE (r_pobj) to_42\IN|similar|a (r_prep) way_41\NN|NONE (r_pobj) in_38\IN|if|patients (r_prep) respond_37\VBP|to (l_nsubj) patients_6\NNS|if|in (l_prep) with_7\IN|NONE (l_pobj) disorder_9\NN|NONE (l_conj) patients_14\NNS|(|panic|and|)|PD (l_prep) with_15\IN|NONE (l_pobj) depression_17\NN|NONE
D002110_D003865 NONE caffeine_51\NN|NONE (r_compound) challenge_52\NN|oral|an (r_compound) test_53\NN|NONE (r_pobj) by_48\IN|panic (r_prep) attacks_47\NNS|NONE (r_pobj) of_45\IN|the (r_prep) induction_44\NN|NONE (r_pobj) to_42\IN|similar|a (r_prep) way_41\NN|NONE (r_pobj) in_38\IN|if|patients (r_prep) respond_37\VBP|to (l_nsubj) patients_6\NNS|if|in (l_prep) with_7\IN|NONE (l_pobj) disorder_9\NN|NONE (l_conj) patients_14\NNS|(|panic|and|)|PD (l_prep) with_15\IN|NONE (l_pobj) depression_17\NN|NONE (l_prep) with_18\IN|major (l_pobj) attacks_20\NNS|NONE (l_appos) MDP_22\NNP|(|)|panic|)|Diagnostic|(
D002110_D003865 NONE caffeine_56\NN|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN|NONE (r_pobj) after_53\IN|total|attack|. (r_prep) had_49\VBD|NONE (l_nsubj) total_1\NN|after|attack|. (l_prep) of_2\IN|A (l_pobj) %_4\NN|NONE (l_prep) of_22\IN|%|,|(|n|and|,|of|of|)||)|%|)|.|,|% (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) MDP_25\NNP|NONE
D002110_D003865 NONE caffeine_56\NN|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN|NONE (r_pobj) after_53\IN|total|attack|. (r_prep) had_49\VBD|NONE (l_nsubj) total_1\NN|after|attack|. (l_prep) of_2\IN|A (l_pobj) %_4\NN|NONE (l_prep) of_34\IN|%|,|(|n|and|,|of|)||)|%|of|)|.|,|% (l_pobj) patients_35\NNS|NONE (l_prep) with_36\IN|NONE (l_pobj) MD_37\NNP|NONE
D002110_D003865 NONE caffeine_10\NN|NONE (r_pobj) to_9\IN|more|were (r_prep) sensitive_8\JJ|.|patients (r_acomp) were_6\VBD|NONE (l_nsubj) patients_1\NNS|sensitive|. (l_prep) with_2\IN|The (l_pobj) PD_3\NNP|NONE (l_conj) MDP_5\NNP|and
D002110_D003865 NONE caffeine_10\NN|NONE (r_pobj) to_9\IN|more|were (r_prep) sensitive_8\JJ|.|patients (l_advcl) were_12\VBD|to|more (l_nsubj) patients_13\NNS|than (l_prep) with_14\IN|NONE (l_pobj) MD_15\NNP|NONE
D002110_D003865 NONE caffeine_26\NN|NONE (r_compound) challenge_27\NN|an|oral (r_compound) test_28\NN|NONE (r_pobj) to_23\IN|NONE (r_prep) hyperreactivity_22\NN|that|there|matter|association|and|,|associated (r_conj) is_5\VBZ|.|data (l_advcl) associated_15\VBN|that|there|matter|association|and|,|hyperreactivity (l_prep) with_16\IN|if (l_pobj) PD_17\NNP|NONE (l_conj) MDP_19\NNP|or
D002110_D003866 NONE Caffeine_0\NN|.|in|challenge (r_amod) test_2\NN|NONE (l_prep) in_3\IN|.|Caffeine|challenge (l_pobj) disorder_5\NN|NONE (l_conj) depression_7\NN|and|panic
D002110_D001008 NONE caffeine_17\NN|applied|,|In|.|were|in (r_nsubjpass) administered_28\VBN|NONE (l_prep) in_29\IN|applied|,|In|caffeine|.|were (l_pobj) scales_35\NNS|NONE (l_nmod) form_32\NN|a (l_conj) anxiety_34\NN|and|coffee
D002110_D001008 NONE caffeine_20\NN| (r_npadvmod) free_22\JJ|)|(|placebo|a (r_amod) solution_26\NN|and|mg (r_conj) caffeine_17\NN|applied|,|In|.|were|in (r_nsubjpass) administered_28\VBN|NONE (l_prep) in_29\IN|applied|,|In|caffeine|.|were (l_pobj) scales_35\NNS|NONE (l_nmod) form_32\NN|a (l_conj) anxiety_34\NN|and|coffee
D002110_D016584 CID Caffeine_0\NN|.|in|challenge (r_amod) test_2\NN|NONE (l_prep) in_3\IN|.|Caffeine|challenge (l_pobj) disorder_5\NN|NONE
D002110_D016584 CID Caffeine_0\NN|.|in|challenge (r_amod) test_2\NN|NONE (l_prep) in_3\IN|.|Caffeine|challenge (l_pobj) disorder_5\NN|NONE (l_conj) depression_7\NN|and|panic (l_prep) with_8\IN|NONE (l_pobj) attacks_10\NNS|NONE
D002110_D016584 CID caffeine_51\NN|NONE (r_compound) challenge_52\NN|oral|an (r_compound) test_53\NN|NONE (r_pobj) by_48\IN|panic (r_prep) attacks_47\NNS|NONE (r_pobj) of_45\IN|the (r_prep) induction_44\NN|NONE (r_pobj) to_42\IN|similar|a (r_prep) way_41\NN|NONE (r_pobj) in_38\IN|if|patients (r_prep) respond_37\VBP|to (l_nsubj) patients_6\NNS|if|in (l_prep) with_7\IN|NONE (l_pobj) disorder_9\NN|NONE
D002110_D016584 CID caffeine_51\NN|NONE (r_compound) challenge_52\NN|oral|an (r_compound) test_53\NN|NONE (r_pobj) by_48\IN|panic (r_prep) attacks_47\NNS|NONE (r_pobj) of_45\IN|the (r_prep) induction_44\NN|NONE (r_pobj) to_42\IN|similar|a (r_prep) way_41\NN|NONE (r_pobj) in_38\IN|if|patients (r_prep) respond_37\VBP|to (l_nsubj) patients_6\NNS|if|in (l_prep) with_7\IN|NONE (l_pobj) disorder_9\NN|NONE (l_appos) PD_11\NNP|(|panic|and|patients|)
D002110_D016584 CID caffeine_51\NN|NONE (r_compound) challenge_52\NN|oral|an (r_compound) test_53\NN|NONE (r_pobj) by_48\IN|panic (r_prep) attacks_47\NNS|NONE (r_pobj) of_45\IN|the (r_prep) induction_44\NN|NONE (r_pobj) to_42\IN|similar|a (r_prep) way_41\NN|NONE (r_pobj) in_38\IN|if|patients (r_prep) respond_37\VBP|to (l_nsubj) patients_6\NNS|if|in (l_prep) with_7\IN|NONE (l_pobj) disorder_9\NN|NONE (l_conj) patients_14\NNS|(|panic|and|)|PD (l_prep) with_15\IN|NONE (l_pobj) depression_17\NN|NONE (l_prep) with_18\IN|major (l_pobj) attacks_20\NNS|NONE
D002110_D016584 CID caffeine_51\NN|NONE (r_compound) challenge_52\NN|oral|an (r_compound) test_53\NN|NONE (r_pobj) by_48\IN|panic (r_prep) attacks_47\NNS|NONE
D002110_D016584 CID caffeine_56\NN|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN|NONE (r_pobj) after_53\IN|total|attack|. (r_prep) had_49\VBD|NONE (l_nsubj) total_1\NN|after|attack|. (l_prep) of_2\IN|A (l_pobj) %_4\NN|NONE (l_prep) of_10\IN|%|,|(|n|and|,|of|)||)|%|of|)|.|,|% (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) PD_13\NNP|NONE
D002110_D016584 CID caffeine_56\NN|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN|NONE (r_pobj) after_53\IN|total|attack|. (r_prep) had_49\VBD|NONE (l_dobj) attack_52\NN|total|after|.
D002110_D016584 CID caffeine_10\NN|NONE (r_pobj) to_9\IN|more|were (r_prep) sensitive_8\JJ|.|patients (r_acomp) were_6\VBD|NONE (l_nsubj) patients_1\NNS|sensitive|. (l_prep) with_2\IN|The (l_pobj) PD_3\NNP|NONE
D002110_D016584 CID caffeine_7\NN| (r_npadvmod) free_9\JJ|solution|the (r_amod) intake_11\NN|NONE (r_pobj) after_5\IN|attack|.|was (r_prep) observed_4\VBN|NONE (l_nsubjpass) attack_2\NN|.|was|after
D002110_D016584 CID caffeine_26\NN|NONE (r_compound) challenge_27\NN|an|oral (r_compound) test_28\NN|NONE (r_pobj) to_23\IN|NONE (r_prep) hyperreactivity_22\NN|that|there|matter|association|and|,|associated (r_conj) is_5\VBZ|.|data (l_attr) association_7\NN|that|there|matter|and|,|hyperreactivity|associated (l_prep) between_8\IN|an|, (l_pobj) attacks_10\NNS|NONE
D002110_D016584 CID caffeine_26\NN|NONE (r_compound) challenge_27\NN|an|oral (r_compound) test_28\NN|NONE (r_pobj) to_23\IN|NONE (r_prep) hyperreactivity_22\NN|that|there|matter|association|and|,|associated (r_conj) is_5\VBZ|.|data (l_advcl) associated_15\VBN|that|there|matter|association|and|,|hyperreactivity (l_prep) with_16\IN|if (l_pobj) PD_17\NNP|NONE
D002110_D016584 NONE caffeine_51\NN|NONE (r_compound) challenge_52\NN|oral|an (r_compound) test_53\NN|NONE (r_pobj) by_48\IN|panic (r_prep) attacks_47\NNS|NONE (r_pobj) of_45\IN|the (r_prep) induction_44\NN|NONE (r_pobj) to_42\IN|similar|a (r_prep) way_41\NN|NONE (r_pobj) in_38\IN|if|patients (r_prep) respond_37\VBP|to (l_nsubj) patients_6\NNS|if|in (l_prep) with_7\IN|NONE (l_pobj) disorder_9\NN|NONE (l_conj) patients_14\NNS|(|panic|and|)|PD (l_prep) with_15\IN|NONE (l_pobj) depression_17\NN|NONE (l_prep) with_18\IN|major (l_pobj) attacks_20\NNS|NONE (l_appos) MDP_22\NNP|(|)|panic|)|Diagnostic|(
D002110_D016584 NONE caffeine_56\NN|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN|NONE (r_pobj) after_53\IN|total|attack|. (r_prep) had_49\VBD|NONE (l_nsubj) total_1\NN|after|attack|. (l_prep) of_2\IN|A (l_pobj) %_4\NN|NONE (l_prep) of_22\IN|%|,|(|n|and|,|of|of|)||)|%|)|.|,|% (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) MDP_25\NNP|NONE
D002110_D016584 NONE caffeine_10\NN|NONE (r_pobj) to_9\IN|more|were (r_prep) sensitive_8\JJ|.|patients (r_acomp) were_6\VBD|NONE (l_nsubj) patients_1\NNS|sensitive|. (l_prep) with_2\IN|The (l_pobj) PD_3\NNP|NONE (l_conj) MDP_5\NNP|and
D002110_D016584 NONE caffeine_26\NN|NONE (r_compound) challenge_27\NN|an|oral (r_compound) test_28\NN|NONE (r_pobj) to_23\IN|NONE (r_prep) hyperreactivity_22\NN|that|there|matter|association|and|,|associated (r_conj) is_5\VBZ|.|data (l_advcl) associated_15\VBN|that|there|matter|association|and|,|hyperreactivity (l_prep) with_16\IN|if (l_pobj) PD_17\NNP|NONE (l_conj) MDP_19\NNP|or
D002110_D001523 NONE caffeine_51\NN|NONE (r_compound) challenge_52\NN|oral|an (r_compound) test_53\NN|NONE (r_pobj) by_48\IN|panic (r_prep) attacks_47\NNS|NONE (r_pobj) of_45\IN|the (r_prep) induction_44\NN|NONE (r_pobj) to_42\IN|similar|a (r_prep) way_41\NN|NONE (r_pobj) in_38\IN|if|patients (r_prep) respond_37\VBP|to (l_nsubj) patients_6\NNS|if|in (l_prep) with_7\IN|NONE (l_pobj) disorder_9\NN|NONE (l_conj) patients_14\NNS|(|panic|and|)|PD (l_prep) with_15\IN|NONE (l_pobj) depression_17\NN|NONE (l_prep) with_18\IN|major (l_pobj) attacks_20\NNS|NONE (l_appos) Diagnostic_25\NNP|MDP|(|)|panic|)|( (l_conj) Manual_28\NNP|criteria|,|and (l_prep) of_29\IN|Statistical (l_pobj) Disorders_31\NNP|NONE
10462057
D017330_D000741 CID remoxipride_4\NN|and|in|cells (r_compound) metabolites_5\NNS|NONE (r_pobj) by_3\IN|NONE (r_agent) apoptosis_2\NN|NONE (r_pobj) of_1\IN|:|.|relevance (r_prep) Induction_0\NN|NONE (l_appos) relevance_17\NN|:|.|of (l_prep) to_18\IN|potential (l_pobj) anemia_23\NN|NONE
D017330_D000741 CID remoxipride_19\NN| (r_npadvmod) induced_21\VBN|aplastic (r_amod) anemia_23\NN|NONE
D017330_D000741 CID remoxipride_4\NN|been|with|.|has (r_nsubjpass) associated_14\VBN|NONE (l_prep) with_15\IN|been|remoxipride|.|has (l_pobj) anemia_18\NN|NONE
D017330_D000741 CID amide_10\NN|agent|]|,|[|( (r_appos) remoxipride_4\NN|been|with|.|has (r_nsubjpass) associated_14\VBN|NONE (l_prep) with_15\IN|been|remoxipride|.|has (l_pobj) anemia_18\NN|NONE
D017330_D000741 CID remoxipride_3\NN|and|apoptosis|via|may|that|anemia (r_nsubj) induce_7\VB|contribute|We|. (l_dobj) anemia_9\NN|and|apoptosis|via|may|that|remoxipride
D017330_D000741 CID remoxipride_3\NN|and|apoptosis|via|may|that|anemia (r_nsubj) induce_7\VB|contribute|We|. (r_ccomp) propose_1\VBP|NONE (l_conj) contribute_31\VB|We|induce|. (l_prep) to_32\IN|may (l_pobj) anemia_38\NN|NONE
D017330_D000741 CID remoxipride_44\NN|NONE (r_pobj) with_43\IN|has|been|that (r_prep) associated_42\VBN|aplastic|underlying|acquired|mechanism (r_relcl) anemia_38\NN|NONE (r_pobj) to_32\IN|may (r_prep) contribute_31\VB|We|induce|. (r_conj) propose_1\VBP|NONE (l_ccomp) induce_7\VB|contribute|We|. (l_dobj) anemia_9\NN|and|apoptosis|via|may|that|remoxipride
D017330_D000741 CID remoxipride_44\NN|NONE (r_pobj) with_43\IN|has|been|that (r_prep) associated_42\VBN|aplastic|underlying|acquired|mechanism (r_relcl) anemia_38\NN|NONE
C084325_D009336 NONE NCQ436_8\NNP|NONE (r_pobj) with_7\IN|NONE (r_prep) treated_6\VBN|NONE (r_acl) cells_5\NNS|NONE (r_pobj) in_4\IN|necrosis|had|was|but (r_prep) observed_3\VBN|NONE (l_nsubjpass) necrosis_1\NN|in|had|was|but
C084325_D009336 NONE NCQ436_8\NNP|NONE (r_pobj) with_7\IN|NONE (r_prep) treated_6\VBN|NONE (r_acl) cells_5\NNS|NONE (r_pobj) in_4\IN|necrosis|had|was|but (r_prep) observed_3\VBN|NONE (l_conj) had_11\VBD|in|necrosis|was|but (l_advcl) inducing_20\VBG|,|NCQ|effect|. (l_advmod) apoptosis_21\NN|NONE (l_prep) at_22\IN|NONE (l_pobj) concentrations_24\NNS|NONE (l_conj) necrosis_26\NN|and|at|lower
C112341_D009336 NONE NCQ344_10\NNP|,|effect|inducing|. (r_nsubj) had_11\VBD|in|necrosis|was|but (r_conj) observed_3\VBN|NONE (l_nsubjpass) necrosis_1\NN|in|had|was|but
C112341_D009336 NONE NCQ344_10\NNP|,|effect|inducing|. (r_nsubj) had_11\VBD|in|necrosis|was|but (l_advcl) inducing_20\VBG|,|NCQ|effect|. (l_advmod) apoptosis_21\NN|NONE (l_prep) at_22\IN|NONE (l_pobj) concentrations_24\NNS|NONE (l_conj) necrosis_26\NN|and|at|lower
D001554_D000741 CID benzene_5\NN|and (r_conj) remoxipride_3\NN|and|apoptosis|via|may|that|anemia (r_nsubj) induce_7\VB|contribute|We|. (l_dobj) anemia_9\NN|and|apoptosis|via|may|that|remoxipride
D001554_D000741 CID benzene_5\NN|and (r_conj) remoxipride_3\NN|and|apoptosis|via|may|that|anemia (r_nsubj) induce_7\VB|contribute|We|. (r_ccomp) propose_1\VBP|NONE (l_conj) contribute_31\VB|We|induce|. (l_prep) to_32\IN|may (l_pobj) anemia_38\NN|NONE
C084325_D000741 NONE NCQ436_21\NNP|NONE (r_pobj) of_20\IN|the|induce (r_prep) ability_19\NN|in|that (r_nsubj) apoptosis_26\NN|and|via|may|that|remoxipride|anemia (r_conj) induce_7\VB|contribute|We|. (l_dobj) anemia_9\NN|and|apoptosis|via|may|that|remoxipride
C084325_D000741 NONE NCQ436_21\NNP|NONE (r_pobj) of_20\IN|the|induce (r_prep) ability_19\NN|in|that (r_nsubj) apoptosis_26\NN|and|via|may|that|remoxipride|anemia (r_conj) induce_7\VB|contribute|We|. (r_ccomp) propose_1\VBP|NONE (l_conj) contribute_31\VB|We|induce|. (l_prep) to_32\IN|may (l_pobj) anemia_38\NN|NONE
C112341_D000741 NONE NCQ344_23\NNP|and (r_conj) NCQ436_21\NNP|NONE (r_pobj) of_20\IN|the|induce (r_prep) ability_19\NN|in|that (r_nsubj) apoptosis_26\NN|and|via|may|that|remoxipride|anemia (r_conj) induce_7\VB|contribute|We|. (l_dobj) anemia_9\NN|and|apoptosis|via|may|that|remoxipride
C112341_D000741 NONE NCQ344_23\NNP|and (r_conj) NCQ436_21\NNP|NONE (r_pobj) of_20\IN|the|induce (r_prep) ability_19\NN|in|that (r_nsubj) apoptosis_26\NN|and|via|may|that|remoxipride|anemia (r_conj) induce_7\VB|contribute|We|. (r_ccomp) propose_1\VBP|NONE (l_conj) contribute_31\VB|We|induce|. (l_prep) to_32\IN|may (l_pobj) anemia_38\NN|NONE
6627074
D013390_D020879 NONE succinylcholine_15\NN|NONE (r_pobj) of_14\IN|the (r_prep) administration_13\NN|NONE (r_pobj) following_11\VBG|neuromuscular|prolonged (r_prep) blockade_10\NN|to
D013390_D001049 CID Succinylcholine_0\NN|attempted|.|: (r_compound) apnoea_1\NN|NONE
D013390_D001049 CID succinylcholine_14\NN|NONE (r_compound) apnoea_15\NN|NONE
3323599
D011479_D064420 NONE PS_9\NNP|NONE (r_pobj) of_8\IN|the (r_prep) administration_7\NN|and|that|produces|toxicity (r_nsubj) enhances_10\VBZ|Therefore|,|.|it|is (l_dobj) toxicity_12\NN|and|administration|that|produces
D011692_D007676 CID AMNS_14\NNP|NONE (r_pobj) of_13\IN|the|on (r_prep) toxicity_12\NN|and|administration|that|produces (r_dobj) enhances_10\VBZ|Therefore|,|.|it|is (l_conj) produces_20\VBZ|and|administration|that|toxicity (l_dobj) FSGS_22\NNS|readily (l_prep) in_23\IN|progressive (l_pobj) rats_24\NNS|NONE (l_acl) resulting_25\VBG|NONE (l_prep) in_26\IN|NONE (l_pobj) disease_32\NN|NONE
D011692_D064420 NONE AMNS_14\NNP|NONE (r_pobj) of_13\IN|the|on (r_prep) toxicity_12\NN|and|administration|that|produces
D011479_D007676 NONE PS_9\NNP|NONE (r_pobj) of_8\IN|the (r_prep) administration_7\NN|and|that|produces|toxicity (r_nsubj) enhances_10\VBZ|Therefore|,|.|it|is (l_conj) produces_20\VBZ|and|administration|that|toxicity (l_dobj) FSGS_22\NNS|readily (l_prep) in_23\IN|progressive (l_pobj) rats_24\NNS|NONE (l_acl) resulting_25\VBG|NONE (l_prep) in_26\IN|NONE (l_pobj) disease_32\NN|NONE
D011692_D009401 NONE aminonucleoside_3\JJ|NONE (r_amod) nephrosis_4\NN|NONE
D011692_D005923 CID aminonucleoside_22\NN|NONE (r_pobj) of_19\IN|combined|the (r_prep) administration_18\NN|NONE (r_pobj) by_15\IN|model|was|in|. (r_agent) developed_12\VBN|NONE (l_nsubjpass) model_2\NN|was|by|in|. (l_prep) of_3\IN|FSGS|experimental|(|An|) (l_pobj) sclerosis_7\NN|NONE
D011692_D005923 CID aminonucleoside_22\NN|NONE (r_pobj) of_19\IN|combined|the (r_prep) administration_18\NN|NONE (r_pobj) by_15\IN|model|was|in|. (r_agent) developed_12\VBN|NONE (l_nsubjpass) model_2\NN|was|by|in|. (l_appos) FSGS_9\NNP|of|experimental|(|An|)
D011692_D005923 CID AMNS_24\NNP|puromycin| (r_appos) aminonucleoside_22\NN|NONE (r_pobj) of_19\IN|combined|the (r_prep) administration_18\NN|NONE (r_pobj) by_15\IN|model|was|in|. (r_agent) developed_12\VBN|NONE (l_nsubjpass) model_2\NN|was|by|in|. (l_prep) of_3\IN|FSGS|experimental|(|An|) (l_pobj) sclerosis_7\NN|NONE
D011692_D005923 CID AMNS_24\NNP|puromycin| (r_appos) aminonucleoside_22\NN|NONE (r_pobj) of_19\IN|combined|the (r_prep) administration_18\NN|NONE (r_pobj) by_15\IN|model|was|in|. (r_agent) developed_12\VBN|NONE (l_nsubjpass) model_2\NN|was|by|in|. (l_appos) FSGS_9\NNP|of|experimental|(|An|)
D011692_D005923 CID AMNS_14\NNP|NONE (r_pobj) of_13\IN|the|on (r_prep) toxicity_12\NN|and|administration|that|produces (r_dobj) enhances_10\VBZ|Therefore|,|.|it|is (l_conj) produces_20\VBZ|and|administration|that|toxicity (l_dobj) FSGS_22\NNS|readily
D011479_D005923 NONE sulfate_28\NN|) (r_dobj) protamine_27\NN|)|and|( (r_conj) AMNS_24\NNP|puromycin| (r_appos) aminonucleoside_22\NN|NONE (r_pobj) of_19\IN|combined|the (r_prep) administration_18\NN|NONE (r_pobj) by_15\IN|model|was|in|. (r_agent) developed_12\VBN|NONE (l_nsubjpass) model_2\NN|was|by|in|. (l_prep) of_3\IN|FSGS|experimental|(|An|) (l_pobj) sclerosis_7\NN|NONE
D011479_D005923 NONE sulfate_28\NN|) (r_dobj) protamine_27\NN|)|and|( (r_conj) AMNS_24\NNP|puromycin| (r_appos) aminonucleoside_22\NN|NONE (r_pobj) of_19\IN|combined|the (r_prep) administration_18\NN|NONE (r_pobj) by_15\IN|model|was|in|. (r_agent) developed_12\VBN|NONE (l_nsubjpass) model_2\NN|was|by|in|. (l_appos) FSGS_9\NNP|of|experimental|(|An|)
D011479_D005923 NONE PS_30\NNP|NONE (r_appos) sulfate_28\NN|) (r_dobj) protamine_27\NN|)|and|( (r_conj) AMNS_24\NNP|puromycin| (r_appos) aminonucleoside_22\NN|NONE (r_pobj) of_19\IN|combined|the (r_prep) administration_18\NN|NONE (r_pobj) by_15\IN|model|was|in|. (r_agent) developed_12\VBN|NONE (l_nsubjpass) model_2\NN|was|by|in|. (l_prep) of_3\IN|FSGS|experimental|(|An|) (l_pobj) sclerosis_7\NN|NONE
D011479_D005923 NONE PS_30\NNP|NONE (r_appos) sulfate_28\NN|) (r_dobj) protamine_27\NN|)|and|( (r_conj) AMNS_24\NNP|puromycin| (r_appos) aminonucleoside_22\NN|NONE (r_pobj) of_19\IN|combined|the (r_prep) administration_18\NN|NONE (r_pobj) by_15\IN|model|was|in|. (r_agent) developed_12\VBN|NONE (l_nsubjpass) model_2\NN|was|by|in|. (l_appos) FSGS_9\NNP|of|experimental|(|An|)
D011479_D005923 NONE PS_9\NNP|NONE (r_pobj) of_8\IN|the (r_prep) administration_7\NN|and|that|produces|toxicity (r_nsubj) enhances_10\VBZ|Therefore|,|.|it|is (l_conj) produces_20\VBZ|and|administration|that|toxicity (l_dobj) FSGS_22\NNS|readily
24658375
D014212_D009220 CID acid_4\NN| (r_npadvmod) induced_6\VBN|.|inflammatory|retinoic|trans|in (r_amod) myositis_8\NN|NONE
D014212_D009220 CID ATRA_6\NNP| (r_npadvmod) induced_8\VBN|NONE (r_amod) myositis_9\NN|NONE
D014212_D015473 NONE acid_4\NN| (r_npadvmod) induced_6\VBN|.|inflammatory|retinoic|trans|in (r_amod) myositis_8\NN|NONE (l_prep) in_9\IN|induced|.|inflammatory|retinoic|trans (l_pobj) patient_11\NN|NONE (l_prep) with_12\IN|a (l_pobj) leukemia_15\NN|NONE
D014212_D015473 NONE acid_4\NN|is|with|. (l_appos) component_10\NN|,|trans|ATRA|,|retinoic (l_prep) for_14\IN|a|of (l_pobj) leukemia_17\NN|NONE
D014212_D015473 NONE acid_4\NN|is|with|. (l_appos) component_10\NN|,|trans|ATRA|,|retinoic (l_prep) for_14\IN|a|of (l_pobj) leukemia_17\NN|NONE (l_appos) APL_19\NNP|promyelocytic|(|)|acute
D014212_D015473 NONE ATRA_6\NNP|,|trans|component|,|retinoic (r_appos) acid_4\NN|is|with|. (l_appos) component_10\NN|,|trans|ATRA|,|retinoic (l_prep) for_14\IN|a|of (l_pobj) leukemia_17\NN|NONE
D014212_D015473 NONE ATRA_6\NNP|,|trans|component|,|retinoic (r_appos) acid_4\NN|is|with|. (l_appos) component_10\NN|,|trans|ATRA|,|retinoic (l_prep) for_14\IN|a|of (l_pobj) leukemia_17\NN|NONE (l_appos) APL_19\NNP|promyelocytic|(|)|acute
12535818
D000638_D001919 CID Amiodarone_0\NN|NONE (l_conj) risk_3\NN|and|. (l_prep) of_4\IN|requiring|the (l_pobj) bradyarrhythmia_5\JJ|NONE
D000638_D001919 CID amiodarone_14\NN|NONE (r_pobj) of_13\IN|the (r_prep) use_12\NN|risk|)|whether (r_nsubj) increases_23\VBZ|to (l_dobj) risk_25\NN|use|)|whether (l_prep) of_26\IN|the|requiring (l_pobj) bradyarrhythmia_27\NNS|NONE
D000638_D001919 CID amiodarone_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) during_4\IN|severe (r_prep) bradyarrhythmia_3\NN|NONE
D000638_D001919 CID amiodarone_7\NN|NONE (r_pobj) of_6\IN|the|and|MI (r_prep) use_5\NN|risk|that (r_nsubj) increases_17\VBZ|study|. (l_dobj) risk_19\NN|that|use (l_prep) of_20\IN|requiring|the (l_pobj) bradyarrhythmia_21\NNS|NONE
D000638_D001145 NONE amiodarone_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) during_4\IN|severe (r_prep) bradyarrhythmia_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Reports_0\NNS|.|infrequent (r_nsubj) are_7\VBP|NONE (l_acomp) infrequent_8\JJ|.|Reports (l_conj) limited_10\VBN|and (l_prep) to_11\IN|NONE (l_pobj) studies_12\NNS|NONE (l_acl) assessing_13\VBG|NONE (l_dobj) use_17\NN|NONE (l_prep) in_18\IN|therapy (l_pobj) management_20\NN|NONE (l_prep) of_21\IN|the (l_pobj) patients_22\NNS|NONE (l_prep) with_23\IN|NONE (l_pobj) arrhythmias_25\NNS|NONE
D000638_D009203 NONE Amiodarone_0\NN|NONE (l_conj) risk_3\NN|and|. (l_acl) requiring_6\VBG|of|the (l_dobj) pacemaker_8\NN|NONE (l_prep) in_9\IN|permanent (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|elderly (l_pobj) fibrillation_14\NN|NONE (l_conj) infarction_18\NN|and|atrial
D000638_D009203 NONE amiodarone_7\NN|NONE (r_pobj) of_6\IN|the|and|MI (r_prep) use_5\NN|risk|that (l_conj) MI_16\NNP|of|the|and
D000638_D001281 NONE Amiodarone_0\NN|NONE (l_conj) risk_3\NN|and|. (l_acl) requiring_6\VBG|of|the (l_dobj) pacemaker_8\NN|NONE (l_prep) in_9\IN|permanent (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|elderly (l_pobj) fibrillation_14\NN|NONE
D000638_D001281 NONE amiodarone_14\NN|NONE (l_prep) in_15\IN|NONE (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) fibrillation_19\NN|NONE
D000638_D001281 NONE amiodarone_14\NN|NONE (l_prep) in_15\IN|NONE (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) fibrillation_19\NN|NONE (l_appos) AF_21\NNP|atrial|(
D000638_D001281 NONE amiodarone_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|elderly (l_pobj) AF_12\NNP|NONE
2429800
D014403_D007022 CID tubocurarine_5\NN| (r_advmod) induced_7\VBN|d|in (r_amod) hypotension_8\NN|Histamine|and|.
D006632_D007022 NONE Histamine_0\NN|and|.|hypotension (r_amod) antagonists_1\NNS|NONE (l_conj) hypotension_8\NN|Histamine|and|.
2765447
D019793_D012640 NONE fluorescein_3\NN|intravenous (r_amod) angiography_4\NN|NONE (r_dobj) following_1\VBG|. (r_prep) Convulsion_0\NNP|NONE
D019793_D004830 CID fluorescein_6\NN|for|in|intravenous (r_amod) injection_7\NN|seizures|. (r_dobj) followed_4\VBD|NONE (l_nsubj) seizures_3\NNS|injection|.
3685052
D004986_D007035 NONE ether_1\NN|hypothermia (r_nsubj) produced_2\VBD|.|unclear|;|however|,|relationship (l_dobj) hypothermia_3\NN|ether
D004986_D007035 NONE ether_1\NN|hypothermia (r_nsubj) produced_2\VBD|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD|NONE (l_nsubj) relationship_17\NN|.|unclear|;|produced|however|, (l_prep) of_18\IN|the|to (l_pobj) hypothermia_19\NN|NONE
D009270_D012640 NONE naloxone_1\NN|mg/kg|)|( (r_nmod) challenge_6\NN|also|in|ineffective|. (r_nsubj) was_7\VBD|NONE (l_prep) in_10\IN|also|ineffective|challenge|. (l_pcomp) altering_11\VBG|NONE (l_dobj) thresholds_14\NNS|NONE (l_compound) seizure_13\NN|of|the
D005481_D012640 NONE Flurothyl_0\JJ|seizure|in (r_compound) thresholds_2\NNS|.|neonatally|evaluation|:|with (l_compound) seizure_1\NN|in|Flurothyl
D005481_D012640 NONE Flurothyl_0\JJ|seizure|in (r_compound) thresholds_2\NNS|.|neonatally|evaluation|:|with (r_nsubj) treated_5\VBD|NONE (l_dobj) evaluation_18\NN|.|neonatally|thresholds|:|with (l_prep) of_19\IN|NONE (l_pobj) parameters_21\NNS|NONE (l_prep) in_22\IN|experimental (l_pobj) testing_25\NN|NONE (l_compound) seizure_24\NN|flurothyl
D005481_D012640 NONE flurothyl_23\JJ|seizure (r_compound) testing_25\NN|NONE (r_pobj) in_22\IN|experimental (r_prep) parameters_21\NNS|NONE (r_pobj) of_19\IN|NONE (r_prep) evaluation_18\NN|.|neonatally|thresholds|:|with (r_dobj) treated_5\VBD|NONE (l_nsubj) thresholds_2\NNS|.|neonatally|evaluation|:|with (l_compound) seizure_1\NN|in|Flurothyl
D005481_D012640 NONE flurothyl_23\JJ|seizure (r_compound) testing_25\NN|NONE (l_compound) seizure_24\NN|flurothyl
D005481_D012640 NONE flurothyl_1\JJ|ether|screening|A (r_nmod) technique_5\NN|.|was|)|evaluate (l_compound) screening_4\NN|ether|flurothyl|A (l_compound) seizure_3\NN|NONE
D005481_D012640 NONE flurothyl_1\JJ|ether|screening|A (r_nmod) technique_5\NN|.|was|)|evaluate (r_nsubjpass) used_7\VBN|NONE (l_xcomp) evaluate_9\VB|.|was|technique|) (l_dobj) susceptibility_11\NN|to (l_compound) seizure_10\NN|in|received
D005481_D012640 NONE Flurothyl_0\NNP|NONE (r_compound) ether_1\NN|hypothermia (r_nsubj) produced_2\VBD|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD|NONE (l_nsubj) relationship_17\NN|.|unclear|;|produced|however|, (l_prep) to_20\IN|of|the (l_pobj) induction_22\NN|NONE (l_compound) seizure_21\NN|NONE
D005481_D012640 NONE flurothyl_11\JJ|NONE (r_compound) exposure_12\NN|NONE (r_pobj) of_10\IN|the (r_prep) duration_9\NN|NONE (r_pobj) with_7\IN|was|which (r_prep) correlated_6\VBN|NONE (r_relcl) hypothermia_3\NN|ether (r_dobj) produced_2\VBD|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD|NONE (l_nsubj) relationship_17\NN|.|unclear|;|produced|however|, (l_prep) to_20\IN|of|the (l_pobj) induction_22\NN|NONE (l_compound) seizure_21\NN|NONE
D005481_D012640 NONE Flurothyl_0\JJ|seizure (r_compound) testing_2\NN|be|. (l_compound) seizure_1\NN|Flurothyl
D005481_D012640 NONE Flurothyl_0\JJ|seizure (r_compound) testing_2\NN|be|. (r_nsubj) proved_3\VBD|NONE (l_xcomp) be_5\VB|testing|. (l_attr) technique_10\NN|to (l_relcl) evaluate_14\VB|a|rapid (l_dobj) susceptibility_16\NN|to|with (l_compound) seizure_15\NN|NONE
D005481_D007035 CID Flurothyl_0\NNP|NONE (r_compound) ether_1\NN|hypothermia (r_nsubj) produced_2\VBD|.|unclear|;|however|,|relationship (l_dobj) hypothermia_3\NN|ether
D005481_D007035 CID Flurothyl_0\NNP|NONE (r_compound) ether_1\NN|hypothermia (r_nsubj) produced_2\VBD|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD|NONE (l_nsubj) relationship_17\NN|.|unclear|;|produced|however|, (l_prep) of_18\IN|the|to (l_pobj) hypothermia_19\NN|NONE
D005481_D007035 CID flurothyl_11\JJ|NONE (r_compound) exposure_12\NN|NONE (r_pobj) of_10\IN|the (r_prep) duration_9\NN|NONE (r_pobj) with_7\IN|was|which (r_prep) correlated_6\VBN|NONE (r_relcl) hypothermia_3\NN|ether
D005481_D007035 CID flurothyl_11\JJ|NONE (r_compound) exposure_12\NN|NONE (r_pobj) of_10\IN|the (r_prep) duration_9\NN|NONE (r_pobj) with_7\IN|was|which (r_prep) correlated_6\VBN|NONE (r_relcl) hypothermia_3\NN|ether (r_dobj) produced_2\VBD|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD|NONE (l_nsubj) relationship_17\NN|.|unclear|;|produced|however|, (l_prep) of_18\IN|the|to (l_pobj) hypothermia_19\NN|NONE
D012970_D012640 NONE glutamate_13\NN|NONE (r_pobj) of_11\IN|a|single (r_prep) injection_10\NN|NONE (r_pobj) with_7\IN|.|neonatally|thresholds|evaluation|: (r_prep) treated_5\VBD|NONE (l_nsubj) thresholds_2\NNS|.|neonatally|evaluation|:|with (l_compound) seizure_1\NN|in|Flurothyl
D012970_D012640 NONE glutamate_13\NN|NONE (r_pobj) of_11\IN|a|single (r_prep) injection_10\NN|NONE (r_pobj) with_7\IN|.|neonatally|thresholds|evaluation|: (r_prep) treated_5\VBD|NONE (l_dobj) evaluation_18\NN|.|neonatally|thresholds|:|with (l_prep) of_19\IN|NONE (l_pobj) parameters_21\NNS|NONE (l_prep) in_22\IN|experimental (l_pobj) testing_25\NN|NONE (l_compound) seizure_24\NN|flurothyl
D012970_D012640 NONE MSG_15\NNP|monosodium (r_appos) glutamate_13\NN|NONE (r_pobj) of_11\IN|a|single (r_prep) injection_10\NN|NONE (r_pobj) with_7\IN|.|neonatally|thresholds|evaluation|: (r_prep) treated_5\VBD|NONE (l_nsubj) thresholds_2\NNS|.|neonatally|evaluation|:|with (l_compound) seizure_1\NN|in|Flurothyl
D012970_D012640 NONE MSG_15\NNP|monosodium (r_appos) glutamate_13\NN|NONE (r_pobj) of_11\IN|a|single (r_prep) injection_10\NN|NONE (r_pobj) with_7\IN|.|neonatally|thresholds|evaluation|: (r_prep) treated_5\VBD|NONE (l_dobj) evaluation_18\NN|.|neonatally|thresholds|:|with (l_prep) of_19\IN|NONE (l_pobj) parameters_21\NNS|NONE (l_prep) in_22\IN|experimental (l_pobj) testing_25\NN|NONE (l_compound) seizure_24\NN|flurothyl
D012970_D012640 NONE glutamate_1\NN|(|)|MSG|to (r_nmod) administration_5\NN|convulsions|.|in (r_nsubj) produces_9\VBZ|NONE (l_dobj) convulsions_10\NNS|.|administration|in
D012970_D012640 NONE MSG_3\NNP|(|)|glutamate|to (r_nmod) administration_5\NN|convulsions|.|in (r_nsubj) produces_9\VBZ|NONE (l_dobj) convulsions_10\NNS|.|administration|in
D012970_D012640 NONE MSG_10\NNP|NONE (r_pobj) of_9\IN|neonatal (r_prep) administration_8\NN|if|alterations (r_nsubj) produced_11\VBD|to (l_dobj) alterations_13\NNS|if|administration (l_prep) in_14\IN|permanent (l_pobj) susceptibility_16\NN|NONE (l_compound) seizure_15\NN|NONE
D012970_D012640 NONE MSG_20\NNP|NONE (r_pobj) of_19\IN|g|neonatal (r_prep) injections_18\NNS|that (r_dobj) received_16\VBD|seizure|in (r_relcl) susceptibility_11\NN|to (r_dobj) evaluate_9\VB|.|was|technique|) (r_xcomp) used_7\VBN|NONE (l_nsubjpass) technique_5\NN|.|was|)|evaluate (l_compound) screening_4\NN|ether|flurothyl|A (l_compound) seizure_3\NN|NONE
D012970_D012640 NONE MSG_20\NNP|NONE (r_pobj) of_19\IN|g|neonatal (r_prep) injections_18\NNS|that (r_dobj) received_16\VBD|seizure|in (r_relcl) susceptibility_11\NN|to (l_compound) seizure_10\NN|in|received
D012970_D012640 NONE MSG_0\NNP|NONE (r_compound) treatment_1\NN|alter|.|in|but (r_nsubj) resulted_2\VBD|NONE (l_conj) alter_13\VB|treatment|.|in|but (l_dobj) threshold_15\NN|did|not (l_compound) seizure_14\NN|NONE
D012970_D012640 NONE MSG_19\NNP| (r_npadvmod) treated_21\VBN|NONE (r_amod) mice_22\NNS|NONE (r_pobj) of_18\IN|either (r_prep) control_17\NN|NONE (r_pobj) of_15\IN|seizure|the (r_prep) thresholds_14\NNS|NONE (l_compound) seizure_13\NN|of|the
D004986_D012640 NONE ether_2\NN|flurothyl|screening|A (r_compound) technique_5\NN|.|was|)|evaluate (l_compound) screening_4\NN|ether|flurothyl|A (l_compound) seizure_3\NN|NONE
D004986_D012640 NONE ether_2\NN|flurothyl|screening|A (r_compound) technique_5\NN|.|was|)|evaluate (r_nsubjpass) used_7\VBN|NONE (l_xcomp) evaluate_9\VB|.|was|technique|) (l_dobj) susceptibility_11\NN|to (l_compound) seizure_10\NN|in|received
D004986_D012640 NONE ether_1\NN|hypothermia (r_nsubj) produced_2\VBD|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD|NONE (l_nsubj) relationship_17\NN|.|unclear|;|produced|however|, (l_prep) to_20\IN|of|the (l_pobj) induction_22\NN|NONE (l_compound) seizure_21\NN|NONE
1360900
D005680_D012640 NONE acid_34\NN|NONE (r_pobj) of_30\IN|the (r_prep) synthesis_29\NN|NONE (r_dobj) suppressed_27\VBD|turnover|but|)|.|injection (r_conj) accelerated_16\VBD|NONE (l_nsubj) injection_1\NN|turnover|but|)|.|suppressed (l_prep) of_2\IN|Intracerebroventricular|mouse (l_pobj) acid_4\NN|NONE (l_appos) dose_9\NN|ethacrynic (l_amod) convulsive_8\JJ|%|(
D012701_D012640 NONE 5-hydroxytryptamine_22\CD|NONE (r_pobj) of_21\IN|/|synthesis|the (r_prep) turnover_20\NN|but|)|.|injection|suppressed (r_dobj) accelerated_16\VBD|NONE (l_nsubj) injection_1\NN|turnover|but|)|.|suppressed (l_prep) of_2\IN|Intracerebroventricular|mouse (l_pobj) acid_4\NN|NONE (l_appos) dose_9\NN|ethacrynic (l_amod) convulsive_8\JJ|%|(
D012701_D012640 NONE 5-HT_24\CD|NONE (r_appos) 5-hydroxytryptamine_22\CD|NONE (r_pobj) of_21\IN|/|synthesis|the (r_prep) turnover_20\NN|but|)|.|injection|suppressed (r_dobj) accelerated_16\VBD|NONE (l_nsubj) injection_1\NN|turnover|but|)|.|suppressed (l_prep) of_2\IN|Intracerebroventricular|mouse (l_pobj) acid_4\NN|NONE (l_appos) dose_9\NN|ethacrynic (l_amod) convulsive_8\JJ|%|(
D004976_D012640 CID acid_1\NN| (r_npadvmod) induced_3\VBN|neurotransmitters|.|in|Ethacrynic|and (r_amod) convulsions_4\NNS|NONE
D004976_D012640 CID acid_4\NN|NONE (l_appos) dose_9\NN|ethacrynic (l_amod) convulsive_8\JJ|%|(
D004976_D012640 CID acid_2\NN| (r_npadvmod) induced_4\VBN|ethacrynic (r_amod) convulsions_5\NNS|NONE
D000109_D012640 NONE acetylcholine_36\NN|aminobutyric|and (r_conj) acid_34\NN|NONE (r_pobj) of_30\IN|the (r_prep) synthesis_29\NN|NONE (r_dobj) suppressed_27\VBD|turnover|but|)|.|injection (r_conj) accelerated_16\VBD|NONE (l_nsubj) injection_1\NN|turnover|but|)|.|suppressed (l_prep) of_2\IN|Intracerebroventricular|mouse (l_pobj) acid_4\NN|NONE (l_appos) dose_9\NN|ethacrynic (l_amod) convulsive_8\JJ|%|(
11026989
D014331_D015878 CID tropicamide_6\NN|NONE (r_pobj) with_5\IN|pupil (r_prep) dilation_4\NN|NONE
D014331_D015878 CID tropicamide_28\NN|guttae (r_advmod) using_26\VBG|pupil (r_acl) dilation_25\NN|NONE
24729111
D000638_D007035 CID amiodarone_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|for (r_prep) initiation_18\NN|weeks (r_pobj) after_17\IN|bradycardia|to (r_prep) have_8\VB|.|man|was (l_dobj) bradycardia_9\VBN|after|to (l_conj) hypothermia_11\NN|,
D000638_D003128 CID Amiodarone_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) myxoedema_3\NN|. (r_compound) coma_4\NN|NONE
D000638_D003128 CID amiodarone_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) myxoedema_8\NN|in (r_compound) coma_9\NN|NONE
D000638_D003128 CID amiodarone_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) myxoedema_12\NN|with (r_compound) coma_13\NN|NONE
D000638_D012131 CID amiodarone_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|for (r_prep) initiation_18\NN|weeks (r_pobj) after_17\IN|bradycardia|to (r_prep) have_8\VB|.|man|was (l_dobj) bradycardia_9\VBN|after|to (l_conj) hypothermia_11\NN|, (l_conj) failure_14\NN|and
D000638_D013959 NONE amiodarone_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) myxoedema_12\NN|with (r_compound) coma_13\NN|NONE (l_prep) with_14\IN|myxoedema (l_pobj) history_16\NN|NONE (l_amod) significant_17\JJ|a (l_prep) for_18\IN|NONE (l_pobj) disease_21\NN|NONE
D000638_D001919 CID amiodarone_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|for (r_prep) initiation_18\NN|weeks (r_pobj) after_17\IN|bradycardia|to (r_prep) have_8\VB|.|man|was (l_dobj) bradycardia_9\VBN|after|to
D000638_D001281 NONE amiodarone_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|for (r_prep) initiation_18\NN|weeks (l_prep) for_22\IN|of (l_pobj) fibrillation_24\NN|NONE
D000638_D007037 CID Amiodarone_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) myxoedema_3\NN|. (r_compound) coma_4\NN|NONE
D000638_D007037 CID amiodarone_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) myxoedema_8\NN|in (r_compound) coma_9\NN|NONE
D000638_D007037 CID amiodarone_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) myxoedema_12\NN|with (r_compound) coma_13\NN|NONE
15282950
D007545_D009202 CID isoproterenol_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|against|.|effect (r_advcl) chebula_4\NN|NONE (l_prep) against_5\IN|induced|.|effect (l_pobj) injury_8\NN|NONE
D007545_D009202 CID isoproterenol_18\NN|NONE (r_pobj) in_17\IN|.|induced|effect|was|body (r_prep) examined_16\VBN|NONE (l_conj) induced_25\VBN|.|effect|in|was|body (l_dobj) damage_27\NN|NONE
D010936_D009202 NONE chebula_4\NN|NONE (l_prep) against_5\IN|induced|.|effect (l_pobj) injury_8\NN|NONE
D010936_D009202 NONE fruits_8\NNS|NONE (r_pobj) of_5\IN|ethanolic (r_prep) extract_4\NN|NONE (r_pobj) of_2\IN|Cardioprotective (r_prep) effect_1\NN|.|induced|in|was|body (r_nsubjpass) examined_16\VBN|NONE (l_conj) induced_25\VBN|.|effect|in|was|body (l_dobj) damage_27\NN|NONE
11105626
D015474_D065817 CID isotretinoin_21\VB|NONE (r_pobj) to_20\IN|within (r_prep) exposure_19\NN|to (r_pobj) due_17\IN|.|We|infant (r_prep) report_1\VBP|NONE (l_dobj) infant_4\NN|.|We|due (l_prep) with_5\IN|newborn|a (l_pobj) anomalies_8\NNS|NONE (l_appos) anotia_10\NN|)|(|congenital|multiple
D015474_D004310 CID isotretinoin_21\VB|NONE (r_pobj) to_20\IN|within (r_prep) exposure_19\NN|to (r_pobj) due_17\IN|.|We|infant (r_prep) report_1\VBP|NONE (l_dobj) infant_4\NN|.|We|due (l_prep) with_5\IN|newborn|a (l_pobj) anomalies_8\NNS|NONE (l_appos) anotia_10\NN|)|(|congenital|multiple (l_conj) malformation_15\NN|and
1420650
D003024_D020258 NONE clozapine_29\NN|or (r_conj) lithium_27\NN|NONE (r_pobj) as_26\IN|certain (r_prep) drugs_25\NNS|are|if|in (r_nsubjpass) used_31\VBN|We|be|.|, (r_advcl) consider_1\VBP|NONE (l_ccomp) be_4\VB|We|.|used|, (l_attr) sign_8\NN|asterixis|to (l_prep) of_9\IN|an|overlooked (l_pobj) neurotoxicity_10\NN|NONE
D002220_D020820 NONE carbamazepine_3\NN|NONE (r_compound) therapy_4\NN|NONE (r_pobj) by_2\IN|.|Asterixis (r_agent) induced_1\VBN|NONE (l_nsubj) Asterixis_0\NNS|by|.
D002220_D020820 NONE carbamazepine_24\NN|to (r_dobj) adding_23\VBG|either (r_pcomp) by_22\IN|was|asterixis|in (r_prep) triggered_20\VBN|,|different|psychotropic (l_nsubjpass) asterixis_18\NNS|was|by|in
D002220_D020820 NONE CBZ_26\NNP|)|( (r_appos) carbamazepine_24\NN|to (r_dobj) adding_23\VBG|either (r_pcomp) by_22\IN|was|asterixis|in (r_prep) triggered_20\VBN|,|different|psychotropic (l_nsubjpass) asterixis_18\NNS|was|by|in
D002220_D020820 NONE CBZ_35\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) combination_33\NN|NONE (r_pobj) in_32\IN|are|if|drugs (r_prep) used_31\VBN|We|be|.|, (r_advcl) consider_1\VBP|NONE (l_ccomp) be_4\VB|We|.|used|, (l_nsubj) asterixis_2\NNS|sign|to
D008094_D020820 CID lithium_27\NN|NONE (r_pobj) as_26\IN|certain (r_prep) drugs_25\NNS|are|if|in (r_nsubjpass) used_31\VBN|We|be|.|, (r_advcl) consider_1\VBP|NONE (l_ccomp) be_4\VB|We|.|used|, (l_nsubj) asterixis_2\NNS|sign|to
D002220_D020258 NONE CBZ_35\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) combination_33\NN|NONE (r_pobj) in_32\IN|are|if|drugs (r_prep) used_31\VBN|We|be|.|, (r_advcl) consider_1\VBP|NONE (l_ccomp) be_4\VB|We|.|used|, (l_attr) sign_8\NN|asterixis|to (l_prep) of_9\IN|an|overlooked (l_pobj) neurotoxicity_10\NN|NONE
D003024_D020820 CID clozapine_29\NN|or (r_conj) lithium_27\NN|NONE (r_pobj) as_26\IN|certain (r_prep) drugs_25\NNS|are|if|in (r_nsubjpass) used_31\VBN|We|be|.|, (r_advcl) consider_1\VBP|NONE (l_ccomp) be_4\VB|We|.|used|, (l_nsubj) asterixis_2\NNS|sign|to
D008094_D020258 NONE lithium_27\NN|NONE (r_pobj) as_26\IN|certain (r_prep) drugs_25\NNS|are|if|in (r_nsubjpass) used_31\VBN|We|be|.|, (r_advcl) consider_1\VBP|NONE (l_ccomp) be_4\VB|We|.|used|, (l_attr) sign_8\NN|asterixis|to (l_prep) of_9\IN|an|overlooked (l_pobj) neurotoxicity_10\NN|NONE
3746148
D004176_D003324 NONE dipyridamole_14\NN|NONE (r_compound) infusion_15\NN|NONE (r_pobj) after_13\IN|invasive|by|of|. (r_prep) detection_3\NN|NONE (l_prep) of_4\IN|after|invasive|by|. (l_pobj) disease_7\NN|NONE
D004176_D003324 NONE dipyridamole_3\NN|NONE (r_compound) infusion_4\NN|NONE (r_pobj) after_2\IN|Electrocardiographic|min (r_prep) changes_1\NNS|.|and|compared|were|in (r_nsubjpass) studied_13\VBN|NONE (l_prep) in_14\IN|changes|.|and|compared|were (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN| (l_pobj) disease_20\NN|NONE
D004176_D003324 NONE dipyridamole_4\NN|ECG|the (r_compound) test_6\NN|useful|that (r_nsubj) is_7\VBZ|We|. (l_acomp) useful_9\JJ|test|that (l_prep) as_10\IN|as (l_pobj) test_14\NN|NONE (l_prep) for_15\IN|the|ECG (l_pobj) assessment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) disease_21\NN|NONE
D004176_D009203 NONE dipyridamole_1\NN|NONE (r_pobj) After_0\IN|was|mV|depression|,|.|in (r_prep) observed_15\VBN|NONE (l_prep) in_16\IN|was|After|mV|depression|,|. (l_pobj) %_18\NN|NONE (l_prep) of_19\IN||,|% (l_pobj) group_24\NN|NONE (l_compound) MI_23\NNP|the
D004176_D017202 CID dipyridamole_5\NN| (r_npadvmod) induced_7\VBN|the|myocardial (r_amod) ischemia_9\NN|that|by|is
D004176_D003866 NONE dipyridamole_1\NN|NONE (r_pobj) After_0\IN|was|mV|depression|,|.|in (r_prep) observed_15\VBN|NONE (l_nsubjpass) depression_7\NN|was|After|mV|,|.|in
D004176_D007511 NONE dipyridamole_1\NN|NONE (r_pobj) After_0\IN|was|mV|depression|,|.|in (r_prep) observed_15\VBN|NONE (l_nsubjpass) depression_7\NN|was|After|mV|,|.|in (l_amod) ischemic_3\JJ|segment
D004176_D056989 NONE dipyridamole_1\NN|NONE (r_pobj) After_0\IN|was|mV|depression|,|.|in (r_prep) observed_15\VBN|NONE (l_prep) in_16\IN|was|After|mV|depression|,|. (l_pobj) %_18\NN|NONE (l_appos) %_27\NN|of||, (l_appos) %_36\NN|,|of| (l_prep) of_37\IN|and|%| (l_pobj) group_42\NN|NONE (l_compound) MI_41\NNP|the
D004176_D056988 NONE dipyridamole_1\NN|NONE (r_pobj) After_0\IN|was|mV|depression|,|.|in (r_prep) observed_15\VBN|NONE (l_prep) in_16\IN|was|After|mV|depression|,|. (l_pobj) %_18\NN|NONE (l_appos) %_27\NN|of||, (l_prep) of_28\IN|,|%| (l_pobj) group_33\NN|NONE (l_compound) MI_32\NNP|the
24055495
D005690_D003072 CID galactose_4\NN|term (r_compound) treatment_5\NN|deficits|. (r_nsubj) prevents_6\VBZ|NONE (l_dobj) deficits_8\NNS|treatment|.
D005690_D003072 CID galactose_9\NN|NONE (l_appos) treatment_18\NN|continuous|daily|oral (l_prep) on_19\IN|kg|(|)|in (l_pobj) deficits_21\NNS|NONE
D005690_D003072 CID galactose_4\NN|oral (r_compound) treatment_5\NN|NONE (r_pobj) of_2\IN|One (r_prep) month_1\NN|prevented|after|immediately|.|, (r_nsubj) initiated_6\VBD|NONE (l_conj) prevented_16\VBN|after|month|immediately|.|, (l_dobj) development_17\NN|successfully (l_prep) of_18\IN|NONE (l_pobj) deficits_26\NNS|NONE
D005690_D003072 CID galactose_1\NN|Oral (r_compound) exposure_2\NN|effects|and|be|.|might (r_nsubj) have_4\VB|NONE (l_conj) be_14\VB|effects|and|.|might|exposure (l_acomp) worth_15\JJ|could (l_xcomp) investigating_16\VBG|NONE (l_prep) for_17\IN|NONE (l_pobj) improvement_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) deficits_21\NNS|NONE
D005690_D008569 NONE galactose_5\NN|NONE (r_pobj) of_4\IN|Exclusively|daily|parenteral (r_prep) injections_3\NNS|,|tested|used|and|but|deterioration (r_nsubj) induce_6\VBP|NONE (l_dobj) deterioration_8\NN|,|tested|used|and|but|injections
D005690_D008569 NONE galactose_25\NN|on|oral (r_compound) treatment_26\NN|NONE (r_pobj) of_23\IN|the (r_prep) effects_22\NNS|.|have|never|been (r_nsubjpass) tested_33\VBN|,|used|and|but|injections|deterioration (r_conj) induce_6\VBP|NONE (l_dobj) deterioration_8\NN|,|tested|used|and|but|injections
D005947_D000544 CID glucose_33\NN|and|metabolism|decreased|via (r_compound) transport_34\NN|NONE (r_pobj) by_31\IN|NONE (r_agent) followed_30\VBN|of (r_acl) dysfunction_20\NN|NONE (r_pobj) with_19\IN|that|is|dementia (r_prep) associated_18\VBN|has|research|. (l_nsubjpass) dementia_7\NN|that|with|is (l_prep) of_8\IN|NONE (l_pobj) type_16\NN|NONE (l_nmod) disease_12\NN|(|)|sAD
D005947_D000544 CID glucose_36\NN|transporter (r_compound) GLUT4_38\NNPS|NONE (r_pobj) via_35\IN|and|glucose|metabolism|decreased (r_prep) transport_34\NN|NONE (r_pobj) by_31\IN|NONE (r_agent) followed_30\VBN|of (r_acl) dysfunction_20\NN|NONE (r_pobj) with_19\IN|that|is|dementia (r_prep) associated_18\VBN|has|research|. (l_nsubjpass) dementia_7\NN|that|with|is (l_prep) of_8\IN|NONE (l_pobj) type_16\NN|NONE (l_nmod) disease_12\NN|(|)|sAD
D005947_D000544 CID glucose_41\NN|in|decreased (r_compound) metabolism_42\NN|and|glucose|decreased|via (r_conj) transport_34\NN|NONE (r_pobj) by_31\IN|NONE (r_agent) followed_30\VBN|of (r_acl) dysfunction_20\NN|NONE (r_pobj) with_19\IN|that|is|dementia (r_prep) associated_18\VBN|has|research|. (l_nsubjpass) dementia_7\NN|that|with|is (l_prep) of_8\IN|NONE (l_pobj) type_16\NN|NONE (l_nmod) disease_12\NN|(|)|sAD
D013311_D003072 CID streptozotocin_16\NNS|NONE (r_pobj) with_15\IN|intracerebroventricularly (r_prep) treated_13\VBD|cognitive|in (r_acl) deficits_8\NNS|treatment|.
D013311_D003072 CID streptozotocin_23\NNS| (r_npadvmod) induced_25\VBN|)|icv|rat|(|of|,|tested (r_amod) model_32\NN|NONE (r_pobj) in_22\IN|on|kg|(|) (r_prep) treatment_18\NN|continuous|daily|oral (l_prep) on_19\IN|kg|(|)|in (l_pobj) deficits_21\NNS|NONE
D013311_D003072 CID STZ_27\NNP| (r_nmod) icv_29\NN|)|induced|rat|(|of|,|tested (r_nmod) model_32\NN|NONE (r_pobj) in_22\IN|on|kg|(|) (r_prep) treatment_18\NN|continuous|daily|oral (l_prep) on_19\IN|kg|(|)|in (l_pobj) deficits_21\NNS|NONE
D013311_D003072 CID STZ_10\NNP| (r_compound) icv_12\NN|the (r_compound) administration_13\NN|NONE (r_pobj) after_8\IN|prevented|month|immediately|.|, (r_prep) initiated_6\VBD|NONE (l_conj) prevented_16\VBN|after|month|immediately|.|, (l_dobj) development_17\NN|successfully (l_prep) of_18\IN|NONE (l_pobj) deficits_26\NNS|NONE
D013311_D003072 CID STZ_20\NNP| (r_compound) icv_22\NN| (r_npadvmod) induced_24\VBN|cognitive|the (r_amod) deficits_26\NNS|NONE
D005947_D003704 NONE glucose_33\NN|and|metabolism|decreased|via (r_compound) transport_34\NN|NONE (r_pobj) by_31\IN|NONE (r_agent) followed_30\VBN|of (r_acl) dysfunction_20\NN|NONE (r_pobj) with_19\IN|that|is|dementia (r_prep) associated_18\VBN|has|research|. (l_nsubjpass) dementia_7\NN|that|with|is
D005947_D003704 NONE glucose_36\NN|transporter (r_compound) GLUT4_38\NNPS|NONE (r_pobj) via_35\IN|and|glucose|metabolism|decreased (r_prep) transport_34\NN|NONE (r_pobj) by_31\IN|NONE (r_agent) followed_30\VBN|of (r_acl) dysfunction_20\NN|NONE (r_pobj) with_19\IN|that|is|dementia (r_prep) associated_18\VBN|has|research|. (l_nsubjpass) dementia_7\NN|that|with|is
D005947_D003704 NONE glucose_41\NN|in|decreased (r_compound) metabolism_42\NN|and|glucose|decreased|via (r_conj) transport_34\NN|NONE (r_pobj) by_31\IN|NONE (r_agent) followed_30\VBN|of (r_acl) dysfunction_20\NN|NONE (r_pobj) with_19\IN|that|is|dementia (r_prep) associated_18\VBN|has|research|. (l_nsubjpass) dementia_7\NN|that|with|is
D005690_D000544 NONE galactose_1\NN|Oral (r_compound) exposure_2\NN|effects|and|be|.|might (r_nsubj) have_4\VB|NONE (l_conj) be_14\VB|effects|and|.|might|exposure (l_acomp) worth_15\JJ|could (l_xcomp) investigating_16\VBG|NONE (l_prep) for_17\IN|NONE (l_pobj) improvement_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) deficits_21\NNS|NONE (l_acl) associated_22\VBN|cognitive (l_prep) with_23\IN|NONE (l_pobj) hypometabolism_25\NN|NONE (l_prep) in_26\IN|glucose (l_pobj) AD_27\NN|NONE
D005690_D018149 NONE galactose_1\NN|Oral (r_compound) exposure_2\NN|effects|and|be|.|might (r_nsubj) have_4\VB|NONE (l_conj) be_14\VB|effects|and|.|might|exposure (l_acomp) worth_15\JJ|could (l_xcomp) investigating_16\VBG|NONE (l_prep) for_17\IN|NONE (l_pobj) improvement_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) deficits_21\NNS|NONE (l_acl) associated_22\VBN|cognitive (l_prep) with_23\IN|NONE (l_pobj) hypometabolism_25\NN|NONE
24220752
D003287_D009369 NONE contrast_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) nephropathy_5\NN|NONE (r_pobj) of_1\IN|.|in (r_prep) Incidence_0\NN|NONE (l_prep) in_6\IN|.|of (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|hospitalised (l_pobj) cancer_10\NN|NONE
D003287_D009369 NONE contrast_10\NN| (r_npadvmod) induced_12\VBN|CIN|(|) (r_amod) nephropathy_13\NN|NONE (r_pobj) to_9\IN|in (r_prep) related_8\VBN|possible (l_prep) in_17\IN|to (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|hospitalised (l_pobj) cancer_21\NN|NONE
C051890_D006973 NONE irinotecan_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|more|in|and (r_pobj) after_4\IN|.|CIN (l_conj) in_16\IN|more|treatment|and (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) hypertension_19\NN|NONE
C051890_D006973 NONE irinotecan_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) combination_3\NN|and (r_conj) Hypertension_0\NN|factors|.|may
-1_D006973 NONE bevacizumab_7\NN|P|/|( (r_amod) irinotecan_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|more|in|and (r_pobj) after_4\IN|.|CIN (l_conj) in_16\IN|more|treatment|and (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) hypertension_19\NN|NONE
-1_D006973 NONE bevacizumab_5\NN|/ (r_amod) irinotecan_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) combination_3\NN|and (r_conj) Hypertension_0\NN|factors|.|may
-1_D006973 NONE bevacizumab_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) treatment_2\NN|and (r_conj) Hypertension_0\NN|.|be
D003287_D007674 CID contrast_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) nephropathy_5\NN|NONE
D003287_D007674 CID contrast_10\NN| (r_npadvmod) induced_12\VBN|CIN|(|) (r_amod) nephropathy_13\NN|NONE
D003287_D007674 CID Contrast_0\RB| (r_npadvmod) induced_2\VBN|is (r_amod) nephropathy_3\NN|NONE
17069550
D005702_D019958 NONE galantamine_5\NN|and|.|appeared|tolerated|In|, (r_nsubj) was_6\VBD|NONE (l_conj) appeared_11\VBD|and|.|tolerated|In|,|galantamine (l_xcomp) be_13\VB|NONE (l_acomp) beneficial_14\JJ|to (l_prep) for_15\IN|NONE (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pcomp) interfering_19\VBG|NONE (l_dobj) behaviors_20\NNS|NONE (l_prep) in_21\IN|NONE (l_pobj) children_22\NNS|NONE (l_prep) with_23\IN|NONE (l_pobj) autism_24\NN|NONE (l_appos) aggression_27\NN|, (l_conj) dyscontrol_30\NN|particularly|, (l_conj) inattention_33\NN|behavioral|,|and
D005702_D001523 NONE galantamine_5\NN|and|.|appeared|tolerated|In|, (r_nsubj) was_6\VBD|NONE (l_conj) appeared_11\VBD|and|.|tolerated|In|,|galantamine (l_xcomp) be_13\VB|NONE (l_acomp) beneficial_14\JJ|to (l_prep) for_15\IN|NONE (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pcomp) interfering_19\VBG|NONE (l_dobj) behaviors_20\NNS|NONE (l_prep) in_21\IN|NONE (l_pobj) children_22\NNS|NONE (l_prep) with_23\IN|NONE (l_pobj) autism_24\NN|NONE (l_appos) aggression_27\NN|,
D005702_D001321 NONE galantamine_8\NN|NONE (r_pobj) of_7\IN|,|A|label|in|prospective|. (r_prep) trial_6\NN|NONE (l_prep) in_9\IN|,|A|label|of|prospective|. (l_pobj) disorder_11\NN|NONE
D005702_D001321 NONE galantamine_11\NN|NONE (r_pobj) of_10\IN|in|the (r_prep) use_9\NN|to (l_prep) in_21\IN|the|of (l_pobj) treatment_23\NN|NONE (l_prep) of_24\IN|the (l_pcomp) interfering_25\VBG|NONE (l_dobj) behaviors_26\NNS|NONE (l_prep) in_27\IN|NONE (l_pobj) children_28\NNS|NONE (l_prep) with_29\IN|NONE (l_pobj) autism_30\NN|NONE
D005702_D001321 NONE galantamine_26\NN|NONE (r_pobj) of_25\IN|,|week|a|label (r_prep) trial_24\NN|NONE (r_pobj) in_17\IN|.|children (r_prep) participated_16\VBD|NONE (l_nsubj) children_4\NNS|in|. (l_prep) with_5\IN|)|free|Thirteen (l_pobj) autism_6\NN|NONE
D005702_D001321 NONE galantamine_5\NN|and|.|appeared|tolerated|In|, (r_nsubj) was_6\VBD|NONE (l_conj) appeared_11\VBD|and|.|tolerated|In|,|galantamine (l_xcomp) be_13\VB|NONE (l_acomp) beneficial_14\JJ|to (l_prep) for_15\IN|NONE (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pcomp) interfering_19\VBG|NONE (l_dobj) behaviors_20\NNS|NONE (l_prep) in_21\IN|NONE (l_pobj) children_22\NNS|NONE (l_prep) with_23\IN|NONE (l_pobj) autism_24\NN|NONE
D005702_D006261 CID galantamine_2\NN|,|,|.|Overall|with|tolerated (r_nsubj) was_3\VBD|NONE (l_prep) with_8\IN|,|,|.|Overall|galantamine|tolerated (l_pobj) effects_12\NNS|NONE (l_advmod) apart_13\RB|no|significant|adverse (l_prep) from_14\IN|NONE (l_pobj) headaches_15\NNS|NONE
D005702_D002653 NONE galantamine_5\NN|and|.|appeared|tolerated|In|, (r_nsubj) was_6\VBD|NONE (l_conj) appeared_11\VBD|and|.|tolerated|In|,|galantamine (l_xcomp) be_13\VB|NONE (l_acomp) beneficial_14\JJ|to (l_prep) for_15\IN|NONE (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pcomp) interfering_19\VBG|NONE (l_dobj) behaviors_20\NNS|NONE (l_prep) in_21\IN|NONE (l_pobj) children_22\NNS|NONE (l_prep) with_23\IN|NONE (l_pobj) autism_24\NN|NONE (l_appos) aggression_27\NN|, (l_conj) dyscontrol_30\NN|particularly|,
20595935
D014700_-1 NONE verapamil_7\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) unresponsiveness_5\NN|that|as (r_nsubj) defined_8\VBN|analysis|discriminated|,|. (r_ccomp) revealed_3\VBD|NONE (l_conj) discriminated_15\VBD|analysis|,|defined|. (l_npadvmod) sensitivity_22\NN|respectively|effect (l_acl) associated_46\VBN|%|:|(|,|) (l_prep) with_47\IN|NONE (l_pobj) pseudoprolactinoma_48\NN|NONE
D018967_D006966 CID risperidone_25\NN| (r_npadvmod) induced_27\VBN|PRL|. (r_amod) hyperprolactinemia_28\NN|PRL|,|)|:|%|(|,|,|in|N.|and|but
D018967_D006966 CID risperidone_50\NN| (r_npadvmod) induced_52\VBN|NONE (r_amod) hyperprolactinemia_53\NN|or
D014700_D015175 NONE verapamil_12\NN|NONE (r_pobj) of_11\IN|in|diagnostic|the (r_prep) value_10\NN|we|.|Here|, (l_prep) in_13\IN|of|diagnostic|the (l_pobj) population_15\NN|NONE (l_relcl) screened_19\VBN|a (l_prep) for_20\IN|who|all|were (l_pobj) macroprolactinemia_21\NN|NONE
D014700_D015175 NONE Verapamil_1\NNP|levels|in|significantly|:|macroprolactinoma (r_nsubj) increased_3\VBD|NONE (l_advcl) macroprolactinoma_19\NN|levels|in|significantly|Verapamil|:
D014700_D015175 NONE Verapamil_1\NNP|levels|in|significantly|:|macroprolactinoma (r_nsubj) increased_3\VBD|NONE (l_advcl) macroprolactinoma_19\NN|levels|in|significantly|Verapamil|: (l_appos) PRL_24\NN|NONE (l_conj) microprolactinoma_30\NN|(|:|,|%|)|,|N.|,|macroprolactinemia
D014700_D015175 NONE Verapamil_1\NNP|levels|in|significantly|:|macroprolactinoma (r_nsubj) increased_3\VBD|NONE (l_advcl) macroprolactinoma_19\NN|levels|in|significantly|Verapamil|: (l_appos) PRL_24\NN|NONE (l_appos) macroprolactinemia_41\JJ|(|:|,|%|)|,|N.|,|microprolactinoma
D018967_-1 NONE risperidone_25\NN| (r_npadvmod) induced_27\VBN|PRL|. (r_amod) hyperprolactinemia_28\NN|PRL|,|)|:|%|(|,|,|in|N.|and|but (r_conj) PRL_4\NN|NONE (l_conj) in_12\IN|hyperprolactinemia|PRL|,|)|:|%|(|,|,|N.|and|but (l_pobj) pseudoprolactinoma_13\NN|not
D018967_-1 NONE risperidone_50\NN| (r_npadvmod) induced_52\VBN|NONE (r_amod) hyperprolactinemia_53\NN|or (r_conj) pseudoprolactinoma_48\NN|NONE
D014700_D006966 NONE Verapamil_0\NNP|stimulation|in|loss|:|. (r_compound) test_2\NN|NONE (l_prep) in_3\IN|stimulation|Verapamil|loss|:|. (l_pobj) hyperprolactinemia_4\NN|NONE
D014700_D006966 NONE Verapamil_0\NNP|stimulation (r_compound) test_2\NN|,|previously|but|was|with|.|as (r_nsubjpass) investigated_5\VBN|NONE (l_prep) as_6\IN|,|previously|but|test|was|with|. (l_pobj) tool_8\NN|NONE (l_prep) for_9\IN|a (l_pobj) diagnosis_11\NN|NONE (l_prep) of_12\IN|differential (l_pobj) hyperprolactinemia_13\NN|NONE
D014700_D006966 NONE verapamil_3\NN|NONE (r_pobj) to_2\IN|with|in|Prolactin (r_prep) responses_1\NNS|in|.|were (l_prep) with_16\IN|in|Prolactin|to (l_pobj) hyperprolactinemia_17\NN|NONE
D014700_D006966 NONE verapamil_7\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) unresponsiveness_5\NN|that|as (r_nsubj) defined_8\VBN|analysis|discriminated|,|. (r_ccomp) revealed_3\VBD|NONE (l_conj) discriminated_15\VBD|analysis|,|defined|. (l_npadvmod) sensitivity_22\NN|respectively|effect (l_acl) associated_46\VBN|%|:|(|,|) (l_prep) with_47\IN|NONE (l_pobj) pseudoprolactinoma_48\NN|NONE (l_conj) hyperprolactinemia_53\NN|or
D014700_D006966 NONE Verapamil_0\NNP|NONE (r_compound) responsiveness_1\NN|.|finding|not (r_nsubj) is_2\VBZ|NONE (l_attr) finding_6\NN|.|not|responsiveness (l_prep) for_7\IN|a|reliable (l_pobj) diagnosis_10\NN|NONE (l_prep) of_11\IN|the|differential (l_pobj) hyperprolactinemia_12\NN|NONE
D014700_D006966 NONE verapamil_2\NN|NONE (r_compound) unresponsiveness_3\NN|However|effect|,|. (r_nsubj) discriminates_4\VBZ|NONE (l_dobj) effect_6\NN|However|,|.|unresponsiveness (l_parataxis) inhibited_13\JJ|stalk (l_prep) from_17\IN|functionally|anatomically|,|(|tonus|i.e.|) (l_pobj) causes_19\NNS|NONE (l_prep) of_20\IN|with|other (l_pobj) hyperprolactinemia_21\NN|NONE
3339945
D013806_D020258 NONE Theophylline_0\NNP|in|. (r_amod) neurotoxicity_1\NN|NONE
D013806_D020258 NONE theophylline_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) neurotoxicity_10\NN|is|whether|in
D013806_D020258 NONE theophylline_15\NN|NONE (r_pobj) to_14\IN|in|neurotoxic|the (r_prep) response_13\NN|NONE (l_amod) neurotoxic_12\JJ|in|to|the
D000628_D012640 CID aminophylline_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) infusions_19\NNS|.|until|rats (r_dobj) received_18\VBD|NONE (l_prep) until_22\IN|.|rats|infusions (l_pobj) onset_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) seizures_26\NNS|NONE
6893265
D011441_D056486 CID Propylthiouracil_0\NNP| (r_npadvmod) induced_2\VBN|.|hepatic (r_amod) damage_4\NN|NONE
D011441_D056486 CID propylthiouracil_3\NN| (r_npadvmod) induced_5\VBN|liver (r_amod) damage_7\NN|NONE
16810074
D018738_D006973 NONE hexamethonium_5\NN|NONE (r_pobj) with_4\IN|ganglionic (r_prep) blockade_3\NN|.|,|Similarly|fall|compared (r_nsubj) caused_6\VBD|NONE (l_dobj) fall_10\NN|.|,|Similarly|compared|blockade (l_prep) in_11\IN|greater|a (l_pobj) rats_14\NNS|NONE (l_amod) hypertensive_13\JJ|Hg|LNNA|(|)
D019335_D006973 NONE arginine_21\NN|)|LNNA|through (r_nmod) hypertension_25\NN|NONE
D019335_D006973 NONE LNNA_23\NNP|arginine|)|through (r_nmod) hypertension_25\NN|NONE
D019335_D006973 NONE LNNA_17\NNP|NONE (r_compound) hypertension_18\NN|NONE
D019335_D006973 NONE LNNA_25\NNP|weeks (r_pobj) after_24\IN|was|,|an|pressure|not|in|in|.|at (r_prep) elevated_15\VBN|NONE (l_prep) in_16\IN|was|,|after|an|pressure|not|in|.|at (l_pobj) hypertension_18\NN|NONE
D019335_D006973 NONE LNNA_12\NNS|Hg|hypertensive|(|) (r_nmod) rats_14\NNS|NONE (l_amod) hypertensive_13\JJ|Hg|LNNA|(|)
D009569_D006973 CID oxide_6\NN|NO|)|( (r_nmod) deficiency_10\NN|NONE (r_pobj) by_4\IN|Mechanisms (r_agent) induced_3\VBN|on|:|. (l_nsubj) Mechanisms_0\NNS|by (l_prep) of_1\IN|NONE (l_pobj) hypertension_2\NN|NONE
D009569_D006973 CID NO_8\NNP|)|(|oxide (r_intj) deficiency_10\NN|NONE (r_pobj) by_4\IN|Mechanisms (r_agent) induced_3\VBN|on|:|. (l_nsubj) Mechanisms_0\NNS|by (l_prep) of_1\IN|NONE (l_pobj) hypertension_2\NN|NONE
D009569_D006973 CID oxide_7\NN|NONE (l_prep) in_11\IN|NO|nitric|endothelial|(|derived (l_pobj) hypertension_12\NN|NONE
D009569_D006973 CID NO_9\NNP|nitric|endothelial|(|in|derived (r_appos) oxide_7\NN|NONE (l_prep) in_11\IN|NO|nitric|endothelial|(|derived (l_pobj) hypertension_12\NN|NONE
D009569_D006973 CID NO_7\UH|NONE (r_pobj) of_6\IN|the (r_prep) removal_5\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) created_2\VBN|Experimental (r_acl) hypertension_1\NN|.|mechanisms|,|,|decreased|however
D009569_D006973 CID NO_5\DT|NONE (r_det) deficiency_6\NN|in|while|stress (r_nsubj) increases_7\VBZ|,|that|contribution|not|does|impact (r_advcl) make_26\VB|data|. (l_dobj) contribution_29\NN|,|that|increases|not|does|impact (l_prep) to_30\IN|major|a (l_pobj) form_32\NN|NONE (l_prep) of_33\IN|this (l_pobj) hypertension_34\NN|NONE
D009569_D018754 NONE oxide_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Loss_0\NN|.|hallmark (r_nsubj) is_13\VBZ|NONE (l_attr) hallmark_15\NN|.|Loss (l_prep) of_16\IN|a (l_pobj) dysfunction_18\NN|NONE
D009569_D018754 NONE NO_9\NNP|nitric|endothelial|(|in|derived (r_appos) oxide_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Loss_0\NN|.|hallmark (r_nsubj) is_13\VBZ|NONE (l_attr) hallmark_15\NN|.|Loss (l_prep) of_16\IN|a (l_pobj) dysfunction_18\NN|NONE
1563460
D014859_D020758 CID coumadin_4\NN|anticoagulant (r_amod) therapy_6\NN|NONE (r_pobj) to_3\IN|report|:|.|secondary|Thoracic (r_prep) hematomyelia_1\NNS|NONE
6529939
D011433_D019955 NONE propranolol_6\NN|being (r_pcomp) for_5\IN|NONE (l_pcomp) being_7\VBG|propranolol (l_attr) cause_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) disorder_13\NN|NONE
D011433_D000787 NONE propranolol_28\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) angina_24\NN|NONE
D011433_D001146 CID propranolol_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|rhythm|. (r_xcomp) Alternating_0\VBG|NONE (l_dobj) rhythm_2\NN|induced|.
D011433_D001146 CID propranolol_28\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) angina_24\NN|NONE (r_pobj) for_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) under_21\IN|was|block|in|,|Alternating|. (r_prep) observed_13\VBN|NONE (l_advcl) Alternating_0\VBG|under|was|block|in|,|. (l_dobj) rhythm_2\NN|NONE
D011433_D012848 CID propranolol_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|rhythm|. (r_xcomp) Alternating_0\VBG|NONE (l_dobj) rhythm_2\NN|induced|. (l_conj) block_6\NN|sinus|and
D011433_D012848 CID propranolol_28\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) angina_24\NN|NONE (r_pobj) for_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) under_21\IN|was|block|in|,|Alternating|. (r_prep) observed_13\VBN|NONE (l_nsubjpass) block_11\NN|under|was|in|,|Alternating|.
D011433_D012848 CID propranolol_8\NN|NONE (r_pobj) of_7\IN|and|the (r_prep) withdrawal_6\NN|NONE (r_pobj) with_4\IN|rhythm (r_prep) disappeared_3\VBD|block|restarted|was|. (r_ccomp) seen_22\VBN|NONE (l_nsubjpass) block_20\NN|restarted|was|disappeared|.
24812279
D004317_D066126 NONE Doxorubicin_2\NNP|but|associated|therapeutic|, (r_nsubj) is_6\VBZ|.|: (l_conj) associated_16\VBN|but|therapeutic|Doxorubicin|, (l_prep) with_17\IN|is (l_pobj) cardiotoxicity_24\NN|NONE
D004317_D066126 NONE DOX_4\NNP|) (r_appos) Doxorubicin_2\NNP|but|associated|therapeutic|, (r_nsubj) is_6\VBZ|.|: (l_conj) associated_16\VBN|but|therapeutic|Doxorubicin|, (l_prep) with_17\IN|is (l_pobj) cardiotoxicity_24\NN|NONE
D004317_D066126 NONE DOX_13\NNP|stage (r_compound) cardiotoxicity_14\NN|NONE
D004317_D006333 CID DOX_5\NNP| (r_npadvmod) induced_7\VBN|heart (r_amod) failure_9\NN|NONE
D004317_D009369 NONE Doxorubicin_2\NNP|but|associated|therapeutic|, (r_nsubj) is_6\VBZ|.|: (l_attr) therapeutic_12\NN|but|associated|Doxorubicin|, (l_compound) cancer_11\NN|effective|an
D004317_D009369 NONE DOX_4\NNP|) (r_appos) Doxorubicin_2\NNP|but|associated|therapeutic|, (r_nsubj) is_6\VBZ|.|: (l_attr) therapeutic_12\NN|but|associated|Doxorubicin|, (l_compound) cancer_11\NN|effective|an
D018943_D066126 NONE anthracycline_6\NN|stage (r_amod) cardiotoxicity_7\NN|.|inhibition
3538855
D000617_D008107 NONE aminoglycoside_13\NN|therapy (r_compound) levels_14\NNS|NONE (r_pobj) of_9\IN|,|gender|disease|the (r_prep) duration_8\NN|that|all|risk (l_appos) disease_17\NN|,|of|gender|the
D000617_D058186 NONE aminoglycosides_3\NNS|NONE (r_pobj) of_2\IN|in|Clinical (r_prep) trials_1\NNS|ranges|. (r_nsubj) indicate_8\VBP|NONE (l_ccomp) ranges_20\VBZ|trials|. (l_nsubj) risk_12\NN|and|that|from|is (l_prep) for_13\IN|the|relative (l_pcomp) developing_14\VBG|NONE (l_dobj) failure_17\NN|during
D000617_D007674 CID aminoglycoside_5\NN|NONE (r_compound) nephrotoxicity_6\NN|NONE
D000617_D007674 CID aminoglycoside_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) epidemiology_1\NN| (r_nsubj) induced_5\VBN|NONE (r_amod) nephrotoxicity_6\NN|fully|is|not|.
D000617_D007674 CID aminoglycosides_7\NNS|studies|.|cause (r_dobj) indicate_6\VBP|NONE (l_conj) cause_8\VBP|studies|.|aminoglycosides (l_conj) cause_22\VB|,|but|damage (l_dobj) dysfunction_26\NN|ever|rarely|,|,
D000617_D007674 CID aminoglycoside_13\NN|therapy (r_compound) levels_14\NNS|NONE (r_pobj) of_9\IN|,|gender|disease|the (r_prep) duration_8\NN|that|all|risk (r_nsubj) increase_34\VBP|analysis|. (l_dobj) risk_36\NN|that|all|duration (l_prep) for_37\IN|the (l_pobj) nephrotoxicity_38\NN|NONE
D000617_D007674 CID aminoglycoside_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) nephrotoxicity_16\NN|NONE
D003404_D007674 NONE creatinine_25\NN|high|,|possibly|and|estimated|initial (r_compound) clearance_26\NN|,|advanced (r_conj) age_20\NN|,|liver (r_conj) disease_17\NN|,|of|gender|the (r_appos) duration_8\NN|that|all|risk (r_nsubj) increase_34\VBP|analysis|. (l_dobj) risk_36\NN|that|all|duration (l_prep) for_37\IN|the (l_pobj) nephrotoxicity_38\NN|NONE
D003404_D008107 NONE creatinine_25\NN|high|,|possibly|and|estimated|initial (r_compound) clearance_26\NN|,|advanced (r_conj) age_20\NN|,|liver (r_conj) disease_17\NN|,|of|gender|the
15817013
D014859_D001281 NONE warfarin_8\NN|NONE (r_pobj) on_7\IN|atrial (r_prep) fibrillation_6\NN|NONE
D014859_D001281 NONE warfarin_22\NN|NONE (r_pobj) on_18\IN|atrial (r_prep) fibrillation_17\NN|NONE
D014859_D001281 NONE warfarin_32\NN|NONE (r_pobj) on_31\IN|atrial (r_prep) fibrillation_30\NN|NONE
D014859_D006470 CID warfarin_8\NN|NONE (r_pobj) on_7\IN|atrial (r_prep) fibrillation_6\NN|NONE (r_pobj) in_4\IN|over (r_prep) 75_3\CD|NONE (r_dobj) aged_1\VBN|rate|:|. (r_acl) People_0\NNS|NONE (l_appos) rate_11\NN|:|aged|. (l_prep) of_12\IN|the (l_pobj) hemorrhage_14\NN|NONE
D014859_D006470 CID warfarin_22\NN|NONE (r_pobj) on_18\IN|atrial (r_prep) fibrillation_17\NN|NONE (r_pobj) with_15\IN| (r_prep) aged_11\VBN|admitted (r_acl) people_10\NNS|NONE (r_pobj) in_9\IN|NONE (r_prep) stroke_8\NN|and|major (r_conj) hemorrhage_6\NN|NONE
D014859_D006470 CID warfarin_9\JJ|NONE (r_compound) use_10\NN|,|and (r_conj) strokes_6\NNS|bleeding|major|, (r_conj) episodes_4\NNS|NONE (l_compound) bleeding_3\VBG|strokes|major|,
D014859_D006470 CID warfarin_31\NN|NONE (r_pobj) on_30\IN|stroke|the (r_prep) rate_29\NN|low|, (r_nsubj) was_32\VBD|.|demonstrating|,|in (r_ccomp) resulted_18\VBD|rate|excluding|but|,|high|in (r_conj) was_5\VBD|NONE (l_nsubj) rate_1\NN|excluding|but|,|high|in|resulted (l_prep) of_2\IN|The (l_pobj) hemorrhage_4\NN|NONE
D014859_D006470 CID warfarin_38\JJ|NONE (r_compound) treatment_39\NN|effective (r_nsubj) is_40\VBZ|NONE (r_ccomp) demonstrating_35\VBG|was|.|,|in (r_advcl) resulted_18\VBD|rate|excluding|but|,|high|in (r_conj) was_5\VBD|NONE (l_nsubj) rate_1\NN|excluding|but|,|high|in|resulted (l_prep) of_2\IN|The (l_pobj) hemorrhage_4\NN|NONE
D014859_D020521 NONE warfarin_8\NN|NONE (r_pobj) on_7\IN|atrial (r_prep) fibrillation_6\NN|NONE (r_pobj) in_4\IN|over (r_prep) 75_3\CD|NONE (r_dobj) aged_1\VBN|rate|:|. (r_acl) People_0\NNS|NONE (l_appos) rate_11\NN|:|aged|. (l_prep) of_12\IN|the (l_pobj) hemorrhage_14\NN|NONE (l_conj) stroke_16\NN|and|major
D014859_D020521 NONE warfarin_22\NN|NONE (r_pobj) on_18\IN|atrial (r_prep) fibrillation_17\NN|NONE (r_pobj) with_15\IN| (r_prep) aged_11\VBN|admitted (r_acl) people_10\NNS|NONE (r_pobj) in_9\IN|NONE (r_prep) stroke_8\NN|and|major
D014859_D020521 NONE warfarin_9\JJ|NONE (r_compound) use_10\NN|,|and (r_conj) strokes_6\NNS|bleeding|major|,
D014859_D020521 NONE warfarin_7\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) initiation_5\NN|NONE (r_pobj) after_4\IN|annual|The|stroke (r_prep) rate_3\NN|%|. (l_compound) stroke_2\NN|annual|after|The
D014859_D020521 NONE warfarin_31\NN|NONE (r_pobj) on_30\IN|stroke|the (r_prep) rate_29\NN|low|, (l_compound) stroke_28\NN|the|on
D014859_D020521 NONE warfarin_38\JJ|NONE (r_compound) treatment_39\NN|effective (r_nsubj) is_40\VBZ|NONE (r_ccomp) demonstrating_35\VBG|was|.|,|in (r_advcl) resulted_18\VBD|rate|excluding|but|,|high|in (l_ccomp) was_32\VBD|.|demonstrating|,|in (l_nsubj) rate_29\NN|low|, (l_compound) stroke_28\NN|the|on
19178808
D015742_D006470 NONE propofol_54\NN| (r_compound) remifentanil_56\NN|NONE (r_compound) total_57\JJ|TIVA|i.v.|(|) (r_amod) anesthesia_59\NN|NONE (r_pobj) by_53\IN|NONE (r_agent) induced_52\VBN|controlled|hypotension (r_acl) anesthesia_51\NN|NONE (r_dobj) maintaining_48\VBG|NONE (r_pcomp) in_47\IN|airway|versus (r_prep) using_32\VBG|during|to|conditions (r_advcl) compare_7\VB|purpose|. (l_dobj) conditions_9\NNS|using|during|to (l_prep) including_11\VBG|surgical|,|, (l_pobj) amount_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) bleeding_16\NN|NONE
C071741_D006470 NONE remifentanil_56\NN|NONE (r_compound) total_57\JJ|TIVA|i.v.|(|) (r_amod) anesthesia_59\NN|NONE (r_pobj) by_53\IN|NONE (r_agent) induced_52\VBN|controlled|hypotension (r_acl) anesthesia_51\NN|NONE (r_dobj) maintaining_48\VBG|NONE (r_pcomp) in_47\IN|airway|versus (r_prep) using_32\VBG|during|to|conditions (r_advcl) compare_7\VB|purpose|. (l_dobj) conditions_9\NNS|using|during|to (l_prep) including_11\VBG|surgical|,|, (l_pobj) amount_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) bleeding_16\NN|NONE
D015742_D007022 CID propofol_54\NN| (r_compound) remifentanil_56\NN|NONE (r_compound) total_57\JJ|TIVA|i.v.|(|) (r_amod) anesthesia_59\NN|NONE (r_pobj) by_53\IN|NONE (r_agent) induced_52\VBN|controlled|hypotension (r_acl) anesthesia_51\NN|NONE (l_compound) hypotension_50\NN|induced|controlled
D015742_D007022 CID propofol_19\JJ|remifentanil|| (r_compound) TIVA_23\NNP|NONE (r_pobj) by_18\IN|NONE (r_agent) caused_17\VBN|controlled|hypotension (r_acl) anesthesia_16\NN|NONE (l_compound) hypotension_15\NN|controlled|caused
C071741_D007022 CID remifentanil_56\NN|NONE (r_compound) total_57\JJ|TIVA|i.v.|(|) (r_amod) anesthesia_59\NN|NONE (r_pobj) by_53\IN|NONE (r_agent) induced_52\VBN|controlled|hypotension (r_acl) anesthesia_51\NN|NONE (l_compound) hypotension_50\NN|induced|controlled
C071741_D007022 CID remifentanil_21\NN|||propofol (r_compound) TIVA_23\NNP|NONE (r_pobj) by_18\IN|NONE (r_agent) caused_17\VBN|controlled|hypotension (r_acl) anesthesia_16\NN|NONE (l_compound) hypotension_15\NN|controlled|caused
C071741_D007022 CID remifentanil_15\NN|NONE (r_compound) infusion_16\NN|NONE (r_pobj) of_14\IN|lower (r_prep) rates_13\NNS|and (r_dobj) using_11\VBG|mask (r_xcomp) using_8\VBG|shorter|a (r_acl) period_7\NN|NONE (r_pobj) within_4\IN|.|dose|hypotension|was (r_prep) achieved_3\VBN|NONE (l_nsubjpass) hypotension_1\NN|.|within|dose|was
C071741_D007022 CID remifentanil_22\NN|NONE (r_pobj) of_21\IN|lower|total (r_prep) dose_20\NN|.|within|hypotension|was (r_dobj) achieved_3\VBN|NONE (l_nsubjpass) hypotension_1\NN|.|within|dose|was
C071741_D007022 CID remifentanil_39\NN|NONE (r_pobj) of_38\IN|low (r_prep) doses_37\NNS|NONE (r_pobj) with_35\IN|convenient|induced|in|during (r_prep) hypotension_34\NN|NONE (r_pobj) for_31\IN|NONE (r_prep) allowed_30\VBN|FRLMA|management|and|during (r_conj) using_9\VBG|,|results|In|. (l_prep) during_11\IN|FRLMA|management|allowed|and (l_pobj) anesthesia_14\NN|NONE (l_compound) hypotension_13\NN|controlled|provided
C071741_D007022 CID remifentanil_39\NN|NONE (r_pobj) of_38\IN|low (r_prep) doses_37\NNS|NONE (r_pobj) with_35\IN|convenient|induced|in|during (r_prep) hypotension_34\NN|NONE
7121659
D012293_D006461 CID rifampicin_18\NNS|NONE (r_pobj) of_17\IN|the (r_prep) reintroduction_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN||with| (r_acl) patients_1\NNS|are|. (l_appos) 3_7\CD|with||induced (l_prep) with_8\IN|(|) (l_pobj) thrombopenia_9\NN|NONE (l_conj) hemolysis_11\NN|and
D012293_D013921 CID rifampicin_18\NNS|NONE (r_pobj) of_17\IN|the (r_prep) reintroduction_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN||with| (r_acl) patients_1\NNS|are|. (l_appos) 3_7\CD|with||induced (l_prep) with_8\IN|(|) (l_pobj) thrombopenia_9\NN|NONE
D012293_D058186 NONE rifampicin_18\NNS|NONE (r_pobj) of_17\IN|the (r_prep) reintroduction_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN||with| (r_acl) patients_1\NNS|are|. (l_prep) with_2\IN|||induced (l_pobj) failure_5\NN|NONE
D012293_D051437 NONE rifampicin_4\NN| (r_npadvmod) associated_6\VBN|renal|acute (r_amod) failure_8\NN|NONE
12644816
D013792_D019337 NONE thalidomide_4\NN|NONE (r_pobj) of_3\IN|The|antiangiogenic (r_prep) effects_2\NNS|.|in|have|been (r_nsubjpass) assessed_7\VBN|NONE (l_prep) in_8\IN|effects|.|have|been (l_pobj) trials_10\NNS|NONE (l_prep) in_11\IN|clinical (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) malignancies_18\NNS|NONE
D013792_D011471 NONE thalidomide_11\NN|NONE (l_prep) in_12\IN|dose (l_pobj) cancer_17\NN|NONE
D013792_D011471 NONE thalidomide_8\NN|for|daily (r_dobj) using_7\VBG|an|label (l_prep) for_13\IN|daily|thalidomide (l_pobj) months_17\NNS|NONE (l_prep) in_18\IN| (l_pobj) men_20\NNS|NONE (l_prep) with_21\IN| (l_pobj) cancer_26\NN|NONE
D013792_D010523 CID thalidomide_9\NN|NONE (r_pobj) on_8\IN|who|months (r_prep) completed_5\VBD|seven|the (r_relcl) men_3\NNS|NONE (r_pobj) In_0\IN|.|but|,|in|in|evidence|was (r_prep) found_17\VBN|NONE (l_nsubjpass) evidence_12\NN|.|but|,|in|In|in|was (l_prep) of_13\IN|subclinical (l_pobj) neuropathy_15\NN|NONE
D013792_D010523 CID thalidomide_4\NN|may|option|,|that (r_nsubj) be_6\VB|findings|.|provided (r_ccomp) indicate_2\VBP|NONE (l_ccomp) provided_19\VBD|findings|.|be (l_dobj) maintained_25\VBN|NONE (l_prep) for_26\IN|up|is (l_pobj) development_27\NN|NONE (l_prep) of_28\IN|NONE (l_pobj) neuropathy_30\NN|NONE
D000728_D011471 NONE androgen_13\JJ| (r_npadvmod) independent_15\JJ|prostate (r_amod) cancer_17\NN|NONE
D000728_D011471 NONE androgen_22\JJ| (r_npadvmod) independent_24\JJ|prostate (r_amod) cancer_26\NN|NONE
3990093
D011692_D009401 NONE aminonucleoside_8\JJ|NONE (r_amod) nephrosis_9\NN|NONE
D011692_D009401 NONE PAN_7\NNP|NONE (r_compound) nephrosis_8\NN|NONE
D011692_D007674 NONE aminonucleoside_8\JJ|NONE (r_amod) nephrosis_9\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) rats_6\NNS|NONE (r_pobj) in_5\IN|glomerular (r_prep) sclerosis_4\NN|and|Mesangial|.
D011692_D007674 NONE aminonucleoside_16\NN|)|(|PAN (r_nmod) model_20\NN|.|relationship|in|was (r_advcl) studied_12\VBN|NONE (l_nsubjpass) relationship_2\NN|.|model|in|was (l_prep) between_3\IN|possible|The (l_pobj) dysfunction_5\NN|NONE
D011692_D007674 NONE aminonucleoside_16\NN|)|(|PAN (r_nmod) model_20\NN|.|relationship|in|was (r_advcl) studied_12\VBN|NONE (l_nsubjpass) relationship_2\NN|.|model|in|was (l_prep) between_3\IN|possible|The (l_pobj) dysfunction_5\NN|NONE (l_prep) of_8\IN|mesangial|and|development (l_pobj) sclerosis_10\NN|NONE
D011692_D007674 NONE PAN_18\NNP|)|(|aminonucleoside (r_nmod) model_20\NN|.|relationship|in|was (r_advcl) studied_12\VBN|NONE (l_nsubjpass) relationship_2\NN|.|model|in|was (l_prep) between_3\IN|possible|The (l_pobj) dysfunction_5\NN|NONE
D011692_D007674 NONE PAN_18\NNP|)|(|aminonucleoside (r_nmod) model_20\NN|.|relationship|in|was (r_advcl) studied_12\VBN|NONE (l_nsubjpass) relationship_2\NN|.|model|in|was (l_prep) between_3\IN|possible|The (l_pobj) dysfunction_5\NN|NONE (l_prep) of_8\IN|mesangial|and|development (l_pobj) sclerosis_10\NN|NONE
D011692_D007674 NONE PAN_16\NNP|NONE (r_compound) rats_17\NNS|NONE (r_pobj) of_15\IN|the (r_prep) glomeruli_14\NN|NONE (r_pobj) of_12\IN|+/|.|. (r_prep) %_11\NN|NONE (r_pobj) in_7\IN|At|was|sclerosis|;|were (r_prep) found_6\VBN|NONE (l_nsubjpass) sclerosis_4\NN|At|was|in|;|were
D011692_D007674 NONE PAN_7\NNP|NONE (r_compound) nephrosis_8\NN|NONE (r_pobj) in_6\IN|remnant|kidney|the (r_prep) model_5\NN|NONE (r_pobj) to_1\IN|NONE (r_prep) Similar_0\JJ|may|.|be|development|"|to (r_nsubjpass) related_16\VBN|NONE (l_nsubjpass) development_10\NN|may|Similar|.|be|"|to (l_prep) of_11\IN|the (l_pobj) sclerosis_13\NN|NONE
D011692_D011507 CID PAN_4\NNP|the (r_compound) rats_5\NNS|NONE (r_nsubj) were_6\VBD|severely|given|After|,|and|hr (r_auxpass) proteinuric_8\JJ|NONE
D002244_D011507 NONE carbon_23\NN|.|rats|intravenously|were (r_dobj) given_21\VBN|were|severely|After|,|and|hr (r_conj) proteinuric_8\JJ|NONE
D011692_D012598 NONE PAN_12\NNP|chronic (r_compound) treatment_13\NN|NONE (r_pobj) during_10\IN|Since|not|did|clearance (r_prep) change_9\VB|,|we|.|caused (r_advcl) conclude_16\VBP|NONE (l_ccomp) caused_26\VBN|,|we|.|change (l_agent) by_27\IN|that|is|localization (l_pobj) uptake_31\NN|NONE (l_prep) after_33\IN|an|increased|CC (l_pobj) injection_34\NN|shortly (l_prep) in_35\IN|NONE (l_pobj) areas_38\NNS|NONE (l_relcl) develop_42\VB|vulnerable|apparent (l_nsubj) sclerosis_40\NN|where|subsequently|will
17346443
D003300_D001523 NONE copper_10\NN|hepatic (r_compound) metabolism_11\NN|NONE (r_pobj) of_8\IN|with|an|recessive|autosomal (r_prep) disorder_7\NN|.|disease (l_prep) with_12\IN|an|recessive|autosomal|of (l_pobj) accumulation_15\NN|NONE (l_prep) in_18\IN|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS|NONE (l_conj) disorders_28\NNS|many|and
D003300_D001523 NONE copper_14\NN|toxicity|consequent|and|in (r_compound) accumulation_15\NN|NONE (l_prep) in_18\IN|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS|NONE (l_conj) disorders_28\NNS|many|and
D010396_D017512 CID Penicillamine_0\NN| (r_npadvmod) related_2\VBN|utility|in|and|.|lichenoid (r_amod) dermatitis_4\NN|NONE
D010396_D017512 CID penicillamine_9\NN|and|During|,|after|,|permitted|was (r_nsubjpass) interrupted_11\VBN|NONE (l_prep) after_12\IN|and|During|penicillamine|,|,|permitted|was (l_pobj) appearance_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) dermatitis_18\NN|NONE
D010396_D006527 NONE Penicillamine_0\NN| (r_npadvmod) related_2\VBN|utility|in|and|.|lichenoid (r_amod) dermatitis_4\NN|NONE (l_prep) in_10\IN|utility|related|and|.|lichenoid (l_pobj) patient_14\JJ|NONE (l_compound) disease_13\NN|a|with
D010396_D006527 NONE penicillamine_20\NN| (r_npadvmod) related_22\VBN|side (r_amod) effects_24\NNS|in (r_nsubj) appeared_25\VBD|for|effective|an (r_relcl) treatment_11\NN|.|therapy|In (l_prep) for_12\IN|effective|an|appeared (l_pobj) patient_17\NN|NONE (l_compound) disease_16\NN|Wilson
D010396_D006527 NONE penicillamine_6\NN| (r_npadvmod) treated_8\VBN|disease|Wilson (r_amod) patients_9\NNS|NONE (l_nmod) disease_5\NN|treated|Wilson
D019345_D001008 NONE acetate_9\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) utility_6\NN|in|related|and|.|lichenoid (r_conj) dermatitis_4\NN|NONE (l_prep) in_10\IN|utility|related|and|.|lichenoid (l_pobj) patient_14\JJ|NONE (l_prep) with_15\IN|a|disease (l_pobj) presentation_17\NN|NONE (l_conj) anxiety_19\NN|,|hepatic
D010396_D012871 NONE penicillamine_6\NN| (r_npadvmod) treated_8\VBN|disease|Wilson (r_amod) patients_9\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) most_1\JJS|Since|not|do|develop (r_nsubj) seem_12\VB|conceivable|,|could|it|involved|. (l_xcomp) develop_14\VB|Since|not|do|most (l_dobj) lesion_17\NN|to
D010396_D001008 NONE Penicillamine_0\NN| (r_npadvmod) related_2\VBN|utility|in|and|.|lichenoid (r_amod) dermatitis_4\NN|NONE (l_prep) in_10\IN|utility|related|and|.|lichenoid (l_pobj) patient_14\JJ|NONE (l_prep) with_15\IN|a|disease (l_pobj) presentation_17\NN|NONE (l_conj) anxiety_19\NN|,|hepatic
D003300_D056486 NONE copper_10\NN|hepatic (r_compound) metabolism_11\NN|NONE (r_pobj) of_8\IN|with|an|recessive|autosomal (r_prep) disorder_7\NN|.|disease (l_prep) with_12\IN|an|recessive|autosomal|of (l_pobj) accumulation_15\NN|NONE (l_prep) in_18\IN|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS|NONE (l_conj) disorders_28\NNS|many|and
D003300_D056486 NONE copper_14\NN|toxicity|consequent|and|in (r_compound) accumulation_15\NN|NONE (l_prep) in_18\IN|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS|NONE (l_conj) disorders_28\NNS|many|and
D003300_D006527 NONE copper_10\NN|hepatic (r_compound) metabolism_11\NN|NONE (r_pobj) of_8\IN|with|an|recessive|autosomal (r_prep) disorder_7\NN|.|disease (r_attr) is_3\VBZ|NONE (l_nsubj) disease_2\NN|.|disorder
D003300_D006527 NONE copper_14\NN|toxicity|consequent|and|in (r_compound) accumulation_15\NN|NONE (r_pobj) with_12\IN|an|recessive|autosomal|of (r_prep) disorder_7\NN|.|disease (r_attr) is_3\VBZ|NONE (l_nsubj) disease_2\NN|.|disorder
D003300_D009422 NONE copper_10\NN|hepatic (r_compound) metabolism_11\NN|NONE (r_pobj) of_8\IN|with|an|recessive|autosomal (r_prep) disorder_7\NN|.|disease (l_prep) with_12\IN|an|recessive|autosomal|of (l_pobj) accumulation_15\NN|NONE (l_prep) in_18\IN|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS|NONE (l_conj) disorders_28\NNS|many|and
D003300_D009422 NONE copper_14\NN|toxicity|consequent|and|in (r_compound) accumulation_15\NN|NONE (l_prep) in_18\IN|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS|NONE (l_conj) disorders_28\NNS|many|and
D019345_D017512 NONE acetate_9\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) utility_6\NN|in|related|and|.|lichenoid (r_conj) dermatitis_4\NN|NONE
D019345_D017512 NONE acetate_22\NN|.|continue (r_nsubj) permitted_23\VBD|and|During|penicillamine|,|after|,|was (r_conj) interrupted_11\VBN|NONE (l_prep) after_12\IN|and|During|penicillamine|,|,|permitted|was (l_pobj) appearance_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) dermatitis_18\NN|NONE
D019345_D006527 NONE acetate_9\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) utility_6\NN|in|related|and|.|lichenoid (r_conj) dermatitis_4\NN|NONE (l_prep) in_10\IN|utility|related|and|.|lichenoid (l_pobj) patient_14\JJ|NONE (l_compound) disease_13\NN|a|with
D019345_D006527 NONE acetate_7\NN|NONE (r_pobj) with_5\IN|the (r_prep) therapy_4\NN|.|In|treatment (r_nsubj) represented_8\VBD|NONE (l_dobj) treatment_11\NN|.|therapy|In (l_prep) for_12\IN|effective|an|appeared (l_pobj) patient_17\NN|NONE (l_compound) disease_16\NN|Wilson
D019345_D006527 NONE acetate_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) safety_1\NN|avoid (r_nsubj) allowed_6\VBD|observation|;|in|. (r_ccomp) is_18\VBZ|NONE (l_prep) in_19\IN|allowed|observation|;|. (l_pobj) line_20\NN|NONE (l_prep) with_21\IN|NONE (l_pobj) evidence_24\NN|NONE (l_prep) on_25\IN|growing|the (l_pobj) efficacy_27\NN|NONE (l_prep) of_28\IN|the (l_pobj) drug_30\NN|NONE (l_prep) in_31\IN|the (l_pobj) treatment_33\NN|NONE (l_prep) of_34\IN|the (l_pobj) disease_37\NN|NONE
D003300_D064420 NONE copper_10\NN|hepatic (r_compound) metabolism_11\NN|NONE (r_pobj) of_8\IN|with|an|recessive|autosomal (r_prep) disorder_7\NN|.|disease (l_prep) with_12\IN|an|recessive|autosomal|of (l_pobj) accumulation_15\NN|NONE (l_conj) toxicity_17\NN|consequent|copper|and|in
D003300_D064420 NONE copper_14\NN|toxicity|consequent|and|in (r_compound) accumulation_15\NN|NONE (l_conj) toxicity_17\NN|consequent|copper|and|in
3975902
C024986_D004342 NONE chloride_11\NN|chronic (r_compound) ingestion_12\NN|NONE (r_pobj) by_8\IN|.|dysfunction (r_agent) induced_7\VBN|NONE (l_nsubj) dysfunction_1\NN|.|by (l_conj) hypersensitivity_3\NN|and|pentobarbital|Cardiovascular
D001464_D006973 NONE Barium_0\NN| (r_npadvmod) supplemented_2\VBN|hooded|Evans (r_amod) rats_7\NNS|were|.|by (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|were|.|rats (l_pobj) hypertension_13\NN|NONE
D001464_D006973 NONE barium_21\NN|NONE (r_pobj) of_20\IN|treatment| (r_prep) month_19\NN|NONE (r_pobj) after_17\IN|that|evident (r_prep) was_15\VBD|persistent|a (r_relcl) hypertension_13\NN|NONE
D001464_D009202 NONE barium_37\NN|chronic (r_compound) exposure_38\NN|NONE (r_pobj) by_35\IN|NONE (r_agent) induced_34\VBN|a|undescribed|cardiomyopathic (r_acl) disorder_33\NN|NONE
D001464_D002318 NONE barium_18\NN| (r_npadvmod) induced_20\VBN|significant|other|within (r_amod) disturbances_21\NNS|Analysis|. (l_prep) within_22\IN|significant|induced|other (l_pobj) system_25\NN|NONE
D001464_D008659 NONE barium_37\NN|chronic (r_compound) exposure_38\NN|NONE (r_pobj) by_35\IN|NONE (r_agent) induced_34\VBN|a|undescribed|cardiomyopathic (r_acl) disorder_33\NN|NONE (r_pobj) of_28\IN|the (r_prep) existence_27\NN|.|contractility|Overall|, (r_dobj) suggest_25\VBP|NONE (l_nsubj) contractility_5\NN|.|Overall|,|existence (l_conj) disturbances_13\NNS|characteristics|pentobarbital|and|cardiac|the|altered|,
D010424_D004342 NONE pentobarbital_6\NN|hypersensitivity|and|Cardiovascular (r_amod) dysfunction_1\NN|.|by (l_conj) hypersensitivity_3\NN|and|pentobarbital|Cardiovascular
D010424_D004342 NONE pentobarbital_18\NN|demonstrated|a|of|to (r_amod) hypersensitivity_11\NN|.|aspect
D010424_D004342 NONE pentobarbital_24\NN|characteristics|and|disturbances|cardiac|the|altered|, (r_appos) contractility_5\NN|.|Overall|,|existence (l_conj) disturbances_13\NNS|characteristics|pentobarbital|and|cardiac|the|altered|, (l_conj) hypersensitivity_17\NN|,|metabolic|and|the|myocardial
D010424_D002318 NONE pentobarbital_6\NN|hypersensitivity|and|Cardiovascular (r_amod) dysfunction_1\NN|.|by
D010424_D008659 NONE pentobarbital_24\NN|characteristics|and|disturbances|cardiac|the|altered|, (r_appos) contractility_5\NN|.|Overall|,|existence (l_conj) disturbances_13\NNS|characteristics|pentobarbital|and|cardiac|the|altered|,
D010424_D009202 NONE pentobarbital_24\NN|characteristics|and|disturbances|cardiac|the|altered|, (r_appos) contractility_5\NN|.|Overall|,|existence (r_nsubj) suggest_25\VBP|NONE (l_dobj) existence_27\NN|.|contractility|Overall|, (l_prep) of_28\IN|the (l_pobj) disorder_33\NN|NONE
D001464_D004342 NONE barium_6\NN|the (r_compound) effect_7\NN|NONE (r_pobj) of_4\IN|distinctive|The (r_prep) aspect_3\NN|.|hypersensitivity (r_nsubj) was_8\VBD|NONE (l_attr) hypersensitivity_11\NN|.|aspect
D001464_D004342 NONE barium_37\NN|chronic (r_compound) exposure_38\NN|NONE (r_pobj) by_35\IN|NONE (r_agent) induced_34\VBN|a|undescribed|cardiomyopathic (r_acl) disorder_33\NN|NONE (r_pobj) of_28\IN|the (r_prep) existence_27\NN|.|contractility|Overall|, (r_dobj) suggest_25\VBP|NONE (l_nsubj) contractility_5\NN|.|Overall|,|existence (l_conj) disturbances_13\NNS|characteristics|pentobarbital|and|cardiac|the|altered|, (l_conj) hypersensitivity_17\NN|,|metabolic|and|the|myocardial
C024986_D002318 NONE chloride_11\NN|chronic (r_compound) ingestion_12\NN|NONE (r_pobj) by_8\IN|.|dysfunction (r_agent) induced_7\VBN|NONE (l_nsubj) dysfunction_1\NN|.|by
17379047
C081489_D006973 NONE valsartan_2\JJ|hydrochlorothiazide|combination (r_nmod) therapy_6\NN|NONE (r_pobj) of_1\IN|.|at|study|: (r_prep) Comparison_0\NN|NONE (l_appos) study_24\NN|.|at|of|: (l_acl) followed_25\VBN|controlled|a|blind|, (l_agent) by_26\IN|NONE (l_pobj) therapy_31\NN|NONE (l_prep) in_32\IN|combination|term (l_pobj) adults_34\NNS|NONE (l_amod) hypertensive_33\JJ|NONE
C081489_C562386 NONE valsartan_10\JJ|NONE (l_appos) HCTZ)-monotherapy_17\NN|(|VAL (l_conj) combinations_22\NNS|and (l_prep) in_23\IN|dose (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) hypertension_27\NN|NONE
C081489_C562386 NONE VAL_12\NNP|(|HCTZ)monotherapy (r_appos) valsartan_10\JJ|NONE (l_appos) HCTZ)-monotherapy_17\NN|(|VAL (l_conj) combinations_22\NNS|and (l_prep) in_23\IN|dose (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) hypertension_27\NN|NONE
C081489_C562386 NONE VAL_34\NNP|:||treatment (r_appos) groups_32\NNS|NONE (r_pobj) to_27\IN|Patients|.|sitting|were|mean (r_prep) randomized_26\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|sitting|to|were|mean (l_prep) with_1\IN|NONE (l_pobj) hypertension_3\NN|NONE
C081489_C562386 NONE VAL_46\NNP|,|/.|/.|placebo|or|;|/ (r_nmod) HCTZ_48\NNP||HCTZ|;|;|mg (r_appos) VAL_34\NNP|:||treatment (r_appos) groups_32\NNS|NONE (r_pobj) to_27\IN|Patients|.|sitting|were|mean (r_prep) randomized_26\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|sitting|to|were|mean (l_prep) with_1\IN|NONE (l_pobj) hypertension_3\NN|NONE
D006852_D007008 CID HCTZ_9\NNP|(|)|% (r_compound) combinations_10\NNS|NONE (r_pobj) with_6\IN|than (r_prep) lower_5\JJR|incidence|. (r_acomp) was_4\VBD|NONE (l_nsubj) incidence_1\NN|lower|. (l_prep) of_2\IN|The (l_pobj) hypokalemia_3\NN|NONE
D006852_D007008 CID HCTZ_17\NNP|(|)|% (r_compound) monotherapies_18\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) than_15\IN|with (r_prep) lower_5\JJR|incidence|. (r_acomp) was_4\VBD|NONE (l_nsubj) incidence_1\NN|lower|. (l_prep) of_2\IN|The (l_pobj) hypokalemia_3\NN|NONE
D006852_D007008 CID HCTZ_10\NNP|NONE (r_pobj) with_7\IN|combination (r_prep) therapies_6\NNS|were|.|with|,|tolerated|In|, (r_nsubjpass) associated_12\VBN|NONE (l_conj) tolerated_25\VBN|were|.|therapies|with|,|In|, (l_conj) associated_29\VBN|were|and|well|, (l_prep) with_30\IN|were (l_pobj) hypokalemia_32\NN|NONE
D006852_D007008 CID HCTZ_34\NNP|NONE (r_pobj) than_33\IN|less (r_prep) hypokalemia_32\NN|NONE
D006852_D006973 NONE hydrochlorothiazide_4\JJ|valsartan|combination (r_compound) therapy_6\NN|NONE (r_pobj) of_1\IN|.|at|study|: (r_prep) Comparison_0\NN|NONE (l_appos) study_24\NN|.|at|of|: (l_acl) followed_25\VBN|controlled|a|blind|, (l_agent) by_26\IN|NONE (l_pobj) therapy_31\NN|NONE (l_prep) in_32\IN|combination|term (l_pobj) adults_34\NNS|NONE (l_amod) hypertensive_33\JJ|NONE
C081489_D007008 NONE VAL_7\NNP|/ (r_nmod) HCTZ_9\NNP|(|)|% (r_compound) combinations_10\NNS|NONE (r_pobj) with_6\IN|than (r_prep) lower_5\JJR|incidence|. (r_acomp) was_4\VBD|NONE (l_nsubj) incidence_1\NN|lower|. (l_prep) of_2\IN|The (l_pobj) hypokalemia_3\NN|NONE
C081489_D007008 NONE VAL_8\NNP|/ (r_nmod) HCTZ_10\NNP|NONE (r_pobj) with_7\IN|combination (r_prep) therapies_6\NNS|were|.|with|,|tolerated|In|, (r_nsubjpass) associated_12\VBN|NONE (l_conj) tolerated_25\VBN|were|.|therapies|with|,|In|, (l_conj) associated_29\VBN|were|and|well|, (l_prep) with_30\IN|were (l_pobj) hypokalemia_32\NN|NONE
D006852_C562386 NONE hydrochlorothiazide_15\NN|)|or|( (r_conj) VAL_12\NNP|(|HCTZ)monotherapy (r_appos) valsartan_10\JJ|NONE (l_appos) HCTZ)-monotherapy_17\NN|(|VAL (l_conj) combinations_22\NNS|and (l_prep) in_23\IN|dose (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) hypertension_27\NN|NONE
D006852_C562386 NONE HCTZ)-monotherapy_17\NN|(|VAL (l_conj) combinations_22\NNS|and (l_prep) in_23\IN|dose (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) hypertension_27\NN|NONE
D006852_C562386 NONE HCTZ_40\NNP||;|HCTZ|;|mg (r_appos) VAL_34\NNP|:||treatment (r_appos) groups_32\NNS|NONE (r_pobj) to_27\IN|Patients|.|sitting|were|mean (r_prep) randomized_26\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|sitting|to|were|mean (l_prep) with_1\IN|NONE (l_pobj) hypertension_3\NN|NONE
D006852_C562386 NONE HCTZ_48\NNP||HCTZ|;|;|mg (r_appos) VAL_34\NNP|:||treatment (r_appos) groups_32\NNS|NONE (r_pobj) to_27\IN|Patients|.|sitting|were|mean (r_prep) randomized_26\VBN|NONE (l_nsubjpass) Patients_0\NNS|.|sitting|to|were|mean (l_prep) with_1\IN|NONE (l_pobj) hypertension_3\NN|NONE
24068571
D015742_D003693 NONE propofol_19\NN|NONE (r_pcomp) to_18\IN|df (r_prep) compared_17\VBN|with|was|significantly|.|use (r_prep) associated_6\VBN|NONE (l_prep) with_7\IN|was|significantly|compared|.|use (l_pobj) risk_14\NN|NONE (l_prep) for_15\IN|higher|an (l_pobj) delirium_16\NN|NONE
D013874_D003693 CID thiopentone_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|with|was|significantly|compared|. (r_nsubjpass) associated_6\VBN|NONE (l_prep) with_7\IN|was|significantly|compared|.|use (l_pobj) risk_14\NN|NONE (l_prep) for_15\IN|higher|an (l_pobj) delirium_16\NN|NONE
10933650
C059765_D007683 CID AmB_11\VBN| (r_dep) treated_13\VBN|D (r_amod) rats_14\NNS|NONE (r_pobj) in_8\IN|tubular (r_prep) necrosis_7\NN|but|.|examination|change
D000666_D064420 NONE B_7\NN|nanosphere (r_dobj) incorporating_5\VBG|a (r_acl) lipid_3\NN|effective|.|and|,|,|has|NS (r_nsubj) is_9\VBZ|NONE (l_conj) has_15\VBZ|effective|.|and|,|,|lipid|NS (l_dobj) toxicity_17\NN|NONE
D000666_D064420 NONE Fungizone_9\NNP|sodium|( (r_nmod) deoxycholate_15\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) that_7\DT|NS (r_pobj) with_6\IN|NONE (r_punct) ;_16\:|in|AmB|following|by|and|cultures (r_punct) using_23\VBG|toxicity|We|. (r_advcl) compared_1\VBD|NONE (l_dobj) toxicity_3\NN|using|We|.
D000666_D064420 NONE B_44\NNP|NONE (r_pobj) of_42\IN|pharmacokinetic (r_prep) study_41\NN|the|and (r_conj) kidney_38\NN|NONE (r_pobj) of_36\IN|histopathological (r_prep) study_35\NN|biochemical|, (r_appos) analysis_32\NN|NONE (r_pobj) by_30\IN|in|AmB|following|and|cultures|; (r_prep) using_23\VBG|toxicity|We|. (r_advcl) compared_1\VBD|NONE (l_dobj) toxicity_3\NN|using|We|.
C059765_D064420 NONE deoxycholate_15\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) that_7\DT|NS (r_pobj) with_6\IN|NONE (r_punct) ;_16\:|in|AmB|following|by|and|cultures (r_punct) using_23\VBG|toxicity|We|. (r_advcl) compared_1\VBD|NONE (l_dobj) toxicity_3\NN|using|We|.
C059765_D064420 NONE AmB_19\NNP|in|following|by|and|cultures|; (r_nsubj) using_23\VBG|toxicity|We|. (r_advcl) compared_1\VBD|NONE (l_dobj) toxicity_3\NN|using|We|.
D000666_D007674 NONE B._13\NNP|by|of (r_appos) Attenuation_0\NN|NONE (l_prep) of_1\IN|by|B. (l_pobj) nephrotoxicity_2\NN|NONE
D000666_D007674 NONE B_12\NNP|NONE (r_pobj) of_10\IN|into (r_prep) incorporation_9\NN|NS|nephrotoxicity|that (r_nsubj) attenuates_18\VBZ|in (l_dobj) nephrotoxicity_20\NN|NS|that|incorporation
D000666_D007674 NONE B._23\NNP|NONE (r_pobj) of_21\IN|the (r_prep) nephrotoxicity_20\NN|NS|that|incorporation
9881641
D019806_D007022 CID levcromakalim_14\RB| (r_npadvmod) produced_16\VBN|in|a (r_amod) decrease_17\NN|which (r_dobj) abolished_12\VBD|, (r_relcl) glibenclamide_9\NN|NONE (r_pobj) by_8\IN|.|Hypotension|was|significantly (r_agent) attenuated_7\VBN|NONE (l_nsubjpass) Hypotension_0\NN|.|was|significantly|by
C040442_D007022 CID helodermin_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) produced_4\VBN|sensitive|. (r_acl) hypotension_3\NN|NONE
C040442_D007022 CID Helodermin_0\NNP|hypotension|. (r_nsubj) produced_1\VBD|NONE (l_dobj) hypotension_2\NN|Helodermin|.
C040442_D007022 CID helodermin_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypotension_7\NN|not|did|Oxyhemoglobin|shortened|.|,
C040442_D007022 CID helodermin_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypotension_7\NN|not|did|Oxyhemoglobin|shortened|.|, (r_dobj) affect_3\VB|NONE (l_advcl) shortened_11\VBD|hypotension|not|did|Oxyhemoglobin|.|, (l_dobj) duration_13\NN|whereas|it (l_prep) of_14\IN|the (l_pobj) acetylcholine_15\NN|NONE (l_appos) hypotension_18\NN|NONE
C040442_D007022 CID helodermin_4\NN| (r_npadvmod) produced_6\VBN|NONE (r_amod) hypotension_7\NN|that|attributable
D011188_D007022 NONE K+_18\NNP|exist|sensitive|,|channels (r_amod) channels_19\NNS|NONE (r_pobj) of_14\IN|the (r_prep) activation_13\NN|NONE (r_pobj) to_11\IN|partly (r_prep) attributable_10\JJ|that|hypotension (r_acomp) is_8\VBZ|findings|. (l_nsubj) hypotension_7\NN|that|attributable
D011188_D007022 NONE K(ATP_21\NNP|)|)|( (r_nmod) channels_23\NNS|exist|sensitive|,|K+ (r_appos) channels_19\NNS|NONE (r_pobj) of_14\IN|the (r_prep) activation_13\NN|NONE (r_pobj) to_11\IN|partly (r_prep) attributable_10\JJ|that|hypotension (r_acomp) is_8\VBZ|findings|. (l_nsubj) hypotension_7\NN|that|attributable
D005905_D007022 NONE Glibenclamide_0\NN| (r_npadvmod) sensitive_2\JJ|.|produced (r_amod) hypotension_3\NN|NONE
D005905_D007022 NONE glibenclamide_9\NN|NONE (r_pobj) by_8\IN|.|Hypotension|was|significantly (r_agent) attenuated_7\VBN|NONE (l_nsubjpass) Hypotension_0\NN|.|was|significantly|by
D005905_D007022 NONE glibenclamide_15\NN| (r_npadvmod) sensitive_17\JJ|exist|,|channels|K+ (r_amod) channels_19\NNS|NONE (r_pobj) of_14\IN|the (r_prep) activation_13\NN|NONE (r_pobj) to_11\IN|partly (r_prep) attributable_10\JJ|that|hypotension (r_acomp) is_8\VBZ|findings|. (l_nsubj) hypotension_7\NN|that|attributable
D000109_D007022 CID acetylcholine_15\NN|NONE (r_pobj) of_14\IN|the (r_prep) duration_13\NN|whereas|it (r_dobj) shortened_11\VBD|hypotension|not|did|Oxyhemoglobin|.|, (r_advcl) affect_3\VB|NONE (l_dobj) hypotension_7\NN|not|did|Oxyhemoglobin|shortened|.|,
D000109_D007022 CID acetylcholine_15\NN|NONE (l_appos) hypotension_18\NN|NONE
D000109_D007022 CID ACh)-produced_17\JJ|( (r_amod) hypotension_18\NN|NONE (r_appos) acetylcholine_15\NN|NONE (r_pobj) of_14\IN|the (r_prep) duration_13\NN|whereas|it (r_dobj) shortened_11\VBD|hypotension|not|did|Oxyhemoglobin|.|, (r_advcl) affect_3\VB|NONE (l_dobj) hypotension_7\NN|not|did|Oxyhemoglobin|shortened|.|,
D000109_D007022 CID ACh)-produced_17\JJ|( (r_amod) hypotension_18\NN|NONE
D009569_D007022 NONE oxide_7\NN|NONE (r_dobj) relaxing_5\VBG|endothelium| (r_xcomp) derived_4\VBN|( (r_acl) EDRF_0\NN|play|.|does|not (r_nsubj) seem_10\VB|NONE (l_xcomp) play_12\VB|EDRF|.|does|not (l_dobj) role_15\NN|to (l_prep) in_16\IN|important|an (l_pobj) hypotension_21\NN|NONE
D000255_D007022 NONE K(ATP_21\NNP|)|)|( (r_nmod) channels_23\NNS|exist|sensitive|,|K+ (r_appos) channels_19\NNS|NONE (r_pobj) of_14\IN|the (r_prep) activation_13\NN|NONE (r_pobj) to_11\IN|partly (r_prep) attributable_10\JJ|that|hypotension (r_acomp) is_8\VBZ|findings|. (l_nsubj) hypotension_7\NN|that|attributable
1158089
D013752_D003866 NONE tetracycline_23\NN|NONE (r_pobj) of_22\IN|accumulation|and (r_prep) dose_21\NN|NONE (l_conj) accumulation_26\NN|and|of (l_prep) of_27\IN|by|both (l_pobj) triglyceride_28\NN|NONE (l_prep) in_29\IN|NONE (l_pobj) liver_31\NN|NONE (l_conj) depression_33\NN|of|the|and
D013752_D003866 NONE tetracycline_19\NN|NONE (r_pobj) of_18\IN|on|the (r_prep) effects_17\NNS|NONE (l_prep) on_20\IN|of|the (l_pobj) depression_21\NN|NONE
D019301_D003866 NONE acid_5\NN|NONE (r_pobj) of_2\IN|as (r_prep) provision_1\NN|NONE (r_pobj) With_0\IN|,|relationship|between|was|. (r_prep) observed_19\VBN|NONE (l_prep) between_20\IN|,|relationship|With|was|. (l_pobj) dose_21\NN|NONE (l_conj) accumulation_26\NN|and|of (l_prep) of_27\IN|by|both (l_pobj) triglyceride_28\NN|NONE (l_prep) in_29\IN|NONE (l_pobj) liver_31\NN|NONE (l_conj) depression_33\NN|of|the|and
D013752_D005234 CID tetracycline_4\NN|NONE (r_pobj) by_3\IN|in (r_agent) induced_2\VBN|Fatty|. (r_acl) liver_1\NN|NONE
D013752_D005234 CID tetracycline_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|response|mechanisms|, (r_acl) relationships_3\NNS|in|were|. (l_conj) mechanisms_6\NNS|response|induced|, (l_conj) differences_10\NNS|biochemical|and|, (l_prep) in_11\IN|sex (l_pobj) liver_15\NN|NONE
D013752_D005234 CID tetracycline_37\NN|NONE (r_pobj) to_36\IN|NONE (r_prep) response_35\NN|NONE (r_pobj) in_34\IN|of|the (r_prep) production_26\NN|NONE (l_prep) of_27\IN|the|in (l_pobj) liver_33\NN|NONE
D014280_D005234 NONE triglyceride_4\NN|NONE (r_pobj) of_3\IN|hepatic|Depressed (r_prep) secretion_2\NN|indicating|.|%|, (r_nsubj) accounted_5\VBD|NONE (l_advcl) indicating_17\VBG|.|secretion|%|, (l_ccomp) involved_23\VBN|NONE (l_prep) in_24\IN|mechanisms|must|be|that (l_pobj) production_26\NN|NONE (l_prep) of_27\IN|the|in (l_pobj) liver_33\NN|NONE
D014280_D005234 NONE triglyceride_15\NN|NONE (r_pobj) of_12\IN| (r_prep) %_11\NN|indicating|.|secretion|, (r_dobj) accounted_5\VBD|NONE (l_advcl) indicating_17\VBG|.|secretion|%|, (l_ccomp) involved_23\VBN|NONE (l_prep) in_24\IN|mechanisms|must|be|that (l_pobj) production_26\NN|NONE (l_prep) of_27\IN|the|in (l_pobj) liver_33\NN|NONE
D014280_D005234 NONE triglyceride_29\NN| (r_npadvmod) rich_31\JJ|fatty|the (r_amod) liver_33\NN|NONE
D014280_D003866 NONE triglyceride_28\NN|NONE (l_prep) in_29\IN|NONE (l_pobj) liver_31\NN|NONE (l_conj) depression_33\NN|of|the|and
D014280_D003866 NONE triglyceride_37\NN|NONE (r_pobj) of_36\IN|NONE (r_prep) output_35\NN|NONE (r_pobj) of_34\IN|the|depression|and (r_prep) liver_31\NN|NONE (l_conj) depression_33\NN|of|the|and
D014280_D003866 NONE triglyceride_25\NN|NONE (r_pobj) of_24\IN|NONE (r_prep) output_23\NN|NONE (r_pobj) of_22\IN|under (r_prep) depression_21\NN|NONE
1289188
D003676_D058186 NONE desferrioxamine_6\NN|intravenous (r_compound) therapy_7\NN|NONE (r_pobj) during_4\IN|NONE (r_prep) occurring_3\VBG|recovery|.|:|Acute|renal (r_acl) failure_2\NN|NONE
D003676_D058186 NONE desferrioxamine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) caused_22\VBN|renal|progressive|acute (r_acl) failure_21\NN|NONE
D003676_D013789 NONE desferrioxamine_11\NN|.|because|was|patient (r_dobj) undergoing_8\VBG|NONE (l_nsubj) patient_1\NN|.|because|was|desferrioxamine (l_prep) with_2\IN|A (l_pobj) thalassemia_6\NN|NONE
D003676_D013789 NONE DFX_13\NNP|by|)|( (r_nmod) treatment_15\NN|home|intravenous (r_appos) desferrioxamine_11\NN|.|because|was|patient (r_dobj) undergoing_8\VBG|NONE (l_nsubj) patient_1\NN|.|because|was|desferrioxamine (l_prep) with_2\IN|A (l_pobj) thalassemia_6\NN|NONE
24309294
D012844_D000647 NONE CCK-8_5\NNP|reversed|amnesia|and|decreases|that|significantly (r_punct) alleviated_7\VBN|We|previously|.|have (l_dobj) amnesia_11\NN|reversed|and|CCK|decreases|that|significantly
D009020_D000647 CID morphine_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) amnesia_11\NN|reversed|and|CCK|decreases|that|significantly
D009020_D000647 CID morphine_25\NN| (r_npadvmod) treated_27\VBN|NONE (r_amod) animals_28\NNS|NONE (r_pobj) in_24\IN|CA|of|the (r_prep) region_20\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) decreases_16\VBZ|reversed|amnesia|and|CCK|that|significantly (r_conj) alleviated_7\VBN|We|previously|.|have (l_dobj) amnesia_11\NN|reversed|and|CCK|decreases|that|significantly
D009020_D008569 NONE morphine_10\NN|NONE (r_pobj) of_9\IN|through|the|on (r_prep) effect_8\NN|that|suggest|CCK|and (r_dobj) attenuates_6\VBZ|.|results (l_conj) suggest_18\VBP|that|CCK|effect|and (l_dobj) function_21\NN|NONE (l_prep) on_24\IN|an|of|ameliorative (l_pobj) impairment_29\NN|CCK
D009020_D008569 NONE morphine_25\NN| (r_npadvmod) induced_27\VBN|memory (r_amod) impairment_29\NN|CCK
D012844_D008569 NONE CCK-8_5\NNP|that|suggest|effect|and (r_nsubj) attenuates_6\VBZ|.|results (l_conj) suggest_18\VBP|that|CCK|effect|and (l_dobj) function_21\NN|NONE (l_prep) on_24\IN|an|of|ameliorative (l_pobj) impairment_29\NN|CCK
D012844_D008569 NONE CCK-8_23\NNP|impairment (r_punct) on_24\IN|an|of|ameliorative (l_pobj) impairment_29\NN|CCK
15630069
D018967_D011618 NONE risperidone_25\NN|,|or (r_conj) olanzapine_22\NN|either|, (r_conj) clozapine_20\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|and|by (r_conj) matched_11\VBN|nonobese|with|,|six|, (r_acl) subjects_4\NNS|.|in|were (l_prep) with_5\IN|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN|NONE (l_conj) disorder_9\NN|or
D003024_D012559 NONE clozapine_20\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|and|by (r_conj) matched_11\VBN|nonobese|with|,|six|, (r_acl) subjects_4\NNS|.|in|were (l_prep) with_5\IN|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN|NONE
D005947_D012559 NONE Glucose_0\NN|:|test|.|in (r_nsubj) metabolism_1\NN|NONE (l_prep) in_2\IN|:|test|.|Glucose (l_pobj) patients_3\NNS|NONE (l_prep) with_4\IN|NONE (l_pobj) schizophrenia_5\NN|NONE
D005947_D012559 NONE glucose_16\NN|NONE (r_compound) tolerance_17\NN|intravenous|analysis|sampled|and|a (r_compound) test_18\NN|:|.|in|Glucose (r_appos) metabolism_1\NN|NONE (l_prep) in_2\IN|:|test|.|Glucose (l_pobj) patients_3\NNS|NONE (l_prep) with_4\IN|NONE (l_pobj) schizophrenia_5\NN|NONE
D005947_D012559 NONE glucose_32\NN|NONE (r_compound) metabolism_33\NN|are|or|increasing|agents|directly|whether (r_dobj) affecting_31\VBG|it|unclear|increasing|,|. (r_ccomp) remains_24\VBZ|NONE (l_advcl) increasing_11\VBG|it|unclear|affecting|,|. (l_prep) in_12\IN|incidence|While|may|be (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) schizophrenia_15\NN|NONE
D005947_D012559 NONE glucose_18\NN|NONE (r_compound) tolerance_19\NN|and|analysis|sampled|a|intravenous (r_compound) test_20\NN|NONE (r_dobj) using_13\VBG|NONE (r_advcl) evaluated_12\VBD|NONE (r_acl) schizophrenia_11\NN|NONE
C076029_D012559 NONE olanzapine_22\NN|either|, (r_conj) clozapine_20\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|and|by (r_conj) matched_11\VBN|nonobese|with|,|six|, (r_acl) subjects_4\NNS|.|in|were (l_prep) with_5\IN|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN|NONE
D003024_D007333 CID clozapine_20\NN|<|olanzapine|(|)|< (r_nmod) risperidone_24\NNP|)|,|with (r_appos) P<.001_17\NNP|There|=|;|difference (r_appos) was_1\VBD|NONE (l_attr) difference_4\NN|There|=|;|P<. (l_prep) in_5\IN|significant|among|a (l_pobj) index_8\NN|NONE (l_compound) sensitivity_7\NN|NONE
D003024_D007333 CID clozapine_20\NN|<|olanzapine|(|)|< (r_nmod) risperidone_24\NNP|)|,|with (r_appos) P<.001_17\NNP|There|=|;|difference (l_prep) with_27\IN|risperidone|)|, (l_pobj) subjects_28\NNS|NONE (l_acl) exhibiting_34\VBG|received (l_dobj) resistance_37\NN|compared
D003024_D007333 CID clozapine_31\NN|who (r_dobj) received_30\VBD|exhibiting (r_relcl) subjects_28\NNS|NONE (r_pobj) with_27\IN|risperidone|)|, (r_prep) P<.001_17\NNP|There|=|;|difference (r_appos) was_1\VBD|NONE (l_attr) difference_4\NN|There|=|;|P<. (l_prep) in_5\IN|significant|among|a (l_pobj) index_8\NN|NONE (l_compound) sensitivity_7\NN|NONE
D003024_D007333 CID clozapine_31\NN|who (r_dobj) received_30\VBD|exhibiting (r_relcl) subjects_28\NNS|NONE (l_acl) exhibiting_34\VBG|received (l_dobj) resistance_37\NN|compared
D003024_D007333 CID clozapine_47\NN|NONE (r_appos) risperidone_45\NN|NONE (r_pobj) with_44\IN|who|were (r_prep) treated_43\VBN|NONE (r_relcl) subjects_40\NNS|NONE (r_pobj) with_39\IN|NONE (r_prep) compared_38\VBN|resistance (r_prep) exhibiting_34\VBG|received (r_acl) subjects_28\NNS|NONE (r_pobj) with_27\IN|risperidone|)|, (r_prep) P<.001_17\NNP|There|=|;|difference (r_appos) was_1\VBD|NONE (l_attr) difference_4\NN|There|=|;|P<. (l_prep) in_5\IN|significant|among|a (l_pobj) index_8\NN|NONE (l_compound) sensitivity_7\NN|NONE
D003024_D007333 CID clozapine_47\NN|NONE (r_appos) risperidone_45\NN|NONE (r_pobj) with_44\IN|who|were (r_prep) treated_43\VBN|NONE (r_relcl) subjects_40\NNS|NONE (r_pobj) with_39\IN|NONE (r_prep) compared_38\VBN|resistance (r_prep) exhibiting_34\VBG|received (l_dobj) resistance_37\NN|compared
D003024_D007333 CID clozapine-_2\NN|treated (r_nmod) groups_7\NNS|resistance|compared|. (r_nsubj) displayed_8\VBD|NONE (l_dobj) resistance_11\NN|groups|compared|.
D003024_D007333 CID clozapine_2\NN|and|olanzapine (r_dobj) taking_1\VBG|NONE (r_acl) Patients_0\NNS|must|be|.|for (r_nsubjpass) examined_7\VBN|NONE (l_prep) for_8\IN|must|be|Patients|. (l_pobj) resistance_10\NN|NONE
C076029_D007333 CID olanzapine_22\RB|<|clozapine|(|)|< (r_nmod) risperidone_24\NNP|)|,|with (r_appos) P<.001_17\NNP|There|=|;|difference (r_appos) was_1\VBD|NONE (l_attr) difference_4\NN|There|=|;|P<. (l_prep) in_5\IN|significant|among|a (l_pobj) index_8\NN|NONE (l_compound) sensitivity_7\NN|NONE
C076029_D007333 CID olanzapine_22\RB|<|clozapine|(|)|< (r_nmod) risperidone_24\NNP|)|,|with (r_appos) P<.001_17\NNP|There|=|;|difference (l_prep) with_27\IN|risperidone|)|, (l_pobj) subjects_28\NNS|NONE (l_acl) exhibiting_34\VBG|received (l_dobj) resistance_37\NN|compared
C076029_D007333 CID olanzapine_33\RB|and (r_conj) clozapine_31\NN|who (r_dobj) received_30\VBD|exhibiting (r_relcl) subjects_28\NNS|NONE (r_pobj) with_27\IN|risperidone|)|, (r_prep) P<.001_17\NNP|There|=|;|difference (r_appos) was_1\VBD|NONE (l_attr) difference_4\NN|There|=|;|P<. (l_prep) in_5\IN|significant|among|a (l_pobj) index_8\NN|NONE (l_compound) sensitivity_7\NN|NONE
C076029_D007333 CID olanzapine_33\RB|and (r_conj) clozapine_31\NN|who (r_dobj) received_30\VBD|exhibiting (r_relcl) subjects_28\NNS|NONE (l_acl) exhibiting_34\VBG|received (l_dobj) resistance_37\NN|compared
C076029_D007333 CID olanzapine_4\RB| (r_npadvmod) treated_6\VBN|clozapine (r_amod) groups_7\NNS|resistance|compared|. (r_nsubj) displayed_8\VBD|NONE (l_dobj) resistance_11\NN|groups|compared|.
C076029_D007333 CID olanzapine_4\NN|clozapine|and (r_conj) taking_1\VBG|NONE (r_acl) Patients_0\NNS|must|be|.|for (r_nsubjpass) examined_7\VBN|NONE (l_prep) for_8\IN|must|be|Patients|. (l_pobj) resistance_10\NN|NONE
D005947_D007333 NONE glucose_6\NN|fasting|index|,|and (r_dobj) Fasting_4\VBG|.|MAIN|:|OUTCOME (l_conj) index_15\NN|fasting|,|glucose|and (l_compound) sensitivity_14\NN|,|assessment
D005947_D007333 NONE glucose_6\NN|fasting|index|,|and (r_dobj) Fasting_4\VBG|.|MAIN|:|OUTCOME (l_conj) index_15\NN|fasting|,|glucose|and (l_conj) assessment_19\NN|sensitivity|, (l_prep) of_20\IN|model|,|and|effectiveness (l_pobj) resistance_22\NN|NONE
D005947_D007333 NONE glucose_25\NN|NONE (r_compound) effectiveness_26\NN|model|,|and|of (r_conj) assessment_19\NN|sensitivity|, (r_conj) index_15\NN|fasting|,|glucose|and (l_compound) sensitivity_14\NN|,|assessment
D005947_D007333 NONE glucose_25\NN|NONE (r_compound) effectiveness_26\NN|model|,|and|of (r_conj) assessment_19\NN|sensitivity|, (l_prep) of_20\IN|model|,|and|effectiveness (l_pobj) resistance_22\NN|NONE
D005947_D007333 NONE glucose_15\NN|NONE (r_compound) effectiveness_16\NN|NONE (r_pobj) of_14\IN|NONE (r_prep) impairment_13\NN|significant|insulin|and (r_conj) resistance_11\NN|groups|compared|.
D018967_D012559 NONE risperidone_25\NN|,|or (r_conj) olanzapine_22\NN|either|, (r_conj) clozapine_20\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|and|by (r_conj) matched_11\VBN|nonobese|with|,|six|, (r_acl) subjects_4\NNS|.|in|were (l_prep) with_5\IN|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN|NONE
D005947_D003920 NONE glucose_32\NN|NONE (r_compound) metabolism_33\NN|are|or|increasing|agents|directly|whether (r_dobj) affecting_31\VBG|it|unclear|increasing|,|. (r_ccomp) remains_24\VBZ|NONE (l_advcl) increasing_11\VBG|it|unclear|affecting|,|. (l_nsubj) incidence_2\NN|in|While|may|be (l_prep) of_3\IN|the (l_pobj) mellitus_8\NN|NONE
D005947_D003920 NONE glucose_32\NN|NONE (r_compound) metabolism_33\NN|are|or|increasing|agents|directly|whether (r_dobj) affecting_31\VBG|it|unclear|increasing|,|. (l_conj) increasing_36\VBG|are|metabolism|or|agents|directly|whether (l_dobj) factors_39\NNS|simply (l_prep) for_40\IN|known|risk (l_pobj) diabetes_41\NNS|NONE
C076029_D011618 NONE olanzapine_22\NN|either|, (r_conj) clozapine_20\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|and|by (r_conj) matched_11\VBN|nonobese|with|,|six|, (r_acl) subjects_4\NNS|.|in|were (l_prep) with_5\IN|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN|NONE (l_conj) disorder_9\NN|or
D018967_D007333 NONE risperidone_24\NNP|)|,|with (r_appos) P<.001_17\NNP|There|=|;|difference (r_appos) was_1\VBD|NONE (l_attr) difference_4\NN|There|=|;|P<. (l_prep) in_5\IN|significant|among|a (l_pobj) index_8\NN|NONE (l_compound) sensitivity_7\NN|NONE
D018967_D007333 NONE risperidone_24\NNP|)|,|with (r_appos) P<.001_17\NNP|There|=|;|difference (l_prep) with_27\IN|risperidone|)|, (l_pobj) subjects_28\NNS|NONE (l_acl) exhibiting_34\VBG|received (l_dobj) resistance_37\NN|compared
D018967_D007333 NONE risperidone_45\NN|NONE (r_pobj) with_44\IN|who|were (r_prep) treated_43\VBN|NONE (r_relcl) subjects_40\NNS|NONE (r_pobj) with_39\IN|NONE (r_prep) compared_38\VBN|resistance (r_prep) exhibiting_34\VBG|received (r_acl) subjects_28\NNS|NONE (r_pobj) with_27\IN|risperidone|)|, (r_prep) P<.001_17\NNP|There|=|;|difference (r_appos) was_1\VBD|NONE (l_attr) difference_4\NN|There|=|;|P<. (l_prep) in_5\IN|significant|among|a (l_pobj) index_8\NN|NONE (l_compound) sensitivity_7\NN|NONE
D018967_D007333 NONE risperidone_45\NN|NONE (r_pobj) with_44\IN|who|were (r_prep) treated_43\VBN|NONE (r_relcl) subjects_40\NNS|NONE (r_pobj) with_39\IN|NONE (r_prep) compared_38\VBN|resistance (r_prep) exhibiting_34\VBG|received (l_dobj) resistance_37\NN|compared
D018967_D007333 NONE risperidone_49\NN|NONE (r_pobj) vs_48\IN|)|( (r_prep) clozapine_47\NN|NONE (r_appos) risperidone_45\NN|NONE (r_pobj) with_44\IN|who|were (r_prep) treated_43\VBN|NONE (r_relcl) subjects_40\NNS|NONE (r_pobj) with_39\IN|NONE (r_prep) compared_38\VBN|resistance (r_prep) exhibiting_34\VBG|received (r_acl) subjects_28\NNS|NONE (r_pobj) with_27\IN|risperidone|)|, (r_prep) P<.001_17\NNP|There|=|;|difference (r_appos) was_1\VBD|NONE (l_attr) difference_4\NN|There|=|;|P<. (l_prep) in_5\IN|significant|among|a (l_pobj) index_8\NN|NONE (l_compound) sensitivity_7\NN|NONE
D018967_D007333 NONE risperidone_49\NN|NONE (r_pobj) vs_48\IN|)|( (r_prep) clozapine_47\NN|NONE (r_appos) risperidone_45\NN|NONE (r_pobj) with_44\IN|who|were (r_prep) treated_43\VBN|NONE (r_relcl) subjects_40\NNS|NONE (r_pobj) with_39\IN|NONE (r_prep) compared_38\VBN|resistance (r_prep) exhibiting_34\VBG|received (l_dobj) resistance_37\NN|compared
D018967_D007333 NONE risperidone_19\NN| (r_npadvmod) treated_21\VBN|NONE (r_amod) subjects_22\NNS|NONE (r_pobj) with_18\IN|NONE (r_prep) compared_17\VBN|groups|resistance|. (r_prep) displayed_8\VBD|NONE (l_dobj) resistance_11\NN|groups|compared|.
D003024_D011618 NONE clozapine_20\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|and|by (r_conj) matched_11\VBN|nonobese|with|,|six|, (r_acl) subjects_4\NNS|.|in|were (l_prep) with_5\IN|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN|NONE (l_conj) disorder_9\NN|or
19841052
D016578_D006679 CID cocaine_13\NN|crack (r_pobj) of_11\IN|daily (r_prep) smokers_10\NNS|NONE (r_pobj) among_8\IN|HIV (r_prep) seroconversion_7\NN|NONE
D016578_D006679 CID cocaine_22\NN|NONE (r_dobj) crack_21\VB|NONE (r_pcomp) of_20\IN|daily (r_prep) smokers_19\NNS|who (r_attr) were_17\VBD|NONE (r_relcl) participants_15\NNS|NONE (r_pobj) among_14\IN|HIV (r_prep) seroconversion_13\NN|NONE
D016578_D006679 CID cocaine_3\NN|crack (r_pobj) of_1\IN|NONE (r_prep) Smoking_0\NN|was|.|be (r_nsubjpass) found_5\VBN|NONE (l_xcomp) be_7\VB|was|.|Smoking (l_attr) factor_11\NN|to (l_prep) for_12\IN|an|risk|independent (l_pobj) seroconversion_14\NN|NONE
D016578_D015658 NONE cocaine_3\NN|as (r_dobj) crack_2\VB|NONE (l_prep) as_4\IN|cocaine (l_pobj) factor_7\NN|NONE (l_prep) for_8\IN|a|risk (l_pobj) infection_10\NN|NONE
D016578_D015658 NONE cocaine_10\NN|smoking|that (r_dobj) crack_9\VBP|has|possible|the (r_relcl) role_6\NN|NONE (l_acl) has_11\VBZ|possible|crack|the (l_prep) on_12\IN|NONE (l_pobj) incidence_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) infection_17\NN|NONE
D016578_D015658 NONE cocaine_6\NN|NONE (r_pobj) of_4\IN|increasing|the (r_prep) use_3\NN|NONE (r_pobj) Given_0\VBN|we|,|examine|. (r_prep) sought_9\VBD|NONE (l_xcomp) examine_11\VB|we|,|.|Given (l_ccomp) become_19\VBN|to (l_attr) factor_22\NN|has|use|whether (l_prep) for_23\IN|risk|a (l_pobj) infection_25\NN|NONE
851038
D011188_D007008 NONE potassium_11\NN|NONE (r_pobj) of_10\IN|renal|the (r_prep) excretion_9\NN|NONE (r_pobj) on_6\IN|L| (r_prep) dopa_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) influence_1\NN|.|in|was (r_nsubjpass) studied_13\VBN|NONE (l_prep) in_14\IN|.|was|influence (l_pobj) patients_16\NNS|in|and (l_prep) with_17\IN| (l_pobj) hypokalemia_18\NN|NONE
D011188_D007008 NONE potassium_38\NN|NONE (r_pobj) of_37\IN|plasma (r_prep) concentration_36\NN|,|filtration|glomerular (r_conj) rate_33\NN|renal|,|plasma (r_conj) flow_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) determination_25\NN|NONE (r_pobj) by_24\IN|normokalemic| (r_prep) patients_23\NNS|NONE (r_pobj) in_20\IN|and|patients (r_conj) in_14\IN|.|was|influence (l_pobj) patients_16\NNS|in|and (l_prep) with_17\IN| (l_pobj) hypokalemia_18\NN|NONE
D011188_D007008 NONE potassium_47\NN|NONE (r_pobj) of_46\IN|urinary (r_prep) excretion_45\NN|and|as|sodium (r_conj) potassium_38\NN|NONE (r_pobj) of_37\IN|plasma (r_prep) concentration_36\NN|,|filtration|glomerular (r_conj) rate_33\NN|renal|,|plasma (r_conj) flow_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) determination_25\NN|NONE (r_pobj) by_24\IN|normokalemic| (r_prep) patients_23\NNS|NONE (r_pobj) in_20\IN|and|patients (r_conj) in_14\IN|.|was|influence (l_pobj) patients_16\NNS|in|and (l_prep) with_17\IN| (l_pobj) hypokalemia_18\NN|NONE
D000450_D007008 NONE aldosterone_51\NN|and (r_conj) sodium_49\NN|, (r_conj) potassium_47\NN|NONE (r_pobj) of_46\IN|urinary (r_prep) excretion_45\NN|and|as|sodium (r_conj) potassium_38\NN|NONE (r_pobj) of_37\IN|plasma (r_prep) concentration_36\NN|,|filtration|glomerular (r_conj) rate_33\NN|renal|,|plasma (r_conj) flow_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) determination_25\NN|NONE (r_pobj) by_24\IN|normokalemic| (r_prep) patients_23\NNS|NONE (r_pobj) in_20\IN|and|patients (r_conj) in_14\IN|.|was|influence (l_pobj) patients_16\NNS|in|and (l_prep) with_17\IN| (l_pobj) hypokalemia_18\NN|NONE
D012964_D007008 NONE sodium_40\NN|excretion|and|as (r_conj) potassium_38\NN|NONE (r_pobj) of_37\IN|plasma (r_prep) concentration_36\NN|,|filtration|glomerular (r_conj) rate_33\NN|renal|,|plasma (r_conj) flow_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) determination_25\NN|NONE (r_pobj) by_24\IN|normokalemic| (r_prep) patients_23\NNS|NONE (r_pobj) in_20\IN|and|patients (r_conj) in_14\IN|.|was|influence (l_pobj) patients_16\NNS|in|and (l_prep) with_17\IN| (l_pobj) hypokalemia_18\NN|NONE
D012964_D007008 NONE sodium_49\NN|, (r_conj) potassium_47\NN|NONE (r_pobj) of_46\IN|urinary (r_prep) excretion_45\NN|and|as|sodium (r_conj) potassium_38\NN|NONE (r_pobj) of_37\IN|plasma (r_prep) concentration_36\NN|,|filtration|glomerular (r_conj) rate_33\NN|renal|,|plasma (r_conj) flow_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) determination_25\NN|NONE (r_pobj) by_24\IN|normokalemic| (r_prep) patients_23\NNS|NONE (r_pobj) in_20\IN|and|patients (r_conj) in_14\IN|.|was|influence (l_pobj) patients_16\NNS|in|and (l_prep) with_17\IN| (l_pobj) hypokalemia_18\NN|NONE
D007980_D007008 CID dopa_11\NN| (r_npadvmod) treated_13\VBN|some|parkinsonian (r_amod) patients_15\NNS|NONE (r_pobj) in_7\IN|Hypokalemia|was|. (r_prep) observed_6\VBN|NONE (l_nsubjpass) Hypokalemia_0\NNP|in|was|.
D007980_D007008 CID dopa_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) influence_1\NN|.|in|was (r_nsubjpass) studied_13\VBN|NONE (l_prep) in_14\IN|.|was|influence (l_pobj) patients_16\NNS|in|and (l_prep) with_17\IN| (l_pobj) hypokalemia_18\NN|NONE
D007980_D010300 NONE dopa_5\NN|in (r_compound) treatment_6\NN|NONE (l_prep) in_7\IN|dopa (l_pobj) patients_9\NNS|NONE (l_amod) parkinsonian_8\JJ|NONE
D007980_D010300 NONE dopa_11\NN| (r_npadvmod) treated_13\VBN|some|parkinsonian (r_amod) patients_15\NNS|NONE (l_amod) parkinsonian_14\JJ|treated|some
20129423
D002220_D004802 CID carbamazepine_1\NN|.|hypersensitivity (r_nsubj) induced_2\VBD|NONE (l_dobj) hypersensitivity_6\NN|.|carbamazepine (l_amod) eosinophilic_4\JJ|myocarditis|fulminant|(|)|emphasis
D002220_D009205 CID carbamazepine_1\NN|.|hypersensitivity (r_nsubj) induced_2\VBD|NONE (l_dobj) hypersensitivity_6\NN|.|carbamazepine (l_amod) myocarditis_8\NN|fulminant|eosinophilic|(|)|emphasis
D002220_D009205 CID carbamazepine_10\NN|NONE (r_pobj) of_9\IN|rare|side (r_prep) effect_8\NN|.|,|is|although|myocarditis|fatal (r_nsubj) necrotizing_12\VBG|NONE (l_oprd) myocarditis_17\NN|.|,|is|although|fatal|effect
D002220_D009205 CID carbamazepine_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) administration_9\NN|NONE (r_pobj) to_8\IN|myocarditis (r_prep) secondary_7\JJ|NONE (l_advmod) myocarditis_6\NN|to
D002220_D009205 CID carbamazepine_12\NN|NONE (r_pobj) of_10\IN|second|the|induced (r_prep) case_9\NN|this|To|. (l_acl) induced_13\VBN|second|of|the (l_dobj) myocarditis_14\NN|NONE
D002220_D004342 CID carbamazepine_1\NN|.|hypersensitivity (r_nsubj) induced_2\VBD|NONE (l_dobj) hypersensitivity_6\NN|.|carbamazepine
D002220_D004342 CID carbamazepine_1\NN|.|hypersensitivity (r_nsubj) induced_2\VBD|NONE (l_dobj) hypersensitivity_6\NN|.|carbamazepine (l_appos) emphasis_10\NN|myocarditis|fulminant|eosinophilic|(|) (l_prep) on_11\IN|NONE (l_pobj) characteristics_15\NNS|NONE (l_prep) of_20\IN|,|anatomical|mechanisms (l_pobj) hypersensitivity_22\NN|NONE
D002220_D004342 CID carbamazepine_10\NN|NONE (r_pobj) of_9\IN|rare|side (r_prep) effect_8\NN|.|,|is|although|myocarditis|fatal (r_nsubj) necrotizing_12\VBG|NONE (l_oprd) myocarditis_17\NN|.|,|is|although|fatal|effect (l_nmod) hypersensitivity_15\NN|eosinophilic
D002220_D004342 CID carbamazepine_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) administration_9\NN|NONE (r_pobj) to_8\IN|myocarditis (r_prep) secondary_7\JJ|NONE (r_amod) hypersensitivity_5\NN|NONE
10327032
D000644_D001424 NONE ammonium_2\NN|onset|Higher|and (r_compound) levels_3\NNS|in|.|and|in|were (r_nsubjpass) seen_11\VBN|NONE (l_prep) in_12\IN|levels|.|and|in|were (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN| (l_pobj) infections_17\NNS|NONE
D005472_D007239 NONE 5-fluorouracil_13\CD|complication (r_punct) with_14\IN|who|infusion (l_pobj) complication_16\NN|fluorouracil (l_prep) of_17\IN|the (l_pobj) dehydration_18\NN|NONE (l_conj) infection_20\NN|and
D005472_D009369 NONE 5-fluorouracil_13\CD|complication (r_punct) with_14\IN|who|infusion (r_prep) received_9\VBD|cancer (r_relcl) patients_7\NNS|NONE (l_compound) cancer_6\NN|received
D005472_D009369 NONE 5-fluorouracil_21\CD|( (r_punct) 5-FU_23\CD|NONE (r_pobj) of_20\IN|continuous (r_prep) infusion_19\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) related_16\VBN|hyperammonemic|transient (r_acl) encephalopathy_15\NN|NONE (r_pobj) of_12\IN| (r_prep) episodes_11\NNS|who (r_dobj) had_9\VBD|)||cancer (r_relcl) patients_7\NNS|,|From|.|were (l_compound) cancer_6\NN|had|)|
D005472_D009369 NONE 5-FU_23\CD|NONE (r_pobj) of_20\IN|continuous (r_prep) infusion_19\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) related_16\VBN|hyperammonemic|transient (r_acl) encephalopathy_15\NN|NONE (r_pobj) of_12\IN| (r_prep) episodes_11\NNS|who (r_dobj) had_9\VBD|)||cancer (r_relcl) patients_7\NNS|,|From|.|were (l_compound) cancer_6\NN|had|)|
D005472_D003681 NONE 5-fluorouracil_13\CD|complication (r_punct) with_14\IN|who|infusion (l_pobj) complication_16\NN|fluorouracil (l_prep) of_17\IN|the (l_pobj) dehydration_18\NN|NONE
D000644_D022124 NONE ammonium_2\NN|onset|Higher|and (r_compound) levels_3\NNS|in|.|and|in|were (l_conj) onset_7\NN|ammonium|Higher|and (l_prep) of_8\IN|rapid (l_pobj) hyperammonemia_9\NN|NONE
D005472_D022124 CID 5-fluorouracil_13\CD|complication (r_punct) with_14\IN|who|infusion (r_prep) received_9\VBD|cancer (r_relcl) patients_7\NNS|NONE (r_pobj) in_5\IN|transient|hyperammonemic (r_prep) encephalopathy_4\NN|NONE
D005472_D022124 CID 5-fluorouracil_21\CD|( (r_punct) 5-FU_23\CD|NONE (r_pobj) of_20\IN|continuous (r_prep) infusion_19\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) related_16\VBN|hyperammonemic|transient (r_acl) encephalopathy_15\NN|NONE
D005472_D022124 CID 5-FU_23\CD|NONE (r_pobj) of_20\IN|continuous (r_prep) infusion_19\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) related_16\VBN|hyperammonemic|transient (r_acl) encephalopathy_15\NN|NONE
D005472_D022124 CID 5-FU_42\CD|NONE (r_pobj) of_41\IN|(|high|m|)|daily (r_prep) doses_32\NNS|respectively (r_dobj) receiving_29\VBG|nine (r_acl) patients_28\NNS|) (r_pobj) in_26\IN|in|levels|.|and|were (r_prep) seen_11\VBN|NONE (l_nsubjpass) levels_3\NNS|in|.|and|in|were (l_conj) onset_7\NN|ammonium|Higher|and (l_prep) of_8\IN|rapid (l_pobj) hyperammonemia_9\NN|NONE
D005472_D022124 CID 5-FU_13\CD|NONE (r_pobj) of_12\IN|continuous (r_prep) infusion_11\NN|NONE (r_dobj) receiving_9\VBG|NONE (r_acl) patients_8\NNS|NONE (r_pobj) in_7\IN|.|In|encephalopathy|,|can (r_prep) occur_6\VB|NONE (l_nsubj) encephalopathy_4\NN|.|In|,|can|in
D005472_D001424 NONE 5-FU_42\CD|NONE (r_pobj) of_41\IN|(|high|m|)|daily (r_prep) doses_32\NNS|respectively (r_dobj) receiving_29\VBG|nine (r_acl) patients_28\NNS|) (r_pobj) in_26\IN|in|levels|.|and|were (r_prep) seen_11\VBN|NONE (l_prep) in_12\IN|levels|.|and|in|were (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN| (l_pobj) infections_17\NNS|NONE
D005472_D001927 CID 5-fluorouracil_13\CD|complication (r_punct) with_14\IN|who|infusion (r_prep) received_9\VBD|cancer (r_relcl) patients_7\NNS|NONE (r_pobj) in_5\IN|transient|hyperammonemic (r_prep) encephalopathy_4\NN|NONE
D005472_D001927 CID 5-fluorouracil_21\CD|( (r_punct) 5-FU_23\CD|NONE (r_pobj) of_20\IN|continuous (r_prep) infusion_19\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) related_16\VBN|hyperammonemic|transient (r_acl) encephalopathy_15\NN|NONE
D005472_D001927 CID 5-FU_23\CD|NONE (r_pobj) of_20\IN|continuous (r_prep) infusion_19\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) related_16\VBN|hyperammonemic|transient (r_acl) encephalopathy_15\NN|NONE
D005472_D001927 CID 5-FU_13\CD|NONE (r_pobj) of_12\IN|continuous (r_prep) infusion_11\NN|NONE (r_dobj) receiving_9\VBG|NONE (r_acl) patients_8\NNS|NONE (r_pobj) in_7\IN|.|In|encephalopathy|,|can (r_prep) occur_6\VB|NONE (l_nsubj) encephalopathy_4\NN|.|In|,|can|in
3109094
D015080_D001745 NONE mesna_20\NN|NONE (r_pobj) by_19\IN|their (r_prep) prevention_18\NN|and|of|induced|the (r_conj) lesions_8\NNS|NONE (l_prep) of_9\IN|and|prevention|induced|the (l_pobj) bladder_12\NN|NONE
D003520_D004487 NONE cyclophosphamide_2\NN| (r_npadvmod) induced_4\VBN|developed (r_amod) cystitis_5\NN|is|edema|.|by (r_nsubjpass) characterized_7\VBN|NONE (l_dobj) edema_18\NN|is|.|by|cystitis
D003520_D003556 NONE cyclophosphamide_2\NN| (r_npadvmod) induced_4\VBN|developed (r_amod) cystitis_5\NN|is|edema|.|by
D003520_D001745 CID cyclophosphamide_5\NN| (r_npadvmod) induced_7\VBN|and|prevention|of|the (r_amod) lesions_8\NNS|NONE (l_prep) of_9\IN|and|prevention|induced|the (l_pobj) bladder_12\NN|NONE
D003520_D009336 NONE cyclophosphamide_2\NN| (r_npadvmod) induced_4\VBN|developed (r_amod) cystitis_5\NN|is|edema|.|by (r_nsubjpass) characterized_7\VBN|NONE (l_dobj) edema_18\NN|is|.|by|cystitis (l_acl) owing_19\VBG|,|submucosal|severe (l_prep) to_20\IN|NONE (l_pobj) damage_21\NN|NONE (l_prep) to_22\IN|NONE (l_pobj) bed_25\NN|NONE (l_conj) necroses_29\NNS|the|and|microvascular
11380496
D011441_D019226 CID PTU_36\NNP|NONE (r_compound) therapy_37\NN|NONE (r_dobj) stopping_35\VBG|weeks (r_pcomp) after_34\IN|decreased|,|and|symptoms (r_prep) resolved_31\VBD|she|fever|,|but (r_conj) developed_18\VBD|,|In|to|and|titre (l_dobj) fever_21\NN|she|resolved|,|but (l_conj) ulcers_24\NNS|higher|,|a
D011441_D019226 CID PTU_56\NNP|NONE (r_dobj) discontinuing_55\VBG|NONE (r_pcomp) after_54\IN|by|titre|to|. (r_prep) decreased_45\VBD|,|after|and|symptoms (r_conj) resolved_31\VBD|she|fever|,|but (r_conj) developed_18\VBD|,|In|to|and|titre (l_dobj) fever_21\NN|she|resolved|,|but (l_conj) ulcers_24\NNS|higher|,|a
D011441_D018771 CID PTU_36\NNP|NONE (r_compound) therapy_37\NN|NONE (r_dobj) stopping_35\VBG|weeks (r_pcomp) after_34\IN|decreased|,|and|symptoms (r_prep) resolved_31\VBD|she|fever|,|but (r_conj) developed_18\VBD|,|In|to|and|titre (l_dobj) fever_21\NN|she|resolved|,|but (l_conj) ulcers_24\NNS|higher|,|a (l_conj) polyarthralgia_26\NN|oral|and
D011441_D018771 CID PTU_56\NNP|NONE (r_dobj) discontinuing_55\VBG|NONE (r_pcomp) after_54\IN|by|titre|to|. (r_prep) decreased_45\VBD|,|after|and|symptoms (r_conj) resolved_31\VBD|she|fever|,|but (r_conj) developed_18\VBD|,|In|to|and|titre (l_dobj) fever_21\NN|she|resolved|,|but (l_conj) ulcers_24\NNS|higher|,|a (l_conj) polyarthralgia_26\NN|oral|and
D011441_D005334 CID PTU_36\NNP|NONE (r_compound) therapy_37\NN|NONE (r_dobj) stopping_35\VBG|weeks (r_pcomp) after_34\IN|decreased|,|and|symptoms (r_prep) resolved_31\VBD|she|fever|,|but (r_conj) developed_18\VBD|,|In|to|and|titre (l_dobj) fever_21\NN|she|resolved|,|but
D011441_D005334 CID PTU_56\NNP|NONE (r_dobj) discontinuing_55\VBG|NONE (r_pcomp) after_54\IN|by|titre|to|. (r_prep) decreased_45\VBD|,|after|and|symptoms (r_conj) resolved_31\VBD|she|fever|,|but (r_conj) developed_18\VBD|,|In|to|and|titre (l_dobj) fever_21\NN|she|resolved|,|but
D011441_D006111 NONE propylthiouracil_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) treated_19\VBN|disease|Graves (r_acl) patients_18\NNS|NONE (l_compound) disease_17\NN|treated|Graves
D011441_D006111 NONE propylthiouracil_22\NN|NONE (r_pobj) with_21\IN|were|who (r_prep) treated_20\VBN|Graves (r_relcl) disease_17\NN|NONE
D011441_D006111 NONE PTU_24\NNP|NONE (r_appos) propylthiouracil_22\NN|NONE (r_pobj) with_21\IN|were|who (r_prep) treated_20\VBN|Graves (r_relcl) disease_17\NN|NONE
D011441_D006111 NONE PTU_21\NNP|NONE (r_compound) therapy_22\NN|NONE (r_pobj) during_20\IN|the|of (r_prep) appearance_13\NN|NONE (r_pobj) between_11\IN|the|temporal (r_prep) relationship_10\NN|NONE (r_pobj) on_7\IN|no (r_prep) studies_6\NNS|there|,|,|on|Nevertheless|or|.|have (r_attr) been_4\VBN|NONE (l_conj) on_25\IN|there|,|,|Nevertheless|or|studies|.|have (l_pobj) ANCA_31\NNP|incidence| (l_prep) in_32\IN|NONE (l_pobj) patients_37\NNS|NONE (l_compound) disease_36\NN|Graves
D011441_D006111 NONE PTU_27\NNP|NONE (r_compound) therapy_28\NN|NONE (r_dobj) starting_26\VBG|NONE (r_pcomp) after_25\IN|development|the (r_prep) vasculitis_24\NN|NONE (r_pobj) for_21\IN|We|due|.|patients|and|, (r_conj) investigated_1\VBD|NONE (l_prep) due_7\IN|We|.|patients|and|,|for (l_pobj) disease_11\NN|to
D011441_D014652 NONE PTU_24\NNP|continued (r_compound) therapy_25\NN|NONE (r_pobj) despite_22\IN|respectively|,|,|titres|but|developed|,|In|transiently|to|, (r_prep) increased_11\VBD|NONE (l_conj) developed_31\VBD|respectively|despite|,|,|titres|but|,|In|transiently|to|, (l_nsubj) disorders_30\NNS|.
D011441_D014657 NONE propylthiouracil_22\NN|NONE (r_pobj) with_21\IN|were|who (r_prep) treated_20\VBN|Graves (r_relcl) disease_17\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) in_12\IN|been|has|vasculitis|. (r_prep) reported_11\VBN|NONE (l_nsubjpass) vasculitis_8\NN|been|has|in|.
D011441_D014657 NONE PTU_24\NNP|NONE (r_appos) propylthiouracil_22\NN|NONE (r_pobj) with_21\IN|were|who (r_prep) treated_20\VBN|Graves (r_relcl) disease_17\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) in_12\IN|been|has|vasculitis|. (r_prep) reported_11\VBN|NONE (l_nsubjpass) vasculitis_8\NN|been|has|in|.
D011441_D014657 NONE PTU_21\NNP|NONE (r_compound) therapy_22\NN|NONE (r_pobj) during_20\IN|the|of (r_prep) appearance_13\NN|NONE (l_prep) of_14\IN|the|during (l_pobj) MPO_15\NNP|NONE (l_appos) ANCA_17\NNP| (l_conj) vasculitis_19\NN|and
D011441_D014657 NONE PTU_27\NNP|NONE (r_compound) therapy_28\NN|NONE (r_dobj) starting_26\VBG|NONE (r_pcomp) after_25\IN|development|the (r_prep) vasculitis_24\NN|NONE
D011441_D006980 NONE PTU_27\NNP|NONE (r_compound) therapy_28\NN|NONE (r_dobj) starting_26\VBG|NONE (r_pcomp) after_25\IN|development|the (r_prep) vasculitis_24\NN|NONE (r_pobj) for_21\IN|We|due|.|patients|and|, (r_conj) investigated_1\VBD|NONE (l_dobj) patients_4\NNS|We|due|.|and|,|for (l_prep) with_5\IN||untreated (l_pobj) hyperthyroidism_6\NN|NONE
11176729
D017706_D006333 NONE lisinopril_15\NN|NONE (l_prep) in_16\IN|dose (l_pobj) CHF_17\NNP|NONE
D000806_D006947 NONE inhibitor_8\NN|previously|not (r_dobj) receiving_5\VBG| (r_acl) patients_2\NNS|NONE (r_pobj) Of_0\IN|to|be|or|,|could|not|because|doses|.|because (r_prep) titrated_18\VBN|NONE (l_conj) because_38\IN|to|be|or|,|could|not|Of|doses|.|because (l_pobj) dysfunction_41\NN|of (l_conj) hyperkalemia_43\NN|or|(|)|renal|%
D000806_D007022 NONE inhibitor_8\NN|previously|not (r_dobj) receiving_5\VBG| (r_acl) patients_2\NNS|NONE (r_pobj) Of_0\IN|to|be|or|,|could|not|because|doses|.|because (r_prep) titrated_18\VBN|NONE (l_prep) because_26\IN|to|be|or|,|could|not|Of|because|doses|. (l_pobj) symptoms_28\NNS|of (l_acl) related_30\VBD|NONE (l_prep) to_31\IN|possibly (l_pobj) hypotension_32\NN|NONE
D000806_D006333 NONE inhibitors_9\NNS|NONE (r_pobj) of_4\IN|high (r_prep) doses_3\NNS|NONE (r_pobj) of_1\IN|in|results|.|: (r_prep) Toleration_0\NN|NONE (l_prep) in_10\IN|of|results|.|: (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) failure_15\NN|NONE
D000806_D006333 NONE inhibitors_9\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|receiving|mortality|,|but (r_nsubj) reduces_10\VBZ|NONE (l_dobj) mortality_11\NN|receiving|Treatment|,|but (l_prep) in_14\IN|morbidity|and (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) failure_19\NN|NONE
D000806_D006333 NONE inhibitors_9\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|receiving|mortality|,|but (r_nsubj) reduces_10\VBZ|NONE (l_dobj) mortality_11\NN|receiving|Treatment|,|but (l_prep) in_14\IN|morbidity|and (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) failure_19\NN|NONE (l_appos) CHF_21\NNP|heart|chronic
D000806_D006333 NONE inhibitor_5\NN|ACE|in (r_compound) therapy_6\NN|can|maintained|be|and|successfully|to|,|that|warranted|and (l_prep) in_7\IN|inhibitor|ACE (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|most (l_pobj) CHF_11\NNP|NONE
D000806_D007674 NONE inhibitor_8\NN|previously|not (r_dobj) receiving_5\VBG| (r_acl) patients_2\NNS|NONE (r_pobj) Of_0\IN|to|be|or|,|could|not|because|doses|.|because (r_prep) titrated_18\VBN|NONE (l_conj) because_38\IN|to|be|or|,|could|not|Of|doses|.|because (l_pobj) dysfunction_41\NN|of
2383364
C048279_D010146 CID CHP_6\NNP|ratings|and (r_compound) concentration_7\NN|NONE (l_conj) ratings_11\NNS|and|CHP (l_prep) of_12\IN|on|patients (l_pobj) pain_13\NN|NONE
C048279_D010146 CID CHP_4\NNP|cent|The|. (r_compound) cream_5\NN|closest|in (r_nsubj) was_6\VBD|;|however|statistically|none|,|from|. (l_prep) in_10\IN|cream|closest (l_pobj) tolerance_12\NN|NONE (l_compound) pain_11\NN|NONE
C048279_D002056 NONE diphosphanilate_6\NN|NONE (r_pobj) of_3\IN|agent|tolerance|:|. (r_prep) study_2\NN|NONE (l_appos) agent_11\NN|of|tolerance|:|. (l_prep) for_12\IN|new|a|topical (l_pobj) burns_13\NNS|NONE
C048279_D002056 NONE phosphanilate_1\NN|has|as|but|,|been|reported (r_nsubjpass) evaluated_16\VBN|NONE (l_prep) as_17\IN|has|but|,|been|reported|phosphanilate (l_pobj) wound_21\NN|NONE (l_compound) burn_20\NN|dressing|topical|a
C048279_D002056 NONE CHP_3\NNP|,|agent|,|Chlorhexidine (r_appos) phosphanilate_1\NN|has|as|but|,|been|reported (r_nsubjpass) evaluated_16\VBN|NONE (l_prep) as_17\IN|has|but|,|been|reported|phosphanilate (l_pobj) wound_21\NN|NONE (l_compound) burn_20\NN|dressing|topical|a
C048279_D002056 NONE CHP_10\NNP|four|different (r_compound) concentrations_11\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) each_6\DT|NONE (r_pobj) with_5\IN|vehicle|was|,|,|site|.|from (r_prep) treated_4\VBN|NONE (l_nsubjpass) site_2\NN|vehicle|was|,|,|.|from|with (l_compound) burn_1\NN|One
C048279_D002056 NONE CHP_10\NNP|four|different (r_compound) concentrations_11\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) each_6\DT|NONE (r_pobj) with_5\IN|vehicle|was|,|,|site|.|from (r_prep) treated_4\VBN|NONE (l_dobj) vehicle_23\NN|was|,|,|site|.|from|with (l_conj) cream_34\NN|their|and|, (l_appos) agent_38\NN||)|,|sulphadiazine|(|AgSD (l_acl) used_40\VBN|an|antimicrobial (l_prep) for_41\IN|frequently (l_pobj) treatment_43\NN|NONE (l_prep) of_44\IN|topical (l_pobj) wounds_46\NNS|NONE (l_compound) burn_45\NN|NONE
D012837_D010146 NONE AgSD_9\NNP|NONE (r_pobj) to_8\IN|NONE (r_prep) closest_7\JJS|cream|in (r_acomp) was_6\VBD|;|however|statistically|none|,|from|. (l_prep) in_10\IN|cream|closest (l_pobj) tolerance_12\NN|NONE (l_compound) pain_11\NN|NONE
D012837_D010146 NONE AgSD_23\NNP|from|or (r_pobj) from_22\IN|;|however|statistically|none|was|,|. (r_prep) differed_20\VBD|NONE (l_ccomp) was_6\VBD|;|however|statistically|none|,|from|. (l_prep) in_10\IN|cream|closest (l_pobj) tolerance_12\NN|NONE (l_compound) pain_11\NN|NONE
D012837_D002056 NONE sulphadiazine_30\NN||)|,|agent|(|AgSD (r_nmod) cream_34\NN|their|and|, (r_conj) vehicle_23\NN|was|,|,|site|.|from|with (r_dobj) treated_4\VBN|NONE (l_nsubjpass) site_2\NN|vehicle|was|,|,|.|from|with (l_compound) burn_1\NN|One
D012837_D002056 NONE sulphadiazine_30\NN||)|,|agent|(|AgSD (r_nmod) cream_34\NN|their|and|, (l_appos) agent_38\NN||)|,|sulphadiazine|(|AgSD (l_acl) used_40\VBN|an|antimicrobial (l_prep) for_41\IN|frequently (l_pobj) treatment_43\NN|NONE (l_prep) of_44\IN|topical (l_pobj) wounds_46\NNS|NONE (l_compound) burn_45\NN|NONE
D012837_D002056 NONE AgSD_32\NNP||)|,|agent|sulphadiazine|( (r_nmod) cream_34\NN|their|and|, (r_conj) vehicle_23\NN|was|,|,|site|.|from|with (r_dobj) treated_4\VBN|NONE (l_nsubjpass) site_2\NN|vehicle|was|,|,|.|from|with (l_compound) burn_1\NN|One
D012837_D002056 NONE AgSD_32\NNP||)|,|agent|sulphadiazine|( (r_nmod) cream_34\NN|their|and|, (l_appos) agent_38\NN||)|,|sulphadiazine|(|AgSD (l_acl) used_40\VBN|an|antimicrobial (l_prep) for_41\IN|frequently (l_pobj) treatment_43\NN|NONE (l_prep) of_44\IN|topical (l_pobj) wounds_46\NNS|NONE (l_compound) burn_45\NN|NONE
9725303
D019469_D015658 NONE indinavir_17\NNS|NONE (r_dobj) receiving_16\VBG|six|infected (r_acl) patients_15\NNS|NONE (l_amod) infected_14\VBN|six|receiving
D019469_D015658 NONE indinavir_25\NNS|NONE (r_compound) therapy_26\NN|who (r_dobj) receive_24\VBP|with (r_relcl) patients_19\NNS|NONE (l_prep) with_20\IN|receive (l_pobj) infection_22\NN|NONE
D019469_D014514 CID indinavir_17\NNS|NONE (r_dobj) receiving_16\VBG|six|infected (r_acl) patients_15\NNS|NONE (r_pobj) in_10\IN|,|.|features|inhibitor|We|: (r_prep) describe_2\VBP|NONE (l_dobj) features_6\NNS|,|.|in|inhibitor|We|: (l_prep) of_7\IN|CT|unique|the (l_pobj) calculi_9\NNS|NONE
D019469_D014514 NONE indinavir_25\NNS|NONE (r_compound) therapy_26\NN|who (r_dobj) receive_24\VBP|with (r_relcl) patients_19\NNS|NONE (r_pobj) in_18\IN|or|obstruction|ureteric (r_prep) stones_15\NNS|NONE (l_conj) obstruction_17\NN|or|in|ureteric
D019469_D052878 NONE indinavir_17\NNS|NONE (r_dobj) receiving_16\VBG|six|infected (r_acl) patients_15\NNS|NONE (r_pobj) in_10\IN|,|.|features|inhibitor|We|: (r_prep) describe_2\VBP|NONE (l_dobj) inhibitor_25\NN|,|.|features|in|We|: (l_relcl) associated_29\VBN|,|the|protease|used (l_prep) with_30\IN|which|is (l_pobj) incidence_33\NN|NONE (l_prep) of_34\IN|an|increased (l_pobj) urolithiasis_35\NN|NONE
D019469_D014517 NONE indinavir_11\NNS|NONE (r_compound) therapy_12\NN|NONE (r_dobj) undergoing_10\VBG|with (r_acl) patients_7\NNS|NONE (r_pobj) in_6\IN|obstruction (r_prep) causing_3\VBG|crystal|. (l_dobj) obstruction_5\NN|in
D019469_D014517 NONE indinavir_5\JJ|precipitated (r_compound) crystals_6\NNS|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|Ureteric (r_acl) obstruction_1\NN|difficult|.|may
D019469_D014517 NONE indinavir_25\NNS|NONE (r_compound) therapy_26\NN|who (r_dobj) receive_24\VBP|with (r_relcl) patients_19\NNS|NONE (r_pobj) in_18\IN|or|obstruction|ureteric (r_prep) stones_15\NNS|NONE (l_conj) obstruction_17\NN|or|in|ureteric
10401555
D012601_D008569 CID scopolamine_13\NN|NONE (r_pobj) by_12\IN|in (r_agent) induced_11\VBN|learning (r_acl) impairment_10\NN|NONE
D012601_D008569 CID scopolamine_23\NN|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|of (r_acl) impairment_16\NN|whether|could|using|FQ (l_prep) of_17\IN|induced (l_pobj) learning_18\NN|NONE (l_conj) memory_20\NN|and
D012601_D007859 CID scopolamine_13\NN|NONE (r_pobj) by_12\IN|in (r_agent) induced_11\VBN|learning (r_acl) impairment_10\NN|NONE
D012601_D007859 CID scopolamine_23\NN|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|of (r_acl) impairment_16\NN|whether|could|using|FQ (l_prep) of_17\IN|induced (l_pobj) learning_18\NN|NONE (l_conj) memory_20\NN|and
C111148_D006930 NONE nocistatin_5\NN|,|On|recently|from|.|is (r_advmod) isolated_8\VBN|NONE (l_prep) from_9\IN|,|On|nocistatin|recently|.|is (l_pobj) precursor_12\NN|NONE (l_prep) as_13\IN|the|same (l_pobj) allodynia_20\NN|nociceptin
C111148_D006930 NONE nocistatin_5\NN|,|On|recently|from|.|is (r_advmod) isolated_8\VBN|NONE (l_prep) from_9\IN|,|On|nocistatin|recently|.|is (l_pobj) precursor_12\NN|NONE (l_prep) as_13\IN|the|same (l_pobj) allodynia_20\NN|nociceptin (l_conj) hyperalgesia_22\NN|induced|and
C096012_D007859 NONE Nociceptin_0\NNP|/ (r_nmod) orphanin_2\NN|and|.|nocistatin (r_compound) FQ_3\NNP|NONE (l_conj) nocistatin_5\NNS|orphanin|and|. (l_prep) on_6\IN|NONE (l_pobj) impairment_10\NN|NONE
C096012_D007859 NONE FQ_3\NNP|NONE (l_conj) nocistatin_5\NNS|orphanin|and|. (l_prep) on_6\IN|NONE (l_pobj) impairment_10\NN|NONE
C096012_D007859 NONE nociceptin_8\NN|/ (r_nmod) orphanin_10\VB|and|nocistatin (r_compound) FQ_11\NNP|whether|could|impairment|using (r_nsubj) modulate_15\VB|to (l_dobj) impairment_16\NN|whether|could|using|FQ (l_prep) of_17\IN|induced (l_pobj) learning_18\NN|NONE (l_conj) memory_20\NN|and
C096012_D007859 NONE FQ_11\NNP|whether|could|impairment|using (r_nsubj) modulate_15\VB|to (l_dobj) impairment_16\NN|whether|could|using|FQ (l_prep) of_17\IN|induced (l_pobj) learning_18\NN|NONE (l_conj) memory_20\NN|and
C111148_D007859 NONE nocistatin_5\NNS|orphanin|and|. (l_prep) on_6\IN|NONE (l_pobj) impairment_10\NN|NONE
C111148_D007859 NONE nocistatin_13\NN|and|orphanin (r_conj) FQ_11\NNP|whether|could|impairment|using (r_nsubj) modulate_15\VB|to (l_dobj) impairment_16\NN|whether|could|using|FQ (l_prep) of_17\IN|induced (l_pobj) learning_18\NN|NONE (l_conj) memory_20\NN|and
C096012_D008569 NONE Nociceptin_0\NNP|/ (r_nmod) orphanin_2\NN|and|.|nocistatin (r_compound) FQ_3\NNP|NONE (l_conj) nocistatin_5\NNS|orphanin|and|. (l_prep) on_6\IN|NONE (l_pobj) impairment_10\NN|NONE
C096012_D008569 NONE FQ_3\NNP|NONE (l_conj) nocistatin_5\NNS|orphanin|and|. (l_prep) on_6\IN|NONE (l_pobj) impairment_10\NN|NONE
C096012_D008569 NONE nociceptin_8\NN|/ (r_nmod) orphanin_10\VB|and|nocistatin (r_compound) FQ_11\NNP|whether|could|impairment|using (r_nsubj) modulate_15\VB|to (l_dobj) impairment_16\NN|whether|could|using|FQ (l_prep) of_17\IN|induced (l_pobj) learning_18\NN|NONE (l_conj) memory_20\NN|and
C096012_D008569 NONE FQ_11\NNP|whether|could|impairment|using (r_nsubj) modulate_15\VB|to (l_dobj) impairment_16\NN|whether|could|using|FQ (l_prep) of_17\IN|induced (l_pobj) learning_18\NN|NONE (l_conj) memory_20\NN|and
C111148_D008569 NONE nocistatin_5\NNS|orphanin|and|. (l_prep) on_6\IN|NONE (l_pobj) impairment_10\NN|NONE
C111148_D008569 NONE nocistatin_13\NN|and|orphanin (r_conj) FQ_11\NNP|whether|could|impairment|using (r_nsubj) modulate_15\VB|to (l_dobj) impairment_16\NN|whether|could|using|FQ (l_prep) of_17\IN|induced (l_pobj) learning_18\NN|NONE (l_conj) memory_20\NN|and
C096012_D006930 NONE nociceptin_14\NN|allodynia (r_amod) as_13\IN|the|same (l_pobj) allodynia_20\NN|nociceptin
C096012_D006930 NONE nociceptin_14\NN|allodynia (r_amod) as_13\IN|the|same (l_pobj) allodynia_20\NN|nociceptin (l_conj) hyperalgesia_22\NN|induced|and
C096012_D006930 NONE nociceptin_17\RB| (r_advmod) induced_19\VBN|hyperalgesia|and (r_amod) allodynia_20\NN|nociceptin
C096012_D006930 NONE nociceptin_17\RB| (r_advmod) induced_19\VBN|hyperalgesia|and (r_amod) allodynia_20\NN|nociceptin (l_conj) hyperalgesia_22\NN|induced|and
3323259
D009553_D008881 NONE nimodipine_6\RB|in|potentially (r_nsubj) useful_8\JJ|.|Selectivity (l_prep) in_9\IN|nimodipine|potentially (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) hemorrhage_14\NN|NONE (l_conj) headache_17\NN|,|subarachnoid
C038806_D006973 NONE dihydropyridine_3\NN|for|As|the|first (r_advmod) available_4\JJ|angina|,|.|nifedipine (r_advcl) controls_13\NNS|NONE (l_dobj) angina_14\NN|,|available|.|nifedipine (l_conj) hypertension_16\NN|with|and
D015737_D000787 NONE nisoldipine_5\NN|NONE (r_pobj) of_4\IN|vasodilating|The|coronary (r_prep) properties_3\NNS|to|have|. (r_nsubj) led_7\VBN|NONE (l_prep) to_8\IN|properties|have|. (l_pobj) investigation_10\NN|NONE (l_prep) for_14\IN|of|the (l_pobj) use_15\NN|NONE (l_prep) in_16\IN|NONE (l_pobj) angina_17\NN|NONE
D009543_D000787 NONE nifedipine_12\NN|angina|,|available|. (r_amod) controls_13\NNS|NONE (l_dobj) angina_14\NN|,|available|.|nifedipine
C038806_D005483 NONE dihydropyridine_4\JJ|NONE (r_compound) calcium_5\NN|the (r_compound) channel_6\NN|NONE (r_compound) blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|,
C038806_D004244 NONE dihydropyridine_4\JJ|NONE (r_compound) calcium_5\NN|the (r_compound) channel_6\NN|NONE (r_compound) blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|, (l_conj) edema_21\NN|, (l_conj) nausea_23\NN|, (l_conj) anorexia_25\NN|, (l_conj) dizziness_28\NN|,|and
D009553_D013345 NONE nimodipine_6\RB|in|potentially (r_nsubj) useful_8\JJ|.|Selectivity (l_prep) in_9\IN|nimodipine|potentially (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) hemorrhage_14\NN|NONE
D002121_D004487 CID blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|, (l_conj) edema_21\NN|,
D002121_D005483 CID blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|,
D009553_D003704 NONE nimodipine_6\RB|in|potentially (r_nsubj) useful_8\JJ|.|Selectivity (l_prep) in_9\IN|nimodipine|potentially (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) hemorrhage_14\NN|NONE (l_conj) headache_17\NN|,|subarachnoid (l_conj) dementia_19\NN|,|migraine
C038806_D006261 NONE dihydropyridine_4\JJ|NONE (r_compound) calcium_5\NN|the (r_compound) channel_6\NN|NONE (r_compound) blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being
D009568_D006973 NONE nitrendipine_7\NN|NONE (r_pobj) with_6\IN|daily|possible|Once (r_prep) dosage_4\NN|schedule|. (r_nsubj) offers_10\VBZ|NONE (l_dobj) schedule_14\NN|dosage|. (l_relcl) encourages_17\VBZ|administration|convenient|,|a (l_dobj) compliance_19\NN|which (l_prep) in_20\IN|patient (l_pobj) therapy_24\NN|NONE (l_prep) of_25\IN|term (l_pobj) hypertension_26\NN|NONE
D002121_D006261 CID blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being
C038806_D000855 NONE dihydropyridine_4\JJ|NONE (r_compound) calcium_5\NN|the (r_compound) channel_6\NN|NONE (r_compound) blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|, (l_conj) edema_21\NN|, (l_conj) nausea_23\NN|, (l_conj) anorexia_25\NN|,
D015737_D006973 NONE nisoldipine_9\NN|and (r_conj) nitrendipine_7\NN|NONE (r_pobj) with_6\IN|daily|possible|Once (r_prep) dosage_4\NN|schedule|. (r_nsubj) offers_10\VBZ|NONE (l_dobj) schedule_14\NN|dosage|. (l_relcl) encourages_17\VBZ|administration|convenient|,|a (l_dobj) compliance_19\NN|which (l_prep) in_20\IN|patient (l_pobj) therapy_24\NN|NONE (l_prep) of_25\IN|term (l_pobj) hypertension_26\NN|NONE
D009553_D020521 NONE nimodipine_6\RB|in|potentially (r_nsubj) useful_8\JJ|.|Selectivity (l_prep) in_9\IN|nimodipine|potentially (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) hemorrhage_14\NN|NONE (l_conj) headache_17\NN|,|subarachnoid (l_conj) dementia_19\NN|,|migraine (l_conj) stroke_22\NN|,|and
D002121_D000855 CID blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|, (l_conj) edema_21\NN|, (l_conj) nausea_23\NN|, (l_conj) anorexia_25\NN|,
D002121_-1 NONE blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|,
D009543_D006973 NONE nifedipine_12\NN|angina|,|available|. (r_amod) controls_13\NNS|NONE (l_dobj) angina_14\NN|,|available|.|nifedipine (l_conj) hypertension_16\NN|with|and
D002121_D009325 CID blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|, (l_conj) edema_21\NN|, (l_conj) nausea_23\NN|,
C038806_-1 NONE dihydropyridine_4\JJ|NONE (r_compound) calcium_5\NN|the (r_compound) channel_6\NN|NONE (r_compound) blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|,
C038806_D009325 NONE dihydropyridine_4\JJ|NONE (r_compound) calcium_5\NN|the (r_compound) channel_6\NN|NONE (r_compound) blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|, (l_conj) edema_21\NN|, (l_conj) nausea_23\NN|,
D002121_D004244 CID blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|, (l_conj) edema_21\NN|, (l_conj) nausea_23\NN|, (l_conj) anorexia_25\NN|, (l_conj) dizziness_28\NN|,|and
D002118_D002318 NONE calcium_6\NN|NONE (r_pobj) of_5\IN|the|in (r_prep) importance_4\NN|NONE (l_prep) in_7\IN|the|of (l_pobj) pathogenesis_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) disease_12\NN|NONE
D002118_D002318 NONE calcium_6\NN|NONE (r_pobj) of_5\IN|the|in (r_prep) importance_4\NN|NONE (r_pobj) of_2\IN|Increasing (r_prep) recognition_1\NN|into|has|.|research (r_nsubj) stimulated_14\VBN|NONE (l_prep) into_16\IN|has|recognition|.|research (l_pobj) use_18\NN|NONE (l_acl) blocking_22\VBG|the|of (l_prep) for_24\IN|agents (l_pobj) treatment_25\NN|NONE (l_prep) of_26\IN|NONE (l_pobj) variety_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) diseases_31\NNS|NONE
C038806_D004487 NONE dihydropyridine_4\JJ|NONE (r_compound) calcium_5\NN|the (r_compound) channel_6\NN|NONE (r_compound) blockers_7\NNS|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN|NONE (l_prep) with_13\IN|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN|being (l_conj) flushing_17\NN|, (l_conj) palpitations_19\NNS|facial|, (l_conj) edema_21\NN|,
C038806_D000787 NONE dihydropyridine_3\NN|for|As|the|first (r_advmod) available_4\JJ|angina|,|.|nifedipine (r_advcl) controls_13\NNS|NONE (l_dobj) angina_14\NN|,|available|.|nifedipine
D002121_D002318 NONE agents_23\NNS|for (r_dobj) blocking_22\VBG|the|of (r_acl) use_18\NN|NONE (r_pobj) into_16\IN|has|recognition|.|research (r_prep) stimulated_14\VBN|NONE (l_nsubj) recognition_1\NN|into|has|.|research (l_prep) of_2\IN|Increasing (l_pobj) importance_4\NN|NONE (l_prep) in_7\IN|the|of (l_pobj) pathogenesis_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) disease_12\NN|NONE
D002121_D002318 NONE agents_23\NNS|for (r_dobj) blocking_22\VBG|the|of (l_prep) for_24\IN|agents (l_pobj) treatment_25\NN|NONE (l_prep) of_26\IN|NONE (l_pobj) variety_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) diseases_31\NNS|NONE
2884595
D006632_D001927 NONE histamine_2\NN|H (r_compound) receptors_4\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Blockade_0\NN|.|mortality|may (r_nsubj) reduce_6\VB|NONE (l_dobj) mortality_7\NN|.|Blockade|may (l_prep) in_8\IN|NONE (l_pobj) encephalopathy_13\NN|NONE
D006632_D014917 NONE histamine_2\NN|H (r_compound) receptors_4\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Blockade_0\NN|.|mortality|may (r_nsubj) reduce_6\VB|NONE (l_dobj) mortality_7\NN|.|Blockade|may (l_prep) in_8\IN|NONE (l_pobj) encephalopathy_13\NN|NONE (l_compound) pertussis_9\NN|in|induced
2710809
D009116_D001919 NONE muscarine_25\NN|NONE (r_compound) receptors_26\NNS|NONE (r_pobj) on_24\IN|related|of|a|dual (r_prep) effect_18\NN|NONE (r_pobj) to_12\IN|and|speed (r_conj) to_6\IN|.|is|Bradycardia (r_prep) attributed_5\VBN|NONE (l_nsubjpass) Bradycardia_0\NNS|.|to|is
D001285_D001919 NONE atropine_20\NN| (r_npadvmod) like_22\JJ|NONE (r_amod) drugs_23\NNS|NONE (r_pobj) of_19\IN|related|a|dual|on (r_prep) effect_18\NN|NONE (r_pobj) to_12\IN|and|speed (r_conj) to_6\IN|.|is|Bradycardia (r_prep) attributed_5\VBN|NONE (l_nsubjpass) Bradycardia_0\NNS|.|to|is
C036432_D014277 NONE lactate_21\NN|NONE (r_pobj) of_17\IN|intravenous (r_prep) application_16\NN|.|to|In|, (r_nsubj) led_22\VBD|NONE (l_prep) In_0\IN|application|.|to|, (l_pobj) patient_6\NN|NONE (l_acl) suffering_7\NN|old|male|a (l_prep) from_8\IN|NONE (l_pobj) neuralgia_13\NN|NONE
C036432_D006562 NONE lactate_21\NN|NONE (r_pobj) of_17\IN|intravenous (r_prep) application_16\NN|.|to|In|, (r_nsubj) led_22\VBD|NONE (l_prep) In_0\IN|application|.|to|, (l_pobj) patient_6\NN|NONE (l_acl) suffering_7\NN|old|male|a (l_prep) from_8\IN|NONE (l_pobj) neuralgia_13\NN|NONE (l_nmod) postzosteric_11\JJ|severe|a|trigeminal
C036432_D004401 NONE lactate_21\NN|NONE (r_pobj) of_17\IN|intravenous (r_prep) application_16\NN|.|to|In|, (r_nsubj) led_22\VBD|NONE (l_prep) to_23\IN|application|.|In|, (l_pobj) reaction_29\NN|NONE (l_acl) characterized_30\VBN|a|paradoxical|lasting (l_agent) by_31\IN|NONE (l_pobj) bradycardia_33\NN|NONE (l_conj) dysarthria_35\NN|,|considerable
C036432_D001919 NONE lactate_21\NN|NONE (r_pobj) of_17\IN|intravenous (r_prep) application_16\NN|.|to|In|, (r_nsubj) led_22\VBD|NONE (l_prep) to_23\IN|application|.|In|, (l_pobj) reaction_29\NN|NONE (l_acl) characterized_30\VBN|a|paradoxical|lasting (l_agent) by_31\IN|NONE (l_pobj) bradycardia_33\NN|NONE
C036432_D003680 NONE lactate_21\NN|NONE (r_pobj) of_17\IN|intravenous (r_prep) application_16\NN|.|to|In|, (r_nsubj) led_22\VBD|NONE (l_prep) to_23\IN|application|.|In|, (l_pobj) reaction_29\NN|NONE (l_acl) characterized_30\VBN|a|paradoxical|lasting (l_agent) by_31\IN|NONE (l_pobj) bradycardia_33\NN|NONE (l_conj) dysarthria_35\NN|,|considerable (l_conj) dysphagia_38\NN|and|,
D001712_D001919 CID biperiden_3\VBN|NONE (l_nsubj) Bradycardia_0\NNS|.
D001712_D001919 CID biperiden_3\VBN|NONE (r_pobj) by_2\IN|NONE (r_agent) induced_1\VBN|NONE (r_acl) Bradycardia_0\NNS|.|to|is
12865514
D007980_D009127 NONE levodopa_29\RB| (r_npadvmod) induced_31\VBN|NONE (r_amod) dyskinesias_32\NNS|and|, (r_conj) rigidity_26\NN|particularly|,
D007980_D018476 NONE levodopa_29\RB| (r_npadvmod) induced_31\VBN|NONE (r_amod) dyskinesias_32\NNS|and|, (r_conj) rigidity_26\NN|particularly|, (r_conj) bradykinesia_24\JJ|Stages|,|)|and
D007980_D004409 CID levodopa_29\RB| (r_npadvmod) induced_31\VBN|NONE (r_amod) dyskinesias_32\NNS|and|,
D007980_D004409 CID levodopa_4\JJ|the (r_compound) dose_5\NN|NONE (r_pobj) in_2\IN|The (r_prep) reduction_1\NN|useful|. (r_nsubj) is_6\VBZ|NONE (l_acomp) useful_7\JJ|.|reduction (l_prep) in_8\IN|NONE (l_pcomp) controlling_9\VBG|NONE (l_dobj) dyskinesias_13\NNS|NONE
D007980_D010300 NONE levodopa_29\RB| (r_npadvmod) induced_31\VBN|NONE (r_amod) dyskinesias_32\NNS|and|, (r_conj) rigidity_26\NN|particularly|, (r_conj) bradykinesia_24\JJ|Stages|,|)|and (r_conj) scale_19\NN|suffering|three (r_appos) patients_3\NNS|implantation|. (l_acl) suffering_4\VBG|scale|three (l_prep) from_5\IN|NONE (l_pobj) disease_9\NN|NONE
16323982
D004967_D050171 NONE estrogen_47\NN|NONE (r_pobj) by_46\IN|NONE (r_agent) caused_45\VBN|the|hyperglyceridemic|known (r_acl) effect_44\NN|NONE
D004967_D003324 NONE estrogen_47\NN|NONE (r_pobj) by_46\IN|NONE (r_agent) caused_45\VBN|the|hyperglyceridemic|known (r_acl) effect_44\NN|NONE (r_pobj) than_38\IN|I (r_prep) other_37\JJ|arteriosclerosis|is|through|,|. (r_conj) mediated_17\VBN|NONE (l_nsubjpass) arteriosclerosis_2\NN|other|is|through|,|.
D002784_D003324 NONE cholesterol_22\NN|NONE (r_pobj) in_20\IN|NONE (r_prep) changes_19\NNS|NONE (r_pobj) through_18\IN|other|arteriosclerosis|is|,|. (r_prep) mediated_17\VBN|NONE (l_nsubjpass) arteriosclerosis_2\NN|other|is|through|,|.
D002784_D050171 NONE cholesterol_22\NN|NONE (r_pobj) in_20\IN|NONE (r_prep) changes_19\NNS|NONE (r_pobj) through_18\IN|other|arteriosclerosis|is|,|. (r_prep) mediated_17\VBN|NONE (l_conj) other_37\JJ|arteriosclerosis|is|through|,|. (l_prep) than_38\IN|I (l_pobj) effect_44\NN|NONE
D017373_D050171 CID CPA_14\NN|prolonged (r_compound) therapy_15\NN|NONE (r_pobj) by_12\IN|as (r_agent) caused_11\VBN|Ischaemic|coronary|with (r_advcl) arteriosclerosis_2\NN|other|is|through|,|. (r_nsubjpass) mediated_17\VBN|NONE (l_conj) other_37\JJ|arteriosclerosis|is|through|,|. (l_prep) than_38\IN|I (l_pobj) effect_44\NN|NONE
D017373_D003324 CID CPA_14\NN|prolonged (r_compound) therapy_15\NN|NONE (r_pobj) by_12\IN|as (r_agent) caused_11\VBN|Ischaemic|coronary|with (r_advcl) arteriosclerosis_2\NN|other|is|through|,|.
D017373_D003327 NONE CPA_7\NN|NONE (r_compound) treatment_8\NN|NONE (r_pobj) on_6\IN|. (r_prep) years_5\NNS|NONE (r_pobj) of_3\IN|a (r_prep) period_2\NN|NONE (r_pobj) After_0\IN|patients|affected|.|were|, (r_prep) found_18\VBN|NONE (l_xcomp) affected_21\VBN|patients|After|.|were|, (l_agent) by_22\IN|be|to (l_pobj) disease_25\NN|NONE
16723784
D015764_D001282 NONE bepridil_6\NN|NONE (r_amod) administration_7\NN|NONE (r_pobj) during_5\IN|adverse|for (r_prep) effects_4\NNS|NONE (l_prep) for_8\IN|during|adverse (l_pobj) fibrillation_10\NN|NONE (l_conj) flutter_12\JJ|and|atrial
D015764_D001282 NONE hydrochloride_1\NN|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN|NONE (l_prep) as_8\IN|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN|NONE (l_prep) for_12\IN|an|effective (l_pobj) fibrillation_14\NN|NONE (l_conj) flutter_20\NN|AF|atrial|(
D015764_D001282 NONE hydrochloride_1\NN|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN|NONE (l_prep) as_8\IN|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN|NONE (l_prep) for_12\IN|an|effective (l_pobj) fibrillation_14\NN|NONE (l_conj) flutter_20\NN|AF|atrial|( (l_appos) AFL_22\NNP|(|)|atrial
D015764_D001282 NONE Bpd_3\NNP|NONE (r_appos) hydrochloride_1\NN|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN|NONE (l_prep) as_8\IN|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN|NONE (l_prep) for_12\IN|an|effective (l_pobj) fibrillation_14\NN|NONE (l_conj) flutter_20\NN|AF|atrial|(
D015764_D001282 NONE Bpd_3\NNP|NONE (r_appos) hydrochloride_1\NN|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN|NONE (l_prep) as_8\IN|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN|NONE (l_prep) for_12\IN|an|effective (l_pobj) fibrillation_14\NN|NONE (l_conj) flutter_20\NN|AF|atrial|( (l_appos) AFL_22\NNP|(|)|atrial
D015764_D001282 NONE Bpd_0\NNP|was|.|to (r_nsubjpass) administered_2\VBN|NONE (l_prep) to_3\IN|was|.|Bpd (l_pobj) patients_5\NNS|NONE (l_acl) comprising_14\VBG||(|males|) (l_dobj) cases_20\NNS|NONE (l_compound) AFL_19\NNP|AF||
D015764_D001281 NONE bepridil_6\NN|NONE (r_amod) administration_7\NN|NONE (r_pobj) during_5\IN|adverse|for (r_prep) effects_4\NNS|NONE (l_prep) for_8\IN|during|adverse (l_pobj) fibrillation_10\NN|NONE (l_conj) flutter_12\JJ|and|atrial
D015764_D001281 NONE hydrochloride_1\NN|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN|NONE (l_prep) as_8\IN|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN|NONE (l_prep) for_12\IN|an|effective (l_pobj) fibrillation_14\NN|NONE
D015764_D001281 NONE hydrochloride_1\NN|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN|NONE (l_prep) as_8\IN|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN|NONE (l_prep) for_12\IN|an|effective (l_pobj) fibrillation_14\NN|NONE (l_appos) AF_16\NNP|atrial|(|flutter
D015764_D001281 NONE Bpd_3\NNP|NONE (r_appos) hydrochloride_1\NN|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN|NONE (l_prep) as_8\IN|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN|NONE (l_prep) for_12\IN|an|effective (l_pobj) fibrillation_14\NN|NONE
D015764_D001281 NONE Bpd_3\NNP|NONE (r_appos) hydrochloride_1\NN|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN|NONE (l_prep) as_8\IN|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN|NONE (l_prep) for_12\IN|an|effective (l_pobj) fibrillation_14\NN|NONE (l_appos) AF_16\NNP|atrial|(|flutter
D015764_D001281 NONE Bpd_0\NNP|was|.|to (r_nsubjpass) administered_2\VBN|NONE (l_prep) to_3\IN|was|.|Bpd (l_pobj) patients_5\NNS|NONE (l_acl) comprising_14\VBG||(|males|) (l_dobj) cases_20\NNS|NONE (l_nmod) AF_16\NNP||AFL|
15321332
D004329_D001008 CID droperidol_9\NN|to (r_pobj) due_5\IN|of|A|. (r_prep) case_1\NN|NONE (l_prep) of_2\IN|A|.|due (l_pobj) anxiety_4\NN|NONE
D004329_D001008 CID droperidol_3\NN| (r_npadvmod) induced_5\VBN|psychological (r_amod) disturbance_7\NN|NONE
19920070
D010634_D006529 CID phenobarbital_21\JJ|NONE (r_amod) administration_22\NN|NONE (r_pobj) after_20\IN|NONE (r_prep) hepatomegaly_19\NN|of|specific|and|.
6806735
D006585_D005767 NONE HMM_0\UH|gastrointestinal (r_compound) toxicity_2\NN|.|discontinuation
C034868_D010051 NONE CPDD_20\NNP|NONE (r_appos) cisplatinum_18\NN|NONE (r_pobj) of_17\IN|a (r_prep) combination_16\NN|NONE (r_pobj) with_14\IN|were|During|patients|,|m|,|. (r_prep) treated_13\VBN|NONE (l_nsubjpass) patients_8\NNS|were|During|,|with|m|,|. (l_prep) with_9\IN| (l_pobj) cancer_11\NN|NONE
D006585_D010051 NONE hexamethylmelamine_16\NN|and (r_conj) cyclophosphamide_14\NN|,|platinum|, (r_conj) adriamycin_12\NNS|NONE (r_pobj) of_7\IN|a (r_prep) combination_6\NN|NONE (r_pobj) with_4\IN|.|of (r_prep) Treatment_0\NN|NONE (l_prep) of_1\IN|.|with (l_pobj) cancer_3\NN|NONE
D006585_D010051 NONE hexamethylmelamine_47\NN|and|,|on|mg||,|adriamycin|,|;|/|m (r_conj) m2_26\NN|were|During|patients|,|with|,|. (r_npadvmod) treated_13\VBN|NONE (l_nsubjpass) patients_8\NNS|were|During|,|with|m|,|. (l_prep) with_9\IN| (l_pobj) cancer_11\NN|NONE
D006585_D010051 NONE HMM_49\NNP|,|daily|for|, (r_appos) hexamethylmelamine_47\NN|and|,|on|mg||,|adriamycin|,|;|/|m (r_conj) m2_26\NN|were|During|patients|,|with|,|. (r_npadvmod) treated_13\VBN|NONE (l_nsubjpass) patients_8\NNS|were|During|,|with|m|,|. (l_prep) with_9\IN| (l_pobj) cancer_11\NN|NONE
D004317_D010051 NONE adriamycin_12\NNS|NONE (r_pobj) of_7\IN|a (r_prep) combination_6\NN|NONE (r_pobj) with_4\IN|.|of (r_prep) Treatment_0\NN|NONE (l_prep) of_1\IN|.|with (l_pobj) cancer_3\NN|NONE
D004317_D010051 NONE adriamycin_28\NNS|and|,|on|mg||,|,|;|/|hexamethylmelamine|m (r_amod) m2_26\NN|were|During|patients|,|with|,|. (r_npadvmod) treated_13\VBN|NONE (l_nsubjpass) patients_8\NNS|were|During|,|with|m|,|. (l_prep) with_9\IN| (l_pobj) cancer_11\NN|NONE
D003520_D010051 NONE cyclophosphamide_14\NN|,|platinum|, (r_conj) adriamycin_12\NNS|NONE (r_pobj) of_7\IN|a (r_prep) combination_6\NN|NONE (r_pobj) with_4\IN|.|of (r_prep) Treatment_0\NN|NONE (l_prep) of_1\IN|.|with (l_pobj) cancer_3\NN|NONE
D003520_D010051 NONE cyclophosphamide_35\NN||mg|/|, (r_conj) m2_33\NN|, (r_conj) adriamycin_28\NNS|and|,|on|mg||,|,|;|/|hexamethylmelamine|m (r_amod) m2_26\NN|were|During|patients|,|with|,|. (r_npadvmod) treated_13\VBN|NONE (l_nsubjpass) patients_8\NNS|were|During|,|with|m|,|. (l_prep) with_9\IN| (l_pobj) cancer_11\NN|NONE
D002945_D010051 NONE platinum_10\NN|,|,|cyclophosphamide (r_nmod) adriamycin_12\NNS|NONE (r_pobj) of_7\IN|a (r_prep) combination_6\NN|NONE (r_pobj) with_4\IN|.|of (r_prep) Treatment_0\NN|NONE (l_prep) of_1\IN|.|with (l_pobj) cancer_3\NN|NONE
D002945_D010051 NONE cisplatinum_18\NN|NONE (r_pobj) of_17\IN|a (r_prep) combination_16\NN|NONE (r_pobj) with_14\IN|were|During|patients|,|m|,|. (r_prep) treated_13\VBN|NONE (l_nsubjpass) patients_8\NNS|were|During|,|with|m|,|. (l_prep) with_9\IN| (l_pobj) cancer_11\NN|NONE
24275640
D004317_D066126 CID doxorubicin_12\NN|NONE (r_pobj) of_11\IN|single (r_prep) doses_10\NNS|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) after_4\IN|NONE (r_prep) cardiotoxicity_3\NN|NONE
D004317_D066126 CID doxorubicin_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) mechanism_1\NN|cardiotoxicity|.|controversial (r_nsubj) remains_7\VBZ|NONE (l_nsubj) cardiotoxicity_6\NN|.|controversial|mechanism
D004317_D066126 CID DOX)-induced_5\JJ|( (r_amod) cardiotoxicity_6\NN|.|controversial|mechanism
D004317_D066126 CID DOX_17\NNP|NONE (r_pobj) of_16\IN|a|single (r_prep) dose_15\NN|NONE (r_pobj) by_12\IN|only (r_agent) induced_11\VBN|acute (r_acl) cardiotoxicity_10\NN|NONE
D004317_D006331 NONE DOX_3\NNP|NONE (r_pobj) of_2\IN|Single (r_prep) dose_1\NN|.|with|was (r_nsubjpass) associated_5\VBN|NONE (l_prep) with_6\IN|dose|.|was (l_pobj) disarrangement_9\NN|NONE
D004317_D009336 CID DOX_3\NNP|NONE (r_pobj) of_2\IN|Single (r_prep) dose_1\NN|.|with|was (r_nsubjpass) associated_5\VBN|NONE (l_prep) with_6\IN|dose|.|was (l_pobj) disarrangement_9\NN|NONE (l_conj) necrosis_11\NN|cardiac|increased|,
3409843
D002220_D004827 NONE carbamazepine_8\NN|in (r_compound) treatment_9\NN|to (l_prep) in_10\IN|carbamazepine (l_pobj) woman_13\NN|NONE (l_amod) epileptic_12\JJ|an
D002220_D001855 NONE carbamazepine_9\NN|NONE (r_pobj) to_8\IN|NONE (r_pcomp) due_7\IN|of (r_prep) concerns_1\NNS|NONE (l_prep) of_2\IN|due (l_pobj) toxicity_6\NN|NONE
D002220_D000741 CID carbamazepine_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) treated_6\VBN|a (r_acl) patient_5\NN|NONE (r_pobj) in_3\IN|.|Fatal|aplastic (r_prep) anemia_2\NN|NONE
D002220_D000741 CID carbamazepine_8\NN|in (r_compound) treatment_9\NN|to (r_pobj) due_6\IN|of|A (r_amod) case_1\NN|.|is (l_prep) of_2\IN|due|A (l_pobj) anemia_5\NN|NONE
2021990
D002927_D007022 CID cimetidine_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) caused_12\VBN|NONE (r_acl) hypotension_11\NN|NONE
D002927_D007022 CID cimetidine_22\NN|NONE (r_pobj) of_21\IN|the|vasodilating (r_prep) activity_20\NN|,|is|through|,|since|in (r_nsubjpass) mediated_24\VBN|,|antagonist|useful|that|may (r_advcl) be_7\VB|We|. (l_acomp) useful_8\JJ|,|antagonist|that|may|mediated (l_prep) in_9\IN|NONE (l_pcomp) preventing_10\VBG|NONE (l_dobj) hypotension_11\NN|NONE
8996419
D003276_D020246 NONE OCs_11\NNS|NONE (r_pobj) of_9\IN|NONE (r_prep) use_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN||the|of (r_acl) cases_3\NNS|NONE (r_pobj) Of_0\IN|.|and||five|,|as|were (r_prep) recorded_15\VBN|NONE (l_prep) as_16\IN|.|and||five|Of|,|were (l_pobj) thrombosis_20\NN|NONE
D003276_D020246 NONE OCs_11\NNS|NONE (r_pobj) of_9\IN|NONE (r_prep) use_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN||the|of (r_acl) cases_3\NNS|NONE (r_pobj) Of_0\IN|.|and||five|,|as|were (r_prep) recorded_15\VBN|NONE (l_conj) five_28\CD|.|and||Of|,|as|were (l_prep) as_29\IN|NONE (l_pobj) thrombosis_31\NN|NONE
D011372_D054556 NONE progestagen_15\NN|NONE (r_nmod) OCs_18\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) users_13\NNS|two (r_attr) were_12\VBD|, (r_relcl) VTE_7\NNP|NONE
C033273_D054556 NONE gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE
C033273_D054556 NONE gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE (l_appos) VTE_16\NNP|(|venous|)
C033273_D054556 NONE gestodene_26\NN|NONE (r_pobj) of_25\IN|with (r_prep) users_24\NNS|NONE (r_pobj) in_23\IN|NONE (r_prep) than_22\IN|.|higher|in|risk|Among|, (r_prep) was_12\VBD|NONE (l_nsubj) risk_9\NN|than|.|higher|in|Among|, (l_prep) of_10\IN|the (l_pobj) VTE_11\NNP|NONE
D004997_D054556 NONE ethinyloestradiol_21\NN|NONE (r_pobj) with_18\IN|of (r_prep) users_15\NNS|NONE (r_pobj) in_14\IN|than|.|higher|risk|Among|, (r_prep) was_12\VBD|NONE (l_nsubj) risk_9\NN|than|.|higher|in|Among|, (l_prep) of_10\IN|the (l_pobj) VTE_11\NNP|NONE
D004997_D054556 NONE ethinyloestradiol_32\NN|NONE (r_pobj) with_29\IN|of (r_prep) users_24\NNS|NONE (r_pobj) in_23\IN|NONE (r_prep) than_22\IN|.|higher|in|risk|Among|, (r_prep) was_12\VBD|NONE (l_nsubj) risk_9\NN|than|.|higher|in|Among|, (l_prep) of_10\IN|the (l_pobj) VTE_11\NNP|NONE
D004997_D054556 NONE ethinyloestradiol_27\NN|plus (r_appos) desogestrel_23\NN|NONE (r_pobj) for_22\IN|.|) (r_prep) 3.49_16\CD|for|ratios|With|.|, (r_attr) were_15\VBD|NONE (l_nsubj) ratios_12\NNS|for|With|.|.|, (l_prep) for_13\IN|the|odds (l_pobj) VTE_14\NNP|NONE
D003276_D054556 CID contraceptives_13\NNS|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|venous (r_acl) thromboembolism_8\NN|NONE
D003276_D054556 CID contraceptives_25\NNS|who (r_dobj) used_23\VBD|NONE (r_relcl) women_21\NNS|NONE (r_pobj) in_20\IN|NONE (r_prep) higher_19\JJR|incidence|containing|that (r_acomp) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE
D003276_D054556 CID contraceptives_25\NNS|who (r_dobj) used_23\VBD|NONE (r_relcl) women_21\NNS|NONE (r_pobj) in_20\IN|NONE (r_prep) higher_19\JJR|incidence|containing|that (r_acomp) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE (l_appos) VTE_16\NNP|(|venous|)
D003276_D054556 CID OCs_27\NNP|oral|(|) (r_appos) contraceptives_25\NNS|who (r_dobj) used_23\VBD|NONE (r_relcl) women_21\NNS|NONE (r_pobj) in_20\IN|NONE (r_prep) higher_19\JJR|incidence|containing|that (r_acomp) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE
D003276_D054556 CID OCs_27\NNP|oral|(|) (r_appos) contraceptives_25\NNS|who (r_dobj) used_23\VBD|NONE (r_relcl) women_21\NNS|NONE (r_pobj) in_20\IN|NONE (r_prep) higher_19\JJR|incidence|containing|that (r_acomp) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE (l_appos) VTE_16\NNP|(|venous|)
D003276_D054556 CID OCs_42\NNS|NONE (r_pobj) of_41\IN|NONE (r_prep) users_40\NNS|NONE (r_pobj) in_39\IN|NONE (r_prep) than_38\IN|desogestrel|progestagens|the|generation|or (r_prep) gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE
D003276_D054556 CID OCs_42\NNS|NONE (r_pobj) of_41\IN|NONE (r_prep) users_40\NNS|NONE (r_pobj) in_39\IN|NONE (r_prep) than_38\IN|desogestrel|progestagens|the|generation|or (r_prep) gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE (l_appos) VTE_16\NNP|(|venous|)
D003276_D054556 CID OC_17\NNP|and (r_conj) VTE_15\NNP|with
D003276_D054556 CID OC_17\NNP|the|main (r_compound) preparations_18\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) users_13\NNS|NONE (r_pobj) in_12\IN|incidence (r_prep) compare_8\VB|and|to (l_dobj) incidence_9\NN|in (l_prep) of_10\IN|NONE (l_pobj) VTE_11\NNP|NONE
D003276_D054556 CID OC_17\NNP|the|main (r_compound) preparations_18\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) users_13\NNS|NONE (r_pobj) in_12\IN|incidence (r_prep) compare_8\VB|and|to (r_conj) estimate_6\VB|a|cohort (r_relcl) analysis_4\NN|study|We|.|,|and (r_dobj) did_1\VBD|NONE (l_conj) study_26\NN|We|.|,|and|analysis (l_acl) calculate_28\VB|nested|a|,|after|control (l_dobj) ratios_31\NNS|to (l_prep) of_32\IN|associated|odds|the (l_pobj) VTE_33\NNP|NONE
D003276_D054556 CID OC_41\NNP|NONE (r_pobj) of_40\IN|different (r_prep) types_39\NNS|NONE (r_pobj) of_37\IN|NONE (r_prep) use_36\NN|NONE (r_pobj) with_35\IN|NONE (r_prep) associated_34\VBN|odds|of|the (r_acl) ratios_31\NNS|to (r_dobj) calculate_28\VB|nested|a|,|after|control (r_acl) study_26\NN|We|.|,|and|analysis (r_conj) did_1\VBD|NONE (l_dobj) analysis_4\NN|study|We|.|,|and (l_relcl) estimate_6\VB|a|cohort (l_conj) compare_8\VB|and|to (l_dobj) incidence_9\NN|in (l_prep) of_10\IN|NONE (l_pobj) VTE_11\NNP|NONE
D003276_D054556 CID OC_41\NNP|NONE (r_pobj) of_40\IN|different (r_prep) types_39\NNS|NONE (r_pobj) of_37\IN|NONE (r_prep) use_36\NN|NONE (r_pobj) with_35\IN|NONE (r_prep) associated_34\VBN|odds|of|the (r_acl) ratios_31\NNS|to (l_prep) of_32\IN|associated|odds|the (l_pobj) VTE_33\NNP|NONE
D003276_D054556 CID OCs_18\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) users_13\NNS|two (r_attr) were_12\VBD|, (r_relcl) VTE_7\NNP|NONE
D003276_D054556 CID OCs_11\NNS|NONE (r_pobj) of_9\IN|NONE (r_prep) use_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN||the|of (r_acl) cases_3\NNS|NONE (l_prep) of_4\IN||the|associated (l_pobj) VTE_5\NNP|NONE
D003276_D054556 CID OC_17\NNP|NONE (r_pobj) of_15\IN|current (r_prep) users_14\NNS|NONE (r_pobj) in_12\IN|,|. (r_prep) 4.10_11\CD|.|rate (r_attr) was_10\VBD|NONE (l_nsubj) rate_2\NN|.|. (l_prep) of_3\IN|per|The|crude (l_pobj) VTE_4\NNP|NONE
D003276_D054556 CID OCs_26\NNS|NONE (r_pobj) of_22\IN|NONE (r_prep) users_21\NNS|NONE (r_pobj) in_20\IN|.|,|and (r_prep) 3.10_19\CD|,|in (r_appos) 4.10_11\CD|.|rate (r_attr) was_10\VBD|NONE (l_nsubj) rate_2\NN|.|. (l_prep) of_3\IN|per|The|crude (l_pobj) VTE_4\NNP|NONE
D003276_D054556 CID OCs_21\NNS|NONE (r_pobj) to_17\IN|generation (r_prep) relative_16\JJ|NONE (r_pobj) of_12\IN|NONE (r_prep) users_11\NNS|NONE (r_pobj) in_10\IN|the|of|rate (r_prep) ratio_7\NN|.|%|After|, (l_prep) of_8\IN|the|in|rate (l_pobj) VTE_9\NNP|NONE
D003276_D054556 CID OCs_21\NNS|NONE (r_pobj) of_13\IN|NONE (r_prep) users_12\NNS|NONE (r_pobj) between_11\IN|of|the (r_prep) risk_8\NN|NONE (l_prep) of_9\IN|the|between (l_pobj) VTE_10\NNP|NONE
D003276_D054556 CID OCs_5\NNS|NONE (r_pobj) With_0\IN|for|ratios|.|.|, (r_prep) were_15\VBD|NONE (l_nsubj) ratios_12\NNS|for|With|.|.|, (l_prep) for_13\IN|the|odds (l_pobj) VTE_14\NNP|NONE
D017135_D054556 NONE desogestrel_37\NN|progestagens|the|generation|or|than (r_conj) gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE
D017135_D054556 NONE desogestrel_37\NN|progestagens|the|generation|or|than (r_conj) gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE (l_appos) VTE_16\NNP|(|venous|)
D017135_D054556 NONE desogestrel_17\NN|NONE (r_pobj) of_16\IN|with (r_prep) users_15\NNS|NONE (r_pobj) in_14\IN|than|.|higher|risk|Among|, (r_prep) was_12\VBD|NONE (l_nsubj) risk_9\NN|than|.|higher|in|Among|, (l_prep) of_10\IN|the (l_pobj) VTE_11\NNP|NONE
D017135_D054556 NONE desogestrel_28\NN|or (r_conj) gestodene_26\NN|NONE (r_pobj) of_25\IN|with (r_prep) users_24\NNS|NONE (r_pobj) in_23\IN|NONE (r_prep) than_22\IN|.|higher|in|risk|Among|, (r_prep) was_12\VBD|NONE (l_nsubj) risk_9\NN|than|.|higher|in|Among|, (l_prep) of_10\IN|the (l_pobj) VTE_11\NNP|NONE
D017135_D054556 NONE desogestrel_23\NN|NONE (r_pobj) for_22\IN|.|) (r_prep) 3.49_16\CD|for|ratios|With|.|, (r_attr) were_15\VBD|NONE (l_nsubj) ratios_12\NNS|for|With|.|.|, (l_prep) for_13\IN|the|odds (l_pobj) VTE_14\NNP|NONE
D011374_D054556 NONE progestagens_34\NNS|desogestrel|the|generation|or|than (r_compound) gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE
D011374_D054556 NONE progestagens_34\NNS|desogestrel|the|generation|or|than (r_compound) gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE (l_appos) VTE_16\NNP|(|venous|)
D011374_D054556 NONE progestagens_47\NNS|NONE (r_dobj) containing_43\VBG|NONE (r_acl) OCs_42\NNS|NONE (r_pobj) of_41\IN|NONE (r_prep) users_40\NNS|NONE (r_pobj) in_39\IN|NONE (r_prep) than_38\IN|desogestrel|progestagens|the|generation|or (r_prep) gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE
D011374_D054556 NONE progestagens_47\NNS|NONE (r_dobj) containing_43\VBG|NONE (r_acl) OCs_42\NNS|NONE (r_pobj) of_41\IN|NONE (r_prep) users_40\NNS|NONE (r_pobj) in_39\IN|NONE (r_prep) than_38\IN|desogestrel|progestagens|the|generation|or (r_prep) gestodene_35\NN|NONE (r_dobj) containing_29\VBG|higher|incidence|that (r_advcl) was_18\VBD|.|studies (l_nsubj) incidence_11\NN|higher|containing|that (l_prep) of_12\IN|the (l_pobj) thromboembolism_14\NN|NONE (l_appos) VTE_16\NNP|(|venous|)
D011374_D054556 NONE progestagens_6\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) users_1\NNS|NONE (r_pobj) Among_0\IN|than|.|higher|in|risk|, (r_prep) was_12\VBD|NONE (l_nsubj) risk_9\NN|than|.|higher|in|Among|, (l_prep) of_10\IN|the (l_pobj) VTE_11\NNP|NONE
D011374_D054556 NONE progestagens_41\NNS|NONE (r_pobj) for_35\IN|ratios|With|.|.|, (r_prep) were_15\VBD|NONE (l_nsubj) ratios_12\NNS|for|With|.|.|, (l_prep) for_13\IN|the|odds (l_pobj) VTE_14\NNP|NONE
D003276_D013927 NONE OCs_11\NNS|NONE (r_pobj) of_9\IN|NONE (r_prep) use_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN||the|of (r_acl) cases_3\NNS|NONE (r_pobj) Of_0\IN|.|and||five|,|as|were (r_prep) recorded_15\VBN|NONE (l_prep) as_16\IN|.|and||five|Of|,|were (l_pobj) thrombosis_20\NN|NONE (l_appos) 35_22\CD|,|vein|, (l_prep) as_23\IN|NONE (l_pobj) thrombosis_25\NN|NONE
18422462
D018119_D010523 CID T_21\NN|d (r_compound) therapy_22\NN|with|and|rash (r_conj) developing_17\VBG|NONE (l_prep) with_23\IN|and|rash|therapy (l_pcomp) developing_24\VBG|. (l_dobj) neuropathy_26\NN|NONE
D000409_D000740 NONE alanine_32\NN|NONE (r_compound) aminotransferase_33\FW|NONE (r_pobj) with_31\IN|(|clinical (r_prep) jaundice_30\NN|> (r_appos) hepatitis_27\NN|upper|CD|)|of||in (r_nsubj) limits_38\NNS|in|anemia|and|.|was (r_conj) observed_12\VBN|NONE (l_nsubjpass) anemia_2\NN|in|and|limits|.|was
D019829_D005076 CID NVP_11\NNP|NONE (r_compound) therapy_12\NN|.|,|was|with|Among|significantly (r_nsubjpass) associated_15\VBN|NONE (l_prep) with_16\IN|.|therapy|,|was|Among|significantly (l_pcomp) developing_17\VBG|NONE (l_dobj) rash_18\NN|with|and|therapy
D019829_D010523 NONE NVP_11\NNP|NONE (r_compound) therapy_12\NN|.|,|was|with|Among|significantly (r_nsubjpass) associated_15\VBN|NONE (l_prep) with_16\IN|.|therapy|,|was|Among|significantly (l_pcomp) developing_17\VBG|NONE (l_prep) with_23\IN|and|rash|therapy (l_pcomp) developing_24\VBG|. (l_dobj) neuropathy_26\NN|NONE
D018119_D005076 NONE T_21\NN|d (r_compound) therapy_22\NN|with|and|rash (r_conj) developing_17\VBG|NONE (l_dobj) rash_18\NN|with|and|therapy
D000409_D007565 NONE alanine_32\NN|NONE (r_compound) aminotransferase_33\FW|NONE (r_pobj) with_31\IN|(|clinical (r_prep) jaundice_30\NN|>
D000409_D056486 NONE alanine_32\NN|NONE (r_compound) aminotransferase_33\FW|NONE (r_pobj) with_31\IN|(|clinical (r_prep) jaundice_30\NN|> (r_appos) hepatitis_27\NN|upper|CD|)|of||in
18450790
D013792_D008178 NONE thalidomide_30\NN|NONE (r_pobj) with_29\IN|and|use|.|CLE|( (r_prep) treated_28\VBN|measure|aims|amplitude (r_parataxis) were_4\VBD|NONE (l_punct) amplitude_17\VBP|measure|aims|treated (l_prep) in_18\IN|NONE (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) erythematosus_24\NN|NONE
D013792_D008178 NONE thalidomide_30\NN|NONE (r_pobj) with_29\IN|and|use|.|CLE|( (r_prep) treated_28\VBN|measure|aims|amplitude (l_nsubj) CLE_26\NNP|and|use|with|.|(
D013792_D008178 NONE thalidomide_41\NN|NONE (r_pobj) of_40\IN|neurotoxic|the (r_prep) potential_39\NN|to (r_dobj) identify_36\VB|findings (r_xcomp) use_32\VB|and|with|.|CLE|( (r_conj) treated_28\VBN|measure|aims|amplitude (r_parataxis) were_4\VBD|NONE (l_punct) amplitude_17\VBP|measure|aims|treated (l_prep) in_18\IN|NONE (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) erythematosus_24\NN|NONE
D013792_D008178 NONE thalidomide_41\NN|NONE (r_pobj) of_40\IN|neurotoxic|the (r_prep) potential_39\NN|to (r_dobj) identify_36\VB|findings (r_xcomp) use_32\VB|and|with|.|CLE|( (r_conj) treated_28\VBN|measure|aims|amplitude (l_nsubj) CLE_26\NNP|and|use|with|.|(
D013792_D008178 NONE thalidomide_17\NN|and (r_pobj) with_16\IN|NONE (r_prep) treatment_15\NN|NONE (r_pobj) during_14\IN|in|Clinical (r_prep) data_7\NNS|months|.|were|discontinuation|after|PATIENTS (l_prep) in_8\IN|during|Clinical (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|female| (l_pobj) CLE_13\NNP|NONE
D013792_D010523 CID Thalidomide_0\NNP|NONE (l_conj) neurotoxicity_3\NN|and|.|study|:
D013792_D010523 CID thalidomide_17\NN|NONE (r_pobj) of_16\IN|different (r_prep) doses_15\NNS|NONE (r_pobj) with_13\IN|NONE (r_prep) treated_12\VBN|NONE (r_acl) patients_11\NNS|NONE (r_pobj) in_10\IN|high|a|of (r_prep) incidence_5\NN|.|studies (l_prep) of_6\IN|high|in|a (l_pobj) neuropathy_9\NN|NONE
D013792_D020258 NONE thalidomide_30\NN|NONE (r_pobj) with_29\IN|and|use|.|CLE|( (r_prep) treated_28\VBN|measure|aims|amplitude (l_conj) use_32\VB|and|with|.|CLE|( (l_xcomp) identify_36\VB|findings (l_dobj) potential_39\NN|to (l_amod) neurotoxic_38\JJ|the|of
D013792_D020258 NONE thalidomide_41\NN|NONE (r_pobj) of_40\IN|neurotoxic|the (r_prep) potential_39\NN|to (l_amod) neurotoxic_38\JJ|the|of
D013792_D020258 NONE thalidomide_10\NN|NONE (r_pobj) of_9\IN|neurotoxic|subclinical (r_prep) potential_8\NN|NONE (l_amod) neurotoxic_7\JJ|of|subclinical
24894748
D008790_D003324 NONE metoprolol_8\NN|course|day|.|was (l_prep) for_13\IN|day|man (l_pobj) disease_17\NN|NONE
C041359_D003221 NONE terbinafine_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|for|.|,|was|to|he (r_prep) brought_10\VBN|NONE (l_prep) for_15\IN|.|,|was|On|to|he (l_pobj) decrease_17\NN|NONE (l_prep) of_18\IN|a (l_pobj) status_22\NN|NONE (l_conj) confusion_24\NN|health|global|,|his
C041359_D014009 NONE terbinafine_25\NN|NONE (r_pobj) of_23\IN|day|a (r_prep) course_22\NN|metoprolol|day|.|was (r_dobj) prescribed_19\VBN|NONE (l_npadvmod) day_29\NN|course|metoprolol|.|was (l_prep) for_30\IN|mg||/ (l_pobj) onychomycosis_31\NN|NONE
C041359_D001919 CID terbinafine_3\NN|A (r_compound) combination_4\NN|bradycardia|. (r_nsubj) induced_5\VBN|NONE (l_dobj) bradycardia_6\NN|combination|.
C041359_D064420 NONE terbinafine_29\NN|and (r_conj) metoprolol_27\NN|NONE (r_pobj) between_26\IN|drug|the (r_prep) interaction_25\NN|sinus|and (r_conj) bradycardia_21\NNP|NONE (r_pobj) between_16\IN|a|probable (r_prep) relationship_15\NN|score|. (r_dobj) indicates_12\VBZ|NONE (l_nsubj) score_1\NN|relationship|. (l_prep) on_4\IN|A|of (l_pobj) scale_11\NN|NONE (l_compound) probability_10\NN|the|Naranjo (l_compound) reaction_9\NN|NONE
D008790_D064420 NONE metoprolol_27\NN|NONE (r_pobj) between_26\IN|drug|the (r_prep) interaction_25\NN|sinus|and (r_conj) bradycardia_21\NNP|NONE (r_pobj) between_16\IN|a|probable (r_prep) relationship_15\NN|score|. (r_dobj) indicates_12\VBZ|NONE (l_nsubj) score_1\NN|relationship|. (l_prep) on_4\IN|A|of (l_pobj) scale_11\NN|NONE (l_compound) probability_10\NN|the|Naranjo (l_compound) reaction_9\NN|NONE
D008790_D001919 CID metoprolol_1\NN|NONE (r_compound) terbinafine_3\NN|A (r_compound) combination_4\NN|bradycardia|. (r_nsubj) induced_5\VBN|NONE (l_dobj) bradycardia_6\NN|combination|.
D008790_D012804 NONE metoprolol_7\NN|NONE (r_pobj) by_6\IN|.|report (r_agent) induced_5\VBN|NONE (l_advcl) report_1\VB|.|by (l_dobj) bradycardia_4\NN|To|sinus
D008790_D012804 NONE metoprolol_27\NN|NONE (r_pobj) between_26\IN|drug|the (r_prep) interaction_25\NN|sinus|and (r_conj) bradycardia_21\NNP|NONE
D008790_D012804 NONE metoprolol_10\NN|NONE (r_poss) clearance_12\NN|,|leading|terbinafine|By|,|had|. (r_dobj) decreased_9\VBN|NONE (l_advcl) leading_14\VBG|,|terbinafine|By|clearance|,|had|. (l_prep) in_15\IN|NONE (l_pobj) accumulation_17\NN|NONE (l_relcl) resulted_20\VBN|metoprolol (l_prep) in_21\IN|has|which (l_pobj) bradycardia_25\NN|NONE
D008790_D012804 NONE metoprolol_16\NN|resulted (r_compound) accumulation_17\NN|NONE (l_relcl) resulted_20\VBN|metoprolol (l_prep) in_21\IN|has|which (l_pobj) bradycardia_25\NN|NONE
D008790_D014009 NONE metoprolol_8\NN|course|day|.|was (r_nsubjpass) prescribed_19\VBN|NONE (l_npadvmod) day_29\NN|course|metoprolol|.|was (l_prep) for_30\IN|mg||/ (l_pobj) onychomycosis_31\NN|NONE
C041359_D003324 NONE terbinafine_25\NN|NONE (r_pobj) of_23\IN|day|a (r_prep) course_22\NN|metoprolol|day|.|was (r_dobj) prescribed_19\VBN|NONE (l_nsubjpass) metoprolol_8\NN|course|day|.|was (l_prep) for_13\IN|day|man (l_pobj) disease_17\NN|NONE
C041359_D012804 NONE terbinafine_9\NN|and|management|drug (r_compound) interaction_13\NN|and (r_conj) metoprolol_7\NN|NONE (r_pobj) by_6\IN|.|report (r_agent) induced_5\VBN|NONE (l_advcl) report_1\VB|.|by (l_dobj) bradycardia_4\NN|To|sinus
C041359_D012804 NONE terbinafine_29\NN|and (r_conj) metoprolol_27\NN|NONE (r_pobj) between_26\IN|drug|the (r_prep) interaction_25\NN|sinus|and (r_conj) bradycardia_21\NNP|NONE
C041359_D012804 NONE terbinafine_7\NN|,|leading|By|clearance|,|had|. (r_nsubj) decreased_9\VBN|NONE (l_advcl) leading_14\VBG|,|terbinafine|By|clearance|,|had|. (l_prep) in_15\IN|NONE (l_pobj) accumulation_17\NN|NONE (l_relcl) resulted_20\VBN|metoprolol (l_prep) in_21\IN|has|which (l_pobj) bradycardia_25\NN|NONE
19715529
12051122
D014750_D007010 CID Vincristine_14\NNP|NONE (r_pobj) of_13\IN|the (r_prep) use_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) reported_9\VBN|inappropriate|diuretic| (r_acl) hormone_8\NN|NONE (r_pobj) of_3\IN|NONE (r_prep) syndrome_2\NN|and|? (r_conj) Hyponatremia_0\NNP|NONE
D014750_D007010 CID vincristine_32\NN| (r_npadvmod) treated_34\VBN|NONE (r_amod) patients_35\NNS|NONE (r_pobj) among_31\IN|(|) (r_prep) SIADH_29\NNP||diuretic (r_appos) hormone_27\NN|NONE (r_pobj) of_23\IN|inappropriate (r_prep) secretion_22\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) syndrome_19\NN|and/or (r_conj) hyponatremia_17\NN|NONE
D014750_D007010 CID vincristine_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) use_31\NN|NONE (r_pobj) during_29\IN|been|that|had (r_prep) reported_28\VBN|and|database|the|Eli (r_relcl) Lilly_4\NNP|We|as|. (l_conj) database_11\NN|and|the|Eli|reported (l_prep) for_12\IN|event|Company|computerized (l_pobj) cases_15\NNS|NONE (l_prep) of_16\IN|all|reported (l_pobj) hyponatremia_17\NN|NONE
D014750_D007010 CID vincristine_11\NN|NONE (r_compound) use_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBD|A|of (r_acl) total_1\NN|were|. (l_prep) of_2\IN|A|associated (l_pobj) cases_4\NNS|NONE (l_prep) of_5\IN| (l_pobj) hyponatremia_6\NN|NONE
D014750_D007010 CID vincristine_17\NN|NONE (r_compound) use_18\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) associated_15\VBD|increased|of (r_acl) risk_10\NN|NONE (l_prep) of_11\IN|increased|associated (l_pobj) hyponatremia_12\NN|NONE
D014750_D007177 CID Vincristine_14\NNP|NONE (r_pobj) of_13\IN|the (r_prep) use_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) reported_9\VBN|inappropriate|diuretic| (r_acl) hormone_8\NN|NONE
D014750_D007177 CID vincristine_32\NN| (r_npadvmod) treated_34\VBN|NONE (r_amod) patients_35\NNS|NONE (r_pobj) among_31\IN|(|) (r_prep) SIADH_29\NNP||diuretic (r_appos) hormone_27\NN|NONE
D014750_D007177 CID vincristine_32\NN| (r_npadvmod) treated_34\VBN|NONE (r_amod) patients_35\NNS|NONE (r_pobj) among_31\IN|(|) (r_prep) SIADH_29\NNP||diuretic
D014750_D007177 CID vincristine_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) use_31\NN|NONE (r_pobj) during_29\IN|been|that|had (r_prep) reported_28\VBN|and|database|the|Eli (r_relcl) Lilly_4\NNP|We|as|. (l_conj) database_11\NN|and|the|Eli|reported (l_prep) for_12\IN|event|Company|computerized (l_pobj) cases_15\NNS|NONE (l_prep) of_16\IN|all|reported (l_pobj) hyponatremia_17\NN|NONE (l_conj) SIADH_19\NNP|and/or
D014750_D007177 CID vincristine_11\NN|NONE (r_compound) use_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBD|A|of (r_acl) total_1\NN|were|. (l_prep) of_2\IN|A|associated (l_pobj) cases_4\NNS|NONE (l_prep) of_5\IN| (l_pobj) hyponatremia_6\NN|NONE (l_conj) SIADH_8\NNP|and/or
D014750_D007177 CID vincristine_17\NN|NONE (r_compound) use_18\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) associated_15\VBD|increased|of (r_acl) risk_10\NN|NONE (l_prep) of_11\IN|increased|associated (l_pobj) hyponatremia_12\NN|NONE (l_conj) SIADH_14\NNP|and/or
D014750_D007177 CID vincristine_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) associated_7\VBN|overall|reported|of|the (r_acl) rate_4\NN|Although|low (l_prep) of_5\IN|overall|reported|the|associated (l_pobj) SIADH_6\NNP|NONE
15605432
D010100_D066126 NONE oxygen_12\NN|be|if (r_nsubj) reported_19\VBD|to (r_ccomp) determine_8\VB|.|resulted|purpose|adriamycin (r_xcomp) was_6\VBD|NONE (l_conj) resulted_29\VBD|determine|.|purpose|adriamycin (l_nsubj) cardiotoxicity_27\NN|determine|actually|and|in|,
D004317_D066126 NONE adriamycin_24\NNS|determine|.|resulted|purpose (r_acomp) was_6\VBD|NONE (l_conj) resulted_29\VBD|determine|.|purpose|adriamycin (l_nsubj) cardiotoxicity_27\NN|determine|actually|and|in|,
D004317_D066126 NONE ADR)-induced_26\JJ|( (r_compound) cardiotoxicity_27\NN|determine|actually|and|in|,
D004317_D028361 CID adriamycin_6\NNS| (r_npadvmod) induced_8\VBN|mitochondrial|cardiac (r_amod) injury_11\NN|NONE
D004317_D028361 CID ADR_3\NNP|adducts|at (r_nsubj) induced_4\VBD|.|data (l_prep) at_11\IN|adducts|ADR (l_pobj) point_15\NN|NONE (l_prep) as_16\IN|time|the|same (l_pcomp) appeared_21\VBD|NONE (l_nsubj) injury_19\NN|initially|when
D009584_D066126 NONE ROS)/nitrogen_14\NN|(|)|(|RNS (r_compound) species_15\NNS|reactive|elevated (r_appos) oxygen_12\NN|be|if (r_nsubj) reported_19\VBD|to (r_ccomp) determine_8\VB|.|resulted|purpose|adriamycin (r_xcomp) was_6\VBD|NONE (l_conj) resulted_29\VBD|determine|.|purpose|adriamycin (l_nsubj) cardiotoxicity_27\NN|determine|actually|and|in|,
C027576_D028361 NONE 4HNE_5\CD| (r_compound) protein_7\NN|in (r_compound) adducts_8\NNS|ADR|at (r_dobj) induced_4\VBD|.|data (l_prep) at_11\IN|adducts|ADR (l_pobj) point_15\NN|NONE (l_prep) as_16\IN|time|the|same (l_pcomp) appeared_21\VBD|NONE (l_nsubj) injury_19\NN|initially|when
8184922
D007545_D006332 CID isoproterenol_17\NN| (r_npadvmod) induced_19\VBN|cardiac (r_amod) hypertrophy_21\NN|NONE
20959502
D017576_D008581 NONE daptomycin_7\NN|NONE (l_prep) in_8\IN|dose (l_pobj) meningitis_12\NN|NONE
D017576_D008581 NONE daptomycin_23\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBD|suspected|MSSA (r_acl) meningitis_17\NN|NONE
D017576_D008581 NONE daptomycin_4\JJ|.|and|initiated|was|Nafcillin (r_conj) discontinued_2\VBN|NONE (l_conj) initiated_9\VBN|.|and|daptomycin|was|Nafcillin (l_prep) for_10\IN|was|and|continued (l_pobj) meningitis_12\NN|NONE
D017576_D016470 NONE daptomycin_23\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBD|suspected|MSSA (r_acl) meningitis_17\NN|NONE (r_pobj) with_14\IN|MSSA|)|( (r_prep) bacteremia_13\XX|sensitive|Staphylococcus
D017576_D016470 NONE Daptomycin_0\NNP|.|in|was|nephritis (r_nsubjpass) initiated_2\VBN|NONE (l_dobj) nephritis_14\NN|Daptomycin|.|in|was (l_conj) relapsing_16\VBG|and|acute|interstitial|induced (l_dobj) bacteremia_17\NN|NONE
D017576_D016470 NONE daptomycin_3\NN|may|option|. (r_nsubj) be_5\VB|NONE (l_attr) option_8\NN|daptomycin|may|. (l_prep) for_9\IN|an|alternative (l_pobj) bacteremia_11\VBG|NONE
D009254_D016470 NONE nafcillin_9\NN| (r_npadvmod) induced_11\VBN|and|acute|interstitial|relapsing (r_amod) nephritis_14\NN|Daptomycin|.|in|was (l_conj) relapsing_16\VBG|and|acute|interstitial|induced (l_dobj) bacteremia_17\NN|NONE
D008712_D016470 NONE methicillin_5\NN| (r_npadvmod) sensitive_7\JJ|bacteremia|Staphylococcus (r_amod) aureus_9\NNP|NONE (l_appos) bacteremia_13\XX|sensitive|Staphylococcus
D009254_D008581 NONE Nafcillin_0\NNP|.|and|initiated|daptomycin|was (r_nsubjpass) discontinued_2\VBN|NONE (l_conj) initiated_9\VBN|.|and|daptomycin|was|Nafcillin (l_prep) for_10\IN|was|and|continued (l_pobj) meningitis_12\NN|NONE
D008712_D008581 NONE methicillin_5\NN| (r_npadvmod) sensitive_7\JJ|bacteremia|Staphylococcus (r_amod) aureus_9\NNP|NONE (l_appos) bacteremia_13\XX|sensitive|Staphylococcus (l_prep) with_14\IN|MSSA|)|( (l_pobj) meningitis_17\NN|NONE
D003404_D058186 NONE creatinine_12\JJ|(|renal|acute|, (r_appos) failure_9\NN|)|from
D017576_D009395 NONE Daptomycin_0\NNP|.|in|was|nephritis (r_nsubjpass) initiated_2\VBN|NONE (l_dobj) nephritis_14\NN|Daptomycin|.|in|was
D009254_D009395 CID nafcillin_9\NN| (r_npadvmod) induced_11\VBN|and|acute|interstitial|relapsing (r_amod) nephritis_14\NN|Daptomycin|.|in|was
89511
D004967_D004714 NONE oestrogen_4\NN|dose|Cyclical|with (r_compound) therapy_5\NN|does|not|.|increase (r_nsubj) seem_15\VB|NONE (l_xcomp) increase_17\VB|does|not|.|therapy (l_dobj) risk_19\NN|to (l_prep) of_20\IN|the (l_pobj) hyperplasia_22\NN|NONE
D004967_D009369 NONE oestrogen_16\NN|difficulty|inappropriate|unopposed|and (r_compound) therapy_17\NN|NONE (l_conj) difficulty_20\NN|inappropriate|unopposed|and|oestrogen (l_prep) in_21\IN|the (l_pcomp) distinguishing_22\VBG|NONE (l_prep) from_25\IN|hyperplasia (l_pobj) malignancy_26\NN|NONE
D004967_D014591 NONE oestrogen_10\NN|NONE (r_compound) therapy_11\NN|NONE (r_dobj) receiving_9\VBG|climacteric (r_acl) women_8\NNS|NONE (r_pobj) in_6\IN|.|and|of|treatment (r_prep) Prevention_0\NN|NONE (l_prep) of_3\IN|.|in|and|treatment (l_pobj) disease_5\NN|NONE
D004967_D014591 NONE oestrogen_16\NN|NONE (r_compound) therapy_17\NN|NONE (r_dobj) receiving_15\VBG||climacteric (r_acl) women_14\NNS|NONE (r_pobj) among_11\IN|in|regimens|.|are (r_prep) described_4\VBN|NONE (l_prep) in_5\IN|among|regimens|.|are (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN| (l_pobj) disease_10\NN|NONE
D011372_D004714 NONE progestagen_12\NN|NONE (r_pobj) of_11\IN| (r_prep) days_10\NNS|NONE (r_pobj) with_6\IN|oestrogen|dose|Cyclical (r_prep) therapy_5\NN|does|not|.|increase (r_nsubj) seem_15\VB|NONE (l_xcomp) increase_17\VB|does|not|.|therapy (l_dobj) risk_19\NN|to (l_prep) of_20\IN|the (l_pobj) hyperplasia_22\NN|NONE
D004967_D002277 NONE oestrogen_4\NN|dose|Cyclical|with (r_compound) therapy_5\NN|does|not|.|increase (r_nsubj) seem_15\VB|NONE (l_xcomp) increase_17\VB|does|not|.|therapy (l_dobj) risk_19\NN|to (l_prep) of_20\IN|the (l_pobj) hyperplasia_22\NN|NONE (l_conj) carcinoma_24\NN|or|endometrial
D009640_D006965 NONE norethisterone_8\NN| (r_amod) mg_7\NN|NONE (r_pobj) of_5\IN| (r_prep) days_4\NNS|NONE (r_pobj) of_2\IN|Two (r_prep) courses_1\NNS|reversion||.|and (r_nsubj) caused_10\VBN|NONE (l_dobj) reversion_11\NN||courses|.|and (l_prep) in_14\IN|to (l_pobj) cases_17\NNS|NONE (l_prep) of_18\IN||all (l_pobj) hyperplasia_20\NN|NONE
D009640_D006965 NONE norethisterone_8\NN| (r_amod) mg_7\NN|NONE (r_pobj) of_5\IN| (r_prep) days_4\NNS|NONE (r_pobj) of_2\IN|Two (r_prep) courses_1\NNS|reversion||.|and (r_nsubj) caused_10\VBN|NONE (l_conj) 6_22\CD|reversion|courses|.|and (l_prep) of_23\IN|NONE (l_pobj) cases_26\NNS|NONE (l_prep) of_27\IN|the| (l_pobj) hyperplasia_29\NN|NONE
D004967_D006965 CID oestrogen_6\NN|unopposed (r_compound) therapy_7\NN|NONE (r_pobj) with_4\IN|without|.|hyperplasia|was (r_prep) associated_3\VBN|NONE (l_nsubjpass) hyperplasia_1\NN|without|with|.|was
D004967_D006965 CID oestrogen_16\NN|difficulty|inappropriate|unopposed|and (r_compound) therapy_17\NN|NONE (l_conj) difficulty_20\NN|inappropriate|unopposed|and|oestrogen (l_prep) in_21\IN|the (l_pcomp) distinguishing_22\VBG|NONE (l_dobj) hyperplasia_24\NN|from
D004967_D016889 NONE oestrogen_16\NN|difficulty|inappropriate|unopposed|and (r_compound) therapy_17\NN|NONE (r_pobj) of_11\IN|the (r_prep) problems_10\NNS|.|referred (r_dobj) demonstrated_8\VBD|NONE (l_csubj) referred_5\VBD|.|problems (l_nsubj) cases_1\NNS|from (l_prep) of_2\IN| (l_pobj) carcinoma_4\NN|NONE
D011372_D006965 NONE progestagen_9\NN|NONE (r_pobj) without_8\IN|with|.|hyperplasia|was (r_prep) associated_3\VBN|NONE (l_nsubjpass) hyperplasia_1\NN|without|with|.|was
D011372_D002277 NONE progestagen_12\NN|NONE (r_pobj) of_11\IN| (r_prep) days_10\NNS|NONE (r_pobj) with_6\IN|oestrogen|dose|Cyclical (r_prep) therapy_5\NN|does|not|.|increase (r_nsubj) seem_15\VB|NONE (l_xcomp) increase_17\VB|does|not|.|therapy (l_dobj) risk_19\NN|to (l_prep) of_20\IN|the (l_pobj) hyperplasia_22\NN|NONE (l_conj) carcinoma_24\NN|or|endometrial
8748050
D000639_D003866 NONE amitriptyline_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) course_10\NN|NONE (r_pobj) in_8\IN|NONE (r_prep) developed_7\VBN|NONE (r_acl) encephalopathy_6\NN|NONE (r_pobj) of_5\IN|a (r_prep) case_4\NN|report|,|.|during (r_dobj) describes_2\VBZ|NONE (l_prep) during_15\IN|report|,|.|case (l_pobj) remission_17\NN|NONE (l_prep) of_18\IN|a (l_pobj) depression_20\NN|NONE
D000639_D020230 NONE amitriptyline_2\NN|NONE (r_compound) therapy_3\NN|NONE (r_pobj) during_1\IN|NONE (r_prep) Encephalopathy_0\VBG|:|?|syndrome (r_nsubj) are_5\VBP|NONE (l_attr) syndrome_8\NN|:|?|Encephalopathy (l_conj) disorders_13\NNS|and|malignant|neuroleptic (l_compound) syndrome_11\NN|spectrum|serotonin
D000639_D001927 CID amitriptyline_2\NN|NONE (r_compound) therapy_3\NN|NONE (r_pobj) during_1\IN|NONE (r_prep) Encephalopathy_0\VBG|:|?|syndrome
D000639_D001927 CID amitriptyline_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) course_10\NN|NONE (r_pobj) in_8\IN|NONE (r_prep) developed_7\VBN|NONE (r_acl) encephalopathy_6\NN|NONE
D000639_D009459 NONE amitriptyline_2\NN|NONE (r_compound) therapy_3\NN|NONE (r_pobj) during_1\IN|NONE (r_prep) Encephalopathy_0\VBG|:|?|syndrome (r_nsubj) are_5\VBP|NONE (l_attr) syndrome_8\NN|:|?|Encephalopathy
24535067
D005045_D009069 NONE etomidate_19\NN|during|according (r_advcl) graded_9\VBN|which|were|and (r_conj) observed_7\VBN|.|,|movements|are (r_advcl) evaluated_3\VBN|NONE (l_nsubjpass) movements_1\NNS|.|,|observed|are
D008874_D009207 NONE midazolam_13\NN|, (r_appos) Fentanyl_11\NN|induced|:|:|is (r_appos) myoclonus_5\NN|NONE
D008874_D009207 NONE midazolam_15\NN|, (r_conj) fentanyl_13\NN|NONE (r_pobj) of_12\IN|combination|the (r_prep) effectiveness_11\NN|to (l_conj) combination_19\NN|the|of (l_relcl) prevent_25\VB|a|of (l_dobj) myoclonus_29\NN|to
D008874_D009207 NONE midazolam_23\NN|and (r_conj) fentanyl_21\NN|NONE (r_pobj) of_20\IN|prevent|a (r_prep) combination_19\NN|the|of (l_relcl) prevent_25\VB|a|of (l_dobj) myoclonus_29\NN|to
D008874_D009207 NONE midazolam_11\NN|and (r_conj) fentanyl_9\NN|NONE (r_pobj) of_8\IN|or|combination (r_prep) fentanyl_5\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) pretreatment_3\NN|that|effective (r_nsubj) was_12\VBD|We|. (l_acomp) effective_13\JJ|that|pretreatment (l_prep) in_14\IN|NONE (l_pcomp) preventing_15\VBG|NONE (l_dobj) myoclonus_19\NN|NONE
D005045_D009207 CID etomidate_2\NN| (r_npadvmod) induced_4\VBN|:|:|Fentanyl|is (r_amod) myoclonus_5\NN|NONE
D005045_D009207 CID etomidate_26\NN| (r_npadvmod) induced_28\VBN|NONE (r_amod) myoclonus_29\NN|to
D005045_D009207 CID etomidate_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) myoclonus_19\NN|NONE
D005045_D010146 NONE etomidate_6\NN|NONE (r_xcomp) due_4\IN|The|of (r_prep) severity_1\NN|pressure|, (l_prep) of_2\IN|The|due (l_pobj) pain_3\NN|NONE
D005283_D009207 NONE Fentanyl_11\NN|induced|:|:|is (r_appos) myoclonus_5\NN|NONE
D005283_D009207 NONE fentanyl_13\NN|NONE (r_pobj) of_12\IN|combination|the (r_prep) effectiveness_11\NN|to (l_conj) combination_19\NN|the|of (l_relcl) prevent_25\VB|a|of (l_dobj) myoclonus_29\NN|to
D005283_D009207 NONE fentanyl_21\NN|NONE (r_pobj) of_20\IN|prevent|a (r_prep) combination_19\NN|the|of (l_relcl) prevent_25\VB|a|of (l_dobj) myoclonus_29\NN|to
D005283_D009207 NONE fentanyl_5\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) pretreatment_3\NN|that|effective (r_nsubj) was_12\VBD|We|. (l_acomp) effective_13\JJ|that|pretreatment (l_prep) in_14\IN|NONE (l_pcomp) preventing_15\VBG|NONE (l_dobj) myoclonus_19\NN|NONE
D005283_D009207 NONE fentanyl_9\NN|NONE (r_pobj) of_8\IN|or|combination (r_prep) fentanyl_5\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) pretreatment_3\NN|that|effective (r_nsubj) was_12\VBD|We|. (l_acomp) effective_13\JJ|that|pretreatment (l_prep) in_14\IN|NONE (l_pcomp) preventing_15\VBG|NONE (l_dobj) myoclonus_19\NN|NONE
24802403
D010433_D003072 CID pentylenetetrazole_23\NN| (r_npadvmod) induced_25\VBN|kindling (r_amod) animals_27\NNS|NONE (r_pobj) in_22\IN|NONE (r_prep) observed_21\VBN|ameliorative|on|of|the (r_acl) effects_8\NNS|to (l_prep) on_11\IN|ameliorative|observed|of|the (l_pobj) seizures_12\NNS|NONE (l_conj) impairment_15\NN|,
D008687_D012640 NONE Metformin_0\NNP|against|. (r_nsubj) protects_1\VBZ|NONE (l_prep) against_2\IN|Metformin|. (l_pobj) seizures_3\NNS|NONE
D008687_D012640 NONE metformin_10\NN|NONE (r_pobj) of_9\IN|ameliorative|observed|on|the (r_prep) effects_8\NNS|to (l_prep) on_11\IN|ameliorative|observed|of|the (l_pobj) seizures_12\NNS|NONE
D008687_D012640 NONE metformin_6\NN|that|may|agent (r_nsubj) be_8\VB|Thus|.|study (l_attr) agent_11\NN|that|metformin|may (l_prep) for_12\IN|potential|a (l_pobj) treatment_14\NN|NONE (l_conj) medicine_22\NN|the|of|as (l_acl) induced_26\VBN|protective|a|against (l_agent) by_27\IN|NONE (l_pobj) seizures_28\NNS|NONE
D008687_D003072 NONE metformin_10\NN|NONE (r_pobj) of_9\IN|ameliorative|observed|on|the (r_prep) effects_8\NNS|to (l_prep) on_11\IN|ameliorative|observed|of|the (l_pobj) seizures_12\NNS|NONE (l_conj) impairment_15\NN|,
D008687_D003072 NONE metformin_3\NN|progression|,|ameliorated|that (r_nsubj) suppressed_4\VBD|We|. (l_conj) ameliorated_10\VBD|metformin|progression|,|that (l_dobj) impairment_13\NN|and|decreased
D008687_D003072 NONE metformin_6\NN|that|may|agent (r_nsubj) be_8\VB|Thus|.|study (l_attr) agent_11\NN|that|metformin|may (l_prep) for_12\IN|potential|a (l_pobj) treatment_14\NN|NONE (l_conj) medicine_22\NN|the|of|as (l_prep) against_23\IN|induced|protective|a (l_pobj) impairment_25\NN|NONE
D010433_D008569 CID pentylenetetrazole_14\NN| (r_npadvmod) induced_16\VBN|in (r_amod) kindling_17\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|damage|and (r_acl) impairments_8\NNS|,|learning
D008687_D007859 NONE Metformin_0\NNP|against|. (r_nsubj) protects_1\VBZ|NONE (l_prep) against_2\IN|Metformin|. (l_pobj) seizures_3\NNS|NONE (l_conj) impairments_8\NNS|,|learning
D010433_D007859 CID pentylenetetrazole_14\NN| (r_npadvmod) induced_16\VBN|in (r_amod) kindling_17\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|damage|and (r_acl) impairments_8\NNS|,|learning
D008687_D008569 NONE Metformin_0\NNP|against|. (r_nsubj) protects_1\VBZ|NONE (l_prep) against_2\IN|Metformin|. (l_pobj) seizures_3\NNS|NONE (l_conj) impairments_8\NNS|,|learning
D010433_D012640 CID pentylenetetrazole_14\NN| (r_npadvmod) induced_16\VBN|in (r_amod) kindling_17\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|damage|and (r_acl) impairments_8\NNS|,|learning (r_conj) seizures_3\NNS|NONE
D010433_D012640 CID pentylenetetrazole_23\NN| (r_npadvmod) induced_25\VBN|kindling (r_amod) animals_27\NNS|NONE (r_pobj) in_22\IN|NONE (r_prep) observed_21\VBN|ameliorative|on|of|the (r_acl) effects_8\NNS|to (l_prep) on_11\IN|ameliorative|observed|of|the (l_pobj) seizures_12\NNS|NONE
D008687_D004827 NONE metformin_6\NN|that|may|agent (r_nsubj) be_8\VB|Thus|.|study (l_attr) agent_11\NN|that|metformin|may (l_prep) for_12\IN|potential|a (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the|as|medicine (l_pobj) epilepsy_16\NN|NONE
25006369
D013390_D005207 CID succinylcholine_11\NN|NONE (r_compound) administration_12\NN|NONE (r_pobj) following_10\VBG|to|fasciculation (r_prep) decrease_6\VB|precurarizing|.|Optimal|of (l_dobj) fasciculation_7\NN|to|following
D013390_D005207 CID Succinylcholine_0\NNP|commonly|.|effects (r_nsubj) produces_2\VBZ|NONE (l_dobj) effects_5\NNS|commonly|Succinylcholine|. (l_prep) including_7\VBG|adverse|,|frequent (l_pobj) fasciculation_9\NN|NONE
D013390_D005207 CID succinylcholine_11\NN| (r_npadvmod) induced_13\VBN|and|myalgia (r_amod) fasciculation_14\NN|to
D013390_D005207 CID succinylcholine_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) produced_28\VBN|NONE (r_acl) onset_27\NN|NONE (r_pobj) of_26\IN|the (r_prep) speed_25\NN|NONE (r_pobj) on_23\IN|NONE (r_prep) rocuronium_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) influence_20\NN|NONE (r_dobj) evaluated_18\VBD|dose|.|study|and|prevent (r_conj) identified_3\VBD|NONE (l_advcl) prevent_10\VB|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN|to
D013390_D005207 CID succinylcholine_3\NN|and|,|patients|.|assessed (r_dobj) received_2\VBD|NONE (l_conj) assessed_15\VBN|and|,|patients|.|succinylcholine (l_dobj) incidence_17\NN|were|assessed|, (l_prep) of_20\IN|severity|the|and (l_pobj) fasciculations_21\NNS|NONE
D013390_D063806 CID succinylcholine_11\NN|NONE (r_compound) administration_12\NN|NONE (r_pobj) following_10\VBG|to|fasciculation (r_prep) decrease_6\VB|precurarizing|.|Optimal|of (l_dobj) fasciculation_7\NN|to|following (l_conj) myalgia_9\NN|and
D013390_D063806 CID Succinylcholine_0\NNP|commonly|.|effects (r_nsubj) produces_2\VBZ|NONE (l_dobj) effects_5\NNS|commonly|Succinylcholine|. (l_prep) including_7\VBG|adverse|,|frequent (l_pobj) fasciculation_9\NN|NONE (l_conj) myalgia_11\NN|muscle|and
D013390_D063806 CID succinylcholine_11\NN| (r_npadvmod) induced_13\VBN|and|myalgia (r_amod) fasciculation_14\NN|to (l_conj) myalgia_16\NN|induced|and
D013390_D063806 CID succinylcholine_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) produced_28\VBN|NONE (r_acl) onset_27\NN|NONE (r_pobj) of_26\IN|the (r_prep) speed_25\NN|NONE (r_pobj) on_23\IN|NONE (r_prep) rocuronium_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) influence_20\NN|NONE (r_dobj) evaluated_18\VBD|dose|.|study|and|prevent (r_conj) identified_3\VBD|NONE (l_advcl) prevent_10\VB|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN|to (l_conj) myalgia_16\NN|induced|and
D013390_D063806 CID succinylcholine_3\NN|and|,|patients|.|assessed (r_dobj) received_2\VBD|NONE (l_conj) assessed_15\VBN|and|,|patients|.|succinylcholine (l_advcl) assessed_26\VBN|were|incidence|, (l_nsubjpass) myalgia_24\NN|was|at|while
C061870_D063806 NONE rocuronium_4\NN|NONE (r_pobj) of_3\IN|precurarizing|.|decrease|Optimal (r_prep) dose_2\NN|NONE (l_acl) decrease_6\VB|precurarizing|.|Optimal|of (l_dobj) fasciculation_7\NN|to|following (l_conj) myalgia_9\NN|and
C061870_D063806 NONE rocuronium_8\NN|NONE (r_pobj) of_7\IN|the|optimal (r_prep) dose_6\NN|evaluated|.|study|and|prevent (r_dobj) identified_3\VBD|NONE (l_advcl) prevent_10\VB|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN|to (l_conj) myalgia_16\NN|induced|and
C061870_D063806 NONE rocuronium_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) influence_20\NN|NONE (r_dobj) evaluated_18\VBD|dose|.|study|and|prevent (r_conj) identified_3\VBD|NONE (l_advcl) prevent_10\VB|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN|to (l_conj) myalgia_16\NN|induced|and
C061870_D063806 NONE rocuronium_15\NN|NONE (r_pobj) of_14\IN|NONE (r_prep) dose_13\NN|NONE (r_dobj) precurarizing_12\VBG|NONE (r_pcomp) of_11\IN|the (r_prep) amount_10\NN|NONE (r_dobj) increasing_8\VBG|NONE (r_pcomp) to_7\IN|NONE (r_prep) according_6\VBG|to (r_prep) decrease_5\VB|but|Those|,|was (r_xcomp) tend_3\VBP|NONE (l_nsubj) Those_0\DT|but|,|decrease|was (l_prep) of_1\IN|NONE (l_pobj) myalgia_2\NN|NONE
C061870_D063806 NONE rocuronium_4\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Precurarization_0\NN|dose|and|.|precurarization|, (r_nsubj) was_5\VBD|NONE (l_attr) dose_8\NN|Precurarization|and|.|precurarization|, (l_acl) considering_9\VBG|the|optimal (l_dobj) reduction_11\NN|NONE (l_prep) in_12\IN|the (l_pobj) incidence_14\NN|NONE (l_prep) of_17\IN|the|and|severity (l_pobj) fasciculation_18\NN|NONE (l_conj) myalgia_20\NN|and
C061870_D005207 NONE rocuronium_4\NN|NONE (r_pobj) of_3\IN|precurarizing|.|decrease|Optimal (r_prep) dose_2\NN|NONE (l_acl) decrease_6\VB|precurarizing|.|Optimal|of (l_dobj) fasciculation_7\NN|to|following
C061870_D005207 NONE rocuronium_8\NN|NONE (r_pobj) of_7\IN|the|optimal (r_prep) dose_6\NN|evaluated|.|study|and|prevent (r_dobj) identified_3\VBD|NONE (l_advcl) prevent_10\VB|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN|to
C061870_D005207 NONE rocuronium_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) influence_20\NN|NONE (r_dobj) evaluated_18\VBD|dose|.|study|and|prevent (r_conj) identified_3\VBD|NONE (l_advcl) prevent_10\VB|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN|to
C061870_D005207 NONE rocuronium_19\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) dose_17\NN|NONE (r_dobj) precurarizing_16\VBG|NONE (r_pcomp) of_15\IN|)|the|P|( (r_prep) amount_14\NN|NONE (r_dobj) increasing_12\VBG|NONE (r_pcomp) with_11\IN|significantly (r_prep) less_10\JJR|.|incidence (r_acomp) was_8\VBD|NONE (l_nsubj) incidence_1\NN|.|less (l_prep) of_4\IN|The|severity|and (l_pobj) fasciculation_7\NN|NONE
C061870_D005207 NONE rocuronium_4\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Precurarization_0\NN|dose|and|.|precurarization|, (r_nsubj) was_5\VBD|NONE (l_attr) dose_8\NN|Precurarization|and|.|precurarization|, (l_acl) considering_9\VBG|the|optimal (l_dobj) reduction_11\NN|NONE (l_prep) in_12\IN|the (l_pobj) incidence_14\NN|NONE (l_prep) of_17\IN|the|and|severity (l_pobj) fasciculation_18\NN|NONE
8188982
D009599_D007022 CID nitroprusside_42\NN|(|phenylephrine|hypertension|SN)induced (r_amod) hypotension_45\NN|NONE
D009599_D007022 CID SN)-induced_44\JJ|(|phenylephrine|hypertension|nitroprusside (r_amod) hypotension_45\NN|NONE
D009599_D007022 CID SN_13\NNP| (r_npadvmod) induced_15\VBN|NONE (r_amod) hypotension_16\NN|NONE
D001127_D006973 CID AVP_4\NNP|NONE (r_pobj) of_3\IN|cardiovascular|Central|in|. (r_prep) effects_2\NNS|NONE (l_prep) in_7\IN|cardiovascular|Central|of|. (l_pobj) rats_12\NNS|NONE (l_amod) hypertensive_11\JJ|normotensive
D001127_D006973 CID vasopressin_13\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) influence_9\NN|to|on|and|of|rats|and (r_dobj) compare_8\VB|purpose|. (l_conj) rats_51\NNS|to|on|influence|and|of|and (l_amod) hypertensive_47\JJ|SHR|(|)
D001127_D006973 CID AVP_15\NNP|arginine|central|(|) (r_appos) vasopressin_13\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) influence_9\NN|to|on|and|of|rats|and (r_dobj) compare_8\VB|purpose|. (l_conj) rats_51\NNS|to|on|influence|and|of|and (l_amod) hypertensive_47\JJ|SHR|(|)
D010656_D007022 NONE phenylephrine_36\NN|(|hypertension|nitroprusside|SN)induced (r_nmod) hypotension_45\NN|NONE
D010656_D007022 NONE Phe)-induced_38\VBN|sodium|and|( (r_amod) hypertension_39\NN|(|phenylephrine|nitroprusside|SN)induced (r_nmod) hypotension_45\NN|NONE
D010656_D006973 CID phenylephrine_36\NN|(|hypertension|nitroprusside|SN)induced (r_nmod) hypotension_45\NN|NONE (l_nmod) hypertension_39\NN|(|phenylephrine|nitroprusside|SN)induced
D010656_D006973 CID Phe)-induced_38\VBN|sodium|and|( (r_amod) hypertension_39\NN|(|phenylephrine|nitroprusside|SN)induced
D009599_D006973 NONE nitroprusside_42\NN|(|phenylephrine|hypertension|SN)induced (r_amod) hypotension_45\NN|NONE (l_nmod) hypertension_39\NN|(|phenylephrine|nitroprusside|SN)induced
D009599_D006973 NONE SN)-induced_44\JJ|(|phenylephrine|hypertension|nitroprusside (r_amod) hypotension_45\NN|NONE (l_nmod) hypertension_39\NN|(|phenylephrine|nitroprusside|SN)induced
D001127_D007022 NONE AVP_11\NNP|NONE (r_pobj) of_10\IN|LV (r_prep) administration_9\NN|NONE (r_pobj) after_7\IN|CCB|was|in|during|. (r_prep) reduced_2\VBN|NONE (l_prep) during_12\IN|CCB|was|in|after|. (l_pobj) hypotension_16\NN|NONE
23892921
C467567_D009101 NONE lenalidomide_12\NN|NONE (r_pobj) of_11\IN|the|safety|and (r_prep) efficacy_8\NN|NONE (r_pobj) on_6\IN|in|study|.|world|:|"|" (r_prep) data_5\NNS|NONE (l_prep) in_15\IN|study|.|world|:|"|on|" (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) myeloma_22\NN|NONE
C467567_D009101 NONE lenalidomide_12\NN|NONE (r_pobj) of_11\IN|the|safety|and (r_prep) efficacy_8\NN|NONE (r_pobj) on_6\IN|in|study|.|world|:|"|" (r_prep) data_5\NNS|NONE (l_appos) study_34\NN|in|.|world|:|"|on|" (l_prep) of_35\IN|a (l_pobj) Group_40\NNP|NONE (l_compound) Myeloma_38\NNP|the|Greek|Study
C467567_D009101 NONE Lenalidomide_0\NNP|is|,|standard|but (r_nsubj) is_6\VBZ|NONE (l_attr) standard_8\NN|is|Lenalidomide|,|but (l_prep) for_11\IN|of|a (l_pobj) myeloma_16\NN|NONE
C467567_D009101 NONE Lenalidomide_0\NNP|is|,|standard|but (r_nsubj) is_6\VBZ|NONE (l_attr) standard_8\NN|is|Lenalidomide|,|but (l_prep) for_11\IN|of|a (l_pobj) myeloma_16\NN|NONE (l_appos) RRMM_18\NNP|multiple|refractory|relapsed
C467567_D009101 NONE RD_4\NNP|NONE (r_appos) dexamethasone_2\NN|and (r_conj) Lenalidomide_0\NNP|is|,|standard|but (r_nsubj) is_6\VBZ|NONE (l_attr) standard_8\NN|is|Lenalidomide|,|but (l_prep) for_11\IN|of|a (l_pobj) myeloma_16\NN|NONE
C467567_D009101 NONE RD_4\NNP|NONE (r_appos) dexamethasone_2\NN|and (r_conj) Lenalidomide_0\NNP|is|,|standard|but (r_nsubj) is_6\VBZ|NONE (l_attr) standard_8\NN|is|Lenalidomide|,|but (l_prep) for_11\IN|of|a (l_pobj) myeloma_16\NN|NONE (l_appos) RRMM_18\NNP|multiple|refractory|relapsed
C467567_D009101 NONE RD_7\NNP|who|in (r_dobj) received_6\VBD||RRMM (r_relcl) patients_4\NNS|We|. (l_compound) RRMM_3\NNP|received|
C467567_D009101 NONE RD_4\NNP|that|in|effective (r_nsubj) is_5\VBZ|study (l_acomp) effective_6\JJ|that|in|RD (l_conj) safe_8\JJ|and (l_prep) in_9\IN|NONE (l_pobj) RRMM_10\NNP|NONE
D003907_D009101 NONE dexamethasone_14\NN|and (r_conj) lenalidomide_12\NN|NONE (r_pobj) of_11\IN|the|safety|and (r_prep) efficacy_8\NN|NONE (r_pobj) on_6\IN|in|study|.|world|:|"|" (r_prep) data_5\NNS|NONE (l_prep) in_15\IN|study|.|world|:|"|on|" (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) myeloma_22\NN|NONE
D003907_D009101 NONE dexamethasone_14\NN|and (r_conj) lenalidomide_12\NN|NONE (r_pobj) of_11\IN|the|safety|and (r_prep) efficacy_8\NN|NONE (r_pobj) on_6\IN|in|study|.|world|:|"|" (r_prep) data_5\NNS|NONE (l_appos) study_34\NN|in|.|world|:|"|on|" (l_prep) of_35\IN|a (l_pobj) Group_40\NNP|NONE (l_compound) Myeloma_38\NNP|the|Greek|Study
D003907_D009101 NONE dexamethasone_2\NN|and (r_conj) Lenalidomide_0\NNP|is|,|standard|but (r_nsubj) is_6\VBZ|NONE (l_attr) standard_8\NN|is|Lenalidomide|,|but (l_prep) for_11\IN|of|a (l_pobj) myeloma_16\NN|NONE
D003907_D009101 NONE dexamethasone_2\NN|and (r_conj) Lenalidomide_0\NNP|is|,|standard|but (r_nsubj) is_6\VBZ|NONE (l_attr) standard_8\NN|is|Lenalidomide|,|but (l_prep) for_11\IN|of|a (l_pobj) myeloma_16\NN|NONE (l_appos) RRMM_18\NNP|multiple|refractory|relapsed
D003907_D009101 NONE RD_4\NNP|NONE (r_appos) dexamethasone_2\NN|and (r_conj) Lenalidomide_0\NNP|is|,|standard|but (r_nsubj) is_6\VBZ|NONE (l_attr) standard_8\NN|is|Lenalidomide|,|but (l_prep) for_11\IN|of|a (l_pobj) myeloma_16\NN|NONE
D003907_D009101 NONE RD_4\NNP|NONE (r_appos) dexamethasone_2\NN|and (r_conj) Lenalidomide_0\NNP|is|,|standard|but (r_nsubj) is_6\VBZ|NONE (l_attr) standard_8\NN|is|Lenalidomide|,|but (l_prep) for_11\IN|of|a (l_pobj) myeloma_16\NN|NONE (l_appos) RRMM_18\NNP|multiple|refractory|relapsed
D003907_D009101 NONE RD_7\NNP|who|in (r_dobj) received_6\VBD||RRMM (r_relcl) patients_4\NNS|We|. (l_compound) RRMM_3\NNP|received|
D003907_D009101 NONE RD_4\NNP|that|in|effective (r_nsubj) is_5\VBZ|study (l_acomp) effective_6\JJ|that|in|RD (l_conj) safe_8\JJ|and (l_prep) in_9\IN|NONE (l_pobj) RRMM_10\NNP|NONE
12359538
D003042_D009336 NONE cocaine_19\NN| (r_npadvmod) associated_21\VBN|chest|MI|and (r_amod) pain_23\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) patients_17\NNS|NONE (r_pobj) in_16\IN|NONE (r_prep) necrosis_15\NN|NONE
D003042_D002637 NONE cocaine_7\NN| (r_npadvmod) associated_9\VBN|chest (r_amod) pain_11\NN|NONE
D003042_D002637 NONE cocaine_24\NN| (r_npadvmod) associated_26\VBN|chest (r_amod) pain_28\NN|NONE
D003042_D002637 NONE cocaine_10\NN|NONE (r_compound) chest_11\NN|NONE (r_compound) pain_12\NN|NONE
D003042_D002637 NONE cocaine_19\NN| (r_npadvmod) associated_21\VBN|chest|MI|and (r_amod) pain_23\NN|NONE
D003042_D009203 CID cocaine_24\NN| (r_npadvmod) associated_26\VBN|chest (r_amod) pain_28\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) patients_22\NNS|NONE (r_pobj) in_21\IN|NONE (r_prep) difficult_20\JJ|.|abnormalities|diagnosis (r_ccomp) make_11\VBP|NONE (l_dobj) diagnosis_13\NN|.|difficult|abnormalities (l_prep) of_14\IN|accurate (l_pobj) infarction_16\NN|NONE
D003042_D009203 CID cocaine_24\NN| (r_npadvmod) associated_26\VBN|chest (r_amod) pain_28\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) patients_22\NNS|NONE (r_pobj) in_21\IN|NONE (r_prep) difficult_20\JJ|.|abnormalities|diagnosis (r_ccomp) make_11\VBP|NONE (l_dobj) diagnosis_13\NN|.|difficult|abnormalities (l_prep) of_14\IN|accurate (l_pobj) infarction_16\NN|NONE (l_appos) MI_18\NNP|)|myocardial|(
D003042_D009203 CID cocaine_10\NN|NONE (r_compound) chest_11\NN|NONE (r_compound) pain_12\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) patients_8\NNS|NONE (r_pobj) in_7\IN|admitted|troponin (r_prep) positivity_6\NN|NONE (l_acl) admitted_13\VBD|in|troponin (l_prep) for_14\IN|NONE (l_pobj) exclusion_15\NN|NONE (l_prep) of_16\IN|NONE (l_pobj) MI_17\NNP|NONE
D003042_D009203 CID cocaine_10\NN|NONE (r_compound) use_11\NN|NONE (r_pobj) after_9\IN|for (r_prep) admitted_5\VBN|NONE (l_prep) for_6\IN|after (l_pobj) MI_8\NNP|NONE
D003042_D009203 CID cocaine_19\NN| (r_npadvmod) associated_21\VBN|chest|MI|and (r_amod) pain_23\NN|NONE (l_conj) MI_26\NNP|chest|associated|and
D003042_D009202 NONE cocaine_24\NN| (r_npadvmod) associated_26\VBN|chest (r_amod) pain_28\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) patients_22\NNS|NONE (r_pobj) in_21\IN|NONE (r_prep) difficult_20\JJ|.|abnormalities|diagnosis (r_ccomp) make_11\VBP|NONE (l_nsubj) abnormalities_2\NNS|.|difficult|diagnosis (l_acl) associated_7\VBN|and|elevations|electrocardiogram|Baseline (l_prep) with_8\IN|not (l_pobj) necrosis_10\NN|NONE
25080425
D001622_D017202 NONE betaine_11\NN|NONE (r_pobj) of_10\IN|induced|cardioprotective|the|on (r_prep) effects_9\NNS|to (l_prep) on_12\IN|induced|of|cardioprotective|the (l_pobj) ischemia_15\NN|NONE
D001622_D017202 NONE betaine_7\NN|NONE (r_compound) pretreatment_8\NN|NONE (r_nsubj) attenuated_9\VBD|induced|that|myocardial|via|acute (r_amod) ischemia_15\NN|,|results|.|In
D001622_D020257 NONE betaine_3\NN|NONE (r_pobj) of_2\IN|mg/kg|Oral (r_prep) administration_1\NN|and|significantly|.|level|prevented (r_nsubj) reduced_11\VBD|NONE (l_conj) prevented_22\VBN|and|significantly|administration|.|level (l_dobj) remodeling_25\NN|NONE
D007545_D009202 NONE isoproterenol_15\NN| (r_npadvmod) induced_17\VBN|acute|myocardial|in (r_amod) injury_20\NN|Regulation|.
D001622_D009202 NONE betaine_13\NN|NONE (r_pobj) by_12\IN|of (r_prep) Regulation_0\NN|.|injury (r_nsubj) attenuates_14\VBZ|NONE (l_dobj) injury_20\NN|Regulation|.
D001622_D009202 NONE betaine_4\NN|NONE (l_prep) on_5\IN|NONE (l_pobj) damage_7\NN|NONE
D007545_D017202 CID isoproterenol_12\NN|NONE (r_pobj) of_11\IN|(|mg/kg|subcutaneous|) (r_prep) injection_10\NN|NONE (r_pobj) by_8\IN|in|was|.|injury|for|, (r_agent) induced_5\VBN|NONE (l_nsubjpass) injury_3\NN|in|was|.|for|by|,
D007545_D017202 CID isoproterenol_10\NN| (r_npadvmod) induced_12\VBN|that|myocardial|via|attenuated|acute (r_amod) ischemia_15\NN|,|results|.|In
15614572
D006220_D009062 NONE haloperidol_19\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|NONE (r_acl) catalepsy_16\NN|NONE (r_pobj) on_15\IN|was|.|,|on|effect|,|in (r_prep) studied_47\VBN|NONE (l_nsubjpass) effect_1\NN|was|.|on|,|on|,|in (l_prep) of_2\IN|The (l_pobj) pretreatment_3\NN|NONE (l_prep) on_6\IN|with (l_pobj) stereotypies_13\NNS|NONE
D001058_D002375 CID apomorphine_9\NN|and (r_conj) dexamphetamine-_7\FW| (r_npadvmod) induced_11\VBN|oral (r_amod) stereotypies_13\NNS|NONE (r_pobj) on_6\IN|with (r_prep) pretreatment_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|.|on|,|on|,|in (r_nsubjpass) studied_47\VBN|NONE (l_prep) on_15\IN|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN|NONE
D001058_D002375 CID apomorphine_21\NN|and|mg/kg (r_conj) haloperidol_19\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|NONE (r_acl) catalepsy_16\NN|NONE
D001058_D002375 CID apomorphine_16\NN|not|did|catalepsy (r_dobj) antagonize_15\VB|Trazodone|did|catalepsy|not|,|.|and (r_conj) induce_9\VB|NONE (l_dobj) catalepsy_10\NN|Trazodone|did|not|,|.|antagonize|and
D001058_D002375 CID apomorphine_16\NN|not|did|catalepsy (r_dobj) antagonize_15\VB|Trazodone|did|catalepsy|not|,|.|and (l_dobj) catalepsy_31\NN|not|did|apomorphine
D001058_D002375 CID apomorphine_25\NN|and|)|mg/kg|( (r_conj) stereotypy_23\NN|kg)induced (r_nmod) catalepsy_31\NN|not|did|apomorphine (r_dobj) antagonize_15\VB|Trazodone|did|catalepsy|not|,|.|and (r_conj) induce_9\VB|NONE (l_dobj) catalepsy_10\NN|Trazodone|did|not|,|.|antagonize|and
D001058_D002375 CID apomorphine_25\NN|and|)|mg/kg|( (r_conj) stereotypy_23\NN|kg)induced (r_nmod) catalepsy_31\NN|not|did|apomorphine
D001058_D002375 CID apomorphine_13\NN|NONE (r_dobj) antagonized_12\VBN|i.p.|,|Trazodone|mg/kg|catalepsy|and|. (r_conj) induced_9\VBN|NONE (l_dobj) catalepsy_10\NN|i.p.|,|Trazodone|mg/kg|and|.|antagonized
D001058_D009062 NONE apomorphine_9\NN|and (r_conj) dexamphetamine-_7\FW| (r_npadvmod) induced_11\VBN|oral (r_amod) stereotypies_13\NNS|NONE
D001058_D009062 NONE apomorphine_21\NN|and|mg/kg (r_conj) haloperidol_19\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|NONE (r_acl) catalepsy_16\NN|NONE (r_pobj) on_15\IN|was|.|,|on|effect|,|in (r_prep) studied_47\VBN|NONE (l_nsubjpass) effect_1\NN|was|.|on|,|on|,|in (l_prep) of_2\IN|The (l_pobj) pretreatment_3\NN|NONE (l_prep) on_6\IN|with (l_pobj) stereotypies_13\NNS|NONE
D014196_D002375 NONE trazodone_5\NN|NONE (r_pobj) with_4\IN|on (r_prep) pretreatment_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|.|on|,|on|,|in (r_nsubjpass) studied_47\VBN|NONE (l_prep) on_15\IN|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN|NONE
D014196_D002375 NONE trazodone_4\NN|catalepsy|in|whether (r_nsubj) induces_5\VBZ|We|.|also (l_dobj) catalepsy_6\NN|in|trazodone|whether
D014196_D002375 NONE Trazodone_0\NNP|did|catalepsy|not|,|.|antagonize|and (r_nsubj) induce_9\VB|NONE (l_dobj) catalepsy_10\NN|Trazodone|did|not|,|.|antagonize|and
D014196_D002375 NONE Trazodone_0\NNP|did|catalepsy|not|,|.|antagonize|and (r_nsubj) induce_9\VB|NONE (l_conj) antagonize_15\VB|Trazodone|did|catalepsy|not|,|.|and (l_dobj) catalepsy_31\NN|not|did|apomorphine
D014196_D002375 NONE trazodone_11\NNP|dexamphetamine|i.p.|enhanced|, (r_nmod) stereotypy_14\NN| (r_pobj) with_3\IN|However|,|and|antagonized|,|. (r_prep) pretreatment_2\NN|NONE (l_conj) antagonized_17\VBD|However|,|and|with|,|. (l_dobj) catalepsy_19\NN|NONE
D014196_D002375 NONE Trazodone_0\NNP|i.p.|,|mg/kg|catalepsy|and|.|antagonized (r_nsubj) induced_9\VBN|NONE (l_dobj) catalepsy_10\NN|i.p.|,|Trazodone|mg/kg|and|.|antagonized
D014196_D002375 NONE trazodone_3\NNP|that|neurons|,|and|potentiates|, (r_nsubj) releases_20\VBZ|We|. (l_conj) potentiates_34\VBZ|trazodone|that|neurons|,|and|, (l_conj) antagonizes_38\VBZ|stereotypy|thereby|and (l_dobj) catalepsy_40\NN|NONE
D014196_D009062 NONE trazodone_5\NN|NONE (r_pobj) with_4\IN|on (r_prep) pretreatment_3\NN|NONE (l_prep) on_6\IN|with (l_pobj) stereotypies_13\NNS|NONE
D012701_D002375 NONE 5-HT_16\CD|NONE (r_compound) 2C_17\NNP|the (r_compound) receptors_18\NNS|NONE (r_dobj) blocking_14\VBG|NONE (r_pcomp) by_13\IN|mg/kg|, (r_prep) trazodone_3\NNP|that|neurons|,|and|potentiates|, (r_nsubj) releases_20\VBZ|We|. (l_conj) potentiates_34\VBZ|trazodone|that|neurons|,|and|, (l_conj) antagonizes_38\VBZ|stereotypy|thereby|and (l_dobj) catalepsy_40\NN|NONE
D012701_D002375 NONE 5-HT_30\CD|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|tonic (r_acl) inhibition_27\NN|NONE (r_pobj) from_25\IN|nigrostriatal|DAergic|the (r_prep) neurons_24\NNS|trazodone|that|,|and|potentiates|, (r_dobj) releases_20\VBZ|We|. (l_conj) potentiates_34\VBZ|trazodone|that|neurons|,|and|, (l_conj) antagonizes_38\VBZ|stereotypy|thereby|and (l_dobj) catalepsy_40\NN|NONE
D003913_D009062 NONE dexamphetamine-_7\FW| (r_npadvmod) induced_11\VBN|oral (r_amod) stereotypies_13\NNS|NONE
D006220_D002375 CID haloperidol_19\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|NONE (r_acl) catalepsy_16\NN|NONE
D006220_D002375 CID haloperidol_18\NN|behavior|, (r_det) catalepsy_19\NN|NONE
D006220_D002375 CID haloperidol_39\NN|NONE (r_det) catalepsy_40\NN|NONE
D004874_D002375 NONE ergometrine_30\NN| (r_advmod) induced_32\VBN|(|)|erections|and|shake|WDS (r_amod) behavior_39\NN|NONE (r_pobj) on_29\IN|was|.|on|,|effect|,|in (r_prep) studied_47\VBN|NONE (l_prep) on_15\IN|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN|NONE
D004874_D002375 NONE ergometrine_21\NN| (r_advmod) induced_23\VBN|erections|and|WDS (r_amod) behavior_25\NN|haloperidol|, (r_conj) catalepsy_19\NN|NONE
D003913_D002375 NONE dexamphetamine-_7\FW| (r_npadvmod) induced_11\VBN|oral (r_amod) stereotypies_13\NNS|NONE (r_pobj) on_6\IN|with (r_prep) pretreatment_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|.|on|,|on|,|in (r_nsubjpass) studied_47\VBN|NONE (l_prep) on_15\IN|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN|NONE
D003913_D002375 NONE dexamphetamine_13\NN|trazodone|i.p.|enhanced|, (r_compound) stereotypy_14\NN| (r_pobj) with_3\IN|However|,|and|antagonized|,|. (r_prep) pretreatment_2\NN|NONE (l_conj) antagonized_17\VBD|However|,|and|with|,|. (l_dobj) catalepsy_19\NN|NONE
D003913_D002375 NONE dexamphetamine_15\NN|NONE (r_compound) stereotypies_16\NNS|and (r_conj) apomorphine_13\NN|NONE (r_dobj) antagonized_12\VBN|i.p.|,|Trazodone|mg/kg|catalepsy|and|. (r_conj) induced_9\VBN|NONE (l_dobj) catalepsy_10\NN|i.p.|,|Trazodone|mg/kg|and|.|antagonized
D003913_D002375 NONE dexamphetamine_35\NN|NONE (r_compound) stereotypy_36\NN|thereby|antagonizes|and (r_dobj) potentiates_34\VBZ|trazodone|that|neurons|,|and|, (l_conj) antagonizes_38\VBZ|stereotypy|thereby|and (l_dobj) catalepsy_40\NN|NONE
D004874_D009062 NONE ergometrine_30\NN| (r_advmod) induced_32\VBN|(|)|erections|and|shake|WDS (r_amod) behavior_39\NN|NONE (r_pobj) on_29\IN|was|.|on|,|effect|,|in (r_prep) studied_47\VBN|NONE (l_nsubjpass) effect_1\NN|was|.|on|,|on|,|in (l_prep) of_2\IN|The (l_pobj) pretreatment_3\NN|NONE (l_prep) on_6\IN|with (l_pobj) stereotypies_13\NNS|NONE
D005473_D009062 NONE fluoxetine_41\NN| (r_advmod) induced_43\VBN|penile (r_amod) erections_45\NNS|(|)|induced|and|shake|WDS (r_conj) behavior_39\NN|NONE (r_pobj) on_29\IN|was|.|on|,|effect|,|in (r_prep) studied_47\VBN|NONE (l_nsubjpass) effect_1\NN|was|.|on|,|on|,|in (l_prep) of_2\IN|The (l_pobj) pretreatment_3\NN|NONE (l_prep) on_6\IN|with (l_pobj) stereotypies_13\NNS|NONE
D005473_D002375 NONE fluoxetine_41\NN| (r_advmod) induced_43\VBN|penile (r_amod) erections_45\NNS|(|)|induced|and|shake|WDS (r_conj) behavior_39\NN|NONE (r_pobj) on_29\IN|was|.|on|,|effect|,|in (r_prep) studied_47\VBN|NONE (l_prep) on_15\IN|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN|NONE
D005473_D002375 NONE fluoxetine_27\NN| (r_advmod) induced_29\VBN|penile (r_amod) erections_31\NNS|and|induced|WDS (r_conj) behavior_25\NN|haloperidol|, (r_conj) catalepsy_19\NN|NONE
11425091
D003042_D006470 NONE cocaine_1\NN|NONE (r_compound) exposure_2\NN|has|with|been|. (r_nsubjpass) linked_5\VBN|NONE (l_prep) with_6\IN|has|exposure|been|. (l_pobj) hemorrhage_8\NN|NONE
D003042_D019970 NONE cocaine_5\NN| (r_npadvmod) exposed_7\VBN|the (r_amod) group_8\NN|NONE (r_pobj) to_3\IN|was|.|were|Infants (r_prep) assigned_2\VBN|NONE (l_advcl) was_11\VBD|.|were|to|Infants (l_attr) history_14\NN|if|there|were (l_prep) of_15\IN|a|or|maternal (l_pobj) abuse_17\NN|NONE
D003042_D003560 CID cocaine_1\NN|NONE (r_compound) exposure_2\NN|has|with|been|. (r_nsubjpass) linked_5\VBN|NONE (l_prep) with_6\IN|has|exposure|been|. (l_pobj) hemorrhage_8\NN|NONE (l_conj) formation_11\NN|subependymal|and (l_prep) of_12\IN|are|the (l_pobj) cysts_13\NNS|NONE
D003042_D003560 CID cocaine_6\NN|NONE (r_compound) exposure_7\NN|if|incidence (r_nsubj) increases_8\VBZ|to (l_dobj) incidence_10\NN|exposure|if (l_prep) of_11\IN|the (l_pobj) cysts_13\NNS|NONE
D003042_D003560 CID cocaine_9\NN|NONE (r_pobj) to_8\IN|prenatally (r_prep) exposed_7\VBN|NONE (r_acl) infants_6\NNS|NONE (r_pobj) in_5\IN|subependymal (r_prep) cysts_4\NNS|NONE
D003042_D003560 CID cocaine_16\NN|NONE (r_pobj) to_15\IN|who|were (r_prep) exposed_14\VBN|preterm (r_relcl) infants_11\NNS|NONE (r_pobj) in_9\IN|subependymal|cyst (r_prep) formation_8\NN|NONE (l_compound) cyst_7\NN|subependymal|in
D003042_D007235 CID cocaine_1\NN|.|in|findings|and (r_compound) exposure_2\NN|NONE (l_prep) in_7\IN|.|findings|cocaine|and (l_pobj) infants_9\NNS|NONE
D003042_D007235 CID cocaine_6\NN|NONE (r_compound) exposure_7\NN|if|incidence (r_nsubj) increases_8\VBZ|to (l_dobj) incidence_10\NN|exposure|if (l_prep) of_11\IN|the (l_pobj) cysts_13\NNS|NONE (l_prep) in_14\IN|subependymal (l_pobj) infants_16\NNS|NONE
D003042_D007235 CID cocaine_16\NN|NONE (r_pobj) to_15\IN|who|were (r_prep) exposed_14\VBN|preterm (r_relcl) infants_11\NNS|NONE
D003042_D001927 CID cocaine_6\NN|NONE (r_compound) exposure_7\NN|if|incidence (r_nsubj) increases_8\VBZ|to (l_dobj) incidence_10\NN|exposure|if (l_prep) of_11\IN|the (l_pobj) cysts_13\NNS|NONE
D003042_D001927 CID cocaine_9\NN|NONE (r_pobj) to_8\IN|prenatally (r_prep) exposed_7\VBN|NONE (r_acl) infants_6\NNS|NONE (r_pobj) in_5\IN|subependymal (r_prep) cysts_4\NNS|NONE
D003042_D001927 CID cocaine_16\NN|NONE (r_pobj) to_15\IN|who|were (r_prep) exposed_14\VBN|preterm (r_relcl) infants_11\NNS|NONE (r_pobj) in_9\IN|subependymal|cyst (r_prep) formation_8\NN|NONE (l_compound) cyst_7\NN|subependymal|in
17954033
D019259_D006509 NONE lamivudine_20\NN| (r_npadvmod) untreated_22\VBN|B|chronic (r_amod) patients_26\NNS|NONE (r_pobj) in_19\IN|natural|genome (r_prep) variability_18\NN|NONE (r_pobj) as_15\IN|that|mutants (r_prep) occur_14\VBP|.|studies (l_nsubj) mutants_7\NNS|that|as (l_appos) virus_12\NN|(|)|the|motif (l_compound) B_11\NNP|resistant
D019259_D019694 NONE lamivudine_6\NN| (r_npadvmod) untreated_8\VBN|with|Iranian (r_amod) patients_10\NNS|NONE (l_prep) with_11\IN|untreated|Iranian (l_pobj) infection_16\NN|NONE
D019259_D019694 NONE Lamivudine_0\NNP|for|is|. (r_nsubjpass) used_2\VBN|NONE (l_prep) for_3\IN|is|Lamivudine|. (l_pobj) treatment_5\NN|NONE (l_prep) of_6\IN|the (l_pobj) patients_10\NNS|NONE (l_compound) B_9\NNP|chronic
D019259_D019694 NONE lamivudine_20\NN| (r_npadvmod) untreated_22\VBN|B|chronic (r_amod) patients_26\NNS|NONE (l_compound) B_25\NNP|chronic|untreated
D019259_D019694 NONE lamivudine_14\NN| (r_npadvmod) untreated_16\VBN|chronic|in|B (r_amod) patients_20\NNS|NONE (l_compound) B_19\NNP|chronic|untreated|in
D019259_D019694 NONE lamivudine_14\NN|NONE (r_pobj) with_13\IN|who|had|not|been (r_prep) treated_12\VBN|chronic||B (r_relcl) patients_7\NNS|NONE (l_compound) B_6\NNP|chronic|treated|
D019259_D019694 NONE lamivudine_9\NN| (r_npadvmod) untreated_11\VBN|with (r_amod) patients_12\NNS|NONE (l_prep) with_13\IN|untreated (l_pobj) B_16\NNP|NONE
D019259_D019694 NONE lamivudine_9\NN| (r_npadvmod) untreated_11\VBN|with (r_amod) patients_12\NNS|NONE (r_pobj) in_8\IN|YMDD|motif (r_prep) mutants_7\NNS|NONE (r_pobj) of_4\IN|natural|the (r_prep) occurrence_3\NN|been|Although|has (r_nsubjpass) reported_19\VBN|not|were|mutants|in|,|. (r_advcl) detected_25\VBN|NONE (l_prep) in_26\IN|not|reported|were|mutants|,|. (l_pobj) patients_34\NNS|NONE (l_compound) B_33\NNP|Iranian|untreated|chronic
D019259_D019694 NONE lamivudine_28\NN| (r_npadvmod) untreated_30\VBN|B|Iranian|chronic (r_amod) patients_34\NNS|NONE (r_pobj) in_26\IN|not|reported|were|mutants|,|. (r_prep) detected_25\VBN|NONE (l_advcl) reported_19\VBN|not|were|mutants|in|,|. (l_nsubjpass) occurrence_3\NN|been|Although|has (l_prep) of_4\IN|natural|the (l_pobj) mutants_7\NNS|NONE (l_prep) in_8\IN|YMDD|motif (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|untreated (l_pobj) B_16\NNP|NONE
D019259_D019694 NONE lamivudine_28\NN| (r_npadvmod) untreated_30\VBN|B|Iranian|chronic (r_amod) patients_34\NNS|NONE (l_compound) B_33\NNP|Iranian|untreated|chronic
2484903
D008713_D047508 CID methimazole_13\NN| (r_npadvmod) associated_15\VBN|hepatocellular|fatal (r_amod) necrosis_17\NN|NONE
D008713_D056486 NONE methimazole_13\NN| (r_npadvmod) associated_15\VBN|hepatocellular|fatal (r_amod) necrosis_17\NN|NONE (r_pobj) of_11\IN|one|case|and (r_prep) case_10\NN|of|,|Two (r_appos) cases_1\NNS|.|are (l_prep) of_2\IN|case|,|Two (l_pobj) hepatitis_7\NN|NONE
D011441_D047508 NONE propylthiouracil_3\NN| (r_npadvmod) associated_5\VBN|acute (r_amod) hepatitis_7\NN|NONE (r_pobj) of_2\IN|case|,|Two (r_prep) cases_1\NNS|.|are (l_appos) case_10\NN|of|,|Two (l_prep) of_11\IN|one|case|and (l_pobj) necrosis_17\NN|NONE
D011441_D047508 NONE propylthiouracil_22\NN| (r_npadvmod) associated_24\VBN|like (r_amod) syndrome_28\NN|NONE (r_pobj) of_21\IN|one (r_prep) case_20\NN|one|of|and (r_conj) case_10\NN|of|,|Two (l_prep) of_11\IN|one|case|and (l_pobj) necrosis_17\NN|NONE
D011441_D056486 CID propylthiouracil_3\NN| (r_npadvmod) associated_5\VBN|acute (r_amod) hepatitis_7\NN|NONE
D011441_D056486 CID propylthiouracil_22\NN| (r_npadvmod) associated_24\VBN|like (r_amod) syndrome_28\NN|NONE (r_pobj) of_21\IN|one (r_prep) case_20\NN|one|of|and (r_conj) case_10\NN|of|,|Two (r_appos) cases_1\NNS|.|are (l_prep) of_2\IN|case|,|Two (l_pobj) hepatitis_7\NN|NONE
D011441_D008180 CID propylthiouracil_3\NN| (r_npadvmod) associated_5\VBN|acute (r_amod) hepatitis_7\NN|NONE (r_pobj) of_2\IN|case|,|Two (r_prep) cases_1\NNS|.|are (l_appos) case_10\NN|of|,|Two (l_conj) case_20\NN|one|of|and (l_prep) of_21\IN|one (l_pobj) syndrome_28\NN|NONE
D011441_D008180 CID propylthiouracil_22\NN| (r_npadvmod) associated_24\VBN|like (r_amod) syndrome_28\NN|NONE
D008713_D008180 NONE methimazole_13\NN| (r_npadvmod) associated_15\VBN|hepatocellular|fatal (r_amod) necrosis_17\NN|NONE (r_pobj) of_11\IN|one|case|and (r_prep) case_10\NN|of|,|Two (l_conj) case_20\NN|one|of|and (l_prep) of_21\IN|one (l_pobj) syndrome_28\NN|NONE
17484470
D011433_D008944 NONE propranolol_6\NN|NONE (r_pobj) by_5\IN|failure|was (r_agent) induced_4\VBN|;|absence|was|by|. (r_ccomp) confirmed_21\VBN|NONE (l_nsubjpass) absence_17\NN|;|induced|was|by|. (l_prep) of_18\IN|an (l_pobj) MR_19\NNP|NONE
D011433_D006333 CID propranolol_6\NN|NONE (r_pobj) by_5\IN|failure|was (r_agent) induced_4\VBN|;|absence|was|by|. (l_nsubjpass) failure_2\NN|by|was
23535177
D007980_D004409 CID levodopa_19\RB| (r_npadvmod) induced_21\VBN|)|LIDs|( (r_amod) dyskinesias_22\NNS|Parkinson|and|)|(|PD
D007980_D004409 CID levodopa_19\RB| (r_npadvmod) induced_21\VBN|)|LIDs|( (r_amod) dyskinesias_22\NNS|Parkinson|and|)|(|PD (l_appos) LIDs_24\NNPS|)|induced|(
D007980_D010300 NONE levodopa_19\RB| (r_npadvmod) induced_21\VBN|)|LIDs|( (r_amod) dyskinesias_22\NNS|Parkinson|and|)|(|PD (r_conj) disease_14\NN|NONE
D007980_D010300 NONE levodopa_19\RB| (r_npadvmod) induced_21\VBN|)|LIDs|( (r_amod) dyskinesias_22\NNS|Parkinson|and|)|(|PD (r_conj) disease_14\NN|NONE (l_appos) PD_16\NNP|Parkinson|and|)|(|dyskinesias
6585590
D004317_D066126 NONE doxorubicin_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) nephrotoxicity_6\NN|in|,|and (r_conj) cardiotoxicity_3\NN|,|Antitumor|.
D004317_D066126 NONE doxorubicin_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|NONE (r_acl) nephrotoxicity_6\NN|and|, (r_conj) cardiotoxicity_3\NN|Antitumor|,
D004317_D066126 NONE doxorubicin_17\NN|mg|/ (r_nmod) kg_19\NNS|NONE (r_pobj) of_14\IN|a (r_prep) dose_13\NN|NONE (r_pobj) at_11\IN|scored|.|was|only (r_prep) observed_10\VBN|NONE (l_ccomp) scored_4\VBD|at|.|was|only (l_nsubj) evidence_1\NN|as (l_prep) of_2\IN|Histologic (l_pobj) cardiotoxicity_3\NN|NONE
D004317_D000419 CID doxorubicin_14\NN|mg|/ (r_nmod) kg_16\NNS|NONE (r_pobj) of_11\IN|resulted|a|, (r_prep) dose_10\NN|NONE (l_relcl) resulted_19\VBD|of|a|, (l_prep) in_20\IN|which (l_pobj) albuminuria_21\NN|NONE
D004317_D009369 NONE doxorubicin_18\NN|NONE (r_pobj) of_17\IN|iv (r_prep) injections_16\NNS|NONE (r_pobj) with_14\IN|on|Animals|followed|)|,|.|were|body (r_prep) treated_13\VBN|NONE (l_nsubjpass) Animals_0\NNS|with|on|followed|)|,|.|were|body (l_prep) with_1\IN|+/|,|) (l_pobj) tumor_3\NN|NONE
D004317_D009369 NONE doxorubicin_7\NN|mg|/ (r_nmod) kg_9\NNS|NONE (r_pobj) with_4\IN|was|regression|. (r_prep) observed_3\VBN|NONE (l_nsubjpass) regression_1\NN|was|.|with (l_compound) Tumor_0\NN|NONE
D004317_D009369 NONE doxorubicin_10\NN|/|mg (r_nmod) kg_12\NNS|NONE (r_pobj) with_7\IN|was|disappearance|. (r_prep) induced_6\VBN|NONE (l_nsubjpass) disappearance_1\NN|was|with|. (l_prep) of_2\IN|Complete (l_pobj) tumor_4\NN|NONE
D004317_D007674 NONE doxorubicin_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) nephrotoxicity_6\NN|in|,|and
D004317_D007674 NONE doxorubicin_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|NONE (r_acl) nephrotoxicity_6\NN|and|,
D004317_D007674 NONE doxorubicin_14\NN|mg|/ (r_nmod) kg_16\NNS|NONE (r_pobj) of_11\IN|resulted|a|, (r_prep) dose_10\NN|NONE (r_pobj) above_8\IN|evidence|was|. (r_prep) seen_7\VBN|NONE (l_nsubjpass) evidence_2\NN|above|was|. (l_prep) of_3\IN|microscopic|Light (l_pobj) damage_5\NN|NONE
D004317_-1 NONE doxorubicin_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) nephrotoxicity_6\NN|in|,|and (r_conj) cardiotoxicity_3\NN|,|Antitumor|. (l_prep) in_9\IN|nephrotoxicity|,|and (l_pobj) rat_21\NN|NONE (l_amod) bearing_15\VBG|the|WSL|solid|IgM (l_compound) immunocytoma_13\NN|
D004317_-1 NONE doxorubicin_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|NONE (r_acl) nephrotoxicity_6\NN|and|, (r_conj) cardiotoxicity_3\NN|Antitumor|, (r_conj) activity_1\NN|bearing|in|.|were (r_nsubjpass) studied_11\VBN|NONE (l_advcl) bearing_21\VBG|activity|in|.|were (l_dobj) immunocytoma_26\NN|each
2650911
D004958_D009369 NONE estradiol_10\NN|NONE (r_pobj) of_7\IN|in|the|vivo (r_prep) injection_6\NN|NONE (r_pobj) following_2\VBG|was|over|Radiolabelling|,|, (r_prep) increased_13\VBN|concentration|analysis|;|. (l_prep) over_15\IN|was|Radiolabelling|following|,|, (l_pobj) nuclei_17\NNS|only (l_prep) of_18\IN|the (l_pobj) cells_20\NNS|NONE (l_compound) tumor_19\NN|NONE
D004054_D002292 CID diethylstilbesterol_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) nuclei_7\NNS|NONE (r_pobj) in_6\IN|binding|estrogen (r_prep) sites_5\NNS|NONE (r_pobj) of_2\IN|Autoradiographic (r_prep) evidence_1\NN|.|carcinomas (r_nsubj) induced_10\VBN|NONE (l_dobj) carcinomas_13\NNS|.|evidence
D004054_D002292 CID diethylstilbesterol_13\NN|NONE (r_pobj) in_7\IN|NONE (r_prep) autoradiography_6\NN|NONE (r_pobj) by_5\IN|induced|.|were|sites (r_agent) demonstrated_4\VBN|NONE (l_conj) induced_14\VBD|.|were|sites|by (l_dobj) carcinomas_16\NNS|in
D004967_D002292 NONE estrogen_3\NN|binding|in (r_nmod) sites_5\NNS|NONE (r_pobj) of_2\IN|Autoradiographic (r_prep) evidence_1\NN|.|carcinomas (r_nsubj) induced_10\VBN|NONE (l_dobj) carcinomas_13\NNS|.|evidence
D004967_D002292 NONE Estrogen_0\NN|binding (r_nmod) sites_2\NNS|induced|.|were|by (r_nsubjpass) demonstrated_4\VBN|NONE (l_conj) induced_14\VBD|.|were|sites|by (l_dobj) carcinomas_16\NNS|in
D004967_D002292 NONE estrogen_13\NN|NONE (r_pobj) of_12\IN|vivo (r_prep) binding_11\NN|NONE (r_pobj) in_9\IN|the (r_prep) preferential_8\NN|to (r_dobj) documenting_6\VBG|the|first|induced|published (r_acl) report_5\NN|.|This (l_acl) induced_20\VBD|the|documenting|first|published (l_dobj) carcinomas_23\NNS|NONE
D004967_D002292 NONE estrogen_19\NN|NONE (r_pobj) in_18\IN|NONE (r_prep) cells_17\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) nuclei_15\NNS|NONE (r_pobj) to_14\IN|preferential (r_prep) documenting_6\VBG|the|first|induced|published (r_acl) report_5\NN|.|This (l_acl) induced_20\VBD|the|documenting|first|published (l_dobj) carcinomas_23\NNS|NONE
D012834_D009369 NONE silver_33\NN|reduced|over|than (r_compound) grains_34\NNS|NONE (r_pobj) of_31\IN|a|higher|.times (r_prep) concentration_30\NN|increased|analysis|;|. (r_dobj) revealed_24\VBD|NONE (l_ccomp) increased_13\VBN|concentration|analysis|;|. (l_prep) over_15\IN|was|Radiolabelling|following|,|, (l_pobj) nuclei_17\NNS|only (l_prep) of_18\IN|the (l_pobj) cells_20\NNS|NONE (l_compound) tumor_19\NN|NONE
17297207
D011803_D007565 NONE quinine_25\NN|NONE (r_compound) infusion_26\NN|was (r_nsubjpass) reported_28\VBN|while (r_ccomp) getting_24\VBG|there|that|case|) (r_advcl) was_5\VBD|was|It|. (l_attr) case_7\NN|there|that|getting|) (l_prep) of_8\IN|contraction|a (l_pobj) patient_11\NN|NONE (l_prep) with_12\IN|severe|malaria (l_pobj) jaundice_13\NN|NONE
D011803_D007565 NONE quinine_11\NN|in (r_compound) infusion_12\NN|% (r_dobj) got_10\VBD|.|as|was|and|Patient (r_conj) diagnosed_3\VBN|NONE (l_prep) as_4\IN|.|got|was|and|Patient (l_pobj) malaria_6\NN|NONE (l_prep) with_7\IN|severe (l_pobj) jaundice_8\NN|NONE
D011803_D016778 NONE Quinine_0\NN| (r_npadvmod) induced_2\VBN|in|. (r_amod) arrhythmia_3\NN|NONE (l_prep) in_4\IN|.|induced (l_pobj) patient_6\NN|NONE (l_prep) with_7\IN|a (l_pobj) malaria_9\NN|NONE
D011803_D016778 NONE quinine_25\NN|NONE (r_compound) infusion_26\NN|was (r_nsubjpass) reported_28\VBN|while (r_ccomp) getting_24\VBG|there|that|case|) (r_advcl) was_5\VBD|was|It|. (l_attr) case_7\NN|there|that|getting|) (l_prep) of_8\IN|contraction|a (l_pobj) patient_11\NN|NONE (l_compound) malaria_10\NN|severe|with
D011803_D016778 NONE quinine_11\NN|in (r_compound) infusion_12\NN|% (r_dobj) got_10\VBD|.|as|was|and|Patient (r_conj) diagnosed_3\VBN|NONE (l_prep) as_4\IN|.|got|was|and|Patient (l_pobj) malaria_6\NN|NONE
D011803_D001145 NONE Quinine_0\NN| (r_npadvmod) induced_2\VBN|in|. (r_amod) arrhythmia_3\NN|NONE
D011803_D001145 NONE quinine_25\NN|NONE (r_compound) infusion_26\NN|was (r_nsubjpass) reported_28\VBN|while (r_ccomp) getting_24\VBG|there|that|case|) (r_advcl) was_5\VBD|was|It|. (l_attr) case_7\NN|there|that|getting|) (l_prep) of_8\IN|contraction|a (l_pobj) patient_11\NN|NONE (l_prep) with_12\IN|severe|malaria (l_pobj) jaundice_13\NN|NONE (l_relcl) presented_15\VBD|NONE (l_prep) with_16\IN|who (l_pobj) arrhythmia_17\NN|NONE
D011803_D001145 NONE Quinine_0\NN|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ|NONE (l_attr) alkaloid_8\NN|arrhythmic|.|,|,|Quinine|,|like (l_relcl) has_10\VBZ|a|chincona (l_dobj) property_14\NN|that (l_amod) arrhythmic_13\JJ|NONE
D011803_D001145 NONE Quinine_0\NN|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ|NONE (l_advcl) arrhythmic_21\JJ|alkaloid|.|,|,|Quinine|,|like
D011803_D001145 NONE Quinine_0\NN|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ|NONE (l_advcl) arrhythmic_21\JJ|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB|although|also||it (l_dobj) arrhythmias_26\NNS|can|that
D011803_D001145 NONE Quinine_0\NN|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ|NONE (l_advcl) arrhythmic_21\JJ|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB|although|also||it (l_dobj) arrhythmias_26\NNS|can|that (l_prep) including_28\VBG|,|various (l_pobj) arrhythmia_30\NN|NONE
D011803_D001145 NONE quinine_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN|NONE (l_prep) because_12\IN|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN|of (l_amod) arrhythmic_17\JJ|its|in|,
D011803_-1 NONE quinine_4\NN|NONE (r_compound) infusion_5\NN|NONE (r_pobj) of_3\IN| (r_prep) hours_2\NNS|NONE (r_pobj) After_0\IN|patient|showed|palpitation (r_prep) felt_8\VBD|NONE (l_dobj) palpitation_9\NN|After|patient|showed
D011803_D014839 NONE quinine_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN|NONE (l_prep) because_12\IN|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN|of (l_prep) in_21\IN|its|arrhythmic|, (l_pobj) patients_23\NNS|especially (l_relcl) have_25\VBP|older (l_dobj) diseases_27\NNS|who (l_conj) patients_29\NNS|or|heart (l_prep) with_30\IN|NONE (l_pobj) disorder_32\NN|NONE (l_relcl) occurs_38\VBZ|)|electrolyte|(|hypokalemia (l_advcl) vomiting_41\NN|which|frequently|due
D011803_D008288 NONE quinine_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN|NONE (l_prep) because_12\IN|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN|of (l_prep) in_21\IN|its|arrhythmic|, (l_pobj) patients_23\NNS|especially (l_relcl) have_25\VBP|older (l_dobj) diseases_27\NNS|who (l_conj) patients_29\NNS|or|heart (l_prep) with_30\IN|NONE (l_pobj) disorder_32\NN|NONE (l_relcl) occurs_38\VBZ|)|electrolyte|(|hypokalemia (l_advcl) vomiting_41\NN|which|frequently|due (l_conj) diarrhea_44\NN|or|and (l_prep) in_45\IN|NONE (l_pobj) cases_47\NNS|NONE (l_compound) malaria_46\NN|NONE
D005947_D007565 NONE dextrose_14\NN|NONE (r_pobj) in_13\IN|quinine (r_prep) infusion_12\NN|% (r_dobj) got_10\VBD|.|as|was|and|Patient (r_conj) diagnosed_3\VBN|NONE (l_prep) as_4\IN|.|got|was|and|Patient (l_pobj) malaria_6\NN|NONE (l_prep) with_7\IN|severe (l_pobj) jaundice_8\NN|NONE
D011802_D018879 NONE quinidine_3\NN|NONE (r_pobj) like_2\IN|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ|NONE (l_advcl) arrhythmic_21\JJ|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB|although|also||it (l_dobj) arrhythmias_26\NNS|can|that (l_prep) including_28\VBG|,|various (l_pobj) arrhythmia_30\NN|NONE (l_prep) as_32\IN|severe (l_pobj) PVC_34\NN|such
D011803_D018879 CID quinine_25\NN|NONE (r_compound) infusion_26\NN|was (r_nsubjpass) reported_28\VBN|while (r_ccomp) getting_24\VBG|there|that|case|) (r_advcl) was_5\VBD|was|It|. (l_attr) case_7\NN|there|that|getting|) (l_appos) contraction_21\NN|a|of
D011803_D018879 CID quinine_4\NN|NONE (r_compound) infusion_5\NN|NONE (r_pobj) of_3\IN| (r_prep) hours_2\NNS|NONE (r_pobj) After_0\IN|patient|showed|palpitation (r_prep) felt_8\VBD|NONE (l_parataxis) showed_16\VBD|After|patient|palpitation (l_dobj) contraction_19\NN|(|.|wave|recording
D011803_D018879 CID quinine_4\NN|NONE (r_compound) infusion_5\NN|NONE (r_pobj) of_3\IN| (r_prep) hours_2\NNS|NONE (r_pobj) After_0\IN|patient|showed|palpitation (r_prep) felt_8\VBD|NONE (l_parataxis) showed_16\VBD|After|patient|palpitation (l_dobj) contraction_19\NN|(|.|wave|recording (l_appos) PVC_21\NN|>|ventricular|premature
D011803_D018879 CID Quinine_0\NN|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ|NONE (l_advcl) arrhythmic_21\JJ|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB|although|also||it (l_dobj) arrhythmias_26\NNS|can|that (l_prep) including_28\VBG|,|various (l_pobj) arrhythmia_30\NN|NONE (l_prep) as_32\IN|severe (l_pobj) PVC_34\NN|such
D005947_D016778 NONE dextrose_14\NN|NONE (r_pobj) in_13\IN|quinine (r_prep) infusion_12\NN|% (r_dobj) got_10\VBD|.|as|was|and|Patient (r_conj) diagnosed_3\VBN|NONE (l_prep) as_4\IN|.|got|was|and|Patient (l_pobj) malaria_6\NN|NONE
D011803_D006331 NONE quinine_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN|NONE (l_prep) because_12\IN|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN|of (l_prep) in_21\IN|its|arrhythmic|, (l_pobj) patients_23\NNS|especially (l_relcl) have_25\VBP|older (l_dobj) diseases_27\NNS|who
D011803_D007008 NONE quinine_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN|NONE (l_prep) because_12\IN|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN|of (l_prep) in_21\IN|its|arrhythmic|, (l_pobj) patients_23\NNS|especially (l_relcl) have_25\VBP|older (l_dobj) diseases_27\NNS|who (l_conj) patients_29\NNS|or|heart (l_prep) with_30\IN|NONE (l_pobj) disorder_32\NN|NONE (l_appos) hypokalemia_34\NN|)|electrolyte|occurs|(
D011803_D003967 NONE quinine_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN|NONE (l_prep) because_12\IN|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN|of (l_prep) in_21\IN|its|arrhythmic|, (l_pobj) patients_23\NNS|especially (l_relcl) have_25\VBP|older (l_dobj) diseases_27\NNS|who (l_conj) patients_29\NNS|or|heart (l_prep) with_30\IN|NONE (l_pobj) disorder_32\NN|NONE (l_relcl) occurs_38\VBZ|)|electrolyte|(|hypokalemia (l_advcl) vomiting_41\NN|which|frequently|due (l_conj) diarrhea_44\NN|or|and
D011803_D014883 NONE quinine_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN|NONE (l_prep) because_12\IN|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN|of (l_prep) in_21\IN|its|arrhythmic|, (l_pobj) patients_23\NNS|especially (l_relcl) have_25\VBP|older (l_dobj) diseases_27\NNS|who (l_conj) patients_29\NNS|or|heart (l_prep) with_30\IN|NONE (l_pobj) disorder_32\NN|NONE
D011803_D012848 NONE quinine_4\NN|NONE (r_compound) infusion_5\NN|NONE (r_pobj) of_3\IN| (r_prep) hours_2\NNS|NONE (r_pobj) After_0\IN|patient|showed|palpitation (r_prep) felt_8\VBD|NONE (l_parataxis) showed_16\VBD|After|patient|palpitation (l_ccomp) wave_39\VBP|(|contraction|.|recording (l_nmod) block_35\NN|U|positive|,
D011188_D018879 NONE potassium_29\NN|NONE (r_compound) level_30\NN|meq/|,|reduced (r_nsubj) was_31\VBD|NONE (l_ccomp) reduced_12\VBN|meq/|,|level (l_nsubj) frequency_9\NN|,|was|felt|to (l_prep) of_10\IN|the (l_pobj) PVC_11\NNP|NONE
D011802_D001145 NONE quinidine_3\NN|NONE (r_pobj) like_2\IN|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ|NONE (l_attr) alkaloid_8\NN|arrhythmic|.|,|,|Quinine|,|like (l_relcl) has_10\VBZ|a|chincona (l_dobj) property_14\NN|that (l_amod) arrhythmic_13\JJ|NONE
D011802_D001145 NONE quinidine_3\NN|NONE (r_pobj) like_2\IN|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ|NONE (l_advcl) arrhythmic_21\JJ|alkaloid|.|,|,|Quinine|,|like
D011802_D001145 NONE quinidine_3\NN|NONE (r_pobj) like_2\IN|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ|NONE (l_advcl) arrhythmic_21\JJ|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB|although|also||it (l_dobj) arrhythmias_26\NNS|can|that
D011802_D001145 NONE quinidine_3\NN|NONE (r_pobj) like_2\IN|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ|NONE (l_advcl) arrhythmic_21\JJ|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB|although|also||it (l_dobj) arrhythmias_26\NNS|can|that (l_prep) including_28\VBG|,|various (l_pobj) arrhythmia_30\NN|NONE
3084231
D014635_D022124 CID acid_25\NN|NONE (r_pobj) of_23\IN|toxic (r_prep) effect_22\NN|central|CNS|nervous|;|(|effect|a|direct|) (r_appos) system_17\NN|.|mechanisms|: (l_appos) effect_30\NN|central|CNS|nervous|;|(|effect|a|direct|) (l_conj) effect_41\NN|;|and|secondary|epileptogenic|paradoxical|a (l_acl) mediated_42\VBN|indirect|toxic|CNS|an (l_prep) through_43\IN|NONE (l_pobj) hyperammonemia_48\NN|NONE
D014635_D022124 CID acid_45\NN| (r_npadvmod) induced_47\VBN|valproic (r_amod) hyperammonemia_48\NN|NONE
D014635_D003704 CID acid_2\NN| (r_npadvmod) induced_4\VBN|Reversible|:|valproic|.|report (r_amod) dementia_5\NN|NONE
D014635_D003704 CID acid_2\NN| (r_npadvmod) induced_4\VBN|valproic|Reversible (r_amod) dementia_5\NN|.|in|was
D014635_D004827 NONE acid_2\NN| (r_npadvmod) induced_4\VBN|valproic|Reversible (r_amod) dementia_5\NN|.|in|was (r_nsubjpass) documented_7\VBN|NONE (l_prep) in_8\IN|.|dementia|was (l_pobj) man_13\NN|NONE (l_prep) with_14\IN|a|had|old (l_pobj) epilepsy_15\NN|NONE
2083961
D012293_D014839 NONE Rifampicin_0\NNP|thrice|was|as|and|developed (r_nsubjpass) administered_2\VBN|NONE (l_conj) developed_17\VBD|thrice|was|as|Rifampicin|and (l_dobj) effects_20\NNS|time|.|he (l_prep) like_21\IN|untoward|side (l_pobj) nausea_22\NN|NONE (l_conj) vomiting_24\NN|,
D012293_D005334 NONE Rifampicin_0\NNP|thrice|was|as|and|developed (r_nsubjpass) administered_2\VBN|NONE (l_conj) developed_17\VBD|thrice|was|as|Rifampicin|and (l_dobj) effects_20\NNS|time|.|he (l_prep) like_21\IN|untoward|side (l_pobj) nausea_22\NN|NONE (l_conj) vomiting_24\NN|, (l_conj) fever_26\NN|and
D012293_D058186 CID rifampicin_5\NNS|to (r_pobj) due_3\IN|Acute|renal|. (r_prep) failure_2\NN|NONE
D012293_D009325 NONE Rifampicin_0\NNP|thrice|was|as|and|developed (r_nsubjpass) administered_2\VBN|NONE (l_conj) developed_17\VBD|thrice|was|as|Rifampicin|and (l_dobj) effects_20\NNS|time|.|he (l_prep) like_21\IN|untoward|side (l_pobj) nausea_22\NN|NONE
23949582
D007069_D030342 NONE IFO_3\NNP|NONE (r_poss) genotoxicity_5\NN|.|,|Mesna|acts|significantly
D015080_D030342 NONE Mesna_0\NNP|.|,|genotoxicity|acts|significantly (r_nsubj) reduces_2\VBZ|NONE (l_dobj) genotoxicity_5\NN|.|,|Mesna|acts|significantly
19154241
D008094_D006934 CID lithium_6\NN| (r_npadvmod) treated_8\VBN|had|a (r_amod) patient_9\NN|NONE (l_relcl) had_11\VBD|treated|a (l_dobj) hypercalcemia_13\NN|who|understand
D008094_D006934 CID lithium_6\NN| (r_npadvmod) treated_8\VBN|NONE (r_amod) patients_9\NNS|NONE (r_pobj) of_5\IN| (r_prep) %_4\NN|hypercalcemic|. (r_nsubj) become_10\VBP|NONE (l_acomp) hypercalcemic_11\JJ|%|.
D008094_D049950 NONE lithium_16\NN|term (r_compound) therapy_17\NN|NONE (r_pobj) of_12\IN|side|rare|a (r_prep) effect_11\NN|hyperparathyroidism|. (r_attr) is_2\VBZ|NONE (l_nsubj) hyperparathyroidism_1\NN|effect|.
D008094_D006961 CID lithium_3\NN|leading (r_compound) therapy_4\NN|case|:|a|. (l_acl) leading_5\VBG|lithium (l_prep) to_6\IN|NONE (l_pobj) hyperparathyroidism_7\NN|NONE
8318674
D003561_D011654 CID C_10\NN|NONE (r_pobj) after_4\IN|.|shock|;|and|role|Pulmonary (r_prep) edema_1\NN|NONE
D003561_D012128 NONE C_29\NNP|that|with|be|may (r_nsubjpass) associated_32\VBN|we|.|,|thought (r_ccomp) hypothesize_22\VBP|NONE (l_advcl) thought_5\VBN|we|associated|.|, (l_xcomp) involved_8\VBN|As|are|TNF (l_prep) in_9\IN|be|to (l_pobj) development_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) shock_14\NN|NONE (l_conj) syndrome_19\NN|septic|and
D003561_D012769 CID C_10\NN|NONE (r_pobj) after_4\IN|.|shock|;|and|role|Pulmonary (r_prep) edema_1\NN|NONE (l_conj) shock_3\NN|after|.|;|and|role|Pulmonary
D003561_D012769 CID C_29\NNP|that|with|be|may (r_nsubjpass) associated_32\VBN|we|.|,|thought (r_ccomp) hypothesize_22\VBP|NONE (l_advcl) thought_5\VBN|we|associated|.|, (l_xcomp) involved_8\VBN|As|are|TNF (l_prep) in_9\IN|be|to (l_pobj) development_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) shock_14\NN|NONE
D003561_D008223 NONE C_10\NN|NONE (l_prep) for_11\IN||aracytine|dose (l_pobj) lymphoma_12\NN|NONE
D003561_D008223 NONE C_13\NNP|NONE (r_pobj) with_7\IN|in|for (r_prep) treated_6\VBN|consecutive| (l_prep) for_14\IN|in|with (l_pobj) lymphomas_15\NNS|NONE
19338378
C031942_D013921 NONE argatroban_9\JJ|in (r_amod) therapy_10\NN|NONE (l_prep) in_11\IN|argatroban (l_pobj) thrombocytopenia_15\NN|NONE
C031942_D013921 NONE Argatroban_0\NNP|for|and|.|inhibitor (r_nsubj) is_1\VBZ|NONE (l_attr) inhibitor_8\NN|for|and|.|Argatroban (l_acl) used_9\VBN|a|direct|,|metabolized|thrombin (l_prep) in_16\IN|for (l_pobj) thrombocytopenia_20\NN|NONE
C031942_D013921 NONE Argatroban_0\NNP|for|and|.|inhibitor (r_nsubj) is_1\VBZ|NONE (l_attr) inhibitor_8\NN|for|and|.|Argatroban (l_acl) used_9\VBN|a|direct|,|metabolized|thrombin (l_prep) in_16\IN|for (l_pobj) thrombocytopenia_20\NN|NONE (l_appos) HIT_22\NNP|induced|)|(
C031942_D013921 NONE Argatroban_0\NNP|for|and|.|inhibitor (r_nsubj) is_1\VBZ|NONE (l_conj) for_25\IN|and|.|Argatroban|inhibitor (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN|undergoing (l_conj) at_29\IN|or (l_pobj) risk_30\NN|NONE (l_prep) of_31\IN|NONE (l_pobj) HIT_32\NNP|NONE
C031942_D013921 NONE argatroban_11\JJ|in (r_amod) therapy_12\NN|NONE (l_prep) in_13\IN|argatroban (l_pobj) HIT_14\NNP|NONE
C031942_D013921 NONE argatroban_5\JJ|recommended|in (r_amod) dose_6\NN|(|min (l_prep) in_7\IN|recommended|argatroban (l_pobj) HIT_8\NNP|NONE
C031942_D013921 NONE argatroban_6\JJ|in|including|, (r_amod) therapy_7\NN|NONE (l_prep) in_8\IN|argatroban|including|, (l_pobj) HIT_9\NNP|NONE
C031942_D013921 NONE argatroban_6\JJ|in|including|, (r_amod) therapy_7\NN|NONE (r_pobj) with_5\IN|Improved|of (r_prep) familiarity_1\NN|.|may|reduction|, (r_nsubj) facilitate_20\VB|NONE (l_dobj) reduction_21\NN|familiarity|.|may|, (l_prep) of_22\IN|NONE (l_pobj) harm_23\NN|NONE (l_acl) associated_24\VBN|NONE (l_prep) with_25\IN|NONE (l_pobj) thromboses_30\NNS|NONE (l_nmod) HIT_26\NNP|(|treatment|or|)|fewer
C031942_D013921 NONE argatroban_38\JJ|fewer|medication (r_amod) errors_40\NNS|)|(|its (r_appos) treatment_34\NN|(|or|)|HIT|fewer (r_conj) thromboses_30\NNS|NONE (r_pobj) with_25\IN|NONE (r_prep) associated_24\VBN|NONE (r_acl) harm_23\NN|NONE (r_pobj) of_22\IN|NONE (r_prep) reduction_21\NN|familiarity|.|may|, (r_dobj) facilitate_20\VB|NONE (l_nsubj) familiarity_1\NN|.|may|reduction|, (l_prep) with_5\IN|Improved|of (l_pobj) therapy_7\NN|NONE (l_prep) in_8\IN|argatroban|including|, (l_pobj) HIT_9\NNP|NONE
C031942_D013921 NONE argatroban_38\JJ|fewer|medication (r_amod) errors_40\NNS|)|(|its (r_appos) treatment_34\NN|(|or|)|HIT|fewer (r_conj) thromboses_30\NNS|NONE (l_nmod) HIT_26\NNP|(|treatment|or|)|fewer
D006493_D013927 NONE heparin_17\NN| (r_npadvmod) induced_19\VBN|HIT|)|( (r_amod) thrombocytopenia_20\NN|NONE (r_pobj) in_16\IN|for (r_prep) used_9\VBN|a|direct|,|metabolized|thrombin (l_prep) for_10\IN|in (l_pobj) prophylaxis_11\NN|NONE (l_conj) treatment_13\NN|or (l_prep) of_14\IN|NONE (l_pobj) thrombosis_15\NN|NONE
C031942_D006470 CID argatroban_3\NN|NONE (r_amod) with_2\IN|NONE (r_prep) bleeding_1\VBG|NONE
C031942_D008107 NONE argatroban_5\JJ|recommended|in (r_amod) dose_6\NN|(|min (r_nsubj) is_9\VBZ|NONE (l_attr) min_15\NN|dose|( (l_acl) reduced_17\VBN|/|)|adjusted|(||microg|kg|, (l_prep) in_18\IN|NONE (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) impairment_22\NN|and|in
D006493_D013921 NONE heparin_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) thrombocytopenia_15\NN|NONE
D006493_D013921 NONE heparin_17\NN| (r_npadvmod) induced_19\VBN|HIT|)|( (r_amod) thrombocytopenia_20\NN|NONE
D006493_D013921 NONE heparin_17\NN| (r_npadvmod) induced_19\VBN|HIT|)|( (r_amod) thrombocytopenia_20\NN|NONE (l_appos) HIT_22\NNP|induced|)|(
D006493_D013921 NONE heparin_17\NN| (r_npadvmod) induced_19\VBN|HIT|)|( (r_amod) thrombocytopenia_20\NN|NONE (r_pobj) in_16\IN|for (r_prep) used_9\VBN|a|direct|,|metabolized|thrombin (r_acl) inhibitor_8\NN|for|and|.|Argatroban (r_attr) is_1\VBZ|NONE (l_conj) for_25\IN|and|.|Argatroban|inhibitor (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN|undergoing (l_conj) at_29\IN|or (l_pobj) risk_30\NN|NONE (l_prep) of_31\IN|NONE (l_pobj) HIT_32\NNP|NONE
C031942_D009765 NONE argatroban_3\NN|has|For|been|in|,|not (r_advmod) investigated_7\VBN|be|;|unnecessary|,|adjustment|and (r_ccomp) is_15\VBZ|NONE (l_acomp) unnecessary_16\JJ|be|;|,|adjustment|investigated|and (l_prep) for_17\IN|NONE (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|,|adult (l_conj) ethnicity_25\NN|, (l_conj) obesity_27\NN|/|race|or
C031942_D013927 NONE Argatroban_0\NNP|for|and|.|inhibitor (r_nsubj) is_1\VBZ|NONE (l_attr) inhibitor_8\NN|for|and|.|Argatroban (l_acl) used_9\VBN|a|direct|,|metabolized|thrombin (l_prep) for_10\IN|in (l_pobj) prophylaxis_11\NN|NONE (l_conj) treatment_13\NN|or (l_prep) of_14\IN|NONE (l_pobj) thrombosis_15\NN|NONE
12948256
D004977_D014388 NONE ethambutol_10\NN|NONE (l_prep) for_11\IN|NONE (l_pobj) tuberculosis_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) node_18\NN|NONE
D004977_D014397 NONE ethambutol_10\NN|NONE (l_prep) for_11\IN|NONE (l_pobj) tuberculosis_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) node_18\NN|NONE
D004977_D009901 CID Ethambutol_0\NNP|. (r_nmod) neuropathy_3\NN|NONE
D004977_D009901 CID ethambutol_5\NN|NONE (r_amod) neuropathy_8\NN|NONE
D004977_D009901 CID ethambutol_10\NN|NONE (r_pobj) with_9\IN|being (r_prep) treated_8\VBN|NONE (r_pcomp) after_6\IN|who|neuropathy (r_prep) developed_3\VBD|Thirteen (l_dobj) neuropathy_5\NN|who|after
D004977_D009901 CID ethambutol_19\NN|NONE (r_amod) therapy_20\NN|at (r_dobj) starting_18\VBG|NONE (r_pcomp) after_17\IN|patients|.|:|neuropathy|) (r_prep) had_3\VBD|NONE (l_dobj) neuropathy_5\NN|patients|.|:|after|)
D004977_D009901 CID ethambutol_11\NN|NONE (r_amod) therapy_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) patients_9\NNS|NONE (r_pobj) in_8\IN|.|recognition|be|should (r_prep) considered_7\VBN|NONE (l_nsubjpass) recognition_1\NN|.|in|be|should (l_prep) of_2\IN|Early (l_pobj) neuropathy_4\NN|NONE
8312343
D004317_D002311 NONE doxorubicin_49\NN|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (r_conj) disease_13\NN|for (r_appos) Indications_0\NNS|,|cardiomyopathy|. (r_nsubj) were_3\VBD|NONE (l_attr) cardiomyopathy_5\NN|,|Indications|.
D004317_D006349 NONE doxorubicin_49\NN|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (r_conj) disease_13\NN|for (l_appos) disease_42\NN|,|doxorubicin|with|)|and|)|%|(|,|heart|cardiomyopathy|(|%|congenital|,
D004317_D009202 CID doxorubicin_49\NN|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (l_appos) cardiomyopathy_50\NN|%
D004317_D006331 NONE doxorubicin_49\NN|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (r_conj) disease_13\NN|for
D004317_D002312 NONE doxorubicin_49\NN|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (r_conj) disease_13\NN|for (l_conj) cardiomyopathy_34\NN|,|doxorubicin|with|)|and|)|%|disease|(|,|heart|(|%|congenital|,
D015774_D003586 NONE ganciclovir_6\NN|NONE (r_pobj) with_5\IN|were|.|infections|successfully (r_prep) treated_3\VBN|NONE (l_nsubjpass) infections_1\NNS|were|with|.|successfully
11401944
C086123_D016171 NONE azimilide_34\NN|dl|and| (r_conj) sotalol_32\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|QT (r_acl) prolongation_27\NN|NONE (r_pobj) with_25\IN|to|pointes (r_prep) initiate_18\VB|a (l_dobj) pointes_21\FW|with|to
C086123_D016171 NONE azimilide_34\NN|dl|and| (r_conj) sotalol_32\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|QT (r_acl) prolongation_27\NN|NONE (r_pobj) with_25\IN|to|pointes (r_prep) initiate_18\VB|a (l_dobj) pointes_21\FW|with|to (l_appos) TdP_23\NN|de|torsade|)|(
D013015_D016171 CID sotalol_32\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|QT (r_acl) prolongation_27\NN|NONE (r_pobj) with_25\IN|to|pointes (r_prep) initiate_18\VB|a (l_dobj) pointes_21\FW|with|to
D013015_D016171 CID sotalol_32\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|QT (r_acl) prolongation_27\NN|NONE (r_pobj) with_25\IN|to|pointes (r_prep) initiate_18\VB|a (l_dobj) pointes_21\FW|with|to (l_appos) TdP_23\NN|de|torsade|)|(
D013015_D016171 CID sotalol_7\NN|NONE (r_pobj) by_4\IN|in|An (r_prep) increase_1\NN|.|propagation (r_nsubj) facilitated_8\VBN|NONE (l_dobj) propagation_10\NN|.|increase (l_relcl) initiated_14\VBD|transmural|of (l_dobj) episodes_16\NNS|in|that (l_prep) of_17\IN|multiple (l_pobj) TdP_19\NN|NONE
C086123_D008133 NONE azimilide_34\NN|dl|and| (r_conj) sotalol_32\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|QT (r_acl) prolongation_27\NN|NONE
C086123_D008133 NONE azimilide_6\NN|both|dl||and (r_conj) sotalol_4\NNS|Although|rarely|EADs (r_nsubj) induced_8\VBD|,|,|.|in|EADs|pronounced|they (r_advcl) produced_16\VBD|NONE (l_relcl) pronounced_25\VBN|,|,|.|in|EADs|induced|they (l_ccomp) seen_29\VBN|more|in (l_nsubjpass) prolongation_27\NN|was
D013015_D008133 CID sotalol_32\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|QT (r_acl) prolongation_27\NN|NONE
D013015_D008133 CID Sotalol_2\NNP|,|in|leading|.|preferentially|duration (r_nsubj) prolonged_4\VBD|NONE (l_advcl) leading_26\VBG|,|Sotalol|in|.|preferentially|duration (l_prep) to_27\IN|NONE (l_pobj) prolongation_29\NN|NONE
D013015_D008133 CID sotalol_4\NNS|Although|rarely|EADs (r_nsubj) induced_8\VBD|,|,|.|in|EADs|pronounced|they (r_advcl) produced_16\VBD|NONE (l_relcl) pronounced_25\VBN|,|,|.|in|EADs|induced|they (l_ccomp) seen_29\VBN|more|in (l_nsubjpass) prolongation_27\NN|was
6517710
D011796_D013927 NONE hydrochloride_8\NN|ppm (r_appos) quinacrine_7\NN|percent|in|simultaneously (r_dobj) given_4\VBN|have|.|,|thrombosis (r_csubj) had_18\VBD|NONE (l_dobj) thrombosis_19\NN|have|.|,|given
D012977_D003328 NONE nitrite_13\NN|and (r_conj) hydrochloride_8\NN|ppm (r_appos) quinacrine_7\NN|percent|in|simultaneously (r_dobj) given_4\VBN|have|.|,|thrombosis (r_csubj) had_18\VBD|NONE (l_advcl) have_36\VB|.|,|thrombosis|given (l_dobj) thrombosis_38\NN|did|while|not|rats
D011796_D003328 CID hydrochloride_10\NN|NONE (r_dobj) ingesting_8\VBG|F (r_acl) rats_7\NNS|NONE (r_pobj) of_5\IN|the (r_prep) heart_4\NN|NONE (r_dobj) involving_2\VBG|.|Atrial (r_acl) thrombosis_1\NN|NONE
D011796_D003328 CID hydrochloride_6\NN|ppm|in (r_appos) quinacrine_5\NN|NONE (r_pobj) with_2\IN|.|developed|Rats (r_prep) treated_1\VBD|NONE (l_conj) developed_11\VBD|with|.|Rats (l_dobj) incidence_14\NN|all (l_prep) of_15\IN|a|high (l_pobj) thrombosis_18\NN|NONE
D011796_D003328 CID hydrochloride_8\NN|ppm (r_appos) quinacrine_7\NN|percent|in|simultaneously (r_dobj) given_4\VBN|have|.|,|thrombosis (r_csubj) had_18\VBD|NONE (l_advcl) have_36\VB|.|,|thrombosis|given (l_dobj) thrombosis_38\NN|did|while|not|rats
D012977_D013927 NONE nitrite_13\NN|and (r_conj) hydrochloride_8\NN|ppm (r_appos) quinacrine_7\NN|percent|in|simultaneously (r_dobj) given_4\VBN|have|.|,|thrombosis (r_csubj) had_18\VBD|NONE (l_dobj) thrombosis_19\NN|have|.|,|given
7661171
D007213_D005355 NONE indomethacin_8\NN| (r_npadvmod) induced_10\VBN|in|renal (r_amod) dysfunction_12\NN|NONE (l_prep) in_13\IN|renal|induced (l_pobj) cirrhosis_16\NN|NONE
D007213_D005355 NONE indomethacin_12\NN| (r_npadvmod) induced_14\VBN|in|renal|the (r_amod) dysfunction_16\NN|to|acutely (l_prep) in_17\IN|induced|renal|the (l_pobj) patients_21\NNS|NONE (l_amod) cirrhotic_20\JJ|compensated
D007213_D005355 NONE indomethacin_31\NN|NONE (r_pobj) of_30\IN|doses|and| (r_prep) mg_29\NN|NONE (r_pobj) of_27\IN|oral|an (r_prep) combination_26\NN|NONE (r_pobj) after_23\IN|and (r_conj) before_21\RB|in|Parameters|were|by|. (r_prep) assessed_11\VBN|NONE (l_prep) in_15\IN|Parameters|were|by|before|. (l_pobj) patients_20\NNS|NONE (l_amod) cirrhotic_19\JJ|compensated|
D007213_D005355 NONE indomethacin_17\NN|NONE (r_pobj) of_16\IN|the|adverse (r_prep) effects_15\NNS|to (r_dobj) prevent_12\VB|of|this|apparent (r_acl) ability_5\NN|However|with|is|,|until (r_nsubjpass) confirmed_22\VBN|prudent|would|.|it|,|avoid (r_advcl) be_30\VB|NONE (l_xcomp) avoid_33\VB|prudent|confirmed|would|.|it|, (l_dobj) therapy_38\NN|to (l_prep) in_39\IN|inflammatory|nonsteroidal (l_pobj) patients_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cirrhosis_42\NN|NONE
D016595_D005355 NONE misoprostol_6\NN|NONE (r_pobj) of_5\IN|dependent|.|The|on (r_prep) effect_4\NN|NONE (l_prep) on_7\IN|dependent|of|.|The (l_pobj) dysfunction_12\NN|NONE (l_prep) in_13\IN|renal|induced (l_pobj) cirrhosis_16\NN|NONE
D016595_D005355 NONE Misoprostol_0\NNP|.|counteract|has|been (r_nsubjpass) shown_7\VBN|NONE (l_xcomp) counteract_10\VB|.|has|Misoprostol|been (l_dobj) dysfunction_16\NN|to|acutely (l_prep) in_17\IN|induced|renal|the (l_pobj) patients_21\NNS|NONE (l_amod) cirrhotic_20\JJ|compensated
D016595_D005355 NONE misoprostol_36\NN|NONE (r_pobj) of_35\IN|various (r_prep) doses_34\NNS|and||of (r_conj) mg_29\NN|NONE (r_pobj) of_27\IN|oral|an (r_prep) combination_26\NN|NONE (r_pobj) after_23\IN|and (r_conj) before_21\RB|in|Parameters|were|by|. (r_prep) assessed_11\VBN|NONE (l_prep) in_15\IN|Parameters|were|by|before|. (l_pobj) patients_20\NNS|NONE (l_amod) cirrhotic_19\JJ|compensated|
D016595_D005355 NONE misoprostol_10\NNP|NONE (r_pobj) of_9\IN| (r_prep) micrograms_8\NNS|NONE (r_pobj) of_6\IN|this|apparent|prevent (r_prep) ability_5\NN|However|with|is|,|until (r_nsubjpass) confirmed_22\VBN|prudent|would|.|it|,|avoid (r_advcl) be_30\VB|NONE (l_xcomp) avoid_33\VB|prudent|confirmed|would|.|it|, (l_dobj) therapy_38\NN|to (l_prep) in_39\IN|inflammatory|nonsteroidal (l_pobj) patients_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cirrhosis_42\NN|NONE
D016595_D007674 NONE misoprostol_6\NN|NONE (r_pobj) of_5\IN|dependent|.|The|on (r_prep) effect_4\NN|NONE (l_prep) on_7\IN|dependent|of|.|The (l_pobj) dysfunction_12\NN|NONE
D016595_D007674 NONE Misoprostol_0\NNP|.|counteract|has|been (r_nsubjpass) shown_7\VBN|NONE (l_xcomp) counteract_10\VB|.|has|Misoprostol|been (l_dobj) dysfunction_16\NN|to|acutely
D012964_D005355 NONE sodium_6\NN|and|renal (r_conj) hemodynamics_3\NNS|NONE (r_pobj) of_1\IN|handling (r_prep) Parameters_0\NNS|in|were|by|before|. (r_nsubjpass) assessed_11\VBN|NONE (l_prep) in_15\IN|Parameters|were|by|before|. (l_pobj) patients_20\NNS|NONE (l_amod) cirrhotic_19\JJ|compensated|
D007213_D007674 CID indomethacin_8\NN| (r_npadvmod) induced_10\VBN|in|renal (r_amod) dysfunction_12\NN|NONE
D007213_D007674 CID indomethacin_12\NN| (r_npadvmod) induced_14\VBN|in|renal|the (r_amod) dysfunction_16\NN|to|acutely
11385188
D003042_D009202 CID cocaine_18\NN|young|chronic|asymptomatic (r_compound) users_19\NNS|NONE (r_pobj) in_14\IN|% (r_prep) common_9\JJ|that|disease (r_acomp) is_8\VBZ|We|. (l_nsubj) disease_7\NN|that|common
D003042_D003324 CID cocaine_18\NN|young|chronic|asymptomatic (r_compound) users_19\NNS|NONE (r_pobj) in_14\IN|% (r_prep) common_9\JJ|that|disease (r_acomp) is_8\VBZ|We|. (l_nsubj) disease_7\NN|that|common
D003042_D006331 NONE cocaine_7\NN|chronic|asymptomatic (r_compound) users_8\NNS|NONE (r_pobj) in_4\IN|.|of (r_prep) Prevalence_0\NN|NONE (l_prep) of_1\IN|.|in (l_pobj) disease_3\NN|NONE
D003042_D006331 NONE cocaine_12\NN|asymptomatic|chronic|young (r_compound) users_13\NNS|NONE (r_pobj) in_7\IN|heart (r_prep) disease_6\NN|NONE
D003042_D006331 NONE cocaine_16\NN|controls||and (r_compound) users_17\NNS|the|of|, (r_conj) prevalence_3\NN|To (l_prep) of_4\IN|the|users|, (l_pobj) disease_6\NN|NONE
24091473
C476513_D066126 NONE levobupivacaine_9\NN| (r_npadvmod) induced_11\VBN|in|cardiac (r_amod) toxicity_13\NN|NONE
D004837_D066126 NONE epinephrine_4\NN|, (l_conj) both_7\DT|,|or (l_prep) in_8\IN|NONE (l_pobj) toxicity_13\NN|NONE
D004837_D064420 NONE epinephrine_8\NN|lipid|, (r_conj) emulsion_6\NN|NONE (r_pobj) of_4\IN|optimal|The|dosing (r_prep) regimens_3\NNS|are|not|in|yet|. (r_nsubjpass) determined_15\VBN|NONE (l_prep) in_16\IN|are|not|yet|regimens|. (l_pobj) neonates_17\NNS|NONE (l_prep) in_18\IN|NONE (l_pobj) cases_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) toxicity_24\NN|NONE
C476513_D002318 CID levobupivacaine_3\PRP|piglets|.|occurred (r_dobj) received_2\VBD|NONE (l_advcl) occurred_7\VBD|piglets|.|levobupivacaine (l_nsubj) collapse_6\NN|until
16911931
D019259_D006509 NONE lamivudine_7\NN|NONE (r_pobj) with_6\IN|after (r_prep) combined_5\VBN|B|Intramuscular|immune|. (r_acl) globulin_4\NN|NONE (l_compound) B_2\NNP|Intramuscular|combined|immune|.
D019259_D006509 NONE lamivudine_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) prevention_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) recurrence_13\NN|NONE (l_compound) B_12\NNP|NONE
D019259_D006509 NONE lamivudine_9\NN|)|and (r_conj) HBIg_6\NNP|Combined|after|immune|B|( (r_appos) globulin_4\NN|significantly|.|survival|has (l_compound) B_2\NNP|Combined|after|immune|(|HBIg
D019259_D006509 NONE lamivudine_9\NN|)|and (l_prep) in_10\IN|NONE (l_pobj) prophylaxis_11\NN|NONE (l_prep) of_12\IN|NONE (l_pobj) recurrence_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) B_17\NNP|NONE
D006514_D006509 NONE HBsAg_27\JJ|positive (r_nmod) patients_29\NNS|NONE (r_pobj) of_26\IN|the (r_prep) survival_25\NN|significantly|.|globulin|has (r_dobj) improved_23\VBN|NONE (l_nsubj) globulin_4\NN|significantly|.|survival|has (l_compound) B_2\NNP|Combined|after|immune|(|HBIg
D006514_D006509 NONE HBsAg_27\JJ|positive (r_nmod) patients_29\NNS|NONE (r_pobj) of_26\IN|the (r_prep) survival_25\NN|significantly|.|globulin|has (r_dobj) improved_23\VBN|NONE (l_nsubj) globulin_4\NN|significantly|.|survival|has (l_appos) HBIg_6\NNP|Combined|after|immune|B|( (l_conj) lamivudine_9\NN|)|and (l_prep) in_10\IN|NONE (l_pobj) prophylaxis_11\NN|NONE (l_prep) of_12\IN|NONE (l_pobj) recurrence_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) B_17\NNP|NONE
20034406
D010862_D013226 CID pilocarpine_12\NN| (r_npadvmod) induced_14\VBN|epilepticus (r_amod) status_15\NN|NONE (l_amod) epilepticus_16\NN|induced
D010862_D013226 CID pilocarpine_17\NN|NONE (r_amod) injection_18\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|status|(|epilepticus|) (r_acl) SE_13\NNP|NONE (l_nmod) epilepticus_11\NN|status|(|induced|)
D010862_D013226 CID pilocarpine_17\NN|NONE (r_amod) injection_18\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|status|(|epilepticus|) (r_acl) SE_13\NNP|NONE
D010862_D013226 CID pilocarpine_4\NN|NONE (r_amod) injection_5\NN|NONE (r_pobj) by_3\IN|SE|was|. (r_agent) induced_2\VBN|NONE (l_nsubjpass) SE_0\NNP|by|was|.
D010862_D013226 CID pilocarpine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) SE_18\NNP|NONE
6985297
D015764_D001919 CID bepridil_6\NN|NONE (r_pcomp) by_5\IN|Studies|. (r_prep) induced_4\VBN|NONE (l_nsubj) Studies_0\NNS|by|. (l_prep) on_1\IN|NONE (l_pobj) bradycardia_3\NN|NONE
D015764_D001919 CID Bepridil_0\NN|compound|bradycardia|,|, (r_advmod) induced_13\VBD|,|.|were|mechanisms|in (l_dobj) bradycardia_15\NNS|Bepridil|compound|,|,
D015764_D013610 NONE Bepridil_0\NN|compound|bradycardia|,|, (r_advmod) induced_13\VBD|,|.|were|mechanisms|in (l_dobj) bradycardia_15\NNS|Bepridil|compound|,|, (l_conj) effect_24\NN|and|persistent (l_amod) tachycardial_23\JJ|a
D015764_D000787 NONE Bepridil_0\NN|compound|bradycardia|,|, (r_advmod) induced_13\VBD|,|.|were|mechanisms|in (l_nsubj) compound_5\NN|Bepridil|bradycardia|,|, (l_prep) for_6\IN|active|a|novel (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|prophylactic (l_pobj) attacks_11\NNS|NONE
7949506
D013148_D006929 NONE spironolactone_16\CD|woman|and|.|was|d|with (r_conj) treated_8\VBN|NONE (l_nsubjpass) woman_4\NN|and|.|was|d|with|spironolactone (l_prep) with_5\IN|A|old (l_pobj) hyperaldosteronism_6\NN|NONE
D003000_D007022 CID clonidine_10\NN|NONE (r_pobj) between_9\IN|adverse|possible|resulting|a (r_prep) interaction_8\NN|NONE (l_acl) resulting_13\VBG|adverse|possible|between|a (l_prep) in_14\IN|NONE (l_pobj) block_19\NN|NONE (l_prep) in_20\IN|atrioventricular|)|AV|( (l_pobj) patients_22\NNS|NONE (l_conj) hypotension_25\NN|both|and
D003000_D007022 CID clonidine_8\NN|NONE (r_pobj) of_7\IN|a|bid|minimal (r_prep) dose_6\NN|NONE (r_pobj) of_3\IN|the (r_prep) addition_2\NN|NONE (r_pobj) After_0\IN|block|she|, (r_prep) developed_16\VBD|NONE (l_dobj) block_19\NN|she|After|, (l_conj) hypotension_22\NN|,|AV|and|resolved|complete
D003000_D054537 CID clonidine_10\NN|NONE (r_pobj) between_9\IN|adverse|possible|resulting|a (r_prep) interaction_8\NN|NONE (l_acl) resulting_13\VBG|adverse|possible|between|a (l_prep) in_14\IN|NONE (l_pobj) block_19\NN|NONE
D003000_D054537 CID clonidine_8\NN|NONE (r_pobj) of_7\IN|a|bid|minimal (r_prep) dose_6\NN|NONE (r_pobj) of_3\IN|the (r_prep) addition_2\NN|NONE (r_pobj) After_0\IN|block|she|, (r_prep) developed_16\VBD|NONE (l_dobj) block_19\NN|she|After|,
D003000_D054537 CID clonidine_4\JJ|NONE (r_pobj) of_3\IN|the (r_prep) addition_2\NN|bid (r_pobj) After_0\IN|.|she|block (r_prep) developed_9\VBD|NONE (l_dobj) block_12\NN|After|.|she
D014700_D054537 CID verapamil_12\NN|and (r_conj) clonidine_10\NN|NONE (r_pobj) between_9\IN|adverse|possible|resulting|a (r_prep) interaction_8\NN|NONE (l_acl) resulting_13\VBG|adverse|possible|between|a (l_prep) in_14\IN|NONE (l_pobj) block_19\NN|NONE
D014700_D007022 CID verapamil_12\NN|and (r_conj) clonidine_10\NN|NONE (r_pobj) between_9\IN|adverse|possible|resulting|a (r_prep) interaction_8\NN|NONE (l_acl) resulting_13\VBG|adverse|possible|between|a (l_prep) in_14\IN|NONE (l_pobj) block_19\NN|NONE (l_prep) in_20\IN|atrioventricular|)|AV|( (l_pobj) patients_22\NNS|NONE (l_conj) hypotension_25\NN|both|and
D014700_D006929 NONE verapamil_10\NN|NONE (r_pobj) with_9\IN|woman|and|.|was|d|spironolactone (r_prep) treated_8\VBN|NONE (l_nsubjpass) woman_4\NN|and|.|was|d|with|spironolactone (l_prep) with_5\IN|A|old (l_pobj) hyperaldosteronism_6\NN|NONE
11135381
D008729_D014550 NONE methoxamine_2\NN|NONE (l_prep) on_3\IN|NONE (l_pobj) pressure_6\NN|NONE (l_prep) with_9\IN|in|maximum|urethral (l_pobj) incontinence_12\NN|NONE
D008729_D014550 NONE methoxamine_6\NN|NONE (r_pobj) of_4\IN|incremental|(|saline|) (r_prep) doses_3\NNS|Half (r_dobj) log_1\NN|.|were|measuring|to (r_csubjpass) administered_13\VBN|NONE (l_prep) to_14\IN|log|.|were|measuring (l_pobj) group_16\NN|NONE (l_prep) with_19\IN|of|a (l_pobj) incontinence_22\NN|NONE
D008729_D006973 CID Methoxamine_0\NNP|but|increases|caused|. (r_nsubj) evoked_1\VBD|NONE (l_conj) caused_13\VBD|Methoxamine|but|increases|. (l_dobj) rise_16\NN|NONE (l_prep) in_17\IN|a|and|fall|significant (l_pobj) pressure_20\NN|NONE
3191389
D010862_D013226 CID pilocarpine_4\NN|.|followed|in (r_nsubj) induces_5\VBZ|NONE (l_prep) in_6\IN|.|pilocarpine|followed (l_pobj) seizures_8\NNS|NONE (l_conj) epilepticus_11\NN|and|rats
D007213_D012640 NONE indomethacin_24\NN|, (r_conj) phenylbutazone_22\NN|sodium|, (r_appos) salicylate_20\NN|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS|NONE (r_pobj) of_9\IN|on|the (r_prep) effect_8\NN|to (l_prep) on_31\IN|the|of (l_pobj) seizures_32\NNS|NONE
D007213_D012640 NONE Indomethacin_0\NNP|.|modulate (r_nsubj) failed_15\VBD|NONE (l_xcomp) modulate_17\VB|.|Indomethacin (l_dobj) seizures_18\NNS|to
D012980_D012640 CID salicylate_20\NN|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS|NONE (r_pobj) of_9\IN|on|the (r_prep) effect_8\NN|to (l_prep) on_31\IN|the|of (l_pobj) seizures_32\NNS|NONE
D010862_D001930 NONE pilocarpine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|brain|related (r_acl) damage_21\NN|NONE
D010862_D012640 CID pilocarpine_14\NN|NONE (r_pobj) by_13\IN|in (r_agent) produced_12\VBN|NONE (r_acl) seizures_11\NNS|NONE
D010862_D012640 CID pilocarpine_4\NN|.|followed|in (r_nsubj) induces_5\VBZ|NONE (l_prep) in_6\IN|.|pilocarpine|followed (l_pobj) seizures_8\NNS|NONE
D010862_D012640 CID pilocarpine_35\NN|NONE (r_pobj) by_34\IN|NONE (r_agent) produced_33\VBN|NONE (r_acl) seizures_32\NNS|NONE
D010862_D012640 CID pilocarpine_21\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) produced_19\VBN|NONE (r_acl) seizures_18\NNS|to
D010862_D012640 CID pilocarpine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|brain|related (r_acl) damage_21\NN|NONE (r_pobj) from_16\IN|rats|mg/kg|and|, (r_prep) seizures_12\NNS|acid|.
D010862_D012640 CID pilocarpine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|brain|related (r_acl) damage_21\NN|NONE (l_amod) related_19\VBN|induced|brain (l_npadvmod) seizure_17\NN|
D010862_D012640 CID pilocarpine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) seizures_19\NNS|NONE
D008528_D012640 NONE acid_29\NN|and (r_conj) ibuprofen_26\NNP|, (r_conj) indomethacin_24\NN|, (r_conj) phenylbutazone_22\NN|sodium|, (r_appos) salicylate_20\NN|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS|NONE (r_pobj) of_9\IN|on|the (r_prep) effect_8\NN|to (l_prep) on_31\IN|the|of (l_pobj) seizures_32\NNS|NONE
D008528_D012640 NONE acid_1\NN|.|seizures (r_nsubj) prevented_11\VBN|NONE (l_dobj) seizures_12\NNS|acid|.
D008528_D012640 NONE acid_1\NN|.|seizures (r_nsubj) prevented_11\VBN|NONE (l_dobj) seizures_12\NNS|acid|. (l_prep) from_16\IN|rats|mg/kg|and|, (l_pobj) damage_21\NN|NONE (l_amod) related_19\VBN|induced|brain (l_npadvmod) seizure_17\NN|
D007052_D012640 NONE ibuprofen_26\NNP|, (r_conj) indomethacin_24\NN|, (r_conj) phenylbutazone_22\NN|sodium|, (r_appos) salicylate_20\NN|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS|NONE (r_pobj) of_9\IN|on|the (r_prep) effect_8\NN|to (l_prep) on_31\IN|the|of (l_pobj) seizures_32\NNS|NONE
D007052_D012640 NONE ibuprofen_8\NNP|and|,| (r_conj) mg/kg_5\NN|,|,|mg/kg|, (r_conj) Indomethacin_0\NNP|.|modulate (r_nsubj) failed_15\VBD|NONE (l_xcomp) modulate_17\VB|.|Indomethacin (l_dobj) seizures_18\NNS|to
D008528_D001930 NONE acid_1\NN|.|seizures (r_nsubj) prevented_11\VBN|NONE (l_dobj) seizures_12\NNS|acid|. (l_prep) from_16\IN|rats|mg/kg|and|, (l_pobj) damage_21\NN|NONE
D010653_D012640 CID phenylbutazone_22\NN|sodium|, (r_appos) salicylate_20\NN|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS|NONE (r_pobj) of_9\IN|on|the (r_prep) effect_8\NN|to (l_prep) on_31\IN|the|of (l_pobj) seizures_32\NNS|NONE
7147232
D009599_D007022 CID nitroprusside_10\NN|NONE (l_nsubj) effects_1\NNS|.|on (l_prep) of_2\IN|induced|Cardiovascular (l_pobj) hypotension_3\NN|NONE
D009599_D007022 CID nitroprusside_7\NN|.|induce|are|to (r_nsubjpass) administered_12\VBN|NONE (l_advcl) induce_16\VB|nitroprusside|.|are|to (l_conj) control_18\VB|to|and (l_dobj) hypotension_19\NN|NONE
D009599_D007022 CID SNP_9\NNP|triphosphate (r_appos) nitroprusside_7\NN|.|induce|are|to (r_nsubjpass) administered_12\VBN|NONE (l_advcl) induce_16\VB|nitroprusside|.|are|to (l_conj) control_18\VB|to|and (l_dobj) hypotension_19\NN|NONE
D009599_D007022 CID SNP_4\NNP|similar (r_nmod) decreases_6\NNS|NONE (r_pobj) by_3\IN|NONE (r_agent) produced_2\VBN|NONE (r_acl) hypotension_1\NN|NONE
D010100_D007022 NONE oxygen_66\NN|.|and|)|,|body|rate|( (r_compound) consumption_67\NN|peripheral|product|,|total|)|,|.|( (r_conj) resistance_46\NN|accompanied|pressure|,|pressure|, (r_dobj) left_31\VBD|normal|variables|stopped|within|;|. (l_ccomp) accompanied_5\VBN|pressure|,|pressure|resistance|, (l_nsubjpass) Hypotension_0\NN|by|was
D010100_D007022 NONE oxygen_65\NN|content|)|.|between (r_compound) difference_67\NN|,|.|and|)|(|pressure (r_conj) product_56\NN|total|.|peripheral|increased|,|(|,|) (r_conj) resistance_46\NN|During|p|,|.|were|in (r_appos) observed_8\VBN|NONE (l_prep) During_0\IN|resistance|p|,|.|were|in (l_pobj) hypotension_1\NN|NONE
D000255_D007022 CID triphosphate_7\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) induced_4\VBN|of|Cardiovascular (r_acl) effects_1\NNS|.|on (l_prep) of_2\IN|induced|Cardiovascular (l_pobj) hypotension_3\NN|NONE
D000255_D007022 CID triphosphate_1\NN|SNP (r_nsubj) nitroprusside_7\NN|.|induce|are|to (r_nsubjpass) administered_12\VBN|NONE (l_advcl) induce_16\VB|nitroprusside|.|are|to (l_conj) control_18\VB|to|and (l_dobj) hypotension_19\NN|NONE
D000255_D007022 CID ATP_3\NNP|sodium|Adenosine|(|)|and (r_appos) triphosphate_1\NN|SNP (r_nsubj) nitroprusside_7\NN|.|induce|are|to (r_nsubjpass) administered_12\VBN|NONE (l_advcl) induce_16\VB|nitroprusside|.|are|to (l_conj) control_18\VB|to|and (l_dobj) hypotension_19\NN|NONE
D000255_D007022 CID ATP_3\NNP|NONE (r_pobj) by_2\IN|NONE (r_agent) induced_1\VBN|NONE (r_acl) Hypotension_0\NN|by|was
D000255_D007022 CID ATP_94\NNP|was|after (r_nsubjpass) stopped_96\VBN|normal|left|variables|within|;|. (r_advcl) returned_88\VBD|NONE (l_ccomp) left_31\VBD|normal|variables|stopped|within|;|. (l_ccomp) accompanied_5\VBN|pressure|,|pressure|resistance|, (l_nsubjpass) Hypotension_0\NN|by|was
24665854
D014635_D022124 CID Valproate_0\NNP|.||encephalopathy (r_npadvmod) induced_2\VBN|NONE (l_dobj) encephalopathy_4\NN|.||Valproate (l_det) hyperammonemic_3\JJ|in
D014635_D022124 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|hyperammonemic (r_amod) encephalopathy_4\NN|.|effect (l_det) hyperammonemic_3\JJ|induced
D014635_D022124 CID valproate_12\NN|NONE (r_amod) treatment_13\NN|NONE (r_pobj) of_11\IN|an|uncommon (r_prep) effect_10\NN|.|encephalopathy (r_attr) is_5\VBZ|NONE (l_nsubj) encephalopathy_4\NN|.|effect (l_det) hyperammonemic_3\JJ|induced
D014635_D022124 CID valproate_21\NN|of|the (l_conj) revealed_26\VBN|and|due (l_dobj) consciousness_28\NN|after (l_prep) with_29\IN|impaired (l_pobj) hyperammonemia_30\NN|NONE
D014635_D003244 CID valproate_21\NN|of|the (l_conj) revealed_26\VBN|and|due (l_dobj) consciousness_28\NN|after
D014635_D001927 NONE Valproate_0\NNP|.||encephalopathy (r_npadvmod) induced_2\VBN|NONE (l_dobj) encephalopathy_4\NN|.||Valproate
D014635_D001927 NONE Valproate_0\NNP| (r_npadvmod) induced_2\VBN|hyperammonemic (r_amod) encephalopathy_4\NN|.|effect
D014635_D001927 NONE valproate_12\NN|NONE (r_amod) treatment_13\NN|NONE (r_pobj) of_11\IN|an|uncommon (r_prep) effect_10\NN|.|encephalopathy (r_attr) is_5\VBZ|NONE (l_nsubj) encephalopathy_4\NN|.|effect
D014635_D004827 NONE valproate_21\NN|of|the (l_prep) due_22\JJ|and|revealed (l_prep) to_23\IN|NONE (l_pobj) epilepsy_24\NN|NONE
8603459
D004317_D066126 CID Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|.|monitored (r_amod) cardiotoxicity_3\NN|NONE
D004317_D066126 CID doxorubicin_11\RB| (r_npadvmod) induced_13\VBN|NONE (r_amod) cardiotoxicity_14\NN|to
D004317_D066126 CID doxorubicin_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) cardiotoxicity_16\NN|NONE
D064730_D064420 NONE ICRF-187_16\NNP|NONE (r_pobj) of_15\IN|the (r_prep) protection_14\NN|,|.|exerted|was|using|) (r_nsubjpass) determined_18\VBN|NONE (l_advcl) exerted_3\VBD|protection|,|.|was|using|) (l_dobj) toxicity_5\NN|As|schedule
D064730_D064420 NONE ICRF-187_16\NNP|NONE (r_pobj) of_15\IN|the (r_prep) protection_14\NN|,|.|exerted|was|using|) (r_nsubjpass) determined_18\VBN|NONE (l_xcomp) using_19\VBG|protection|,|.|exerted|was|) (l_dobj) schedule_22\NN|NONE (l_prep) with_23\IN|dose|a (l_pobj) toxicity_26\NN|NONE
D004317_D064420 NONE doxorubicin_34\NN|(|doses|lower|general (r_punct) toxicity_26\NN|NONE (r_pobj) with_23\IN|dose|a (r_prep) schedule_22\NN|NONE (r_dobj) using_19\VBG|protection|,|.|exerted|was|) (r_xcomp) determined_18\VBN|NONE (l_advcl) exerted_3\VBD|protection|,|.|was|using|) (l_dobj) toxicity_5\NN|As|schedule
D004317_D064420 NONE doxorubicin_34\NN|(|doses|lower|general (r_punct) toxicity_26\NN|NONE
D064730_D066126 NONE ICRF-187_24\NNP|NONE (r_pobj) by_23\IN|NONE (r_agent) provided_22\VBN|the (r_acl) protection_21\NN|NONE (r_pobj) by_19\IN|testing|as (r_agent) demonstrated_18\VBN|that (l_nsubj) testing_9\NN|as|by (l_prep) of_10\IN|the (l_pobj) protectors_11\NNS|NONE (l_prep) against_12\IN|NONE (l_pobj) cardiotoxicity_16\NN|NONE
D004317_D006984 NONE doxorubicin_5\RB| (r_npadvmod) treated_7\VBN|NONE (r_amod) animals_8\NNS|NONE (r_pobj) of_4\IN|the (r_prep) hearts_3\NNS|NONE (r_dobj) sacrifice_1\NN|NONE (r_pcomp) After_0\IN|and|were|were (r_prep) enlarged_10\VBN|NONE (l_conj) were_14\VBD|After|and|were (l_acomp) hypertrophic_15\JJ|.|atria
21195121
D005680_D012640 NONE GABA(A_8\NNP|) (r_nmod) receptors_10\NNS|NONE (r_pobj) of_7\IN|the (r_prep) blockage_6\NN|mainly|convulsions (r_dobj) trough_4\VB|It|. (l_nsubj) convulsions_2\NNS|mainly|blockage
D009569_D004827 NONE oxide_1\NN|observed|,|in|due|role|and (r_nsubj) has_9\VBZ|NONE (l_conj) observed_39\VBN|oxide|,|in|due|role|and (l_prep) in_40\IN|NAME|. (l_pobj) models_43\NNS|NONE (l_compound) epilepsy_42\NN|different
D009569_D004827 NONE NO_3\NNP|,|(|)|,|Nitric|neurotransmitter (r_intj) oxide_1\NN|observed|,|in|due|role|and (r_nsubj) has_9\VBZ|NONE (l_conj) observed_39\VBN|oxide|,|in|due|role|and (l_prep) in_40\IN|NAME|. (l_pobj) models_43\NNS|NONE (l_compound) epilepsy_42\NN|different
D009569_D004827 NONE NO_25\DT|NOS (r_det) syntheses_26\NNS|NONE (r_pobj) of_24\IN|arginine (r_prep) precursor_23\NN|NONE (r_pobj) of_18\IN|opposite (r_prep) effects_17\NNS|to (r_pobj) due_14\IN|oxide|observed|,|in|role|and (r_prep) has_9\VBZ|NONE (l_conj) observed_39\VBN|oxide|,|in|due|role|and (l_prep) in_40\IN|NAME|. (l_pobj) models_43\NNS|NONE (l_compound) epilepsy_42\NN|different
D009569_D004827 NONE NO_12\DT|NONE (r_pobj) of_11\IN|on|the (r_prep) effects_10\NNS|to (l_prep) on_13\IN|of|the (l_pobj) characteristics_18\NNS|NONE (l_prep) of_19\IN|in|the|behavioral (l_pobj) epilepsy_23\NN|NONE
D001556_D004827 NONE lindane_20\NN| (r_npadvmod) induced_22\VBN|NONE (r_amod) epilepsy_23\NN|NONE
D009569_D012640 NONE oxide_4\NN|NONE (r_pobj) of_2\IN|in|induced|.|The (r_prep) role_1\NN|NONE (l_prep) in_5\IN|induced|.|The|of (l_pobj) convulsions_6\NNS|NONE
D009569_D012640 NONE NO_6\DT|that|role (r_nsubj) plays_7\VBZ|the (l_dobj) role_9\NN|that|NO (l_prep) in_13\IN|of|a (l_pobj) model_15\NN|NONE (l_prep) of_16\IN|rat (l_pobj) seizures_18\NNS|NONE
D019331_D012640 NONE NAME_8\NNP|NONE (r_pobj) with_5\IN|mg/kg (r_prep) pretreatment_4\NN|following|On|incidence|,|. (r_nsubj) decreased_19\VBD|NONE (l_npadvmod) incidence_21\NN|following|On|,|.|pretreatment (l_compound) convulsion_20\NN|severity|time|and|and
D019331_D012640 NONE NAME_8\NNP|NONE (r_pobj) with_5\IN|mg/kg (r_prep) pretreatment_4\NN|following|On|incidence|,|. (r_nsubj) decreased_19\VBD|NONE (l_npadvmod) incidence_21\NN|following|On|,|.|pretreatment (l_conj) time_27\NN|severity|convulsion|and|and (l_prep) to_28\IN|prolonged|latency (l_pobj) convulsion_29\NN|NONE
D019331_D012640 NONE NAME_8\NNP|NONE (r_pobj) with_5\IN|mg/kg (r_prep) pretreatment_4\NN|following|On|incidence|,|. (r_nsubj) decreased_19\VBD|NONE (l_prep) following_30\VBG|On|incidence|,|.|pretreatment (l_pobj) injection_31\NN|NONE (l_prep) with_32\IN|NONE (l_pobj) dose_35\NN|NONE (l_amod) convulsive_34\JJ|a|(|)|of|mg/kg
D001120_D012640 NONE arginine_5\NN|NONE (r_pobj) of_2\IN|in|)|mg/kg|i.p.|The|, (r_prep) administration_1\NN|shortened|and|incidence|significantly|. (r_nsubj) increased_22\VBD|NONE (l_dobj) incidence_24\NN|shortened|and|administration|significantly|. (l_compound) convulsion_23\NN|and|severity
D001120_D012640 NONE arginine_5\NN|NONE (r_pobj) of_2\IN|in|)|mg/kg|i.p.|The|, (r_prep) administration_1\NN|shortened|and|incidence|significantly|. (r_nsubj) increased_22\VBD|NONE (l_conj) shortened_28\VBN|and|administration|incidence|significantly|. (l_prep) to_31\IN|time (l_pobj) convulsion_33\NN|NONE
D001556_D012640 CID lindane_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|in|.|The|of (r_acl) role_1\NN|NONE (l_prep) in_5\IN|induced|.|The|of (l_pobj) convulsions_6\NNS|NONE
D001556_D012640 CID lindane_37\NN|mg/kg|lower (r_compound) dose_38\NN|NONE (r_pobj) by_35\IN|NONE (r_agent) elicited_34\VBN|first (r_acl) convulsion_33\NN|NONE (r_pobj) to_31\IN|time (r_prep) shortened_28\VBN|and|administration|incidence|significantly|. (r_conj) increased_22\VBD|NONE (l_dobj) incidence_24\NN|shortened|and|administration|significantly|. (l_compound) convulsion_23\NN|and|severity
D001556_D012640 CID lindane_37\NN|mg/kg|lower (r_compound) dose_38\NN|NONE (r_pobj) by_35\IN|NONE (r_agent) elicited_34\VBN|first (r_acl) convulsion_33\NN|NONE
D001556_D012640 CID lindane_37\NN|NONE (r_pobj) of_36\IN|a|(|)|convulsive|mg/kg (r_prep) dose_35\NN|NONE (r_pobj) with_32\IN|NONE (r_prep) injection_31\NN|NONE (r_pobj) following_30\VBG|On|incidence|,|.|pretreatment (r_prep) decreased_19\VBD|NONE (l_npadvmod) incidence_21\NN|following|On|,|.|pretreatment (l_compound) convulsion_20\NN|severity|time|and|and
D001556_D012640 CID lindane_37\NN|NONE (r_pobj) of_36\IN|a|(|)|convulsive|mg/kg (r_prep) dose_35\NN|NONE (r_pobj) with_32\IN|NONE (r_prep) injection_31\NN|NONE (r_pobj) following_30\VBG|On|incidence|,|.|pretreatment (r_prep) decreased_19\VBD|NONE (l_npadvmod) incidence_21\NN|following|On|,|.|pretreatment (l_conj) time_27\NN|severity|convulsion|and|and (l_prep) to_28\IN|prolonged|latency (l_pobj) convulsion_29\NN|NONE
D001556_D012640 CID lindane_37\NN|NONE (r_pobj) of_36\IN|a|(|)|convulsive|mg/kg (r_prep) dose_35\NN|NONE (l_amod) convulsive_34\JJ|a|(|)|of|mg/kg
D001556_D012640 CID lindane_17\NN|NONE (r_compound) seizures_18\NNS|NONE
D019331_D004827 NONE NAME_34\NNP|.|in (r_nsubj) observed_39\VBN|oxide|,|in|due|role|and (l_prep) in_40\IN|NAME|. (l_pobj) models_43\NNS|NONE (l_compound) epilepsy_42\NN|different
D001120_D004827 NONE arginine_21\NN|of (r_nmod) precursor_23\NN|NONE (r_pobj) of_18\IN|opposite (r_prep) effects_17\NNS|to (r_pobj) due_14\IN|oxide|observed|,|in|role|and (r_prep) has_9\VBZ|NONE (l_conj) observed_39\VBN|oxide|,|in|due|role|and (l_prep) in_40\IN|NAME|. (l_pobj) models_43\NNS|NONE (l_compound) epilepsy_42\NN|different
3864191
D012459_D007674 NONE Salicylate_0\NNP|role|.|:|in (r_compound) nephropathy_1\NN|NONE
D011453_D007674 NONE prostaglandins_10\NNS|NONE (r_pobj) of_9\IN|potential (r_prep) role_8\NN|Salicylate|.|:|in (r_appos) nephropathy_1\NN|NONE
D011453_D007674 NONE prostaglandins_6\NNS|NONE (r_pobj) of_5\IN|the|potential|in (r_prep) role_4\NN|We|. (l_prep) in_7\IN|of|the|potential (l_pobj) development_9\NN|NONE (l_prep) of_10\IN|the|in (l_pobj) nephropathy_12\NN|NONE
D011453_D007674 NONE prostaglandin_4\NN|renal (r_amod) synthesis_5\NN|NONE (r_pobj) in_2\IN|The (r_prep) changes_1\NNS|were|by|. (r_nsubjpass) accompanied_7\VBN|NONE (l_agent) by_8\IN|changes|were|. (l_pobj) evidence_9\NN|NONE (l_prep) of_10\IN|rats|but (l_pobj) damage_12\NN|NONE
D011453_D007674 NONE prostaglandin_5\NN|enhanced (r_amod) synthesis_6\NN|lead|,|to|and|that (r_nsubj) contributes_7\VBZ|.|results (l_conj) lead_24\VB|,|synthesis|to|and|that (l_prep) to_25\IN|that|may|inhibition (l_pobj) lesions_29\NNS|NONE (l_conj) deterioration_31\NN|medullary|renal|pathological|and (l_prep) of_32\IN|NONE (l_pobj) function_34\NN|NONE
D011453_D007674 NONE prostaglandin_21\JJ|NONE (r_amod) synthesis_22\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) inhibition_19\NN|to|that|may (r_nsubj) lead_24\VB|,|synthesis|to|and|that (l_prep) to_25\IN|that|may|inhibition (l_pobj) lesions_29\NNS|NONE (l_conj) deterioration_31\NN|medullary|renal|pathological|and (l_prep) of_32\IN|NONE (l_pobj) function_34\NN|NONE
D011453_D006417 NONE prostaglandin_4\NN|renal (r_amod) synthesis_5\NN|NONE (r_pobj) in_2\IN|The (r_prep) changes_1\NNS|were|by|. (r_nsubjpass) accompanied_7\VBN|NONE (l_agent) by_8\IN|changes|were|. (l_pobj) evidence_9\NN|NONE (l_conj) rats_21\NNS|of|but (l_conj) incidence_27\NN|creatinine|;|:|evidenced|jJ (l_prep) of_30\IN|increased|p|severity|and (l_pobj) hematuria_31\NN|NONE
D003404_D007674 NONE creatinine_41\NN|;|:|incidence|evidenced|jJ (r_conj) rats_21\NNS|of|but (r_conj) evidence_9\NN|NONE (l_prep) of_10\IN|rats|but (l_pobj) damage_12\NN|NONE
D001241_D006417 NONE aspirin_14\NN| (r_npadvmod) treated_16\VBN|NONE (r_amod) jj_17\UH|NONE (r_pobj) in_13\IN|renal (r_prep) damage_12\NN|NONE (r_pobj) of_10\IN|rats|but (r_prep) evidence_9\NN|NONE (l_conj) rats_21\NNS|of|but (l_conj) incidence_27\NN|creatinine|;|:|evidenced|jJ (l_prep) of_30\IN|increased|p|severity|and (l_pobj) hematuria_31\NN|NONE
D001241_D006417 NONE aspirin_69\NN| (r_npadvmod) treated_71\VBN|NONE (r_amod) jJ_72\NNP|or|treated|either (r_conj) jj_67\NNS|NONE (r_pobj) to_62\IN|NONE (r_prep) compared_61\VBN|.|) (r_prep) p_57\XX|(|in (r_appos) increase_50\VB|and|increased|;|.|)|serum|( (r_conj) creatinine_41\NN|;|:|incidence|evidenced|jJ (r_conj) rats_21\NNS|of|but (l_conj) incidence_27\NN|creatinine|;|:|evidenced|jJ (l_prep) of_30\IN|increased|p|severity|and (l_pobj) hematuria_31\NN|NONE
D001663_D006932 NONE bilirubin_18\NN|in|marked (r_amod) deposition_19\NN|NONE (r_pobj) to_16\IN|NONE (r_prep) leading_15\VBG|rats|hyperbilirubinemia|.|, (r_advcl) have_4\VBP|NONE (l_dobj) hyperbilirubinemia_6\NN|rats|.|leading|,
-1_D006932 NONE glucuronyl_12\NN|NONE (r_compound) transferase_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) absence_10\NN|to (r_pobj) due_7\IN|unconjugated (r_amod) hyperbilirubinemia_6\NN|rats|.|leading|,
D001241_D007674 CID aspirin_14\NN| (r_npadvmod) treated_16\VBN|NONE (r_amod) jj_17\UH|NONE (r_pobj) in_13\IN|renal (r_prep) damage_12\NN|NONE
D001241_D007674 CID aspirin_69\NN| (r_npadvmod) treated_71\VBN|NONE (r_amod) jJ_72\NNP|or|treated|either (r_conj) jj_67\NNS|NONE (r_pobj) to_62\IN|NONE (r_prep) compared_61\VBN|.|) (r_prep) p_57\XX|(|in (r_appos) increase_50\VB|and|increased|;|.|)|serum|( (r_conj) creatinine_41\NN|;|:|incidence|evidenced|jJ (r_conj) rats_21\NNS|of|but (r_conj) evidence_9\NN|NONE (l_prep) of_10\IN|rats|but (l_pobj) damage_12\NN|NONE
D003404_D006417 NONE creatinine_41\NN|;|:|incidence|evidenced|jJ (r_conj) rats_21\NNS|of|but (l_conj) incidence_27\NN|creatinine|;|:|evidenced|jJ (l_prep) of_30\IN|increased|p|severity|and (l_pobj) hematuria_31\NN|NONE
D011453_D058186 NONE prostaglandin_5\NN|enhanced (r_amod) synthesis_6\NN|lead|,|to|and|that (r_nsubj) contributes_7\VBZ|.|results (l_conj) lead_24\VB|,|synthesis|to|and|that (l_prep) to_25\IN|that|may|inhibition (l_pobj) lesions_29\NNS|NONE
D011453_D058186 NONE prostaglandin_21\JJ|NONE (r_amod) synthesis_22\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) inhibition_19\NN|to|that|may (r_nsubj) lead_24\VB|,|synthesis|to|and|that (l_prep) to_25\IN|that|may|inhibition (l_pobj) lesions_29\NNS|NONE
15815446
C009591_D001930 NONE chloride_18\NN|NONE (r_dobj) using_16\VBG|tissue (r_advcl) staining_14\VBG|NONE (r_pcomp) by_13\IN|,|was|for|A (r_prep) evaluated_12\VBN|by|.|was (l_prep) for_3\IN|,|by|was|A (l_pobj) rats_5\NNS|NONE (l_prep) in_6\IN|eight (l_pobj) injury_10\NN|NONE
D010656_D001930 NONE phenylephrine_17\NN| (r_npadvmod) induced_19\VBN|on (r_amod) hypertension_20\NN|NONE (l_prep) on_21\IN|induced (l_pobj) injury_24\NN|NONE
D010656_D006973 CID phenylephrine_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) hypertension_11\NN|NONE
D010656_D006973 CID phenylephrine_17\NN| (r_npadvmod) induced_19\VBN|on (r_amod) hypertension_20\NN|NONE (r_pobj) of_16\IN|the (r_prep) effect_15\NN|After|, (r_nsubj) was_31\VBD|. (l_prep) After_0\IN|effect|, (l_pobj) min_2\NN|NONE (l_prep) of_3\IN| (l_pobj) occlusion_8\NN|NONE (l_prep) in_9\IN|cerebral|artery|temporary|middle (l_pobj) rats_12\NNS|NONE (l_amod) hypertensive_11\JJ|NONE
D010656_D006973 CID phenylephrine_17\NN| (r_npadvmod) induced_19\VBN|on (r_amod) hypertension_20\NN|NONE
D005070_D006973 NONE Blue_1\NNP|greater|. (r_nsubj) was_9\VBD|NONE (l_acomp) greater_10\JJR|Blue|. (l_prep) in_11\IN|NONE (l_pobj) group_14\NN|NONE (l_nummod) 90/HTN_13\CD|)|.|(|)|(|the|versus|was|+/|,
D005070_D006973 NONE Blue_1\NNP|greater|. (r_nsubj) was_9\VBD|NONE (l_acomp) greater_10\JJR|Blue|. (l_prep) in_11\IN|NONE (l_pobj) group_14\NN|NONE (l_relcl) was_31\VBD|)|.|(|)|(|the|versus|/HTN|+/|, (l_acomp) greater_34\JJR|in|which (l_prep) than_35\IN|NONE (l_pobj) group_38\NN|NONE (l_compound) 15/HTN_37\CD|)|the|+/|(
D010656_D002545 NONE phenylephrine_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) hypertension_11\NN|NONE (r_pobj) of_7\IN|during (r_prep) effect_6\NN|.|:|cerebral|in|Focal (r_appos) ischemia_2\NN|NONE
D010656_D020244 NONE phenylephrine_17\NN| (r_npadvmod) induced_19\VBN|on (r_amod) hypertension_20\NN|NONE (r_pobj) of_16\IN|the (r_prep) effect_15\NN|After|, (r_nsubj) was_31\VBD|. (l_prep) After_0\IN|effect|, (l_pobj) min_2\NN|NONE (l_prep) of_3\IN| (l_pobj) occlusion_8\NN|NONE
C009591_D004487 NONE chloride_18\NN|NONE (l_conj) edema_20\NN|,,triphenyltetrazolium|and
15276093
C451780_D050171 NONE lovastatin_5\NN|NONE (r_appos) Niacin_0\NNP|.|product (r_nsubj) is_6\VBZ|NONE (l_attr) product_10\NN|.|Niacin (l_acl) approved_11\VBN|a|new|combination (l_prep) for_12\IN|NONE (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|NONE (l_pobj) hypercholesterolemia_16\NN|NONE (l_conj) dyslipidemia_19\NN|and|primary
C451780_D050171 NONE lovastatin_30\NN|niacin|and (r_conj) dyslipidemia_23\NN|NONE
C451780_D006937 NONE lovastatin_5\NN|NONE (r_appos) Niacin_0\NNP|.|product (r_nsubj) is_6\VBZ|NONE (l_attr) product_10\NN|.|Niacin (l_acl) approved_11\VBN|a|new|combination (l_prep) for_12\IN|NONE (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|NONE (l_pobj) hypercholesterolemia_16\NN|NONE
D003401_D009135 NONE creatine_3\NN|NONE (r_compound) phosphokinase_4\NN|NONE (r_pobj) of_2\IN|to|An (r_prep) increase_1\NN|,|in|and|limit|observed (r_nsubj) occurred_14\VBD|NONE (l_conj) observed_30\VBN|,|increase|in|and|limit (l_nsubjpass) cases_23\NNS|were|. (l_prep) of_24\IN|no (l_pobj) myopathy_28\NNS|NONE
7479194
D014295_D064420 NONE trimethoprim_14\NN||trimethoprim|, (r_conj) sulfamethoxazole_12\NN|NONE (r_pobj) of_9\IN|large|A|.|based|up|for (r_prep) study_8\NN|NONE (l_prep) for_18\IN|large|A|.|of|based|up (l_pobj) toxicity_22\NN|NONE
D002506_D007674 NONE cephalexin_34\NN|,|trimethoprim|,|,|and (r_conj) prescribed_27\VBD|.|estimate|We|study (r_conj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D008107 CID SMZ_15\NNP|(|) (r_nmod) 5.2/100,000_17\CD|NONE (r_dobj) prescribed_12\VBN|NONE (r_acl) persons_11\NNS|NONE (r_pobj) for_10\IN|NONE (r_prep) similar_9\JJ|and|trimethoprim|risk (r_acomp) was_8\VBD|NONE (l_nsubj) risk_1\NN|and|trimethoprim|similar (l_prep) of_2\IN|The (l_pobj) disease_7\NN|NONE
D015662_D008107 NONE sulfamethoxazole_19\NN||)|(|TMP (r_compound) SMZ_23\NNP|who|were (r_dobj) prescribed_16\VBN|, (r_relcl) people_13\NNS|NONE (r_pobj) of_11\IN|day|follow|a|based (r_prep) study_10\NN|.|prescribed|estimate|We (r_dobj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D008107 NONE SMZ_23\NNP|who|were (r_dobj) prescribed_16\VBN|, (r_relcl) people_13\NNS|NONE (r_pobj) of_11\IN|day|follow|a|based (r_prep) study_10\NN|.|prescribed|estimate|We (r_dobj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D002506_D012871 NONE cephalexin_34\NN|,|trimethoprim|,|,|and (r_conj) prescribed_27\VBD|.|estimate|We|study (r_conj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D014295_D012871 NONE trimethoprim_28\NN|,|cephalexin|,|,|and (r_dobj) prescribed_27\VBD|.|estimate|We|study (r_conj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D004892 NONE SMZ_15\NNP|NONE (r_pobj) to_12\IN|one|was (r_prep) exposed_11\VBN|,|blood|of|; (r_relcl) disorders_5\NNS|patients (l_prep) of_17\IN|,|blood|exposed|; (l_pobj) seven_18\CD|NONE (l_prep) with_19\IN|NONE (l_pobj) multiforme_21\NNS|NONE
D015662_D004892 NONE SMZ_34\NNP|NONE (r_pobj) to_31\IN|were|experienced|.|four|, (r_prep) exposed_30\VBN|NONE (l_ccomp) experienced_3\VBD|were|.|four|,|to (l_dobj) disorders_5\NNS|patients (l_prep) of_17\IN|,|blood|exposed|; (l_pobj) seven_18\CD|NONE (l_prep) with_19\IN|NONE (l_pobj) multiforme_21\NNS|NONE
D014295_D008107 CID trimethoprim_22\NN|and|risk|similar (r_conj) was_8\VBD|NONE (l_nsubj) risk_1\NN|and|trimethoprim|similar (l_prep) of_2\IN|The (l_pobj) disease_7\NN|NONE
D014295_D008107 NONE trimethoprim_28\NN|,|cephalexin|,|,|and (r_dobj) prescribed_27\VBD|.|estimate|We|study (r_conj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D064420 NONE sulfamethoxazole_12\NN|NONE (r_pobj) of_9\IN|large|A|.|based|up|for (r_prep) study_8\NN|NONE (l_prep) for_18\IN|large|A|.|of|based|up (l_pobj) toxicity_22\NN|NONE
D014295_D007674 NONE trimethoprim_28\NN|,|cephalexin|,|,|and (r_dobj) prescribed_27\VBD|.|estimate|We|study (r_conj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D007674 NONE sulfamethoxazole_19\NN||)|(|TMP (r_compound) SMZ_23\NNP|who|were (r_dobj) prescribed_16\VBN|, (r_relcl) people_13\NNS|NONE (r_pobj) of_11\IN|day|follow|a|based (r_prep) study_10\NN|.|prescribed|estimate|We (r_dobj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D007674 NONE SMZ_23\NNP|who|were (r_dobj) prescribed_16\VBN|, (r_relcl) people_13\NNS|NONE (r_pobj) of_11\IN|day|follow|a|based (r_prep) study_10\NN|.|prescribed|estimate|We (r_dobj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D013262 CID SMZ_15\NNP|NONE (r_pobj) to_12\IN|one|was (r_prep) exposed_11\VBN|,|blood|of|; (r_relcl) disorders_5\NNS|patients (l_prep) of_17\IN|,|blood|exposed|; (l_pobj) seven_18\CD|NONE (l_prep) with_19\IN|NONE (l_pobj) multiforme_21\NNS|NONE (l_conj) syndrome_26\NN|erythema|and
D015662_D013262 CID SMZ_34\NNP|NONE (r_pobj) to_31\IN|were|experienced|.|four|, (r_prep) exposed_30\VBN|NONE (l_ccomp) experienced_3\VBD|were|.|four|,|to (l_dobj) disorders_5\NNS|patients (l_prep) of_17\IN|,|blood|exposed|; (l_pobj) seven_18\CD|NONE (l_prep) with_19\IN|NONE (l_pobj) multiforme_21\NNS|NONE (l_conj) syndrome_26\NN|erythema|and
D002506_D008107 NONE cephalexin_34\NN|,|trimethoprim|,|,|and (r_conj) prescribed_27\VBD|.|estimate|We|study (r_conj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D002506_D006402 NONE cephalexin_34\NN|,|trimethoprim|,|,|and (r_conj) prescribed_27\VBD|.|estimate|We|study (r_conj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D012871 NONE sulfamethoxazole_19\NN||)|(|TMP (r_compound) SMZ_23\NNP|who|were (r_dobj) prescribed_16\VBN|, (r_relcl) people_13\NNS|NONE (r_pobj) of_11\IN|day|follow|a|based (r_prep) study_10\NN|.|prescribed|estimate|We (r_dobj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D012871 NONE SMZ_23\NNP|who|were (r_dobj) prescribed_16\VBN|, (r_relcl) people_13\NNS|NONE (r_pobj) of_11\IN|day|follow|a|based (r_prep) study_10\NN|.|prescribed|estimate|We (r_dobj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D002506_D013262 CID cephalexin_13\NN|who (r_dobj) took_12\VBD|a (r_relcl) patient_10\NN|NONE (r_pobj) in_8\IN|case|. (r_prep) occurred_7\VBD|NONE (l_nsubj) case_2\NN|.|in (l_prep) of_3\IN|one|The (l_pobj) necrolysis_6\NN|NONE
D002506_D064420 NONE cephalexin_17\NN|and|, (r_conj) trimethoprim_14\NN||trimethoprim|, (r_conj) sulfamethoxazole_12\NN|NONE (r_pobj) of_9\IN|large|A|.|based|up|for (r_prep) study_8\NN|NONE (l_prep) for_18\IN|large|A|.|of|based|up (l_pobj) toxicity_22\NN|NONE
D014295_D006402 NONE trimethoprim_28\NN|,|cephalexin|,|,|and (r_dobj) prescribed_27\VBD|.|estimate|We|study (r_conj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D006402 NONE sulfamethoxazole_19\NN||)|(|TMP (r_compound) SMZ_23\NNP|who|were (r_dobj) prescribed_16\VBN|, (r_relcl) people_13\NNS|NONE (r_pobj) of_11\IN|day|follow|a|based (r_prep) study_10\NN|.|prescribed|estimate|We (r_dobj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
D015662_D006402 NONE SMZ_23\NNP|who|were (r_dobj) prescribed_16\VBN|, (r_relcl) people_13\NNS|NONE (r_pobj) of_11\IN|day|follow|a|based (r_prep) study_10\NN|.|prescribed|estimate|We (r_dobj) conducted_1\VBD|NONE (l_advcl) estimate_37\VB|.|prescribed|We|study (l_dobj) risk_39\NN|to (l_prep) of_40\IN|the (l_pobj) liver_42\NN|NONE (l_conj) blood_44\NN|serious|, (l_conj) skin_46\NN|, (l_conj) disorders_50\NNS|and|,
8511251
D003042_D017202 CID Cocaine_0\NN|ischemia|. (r_nsubj) induced_1\VBD|NONE (l_dobj) ischemia_3\NN|Cocaine|.
D003042_D017202 CID cocaine_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|of|a (r_acl) case_3\NN|.|We (l_prep) of_4\IN|induced|a (l_pobj) ischemia_6\NN|NONE
D005996_D007511 NONE nitroglycerin_11\NN|NONE (r_pobj) by_10\IN|was (r_agent) reversed_9\VBN|by|probably|.|ischemia (r_conj) induced_3\VBN|NONE (l_nsubj) ischemia_1\NN|by|reversed|probably|.
D002118_D007511 NONE calcium_13\NN|NONE (r_npadvmod) blocking_14\VBG|NONE (r_amod) agents_15\NNS|and (r_conj) nitroglycerin_11\NN|NONE (r_pobj) by_10\IN|was (r_agent) reversed_9\VBN|by|probably|.|ischemia (r_conj) induced_3\VBN|NONE (l_nsubj) ischemia_1\NN|by|reversed|probably|.
D002118_D003329 NONE calcium_13\NN|NONE (r_npadvmod) blocking_14\VBG|NONE (r_amod) agents_15\NNS|and (r_conj) nitroglycerin_11\NN|NONE (r_pobj) by_10\IN|was (r_agent) reversed_9\VBN|by|probably|.|ischemia (r_conj) induced_3\VBN|NONE (l_agent) by_4\IN|reversed|probably|.|ischemia (l_pobj) spasm_7\NN|NONE
D005996_D003329 NONE nitroglycerin_11\NN|NONE (r_pobj) by_10\IN|was (r_agent) reversed_9\VBN|by|probably|.|ischemia (r_conj) induced_3\VBN|NONE (l_agent) by_4\IN|reversed|probably|.|ischemia (l_pobj) spasm_7\NN|NONE
19447152
D012964_D001714 NONE Na(+)/K(+)-ATPase_10\NNP|a (r_compound) inhibitor_11\NN|(|ICV|in|(|)|)|of (r_appos) administration_5\NN|The (r_appos) intracerebroventricular_1\JJ|been|.|has|mimic (r_nsubjpass) suggested_17\VBN|NONE (l_xcomp) mimic_19\VB|been|.|has|intracerebroventricular (l_dobj) symptoms_21\NNS|to (l_prep) of_22\IN|some (l_pobj) mania_25\NN|NONE
D010042_D009069 NONE ouabain_4\NN|hyperlocomotion|that (r_nsubj) induced_10\VBN|remained|findings|and|, (l_dobj) hyperlocomotion_11\NN|ouabain|that
D011188_D001714 NONE Na(+)/K(+)-ATPase_10\NNP|a (r_compound) inhibitor_11\NN|(|ICV|in|(|)|)|of (r_appos) administration_5\NN|The (r_appos) intracerebroventricular_1\JJ|been|.|has|mimic (r_nsubjpass) suggested_17\VBN|NONE (l_xcomp) mimic_19\VB|been|.|has|intracerebroventricular (l_dobj) symptoms_21\NNS|to (l_prep) of_22\IN|some (l_pobj) mania_25\NN|NONE
D010042_D001714 CID ouabain_6\NN|NONE (r_pobj) by_5\IN|model|Evidence|.|: (r_prep) induced_4\VBN|NONE (l_nsubj) model_1\NN|by|Evidence|.|: (l_prep) of_2\IN|Animal (l_pobj) mania_3\NN|NONE
D010042_D001714 CID ouabain_7\NN|NONE (r_pobj) of_6\IN|(|ICV|in|(|inhibitor|)|) (r_prep) administration_5\NN|The (r_appos) intracerebroventricular_1\JJ|been|.|has|mimic (r_nsubjpass) suggested_17\VBN|NONE (l_xcomp) mimic_19\VB|been|.|has|intracerebroventricular (l_dobj) symptoms_21\NNS|to (l_prep) of_22\IN|some (l_pobj) mania_25\NN|NONE
D010042_D001714 CID ouabain_3\NN| (r_npadvmod) induced_5\VBN|mania (r_amod) behavior_9\NN|,|.|In|model|may (l_nmod) mania_6\NN|induced
D010042_D001714 CID ouabain_3\NN| (r_npadvmod) induced_5\VBN|mania (r_amod) behavior_9\NN|,|.|In|model|may (r_nsubj) provide_11\VB|NONE (l_dobj) model_15\NN|,|.|In|may|behavior (l_relcl) test_17\VB|animal|a|useful (l_dobj) hypothesis_19\NN|to (l_prep) of_20\IN|the (l_pobj) involvement_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) stress_25\NN|NONE (l_prep) in_26\IN|oxidative (l_pobj) disorder_28\NN|NONE
733189
C000873_D015356 CID acetate_24\NN|NONE (r_pobj) with_22\IN|in|tissue|head (r_prep) injection_21\NN|NONE (r_dobj) following_14\VBG|NONE (r_prep) blindness_13\NN|NONE (r_pobj) with_12\IN|choriocapillaris (r_prep) occlusions_11\NNS|bilateral|and|retinal
D010406_D015356 NONE penicillin_33\NN|,|or (r_conj) epinephrine_30\NN|, (r_conj) lidocaine_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) combination_26\NN|NONE (r_pobj) in_25\IN|with|tissue|head (r_prep) injection_21\NN|NONE (r_dobj) following_14\VBG|NONE (r_prep) blindness_13\NN|NONE (r_pobj) with_12\IN|choriocapillaris (r_prep) occlusions_11\NNS|bilateral|and|retinal
D004837_D015356 NONE epinephrine_30\NN|, (r_conj) lidocaine_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) combination_26\NN|NONE (r_pobj) in_25\IN|with|tissue|head (r_prep) injection_21\NN|NONE (r_dobj) following_14\VBG|NONE (r_prep) blindness_13\NN|NONE (r_pobj) with_12\IN|choriocapillaris (r_prep) occlusions_11\NNS|bilateral|and|retinal
D004837_D001766 NONE epinephrine_30\NN|, (r_conj) lidocaine_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) combination_26\NN|NONE (r_pobj) in_25\IN|with|tissue|head (r_prep) injection_21\NN|NONE (r_dobj) following_14\VBG|NONE (r_prep) blindness_13\NN|NONE
D008012_D015356 NONE lidocaine_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) combination_26\NN|NONE (r_pobj) in_25\IN|with|tissue|head (r_prep) injection_21\NN|NONE (r_dobj) following_14\VBG|NONE (r_prep) blindness_13\NN|NONE (r_pobj) with_12\IN|choriocapillaris (r_prep) occlusions_11\NNS|bilateral|and|retinal
D008012_D001766 NONE lidocaine_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) combination_26\NN|NONE (r_pobj) in_25\IN|with|tissue|head (r_prep) injection_21\NN|NONE (r_dobj) following_14\VBG|NONE (r_prep) blindness_13\NN|NONE
D010406_D001766 NONE penicillin_33\NN|,|or (r_conj) epinephrine_30\NN|, (r_conj) lidocaine_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) combination_26\NN|NONE (r_pobj) in_25\IN|with|tissue|head (r_prep) injection_21\NN|NONE (r_dobj) following_14\VBG|NONE (r_prep) blindness_13\NN|NONE
D000305_D015356 NONE corticosteroid_13\NN|in|acting (r_compound) suspensions_14\NNS|NONE (r_pobj) of_9\IN|the (r_prep) injection_8\NN|NONE (r_pobj) following_6\VBG|.|retinal|studies|Bilateral|and|occlusion|: (r_prep) artery_2\NN|NONE (l_conj) occlusion_5\NN|.|following|retinal|studies|Bilateral|and|:
C000873_D001766 NONE acetate_24\NN|NONE (r_pobj) with_22\IN|in|tissue|head (r_prep) injection_21\NN|NONE (r_dobj) following_14\VBG|NONE (r_prep) blindness_13\NN|NONE
20566328
C476756_D006331 NONE MitoQ._15\NNP|NONE (r_pobj) by_11\IN|NONE (r_prep) Prevention_10\NN|Mitochondrial (r_appos) impairment_1\NN|to|: (r_nsubj) contributes_2\VBZ|NONE (l_prep) to_3\IN|:|impairment (l_pobj) dysfunction_8\NN|NONE
C476756_D006331 NONE MitoQ_0\NNP|was|.|prevent (r_nsubjpass) shown_9\VBN|NONE (l_xcomp) prevent_12\VB|was|.|MitoQ (l_dobj) abnormalities_15\NNS|completely|to (l_conj) dysfunction_20\NN|as|mitochondrial|these
C476756_-1 NONE MitoQ_0\NNP|was|.|prevent (r_nsubjpass) shown_9\VBN|NONE (l_xcomp) prevent_12\VB|was|.|MitoQ (l_dobj) abnormalities_15\NNS|completely|to (l_conj) dysfunction_20\NN|as|mitochondrial|these (l_acl) characterized_21\VBN|cardiac (l_agent) by_23\IN|here (l_pobj) dysfunction_26\NN|NONE
D003042_D028361 NONE cocaine_4\NN| (r_npadvmod) induced_6\VBN|cardiac (r_amod) dysfunction_8\NN|NONE (r_pobj) to_3\IN|:|impairment (r_prep) contributes_2\VBZ|NONE (l_nsubj) impairment_1\NN|to|:
D003042_D028361 NONE cocaine_15\NN|NONE (r_pobj) to_14\IN|term (r_prep) exposure_13\NN|NONE (r_pobj) after_9\IN|effect|not|,|suggesting|detectable|. (r_prep) was_6\VBD|NONE (l_advcl) suggesting_17\VBG|after|effect|not|,|detectable|. (l_ccomp) were_22\VBD|NONE (l_nsubj) abnormalities_21\NNS|event|that
D003042_D028361 NONE cocaine_35\NN|NONE (r_pobj) to_34\IN|the|pathological (r_prep) response_33\NN|NONE (r_pobj) in_30\IN|a|late|a|primary (r_prep) event_29\NN|abnormalities|that (r_attr) were_22\VBD|NONE (l_nsubj) abnormalities_21\NNS|event|that
D003042_D028361 NONE cocaine_11\NN| (r_npadvmod) induced_13\VBN|cardiac (r_amod) dysfunction_15\NN|due|that|may (r_nsubj) be_17\VB|NONE (l_acomp) due_18\JJ|dysfunction|that|may (l_prep) to_19\IN|NONE (l_pobj) defect_22\NN|NONE
D003042_D006331 CID cocaine_4\NN| (r_npadvmod) induced_6\VBN|cardiac (r_amod) dysfunction_8\NN|NONE
D003042_D006331 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|cardiac (r_amod) dysfunction_22\NN|NONE
D003042_D006331 CID cocaine_11\NN| (r_npadvmod) induced_13\VBN|cardiac (r_amod) dysfunction_15\NN|due|that|may
C476756_D028361 NONE MitoQ._15\NNP|NONE (r_pobj) by_11\IN|NONE (r_prep) Prevention_10\NN|Mitochondrial (r_appos) impairment_1\NN|to|:
C476756_D028361 NONE MitoQ_0\NNP|was|.|prevent (r_nsubjpass) shown_9\VBN|NONE (l_xcomp) prevent_12\VB|was|.|MitoQ (l_dobj) abnormalities_15\NNS|completely|to
8308951
D014859_D001778 NONE warfarin_7\RB| (r_npadvmod) induced_9\VBN|NONE (r_amod) coagulopathy_10\NN|to
D014859_D001778 NONE warfarin_3\JJ|NONE (r_pobj) of_2\IN|Percutaneous|causing (r_prep) absorption_1\NN|in|,|.|is|times|, (l_acl) causing_4\VBG|Percutaneous|of (l_dobj) coagulopathy_5\NN|NONE
D014859_D002543 CID warfarin_3\VB| (r_npadvmod) like_5\JJ|NONE (r_amod) anticoagulant_6\NN|NONE (r_pobj) to_2\IN|.|report|Cutaneous|:|causing (r_prep) exposure_1\NN|NONE (l_acl) causing_7\VBG|.|report|to|Cutaneous|: (l_dobj) hemorrhage_10\NN|NONE
D010894_D001778 NONE piroxicam_5\NN|NONE (r_pobj) with_4\IN|An|took|adverse|,|drug (r_prep) interaction_3\NN|coagulopathy|.|,|may|have (r_nsubj) exacerbated_14\VBN|NONE (l_dobj) coagulopathy_16\NN|.|interaction|,|may|have
D014859_D006406 NONE warfarin_7\RB| (r_npadvmod) induced_9\VBN|NONE (r_amod) coagulopathy_10\NN|to (r_pobj) due_5\IN|A|of (r_prep) case_1\NN|is|. (l_prep) of_2\IN|due|A (l_pobj) hematoma_4\NN|NONE
2718706
D006221_D007022 CID halothane_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) labetalol_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|.|Deliberate (r_acl) hypotension_1\NN|NONE
D006221_D007022 CID halothane_25\NN|inhalation|(|) (r_appos) anaesthetics_23\NNS|NONE (r_pobj) with_21\IN|NONE (r_prep) combination_20\NN|NONE (r_pobj) in_19\IN|hypotensive|a (r_prep) agent_18\NN|NONE (l_amod) hypotensive_17\JJ|in|a
D006221_D007022 CID H_2\NN|concentration|The|during|mean (r_compound) concentration_3\NN|+/|, (l_prep) during_4\IN|H|concentration|The|mean (l_pobj) hypotension_5\NN|NONE
D004737_D007022 CID enflurane_8\NN|, (r_conj) halothane_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) labetalol_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|.|Deliberate (r_acl) hypotension_1\NN|NONE
D004737_D007022 CID enflurane_27\NN|, (r_conj) halothane_25\NN|inhalation|(|) (r_appos) anaesthetics_23\NNS|NONE (r_pobj) with_21\IN|NONE (r_prep) combination_20\NN|NONE (r_pobj) in_19\IN|hypotensive|a (r_prep) agent_18\NN|NONE (l_amod) hypotensive_17\JJ|in|a
D004737_D007022 CID E_18\NN|the|mean|mean|.|and|,|+/ (r_compound) concentration_19\NN|H|The|during|mean (r_appos) concentration_3\NN|+/|, (l_prep) during_4\IN|H|concentration|The|mean (l_pobj) hypotension_5\NN|NONE
D003404_D007022 NONE creatinine_5\NN|the|serum (r_compound) concentration_6\NN|returned|significantly|in|During|.|,|and|before (r_nsubj) rose_7\VBD|NONE (l_prep) During_0\IN|returned|significantly|in|.|,|concentration|and|before (l_pobj) hypotension_1\NN|NONE
D003404_D007022 NONE creatinine_5\NN|the|serum (r_compound) concentration_6\NN|returned|significantly|in|During|.|,|and|before (r_nsubj) rose_7\VBD|NONE (l_prep) before_15\IN|returned|significantly|in|During|.|,|concentration|and (l_pobj) hypotension_16\NN|NONE
D007741_D007022 CID labetalol_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|.|Deliberate (r_acl) hypotension_1\NN|NONE
D007741_D007022 CID labetalol_4\NN|as (r_dobj) using_3\VBG|NONE (l_prep) as_15\IN|labetalol (l_pobj) agent_18\NN|NONE (l_amod) hypotensive_17\JJ|in|a
D007741_D007022 CID labetalol_4\NN|hypotension|that (r_nsubj) induces_5\VBZ|.|results (l_dobj) hypotension_8\NN|that|labetalol
D007741_D006973 NONE labetalol_4\NN|hypotension|that (r_nsubj) induces_5\VBZ|.|results (l_dobj) hypotension_8\NN|that|labetalol (l_conj) hypertension_14\NN|and|adjustable|without
D007741_D013610 NONE labetalol_4\NN|hypotension|that (r_nsubj) induces_5\VBZ|.|results (l_dobj) hypotension_8\NN|that|labetalol (l_prep) without_9\IN|and|adjustable|hypertension (l_pobj) tachycardia_11\NNS|NONE
D007530_D007022 CID isoflurane_10\RB|or (r_conj) enflurane_8\NN|, (r_conj) halothane_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) labetalol_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|.|Deliberate (r_acl) hypotension_1\NN|NONE
D007530_D007022 CID isoflurane_29\RB|or (r_conj) enflurane_27\NN|, (r_conj) halothane_25\NN|inhalation|(|) (r_appos) anaesthetics_23\NNS|NONE (r_pobj) with_21\IN|NONE (r_prep) combination_20\NN|NONE (r_pobj) in_19\IN|hypotensive|a (r_prep) agent_18\NN|NONE (l_amod) hypotensive_17\JJ|in|a
D007530_D007022 CID isoflurane_31\JJ|the (r_amod) group_32\NN|NONE (r_pobj) except_29\IN|to|postoperatively|, (r_prep) returned_18\VBD|significantly|in|During|.|,|concentration|and|before (r_conj) rose_7\VBD|NONE (l_prep) During_0\IN|returned|significantly|in|.|,|concentration|and|before (l_pobj) hypotension_1\NN|NONE
D007530_D007022 CID isoflurane_31\JJ|the (r_amod) group_32\NN|NONE (r_pobj) except_29\IN|to|postoperatively|, (r_prep) returned_18\VBD|significantly|in|During|.|,|concentration|and|before (r_conj) rose_7\VBD|NONE (l_prep) before_15\IN|returned|significantly|in|During|.|,|concentration|and (l_pobj) hypotension_16\NN|NONE
2400986
D002998_D002493 NONE clonazepam_33\NN|NONE (r_pobj) with_32\IN|m (r_prep) busulfan_31\NNS|NONE (r_pobj) under_26\IN|in|gas|mass|without|spectrometry|a (r_prep) assay_11\NN|NONE (l_prep) without_21\IN|in|gas|mass|under|spectrometry|a (l_pobj) disease_25\NN|NONE
D002066_D002493 NONE Busulfan_0\NNS|NONE (r_compound) levels_1\NNS|by|was|were (r_nsubjpass) measured_3\VBN|NONE (l_agent) by_4\IN|was|levels|were (l_pobj) assay_11\NN|NONE (l_prep) without_21\IN|in|gas|mass|under|spectrometry|a (l_pobj) disease_25\NN|NONE
D002066_D002493 NONE busulfan_31\NNS|NONE (r_pobj) under_26\IN|in|gas|mass|without|spectrometry|a (r_prep) assay_11\NN|NONE (l_prep) without_21\IN|in|gas|mass|under|spectrometry|a (l_pobj) disease_25\NN|NONE
D002066_D002493 NONE busulfan_35\NNS|:|fluid|plasma|cerebrospinal (r_amod) ratio_40\NN|.|. (r_nsubj) was_41\VBD|by|levels|were (r_conj) measured_3\VBN|NONE (l_agent) by_4\IN|was|levels|were (l_pobj) assay_11\NN|NONE (l_prep) without_21\IN|in|gas|mass|under|spectrometry|a (l_pobj) disease_25\NN|NONE
D002998_D020258 NONE clonazepam_16\NN|NONE (r_pobj) by_15\IN|efficiently (r_agent) prevented_14\VBN|and|dependent|that|neurotoxicity (r_conj) is_6\VBZ|.|study (l_nsubj) neurotoxicity_5\NN|and|dependent|that|prevented
D002066_D001932 NONE busulfan_20\NNS|before (r_dobj) receiving_16\VBG|of|a|retrospective (r_acl) study_5\NN|We|here|excluded|, (r_dobj) report_1\VBP|NONE (l_conj) excluded_35\VBD|We|study|here|, (l_nsubj) tumors_34\NNS|.
D002066_D012640 CID busulfan_23\NNS|the (r_amod) course_24\NN|NONE (r_pobj) of_21\IN||within|the|or (r_prep) days_20\NNS|NONE (r_pobj) during_17\IN|given|;|.|seizures|% (r_prep) developed_15\VBN|NONE (l_dobj) seizures_16\NNS|given|;|during|.|%
D002998_D009461 NONE clonazepam_18\NN|NONE (r_pobj) of_17\IN|continuous|i.v. (r_prep) infusion_16\NN|NONE (r_pobj) with_13\IN|busulfan|total|a (r_prep) dose_12\NN|were|patients (r_dobj) given_5\VBN|;|.|symptoms|none (r_ccomp) had_21\VBD|NONE (l_dobj) symptoms_24\NNS|;|.|given|none
D002066_D020258 NONE busulfan_8\NNS|NONE (r_pobj) of_4\IN|.|study|dependent|: (r_prep) neurotoxicity_3\NN|NONE
D002066_D020258 NONE Busulfan_0\NNPS|is|be|,|but|remains (r_nsubjpass) known_2\VBN|NONE (l_xcomp) be_4\VB|Busulfan|is|,|but|remains (l_acomp) neurotoxic_5\JJ|to
D002066_D020258 NONE Busulfan_0\NNPS|is|be|,|but|remains (r_nsubjpass) known_2\VBN|NONE (l_conj) remains_15\VBZ|Busulfan|is|be|,|but (l_nsubj) neurotoxicity_14\NN|.|characterized
D002066_D020258 NONE busulfan_3\NNS|total|the (r_compound) dose_4\NN|was|When|into (r_nsubjpass) taken_6\VBN|there|.|difference|, (r_advcl) was_11\VBD|NONE (l_attr) difference_14\NN|there|.|taken|, (l_prep) in_15\IN|patients|significant|a|and (l_pobj) terms_16\NNS|NONE (l_prep) of_17\IN|NONE (l_pobj) incidence_19\JJ|NONE (l_compound) neurotoxicity_18\NN|among
D002066_D020258 NONE busulfan_4\NNS|NONE (r_amod) neurotoxicity_5\NN|and|dependent|that|prevented
D002066_D020258 NONE busulfan_1\NNS|,|A|calculated|resulting|, (r_compound) dose_2\NN|was|.|by|,|close|observed (r_nsubjpass) followed_21\VBN|NONE (l_agent) by_22\IN|was|.|dose|,|close|observed (l_pobj) neurotoxicity_24\NN|NONE
D002066_D020258 NONE busulfan_1\NNS|,|A|calculated|resulting|, (r_compound) dose_2\NN|was|.|by|,|close|observed (r_nsubjpass) followed_21\VBN|NONE (l_advmod) close_26\JJ|was|.|dose|by|,|observed (l_prep) to_27\IN|NONE (l_pobj) incidence_29\NN|NONE (l_compound) neurotoxicity_28\NN|NONE
D002066_D009461 NONE busulfan_10\NNS|with|total|a (r_nmod) dose_12\NN|were|patients (r_dobj) given_5\VBN|;|.|symptoms|none (r_ccomp) had_21\VBD|NONE (l_dobj) symptoms_24\NNS|;|.|given|none
D002066_D009369 NONE busulfan_20\NNS|before (r_dobj) receiving_16\VBG|of|a|retrospective (l_prep) before_24\IN|busulfan (l_pobj) transplantation_27\NN|NONE (l_prep) for_28\IN|bone|marrow (l_pobj) tumors_31\NNS|NONE
9782254
D007980_D009127 NONE DOPA_28\NNP|L|| (r_npadvmod) induced_30\VBN|NONE (r_amod) dyskinesias_31\NNS|and|, (r_conj) rigidity_23\NN|,
D007980_D018476 NONE DOPA_28\NNP|L|| (r_npadvmod) induced_30\VBN|NONE (r_amod) dyskinesias_31\NNS|and|, (r_conj) rigidity_23\NN|, (r_conj) bradykinesia_21\NN|NONE
D007980_D004409 CID DOPA_28\NNP|L|| (r_npadvmod) induced_30\VBN|NONE (r_amod) dyskinesias_31\NNS|and|,
D007980_D010300 NONE DOPA_28\NNP|L|| (r_npadvmod) induced_30\VBN|NONE (r_amod) dyskinesias_31\NNS|and|, (r_conj) rigidity_23\NN|, (r_conj) bradykinesia_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) treatment_19\NN|NONE (r_pobj) for_18\IN|.|patients|between|pallidotomy (r_prep) underwent_8\VBD|NONE (l_nsubj) patients_1\NNS|for|.|between|pallidotomy (l_prep) with_2\IN| (l_pobj) disease_7\NN|NONE
25907210
D010755_D009369 NONE organophosphate_10\NN|insecticide|in|the (r_amod) diazinon_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) exposed_7\VBN|pesticide (r_acl) applicators_6\NNS|NONE (r_pobj) among_4\IN|solid (r_prep) tumours_3\NNS|NONE
D010755_D009369 NONE organophosphate_4\NN|with|common|a (r_compound) insecticide_5\NN|,|, (r_appos) Diazinon_0\NNP|was|previously|with (r_nsubjpass) associated_12\VBN|.|have|studies|risk (r_ccomp) examined_32\VBN|NONE (l_dobj) risk_37\NN|.|associated|have|studies (l_compound) cancer_36\NN|associated
D010755_D008175 NONE organophosphate_4\NN|with|common|a (r_compound) insecticide_5\NN|,|, (r_appos) Diazinon_0\NNP|was|previously|with (r_nsubjpass) associated_12\VBN|.|have|studies|risk (l_prep) with_13\IN|was|Diazinon|previously (l_pobj) cancer_15\NN|NONE
D003976_D009369 NONE diazinon_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) exposed_7\VBN|pesticide (r_acl) applicators_6\NNS|NONE (r_pobj) among_4\IN|solid (r_prep) tumours_3\NNS|NONE
D003976_D009369 NONE Diazinon_0\NNP|was|previously|with (r_nsubjpass) associated_12\VBN|.|have|studies|risk (r_ccomp) examined_32\VBN|NONE (l_dobj) risk_37\NN|.|associated|have|studies (l_compound) cancer_36\NN|associated
D003976_D009369 NONE diazinon_33\NN| (r_npadvmod) associated_35\VBN|cancer (r_amod) risk_37\NN|.|associated|have|studies (l_compound) cancer_36\NN|associated
D003976_D009369 NONE diazinon_3\NN|and|updated|information (r_compound) exposure_4\NN|We|.|evaluate (l_conj) information_8\NN|and|diazinon|updated (l_compound) cancer_6\NN|incidence
D003976_D009369 NONE diazinon_3\NN|and|updated|information (r_compound) exposure_4\NN|We|.|evaluate (r_dobj) used_1\VBD|NONE (l_xcomp) evaluate_10\VB|We|.|exposure (l_dobj) risk_13\NN|to|in (l_compound) tumour_12\NN|solid
D003976_D009369 NONE diazinon_10\NN|at (r_compound) use_11\NN|applicators (r_dobj) reported_8\VBD|.|through|incidence|;|)|was (r_ccomp) assessed_32\VBN|NONE (l_nsubjpass) incidence_30\NN|reported|.|through|;|)|was (l_compound) cancer_29\NN|NONE
D003976_D008175 CID Diazinon_0\NNP|was|previously|with (r_nsubjpass) associated_12\VBN|.|have|studies|risk (l_prep) with_13\IN|was|Diazinon|previously (l_pobj) cancer_15\NN|NONE
D003976_D008175 CID diazinon_33\NN| (r_npadvmod) associated_35\VBN|cancer (r_amod) risk_37\NN|.|associated|have|studies (r_dobj) examined_32\VBN|NONE (l_ccomp) associated_12\VBN|.|have|studies|risk (l_prep) with_13\IN|was|Diazinon|previously (l_pobj) cancer_15\NN|NONE
D003976_D008175 CID diazinon_34\NN|NONE (r_compound) use_35\NN|NONE (r_pobj) of_33\IN|;|IW|(|RR=. (r_prep) days_32\NNS|)|and (r_conj) Ptrend=0.02_28\LS|.|;|%|to|% (r_appos) CI_23\NNP|:|risks|.|;|We (r_npadvmod) observed_2\VBD|NONE (l_dobj) risks_6\NNS|CI|:|.|;|We (l_compound) cancer_5\NN|(|N=|among|elevated|)
D003976_D008175 CID diazinon_4\NNS|NONE (r_pobj) of_3\IN|Our|updated (r_prep) evaluation_2\NN|.|evidence (r_nsubj) provides_5\VBZ|NONE (l_dobj) evidence_7\NN|.|evaluation (l_prep) of_8\IN|additional (l_pobj) association_10\NN|NONE (l_prep) with_11\IN|an (l_pobj) risk_14\NN|NONE (l_compound) cancer_13\NN|NONE
2173761
D018727_D013610 NONE blockade_25\VBP|NONE (l_conj) tachycardia_30\NN|beta|combined|but|prior|receptors
D020110_D007022 CID pinacidil_13\NN|and (r_conj) cromakalim_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|of (r_acl) Vasodilation_0\NN|by|were|abolished|not|. (l_prep) of_1\IN|induced (l_pobj) vessels_6\NNS|NONE (l_conj) hypotension_8\NN|coronary|large|and
D019806_D007022 CID cromakalim_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|of (r_acl) Vasodilation_0\NN|by|were|abolished|not|. (l_prep) of_1\IN|induced (l_pobj) vessels_6\NNS|NONE (l_conj) hypotension_8\NN|coronary|large|and
D000319_D013610 NONE blockade_25\VBP|NONE (l_conj) tachycardia_30\NN|beta|combined|but|prior|receptors
D018727_D007022 NONE blockade_25\VBP|NONE (r_pobj) by_17\IN|were|abolished|not|.|Vasodilation (r_agent) affected_16\VBN|NONE (l_nsubjpass) Vasodilation_0\NN|by|were|abolished|not|. (l_prep) of_1\IN|induced (l_pobj) vessels_6\NNS|NONE (l_conj) hypotension_8\NN|coronary|large|and
D019806_D013610 CID cromakalim_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|of (r_acl) Vasodilation_0\NN|by|were|abolished|not|. (r_nsubjpass) affected_16\VBN|NONE (l_agent) by_17\IN|were|abolished|not|.|Vasodilation (l_pobj) blockade_25\VBP|NONE (l_conj) tachycardia_30\NN|beta|combined|but|prior|receptors
D020110_D013610 CID pinacidil_13\NN|and (r_conj) cromakalim_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|of (r_acl) Vasodilation_0\NN|by|were|abolished|not|. (r_nsubjpass) affected_16\VBN|NONE (l_agent) by_17\IN|were|abolished|not|.|Vasodilation (l_pobj) blockade_25\VBP|NONE (l_conj) tachycardia_30\NN|beta|combined|but|prior|receptors
D000319_D007022 NONE blockade_25\VBP|NONE (r_pobj) by_17\IN|were|abolished|not|.|Vasodilation (r_agent) affected_16\VBN|NONE (l_nsubjpass) Vasodilation_0\NN|by|were|abolished|not|. (l_prep) of_1\IN|induced (l_pobj) vessels_6\NNS|NONE (l_conj) hypotension_8\NN|coronary|large|and
10390729
D011803_D006948 NONE quinine-_33\JJ| (r_npadvmod) sensitive_37\JJ|NONE (r_amod) K(+)-channels_38\NNPS|NONE (r_pobj) to_31\IN|be|to (r_prep) connected_30\VBN|whereas|hyperactivity (r_xcomp) seems_27\VBZ|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN|whereas|connected
D011803_D009069 NONE quinine-_33\JJ| (r_npadvmod) sensitive_37\JJ|NONE (r_amod) K(+)-channels_38\NNPS|NONE (r_pobj) to_31\IN|be|to (r_prep) connected_30\VBN|whereas|hyperactivity (r_xcomp) seems_27\VBZ|blockade|that|not|sufficient (r_advcl) is_13\VBZ|It|is|.|also (l_acomp) sufficient_15\JJ|blockade|that|seems|not (l_xcomp) prevent_17\VB|NONE (l_dobj) hypoactivity_21\NN|to
D009020_D006948 CID morphine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) hypoactivity_21\NN|neither|prevented|In|,|but (r_dobj) affected_17\VBD|NONE (l_conj) prevented_27\VBD|neither|hypoactivity|In|,|but (l_dobj) hyperactivity_32\NN|blockers|.
D009020_D006948 CID morphine_28\NN| (r_npadvmod) induced_30\VBN|secondary (r_amod) hyperactivity_32\NN|blockers|.
D009020_D006948 CID morphine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) hypoactivity_21\NN|to (r_dobj) prevent_17\VB|NONE (r_xcomp) sufficient_15\JJ|blockade|that|seems|not (r_acomp) is_13\VBZ|It|is|.|also (l_advcl) seems_27\VBZ|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN|whereas|connected
D009020_D006948 CID morphine_23\NN| (r_npadvmod) induced_25\VBN|NONE (r_amod) hyperactivity_26\NN|whereas|connected
D009020_D009069 NONE morphine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) hypoactivity_21\NN|neither|prevented|In|,|but
D009020_D009069 NONE morphine_28\NN| (r_npadvmod) induced_30\VBN|secondary (r_amod) hyperactivity_32\NN|blockers|. (r_dobj) prevented_27\VBD|neither|hypoactivity|In|,|but (r_conj) affected_17\VBD|NONE (l_dobj) hypoactivity_21\NN|neither|prevented|In|,|but
D009020_D009069 NONE morphine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) hypoactivity_21\NN|to
D009020_D009069 NONE morphine_23\NN| (r_npadvmod) induced_25\VBN|NONE (r_amod) hyperactivity_26\NN|whereas|connected (r_nsubj) seems_27\VBZ|blockade|that|not|sufficient (r_advcl) is_13\VBZ|It|is|.|also (l_acomp) sufficient_15\JJ|blockade|that|seems|not (l_xcomp) prevent_17\VB|NONE (l_dobj) hypoactivity_21\NN|to
D011188_D006948 NONE K(+)-channel_15\NNP|the (r_compound) blockers_16\NNS|NONE (r_pobj) of_13\IN|NONE (r_prep) neither_12\DT|prevented|hypoactivity|In|,|but (r_nsubj) affected_17\VBD|NONE (l_conj) prevented_27\VBD|neither|hypoactivity|In|,|but (l_dobj) hyperactivity_32\NN|blockers|.
D011188_D006948 NONE K(+)-channel_25\NNP|both (r_compound) blockers_26\NNS|.|hyperactivity (r_nsubj) prevented_27\VBD|neither|hypoactivity|In|,|but (l_dobj) hyperactivity_32\NN|blockers|.
D011188_D006948 NONE K(+)-channels_8\NNPS|NONE (r_pobj) of_7\IN|the (r_prep) blockade_6\NN|that|seems|not|sufficient (r_nsubj) is_13\VBZ|It|is|.|also (l_advcl) seems_27\VBZ|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN|whereas|connected
D011188_D006948 NONE K(+)-channels_38\NNPS|NONE (r_pobj) to_31\IN|be|to (r_prep) connected_30\VBN|whereas|hyperactivity (r_xcomp) seems_27\VBZ|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN|whereas|connected
D015761_D006948 NONE 4-aminopyridine_35\CD|NONE (r_punct) -_36\HYPH|quinine (r_punct) sensitive_37\JJ|NONE (r_amod) K(+)-channels_38\NNPS|NONE (r_pobj) to_31\IN|be|to (r_prep) connected_30\VBN|whereas|hyperactivity (r_xcomp) seems_27\VBZ|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN|whereas|connected
D011188_D009069 NONE K(+)-channel_15\NNP|the (r_compound) blockers_16\NNS|NONE (r_pobj) of_13\IN|NONE (r_prep) neither_12\DT|prevented|hypoactivity|In|,|but (r_nsubj) affected_17\VBD|NONE (l_dobj) hypoactivity_21\NN|neither|prevented|In|,|but
D011188_D009069 NONE K(+)-channel_25\NNP|both (r_compound) blockers_26\NNS|.|hyperactivity (r_nsubj) prevented_27\VBD|neither|hypoactivity|In|,|but (r_conj) affected_17\VBD|NONE (l_dobj) hypoactivity_21\NN|neither|prevented|In|,|but
D011188_D009069 NONE K(+)-channels_8\NNPS|NONE (r_pobj) of_7\IN|the (r_prep) blockade_6\NN|that|seems|not|sufficient (r_nsubj) is_13\VBZ|It|is|.|also (l_acomp) sufficient_15\JJ|blockade|that|seems|not (l_xcomp) prevent_17\VB|NONE (l_dobj) hypoactivity_21\NN|to
D011188_D009069 NONE K(+)-channels_38\NNPS|NONE (r_pobj) to_31\IN|be|to (r_prep) connected_30\VBN|whereas|hyperactivity (r_xcomp) seems_27\VBZ|blockade|that|not|sufficient (r_advcl) is_13\VBZ|It|is|.|also (l_acomp) sufficient_15\JJ|blockade|that|seems|not (l_xcomp) prevent_17\VB|NONE (l_dobj) hypoactivity_21\NN|to
D015761_D009069 NONE 4-aminopyridine_35\CD|NONE (r_punct) -_36\HYPH|quinine (r_punct) sensitive_37\JJ|NONE (r_amod) K(+)-channels_38\NNPS|NONE (r_pobj) to_31\IN|be|to (r_prep) connected_30\VBN|whereas|hyperactivity (r_xcomp) seems_27\VBZ|blockade|that|not|sufficient (r_advcl) is_13\VBZ|It|is|.|also (l_acomp) sufficient_15\JJ|blockade|that|seems|not (l_xcomp) prevent_17\VB|NONE (l_dobj) hypoactivity_21\NN|to
25119790
D003474_D007674 NONE Curcumin_0\NN|nephrotoxicity (r_nsubj) prevents_1\VBZ|NONE (l_dobj) nephrotoxicity_5\NN|Curcumin
D003474_D007674 NONE curcumin_8\NN|NONE (r_pobj) of_4\IN|against|The|potential|protective (r_prep) effect_3\NN|.|was (l_prep) against_20\IN|of|The|potential|protective (l_pobj) injury_23\NN|NONE
D003474_D007674 NONE curcumin_4\NN|that|able (r_nsubj) is_5\VBZ|It|.|is (l_acomp) able_6\JJ|that|curcumin (l_xcomp) attenuate_8\VB|NONE (l_prep) in_9\IN|to (l_pobj) nephropathy_14\NN|and|in
D005947_D007674 NONE glucose_20\NN|,|total (r_conj) protein_18\NN|NONE (r_pobj) of_16\IN|urinary|the (r_prep) excretion_15\NN|NONE (r_pobj) in_12\IN|in|and (r_conj) increase_6\NN|,|determined|injury (r_dobj) included_5\VBD|NONE (l_nsubj) injury_4\NN|,|determined|increase
D005947_D007674 NONE glucose_20\NN|,|total (r_conj) protein_18\NN|NONE (r_pobj) of_16\IN|urinary|the (r_prep) excretion_15\NN|NONE (r_pobj) in_12\IN|in|and (r_conj) increase_6\NN|,|determined|injury (r_dobj) included_5\VBD|NONE (l_conj) determined_75\VBN|,|injury|increase (l_nsubjpass) upregulation_45\NN|was|by|. (l_prep) of_46\IN|decrease (l_pobj) molecule_49\NN|NONE (l_compound) injury_48\NN|kidney
D005947_D009336 NONE glucose_20\NN|,|total (r_conj) protein_18\NN|NONE (r_pobj) of_16\IN|urinary|the (r_prep) excretion_15\NN|NONE (r_pobj) in_12\IN|in|and (r_conj) increase_6\NN|,|determined|injury (r_dobj) included_5\VBD|NONE (l_conj) determined_75\VBN|,|injury|increase (l_nsubjpass) upregulation_45\NN|was|by|. (l_parataxis) decrease_53\NN|of (l_prep) besides_61\IN|KIM)|,|apoptosis|(|and|in (l_prep) of_62\IN|NONE (l_pobj) necrosis_63\NN|NONE
C030272_D011507 CID maleate_12\NN|NONE (r_pobj) of_11\IN|a|single|in (r_prep) injection_10\NN|NONE (r_pobj) by_7\IN|proteinuria|.|were (r_agent) induced_6\VBN|NONE (l_nsubjpass) proteinuria_1\NN|by|.|were
D010100_D007674 NONE oxygen_16\NN|and|mitochondrial|of|activity (r_compound) consumption_17\NN|,|oxidative (r_conj) stress_13\NN|,|hemodynamic (r_conj) alterations_10\NNS|NONE (r_pobj) to_8\IN|NONE (r_prep) relation_7\NN|induced|: (r_appos) nephrotoxicity_5\NN|Curcumin
D012964_D009336 NONE sodium_22\NN|, (r_conj) glucose_20\NN|,|total (r_conj) protein_18\NN|NONE (r_pobj) of_16\IN|urinary|the (r_prep) excretion_15\NN|NONE (r_pobj) in_12\IN|in|and (r_conj) increase_6\NN|,|determined|injury (r_dobj) included_5\VBD|NONE (l_conj) determined_75\VBN|,|injury|increase (l_nsubjpass) upregulation_45\NN|was|by|. (l_parataxis) decrease_53\NN|of (l_prep) besides_61\IN|KIM)|,|apoptosis|(|and|in (l_prep) of_62\IN|NONE (l_pobj) necrosis_63\NN|NONE
C030272_D007674 CID maleate_2\NN| (r_npadvmod) induced_4\VBN|:|relation (r_amod) nephrotoxicity_5\NN|Curcumin
C030272_D007674 CID maleate_26\NN|NONE (r_pobj) by_25\IN|NONE (r_agent) induced_24\VBN|renal|the (r_acl) injury_23\NN|NONE
C030272_D007674 CID Maleate_0\NNP| (r_npadvmod) induced_2\VBN|renal (r_amod) injury_4\NN|,|determined|increase
C030272_D007674 CID Maleate_0\NNP| (r_npadvmod) induced_2\VBN|renal (r_amod) injury_4\NN|,|determined|increase (r_nsubj) included_5\VBD|NONE (l_conj) determined_75\VBN|,|injury|increase (l_nsubjpass) upregulation_45\NN|was|by|. (l_prep) of_46\IN|decrease (l_pobj) molecule_49\NN|NONE (l_compound) injury_48\NN|kidney
C030272_D007674 CID maleate_11\NN| (r_npadvmod) induced_13\VBN|vivo (r_amod) nephropathy_14\NN|and|in
C030272_D009336 CID Maleate_0\NNP| (r_npadvmod) induced_2\VBN|renal (r_amod) injury_4\NN|,|determined|increase (r_nsubj) included_5\VBD|NONE (l_conj) determined_75\VBN|,|injury|increase (l_nsubjpass) upregulation_45\NN|was|by|. (l_parataxis) decrease_53\NN|of (l_prep) besides_61\IN|KIM)|,|apoptosis|(|and|in (l_prep) of_62\IN|NONE (l_pobj) necrosis_63\NN|NONE
D012964_D007674 NONE sodium_22\NN|, (r_conj) glucose_20\NN|,|total (r_conj) protein_18\NN|NONE (r_pobj) of_16\IN|urinary|the (r_prep) excretion_15\NN|NONE (r_pobj) in_12\IN|in|and (r_conj) increase_6\NN|,|determined|injury (r_dobj) included_5\VBD|NONE (l_nsubj) injury_4\NN|,|determined|increase
D012964_D007674 NONE sodium_22\NN|, (r_conj) glucose_20\NN|,|total (r_conj) protein_18\NN|NONE (r_pobj) of_16\IN|urinary|the (r_prep) excretion_15\NN|NONE (r_pobj) in_12\IN|in|and (r_conj) increase_6\NN|,|determined|injury (r_dobj) included_5\VBD|NONE (l_conj) determined_75\VBN|,|injury|increase (l_nsubjpass) upregulation_45\NN|was|by|. (l_prep) of_46\IN|decrease (l_pobj) molecule_49\NN|NONE (l_compound) injury_48\NN|kidney
24434397
D014148_D051437 NONE acid_1\NN|induced|in|.|generalized (r_compound) seizure_6\NN|NONE (l_prep) in_7\IN|acid|induced|.|generalized (l_pobj) failure_9\NN|NONE
D014148_D012640 NONE acid_1\NN|induced|in|.|generalized (r_compound) seizure_6\NN|NONE
D014148_D012640 NONE TNA_14\NNP|NONE (r_pobj) of_13\IN|an (r_prep) overdose_12\NN|to (r_attr) be_10\VB|Thus|,|cause|was|. (r_xcomp) believed_8\VBN|NONE (l_nsubjpass) cause_4\NN|Thus|be|,|was|. (l_prep) of_5\IN|precipitating|the (l_pobj) convulsions_6\NNS|NONE
D014148_D004830 CID TNA_7\NNP|NONE (r_pobj) of_6\IN|sixth|the (r_prep) dose_5\NN|hours (r_pobj) after_2\IN|,|episode|.|she (r_prep) had_10\VBD|NONE (l_dobj) episode_12\NN|,|.|she|after (l_prep) of_13\IN|an (l_pobj) convulsions_17\NNS|NONE
D014148_D062787 NONE TNA_14\NNP|NONE (r_pobj) of_13\IN|an (r_prep) overdose_12\NN|to
D014148_D006470 NONE acid_1\NN|hourly|to|.|control|was (r_nsubjpass) administered_9\VBN|NONE (l_advcl) control_13\VB|hourly|to|.|acid|was (l_xcomp) bleeding_14\NN|to
D014148_D006470 NONE TNA_3\NNP|Tranexamic|g (r_appos) acid_1\NN|hourly|to|.|control|was (r_nsubjpass) administered_9\VBN|NONE (l_advcl) control_13\VB|hourly|to|.|acid|was (l_xcomp) bleeding_14\NN|to
8135424
D003975_D012640 CID diazepam_9\NN|mixed (r_compound) intoxications_10\NNS|NONE (r_pobj) in_5\IN|and|death (r_prep) seizures_2\NNS|.|Flumazenil
D003975_D012640 CID diazepam_17\NN|combined (r_compound) intoxications_18\NNS|NONE (r_pobj) of_13\IN|a (r_prep) model_12\NN|NONE (r_pobj) in_10\IN|incidence (r_prep) increase_5\VB|can|.|seizures|and|Flumazenil (r_conj) unmask_2\VB|NONE (l_dobj) seizures_3\NNS|can|.|increase|and|Flumazenil
D005442_D012640 CID Flumazenil_0\NNP|.|seizures (r_nsubj) induces_1\VBZ|NONE (l_dobj) seizures_2\NNS|.|Flumazenil
D005442_D012640 CID flumazenil_8\JJ|of (r_appos) Administration_3\NN|may|seizures (r_nsubj) unmask_10\VB|.|STUDY|: (l_dobj) seizures_11\NNS|may|Administration
D005442_D012640 CID Flumazenil_0\NNP|can|.|seizures|increase|and (r_nsubj) unmask_2\VB|NONE (l_dobj) seizures_3\NNS|can|.|increase|and|Flumazenil
D003042_D012640 CID cocaine_7\NN| (r_compound) diazepam_9\NN|mixed (r_compound) intoxications_10\NNS|NONE (r_pobj) in_5\IN|and|death (r_prep) seizures_2\NNS|.|Flumazenil
D003042_D012640 CID cocaine_14\NN| (r_compound) benzodiazepine_16\NN|mixed (r_amod) intoxication_17\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) seizures_11\NNS|may|Administration
D003042_D012640 CID cocaine_15\NN| (r_compound) diazepam_17\NN|combined (r_compound) intoxications_18\NNS|NONE (r_pobj) of_13\IN|a (r_prep) model_12\NN|NONE (r_pobj) in_10\IN|incidence (r_prep) increase_5\VB|can|.|seizures|and|Flumazenil (r_conj) unmask_2\VB|NONE (l_dobj) seizures_3\NNS|can|.|increase|and|Flumazenil
D001569_D012640 NONE benzodiazepine_6\JJ|the (r_amod) antagonist_7\NN|NONE (r_pobj) of_4\IN|flumazenil (r_prep) Administration_3\NN|may|seizures (r_nsubj) unmask_10\VB|.|STUDY|: (l_dobj) seizures_11\NNS|may|Administration
D001569_D012640 NONE benzodiazepine_16\NN|mixed (r_amod) intoxication_17\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) seizures_11\NNS|may|Administration
24333387
D013311_D020258 NONE Streptozotocin_12\NNP|NONE (r_pobj) in_11\IN|the|key (r_prep) events_10\NNS|impairment (r_nsubj) induced_16\VBN|neurotoxicity|:|Glial|.|and (r_acl) activation_1\NN|NONE (l_conj) neurotoxicity_6\NN|induced|:|Glial|.|and
D013311_D020258 NONE STZ_0\NNP|NONE (r_compound) treatment_1\NN|and|expression|remains|CaMKIIa|PSD (r_nsubj) showed_2\VBD|NONE (l_conj) remains_25\VBZ|and|expression|CaMKIIa|treatment|PSD (l_nsubj) neurotoxicity_31\NN|,|while|,|.|expression
D013311_D020258 NONE STZ_0\NNP|activation|. (r_nsubj) induced_1\VBN|NONE (l_dobj) activation_3\NN|STZ|. (l_conj) death_7\NN|,|glial (l_conj) post_9\VB|and|apoptotic|cell (l_dobj) neurotoxicity_11\NN|NONE
D013311_D020258 NONE STZ_16\NNP|NONE (r_pobj) in_15\IN|the|induced|key (r_prep) factors_14\NNS|that|activation (r_attr) are_11\VBP|clearly|study|. (l_nsubj) activation_6\NN|that|factors (l_conj) post_8\VB|glial|and (l_dobj) neurotoxicity_10\NN|NONE
D013311_D007249 CID STZ_0\NN|.|expression (r_nsubj) causes_1\VBZ|NONE (l_dobj) expression_3\NN|STZ|. (l_prep) of_4\IN|increased (l_pobj) GFAP_5\NNP|NONE (l_appos) activation_14\NN|CDb|,| (l_conj) neuroinflammation_16\NN|indicating|and|glial|a
D002118_D064420 NONE Ca(2_11\NNP|, (r_conj) nitrite_9\NN|, (r_appos) ROS_7\NNP|NONE (r_pobj) of_6\IN|the (r_prep) level_5\NN|significantly|and|STZ|reduced|)|also|. (r_dobj) increased_3\VBD|NONE (l_conj) reduced_15\VBD|significantly|and|STZ|)|also|.|level (l_dobj) activity_18\NN|NONE (l_prep) in_19\IN|mitochondrial|the (l_pobj) preparation_21\NN|NONE (l_acl) illustrating_22\VBG|synaptosomal (l_dobj) generation_25\NN|NONE (l_conj) excitotoxicity_27\NN|radical|free|and
D013311_D064420 NONE Streptozotocin_15\NNP|NONE (r_pobj) in_13\IN|toxicity|glial|and (r_prep) activation_8\NN|NONE (l_conj) toxicity_12\NN|glial|and|in
D013311_D064420 NONE STZ_17\NNP|ICV (r_appos) Streptozotocin_15\NNP|NONE (r_pobj) in_13\IN|toxicity|glial|and (r_prep) activation_8\NN|NONE (l_conj) toxicity_12\NN|glial|and|in
D013311_D064420 NONE STZ_0\NNP|significantly|and|reduced|)|also|.|level (r_nsubj) increased_3\VBD|NONE (l_conj) reduced_15\VBD|significantly|and|STZ|)|also|.|level (l_dobj) activity_18\NN|NONE (l_prep) in_19\IN|mitochondrial|the (l_pobj) preparation_21\NN|NONE (l_acl) illustrating_22\VBG|synaptosomal (l_dobj) generation_25\NN|NONE (l_conj) excitotoxicity_27\NN|radical|free|and
D009573_D064420 NONE nitrite_9\NN|, (r_appos) ROS_7\NNP|NONE (r_pobj) of_6\IN|the (r_prep) level_5\NN|significantly|and|STZ|reduced|)|also|. (r_dobj) increased_3\VBD|NONE (l_conj) reduced_15\VBD|significantly|and|STZ|)|also|.|level (l_dobj) activity_18\NN|NONE (l_prep) in_19\IN|mitochondrial|the (l_pobj) preparation_21\NN|NONE (l_acl) illustrating_22\VBG|synaptosomal (l_dobj) generation_25\NN|NONE (l_conj) excitotoxicity_27\NN|radical|free|and
D013311_D008569 CID Streptozotocin_12\NNP|NONE (r_pobj) in_11\IN|the|key (r_prep) events_10\NNS|impairment (r_nsubj) induced_16\VBN|neurotoxicity|:|Glial|.|and (l_dobj) impairment_18\NN|events
D013311_D008569 CID Streptozotocin_15\NNP|NONE (r_pobj) in_13\IN|toxicity|glial|and (r_prep) activation_8\NN|NONE (r_pobj) of_6\IN|the (r_prep) role_5\NN|the|present (r_dobj) study_3\NN|NONE (r_pobj) In_0\IN|.|explored (r_prep) induced_19\VBN|NONE (l_ccomp) explored_24\VBN|.|In (l_nsubjpass) rats_22\NNS|was (l_amod) impaired_21\VBN|NONE
D013311_D008569 CID STZ_17\NNP|ICV (r_appos) Streptozotocin_15\NNP|NONE (r_pobj) in_13\IN|toxicity|glial|and (r_prep) activation_8\NN|NONE (r_pobj) of_6\IN|the (r_prep) role_5\NN|the|present (r_dobj) study_3\NN|NONE (r_pobj) In_0\IN|.|explored (r_prep) induced_19\VBN|NONE (l_ccomp) explored_24\VBN|.|In (l_nsubjpass) rats_22\NNS|was (l_amod) impaired_21\VBN|NONE
D013311_D008569 CID STZ_21\NNP|days (r_pobj) after_20\IN|:|in|was|.|In|deficit (r_prep) found_9\VBN|NONE (l_nsubjpass) deficit_7\NN|:|in|was|.|In|after
D013311_D008569 CID STZ_16\NNP|NONE (r_pobj) in_15\IN|the|induced|key (r_prep) factors_14\NNS|that|activation (l_acl) induced_17\VBN|the|in|key (l_dobj) impairment_19\NN|NONE
24587916
D006861_D015431 NONE H2O2_11\NNP|significantly|and|increased (r_dobj) reduced_7\VBD|LF|.|loss|and (r_conj) prevented_1\VBD|NONE (l_dobj) loss_4\NN|LF|.|reduced|and
D003907_D006973 CID dexamethasone_6\NN| (r_npadvmod) induced_8\VBN|in (r_amod) hypertension_9\NN|NONE
D003907_D006973 CID Dexamethasone-_0\NNP|.|associated (r_nsubj) induced_4\VBN|NONE (l_ccomp) associated_7\VBN|.|Dexamethasone (l_nsubjpass) hypertension_5\NN|is|with
D003907_D006973 CID Dex-_2\NNP|NONE (r_appos) Dexamethasone-_0\NNP|.|associated (r_nsubj) induced_4\VBN|NONE (l_ccomp) associated_7\VBN|.|Dexamethasone (l_nsubjpass) hypertension_5\NN|is|with
D003907_D006973 CID Dex_19\NNP|NONE (r_compound) administration_20\NN|NONE (r_pobj) upon_18\IN|oxidative|and|hypertension (r_prep) stress_15\NN|NONE (l_conj) hypertension_17\NN|oxidative|and|upon
D003907_D006973 CID Dex_0\NNP| (r_npadvmod) induced_2\VBN|. (r_amod) hypertension_3\NN|NONE
D003907_D006973 CID Dex_18\NNP| (r_npadvmod) induced_20\VBN|NONE (r_amod) hypertension_21\NN|NONE
23952588
D007980_D004409 CID levodopa_5\NN| (r_npadvmod) induced_7\VBN|with|among (r_amod) dyskinesia_8\NN|NONE
D007980_D004409 CID levodopa_2\NN|pulsatile|Chronic|for (r_compound) therapy_3\NN|to|. (r_nsubj) leads_11\VBZ|NONE (l_prep) to_12\IN|therapy|. (l_pobj) development_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) fluctuations_17\NNS|NONE (l_conj) dyskinesia_19\NN|and|motor
D007980_D004409 CID levodopa_7\NN| (r_npadvmod) induced_9\VBN|among (r_amod) dyskinesia_10\NN|NONE
D007980_D004409 CID levodopa_13\NN|of|median (r_compound) therapy_14\NN|NONE (r_pobj) with_11\IN|in (r_prep) present_2\JJ|Dyskinesia|. (r_acomp) was_1\VBD|NONE (l_nsubj) Dyskinesia_0\NNP|.|present
D007980_D004409 CID levodopa_16\NN|NONE (r_compound) therapy_17\NN|NONE (r_pobj) of_15\IN|duration|.|dose|longer|,|, (r_prep) duration_14\NN|,|.|Patients|age (r_dobj) had_3\VBD|NONE (l_nsubj) Patients_0\NNS|,|.|duration|age (l_prep) with_1\IN|NONE (l_pobj) dyskinesia_2\JJ|NONE
D007980_D004409 CID levodopa_16\NN|NONE (r_compound) therapy_17\NN|NONE (r_pobj) of_15\IN|duration|.|dose|longer|,|, (r_prep) duration_14\NN|,|.|Patients|age (l_appos) dose_37\NN|duration|.|of|longer|,|, (l_conj) scores_48\NNS|and|.|total|higher|levodopa|, (l_appos) p_50\NN|(|total|higher|UPDRS (l_prep) than_54\IN|)|. (l_pobj) patients_55\NNS|NONE (l_prep) without_56\IN|NONE (l_pobj) dyskinesia_57\JJ|NONE
D007980_D004409 CID levodopa_36\NN|and|.|total|higher|scores|, (r_compound) dose_37\NN|duration|.|of|longer|,|, (r_appos) duration_14\NN|,|.|Patients|age (r_dobj) had_3\VBD|NONE (l_nsubj) Patients_0\NNS|,|.|duration|age (l_prep) with_1\IN|NONE (l_pobj) dyskinesia_2\JJ|NONE
D007980_D004409 CID levodopa_36\NN|and|.|total|higher|scores|, (r_compound) dose_37\NN|duration|.|of|longer|,|, (l_conj) scores_48\NNS|and|.|total|higher|levodopa|, (l_appos) p_50\NN|(|total|higher|UPDRS (l_prep) than_54\IN|)|. (l_pobj) patients_55\NNS|NONE (l_prep) without_56\IN|NONE (l_pobj) dyskinesia_57\JJ|NONE
D007980_D004409 CID levodopa_9\NN|,|age (r_compound) therapy_10\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) duration_7\NN|predictors|. (r_attr) were_6\VBD|NONE (l_nsubj) predictors_3\NNS|duration|. (l_prep) of_4\IN|three|The|significant (l_pobj) dyskinesia_5\JJ|NONE
D007980_D004409 CID levodopa_18\NN|total|daily (r_compound) dose_19\NN|onset|,|and (r_conj) age_13\NN|,|levodopa (r_conj) therapy_10\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) duration_7\NN|predictors|. (r_attr) were_6\VBD|NONE (l_nsubj) predictors_3\NNS|duration|. (l_prep) of_4\IN|three|The|significant (l_pobj) dyskinesia_5\JJ|NONE
D007980_D004409 CID levodopa_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) dyskinesia_6\NN|NONE
D007980_D010300 NONE levodopa_5\NN| (r_npadvmod) induced_7\VBN|with|among (r_amod) dyskinesia_8\NN|NONE (l_prep) with_12\IN|induced|among (l_pobj) disease_15\NN|NONE
D007980_D010300 NONE levodopa_2\NN|pulsatile|Chronic|for (r_compound) therapy_3\NN|to|. (l_prep) for_4\IN|pulsatile|levodopa|Chronic (l_pobj) disease_7\NN|NONE
D007980_D010300 NONE levodopa_2\NN|pulsatile|Chronic|for (r_compound) therapy_3\NN|to|. (l_prep) for_4\IN|pulsatile|levodopa|Chronic (l_pobj) disease_7\NN|NONE (l_appos) PD_9\NNP|(|Parkinson|)
D007980_D010300 NONE levodopa_7\NN| (r_npadvmod) induced_9\VBN|among (r_amod) dyskinesia_10\NN|NONE (l_prep) among_11\IN|induced (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|multiethnic|Malaysian (l_pobj) PD_16\NNP|NONE
D007980_D010300 NONE levodopa_14\NN|uninterrupted (r_compound) therapy_15\NN|NONE (r_pobj) on_12\IN||with (r_prep) patients_9\NNS|for (l_prep) with_10\IN|on| (l_pobj) PD_11\NNP|NONE
24588023
D014148_D012640 CID acid_4\NN|NONE (l_conj) seizures_7\NNS|tranexamic|and (l_amod) convulsive_6\JJ|NONE
D014148_D012640 CID acid_4\NN|NONE (l_conj) seizures_7\NNS|tranexamic|and
D014148_D012640 CID acid_37\NN|NONE (r_pobj) of_30\IN|NONE (r_prep) duration_29\NN|circulatory|deep|,|hypothermic (r_conj) arrest_27\NN|heart|,|congestive (r_conj) failure_22\NN|of|, (r_conj) calcification_15\NN|cardiac|, (r_conj) surgery_13\NN|NONE (r_dobj) redo_11\VB|age|predictors|. (r_conj) included_5\VBD|NONE (l_nsubj) predictors_1\NNS|age|redo|. (l_prep) of_2\IN|Independent (l_pobj) seizures_4\NNS|NONE
D014148_D012640 CID acid_9\NN|)|,|tested|.|predictor (r_nsubj) was_10\VBD|NONE (l_attr) predictor_14\NN|)|,|acid|tested|. (l_prep) of_15\IN|strong|a|independent|. (l_pobj) seizures_16\NNS|NONE
D014148_D012640 CID acid_2\NN|As|factor (r_nsubj) is_3\VBZ|be|administration|,|against|should|. (r_advcl) weighed_22\VBN|NONE (l_prep) against_23\IN|be|administration|,|is|should|. (l_pobj) risk_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) seizures_28\NNS|NONE
D014148_D007035 NONE acid_37\NN|NONE (r_pobj) of_30\IN|NONE (r_prep) duration_29\NN|circulatory|deep|,|hypothermic (r_conj) arrest_27\NN|heart|,|congestive (l_amod) hypothermic_25\JJ|duration|circulatory|deep|,
D014148_D006333 NONE acid_37\NN|NONE (r_pobj) of_30\IN|NONE (r_prep) duration_29\NN|circulatory|deep|,|hypothermic (r_conj) arrest_27\NN|heart|,|congestive (r_conj) failure_22\NN|of|,
24040781
D016559_D011507 NONE tacrolimus_31\NN|NONE (r_pobj) from_30\IN|NONE (r_prep) conversion_29\NN|NONE (r_pobj) after_28\IN|proteinuria|who (r_prep) developed_26\VBD|undetermined (l_dobj) proteinuria_27\NN|after|who
D020123_D011507 NONE rapamycin_13\NNS|i|)|( (r_amod) inhibitors_14\NNS|NONE (r_pobj) of_12\IN|mammalian (r_prep) target_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treated_8\VBN|in|an|expected (r_acl) complication_4\NN|.|Proteinuria (r_attr) is_1\VBZ|NONE (l_nsubj) Proteinuria_0\NNP|.|complication
D016559_D000686 NONE tacrolimus_31\NN|NONE (r_pobj) from_30\IN|NONE (r_prep) conversion_29\NN|NONE (r_pobj) after_28\IN|proteinuria|who (r_prep) developed_26\VBD|undetermined (r_relcl) significance_24\NN|NONE (r_pobj) of_22\IN|transplant|monoclonal (r_prep) gammapathy_21\JJ|NONE (r_pobj) with_16\IN|transplant|a (r_prep) patient_15\NN|NONE (r_pobj) in_10\IN|the|unexpected|of (r_prep) diagnosis_7\NN|In|.|we (l_prep) of_8\IN|in|the|unexpected (l_pobj) amyloidosis_9\NN|NONE
C107135_D011507 CID everolimus_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|:|An|.|unexpected|in|amyloidosis (r_acl) diagnosis_2\NN|NONE (l_prep) in_3\IN|:|An|.|unexpected|treated|amyloidosis (l_pobj) patient_8\NN|NONE (l_prep) with_9\IN|a|transplant (l_pobj) proteinuria_10\NN|NONE
C107135_D011507 CID everolimus_33\NN|NONE (r_pobj) to_32\IN|NONE (r_prep) tacrolimus_31\NN|NONE (r_pobj) from_30\IN|NONE (r_prep) conversion_29\NN|NONE (r_pobj) after_28\IN|proteinuria|who (r_prep) developed_26\VBD|undetermined (l_dobj) proteinuria_27\NN|after|who
C107135_D000686 CID everolimus_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|:|An|.|unexpected|in|amyloidosis (r_acl) diagnosis_2\NN|NONE (l_appos) amyloidosis_16\NN|:|An|.|unexpected|in|treated (l_compound) AL_15\NNP|NONE
C107135_D000686 CID everolimus_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|:|An|.|unexpected|in|amyloidosis (r_acl) diagnosis_2\NN|NONE (l_appos) amyloidosis_16\NN|:|An|.|unexpected|in|treated
C107135_D000686 CID everolimus_33\NN|NONE (r_pobj) to_32\IN|NONE (r_prep) tacrolimus_31\NN|NONE (r_pobj) from_30\IN|NONE (r_prep) conversion_29\NN|NONE (r_pobj) after_28\IN|proteinuria|who (r_prep) developed_26\VBD|undetermined (r_relcl) significance_24\NN|NONE (r_pobj) of_22\IN|transplant|monoclonal (r_prep) gammapathy_21\JJ|NONE (r_pobj) with_16\IN|transplant|a (r_prep) patient_15\NN|NONE (r_pobj) in_10\IN|the|unexpected|of (r_prep) diagnosis_7\NN|In|.|we (l_prep) of_8\IN|in|the|unexpected (l_pobj) amyloidosis_9\NN|NONE
6728873
D002110_D012640 CID caffeine_28\NN|in|under|various (r_compound) doses_29\NNS|NONE (r_pobj) at_26\IN|characteristics|were|. (r_prep) scored_25\VBN|NONE (l_nsubjpass) characteristics_2\NNS|were|at|. (l_acl) righting_7\VBG|phenotypic||activity|Five| (l_dobj) ability_8\NN|NONE (l_conj) induction_12\NN|, (l_compound) seizure_11\NN|,|lethality
-1_D064420 NONE alkylxanthines_8\NNS|NONE (r_pobj) of_7\IN|behavioral|in|toxicity (r_prep) testing_6\NN|misleading|may|that (l_compound) toxicity_5\NN|behavioral|in|of
3375885
D005438_D006947 NONE fludrocortisone_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) reversed_7\VBN|Hyperkalemia|and|.|by (r_conj) induced_1\VBN|NONE (l_nsubj) Hyperkalemia_0\NNP|reversed|and|.|by
D005438_D006947 NONE fludrocortisone_13\NN|,|was|.|correcting|,|was (r_nsubjpass) added_15\VBN|NONE (l_advcl) correcting_17\VBG|,|was|fludrocortisone|.|,|was (l_dobj) hyperkalemia_19\NN|allowing|and
D011453_D007674 NONE prostaglandin_17\JJ|synthetase (r_amod) inhibitors_19\NNS|NONE (r_pobj) with_16\IN|to|acidosis (r_prep) type_11\VB|that|disease|patient (r_advcl) predisposed_7\VBD|NONE (l_nsubj) disease_6\NN|that|type|patient
D008528_D006947 NONE acid_14\NN|caused|mefenamic (r_compound) nephropathy_15\NN|NONE (l_relcl) caused_23\VBN|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN|in|,|by|were|without
D008528_D006994 NONE acid_14\NN|caused|mefenamic (r_compound) nephropathy_15\NN|NONE (l_relcl) caused_23\VBN|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN|in|,|by|were|without (l_conj) hypoaldosteronism_21\NN|inappropriate|and
D008528_D007674 CID acid_14\NN|caused|mefenamic (r_compound) nephropathy_15\NN|NONE
D009288_D001172 NONE naproxen_28\NN|both|and (r_conj) indomethacin_26\NN|NONE (r_pobj) by_24\IN|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN|acid|mefenamic (r_relcl) nephropathy_15\NN|NONE (r_pobj) of_12\IN|a (r_prep) history_11\NN|rheumatoid|severe|and (r_conj) arthritis_8\NN|NONE
D011453_D006994 NONE prostaglandin_17\JJ|synthetase (r_amod) inhibitors_19\NNS|NONE (r_pobj) with_16\IN|to|acidosis (r_prep) type_11\VB|that|disease|patient (l_dobj) acidosis_15\NN|to|with
D009288_D006947 CID naproxen_5\NN|and (r_conj) indomethacin_3\NN|NONE (r_pobj) by_2\IN|reversed|Hyperkalemia|and|. (r_prep) induced_1\VBN|NONE (l_nsubj) Hyperkalemia_0\NNP|reversed|and|.|by
D009288_D006947 CID naproxen_28\NN|both|and (r_conj) indomethacin_26\NN|NONE (r_pobj) by_24\IN|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN|in|,|by|were|without
D007213_D006947 CID indomethacin_3\NN|NONE (r_pobj) by_2\IN|reversed|Hyperkalemia|and|. (r_prep) induced_1\VBN|NONE (l_nsubj) Hyperkalemia_0\NNP|reversed|and|.|by
D007213_D006947 CID indomethacin_26\NN|NONE (r_pobj) by_24\IN|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN|in|,|by|were|without
D007213_D006947 CID indomethacin_22\NN|NONE (r_compound) therapy_23\NN|safely|to|be (r_nsubjpass) continued_26\VBN|NONE (r_ccomp) allowing_21\VBG|hyperkalemia|and (r_conj) correcting_17\VBG|,|was|fludrocortisone|.|,|was (l_dobj) hyperkalemia_19\NN|allowing|and
D007213_D007674 NONE indomethacin_26\NN|NONE (r_pobj) by_24\IN|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN|acid|mefenamic (r_relcl) nephropathy_15\NN|NONE
D009288_D007674 NONE naproxen_28\NN|both|and (r_conj) indomethacin_26\NN|NONE (r_pobj) by_24\IN|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN|acid|mefenamic (r_relcl) nephropathy_15\NN|NONE
D008528_D001172 NONE acid_14\NN|caused|mefenamic (r_compound) nephropathy_15\NN|NONE (r_pobj) of_12\IN|a (r_prep) history_11\NN|rheumatoid|severe|and (r_conj) arthritis_8\NN|NONE
D007213_D001172 NONE indomethacin_26\NN|NONE (r_pobj) by_24\IN|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN|acid|mefenamic (r_relcl) nephropathy_15\NN|NONE (r_pobj) of_12\IN|a (r_prep) history_11\NN|rheumatoid|severe|and (r_conj) arthritis_8\NN|NONE
D007213_D006994 CID indomethacin_26\NN|NONE (r_pobj) by_24\IN|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN|in|,|by|were|without (l_conj) hypoaldosteronism_21\NN|inappropriate|and
D009288_D006994 CID naproxen_28\NN|both|and (r_conj) indomethacin_26\NN|NONE (r_pobj) by_24\IN|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN|in|,|by|were|without (l_conj) hypoaldosteronism_21\NN|inappropriate|and
9538487
D008094_D001714 NONE lithium_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|manic (r_acl) depression_12\NN|NONE
D005947_D018500 NONE glucose_11\NN|normal (r_compound) concentrations_12\NNS|NONE (r_pobj) despite_8\IN|he|After|,|polyuric (r_prep) remained_6\VBD|insipidus|testing|,|likely|;|. (r_ccomp) indicated_17\VBD|NONE (l_dobj) insipidus_20\NN|testing|remained|,|likely|;|.
D005947_-1 NONE glucose_11\NN|normal (r_compound) concentrations_12\NNS|NONE (r_pobj) despite_8\IN|he|After|,|polyuric (r_prep) remained_6\VBD|insipidus|testing|,|likely|;|. (l_prep) After_0\IN|he|,|polyuric|despite (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hyperglycaemia_3\NN|NONE
D008094_D006944 CID lithium_5\NN| (r_npadvmod) induced_7\VBN|diabetes (r_amod) insipidus_10\NN|NONE (r_pobj) by_4\IN|.|coma (r_agent) precipitated_3\VBD|NONE (l_nsubj) coma_2\NN|by|.
D008094_D006944 CID lithium_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|manic (r_acl) depression_12\NN|NONE (r_pobj) of_10\IN|a|year (r_prep) history_9\NN|NONE (r_pobj) with_6\IN|coma|man|.|,|with|,|was|, (r_prep) admitted_18\VBN|NONE (l_npadvmod) coma_23\NN|man|with|.|,|with|,|was|,
D008094_-1 NONE lithium_25\NN| (r_npadvmod) induced_27\VBN|to (r_acomp) be_24\VB|NONE (r_xcomp) likely_22\JJ|insipidus|testing|remained|,|;|. (r_amod) indicated_17\VBD|NONE (l_ccomp) remained_6\VBD|insipidus|testing|,|likely|;|. (l_prep) After_0\IN|he|,|polyuric|despite (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hyperglycaemia_3\NN|NONE
D008094_D011141 CID lithium_25\NN| (r_npadvmod) induced_27\VBN|to (r_acomp) be_24\VB|NONE (r_xcomp) likely_22\JJ|insipidus|testing|remained|,|;|. (r_amod) indicated_17\VBD|NONE (l_ccomp) remained_6\VBD|insipidus|testing|,|likely|;|. (l_acomp) polyuric_7\JJ|he|After|,|despite
D008094_D018500 CID lithium_5\NN| (r_npadvmod) induced_7\VBN|diabetes (r_amod) insipidus_10\NN|NONE
D008094_D018500 CID lithium_25\NN| (r_npadvmod) induced_27\VBN|to (r_acomp) be_24\VB|NONE (r_xcomp) likely_22\JJ|insipidus|testing|remained|,|;|. (r_amod) indicated_17\VBD|NONE (l_dobj) insipidus_20\NN|testing|remained|,|likely|;|.
D005947_D011141 NONE glucose_20\NN|NONE (r_pobj) for_19\IN|NONE (r_prep) negative_18\JJ|during|urinalysis|had (r_acomp) been_17\VBN|year|of|,|a (r_relcl) history_6\NN|.|He (l_prep) of_7\IN|year|,|been|a (l_pobj) polyuria_8\NN|NONE
D005947_D011141 NONE glucose_11\NN|normal (r_compound) concentrations_12\NNS|NONE (r_pobj) despite_8\IN|he|After|,|polyuric (r_prep) remained_6\VBD|insipidus|testing|,|likely|;|. (l_acomp) polyuric_7\JJ|he|After|,|despite
D005947_D059606 NONE glucose_20\NN|NONE (r_pobj) for_19\IN|NONE (r_prep) negative_18\JJ|during|urinalysis|had (r_acomp) been_17\VBN|year|of|,|a (r_relcl) history_6\NN|.|He (l_prep) of_7\IN|year|,|been|a (l_pobj) polyuria_8\NN|NONE (l_conj) polydipsia_10\NN|and
2239937
D002119_D006934 CID carbonate_8\NN|calcium (r_compound) therapy_9\NN|NONE (r_pobj) on_6\IN|hemodialysis (r_prep) patients_5\NNS|NONE (r_pobj) in_3\IN|NONE (r_prep) hypercalcemia_2\NN|NONE
D002119_D006934 CID carbonate_15\NN|NONE (r_pobj) to_13\IN|as (r_prep) switching_12\VBG|NONE (r_pcomp) after_11\IN|patients|.|hypercalcemic (r_prep) became_9\VBD|NONE (l_acomp) hypercalcemic_10\JJ|patients|after|.
D010710_D006934 NONE phosphate_19\NN|their|principal (r_compound) binder_20\NN|NONE (r_pobj) as_16\IN|to (r_prep) switching_12\VBG|NONE (r_pcomp) after_11\IN|patients|.|hypercalcemic (r_prep) became_9\VBD|NONE (l_acomp) hypercalcemic_10\JJ|patients|after|.
D002118_D007674 NONE calcium_17\NN|rate|intestinal|and (r_compound) reabsorption_18\NN|NONE (r_pobj) of_15\IN|indirect|in (r_prep) parameters_14\NNS|risk|,|associated (r_appos) factors_5\NNS|to (r_dobj) identify_3\VB|NONE (r_acl) order_1\NN|NONE (r_pobj) In_0\IN|were|.|with (r_prep) compared_28\VBN|NONE (l_prep) with_29\IN|were|.|In (l_pobj) results_30\NNS|NONE (l_prep) in_31\IN|NONE (l_pobj) patients_34\NNS|NONE (l_acl) matched_35\VBN||eucalcemic (l_prep) for_36\IN|NONE (l_pobj) age_37\NN|NONE (l_conj) sex_39\NN|, (l_conj) length_41\NN|, (l_conj) etiology_48\NN|and|on|,|of (l_prep) of_49\IN|NONE (l_pobj) disease_51\NN|NONE
D002118_D006934 NONE calcium_17\NN|rate|intestinal|and (r_compound) reabsorption_18\NN|NONE (r_pobj) of_15\IN|indirect|in (r_prep) parameters_14\NNS|risk|,|associated (r_appos) factors_5\NNS|to (l_acl) associated_6\VBN|risk|parameters|, (l_prep) with_7\IN|NONE (l_pobj) development_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypercalcemia_11\NN|NONE
D002118_D006934 NONE calcium_8\NN|of|peak (r_compound) values_9\NNS|NONE (r_pobj) with_6\IN|hypercalcemic (r_prep) episodes_5\NNS|NONE (l_amod) hypercalcemic_4\JJ|with
D002118_D006934 NONE calcium_8\NN|of|peak (r_compound) values_9\NNS|NONE (r_pobj) with_6\IN|hypercalcemic (r_prep) episodes_5\NNS|NONE (r_dobj) experiencing_3\VBG|NONE (r_pcomp) to_2\IN|NONE (r_prep) addition_1\NN|NONE (r_pobj) In_0\IN|patients|,|increase|. (r_prep) exhibited_31\VBD|NONE (l_nsubj) patients_26\NNS|,|In|increase|. (l_prep) in_27\IN|NONE (l_pobj) group_30\NN|NONE (l_amod) hypercalcemic_29\NN|the
D002118_D006934 NONE calcium_38\NN|mean|the (r_compound) concentration_39\NN|NONE (r_pobj) in_35\IN|a|,|compared|obtained|significant (r_prep) increase_34\NN|patients|,|In|. (r_dobj) exhibited_31\VBD|NONE (l_prep) In_0\IN|patients|,|increase|. (l_pobj) addition_1\NN|NONE (l_prep) to_2\IN|NONE (l_pcomp) experiencing_3\VBG|NONE (l_dobj) episodes_5\NNS|NONE (l_amod) hypercalcemic_4\JJ|with
D002118_D006934 NONE calcium_38\NN|mean|the (r_compound) concentration_39\NN|NONE (r_pobj) in_35\IN|a|,|compared|obtained|significant (r_prep) increase_34\NN|patients|,|In|. (r_dobj) exhibited_31\VBD|NONE (l_nsubj) patients_26\NNS|,|In|increase|. (l_prep) in_27\IN|NONE (l_pobj) group_30\NN|NONE (l_amod) hypercalcemic_29\NN|the
2625524
D000661_D012640 CID amphetamine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) seizures_7\NNS|to
D000661_D012640 CID amphetamine_18\NN|dose (r_compound) exposure_19\NN|NONE (r_pobj) from_14\IN|NONE (r_prep) death_13\NN|NONE (r_pobj) against_12\IN|dopamine|haloperidol|the (r_prep) blocker_10\NN|NONE (r_pobj) for_6\IN|protective|a|without (r_prep) role_5\NN|.|data (l_prep) without_20\IN|protective|for|a (l_pcomp) reducing_21\VBG|NONE (l_dobj) incidence_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) seizures_25\NNS|NONE
D006220_D012640 NONE Haloperidol_0\NNP|lower|prevent|,|but|. (r_nsubj) failed_1\VBD|NONE (l_xcomp) prevent_3\VB|lower|Haloperidol|,|but|. (l_dobj) seizures_7\NNS|to
D006220_D012640 NONE Haloperidol_0\NN|incidence|at|but|,|reach (r_nsubj) decreased_1\VBD|NONE (l_dobj) incidence_3\NN|at|but|Haloperidol|,|reach (l_prep) of_4\IN|the (l_pobj) seizures_8\NNS|NONE
D006220_D012640 NONE haloperidol_11\NN|dopamine|against|the (r_appos) blocker_10\NN|NONE (r_pobj) for_6\IN|protective|a|without (r_prep) role_5\NN|.|data (l_prep) without_20\IN|protective|for|a (l_pcomp) reducing_21\VBG|NONE (l_dobj) incidence_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) seizures_25\NNS|NONE
D006220_D012640 NONE haloperidol_3\NN|ability|In|.|, (r_nsubj) demonstrated_4\VBD|NONE (l_dobj) ability_6\NN|In|.|,|haloperidol (l_acl) reduce_8\VB|an (l_dobj) seizures_12\NNS|to|without
D004298_D012640 NONE dopamine_9\NN|haloperidol|against|the (r_compound) blocker_10\NN|NONE (r_pobj) for_6\IN|protective|a|without (r_prep) role_5\NN|.|data (l_prep) without_20\IN|protective|for|a (l_pcomp) reducing_21\VBG|NONE (l_dobj) incidence_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) seizures_25\NNS|NONE
D003042_D012640 CID cocaine_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) seizures_8\NNS|NONE
D003042_D012640 CID cocaine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) seizures_12\NNS|to|without
11299446
C027429_D010302 CID veralipride_7\NN|NONE (r_pobj) of_6\IN|the (r_prep) use_5\NN|NONE (r_pobj) after_3\IN|of (r_prep) Worsening_0\VBG|.|case|: (l_prep) of_1\IN|after (l_pobj) Parkinsonism_2\NN|NONE
C027429_D010302 CID veralipride_27\NN|NONE (r_pobj) with_26\IN|related (r_prep) symptoms_25\NNS|of (r_appos) therapy_21\NN|NONE (r_pobj) following_20\VBG|has|worsening|who (r_prep) shown_12\VBN|Parkinson|stable (r_relcl) disease_9\NN|NONE
3831029
C037293_D001145 NONE denopamine_8\NN|NONE (r_pobj) of_7\IN|these (r_prep) doses_6\NNS|NONE (r_pobj) by_4\IN|arrhythmias|were|. (r_agent) induced_3\VBN|NONE (l_nsubjpass) arrhythmias_1\NNS|were|.|by
C037293_D006333 NONE denopamine_2\NN|NONE (r_pobj) by_1\IN|of|. (r_prep) Improvement_0\NN|NONE (l_prep) of_6\IN|.|by (l_pobj) failure_11\NN|)
C037293_D006333 NONE TA-064_4\NNP|NONE (r_punct) )_5\-RRB-|failure (r_punct) of_6\IN|.|by (l_pobj) failure_11\NN|)
C037293_D006333 NONE denopamine_3\NN|NONE (r_pobj) of_2\IN|,|agonist|The|, (r_prep) efficacy_1\NN|in|.|was|in (r_nsubjpass) assessed_17\VBN|NONE (l_prep) in_12\IN|efficacy|.|was|in (l_pcomp) improving_13\VBG|NONE (l_dobj) failure_15\NN|NONE
C037293_D006333 NONE denopamine_6\NN|NONE (r_pobj) of_5\IN|clinical|in (r_prep) trials_4\NNS|results|. (l_prep) in_7\IN|clinical|of (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) failure_12\NN|NONE
D010424_D006333 CID pentobarbital_7\NN| (r_npadvmod) induced_9\VBN|in|cardiac (r_amod) failure_11\NN|)
2974281
D007545_D006332 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|rat|in|heart (r_amod) hypertrophy_13\NN|NONE
D007545_D006332 CID isoproterenol_9\NN| (r_npadvmod) induced_11\VBN|in|heart (r_amod) hypertrophy_13\NN|NONE
D007545_D006332 CID isoproterenol_24\NN|to|from (r_dobj) prevent_23\VB|/|potency (l_prep) from_25\IN|isoproterenol|to (l_pcomp) producing_26\VBG|NONE (l_dobj) hypertrophy_28\NN|NONE
D009952_D006332 NONE ornithine_7\NN|NONE (r_compound) decarboxylase_8\NN|the|increased|with (r_compound) activity_9\NN|to (l_prep) with_10\IN|decarboxylase|the|increased (l_pobj) blockers_14\NNS|NONE (l_prep) in_15\IN|both||beta (l_pobj) hearts_17\NNS|NONE
D011433_D006332 NONE propranolol_3\NN|NONE (r_pobj) of_2\IN|.|Subacute|on (r_prep) effects_1\NNS|NONE (l_prep) on_7\IN|of|.|Subacute (l_pobj) hypertrophy_13\NN|NONE
D011433_D006332 NONE propranolol_15\NN|any (l_conj) have_19\VBP|that|blockers|and (l_advcl) prevent_23\VB|/|potency (l_prep) from_25\IN|isoproterenol|to (l_pcomp) producing_26\VBG|NONE (l_dobj) hypertrophy_28\NN|NONE
D011433_D006984 NONE propranolol_1\NN|could|changes|. (r_csubj) stop_6\VB|NONE (l_dobj) changes_8\NNS|could|.|propranolol (l_prep) in_9\IN|the (l_pobj) pattern_14\NN|myosin (l_prep) of_15\IN|isoenzyme (l_pobj) heart_19\NN|NONE (l_amod) hypertrophied_17\JJ|the|rat
24100257
C089750_D054549 CID Zolmitriptan_10\NNP|NONE (r_pobj) to_9\IN|NONE (r_prep) secondary_8\JJ|)|.|ballooning (r_amod) syndrome_6\NN|Takotsubo|(|or (r_conj) syndrome_1\NN|NONE
C089750_D054549 CID Zolmitriptan_10\NNP|NONE (r_pobj) to_9\IN|NONE (r_prep) secondary_8\JJ|)|.|ballooning (r_amod) syndrome_6\NN|Takotsubo|(|or
C089750_D054549 CID zolmitriptan_12\NN|secondary|artery (r_advcl) vasospasm_9\NN|NONE (r_pobj) of_6\IN|multiple (r_prep) cases_5\NNS|search|but|,|associated (r_dobj) revealed_3\VBD|NONE (l_conj) associated_20\VBN|search|but|,|cases (l_prep) with_21\IN|none|were|. (l_pobj) TS_22\NNP|NONE
C089750_D008881 NONE zolmitriptan_9\NN|patient|that|had|sparingly (r_dobj) took_8\VBD|history|.|retrospectively (l_advcl) had_14\VBD|patient|that|zolmitriptan|sparingly (l_dobj) migraines_15\NNS|when|she|only
C089750_D008881 NONE zolmitriptan_8\JJ|daily|before|But|for||.|because|she|was|, (r_dobj) taking_7\VBG|NONE (l_prep) because_17\IN|daily|before|But|zolmitriptan|for||.|she|was|, (l_pobj) headache_22\NN|of
C089750_D003329 CID zolmitriptan_12\NN|secondary|artery (r_advcl) vasospasm_9\NN|NONE
15987266
D010862_D013226 CID pilocarpine_46\NN|NONE (r_pobj) by_45\IN|epilepticus (r_agent) induced_44\VBN|of|(|densitometry|the (l_amod) epilepticus_43\NN|by
D010862_D013226 CID Pilo_48\NNP|NONE (r_appos) pilocarpine_46\NN|NONE (r_pobj) by_45\IN|epilepticus (r_agent) induced_44\VBN|of|(|densitometry|the (l_amod) epilepticus_43\NN|by
D003513_D013226 NONE cycloheximide_56\NN|not (r_pobj) with_55\IN|CHX|or|previously (r_conj) injected_52\VBN|investigate|,|,|we|intensity|. (r_conj) assessed_13\VBD|NONE (l_dobj) intensity_15\NN|investigate|,|,|we|injected|. (l_acl) induced_44\VBN|of|(|densitometry|the (l_amod) epilepticus_43\NN|by
D003513_D013226 NONE CHX_58\NNP|or|with|previously (r_appos) injected_52\VBN|investigate|,|,|we|intensity|. (r_conj) assessed_13\VBD|NONE (l_dobj) intensity_15\NN|investigate|,|,|we|injected|. (l_acl) induced_44\VBN|of|(|densitometry|the (l_amod) epilepticus_43\NN|by
D003513_D004827 NONE cycloheximide_16\NN|NONE (r_pobj) with_15\IN|expression|. (r_prep) treated_14\VBN|NONE (l_nsubj) expression_5\NN|.|with (l_prep) in_6\IN||protein (l_pobj) layer_9\NN|NONE (l_prep) of_10\IN|molecular|hippocampal (l_pobj) rats_13\NNS|NONE (l_amod) epileptic_12\JJ|chronic
19728177
D000082_D001929 CID acetaminophen_27\NN|NONE (r_pobj) from_26\IN|care|and|a|in (r_prep) facility_17\NN|NONE (r_pobj) in_13\IN|.|edema|based|from (r_prep) observations_3\NNS|NONE (l_conj) edema_31\NN|.|in|based|from
D000082_D001929 CID acetaminophen_5\NN|NONE (l_conj) edema_8\NN|and
D000082_D001929 CID acetaminophen_8\NN|NONE (r_compound) overdose_9\NN|NONE (r_pobj) from_7\IN|cerebral (r_prep) edema_6\NN|and
D000082_D062787 NONE acetaminophen_8\NN|NONE (r_compound) overdose_9\NN|NONE
D000082_D017114 CID acetaminophen_27\NN|NONE (r_pobj) from_26\IN|care|and|a|in (r_prep) facility_17\NN|NONE (l_prep) in_18\IN|care|and|from|a (l_pobj) female_23\NN|NONE (l_prep) with_24\IN|a|old (l_pobj) FHF_25\NNP|NONE
D000082_D017114 CID acetaminophen_5\NN|NONE (r_pobj) from_4\IN|.|FHF|evaluation (r_prep) confirmed_2\VBN|NONE (l_dobj) FHF_3\NNP|.|evaluation|from
D000082_D017114 CID acetaminophen_8\NN|NONE (r_compound) overdose_9\NN|NONE (r_pobj) from_7\IN|cerebral (r_prep) edema_6\NN|and (r_conj) FHF_3\NNP|NONE
D000082_D007035 NONE acetaminophen_8\NN|NONE (r_compound) overdose_9\NN|NONE (r_pobj) from_7\IN|cerebral (r_prep) edema_6\NN|and (r_conj) FHF_3\NNP|NONE (r_pobj) with_2\IN|NONE (r_prep) patients_1\NNS|NONE (r_pobj) In_0\IN|hypothermia|potentially|be|could|.|,|as (r_prep) used_17\VBN|NONE (l_nsubjpass) hypothermia_13\NN|potentially|be|could|.|In|,|as
D000082_D064420 NONE acetaminophen_16\NN|NONE (r_pobj) from_15\IN|ingested|presumed (r_prep) toxicity_14\NN|NONE
19531695
D005424_D064420 NONE flecainide_5\JJ|with|is|when (r_nsubjpass) prescribed_7\VBN|toxicity|may|Because (r_advcl) occur_3\VB|with|be|.|should|closely (l_nsubj) toxicity_1\NN|may|Because|prescribed
D005424_D064420 NONE flecainide_16\JJ|plasma (r_amod) concentrations_18\NNS|and|,|inhibitors (r_conj) paroxetine_9\NN|NONE (r_pobj) with_8\IN|is|when|flecainide (r_prep) prescribed_7\VBN|toxicity|may|Because (r_advcl) occur_3\VB|with|be|.|should|closely (l_nsubj) toxicity_1\NN|may|Because|prescribed
D017374_D003693 CID paroxetine_18\NN|NONE (r_pobj) with_17\IN|drug|pharmacokinetic|a (r_prep) interaction_16\NN|NONE (r_pobj) of_12\IN|the (r_prep) role_11\NN|:|.|in (r_appos) Delirium_0\NN|NONE
D017374_D003693 CID paroxetine_16\NN|NONE (r_pobj) with_15\IN|drug|pharmacokinetic|a (r_prep) interaction_14\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|induced (r_acl) delirium_8\NN|NONE
D017374_D003693 CID paroxetine_24\NN|and|a|,|CYPD (l_appos) inhibitor_28\NN|, (l_conj) reports_35\NNS|,|as|CYPD|a (l_prep) of_36\IN|case| (l_pobj) delirium_40\NN|NONE
D017374_D003693 CID paroxetine_33\NN|and (r_conj) flecainide_31\NN|NONE (r_pobj) between_30\IN|a|possible|drug|pharmacokinetic (r_prep) interaction_29\NN|was|Scale|.|; (r_dobj) indicates_24\VBZ|NONE (l_ccomp) was_8\VBD|Scale|.|interaction|; (l_attr) cause_11\NN|According|flecainide|, (l_prep) of_12\IN|the|probable (l_pobj) delirium_16\NN|NONE
D012964_D003693 NONE sodium_8\NN|NONE (r_compound) channels_9\NNS|NONE (r_pobj) with_7\IN|that (r_prep) interact_6\VBP|Flecainide (r_relcl) agents_4\NNS|.|may|delirium (r_nsubj) cause_11\VB|NONE (l_dobj) delirium_12\NN|.|may|agents
D005424_D001281 NONE Flecainide_0\NNP|prior|.|been|had (r_nsubjpass) started_3\VBN|NONE (l_advmod) prior_6\RB|.|Flecainide|been|had (l_prep) for_7\IN|weeks (l_pobj) fibrillation_9\NN|NONE
D017374_D064420 NONE paroxetine_9\NN|NONE (r_pobj) with_8\IN|is|when|flecainide (r_prep) prescribed_7\VBN|toxicity|may|Because (r_advcl) occur_3\VB|with|be|.|should|closely (l_nsubj) toxicity_1\NN|may|Because|prescribed
D005424_D003693 CID flecainide_6\JJ|toxic|plasma (r_amod) concentrations_8\NNS|NONE (r_pobj) with_4\IN|a (r_prep) patient_3\NN|NONE (r_pobj) in_1\IN|role|:|. (r_prep) Delirium_0\NN|NONE
D005424_D003693 CID flecainide_5\RB| (r_advmod) induced_7\VBN|associated (r_amod) delirium_8\NN|NONE
D005424_D003693 CID Flecainide_0\NNP|interact (r_amod) agents_4\NNS|.|may|delirium (r_nsubj) cause_11\VB|NONE (l_dobj) delirium_12\NN|.|may|agents
D005424_D003693 CID flecainide_17\NN|NONE (r_pobj) between_16\IN|the (r_prep) interaction_15\NN|NONE (r_pobj) on_13\IN|,|pharmacokinetic|substrate (r_prep) study_12\NN|.|search|one (l_conj) substrate_21\NN|,|pharmacokinetic|on (l_conj) paroxetine_24\NN|and|a|,|CYPD (l_appos) inhibitor_28\NN|, (l_conj) reports_35\NNS|,|as|CYPD|a (l_prep) of_36\IN|case| (l_pobj) delirium_40\NN|NONE
D005424_D003693 CID flecainide_37\RB| (r_advmod) induced_39\VBN|NONE (r_amod) delirium_40\NN|NONE
D005424_D003693 CID flecainide_7\NN|According|,|cause (r_advmod) was_8\VBD|Scale|.|interaction|; (l_attr) cause_11\NN|According|flecainide|, (l_prep) of_12\IN|the|probable (l_pobj) delirium_16\NN|NONE
D005424_D003693 CID flecainide_31\NN|NONE (r_pobj) between_30\IN|a|possible|drug|pharmacokinetic (r_prep) interaction_29\NN|was|Scale|.|; (r_dobj) indicates_24\VBZ|NONE (l_ccomp) was_8\VBD|Scale|.|interaction|; (l_attr) cause_11\NN|According|flecainide|, (l_prep) of_12\IN|the|probable (l_pobj) delirium_16\NN|NONE
D005424_D003693 CID flecainide_1\JJ|plasma|Supratherapeutic (r_amod) concentrations_3\NNS|may|delirium|. (r_nsubj) cause_5\VB|NONE (l_dobj) delirium_6\NN|may|.|concentrations
6631522
D004317_D066126 CID doxorubicin_23\NN|NONE (r_compound) cardiotoxicity_24\NN|NONE
C013102_D066126 NONE HA_16\NNP|not|factor|changes|I|that (r_nsubj) are_17\VBP|findings|. (l_attr) factor_21\NN|not|changes|HA|I|that (l_prep) in_22\IN|the|initiating (l_pobj) cardiotoxicity_24\NN|NONE
25951420
D052638_D010300 CID matter_9\NN|and (r_conj) ozone_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) associations_3\NNS|with|study|. (r_dobj) describes_2\VBZ|NONE (l_prep) with_10\IN|study|associations|. (l_pobj) disease_13\NN|NONE
D052638_D010300 CID matter_28\NN|to|and|) (r_conj) 0.98_21\CD|;|.|=|odds|:|CI (r_appos) ratio_13\NN|(|positive|of (r_appos) associations_4\NNS|:|.|We (l_prep) of_5\IN|(|ratio|positive (l_pobj) disease_8\NN|NONE
D010126_D010300 CID Ozone_2\NN|NONE (r_pobj) of_1\IN|With|. (r_prep) Associations_0\NNS|NONE (l_prep) With_6\IN|of|. (l_pobj) Disease_9\NNP|NONE
D010126_D010300 CID ozone_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) associations_3\NNS|with|study|. (r_dobj) describes_2\VBZ|NONE (l_prep) with_10\IN|study|associations|. (l_pobj) disease_13\NN|NONE
D010126_D010300 CID ozone_10\NN|NONE (r_pobj) with_9\IN|Parkinson (r_prep) disease_8\NN|NONE
11395263
D000431_D009203 NONE ethanol_5\NN|the|of (r_compound) extract_6\NN|NONE (r_pobj) of_3\IN|rhizomes|The|on|cardioprotective (r_prep) effect_2\NN|has|.|been (l_prep) on_16\IN|rhizomes|The|of|cardioprotective (l_pobj) infarction_21\NN|NONE
D007545_D009203 CID isoproterenol_17\NN| (r_npadvmod) induced_19\VBN|in|myocardial (r_amod) infarction_21\NN|NONE
D007545_D009203 CID isoproterenol_9\NN| (r_npadvmod) induced_11\VBN|myocardial|the (r_amod) infarction_13\NN|maintained|and|.|day(|significantly
2907577
D003404_D009336 NONE creatinine_10\NN|plasma|analysis|,|)|(|and|biochemical (r_conj) urea_8\NN|NONE (l_conj) analysis_16\NN|plasma|,|)|(|creatinine|and|biochemical (l_conj) degree_31\NN|and|functional|and|clearances|indices|urine|( (l_prep) of_32\IN|)|morphological|( (l_pobj) necrosis_33\NN|NONE
D014508_D009336 NONE urea_8\NN|NONE (l_conj) analysis_16\NN|plasma|,|)|(|creatinine|and|biochemical (l_conj) degree_31\NN|and|functional|and|clearances|indices|urine|( (l_prep) of_32\IN|)|morphological|( (l_pobj) necrosis_33\NN|NONE
D000241_D058186 NONE Adenosine_0\NNP|NONE (r_amod) antagonists_1\NNS|.|have|be|been|previously (r_nsubjpass) shown_5\VBN|NONE (l_xcomp) be_7\VB|.|have|been|antagonists|previously (l_prep) in_10\IN|to|of (l_pobj) models_15\NNS|NONE (l_prep) of_16\IN|ischaemic|some (l_pobj) failure_19\NN|NONE
D000241_D058186 NONE Adenosine_0\NNP|NONE (r_amod) antagonists_1\NNS|.|have|be|been|previously (r_nsubjpass) shown_5\VBN|NONE (l_xcomp) be_7\VB|.|have|been|antagonists|previously (l_prep) in_10\IN|to|of (l_pobj) models_15\NNS|NONE (l_prep) of_16\IN|ischaemic|some (l_pobj) failure_19\NN|NONE (l_appos) ARF_21\NNP|acute|renal|)|(
D000241_D058186 NONE adenosine_14\NN|theophylline|, (r_amod) antagonists_15\NNS|NONE (r_pobj) as_13\IN|different (r_prep) potencies_12\NNS|NONE (r_pobj) with_10\IN|three (r_prep) alkylxanthines_9\NNS|NONE (r_pobj) of_7\IN|the (r_prep) effects_6\NNS|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN|NONE (l_prep) in_24\IN|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS|NONE (l_acl) developing_26\VBG|NONE (l_dobj) failure_29\NN|after
D000241_D058186 NONE adenosine_18\NN|little|role|that|, (r_nsubj) plays_19\VBZ|NONE (l_dobj) role_26\NN|little|adenosine|that|, (l_prep) in_27\IN|pathophysiological|any|, (l_pobj) ARF_31\NN|NONE
D010130_D009336 NONE acid_25\NN|H]inulin|) (r_compound) clearances_26\NNS|and|functional|and|indices|urine|degree|( (r_conj) analysis_16\NN|plasma|,|)|(|creatinine|and|biochemical (l_conj) degree_31\NN|and|functional|and|clearances|indices|urine|( (l_prep) of_32\IN|)|morphological|( (l_pobj) necrosis_33\NN|NONE
D005839_D058186 CID gentamicin_4\NN| (r_npadvmod) induced_6\VBN|acute|renal|in (r_amod) failure_9\NN|NONE
D005839_D058186 CID gentamicin_35\NN|NONE (r_pobj) of_34\IN|kg|(||daily (r_prep) injections_33\NNS|NONE (r_pobj) after_30\IN|failure (r_prep) developing_26\VBG|NONE (l_dobj) failure_29\NN|after
D005839_D058186 CID gentamicin_28\NN| (r_npadvmod) induced_30\VBN|NONE (r_amod) ARF_31\NN|NONE
D000241_D007674 NONE Adenosine_0\NNP|NONE (r_amod) antagonists_1\NNS|.|have|be|been|previously (r_nsubjpass) shown_5\VBN|NONE (l_xcomp) be_7\VB|.|have|been|antagonists|previously (l_prep) in_10\IN|to|of (l_pobj) models_15\NNS|NONE (l_amod) ischaemic_12\JJ|of|some (l_conj) nephrotoxic_14\JJ|and
D013806_D058186 NONE theophylline_18\NN|adenosine|, (r_amod) antagonists_15\NNS|NONE (r_pobj) as_13\IN|different (r_prep) potencies_12\NNS|NONE (r_pobj) with_10\IN|three (r_prep) alkylxanthines_9\NNS|NONE (r_pobj) of_7\IN|the (r_prep) effects_6\NNS|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN|NONE (l_prep) in_24\IN|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS|NONE (l_acl) developing_26\VBG|NONE (l_dobj) failure_29\NN|after
C028322_D058186 NONE 8-phenyltheophylline_16\NN|NONE (r_punct) ,_17\,|adenosine|theophylline (r_punct) antagonists_15\NNS|NONE (r_pobj) as_13\IN|different (r_prep) potencies_12\NNS|NONE (r_pobj) with_10\IN|three (r_prep) alkylxanthines_9\NNS|NONE (r_pobj) of_7\IN|the (r_prep) effects_6\NNS|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN|NONE (l_prep) in_24\IN|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS|NONE (l_acl) developing_26\VBG|NONE (l_dobj) failure_29\NN|after
D000241_D007511 NONE Adenosine_0\NNP|NONE (r_amod) antagonists_1\NNS|.|have|be|been|previously (r_nsubjpass) shown_5\VBN|NONE (l_xcomp) be_7\VB|.|have|been|antagonists|previously (l_prep) in_10\IN|to|of (l_pobj) models_15\NNS|NONE (l_amod) ischaemic_12\JJ|of|some
-1_D058186 NONE alkylxanthines_2\NNS|NONE (l_prep) on_3\IN|NONE (l_pobj) failure_9\NN|NONE
-1_D058186 NONE alkylxanthines_9\NNS|NONE (r_pobj) of_7\IN|the (r_prep) effects_6\NNS|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN|NONE (l_prep) in_24\IN|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS|NONE (l_acl) developing_26\VBG|NONE (l_dobj) failure_29\NN|after
-1_D058186 NONE alkylxanthines_10\NNS|NONE (r_pobj) with_8\IN|.|lack|indicates (r_prep) noted_7\VBN|NONE (l_ccomp) indicates_16\VBZ|.|lack|with (l_ccomp) plays_19\VBZ|NONE (l_dobj) role_26\NN|little|adenosine|that|, (l_prep) in_27\IN|pathophysiological|any|, (l_pobj) ARF_31\NN|NONE
C034347_D058186 NONE enprofylline_20\NN|and (r_conj) theophylline_18\NN|adenosine|, (r_amod) antagonists_15\NNS|NONE (r_pobj) as_13\IN|different (r_prep) potencies_12\NNS|NONE (r_pobj) with_10\IN|three (r_prep) alkylxanthines_9\NNS|NONE (r_pobj) of_7\IN|the (r_prep) effects_6\NNS|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN|NONE (l_prep) in_24\IN|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS|NONE (l_acl) developing_26\VBG|NONE (l_dobj) failure_29\NN|after
2983630
D000241_D009421 NONE adenosine_4\NN|an|receptor (r_amod) antagonist_6\NN|caffeine|Because (r_attr) is_2\VBZ|.|have|,|results (r_advcl) suggest_10\VBP|NONE (l_ccomp) have_17\VB|.|,|results|is (l_dobj) abnormalities_18\NNS|that|patients|may (l_prep) in_19\IN|NONE (l_pobj) systems_21\NNS|NONE
D000241_D009421 NONE adenosine_23\NN|NONE (r_dobj) involving_22\VBG|neuronal (r_acl) systems_21\NNS|NONE
D008734_D000379 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|NONE (r_pobj) of_23\IN|and|levels|blood (r_prep) pressure_19\NN|somatic|, (r_conj) symptoms_16\NNS|behavioral|, (r_conj) ratings_13\NNS|NONE (r_pobj) on_11\IN|of|(|)|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE
D008734_D000379 NONE MHPG_26\RB|and|)|cortisol|( (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|NONE (r_pobj) of_23\IN|and|levels|blood (r_prep) pressure_19\NN|somatic|, (r_conj) symptoms_16\NNS|behavioral|, (r_conj) ratings_13\NNS|NONE (r_pobj) on_11\IN|of|(|)|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE
D006854_D016584 NONE cortisol_29\NN|MHPG|and|)|( (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|NONE (r_pobj) of_23\IN|and|levels|blood (r_prep) pressure_19\NN|somatic|, (r_conj) symptoms_16\NNS|behavioral|, (r_conj) ratings_13\NNS|NONE (r_pobj) on_11\IN|of|(|)|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE (l_prep) with_46\IN|NONE (l_pobj) attacks_48\NNS|NONE
D006854_D016584 NONE cortisol_29\NN|MHPG|and|)|( (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|NONE (r_pobj) of_23\IN|and|levels|blood (r_prep) pressure_19\NN|somatic|, (r_conj) symptoms_16\NNS|behavioral|, (r_conj) ratings_13\NNS|NONE (r_pobj) on_11\IN|of|(|)|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE (l_prep) with_46\IN|NONE (l_pobj) attacks_48\NNS|NONE (l_conj) disorder_51\NN|or|panic
D002110_D009421 NONE caffeine_1\NN|antagonist|Because (r_nsubj) is_2\VBZ|.|have|,|results (r_advcl) suggest_10\VBP|NONE (l_ccomp) have_17\VB|.|,|results|is (l_dobj) abnormalities_18\NNS|that|patients|may (l_prep) in_19\IN|NONE (l_pobj) systems_21\NNS|NONE
D002110_D009325 CID Caffeine_0\NN|increases|.|compared (r_nsubj) produced_1\VBD|NONE (l_dobj) increases_4\NNS|Caffeine|.|compared (l_prep) in_5\IN|greater (l_pobj) anxiety_9\NN|NONE (l_conj) nervousness_11\NN|in|,|rated (l_conj) fear_13\NN|, (l_conj) nausea_15\NN|,
D002110_D001008 CID Caffeine_0\NN|increases|.|compared (r_nsubj) produced_1\VBD|NONE (l_dobj) increases_4\NNS|Caffeine|.|compared (l_prep) in_5\IN|greater (l_pobj) anxiety_9\NN|NONE
D002110_D001008 CID caffeine_8\NN| (r_npadvmod) containing_10\VBG|and|beverages (r_amod) foods_11\NNS|NONE (r_dobj) avoiding_7\VBG|NONE (r_pcomp) by_6\IN|may|Patients|. (r_prep) benefit_5\VB|NONE (l_nsubj) Patients_0\NNS|may|by|. (l_prep) with_1\IN|NONE (l_pobj) disorders_3\NNS|NONE
D000241_D016584 NONE adenosine_4\NN|an|receptor (r_amod) antagonist_6\NN|caffeine|Because (r_attr) is_2\VBZ|.|have|,|results (r_advcl) suggest_10\VBP|NONE (l_ccomp) have_17\VB|.|,|results|is (l_nsubj) patients_15\NNS|that|may|abnormalities (l_compound) disorder_14\NN|some
D000241_D016584 NONE adenosine_23\NN|NONE (r_dobj) involving_22\VBG|neuronal (r_acl) systems_21\NNS|NONE (r_pobj) in_19\IN|NONE (r_prep) abnormalities_18\NNS|that|patients|may (r_dobj) have_17\VB|.|,|results|is (l_nsubj) patients_15\NNS|that|may|abnormalities (l_compound) disorder_14\NN|some
D006854_D000379 NONE cortisol_29\NN|MHPG|and|)|( (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|NONE (r_pobj) of_23\IN|and|levels|blood (r_prep) pressure_19\NN|somatic|, (r_conj) symptoms_16\NNS|behavioral|, (r_conj) ratings_13\NNS|NONE (r_pobj) on_11\IN|of|(|)|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|NONE (r_pobj) of_23\IN|and|levels|blood (r_prep) pressure_19\NN|somatic|, (r_conj) symptoms_16\NNS|behavioral|, (r_conj) ratings_13\NNS|NONE (r_pobj) on_11\IN|of|(|)|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE (l_prep) with_46\IN|NONE (l_pobj) attacks_48\NNS|NONE
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|NONE (r_pobj) of_23\IN|and|levels|blood (r_prep) pressure_19\NN|somatic|, (r_conj) symptoms_16\NNS|behavioral|, (r_conj) ratings_13\NNS|NONE (r_pobj) on_11\IN|of|(|)|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE (l_prep) with_46\IN|NONE (l_pobj) attacks_48\NNS|NONE (l_conj) disorder_51\NN|or|panic
D008734_D016584 NONE MHPG_26\RB|and|)|cortisol|( (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|NONE (r_pobj) of_23\IN|and|levels|blood (r_prep) pressure_19\NN|somatic|, (r_conj) symptoms_16\NNS|behavioral|, (r_conj) ratings_13\NNS|NONE (r_pobj) on_11\IN|of|(|)|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE (l_prep) with_46\IN|NONE (l_pobj) attacks_48\NNS|NONE
D008734_D016584 NONE MHPG_26\RB|and|)|cortisol|( (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|NONE (r_pobj) of_23\IN|and|levels|blood (r_prep) pressure_19\NN|somatic|, (r_conj) symptoms_16\NNS|behavioral|, (r_conj) ratings_13\NNS|NONE (r_pobj) on_11\IN|of|(|)|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE (l_prep) with_46\IN|NONE (l_pobj) attacks_48\NNS|NONE (l_conj) disorder_51\NN|or|panic
D002110_-1 NONE Caffeine_0\NN|increases|.|compared (r_nsubj) produced_1\VBD|NONE (l_dobj) increases_4\NNS|Caffeine|.|compared (l_prep) in_5\IN|greater (l_pobj) anxiety_9\NN|NONE (l_conj) nervousness_11\NN|in|,|rated (l_conj) fear_13\NN|, (l_conj) nausea_15\NN|, (l_conj) palpitations_17\NNS|,
D002110_D011595 NONE Caffeine_0\NN|increases|.|compared (r_nsubj) produced_1\VBD|NONE (l_dobj) increases_4\NNS|Caffeine|.|compared (l_prep) in_5\IN|greater (l_pobj) anxiety_9\NN|NONE (l_conj) nervousness_11\NN|in|,|rated (l_conj) fear_13\NN|, (l_conj) nausea_15\NN|, (l_conj) palpitations_17\NNS|, (l_conj) restlessness_19\NN|,
D002110_D014202 CID Caffeine_0\NN|increases|.|compared (r_nsubj) produced_1\VBD|NONE (l_dobj) increases_4\NNS|Caffeine|.|compared (l_prep) in_5\IN|greater (l_pobj) anxiety_9\NN|NONE (l_conj) nervousness_11\NN|in|,|rated (l_conj) fear_13\NN|, (l_conj) nausea_15\NN|, (l_conj) palpitations_17\NNS|, (l_conj) restlessness_19\NN|, (l_conj) tremors_22\NNS|,|and
D002110_D016584 NONE caffeine_4\NN|NONE (r_pobj) of_3\IN|Increased|.|in|anxiogenic (r_prep) effects_2\NNS|NONE (l_prep) in_5\IN|Increased|.|anxiogenic|of (l_pobj) disorders_7\NNS|NONE
D002110_D016584 NONE caffeine_6\NN|NONE (r_pobj) of_5\IN|oral (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|(|)|on|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE (l_prep) with_46\IN|NONE (l_pobj) attacks_48\NNS|NONE
D002110_D016584 NONE caffeine_6\NN|NONE (r_pobj) of_5\IN|oral (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|(|)|on|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE (l_prep) with_46\IN|NONE (l_pobj) attacks_48\NNS|NONE (l_conj) disorder_51\NN|or|panic
D002110_D016584 NONE caffeine_13\NN|NONE (r_pobj) of_12\IN|behavioral|the (r_prep) effects_11\NNS|that|similar (r_nsubj) were_14\VBD|percent|. (l_acomp) similar_15\JJ|that|effects (l_prep) to_16\IN|NONE (l_pobj) those_17\DT|NONE (l_acl) experienced_18\VBN|NONE (l_prep) during_19\IN|NONE (l_pobj) attacks_21\NNS|NONE
D002110_D016584 NONE caffeine_1\NN|antagonist|Because (r_nsubj) is_2\VBZ|.|have|,|results (r_advcl) suggest_10\VBP|NONE (l_ccomp) have_17\VB|.|,|results|is (l_nsubj) patients_15\NNS|that|may|abnormalities (l_compound) disorder_14\NN|some
D002110_D000379 NONE caffeine_6\NN|NONE (r_pobj) of_5\IN|oral (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|(|)|on|The|mg/kg (r_prep) effects_1\NNS|meeting|in|were|. (r_nsubjpass) determined_31\VBN|NONE (l_advcl) meeting_39\VBG|in|were|.|effects (l_dobj) criteria_43\NNS|patients (l_prep) for_44\IN|III (l_pobj) agoraphobia_45\NN|NONE
9128918
D004298_D006966 NONE dopamine_5\NN|NONE (r_compound) neurons_6\NNS|NONE (r_pobj) in_4\IN|NONE (r_prep) changes_3\NNS|.|Chronic|and (r_conj) hyperprolactinemia_1\NN|NONE
D004298_D006966 NONE dopamine_9\NN|a|and|technique|,|receptor (r_compound) antagonist_11\NN|, (r_appos) haloperidol_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) treatment_4\NN|NONE (r_pobj) by_3\IN|Hyperprolactinemia|used|.|was (r_agent) induced_2\VBN|NONE (l_nsubjpass) Hyperprolactinemia_0\NNP|by|used|.|was
D004298_D006966 NONE dopamine_6\NN|)|(|in|DA (r_nmod) concentrations_10\NNS|,|.|After|over|by (r_nsubj) increased_18\VBN|NONE (l_prep) After_0\IN|,|concentrations|.|over|by (l_pobj) months_2\NNS|NONE (l_prep) of_3\IN| (l_pobj) hyperprolactinemia_4\NN|NONE
D004298_D006966 NONE DA_8\NNP|)|(|in|dopamine (r_nmod) concentrations_10\NNS|,|.|After|over|by (r_nsubj) increased_18\VBN|NONE (l_prep) After_0\IN|,|concentrations|.|over|by (l_pobj) months_2\NNS|NONE (l_prep) of_3\IN| (l_pobj) hyperprolactinemia_4\NN|NONE
D004298_D006966 NONE DA_10\NNP|in (r_compound) concentrations_11\NNS|NONE (r_pobj) in_9\IN|a|over|% (r_prep) increase_8\NN|months|. (r_dobj) produced_4\VBD|NONE (l_nsubj) months_1\NNS|increase|. (l_prep) of_2\IN|Nine (l_pobj) hyperprolactinemia_3\NN|NONE
D004298_D006966 NONE DA_2\NNP|NONE (r_compound) response_3\NN|However|was|.|,|followed (r_nsubjpass) lost_5\VBN|NONE (l_advcl) followed_15\VBN|However|was|.|,|response (l_nsubjpass) hyperprolactinemia_13\NN|was|if|by
D004298_D006966 NONE DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_prep) after_70\IN|and|in|in|a|increase (l_pobj) 6-months_71\IN|NONE (l_prep) of_72\IN|NONE (l_pobj) hyperprolactinemia_73\NN|NONE
D004298_D006966 NONE DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_conj) increase_76\NN|and|in|in|after|a (l_prep) after_83\IN|in|in|an (l_pobj) 9-months_84\JJ|NONE (l_prep) of_85\IN|NONE (l_pobj) hyperprolactinemia_86\NN|NONE
D004298_D006966 NONE DA_78\NNP|NONE (r_compound) concentrations_79\NNS|NONE (r_pobj) in_77\IN|in|after|an (r_prep) increase_76\NN|and|in|in|after|a (r_conj) decrease_60\NN|NONE (l_prep) after_70\IN|and|in|in|a|increase (l_pobj) 6-months_71\IN|NONE (l_prep) of_72\IN|NONE (l_pobj) hyperprolactinemia_73\NN|NONE
D004298_D006966 NONE DA_78\NNP|NONE (r_compound) concentrations_79\NNS|NONE (r_pobj) in_77\IN|in|after|an (r_prep) increase_76\NN|and|in|in|after|a (l_prep) after_83\IN|in|in|an (l_pobj) 9-months_84\JJ|NONE (l_prep) of_85\IN|NONE (l_pobj) hyperprolactinemia_86\NN|NONE
D009638_D006966 NONE norepinephrine_10\NN|serotonin|, (r_appos) DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_prep) after_70\IN|and|in|in|a|increase (l_pobj) 6-months_71\IN|NONE (l_prep) of_72\IN|NONE (l_pobj) hyperprolactinemia_73\NN|NONE
D009638_D006966 NONE norepinephrine_10\NN|serotonin|, (r_appos) DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_conj) increase_76\NN|and|in|in|after|a (l_prep) after_83\IN|in|in|an (l_pobj) 9-months_84\JJ|NONE (l_prep) of_85\IN|NONE (l_pobj) hyperprolactinemia_86\NN|NONE
D009638_D006966 NONE NE_12\NNP|NONE (r_appos) norepinephrine_10\NN|serotonin|, (r_appos) DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_prep) after_70\IN|and|in|in|a|increase (l_pobj) 6-months_71\IN|NONE (l_prep) of_72\IN|NONE (l_pobj) hyperprolactinemia_73\NN|NONE
D009638_D006966 NONE NE_12\NNP|NONE (r_appos) norepinephrine_10\NN|serotonin|, (r_appos) DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_conj) increase_76\NN|and|in|in|after|a (l_prep) after_83\IN|in|in|an (l_pobj) 9-months_84\JJ|NONE (l_prep) of_85\IN|NONE (l_pobj) hyperprolactinemia_86\NN|NONE
D006220_D006966 CID haloperidol_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) treatment_4\NN|NONE (r_pobj) by_3\IN|Hyperprolactinemia|used|.|was (r_agent) induced_2\VBN|NONE (l_nsubjpass) Hyperprolactinemia_0\NNP|by|used|.|was
D006220_D006966 CID haloperidol_10\NN| (r_npadvmod) induced_12\VBN|long|a (r_amod) hyperprolactinemia_13\NN|was|if|by
D006897_D006966 NONE acid_63\NN|NONE (r_pobj) in_61\IN|and|in|after|a|increase (r_prep) decrease_60\NN|NONE (l_prep) after_70\IN|and|in|in|a|increase (l_pobj) 6-months_71\IN|NONE (l_prep) of_72\IN|NONE (l_pobj) hyperprolactinemia_73\NN|NONE
D006897_D006966 NONE acid_63\NN|NONE (r_pobj) in_61\IN|and|in|after|a|increase (r_prep) decrease_60\NN|NONE (l_conj) increase_76\NN|and|in|in|after|a (l_prep) after_83\IN|in|in|an (l_pobj) 9-months_84\JJ|NONE (l_prep) of_85\IN|NONE (l_pobj) hyperprolactinemia_86\NN|NONE
D006897_D006966 NONE 5-HIAA_65\CD|(|hydroxyindoleacetic|) (r_appos) acid_63\NN|NONE (r_pobj) in_61\IN|and|in|after|a|increase (r_prep) decrease_60\NN|NONE (l_prep) after_70\IN|and|in|in|a|increase (l_pobj) 6-months_71\IN|NONE (l_prep) of_72\IN|NONE (l_pobj) hyperprolactinemia_73\NN|NONE
D006897_D006966 NONE 5-HIAA_65\CD|(|hydroxyindoleacetic|) (r_appos) acid_63\NN|NONE (r_pobj) in_61\IN|and|in|after|a|increase (r_prep) decrease_60\NN|NONE (l_conj) increase_76\NN|and|in|in|after|a (l_prep) after_83\IN|in|in|an (l_pobj) 9-months_84\JJ|NONE (l_prep) of_85\IN|NONE (l_pobj) hyperprolactinemia_86\NN|NONE
D012701_D006966 NONE serotonin_15\NN|norepinephrine|, (r_appos) DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_prep) after_70\IN|and|in|in|a|increase (l_pobj) 6-months_71\IN|NONE (l_prep) of_72\IN|NONE (l_pobj) hyperprolactinemia_73\NN|NONE
D012701_D006966 NONE serotonin_15\NN|norepinephrine|, (r_appos) DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_conj) increase_76\NN|and|in|in|after|a (l_prep) after_83\IN|in|in|an (l_pobj) 9-months_84\JJ|NONE (l_prep) of_85\IN|NONE (l_pobj) hyperprolactinemia_86\NN|NONE
D012701_D006966 NONE 5-HT_17\CD|)|or|,|metabolites|( (r_appos) serotonin_15\NN|norepinephrine|, (r_appos) DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_prep) after_70\IN|and|in|in|a|increase (l_pobj) 6-months_71\IN|NONE (l_prep) of_72\IN|NONE (l_pobj) hyperprolactinemia_73\NN|NONE
D012701_D006966 NONE 5-HT_17\CD|)|or|,|metabolites|( (r_appos) serotonin_15\NN|norepinephrine|, (r_appos) DA_8\NNP|NONE (r_pobj) of_7\IN|the (r_prep) levels_6\NNS|NONE (r_pobj) in_4\IN|no (r_prep) change_3\NN|.|There|putamen|, (r_attr) was_1\VBD|NONE (l_attr) putamen_39\NNS|.|There|change|, (l_prep) except_57\IN|,|nigra|CP|caudate|, (l_prep) for_58\IN|NONE (l_pobj) decrease_60\NN|NONE (l_conj) increase_76\NN|and|in|in|after|a (l_prep) after_83\IN|in|in|an (l_pobj) 9-months_84\JJ|NONE (l_prep) of_85\IN|NONE (l_pobj) hyperprolactinemia_86\NN|NONE
11936424
D011692_D006984 NONE aminonucleoside_43\NN|)|( (r_nmod) PAN_45\NNP|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD|to (l_dobj) hypertrophy_36\NN|prevented|whether|administration|and
D011692_D006984 NONE PAN_45\NNP|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD|to (l_dobj) hypertrophy_36\NN|prevented|whether|administration|and
C055603_D009404 NONE temocapril_13\NN|NONE (r_pobj) of_12\IN|chronic|,|angiotensin (r_prep) administration_11\NN|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD|to (r_ccomp) determine_8\VB|induced|.|purpose (r_xcomp) was_6\VBD|NONE (l_conj) induced_48\VBN|.|purpose|determine (l_dobj) rats_50\NNS| (l_amod) nephrotic_49\JJ|NONE
C055603_D011507 NONE temocapril_13\NN|NONE (r_pobj) of_12\IN|chronic|,|angiotensin (r_prep) administration_11\NN|prevented|whether|hypertrophy|and (l_appos) angiotensin_23\NN|chronic|,|of (l_acl) reduced_31\VBN|group|,|a|converting|, (l_dobj) proteinuria_32\NN|NONE
C055603_D011507 NONE Temocapril_0\NNP|,|did|at|proteinuria|not|lower|but (r_nsubj) attenuate_3\VB|NONE (l_dobj) proteinuria_4\NN|,|Temocapril|did|at|not|lower|but
C055603_D005921 NONE temocapril_13\NN|NONE (r_pobj) of_12\IN|chronic|,|angiotensin (r_prep) administration_11\NN|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD|to (l_conj) prevented_38\VBN|whether|administration|hypertrophy|and (l_dobj) glomerulosclerosis_39\NN|in|PAN
D000809_D011507 NONE angiotensin_23\NN|chronic|,|of (l_acl) reduced_31\VBN|group|,|a|converting|, (l_dobj) proteinuria_32\NN|NONE
D000809_D006984 NONE angiotensin_23\NN|chronic|,|of (r_appos) administration_11\NN|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD|to (l_dobj) hypertrophy_36\NN|prevented|whether|administration|and
D011692_D009401 CID aminonucleoside_21\JJ|puromycin (r_amod) nephrosis_22\NN|NONE
D011692_D009401 CID PAN_6\NNP|NONE (r_pobj) of_5\IN|in (r_prep) injection_4\NN|NONE (r_pobj) by_3\IN|Nephrosis|.|was (r_agent) induced_2\VBN|NONE (l_nsubjpass) Nephrosis_0\NNP|by|.|was
D011692_D009401 CID PAN_15\NNP|neprotic (r_compound) rats_17\NNS|NONE (l_amod) neprotic_16\JJ|PAN
D000809_D009404 NONE angiotensin_23\NN|chronic|,|of (r_appos) administration_11\NN|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD|to (r_ccomp) determine_8\VB|induced|.|purpose (r_xcomp) was_6\VBD|NONE (l_conj) induced_48\VBN|.|purpose|determine (l_dobj) rats_50\NNS| (l_amod) nephrotic_49\JJ|NONE
D000809_D007674 NONE angiotensin_10\NN|,|, (r_appos) Temocapril_0\NNP|injury|. (r_nsubj) modulates_15\VBZ|NONE (l_dobj) injury_17\NN|.|Temocapril
C055603_D006984 NONE temocapril_13\NN|NONE (r_pobj) of_12\IN|chronic|,|angiotensin (r_prep) administration_11\NN|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD|to (l_dobj) hypertrophy_36\NN|prevented|whether|administration|and
D000809_D005921 NONE angiotensin_23\NN|chronic|,|of (r_appos) administration_11\NN|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD|to (l_conj) prevented_38\VBN|whether|administration|hypertrophy|and (l_dobj) glomerulosclerosis_39\NN|in|PAN
D011692_D007674 NONE aminonucleoside_21\JJ|puromycin (r_amod) nephrosis_22\NN|NONE (r_pobj) in_18\IN|glomerular (r_prep) injury_17\NN|.|Temocapril
D011692_D011507 CID aminonucleoside_43\NN|)|( (r_nmod) PAN_45\NNP|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD|to (l_nsubj) administration_11\NN|prevented|whether|hypertrophy|and (l_appos) angiotensin_23\NN|chronic|,|of (l_acl) reduced_31\VBN|group|,|a|converting|, (l_dobj) proteinuria_32\NN|NONE
D011692_D011507 CID PAN_45\NNP|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD|to (l_nsubj) administration_11\NN|prevented|whether|hypertrophy|and (l_appos) angiotensin_23\NN|chronic|,|of (l_acl) reduced_31\VBN|group|,|a|converting|, (l_dobj) proteinuria_32\NN|NONE
C055603_D009401 NONE Temocapril_0\NNP|injury|. (r_nsubj) modulates_15\VBZ|NONE (l_dobj) injury_17\NN|.|Temocapril (l_prep) in_18\IN|glomerular (l_pobj) nephrosis_22\NN|NONE
C055603_D009401 NONE temocapril_3\NN|that|effective (r_nsubj) was_4\VBD|.|It (l_acomp) effective_5\JJ|temocapril|that (l_prep) in_6\IN|NONE (l_pcomp) retarding_7\VBG|NONE (l_conj) protected_11\VBD|progression|and (l_dobj) function_13\NN|NONE (l_prep) in_14\IN|renal (l_pobj) rats_17\NNS|NONE (l_amod) neprotic_16\JJ|PAN
D011692_D009404 NONE aminonucleoside_43\NN|)|( (r_nmod) PAN_45\NNP|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD|to (r_ccomp) determine_8\VB|induced|.|purpose (r_xcomp) was_6\VBD|NONE (l_conj) induced_48\VBN|.|purpose|determine (l_dobj) rats_50\NNS| (l_amod) nephrotic_49\JJ|NONE
D011692_D009404 NONE PAN_45\NNP|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD|to (r_ccomp) determine_8\VB|induced|.|purpose (r_xcomp) was_6\VBD|NONE (l_conj) induced_48\VBN|.|purpose|determine (l_dobj) rats_50\NNS| (l_amod) nephrotic_49\JJ|NONE
C055603_D007674 NONE Temocapril_0\NNP|injury|. (r_nsubj) modulates_15\VBZ|NONE (l_dobj) injury_17\NN|.|Temocapril
D011692_D005921 NONE aminonucleoside_43\NN|)|( (r_nmod) PAN_45\NNP|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN|whether|administration|hypertrophy|and (l_dobj) glomerulosclerosis_39\NN|in|PAN
D011692_D005921 NONE PAN_45\NNP|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN|whether|administration|hypertrophy|and (l_dobj) glomerulosclerosis_39\NN|in|PAN
D011692_D005921 NONE PAN_26\NNP|the (r_compound) group_27\NN|NONE (r_pobj) in_24\IN| (r_prep) weeks_23\NNS|NONE (r_pobj) at_19\IN|index|.|at|% (r_prep) was_6\VBD|NONE (l_nsubj) index_2\NN|at|.|at|% (l_compound) glomerulosclerosis_1\NN|(|The|GSI|)
D000809_D009401 NONE angiotensin_10\NN|,|, (r_appos) Temocapril_0\NNP|injury|. (r_nsubj) modulates_15\VBZ|NONE (l_dobj) injury_17\NN|.|Temocapril (l_prep) in_18\IN|glomerular (l_pobj) nephrosis_22\NN|NONE
24923469
7492040
D008012_D014693 NONE lidocaine_5\NN|who|in (r_dobj) received_4\VBD| (r_relcl) patients_2\NNS|,|patient (r_nsubj) died_17\VBD|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN|NONE (l_dobj) bradydysrhythmias_20\NNS|died|.|; (l_conj) tachycardia_23\NN|or|;|seizures|, (l_conj) fibrillation_27\NN|or|,|ventricular
D008012_D014693 NONE lidocaine_35\NN|NONE (r_pobj) of_34\IN|interval (r_prep) administration_33\NN|NONE (r_pobj) after_32\IN|experienced (r_prep) seizures_31\NNS|or|tachycardia|;|, (r_conj) bradydysrhythmias_20\NNS|died|.|; (l_conj) tachycardia_23\NN|or|;|seizures|, (l_conj) fibrillation_27\NN|or|,|ventricular
D003042_D017180 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|NONE (r_amod) MI_13\NNP|NONE (r_pobj) of_9\IN|the (r_prep) setting_8\NN|NONE (r_pobj) in_6\IN|who|lidocaine (r_prep) received_4\VBD| (r_relcl) patients_2\NNS|,|patient (r_nsubj) died_17\VBD|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN|NONE (l_dobj) bradydysrhythmias_20\NNS|died|.|; (l_conj) tachycardia_23\NN|or|;|seizures|,
D008012_D009203 NONE lidocaine_3\NN|NONE (r_pobj) of_2\IN|Clinical|in|. (r_prep) safety_1\NN|NONE (l_prep) in_4\IN|Clinical|.|of (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|NONE (l_pobj) infarction_11\NN|NONE
D008012_D009203 NONE lidocaine_8\NN|NONE (r_pobj) of_7\IN|the|in (r_prep) safety_6\NN|To (l_prep) in_9\IN|of|the (l_pobj) setting_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) infarction_17\NN|NONE
D008012_D009203 NONE lidocaine_8\NN|NONE (r_pobj) of_7\IN|the|in (r_prep) safety_6\NN|To (l_prep) in_9\IN|of|the (l_pobj) setting_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) infarction_17\NN|NONE (l_appos) MI_19\NNP|myocardial|)|induced|(
D008012_D009203 NONE lidocaine_10\NN|who|in (r_dobj) received_9\VBD|with (r_relcl) Patients_2\NNS|:|. (l_prep) with_3\IN|received (l_pobj) MI_7\NNP|NONE
D008012_D009203 NONE lidocaine_5\NN|who|in (r_dobj) received_4\VBD| (l_prep) in_6\IN|who|lidocaine (l_pobj) setting_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) MI_13\NNP|NONE
D008012_D009203 NONE lidocaine_35\NN|NONE (r_pobj) of_34\IN|interval (r_prep) administration_33\NN|NONE (r_pobj) after_32\IN|experienced (r_prep) seizures_31\NNS|or|tachycardia|;|, (r_conj) bradydysrhythmias_20\NNS|died|.|; (r_dobj) exhibited_19\VBN|NONE (l_ccomp) died_17\VBD|.|;|bradydysrhythmias (l_nsubj) patients_2\NNS|,|patient (l_relcl) received_4\VBD| (l_prep) in_6\IN|who|lidocaine (l_pobj) setting_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) MI_13\NNP|NONE
D008012_D009203 NONE lidocaine_4\NN|may|toxicity|that (r_nsubj) enhance_6\VB|theoretical (r_acl) concerns_2\NNS|NONE (r_pobj) Despite_0\IN|use|,|not|.|was|with (r_prep) associated_23\VBN|NONE (l_nsubjpass) use_11\NN|,|Despite|not|.|was|with (l_prep) in_14\IN|the|of (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) MI_20\NNP|NONE
D008012_D009203 NONE lidocaine_13\NN|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|,|Despite|not|.|was|with (l_prep) in_14\IN|the|of (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) MI_20\NNP|NONE
D003042_D009203 CID cocaine_7\NN| (r_npadvmod) associated_9\VBN|myocardial (r_amod) infarction_11\NN|NONE
D003042_D009203 CID cocaine_13\NN| (r_npadvmod) induced_15\VBN|myocardial|MI|)|( (r_amod) infarction_17\NN|NONE
D003042_D009203 CID cocaine_13\NN| (r_npadvmod) induced_15\VBN|myocardial|MI|)|( (r_amod) infarction_17\NN|NONE (l_appos) MI_19\NNP|myocardial|)|induced|(
D003042_D009203 CID cocaine_4\NN| (r_npadvmod) associated_6\VBN|NONE (r_amod) MI_7\NNP|NONE
D003042_D009203 CID cocaine_10\NN| (r_npadvmod) associated_12\VBN|NONE (r_amod) MI_13\NNP|NONE
D003042_D009203 CID cocaine_7\NN|NONE (r_compound) toxicity_8\NN|may|that|lidocaine (r_dobj) enhance_6\VB|theoretical (r_acl) concerns_2\NNS|NONE (r_pobj) Despite_0\IN|use|,|not|.|was|with (r_prep) associated_23\VBN|NONE (l_nsubjpass) use_11\NN|,|Despite|not|.|was|with (l_prep) in_14\IN|the|of (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) MI_20\NNP|NONE
D003042_D009203 CID cocaine_17\NN| (r_npadvmod) associated_19\VBN|NONE (r_amod) MI_20\NNP|NONE
D008012_D017180 NONE lidocaine_5\NN|who|in (r_dobj) received_4\VBD| (r_relcl) patients_2\NNS|,|patient (r_nsubj) died_17\VBD|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN|NONE (l_dobj) bradydysrhythmias_20\NNS|died|.|; (l_conj) tachycardia_23\NN|or|;|seizures|,
D008012_D017180 NONE lidocaine_35\NN|NONE (r_pobj) of_34\IN|interval (r_prep) administration_33\NN|NONE (r_pobj) after_32\IN|experienced (r_prep) seizures_31\NNS|or|tachycardia|;|, (r_conj) bradydysrhythmias_20\NNS|died|.|; (l_conj) tachycardia_23\NN|or|;|seizures|,
D003042_D012640 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|NONE (r_amod) MI_13\NNP|NONE (r_pobj) of_9\IN|the (r_prep) setting_8\NN|NONE (r_pobj) in_6\IN|who|lidocaine (r_prep) received_4\VBD| (r_relcl) patients_2\NNS|,|patient (r_nsubj) died_17\VBD|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN|NONE (l_dobj) bradydysrhythmias_20\NNS|died|.|; (l_conj) seizures_31\NNS|or|tachycardia|;|,
D008012_D002493 NONE lidocaine_4\NN|may|toxicity|that (r_nsubj) enhance_6\VB|theoretical (r_acl) concerns_2\NNS|NONE (r_pobj) Despite_0\IN|use|,|not|.|was|with (r_prep) associated_23\VBN|NONE (l_prep) with_24\IN|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN|NONE
D008012_D002493 NONE lidocaine_13\NN|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN|NONE (l_prep) with_24\IN|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN|NONE
D008012_D012640 NONE lidocaine_5\NN|who|in (r_dobj) received_4\VBD| (r_relcl) patients_2\NNS|,|patient (r_nsubj) died_17\VBD|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN|NONE (l_dobj) bradydysrhythmias_20\NNS|died|.|; (l_conj) seizures_31\NNS|or|tachycardia|;|,
D008012_D012640 NONE lidocaine_35\NN|NONE (r_pobj) of_34\IN|interval (r_prep) administration_33\NN|NONE (r_pobj) after_32\IN|experienced (r_prep) seizures_31\NNS|or|tachycardia|;|,
D008012_D064420 NONE lidocaine_4\NN|may|toxicity|that (r_nsubj) enhance_6\VB|theoretical (l_dobj) toxicity_8\NN|may|that|lidocaine
D008012_D064420 NONE lidocaine_13\NN|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN|NONE (l_prep) Despite_0\IN|use|,|not|.|was|with (l_pobj) concerns_2\NNS|NONE (l_acl) enhance_6\VB|theoretical (l_dobj) toxicity_8\NN|may|that|lidocaine
D003042_D002493 NONE cocaine_7\NN|NONE (r_compound) toxicity_8\NN|may|that|lidocaine (r_dobj) enhance_6\VB|theoretical (r_acl) concerns_2\NNS|NONE (r_pobj) Despite_0\IN|use|,|not|.|was|with (r_prep) associated_23\VBN|NONE (l_prep) with_24\IN|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN|NONE
D003042_D002493 NONE cocaine_17\NN| (r_npadvmod) associated_19\VBN|NONE (r_amod) MI_20\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) patients_15\NNS|NONE (r_pobj) in_14\IN|the|of (r_prep) use_11\NN|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN|NONE (l_prep) with_24\IN|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN|NONE
D003042_D014693 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|NONE (r_amod) MI_13\NNP|NONE (r_pobj) of_9\IN|the (r_prep) setting_8\NN|NONE (r_pobj) in_6\IN|who|lidocaine (r_prep) received_4\VBD| (r_relcl) patients_2\NNS|,|patient (r_nsubj) died_17\VBD|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN|NONE (l_dobj) bradydysrhythmias_20\NNS|died|.|; (l_conj) tachycardia_23\NN|or|;|seizures|, (l_conj) fibrillation_27\NN|or|,|ventricular
D008012_D002318 NONE lidocaine_4\NN|may|toxicity|that (r_nsubj) enhance_6\VB|theoretical (r_acl) concerns_2\NNS|NONE (r_pobj) Despite_0\IN|use|,|not|.|was|with (r_prep) associated_23\VBN|NONE (l_prep) with_24\IN|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN|NONE
D008012_D002318 NONE lidocaine_13\NN|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN|NONE (l_prep) with_24\IN|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN|NONE
D008012_D001919 NONE lidocaine_5\NN|who|in (r_dobj) received_4\VBD| (r_relcl) patients_2\NNS|,|patient (r_nsubj) died_17\VBD|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN|NONE (l_dobj) bradydysrhythmias_20\NNS|died|.|;
D008012_D001919 NONE lidocaine_35\NN|NONE (r_pobj) of_34\IN|interval (r_prep) administration_33\NN|NONE (r_pobj) after_32\IN|experienced (r_prep) seizures_31\NNS|or|tachycardia|;|, (r_conj) bradydysrhythmias_20\NNS|died|.|;
D003042_D002318 NONE cocaine_7\NN|NONE (r_compound) toxicity_8\NN|may|that|lidocaine (r_dobj) enhance_6\VB|theoretical (r_acl) concerns_2\NNS|NONE (r_pobj) Despite_0\IN|use|,|not|.|was|with (r_prep) associated_23\VBN|NONE (l_prep) with_24\IN|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN|NONE
D003042_D002318 NONE cocaine_17\NN| (r_npadvmod) associated_19\VBN|NONE (r_amod) MI_20\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) patients_15\NNS|NONE (r_pobj) in_14\IN|the|of (r_prep) use_11\NN|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN|NONE (l_prep) with_24\IN|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN|NONE
D003042_D064420 NONE cocaine_7\NN|NONE (r_compound) toxicity_8\NN|may|that|lidocaine
D003042_D064420 NONE cocaine_17\NN| (r_npadvmod) associated_19\VBN|NONE (r_amod) MI_20\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) patients_15\NNS|NONE (r_pobj) in_14\IN|the|of (r_prep) use_11\NN|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN|NONE (l_prep) Despite_0\IN|use|,|not|.|was|with (l_pobj) concerns_2\NNS|NONE (l_acl) enhance_6\VB|theoretical (l_dobj) toxicity_8\NN|may|that|lidocaine
D003042_D001919 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|NONE (r_amod) MI_13\NNP|NONE (r_pobj) of_9\IN|the (r_prep) setting_8\NN|NONE (r_pobj) in_6\IN|who|lidocaine (r_prep) received_4\VBD| (r_relcl) patients_2\NNS|,|patient (r_nsubj) died_17\VBD|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN|NONE (l_dobj) bradydysrhythmias_20\NNS|died|.|;
17035713
-1_D007674 NONE sulfhydryl_3\NN|a (r_amod) reagent_4\NN|NONE (r_pobj) as_1\IN|.|role|: (r_prep) Chloroacetaldehyde_0\NNP|NONE (l_appos) role_7\NN|.|as|: (l_prep) of_8\IN|the (l_pobj) groups_11\NNS|NONE (l_prep) in_12\IN|thiol|critical (l_pobj) nephropathy_14\NN|NONE
C004656_D009369 NONE Chloroacetaldehyde_0\NNP|.|metabolite (r_nsubj) is_4\VBZ|NONE (l_attr) metabolite_6\NN|.|Chloroacetaldehyde (l_conj) responsible_17\JJ|a|of|and (l_prep) for_18\IN|putatively (l_pobj) damage_20\NN|NONE (l_prep) following_21\VBG|renal (l_pobj) therapy_25\NN|with (l_compound) tumor_24\NN|NONE
C004656_D009369 NONE CAA_2\NNP|)|( (r_appos) Chloroacetaldehyde_0\NNP|.|metabolite (r_nsubj) is_4\VBZ|NONE (l_attr) metabolite_6\NN|.|Chloroacetaldehyde (l_conj) responsible_17\JJ|a|of|and (l_prep) for_18\IN|putatively (l_pobj) damage_20\NN|NONE (l_prep) following_21\VBG|renal (l_pobj) therapy_25\NN|with (l_compound) tumor_24\NN|NONE
C004656_D064420 NONE CAA_2\NNP|NONE (r_pobj) of_1\IN|NONE (r_prep) Toxicity_0\NN|by|trypan|was|.
C004656_D064420 NONE CAA_2\NNP|Thus|.|,|directly|mediating|,|with (r_nsubj) reacts_4\VBZ|NONE (l_advcl) mediating_14\VBG|Thus|.|,|directly|CAA|,|with (l_dobj) toxicity_16\NN|NONE
D007069_D007674 CID ifosfamide_13\JJ|NONE (r_amod) nephropathy_14\NN|NONE
D007069_D007674 CID ifosfamide_11\NN|NONE (r_pobj) of_7\IN|a|responsible|and (r_prep) metabolite_6\NN|.|Chloroacetaldehyde (l_conj) responsible_17\JJ|a|of|and (l_prep) for_18\IN|putatively (l_pobj) damage_20\NN|NONE
D007069_D007674 CID IFO_13\NN|the|agent|)|( (r_appos) ifosfamide_11\NN|NONE (r_pobj) of_7\IN|a|responsible|and (r_prep) metabolite_6\NN|.|Chloroacetaldehyde (l_conj) responsible_17\JJ|a|of|and (l_prep) for_18\IN|putatively (l_pobj) damage_20\NN|NONE
D007069_D007674 CID IFO_27\NN|NONE (r_pobj) with_26\IN|therapy (r_prep) following_21\VBG|renal (r_prep) damage_20\NN|NONE
D007069_D007674 CID IFO_10\NN|NONE (r_compound) nephropathy_11\NN|in|to
D014343_D064420 NONE blue_16\JJ|NONE (r_amod) exclusion_17\NN|and|activity (r_compound) assay_18\NN|NONE (r_dobj) trypan_15\NN|by|was|Toxicity|. (r_advcl) determined_4\VBN|NONE (l_nsubjpass) Toxicity_0\NN|by|trypan|was|.
D007069_D009369 NONE ifosfamide_11\NN|NONE (r_pobj) of_7\IN|a|responsible|and (r_prep) metabolite_6\NN|.|Chloroacetaldehyde (l_conj) responsible_17\JJ|a|of|and (l_prep) for_18\IN|putatively (l_pobj) damage_20\NN|NONE (l_prep) following_21\VBG|renal (l_pobj) therapy_25\NN|with (l_compound) tumor_24\NN|NONE
D007069_D009369 NONE IFO_13\NN|the|agent|)|( (r_appos) ifosfamide_11\NN|NONE (r_pobj) of_7\IN|a|responsible|and (r_prep) metabolite_6\NN|.|Chloroacetaldehyde (l_conj) responsible_17\JJ|a|of|and (l_prep) for_18\IN|putatively (l_pobj) damage_20\NN|NONE (l_prep) following_21\VBG|renal (l_pobj) therapy_25\NN|with (l_compound) tumor_24\NN|NONE
D007069_D009369 NONE IFO_27\NN|NONE (r_pobj) with_26\IN|therapy (r_prep) following_21\VBG|renal (l_pobj) therapy_25\NN|with (l_compound) tumor_24\NN|NONE
D013438_D064420 NONE thiols_12\NNS|NONE (r_pobj) with_5\IN|Thus|.|,|directly|CAA|mediating|, (r_prep) reacts_4\VBZ|NONE (l_advcl) mediating_14\VBG|Thus|.|,|directly|CAA|,|with (l_dobj) toxicity_16\NN|NONE
C004656_D009336 NONE CAA_0\NNP|.|number|induced|, (r_nsubj) reduced_1\VBD|NONE (l_conj) induced_8\VBD|CAA|.|number|, (l_dobj) loss_10\NN|NONE (l_conj) increase_17\NN|a|in|and (l_prep) in_18\IN|an (l_pobj) markers_20\NNS|NONE (l_compound) necrosis_19\NN|NONE
C004656_D009336 NONE CAA_7\NNP|NONE (r_pobj) of_6\IN|the|with (r_prep) reaction_5\NN|which (r_dobj) slowed_3\VBD|,|, (r_relcl) Acidification_0\NN|effects|.|also|could (r_nsubj) attenuate_14\VB|NONE (l_dobj) effects_15\NNS|Acidification|.|also|could (l_prep) on_18\IN|of (l_pobj) markers_20\NNS|NONE (l_compound) necrosis_19\NN|depletion|,
C004656_D009336 NONE CAA_17\NNP|NONE (r_pobj) of_16\IN|on (r_prep) effects_15\NNS|Acidification|.|also|could (l_prep) on_18\IN|of (l_pobj) markers_20\NNS|NONE (l_compound) necrosis_19\NN|depletion|,
D003545_D009336 NONE cysteine_25\NN|NONE (r_compound) protease_26\NN|in (r_compound) inhibition_27\NN|thiol|and (r_conj) depletion_23\NN|,|necrosis (r_conj) markers_20\NNS|NONE (l_compound) necrosis_19\NN|depletion|,
C004656_D007674 NONE Chloroacetaldehyde_0\NNP|NONE (l_appos) role_7\NN|.|as|: (l_prep) of_8\IN|the (l_pobj) groups_11\NNS|NONE (l_prep) in_12\IN|thiol|critical (l_pobj) nephropathy_14\NN|NONE
C004656_D007674 NONE Chloroacetaldehyde_0\NNP|.|metabolite (r_nsubj) is_4\VBZ|NONE (l_attr) metabolite_6\NN|.|Chloroacetaldehyde (l_conj) responsible_17\JJ|a|of|and (l_prep) for_18\IN|putatively (l_pobj) damage_20\NN|NONE
C004656_D007674 NONE CAA_2\NNP|)|( (r_appos) Chloroacetaldehyde_0\NNP|.|metabolite (r_nsubj) is_4\VBZ|NONE (l_attr) metabolite_6\NN|.|Chloroacetaldehyde (l_conj) responsible_17\JJ|a|of|and (l_prep) for_18\IN|putatively (l_pobj) damage_20\NN|NONE
D013438_D009336 NONE thiols_14\NNS|NONE (r_pobj) in_11\IN|a|increase|and (r_prep) loss_10\NN|NONE (l_conj) increase_17\NN|a|in|and (l_prep) in_18\IN|an (l_pobj) markers_20\NNS|NONE (l_compound) necrosis_19\NN|NONE
D013438_D009336 NONE thiol_9\JJ|NONE (r_compound) donors_10\NNS|NONE (r_pobj) with_8\IN|the|of (r_prep) reaction_5\NN|which (r_dobj) slowed_3\VBD|,|, (r_relcl) Acidification_0\NN|effects|.|also|could (r_nsubj) attenuate_14\VB|NONE (l_dobj) effects_15\NNS|Acidification|.|also|could (l_prep) on_18\IN|of (l_pobj) markers_20\NNS|NONE (l_compound) necrosis_19\NN|depletion|,
D013438_D009336 NONE thiol_22\JJ|inhibition|and (r_compound) depletion_23\NN|,|necrosis (r_conj) markers_20\NNS|NONE (l_compound) necrosis_19\NN|depletion|,
D013438_D007674 NONE thiol_10\JJ|in|critical (r_compound) groups_11\NNS|NONE (l_prep) in_12\IN|thiol|critical (l_pobj) nephropathy_14\NN|NONE
9831002
D008774_D009459 CID methylphenidate_4\NN|and|.|malignant|Neuroleptic (r_conj) syndrome_2\NN|NONE
D008774_D009459 CID methylphenidate_13\NN|NONE (r_pobj) by_12\IN|.|presented|probably (r_agent) caused_11\VBN|NONE (l_nsubj) presented_5\VBN|.|by|probably (l_prep) with_6\IN|female (l_pobj) syndrome_9\NN|NONE
D008774_D009459 CID methylphenidate_13\NN|NONE (r_pobj) by_12\IN|probably (r_agent) caused_11\VBN|first|the|with|reported (r_acl) patient_5\JJ|.|This (l_prep) with_6\IN|first|the|reported|caused (l_pobj) syndrome_9\NN|NONE
24072398
D012701_D003866 NONE serotonin_38\NN|and|tyrosine (r_conj) hydroxylase_36\NN|and|HVA|, (r_conj) DOPAC_31\NNP|by|, (r_conj) indicated_21\VBN|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN|NONE (l_nsubjpass) profile_4\NN|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ|induced|This (l_npadvmod) depressive_1\JJ|
D015102_D003866 NONE DOPAC_31\NNP|by|, (r_conj) indicated_21\VBN|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN|NONE (l_nsubjpass) profile_4\NN|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ|induced|This (l_npadvmod) depressive_1\JJ|
D008694_D003866 CID methamphetamine_5\NN|NONE (r_pobj) of_4\IN|single|A|neurotoxic (r_prep) dose_3\NN|.|behaviour (r_nsubj) induces_6\VBZ|NONE (l_dobj) behaviour_14\NN|.|dose (l_amod) like_13\JJ|in|a|lasting (l_amod) depressive_11\JJ|
D008694_D003866 CID Methamphetamine_0\NN|leads|.|disruption (r_nsubj) triggers_4\VBZ|NONE (l_conj) leads_14\VBZ|.|Methamphetamine|disruption (l_prep) to_15\IN|abuse (l_pobj) states_18\NNS|NONE (l_prep) including_19\VBG|negative|emotional (l_pobj) symptoms_21\NNS|NONE
D008694_D003866 CID METH_2\NNP|(|) (r_appos) Methamphetamine_0\NN|leads|.|disruption (r_nsubj) triggers_4\VBZ|NONE (l_conj) leads_14\VBZ|.|Methamphetamine|disruption (l_prep) to_15\IN|abuse (l_pobj) states_18\NNS|NONE (l_prep) including_19\VBG|negative|emotional (l_pobj) symptoms_21\NNS|NONE
D008694_D003866 CID METH_12\NNP|NONE (r_compound) abuse_13\NN|to (r_nsubj) leads_14\VBZ|.|Methamphetamine|disruption (l_prep) to_15\IN|abuse (l_pobj) states_18\NNS|NONE (l_prep) including_19\VBG|negative|emotional (l_pobj) symptoms_21\NNS|NONE
D008694_D003866 CID METH_12\NNP|NONE (r_pobj) of_11\IN|acute|toxic|the (r_prep) dosage_10\NN|also|if|phenotype (r_nsubj) causes_14\VBZ|However|.|it|currently|,|unknown (l_dobj) phenotype_20\NN|also|if|dosage (l_amod) depressive_19\JJ|deficits|and|a|lasting
D008694_D003866 CID METH_23\NNP|a|high|single|mg/kg (r_compound) dose_24\NN|NONE (r_pobj) following_19\VBG|Thus|.|,|we|at|behaviour|now (r_prep) assessed_4\VBD|NONE (l_dobj) behaviour_9\NN|Thus|.|,|we|at|following|now (l_amod) like_8\JJ|the|in (l_npadvmod) depressive_6\JJ|
D008694_D003866 CID METH_7\NNP|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|This|like (r_acl) profile_4\NN|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ|induced|This (l_npadvmod) depressive_1\JJ|
D008694_D003866 CID METH_13\NNP|NONE (r_pobj) of_12\IN|a|high|single (r_prep) dose_11\NN|that|behaviour (r_nsubj) induces_14\VBZ|findings|.|for (l_dobj) behaviour_21\NN|that|dose (l_amod) like_20\JJ|in|lasting (l_amod) depressive_18\JJ|
D006719_D003866 NONE HVA_33\NNP|hydroxylase|and|, (r_conj) DOPAC_31\NNP|by|, (r_conj) indicated_21\VBN|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN|NONE (l_nsubjpass) profile_4\NN|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ|induced|This (l_npadvmod) depressive_1\JJ|
D014443_D003866 NONE tyrosine_35\JJ|and|serotonin (r_compound) hydroxylase_36\NN|and|HVA|, (r_conj) DOPAC_31\NNP|by|, (r_conj) indicated_21\VBN|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN|NONE (l_nsubjpass) profile_4\NN|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ|induced|This (l_npadvmod) depressive_1\JJ|
D008694_D020258 NONE methamphetamine_5\NN|NONE (r_pobj) of_4\IN|single|A|neurotoxic (r_prep) dose_3\NN|.|behaviour (l_amod) neurotoxic_2\JJ|single|of|A
D004298_D003866 NONE dopamine_29\NN|NONE (r_pobj) of_28\IN|the (r_prep) levels_27\NNS|NONE (r_pobj) in_25\IN|a (r_prep) reduction_24\NN|NONE (r_pobj) by_22\IN|,|DOPAC (r_agent) indicated_21\VBN|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN|NONE (l_nsubjpass) profile_4\NN|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ|induced|This (l_npadvmod) depressive_1\JJ|
18801087
D000638_D009369 NONE amiodarone_11\NN| (r_npadvmod) related_13\VBN|pulmonary|and|neoplasm|an (r_amod) lesion_15\NN|NONE (l_conj) neoplasm_18\NN|pulmonary|and|an|related
D000638_D009369 NONE amiodarone_36\NN|NONE (r_compound) treatment_37\NN|NONE (r_pobj) of_35\IN|another|possible (r_prep) complication_34\NN|might|glomerulonephritis|that (r_attr) be_31\VB|NONE (r_ccomp) suggests_26\VBZ|possibility|and|case|.|, (r_conj) highlights_3\VBZ|NONE (l_dobj) possibility_5\NN|suggests|and|case|.|, (l_acl) be_20\VB|the (l_nsubj) diagnosis_8\NN|radiologically|difficult|can|that (l_prep) between_9\IN|differential (l_pobj) lesion_15\NN|NONE (l_conj) neoplasm_18\NN|pulmonary|and|an|related
D000638_D001145 NONE Amiodarone_0\NN|but|drug|,|reported (r_nsubj) is_1\VBZ|NONE (l_attr) drug_6\NN|Amiodarone|but|,|reported (l_amod) arrhythmic_5\JJ|for|an
D000638_D055370 CID Amiodarone_0\NN| (r_npadvmod) related_2\VBN|.|pulmonary|pitfall|in|and|:|glomerulonephritis (r_amod) mass_4\NN|NONE
D000638_D055370 CID amiodarone_36\NN|NONE (r_pobj) with_35\IN|for (r_prep) treatment_34\NN|NONE (r_pobj) after_33\IN|who|mass (r_prep) developed_15\VBD|a (l_dobj) mass_18\NN|after|who
D000638_D055370 CID amiodarone_47\NN| (r_npadvmod) related_49\VBN|an (r_amod) lesion_50\NN|it|that (r_attr) was_45\VBD|NONE (r_ccomp) indicating_42\VBG|was|lesion|.|histologically|of|, (r_advcl) composed_22\VBN|mass|was|but|be|highly|, (r_conj) suspected_5\VBN|NONE (l_nsubjpass) mass_2\NN|was|but|be|highly|,|composed
D000638_D055370 CID amiodarone_11\NN| (r_npadvmod) related_13\VBN|pulmonary|and|neoplasm|an (r_amod) lesion_15\NN|NONE
D000638_D055370 CID amiodarone_36\NN|NONE (r_compound) treatment_37\NN|NONE (r_pobj) of_35\IN|another|possible (r_prep) complication_34\NN|might|glomerulonephritis|that (r_attr) be_31\VB|NONE (r_ccomp) suggests_26\VBZ|possibility|and|case|.|, (r_conj) highlights_3\VBZ|NONE (l_dobj) possibility_5\NN|suggests|and|case|.|, (l_acl) be_20\VB|the (l_nsubj) diagnosis_8\NN|radiologically|difficult|can|that (l_prep) between_9\IN|differential (l_pobj) lesion_15\NN|NONE
D000638_D013610 NONE Amiodarone_0\NN|but|drug|,|reported (r_nsubj) is_1\VBZ|NONE (l_attr) drug_6\NN|Amiodarone|but|,|reported (l_prep) for_7\IN|arrhythmic|an (l_pobj) tachycardia_11\NN|NONE
D000638_D015433 CID Amiodarone_0\NN| (r_npadvmod) related_2\VBN|.|pulmonary|pitfall|in|and|:|glomerulonephritis (r_amod) mass_4\NN|NONE (l_conj) glomerulonephritis_8\NN|.|pulmonary|related|pitfall|in|and|:
D000638_D015433 CID amiodarone_11\NN| (r_npadvmod) related_13\VBN|pulmonary|and|neoplasm|an (r_amod) lesion_15\NN|NONE (r_pobj) between_9\IN|differential (r_prep) diagnosis_8\NN|radiologically|difficult|can|that (r_nsubj) be_20\VB|the (r_acl) possibility_5\NN|suggests|and|case|.|, (r_dobj) highlights_3\VBZ|NONE (l_conj) suggests_26\VBZ|possibility|and|case|.|, (l_ccomp) be_31\VB|NONE (l_nsubj) glomerulonephritis_29\NN|might|that|complication
D000638_D015433 CID amiodarone_36\NN|NONE (r_compound) treatment_37\NN|NONE (r_pobj) of_35\IN|another|possible (r_prep) complication_34\NN|might|glomerulonephritis|that (r_attr) be_31\VB|NONE (l_nsubj) glomerulonephritis_29\NN|might|that|complication
D000638_D008175 NONE amiodarone_47\NN| (r_npadvmod) related_49\VBN|an (r_amod) lesion_50\NN|it|that (r_attr) was_45\VBD|NONE (r_ccomp) indicating_42\VBG|was|lesion|.|histologically|of|, (r_advcl) composed_22\VBN|mass|was|but|be|highly|, (r_conj) suspected_5\VBN|NONE (l_xcomp) be_7\VB|mass|was|but|highly|,|composed (l_attr) cancer_9\NN|to
D000638_D006349 NONE Amiodarone_0\NN| (r_npadvmod) related_2\VBN|.|pulmonary|pitfall|in|and|:|glomerulonephritis (r_amod) mass_4\NN|NONE (l_prep) in_9\IN|.|pulmonary|related|pitfall|and|:|glomerulonephritis (l_pobj) patient_11\NN|NONE (l_prep) with_12\IN|a (l_pobj) disease_15\NN|NONE
D000638_D006349 NONE amiodarone_36\NN|NONE (r_pobj) with_35\IN|for (r_prep) treatment_34\NN|NONE (r_pobj) after_33\IN|who|mass (r_prep) developed_15\VBD|a (r_relcl) patient_13\NN|NONE (r_pobj) in_11\IN|is|herein|. (r_prep) Reported_0\VBN|NONE (l_auxpass) is_2\VBZ|herein|in|. (l_attr) case_5\NN|, (l_prep) of_6\IN|an|autopsy (l_pobj) disease_9\NN|NONE
D000638_D011507 NONE amiodarone_36\NN|NONE (r_pobj) with_35\IN|for (r_prep) treatment_34\NN|NONE (r_pobj) after_33\IN|who|mass (r_prep) developed_15\VBD|a (l_dobj) mass_18\NN|after|who (l_appos) cm_21\NNS|(|)|lung|a|day|( (l_conj) proteinuria_26\NN|in|and|)|.
20927253
D004164_D010024 NONE bisphosphonates_13\NNS|.|are|,|inhibit (r_nsubjpass) used_16\VBN|by|,|is|and|Osteoporosis (r_conj) caused_2\VBN|NONE (l_nsubjpass) Osteoporosis_0\NN|by|,|is|and|used
D004164_D010024 NONE bisphosphonate_11\NN| (r_npadvmod) related_13\VBN|NONE (r_amod) pain_14\NN|be|should|also|before (r_nsubjpass) considered_18\VBN|can|pain|patients|that|and (r_conj) report_7\VB|We|. (l_nsubj) patients_3\NNS|can|considered|pain|that|and (l_prep) with_4\IN|NONE (l_pobj) osteoporosis_5\NN|NONE
D004164_D010024 NONE bisphosphonate_11\NN| (r_npadvmod) related_13\VBN|NONE (r_amod) pain_14\NN|be|should|also|before (r_nsubjpass) considered_18\VBN|can|pain|patients|that|and (l_prep) before_19\IN|be|should|also|pain (l_pcomp) ascribing_20\VBG|NONE (l_prep) to_23\IN|complaint (l_pobj) osteoporosis_24\NN|NONE
D019386_D010146 CID alendronate_6\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) administration_4\NN|NONE (r_pobj) after_3\IN|.|skeletal|Diffuse (r_prep) pain_2\NN|NONE
D019386_D010146 CID alendronate_20\NN|NONE (r_pobj) of_19\IN|three|consecutive (r_prep) administration_18\NN|NONE (r_pobj) after_15\IN|to|with (r_prep) admitted_4\VBN|a (l_prep) with_11\IN|to|after (l_pobj) pain_14\NN|NONE
D004164_D010146 NONE bisphosphonate_11\NN| (r_npadvmod) related_13\VBN|NONE (r_amod) pain_14\NN|be|should|also|before (r_nsubjpass) considered_18\VBN|can|pain|patients|that|and (r_conj) report_7\VB|We|. (l_dobj) pain_8\NN|can|considered|patients|that|and
D004164_D010146 NONE bisphosphonate_11\NN| (r_npadvmod) related_13\VBN|NONE (r_amod) pain_14\NN|be|should|also|before
D019386_D010024 NONE Alendronate_0\NNP|.|effective (r_nsubj) is_5\VBZ|NONE (l_acomp) effective_6\JJ|.|Alendronate (l_prep) for_7\IN|NONE (l_pobj) treatment_10\NN|NONE (l_prep) of_13\IN|the|both|prevention|and (l_pobj) osteoporosis_14\NN|NONE
-1_D010024 NONE biphosphonate_3\NN|,|, (r_appos) Alendronate_0\NNP|.|effective (r_nsubj) is_5\VBZ|NONE (l_acomp) effective_6\JJ|.|Alendronate (l_prep) for_7\IN|NONE (l_pobj) treatment_10\NN|NONE (l_prep) of_13\IN|the|both|prevention|and (l_pobj) osteoporosis_14\NN|NONE
24902786
D013629_D008569 CID tamoxifen_6\NN|or (r_conj) letrozole_4\NN|,|of (r_conj) Administration_0\NN|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD|NONE (l_dobj) memory_10\NN|attenuated|Administration|.|and|significantly|,
D013629_D008569 CID tamoxifen_6\NN|or (r_conj) letrozole_4\NN|,|of (r_conj) Administration_0\NN|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD|NONE (l_conj) attenuated_17\VBD|memory|Administration|.|and|significantly|, (l_dobj) replacement_20\NN|significantly (l_prep) in_21\IN|the|testosterone (l_pcomp) improving_22\VBG|NONE (l_dobj) impairment_29\NN|NONE
D013739_D008569 NONE Testosterone_0\NN|.|impairment (r_nsubj) ameliorates_1\VBZ|NONE (l_dobj) impairment_6\NN|Testosterone|.
D013739_D008569 NONE testosterone_7\NN|NONE (r_pobj) of_6\IN|the|on (r_prep) effects_5\NNS|To (l_prep) on_8\IN|the|of (l_pobj) impairment_13\NN|NONE
D013739_D008569 NONE testosterone_19\NN|the|in (r_compound) replacement_20\NN|significantly (r_dobj) attenuated_17\VBD|memory|Administration|.|and|significantly|, (r_conj) impaired_8\VBD|NONE (l_dobj) memory_10\NN|attenuated|Administration|.|and|significantly|,
D013739_D008569 NONE testosterone_19\NN|the|in (r_compound) replacement_20\NN|significantly (l_prep) in_21\IN|the|testosterone (l_pcomp) improving_22\VBG|NONE (l_dobj) impairment_29\NN|NONE
D013739_D008569 NONE Testosterone_0\NN|NONE (r_compound) administration_1\NN|.|impairment (r_nsubj) ameliorates_2\VBZ|NONE (l_dobj) impairment_9\NN|administration|.
C067431_D008569 CID letrozole_4\NN|,|of (r_conj) Administration_0\NN|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD|NONE (l_dobj) memory_10\NN|attenuated|Administration|.|and|significantly|,
C067431_D008569 CID letrozole_4\NN|,|of (r_conj) Administration_0\NN|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD|NONE (l_conj) attenuated_17\VBD|memory|Administration|.|and|significantly|, (l_dobj) replacement_20\NN|significantly (l_prep) in_21\IN|the|testosterone (l_pcomp) improving_22\VBG|NONE (l_dobj) impairment_29\NN|NONE
D005485_D008569 CID flutamide_2\NN|NONE (r_pobj) of_1\IN|,|letrozole (r_prep) Administration_0\NN|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD|NONE (l_dobj) memory_10\NN|attenuated|Administration|.|and|significantly|,
D005485_D008569 CID flutamide_2\NN|NONE (r_pobj) of_1\IN|,|letrozole (r_prep) Administration_0\NN|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD|NONE (l_conj) attenuated_17\VBD|memory|Administration|.|and|significantly|, (l_dobj) replacement_20\NN|significantly (l_prep) in_21\IN|the|testosterone (l_pcomp) improving_22\VBG|NONE (l_dobj) impairment_29\NN|NONE
D013311_D008569 CID streptozotocin_2\RB| (r_npadvmod) induced_4\VBN|in|memory (r_amod) impairment_6\NN|Testosterone|.
D013311_D008569 CID streptozotocin_9\JJ|memory|in|( (r_nmod) impairment_13\NN|NONE
D013311_D008569 CID STZ)-induced_11\VBN|NONE (r_amod) memory_12\NN|streptozotocin|in|( (r_compound) impairment_13\NN|NONE
D013311_D008569 CID STZ-_23\NNP|memory (r_nmod) impairment_29\NN|NONE (r_dobj) improving_22\VBG|NONE (r_pcomp) in_21\IN|the|testosterone (r_prep) replacement_20\NN|significantly (r_dobj) attenuated_17\VBD|memory|Administration|.|and|significantly|, (r_conj) impaired_8\VBD|NONE (l_dobj) memory_10\NN|attenuated|Administration|.|and|significantly|,
D013311_D008569 CID STZ-_23\NNP|memory (r_nmod) impairment_29\NN|NONE
D013311_D008569 CID STZ-_3\NNP|memory|induced|in (r_nmod) impairment_9\NN|administration|.
8160791
D006152_D007674 NONE monophosphate_7\NN|)|and|(|increase|cGMP (r_nmod) excretion_11\NN|A|significant|in (r_appos) reduction_2\NN|in|.|also|were (r_nsubjpass) observed_25\VBN|NONE (l_prep) in_26\IN|reduction|.|also|were (l_pobj) nephropathy_30\NN|NONE
D006152_D007674 NONE cGMP_9\NN|)|and|(|increase|monophosphate (r_nmod) excretion_11\NN|A|significant|in (r_appos) reduction_2\NN|in|.|also|were (r_nsubjpass) observed_25\VBN|NONE (l_prep) in_26\IN|reduction|.|also|were (l_pobj) nephropathy_30\NN|NONE
D005839_D007674 CID gentamicin_9\NN| (r_npadvmod) mediated_11\VBN|NONE (r_amod) nephropathy_12\NN|NONE
D005839_D007674 CID gentamicin_16\NN|GM)mediated|( (r_nmod) nephropathy_19\NN|NONE
D005839_D007674 CID GM)-mediated_18\JJ|(|gentamicin (r_amod) nephropathy_19\NN|NONE
D005839_D007674 CID GM_2\NNP|NONE (r_pobj) of_1\IN|for|at (r_prep) Administration_0\NN|damage|.|reduction (r_nsubj) induced_12\VBD|NONE (l_dobj) damage_34\NN|.|Administration|reduction
D005839_D007674 CID GM_27\NNP| (r_npadvmod) mediated_29\VBN|NONE (r_amod) nephropathy_30\NN|NONE
D005839_D007674 CID GM_14\NNP| (r_npadvmod) mediated_16\VBN|,||) (r_amod) nephropathy_17\NN|NONE
D005839_D007674 CID GM_43\NNP| (r_npadvmod) induced_45\VBN|renal (r_amod) vasoconstriction_47\NN|NONE (r_pobj) in_42\IN|critical|a (r_prep) role_41\NN|NONE (r_dobj) play_38\VBP|SOD|differ|that||effects (r_conj) have_10\VBP|results|. (l_dobj) effects_12\NNS|SOD|play|differ|that| (l_prep) on_13\IN|protective (l_pobj) nephropathy_17\NN|NONE
D013481_D007674 NONE superoxide_36\JJ|NONE (r_amod) anions_37\NNS|DMTU|,|and|and| (r_conj) SOD_29\NNP|NONE (r_pobj) for_28\IN|mechanisms (r_prep) differ_27\VBP|SOD|play|that||effects (r_conj) have_10\VBP|results|. (l_dobj) effects_12\NNS|SOD|play|differ|that| (l_prep) on_13\IN|protective (l_pobj) nephropathy_17\NN|NONE
C038983_D007674 NONE DMTU_3\NNP|,|but|affect|significantly|In|damage|, (r_nsubj) reduced_5\VBD|NONE (l_dobj) damage_8\NN|,|but|affect|significantly|DMTU|In|,
C038983_D007674 NONE DMTU_9\NNP|both|and (r_conj) SOD_7\NNP|play|differ|that||effects (r_nsubj) have_10\VBP|results|. (l_dobj) effects_12\NNS|SOD|play|differ|that| (l_prep) on_13\IN|protective (l_pobj) nephropathy_17\NN|NONE
C038983_D007674 NONE DMTU_31\NNP|,|and|anions|and| (r_conj) SOD_29\NNP|NONE (r_pobj) for_28\IN|mechanisms (r_prep) differ_27\VBP|SOD|play|that||effects (r_conj) have_10\VBP|results|. (l_dobj) effects_12\NNS|SOD|play|differ|that| (l_prep) on_13\IN|protective (l_pobj) nephropathy_17\NN|NONE
8701013
D015738_D014456 NONE Famotidine_0\NNP|and|showing|.|antagonist (r_nsubj) is_1\VBZ|NONE (l_attr) antagonist_5\NN|and|showing|.|Famotidine (l_acl) used_6\VBD|a|Hreceptor|histamine (l_prep) in_7\IN|NONE (l_pobj) settings_9\NNS|NONE (l_prep) for_10\IN|inpatient (l_pobj) prevention_11\NN|NONE (l_prep) of_12\IN|NONE (l_pobj) ulcers_14\NNS|NONE
D015738_D003693 CID Famotidine_0\NN| (r_npadvmod) associated_2\VBN|. (r_amod) delirium_3\NN|NONE
D015738_D003693 CID famotidine_25\NN|NONE (r_pobj) with_24\IN|been|cases|have|,|.|shown (r_prep) associated_23\VBN|NONE (l_advcl) shown_9\VBN|been|with|cases|have|,|. (l_dobj) propensity_11\NN|Although|all|have (l_acl) cause_13\VB|the (l_dobj) delirium_14\NN|to
D015738_D003693 CID famotidine_7\NN| (r_npadvmod) associated_9\VBN|in (r_amod) delirium_10\NN|NONE
D015738_D003693 CID famotidine_20\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) removal_18\NN|NONE (r_pobj) upon_17\IN|completely|who (r_prep) cleared_15\VBD|hospitalized (r_relcl) patients_13\NNS|NONE (r_pobj) in_11\IN|associated (r_prep) delirium_10\NN|NONE
24684312
D018698_D010146 NONE glutamate_3\NN|NONE (r_pobj) of_2\IN|Intradermal (r_prep) injections_1\NNS|attractive|mimic|. (r_nsubj) are_6\VBP|NONE (l_acomp) attractive_7\JJ|mimic|injections|. (l_xcomp) use_9\VB|NONE (l_prep) in_10\IN|to (l_pobj) models_14\NNS|NONE (l_compound) pain_13\NN|human|experimental
D002211_D013001 NONE capsaicin_5\NN|and (r_conj) glutamate_3\NN|NONE (r_pobj) of_2\IN|Intradermal (r_prep) injections_1\NNS|attractive|mimic|. (r_nsubj) are_6\VBP|NONE (l_advcl) mimic_19\VBP|attractive|injections|. (l_dobj) aspects_21\NNS|because|hyperalgesia (l_prep) of_22\IN|isolated (l_pobj) disorders_25\NNS|NONE
D002211_D010146 NONE capsaicin_5\NN|and (r_conj) glutamate_3\NN|NONE (r_pobj) of_2\IN|Intradermal (r_prep) injections_1\NNS|attractive|mimic|. (r_nsubj) are_6\VBP|NONE (l_acomp) attractive_7\JJ|mimic|injections|. (l_xcomp) use_9\VB|NONE (l_prep) in_10\IN|to (l_pobj) models_14\NNS|NONE (l_compound) pain_13\NN|human|experimental
D018698_D006930 NONE glutamate_1\NN|NONE (l_appos) variability_9\NN|:|Intradermal|and|injections|. (l_prep) of_10\IN|intra (l_pobj) hyperalgesia_12\NN|NONE
D018698_D006930 NONE glutamate_1\NN|NONE (l_appos) variability_9\NN|:|Intradermal|and|injections|. (l_prep) of_10\IN|intra (l_pobj) hyperalgesia_12\NN|NONE (l_conj) allodynia_14\NN|provoked|and
D018698_D006930 NONE glutamate_3\NN|NONE (r_pobj) of_2\IN|Intradermal (r_prep) injections_1\NNS|attractive|mimic|. (r_nsubj) are_6\VBP|NONE (l_advcl) mimic_19\VBP|attractive|injections|. (l_nsubj) hyperalgesia_16\NN|aspects|because
D018698_D006930 NONE glutamate_3\NN|NONE (r_pobj) of_2\IN|Intradermal (r_prep) injections_1\NNS|attractive|mimic|. (r_nsubj) are_6\VBP|NONE (l_advcl) mimic_19\VBP|attractive|injections|. (l_nsubj) hyperalgesia_16\NN|aspects|because (l_conj) allodynia_18\NN|and
D018698_D006930 NONE glutamate_32\NN|NONE (r_compound) injection_33\NN|NONE (r_pobj) after_31\IN|)|P|(|and||g (r_prep) gauges_21\VBZ|Frey (r_pobj) to_18\IN|)|scale|VAS|( (r_prep) response_17\NN|NONE (r_pobj) in_9\IN|marked|a (r_prep) increase_8\NN|NONE (r_pobj) as_5\IN|.|hyperalgesia|was (r_prep) observed_4\VBN|NONE (l_nsubjpass) hyperalgesia_2\NN|.|was|as
D018698_D006930 NONE glutamate_3\NN|NONE (r_nmod) yield_6\NN|hyperalgesic|,|suited|and (r_nmod) responses_11\NNS|, (l_amod) hyperalgesic_8\JJ|,|suited|and|yield
D018698_D006930 NONE glutamate_3\NN|NONE (r_nmod) yield_6\NN|hyperalgesic|,|suited|and (r_nmod) responses_11\NNS|, (l_amod) hyperalgesic_8\JJ|,|suited|and|yield (l_conj) allodynic_10\JJ|reproducible|and
D002211_D006930 CID capsaicin_3\NN|NONE (r_compound) injections_4\NNS|:|Intradermal|variability|and|. (r_conj) glutamate_1\NN|NONE (l_appos) variability_9\NN|:|Intradermal|and|injections|. (l_prep) of_10\IN|intra (l_pobj) hyperalgesia_12\NN|NONE
D002211_D006930 CID capsaicin_3\NN|NONE (r_compound) injections_4\NNS|:|Intradermal|variability|and|. (r_conj) glutamate_1\NN|NONE (l_appos) variability_9\NN|:|Intradermal|and|injections|. (l_prep) of_10\IN|intra (l_pobj) hyperalgesia_12\NN|NONE (l_conj) allodynia_14\NN|provoked|and
D002211_D006930 CID capsaicin_5\NN|and (r_conj) glutamate_3\NN|NONE (r_pobj) of_2\IN|Intradermal (r_prep) injections_1\NNS|attractive|mimic|. (r_nsubj) are_6\VBP|NONE (l_advcl) mimic_19\VBP|attractive|injections|. (l_nsubj) hyperalgesia_16\NN|aspects|because
D002211_D006930 CID capsaicin_5\NN|and (r_conj) glutamate_3\NN|NONE (r_pobj) of_2\IN|Intradermal (r_prep) injections_1\NNS|attractive|mimic|. (r_nsubj) are_6\VBP|NONE (l_advcl) mimic_19\VBP|attractive|injections|. (l_nsubj) hyperalgesia_16\NN|aspects|because (l_conj) allodynia_18\NN|and
D002211_D006930 CID capsaicin_1\NN|NONE (r_pobj) For_0\IN|was|with|hyperalgesia|,|. (r_prep) detected_7\VBN|NONE (l_nsubjpass) hyperalgesia_5\NN|was|with|For|,|.
D002211_D006930 CID Capsaicin_0\NN|NONE (r_compound) injection_1\NN|.|>|reproducible|allodynia|and (r_nsubj) was_2\VBD|NONE (l_acomp) reproducible_3\JJ|.|injection|>|allodynia|and (l_prep) for_4\IN|NONE (l_pobj) hyperalgesia_6\NN|NONE
D002211_D006930 CID Capsaicin_0\NN|NONE (r_compound) injection_1\NN|.|>|reproducible|allodynia|and (r_nsubj) was_2\VBD|NONE (l_attr) allodynia_13\NN|.|injection|>|reproducible|and
D002211_D006930 CID capsaicin_5\NN|and (r_conj) glutamate_3\NN|NONE (r_nmod) yield_6\NN|hyperalgesic|,|suited|and (r_nmod) responses_11\NNS|, (l_amod) hyperalgesic_8\JJ|,|suited|and|yield
D002211_D006930 CID capsaicin_5\NN|and (r_conj) glutamate_3\NN|NONE (r_nmod) yield_6\NN|hyperalgesic|,|suited|and (r_nmod) responses_11\NNS|, (l_amod) hyperalgesic_8\JJ|,|suited|and|yield (l_conj) allodynic_10\JJ|reproducible|and
D018698_D013001 NONE glutamate_3\NN|NONE (r_pobj) of_2\IN|Intradermal (r_prep) injections_1\NNS|attractive|mimic|. (r_nsubj) are_6\VBP|NONE (l_advcl) mimic_19\VBP|attractive|injections|. (l_dobj) aspects_21\NNS|because|hyperalgesia (l_prep) of_22\IN|isolated (l_pobj) disorders_25\NNS|NONE
3925479
D001285_D002375 NONE atropine_5\NN|NONE (r_preconj) ,_4\,|,|blocker|catalepsy|. (r_punct) disrupted_7\VBD|NONE (l_dobj) catalepsy_11\NN|,|,|blocker|.
D006220_D002375 CID haloperidol_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) catalepsy_9\NN|NONE
D006220_D002375 CID haloperidol_19\NN|,|dopaminergic|the (r_appos) blocker_17\NN|NONE (r_pobj) by_14\IN|was|that (r_agent) induced_13\VBN|the (r_relcl) catalepsy_10\NN|NONE
D006220_D002375 CID haloperidol_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) catalepsy_11\NN|,|,|blocker|.
D006220_D002375 CID haloperidol_19\NN|NONE (r_pobj) by_18\IN|that|usually|is (r_agent) induced_17\VBN|the (r_relcl) catalepsy_13\NN|.|,|injection
D006220_D002375 CID haloperidol_15\NN|such (r_pobj) as_14\IN|NONE (r_prep) neuroleptics_12\NNS|NONE (r_pobj) by_11\IN|that|is (r_agent) produced_10\VBN|the (r_relcl) catalepsy_7\NN|is|that|by|actually
D014150_D002375 NONE neuroleptic_25\RB| (r_amod) induced_27\VBN|NONE (r_amod) catalepsy_28\NN|NONE (r_pobj) of_24\IN|full (r_prep) expression_23\NN|NONE (r_pobj) for_21\IN|to|intact (r_prep) be_19\VB|that|mechanisms (r_xcomp) need_17\VBP|that|activation|and|catalepsy (r_conj) promotes_11\VBZ|previous (l_dobj) catalepsy_12\NN|that|need|activation|and
D014150_D002375 NONE neuroleptic_25\RB| (r_amod) induced_27\VBN|NONE (r_amod) catalepsy_28\NN|NONE
D014150_D002375 NONE neuroleptics_12\NNS|NONE (r_pobj) by_11\IN|that|is (r_agent) produced_10\VBN|the (r_relcl) catalepsy_7\NN|is|that|by|actually
D000109_D002375 NONE acetylcholine_4\NN| (r_compound) synthesis_6\NN|,|an|hemicholinium (r_compound) inhibitor_7\NN|NONE (r_pobj) of_2\IN|Intracranial (r_prep) injection_1\NN|.|catalepsy|, (r_nsubj) prevented_11\VBD|NONE (l_dobj) catalepsy_13\NN|.|,|injection
D010862_D002375 CID pilocarpine_6\NN|Large|of|,|, (r_appos) doses_1\NNS|catalepsy|blocked|.|could (r_nsubj) induce_9\VB|NONE (l_dobj) catalepsy_10\NN|blocked|.|doses|could
D010862_D002375 CID pilocarpine_3\NN|NONE (r_pobj) of_2\IN|Low (r_prep) doses_1\NNS|.|enhancement (r_nsubj) caused_4\VBD|NONE (l_dobj) enhancement_7\NN|doses|. (l_prep) of_8\IN|pronounced|a (l_pobj) catalepsy_10\NN|NONE
D006426_D002375 NONE hemicholinium_9\NN|synthesis|,|an (r_appos) inhibitor_7\NN|NONE (r_pobj) of_2\IN|Intracranial (r_prep) injection_1\NN|.|catalepsy|, (r_nsubj) prevented_11\VBD|NONE (l_dobj) catalepsy_13\NN|.|,|injection
25084821
C069541_D008107 NONE quetiapine_23\NN|NONE (r_pobj) to_22\IN|adverse (r_prep) reaction_21\NN|NONE (r_pobj) for_19\IN|diagnostic|a (r_prep) marker_18\NN|fever|may|. (r_attr) be_15\VB|one|dysfunction|and|,|may (r_conj) be_3\VB|NONE (l_nsubj) dysfunction_1\NN|one|and|be|,|may
C069541_D007970 CID quetiapine_7\NN|NONE (r_pobj) with_6\IN|being (r_prep) treated_5\VBN|NONE (r_pcomp) after_3\IN|leucopenia|.|She (r_prep) developed_1\VBD|NONE (l_dobj) leucopenia_2\JJ|.|She|after
C069541_D006528 NONE Quetiapine_0\NNP|neutropenia||.|in (r_npadvmod) induced_2\VBN|NONE (l_prep) in_4\IN|neutropenia||.|Quetiapine (l_pobj) patient_7\NN|NONE (l_prep) with_8\IN|a|bipolar (l_pobj) carcinoma_10\NN|NONE
C069541_D006528 NONE quetiapine_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) after_11\IN|that|neutropenia (r_prep) developed_9\VBD|with|a (r_relcl) patient_4\NN|NONE (l_prep) with_5\IN|a|developed (l_pobj) carcinoma_7\NN|NONE
C069541_D005334 CID quetiapine_23\NN|NONE (r_pobj) to_22\IN|adverse (r_prep) reaction_21\NN|NONE (r_pobj) for_19\IN|diagnostic|a (r_prep) marker_18\NN|fever|may|. (r_attr) be_15\VB|one|dysfunction|and|,|may (l_nsubj) fever_13\NN|marker|may|.
C069541_D001714 NONE Quetiapine_0\NNP|neutropenia||.|in (r_npadvmod) induced_2\VBN|NONE (l_prep) in_4\IN|neutropenia||.|Quetiapine (l_pobj) patient_7\NN|NONE (l_amod) bipolar_6\JJ|a|with
C069541_D009503 CID Quetiapine_0\NNP|neutropenia||.|in (r_npadvmod) induced_2\VBN|NONE (l_dobj) neutropenia_3\NN||.|Quetiapine|in
C069541_D009503 CID Quetiapine_1\NNP|has|.|derivative|: (r_nsubj) is_2\VBZ|NONE (l_advcl) has_12\VBZ|.|Quetiapine|derivative|: (l_dobj) risk_15\NN|which (l_prep) of_16\IN|highest|the (l_pcomp) causing_17\VBG|NONE (l_dobj) dyscrasias_19\NNS|NONE (l_appos) neutropenia_22\NN|blood|,
C069541_D009503 CID quetiapine_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) after_11\IN|that|neutropenia (r_prep) developed_9\VBD|with|a (l_dobj) neutropenia_10\NN|after|that
C069541_D009503 CID quetiapine_9\NN|NONE (r_pobj) of_8\IN|a|side|common (r_prep) effect_7\NN|Although|not|neutropenia (r_attr) is_2\VBZ|cautious|.|should|,|physicians (l_nsubj) neutropenia_1\NN|Although|not|effect
D003024_D009503 NONE clozapine_9\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) similar_7\JJ|dibenzothiazepine|,|,|a (r_amod) derivative_5\JJ|has|.|Quetiapine|: (r_attr) is_2\VBZ|NONE (l_advcl) has_12\VBZ|.|Quetiapine|derivative|: (l_dobj) risk_15\NN|which (l_prep) of_16\IN|highest|the (l_pcomp) causing_17\VBG|NONE (l_dobj) dyscrasias_19\NNS|NONE (l_appos) neutropenia_22\NN|blood|,
D003024_D006402 NONE clozapine_9\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) similar_7\JJ|dibenzothiazepine|,|,|a (r_amod) derivative_5\JJ|has|.|Quetiapine|: (r_attr) is_2\VBZ|NONE (l_advcl) has_12\VBZ|.|Quetiapine|derivative|: (l_dobj) risk_15\NN|which (l_prep) of_16\IN|highest|the (l_pcomp) causing_17\VBG|NONE (l_dobj) dyscrasias_19\NNS|NONE
C069541_D006402 NONE Quetiapine_1\NNP|has|.|derivative|: (r_nsubj) is_2\VBZ|NONE (l_advcl) has_12\VBZ|.|Quetiapine|derivative|: (l_dobj) risk_15\NN|which (l_prep) of_16\IN|highest|the (l_pcomp) causing_17\VBG|NONE (l_dobj) dyscrasias_19\NNS|NONE
18341442
C026098_C562694 NONE Levetiracetam_0\NNP|NONE (l_advcl) phenobarbital_5\JJ|as|. (l_dobj) treatment_6\NN|to (l_prep) in_7\IN|NONE (l_pobj) cats_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) epilepsy_12\NN|NONE
C026098_C562694 NONE levetiracetam_10\NN|NONE (l_advcl) phenobarbital_16\JJ|assess|.|administered (l_dobj) treatment_17\NN|to (l_prep) in_18\IN|NONE (l_pobj) cats_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) epilepsy_25\NN|NONE
C026098_C562694 NONE levetiracetam_3\NN|is|and|well|be|that|in (r_nsubjpass) tolerated_6\VBN|.|Results (l_conj) be_11\VB|is|and|well|that|in|levetiracetam (l_acomp) useful_12\JJ|may (l_prep) as_13\IN|NONE (l_pobj) adjunct_15\NN|NONE (l_relcl) phenobarbital_17\JJ|an (l_dobj) treatment_18\NN|to (l_prep) in_19\IN|NONE (l_pobj) cats_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) epilepsy_23\NN|NONE
C026098_D012640 NONE levetiracetam_7\NN|NONE (r_amod) treatment_8\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) initiation_5\NN|and|frequencies|were|,|recorded (r_nsubjpass) compared_10\VBN|NONE (l_nsubjpass) frequencies_1\NNS|and|were|,|recorded|initiation (l_compound) Seizure_0\NN|before
C026098_D012640 NONE levetiracetam_7\NN|NONE (r_pcomp) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) prior_3\RB|and|higher|classified|,|after|frequency (r_advmod) was_14\VBD|NONE (l_nsubj) frequency_2\NN|and|prior|higher|classified|,|after (l_compound) seizure_1\NN|Median
C026098_D012640 NONE levetiracetam_7\NN|NONE (l_appos) seizures_10\NNS|)|(
C026098_D012640 NONE levetiracetam_7\NN|NONE (r_pcomp) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) prior_3\RB|and|higher|classified|,|after|frequency (r_advmod) was_14\VBD|NONE (l_acomp) higher_16\JJR|and|prior|classified|,|after|frequency (l_prep) than_17\IN|significantly (l_pobj) frequency_20\NN|NONE (l_compound) seizure_19\NN|median
C026098_D012640 NONE levetiracetam_7\NN|NONE (r_pcomp) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) prior_3\RB|and|higher|classified|,|after|frequency (r_advmod) was_14\VBD|NONE (l_prep) after_21\IN|and|prior|higher|classified|,|frequency (l_pobj) initiation_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) treatment_25\NN|NONE (l_appos) seizures_28\NNS|levetiracetam
C026098_D012640 NONE levetiracetam_7\NN|NONE (r_pcomp) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) prior_3\RB|and|higher|classified|,|after|frequency (r_advmod) was_14\VBD|NONE (l_conj) classified_39\VBN|and|prior|higher|,|after|frequency (l_prep) as_40\IN|.|were|cats (l_pcomp) responded_42\VBN|NONE (l_attr) reduction_49\NN|having|levetiracetam (l_prep) in_50\IN|)|,|ie|( (l_pobj) frequency_52\NN|NONE (l_compound) seizure_51\NN|of
C026098_D012640 NONE levetiracetam_24\NN|seizures (r_amod) treatment_25\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) initiation_22\NN|NONE (r_pobj) after_21\IN|and|prior|higher|classified|,|frequency (r_prep) was_14\VBD|NONE (l_nsubj) frequency_2\NN|and|prior|higher|classified|,|after (l_compound) seizure_1\NN|Median
C026098_D012640 NONE levetiracetam_24\NN|seizures (r_amod) treatment_25\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) initiation_22\NN|NONE (r_pobj) after_21\IN|and|prior|higher|classified|,|frequency (r_prep) was_14\VBD|NONE (l_advmod) prior_3\RB|and|higher|classified|,|after|frequency (l_prep) to_4\IN|NONE (l_pobj) treatment_5\NN|NONE (l_prep) with_6\IN|NONE (l_pcomp) levetiracetam_7\NN|NONE (l_appos) seizures_10\NNS|)|(
C026098_D012640 NONE levetiracetam_24\NN|seizures (r_amod) treatment_25\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) initiation_22\NN|NONE (r_pobj) after_21\IN|and|prior|higher|classified|,|frequency (r_prep) was_14\VBD|NONE (l_acomp) higher_16\JJR|and|prior|classified|,|after|frequency (l_prep) than_17\IN|significantly (l_pobj) frequency_20\NN|NONE (l_compound) seizure_19\NN|median
C026098_D012640 NONE levetiracetam_24\NN|seizures (r_amod) treatment_25\NN|NONE (l_appos) seizures_28\NNS|levetiracetam
C026098_D012640 NONE levetiracetam_24\NN|seizures (r_amod) treatment_25\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) initiation_22\NN|NONE (r_pobj) after_21\IN|and|prior|higher|classified|,|frequency (r_prep) was_14\VBD|NONE (l_conj) classified_39\VBN|and|prior|higher|,|after|frequency (l_prep) as_40\IN|.|were|cats (l_pcomp) responded_42\VBN|NONE (l_attr) reduction_49\NN|having|levetiracetam (l_prep) in_50\IN|)|,|ie|( (l_pobj) frequency_52\NN|NONE (l_compound) seizure_51\NN|of
C026098_D012640 NONE levetiracetam_44\VB|reduction|having (r_xcomp) responded_42\VBN|NONE (r_pcomp) as_40\IN|.|were|cats (r_prep) classified_39\VBN|and|prior|higher|,|after|frequency (r_conj) was_14\VBD|NONE (l_nsubj) frequency_2\NN|and|prior|higher|classified|,|after (l_compound) seizure_1\NN|Median
C026098_D012640 NONE levetiracetam_44\VB|reduction|having (r_xcomp) responded_42\VBN|NONE (r_pcomp) as_40\IN|.|were|cats (r_prep) classified_39\VBN|and|prior|higher|,|after|frequency (r_conj) was_14\VBD|NONE (l_advmod) prior_3\RB|and|higher|classified|,|after|frequency (l_prep) to_4\IN|NONE (l_pobj) treatment_5\NN|NONE (l_prep) with_6\IN|NONE (l_pcomp) levetiracetam_7\NN|NONE (l_appos) seizures_10\NNS|)|(
C026098_D012640 NONE levetiracetam_44\VB|reduction|having (r_xcomp) responded_42\VBN|NONE (r_pcomp) as_40\IN|.|were|cats (r_prep) classified_39\VBN|and|prior|higher|,|after|frequency (r_conj) was_14\VBD|NONE (l_acomp) higher_16\JJR|and|prior|classified|,|after|frequency (l_prep) than_17\IN|significantly (l_pobj) frequency_20\NN|NONE (l_compound) seizure_19\NN|median
C026098_D012640 NONE levetiracetam_44\VB|reduction|having (r_xcomp) responded_42\VBN|NONE (r_pcomp) as_40\IN|.|were|cats (r_prep) classified_39\VBN|and|prior|higher|,|after|frequency (r_conj) was_14\VBD|NONE (l_prep) after_21\IN|and|prior|higher|classified|,|frequency (l_pobj) initiation_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) treatment_25\NN|NONE (l_appos) seizures_28\NNS|levetiracetam
C026098_D012640 NONE levetiracetam_44\VB|reduction|having (r_xcomp) responded_42\VBN|NONE (l_attr) reduction_49\NN|having|levetiracetam (l_prep) in_50\IN|)|,|ie|( (l_pobj) frequency_52\NN|NONE (l_compound) seizure_51\NN|of
D010634_C562694 NONE phenobarbital_5\JJ|as|. (l_dobj) treatment_6\NN|to (l_prep) in_7\IN|NONE (l_pobj) cats_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) epilepsy_12\NN|NONE
D010634_C562694 NONE phenobarbital_16\JJ|assess|.|administered (l_dobj) treatment_17\NN|to (l_prep) in_18\IN|NONE (l_pobj) cats_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) epilepsy_25\NN|NONE
D010634_C562694 NONE phenobarbital_12\JJ|NONE (r_pobj) with_11\IN|that|poorly|had|or|was (r_prep) controlled_10\VBN|idiopathic (r_relcl) epilepsy_6\NN|to
D010634_C562694 NONE phenobarbital_22\NN|NONE (r_pobj) with_21\IN|when (r_prep) treated_20\VBN|effects|that (r_advcl) had_15\VBD|that|poorly|or|with|was (r_conj) controlled_10\VBN|idiopathic (r_relcl) epilepsy_6\NN|to
D010634_C562694 NONE phenobarbital_17\JJ|an (l_dobj) treatment_18\NN|to (l_prep) in_19\IN|NONE (l_pobj) cats_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) epilepsy_23\NN|NONE
24341598
D012965_D007674 NONE chloride_6\NN|NONE (r_pobj) of_3\IN|with (r_prep) effects_2\NNS|NONE (l_prep) with_7\IN|of (l_pobj) diltiazem_8\NN|NONE (l_prep) in_9\IN|NONE (l_pobj) prevention_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) nephropathy_15\NN|NONE
D003287_D058186 CID contrast_25\NN|NONE (r_amod) material_26\NN|(|was|%|)|after (r_nsubjpass) injected_28\VBN|,|on|patients|.|failure|Among (r_advcl) developed_13\VBD|NONE (l_dobj) failure_16\NN|,|on|patients|.|injected|Among
D003287_D058186 CID contrast_25\NN|NONE (r_amod) material_26\NN|(|was|%|)|after (r_nsubjpass) injected_28\VBN|,|on|patients|.|failure|Among (r_advcl) developed_13\VBD|NONE (l_dobj) failure_16\NN|,|on|patients|.|injected|Among (l_appos) ARF_18\NNP|(|)|renal|acute
D004110_D007674 NONE diltiazem_8\NN|NONE (l_prep) in_9\IN|NONE (l_pobj) prevention_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) nephropathy_15\NN|NONE
D003287_D007674 NONE contrast_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) nephropathy_15\NN|NONE
D003287_D007674 NONE Contrast_0\RB| (r_npadvmod) induced_2\VBN|CIN (r_amod) nephropathy_3\NN|.|morbidity|significantly
17028363
D004008_D058186 CID diclofenac_20\NN|inflammatory|steroidal|,|a (r_appos) drug_18\NN|NONE (r_pobj) of_10\IN|concomitant|the (r_prep) intake_9\NN|NONE (r_pobj) by_6\IN|injury|.|probably|was (r_agent) aggravated_5\VBN|NONE (l_nsubjpass) injury_2\NN|.|probably|was|by
D000880_D058186 NONE anthraquinones_11\NNS|NONE (r_dobj) containing_10\VBG|slimming (r_acl) pills_9\NNS|NONE (r_pobj) of_7\IN|prolonged (r_prep) intake_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|.|Acute|renal (r_acl) failure_2\NN|NONE
D000880_D058186 NONE anthraquinone_24\NN|NONE (r_compound) derivatives_25\NNS|that (r_dobj) contained_23\VBD|Chinese|a|,|herbal|slimming|proprietary (r_relcl) pill_21\NN|NONE (r_pobj) of_15\IN|prolonged|extracted (r_prep) use_14\NN|NONE (r_pobj) following_12\VBG|who|failure (r_prep) developed_8\VBD|a|old (l_dobj) failure_11\NN|who|following
D000880_D058186 NONE anthraquinone_9\NN| (r_npadvmod) containing_11\VBG|herbal|injury|an|and (r_amod) agent_13\NN|NONE (l_conj) injury_16\NN|herbal|an|and|containing
D000880_D051437 NONE anthraquinone_9\NN| (r_npadvmod) containing_11\VBG|herbal|injury|an|and (r_amod) agent_13\NN|NONE (r_pobj) of_7\IN|the (r_prep) use_6\NN|NONE (r_pobj) between_4\IN|causal|a (r_prep) relationship_3\NN|Although|proven (r_nsubj) remains_17\VBZ|nephropathy|be|.|in|,|should (r_advcl) considered_29\VBN|NONE (l_prep) in_30\IN|nephropathy|remains|be|.|,|should (l_pobj) patients_31\NNS|NONE (l_relcl) present_33\VBP|NONE (l_prep) with_34\IN|who (l_pobj) failure_37\NN|NONE
D034341_D007674 NONE acids_16\NNS|NONE (r_pobj) of_14\IN|the (r_prep) use_13\NN|usually (r_dobj) involving_11\VBG|,|been|Nephropathy|has|previously|. (r_advcl) reported_8\VBN|NONE (l_nsubjpass) Nephropathy_0\NNP|,|been|has|previously|involving|.
D004365_D007674 NONE herbs_4\NNS|NONE (r_pobj) by_2\IN|NONE (r_agent) caused_1\VBN|NONE (r_acl) Nephropathy_0\NNP|,|been|has|previously|involving|.
D004365_D058186 CID herbal_19\JJ|Chinese|a|,|slimming|contained|proprietary (r_amod) pill_21\NN|NONE (r_pobj) of_15\IN|prolonged|extracted (r_prep) use_14\NN|NONE (r_pobj) following_12\VBG|who|failure (r_prep) developed_8\VBD|a|old (l_dobj) failure_11\NN|who|following
D000880_D007674 NONE anthraquinone_9\NN| (r_npadvmod) containing_11\VBG|herbal|injury|an|and (r_amod) agent_13\NN|NONE (r_pobj) of_7\IN|the (r_prep) use_6\NN|NONE (r_pobj) between_4\IN|causal|a (r_prep) relationship_3\NN|Although|proven (r_nsubj) remains_17\VBZ|nephropathy|be|.|in|,|should (r_advcl) considered_29\VBN|NONE (l_nsubjpass) nephropathy_26\NN|remains|be|.|in|,|should
24911645
D005680_D012640 NONE acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (l_dobj) effects_8\NNS|determine|to (l_prep) at_9\IN|GFC|the (l_pobj) doses_10\NNS|NONE (l_prep) on_18\IN|of (l_pobj) parameters_20\NNS|NONE (l_compound) seizure_19\NN|NONE
D005680_D012640 NONE acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (r_xcomp) aimed_3\VBN|The|present|) (r_acl) study_2\NN|as|on|. (r_nsubj) levels_47\NNS|NONE (l_prep) on_51\IN|study|as|. (l_pobj) acetylcholinesterase_52\NN|NONE (l_appos) activity_56\NN|AChE|(|) (l_prep) in_57\IN|NONE (l_pobj) hippocampus_59\NN|NONE (l_prep) after_60\IN|mice (l_pobj) seizures_61\NNS|NONE
D005680_D012640 NONE GABA_38\NNP|,|aminobutyric|(|glutamine (r_appos) acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (l_dobj) effects_8\NNS|determine|to (l_prep) at_9\IN|GFC|the (l_pobj) doses_10\NNS|NONE (l_prep) on_18\IN|of (l_pobj) parameters_20\NNS|NONE (l_compound) seizure_19\NN|NONE
D005680_D012640 NONE GABA_38\NNP|,|aminobutyric|(|glutamine (r_appos) acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (r_xcomp) aimed_3\VBN|The|present|) (r_acl) study_2\NN|as|on|. (r_nsubj) levels_47\NNS|NONE (l_prep) on_51\IN|study|as|. (l_pobj) acetylcholinesterase_52\NN|NONE (l_appos) activity_56\NN|AChE|(|) (l_prep) in_57\IN|NONE (l_pobj) hippocampus_59\NN|NONE (l_prep) after_60\IN|mice (l_pobj) seizures_61\NNS|NONE
D010862_D013226 CID pilocarpine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) status_19\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) installation_14\NN|NONE (r_pobj) of_13\IN|the (r_prep) frequency_12\NN|epilepticus|demonstrated|, (r_dobj) reduce_10\VB|and|activity|GFC|can|that (l_advmod) epilepticus_20\NN|demonstrated|,|frequency
D005978_D012640 NONE glutathione_45\NN|and (r_conj) aspartate_43\NN|, (r_conj) glutamine_41\NN|GABA|,|aminobutyric|( (r_appos) acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (l_dobj) effects_8\NNS|determine|to (l_prep) at_9\IN|GFC|the (l_pobj) doses_10\NNS|NONE (l_prep) on_18\IN|of (l_pobj) parameters_20\NNS|NONE (l_compound) seizure_19\NN|NONE
D005978_D012640 NONE glutathione_45\NN|and (r_conj) aspartate_43\NN|, (r_conj) glutamine_41\NN|GABA|,|aminobutyric|( (r_appos) acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (r_xcomp) aimed_3\VBN|The|present|) (r_acl) study_2\NN|as|on|. (r_nsubj) levels_47\NNS|NONE (l_prep) on_51\IN|study|as|. (l_pobj) acetylcholinesterase_52\NN|NONE (l_appos) activity_56\NN|AChE|(|) (l_prep) in_57\IN|NONE (l_pobj) hippocampus_59\NN|NONE (l_prep) after_60\IN|mice (l_pobj) seizures_61\NNS|NONE
D000596_D012640 NONE acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (l_dobj) effects_8\NNS|determine|to (l_prep) at_9\IN|GFC|the (l_pobj) doses_10\NNS|NONE (l_prep) on_18\IN|of (l_pobj) parameters_20\NNS|NONE (l_compound) seizure_19\NN|NONE
D000596_D012640 NONE acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (r_xcomp) aimed_3\VBN|The|present|) (r_acl) study_2\NN|as|on|. (r_nsubj) levels_47\NNS|NONE (l_prep) on_51\IN|study|as|. (l_pobj) acetylcholinesterase_52\NN|NONE (l_appos) activity_56\NN|AChE|(|) (l_prep) in_57\IN|NONE (l_pobj) hippocampus_59\NN|NONE (l_prep) after_60\IN|mice (l_pobj) seizures_61\NNS|NONE
C573355_D013226 NONE GFC_4\NNP|and|activity|can|that|reduce (r_nsubj) exert_6\VB|results|. (l_conj) reduce_10\VB|and|activity|GFC|can|that (l_advmod) epilepticus_20\NN|demonstrated|,|frequency
D018698_D012640 NONE glutamine_41\NN|GABA|,|aminobutyric|( (r_appos) acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (l_dobj) effects_8\NNS|determine|to (l_prep) at_9\IN|GFC|the (l_pobj) doses_10\NNS|NONE (l_prep) on_18\IN|of (l_pobj) parameters_20\NNS|NONE (l_compound) seizure_19\NN|NONE
D018698_D012640 NONE glutamine_41\NN|GABA|,|aminobutyric|( (r_appos) acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (r_xcomp) aimed_3\VBN|The|present|) (r_acl) study_2\NN|as|on|. (r_nsubj) levels_47\NNS|NONE (l_prep) on_51\IN|study|as|. (l_pobj) acetylcholinesterase_52\NN|NONE (l_appos) activity_56\NN|AChE|(|) (l_prep) in_57\IN|NONE (l_pobj) hippocampus_59\NN|NONE (l_prep) after_60\IN|mice (l_pobj) seizures_61\NNS|NONE
D010862_D012640 CID pilocarpine_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) seizures_14\NNS|NONE
D010862_D012640 CID pilocarpine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) status_19\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) installation_14\NN|NONE (r_pobj) of_13\IN|the (r_prep) frequency_12\NN|epilepticus|demonstrated|, (r_dobj) reduce_10\VB|and|activity|GFC|can|that (l_advcl) demonstrated_23\VBN|epilepticus|,|frequency (l_agent) by_24\IN|as (l_pobj) increase_25\NN|NONE (l_prep) to_28\IN|and|decrease|in (l_pobj) seizure_30\NN|NONE
C573355_D012640 NONE FC_9\NNP|NONE (r_pobj) with_7\IN|in (r_prep) pretreated_6\VBN|Behavioral|.|in (l_prep) in_10\IN|with (l_pobj) seizures_14\NNS|NONE
C573355_D012640 NONE GFC_7\NNP|at|the (r_compound) effects_8\NNS|determine|to (l_prep) at_9\IN|GFC|the (l_pobj) doses_10\NNS|NONE (l_prep) on_18\IN|of (l_pobj) parameters_20\NNS|NONE (l_compound) seizure_19\NN|NONE
C573355_D012640 NONE GFC_7\NNP|at|the (r_compound) effects_8\NNS|determine|to (r_dobj) evaluate_5\VB|NONE (r_xcomp) aimed_3\VBN|The|present|) (r_acl) study_2\NN|as|on|. (r_nsubj) levels_47\NNS|NONE (l_prep) on_51\IN|study|as|. (l_pobj) acetylcholinesterase_52\NN|NONE (l_appos) activity_56\NN|AChE|(|) (l_prep) in_57\IN|NONE (l_pobj) hippocampus_59\NN|NONE (l_prep) after_60\IN|mice (l_pobj) seizures_61\NNS|NONE
C573355_D012640 NONE GFC_0\NNP|,|.|kg|latency|at (r_nsubj) produced_1\VBD|NONE (l_dobj) latency_4\NN|,|.|kg|GFC|at (l_prep) to_5\IN|increased|an (l_pobj) seizure_7\NN|NONE
C573355_D012640 NONE GFC_4\NNP|and|activity|can|that|reduce (r_nsubj) exert_6\VB|results|. (l_conj) reduce_10\VB|and|activity|GFC|can|that (l_advcl) demonstrated_23\VBN|epilepticus|,|frequency (l_agent) by_24\IN|as (l_pobj) increase_25\NN|NONE (l_prep) to_28\IN|and|decrease|in (l_pobj) seizure_30\NN|NONE
D001224_D012640 NONE aspartate_43\NN|, (r_conj) glutamine_41\NN|GABA|,|aminobutyric|( (r_appos) acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (l_dobj) effects_8\NNS|determine|to (l_prep) at_9\IN|GFC|the (l_pobj) doses_10\NNS|NONE (l_prep) on_18\IN|of (l_pobj) parameters_20\NNS|NONE (l_compound) seizure_19\NN|NONE
D001224_D012640 NONE aspartate_43\NN|, (r_conj) glutamine_41\NN|GABA|,|aminobutyric|( (r_appos) acid_36\NN|amino (r_appos) acid_31\NN|NONE (r_pobj) on_29\IN|its (r_prep) effects_28\NNS|and|anticonvulsant|their (r_conj) activity_25\NN|to (r_dobj) determine_22\VB|effects|to (r_advcl) evaluate_5\VB|NONE (r_xcomp) aimed_3\VBN|The|present|) (r_acl) study_2\NN|as|on|. (r_nsubj) levels_47\NNS|NONE (l_prep) on_51\IN|study|as|. (l_pobj) acetylcholinesterase_52\NN|NONE (l_appos) activity_56\NN|AChE|(|) (l_prep) in_57\IN|NONE (l_pobj) hippocampus_59\NN|NONE (l_prep) after_60\IN|mice (l_pobj) seizures_61\NNS|NONE
1905439
D016595_D006261 NONE Misoprostol_0\NNP|.|been|with|has (r_nsubjpass) associated_3\VBN|NONE (l_prep) with_4\IN|.|been|has|Misoprostol (l_pobj) reactions_6\NNS|NONE (l_prep) including_8\VBG|,|adverse (l_pobj) symptoms_10\NNS|NONE (l_conj) problems_13\NNS|,|gastrointestinal (l_conj) headache_16\NN|,|and|gynecologic
D016595_D003693 CID misoprostol_10\NNP|NONE (r_pobj) of_9\IN|NONE (r_prep) administration_8\NN|NONE (r_pobj) with_7\IN|possibly (r_prep) associated_6\VBN|elderly|an (r_acl) woman_4\NN|NONE (r_pobj) in_1\IN|. (r_prep) Delirium_0\NN|NONE
D016595_D003693 CID misoprostol_5\NNP|was|after|returned|and (r_nsubjpass) discontinued_7\VBN|.|significantly|delirium (r_advcl) improved_3\VBD|NONE (l_nsubj) delirium_1\NN|.|significantly|discontinued
D016595_D003693 CID misoprostol_20\NNP|NONE (r_compound) therapy_21\NN|NONE (r_pobj) from_19\IN|.|possibly|delirium|changed|, (r_prep) resulted_18\VBD|NONE (l_nsubj) delirium_12\NN|.|possibly|from|changed|,
12059909
D003520_D006470 CID CY_1\NNP|Early (r_compound) toxicity_2\NN|.|cystitis (r_nsubj) caused_3\VBD|NONE (l_dobj) cystitis_7\NN|.|toxicity (l_amod) haemorrhagic_6\JJ|typical|repaired|a|in
D003520_D064420 NONE cyclophosphamide_3\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) toxicity_1\NN|on|.
D003520_D064420 NONE CY_1\NNP|Early (r_compound) toxicity_2\NN|.|cystitis
D003520_D064420 NONE CY_7\NNP|NONE (r_pobj) of_6\IN|delayed|in (r_prep) toxicity_5\NN|pathology
D003520_D003556 CID CY_1\NNP|Early (r_compound) toxicity_2\NN|.|cystitis (r_nsubj) caused_3\VBD|NONE (l_dobj) cystitis_7\NN|.|toxicity
D003520_D003556 CID CY_4\NNP|ulcerous (r_compound) injection_5\NN|NONE (r_pobj) of_3\IN| (r_prep) days_2\NNS|NONE (r_pobj) After_0\IN|in|.|forms|but|% (r_prep) appeared_15\VBD|NONE (l_nsubj) forms_11\NNS|in|After|.|but|% (l_prep) of_12\IN|ulcerous (l_pobj) cystitis_14\NN|NONE
26002693
C031763_D015464 NONE 1,3-Butadiene_0\CD|NONE (l_conj) CML_2\NNP|:|,
C031763_D015464 NONE 1,3-butadiene_3\CD|NONE (r_pobj) of_2\IN|Epidemiological (r_prep) studies_1\NNS|.|associated|have (r_nsubj) suggest_5\VBN|NONE (l_ccomp) associated_11\VBN|studies|.|have (l_prep) with_12\IN|are|exposures|that (l_pobj) leukemia_15\NN|NONE
C031763_D015464 NONE 1,3-butadiene_3\CD|NONE (r_pobj) of_2\IN|Epidemiological (r_prep) studies_1\NNS|.|associated|have (r_nsubj) suggest_5\VBN|NONE (l_ccomp) associated_11\VBN|studies|.|have (l_prep) with_12\IN|are|exposures|that (l_pobj) leukemia_15\NN|NONE (l_appos) CML_17\NNP|myeloid|)|(|chronic
3289726
D005047_D009422 NONE etoposide_7\NN|dose|for (r_compound) therapy_8\NN|NONE (r_pobj) after_3\IN|Acute|neurologic|. (r_prep) dysfunction_2\NN|NONE
D005047_D009369 NONE Etoposide_0\NNP|been|.|has|in (r_nsubjpass) used_8\VBN|NONE (l_prep) in_9\IN|been|.|has|Etoposide (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) tumors_15\NNS|NONE
D005047_D009369 NONE 213_4\CD|VP (r_punct) )_5\-RRB-|NONE (r_punct) Etoposide_0\NNP|been|.|has|in (r_nsubjpass) used_8\VBN|NONE (l_prep) in_9\IN|been|.|has|Etoposide (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) tumors_15\NNS|NONE
D005047_D064420 NONE etoposide_13\NN|for|dose (r_compound) therapy_14\NN|NONE (r_pobj) of_9\IN|a|significant|new (r_prep) toxicity_8\NN|to
D005047_D019337 NONE Etoposide_0\NNP|been|.|has|in (r_nsubjpass) used_8\VBN|NONE (l_prep) in_9\IN|been|.|has|Etoposide (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) tumors_15\NNS|NONE (l_conj) malignancies_18\NNS|and|solid|many
D005047_D019337 NONE 213_4\CD|VP (r_punct) )_5\-RRB-|NONE (r_punct) Etoposide_0\NNP|been|.|has|in (r_nsubjpass) used_8\VBN|NONE (l_prep) in_9\IN|been|.|has|Etoposide (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) tumors_15\NNS|NONE (l_conj) malignancies_18\NNS|and|solid|many
D005047_D005910 NONE etoposide_7\NN|dose|for (r_compound) therapy_8\NN|NONE (l_prep) for_9\IN|etoposide|dose (l_pobj) glioma_11\NN|NONE
D005047_D005910 NONE etoposide_13\NN|for|dose (r_compound) therapy_14\NN|NONE (l_prep) for_15\IN|etoposide|dose (l_pobj) glioma_17\NN|NONE
1615846
D008148_D006949 NONE lovastatin_32\NN|in|label (r_amod) treatment_33\NN|had|,|of|and|efficacy (l_prep) in_34\IN|label|lovastatin (l_pobj) patients_36\NNS|NONE (l_prep) with_37\IN| (l_pobj) hyperlipidemia_40\NN|NONE
D015248_D006949 NONE gemfibrozil_30\NN| (r_compound) lovastatin_32\NN|in|label (r_amod) treatment_33\NN|had|,|of|and|efficacy (l_prep) in_34\IN|label|lovastatin (l_pobj) patients_36\NNS|NONE (l_prep) with_37\IN| (l_pobj) hyperlipidemia_40\NN|NONE
D015248_D006951 NONE Gemfibrozil_0\NNP| (r_compound) lovastatin_2\NN|for|. (r_amod) therapy_3\NN|NONE (l_prep) for_4\IN|lovastatin|. (l_pobj) hyperlipoproteinemias_6\NNS|NONE
D008148_D002340 NONE lovastatin_32\NN|in|label (r_amod) treatment_33\NN|had|,|of|and|efficacy (r_conj) safety_12\NN|to (l_relcl) had_46\VBD|,|treatment|of|and|efficacy (l_dobj) disease_49\NN|%
D015248_D002340 NONE gemfibrozil_30\NN| (r_compound) lovastatin_32\NN|in|label (r_amod) treatment_33\NN|had|,|of|and|efficacy (r_conj) safety_12\NN|to (l_relcl) had_46\VBD|,|treatment|of|and|efficacy (l_dobj) disease_49\NN|%
D008148_D006951 NONE lovastatin_2\NN|for|. (r_amod) therapy_3\NN|NONE (l_prep) for_4\IN|lovastatin|. (l_pobj) hyperlipoproteinemias_6\NNS|NONE
D003401_D012206 NONE creatine_28\NN|concurrent (r_compound) phosphokinase_29\NN|NONE (r_pobj) with_25\IN|liter| (r_prep) %_24\NN|NONE (r_pobj) in_22\IN|.|patients|rhabdomyolysis|; (r_prep) had_39\VBD|,|Myositis|in|and (l_dobj) rhabdomyolysis_40\NN|.|in|patients|;
D003401_D009212 NONE creatine_28\NN|concurrent (r_compound) phosphokinase_29\NN|NONE (r_pobj) with_25\IN|liter| (r_prep) %_24\NN|NONE (r_pobj) in_22\IN|.|patients|rhabdomyolysis|; (r_prep) had_39\VBD|,|Myositis|in|and (l_dobj) rhabdomyolysis_40\NN|.|in|patients|; (l_conj) myoglobinuria_42\NNS|or
D003401_D009220 NONE creatine_28\NN|concurrent (r_compound) phosphokinase_29\NN|NONE (r_pobj) with_25\IN|liter| (r_prep) %_24\NN|NONE (r_pobj) in_22\IN|.|patients|rhabdomyolysis|; (r_prep) had_39\VBD|,|Myositis|in|and (r_conj) occurred_14\VBD|NONE (l_nsubj) Myositis_0\NNP|had|,|in|and
17384765
D007854_D019958 CID Pb_0\NNP|NONE (r_amod) exposure_1\NN|.|impairments|paralleling (r_nsubj) produced_2\VBD|NONE (l_dobj) impairments_4\NNS|.|paralleling|exposure (l_prep) in_5\IN|lasting (l_pobj) learning_6\NN|NONE (l_conj) attention_8\NN|, (l_conj) control_11\NN|, (l_conj) regulation_15\NN|,|inhibitory|and
D007854_D019958 CID Pb_24\NNP| (r_npadvmod) exposed_26\VBN|NONE (r_amod) children_27\NNS|NONE (r_pobj) in_23\IN|NONE (r_prep) seen_22\VBN|NONE (r_acl) dysfunction_21\NN|NONE (r_pobj) of_20\IN|the (r_prep) areas_19\NNS|NONE (r_dobj) paralleling_17\VBG|.|impairments|exposure (r_advcl) produced_2\VBD|NONE (l_dobj) impairments_4\NNS|.|paralleling|exposure (l_prep) in_5\IN|lasting (l_pobj) learning_6\NN|NONE (l_conj) attention_8\NN|, (l_conj) control_11\NN|, (l_conj) regulation_15\NN|,|inhibitory|and
D007854_D007855 NONE Pb_17\NNP|and|agent|with|,|treatment (r_compound) exposure_18\NN|model (l_appos) agent_28\NN|Pb|and|with|,|treatment (l_prep) for_29\IN|chelating|a|used (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) poisoning_34\NN|NONE
D007854_D003072 NONE lead_11\NN| (r_npadvmod) exposed_13\VBN|NONE (r_amod) rats_14\NNS|NONE (r_pobj) in_10\IN|arousal (r_prep) regulation_9\NN|and|, (r_conj) attention_5\NN|, (r_conj) learning_3\VBG|produces|.|but|chelation (r_xcomp) improves_2\VBZ|NONE (l_conj) produces_16\VBZ|learning|.|but|chelation (l_dobj) impairment_19\NN|in
D007854_D003072 NONE lead_24\JJ|NONE (r_amod) exposure_25\NN|NONE (r_pobj) of_23\IN|the (r_prep) absence_22\NN|NONE (r_pobj) in_20\IN|impairment (r_prep) produces_16\VBZ|learning|.|but|chelation (l_dobj) impairment_19\NN|in
D007854_D003072 NONE Pb_11\NNP|NONE (r_pobj) to_10\IN|previously|not (r_prep) exposed_9\VBN|succimer|of (r_acl) treatment_4\NN|,|In|dysfunction|. (r_nsubj) produced_12\VBD|NONE (l_dobj) dysfunction_19\NN|,|treatment|In|.
D007854_D003072 NONE Pb_29\NNP|the|exposure|higher (r_compound) regimen_31\NN|NONE (r_pobj) by_26\IN|NONE (r_agent) produced_25\VBN|NONE (r_acl) that_24\DT|NONE (r_pobj) to_23\IN|NONE (r_prep) magnitude_22\NN|NONE (r_pobj) in_21\IN|NONE (r_prep) comparable_20\JJ|affective|cognitive (r_amod) dysfunction_19\NN|,|treatment|In|.
D007854_D003072 NONE Pb_24\NNP|NONE (r_compound) exposure_25\NN|to (r_pobj) due_22\IN|can|deficits (r_prep) alleviate_19\VB|These|data|. (l_dobj) deficits_21\NNS|can|due
D004113_D019964 NONE succimer_3\JJ|exposed|of (r_amod) treatment_4\NN|,|In|dysfunction|. (r_nsubj) produced_12\VBD|NONE (l_dobj) dysfunction_19\NN|,|treatment|In|.
D004113_D007855 NONE succimer_22\NN|NONE (r_pobj) with_21\IN|Pb|and|agent|,|treatment (r_prep) exposure_18\NN|model (l_appos) agent_28\NN|Pb|and|with|,|treatment (l_prep) for_29\IN|chelating|a|used (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) poisoning_34\NN|NONE
D004113_D003072 CID Succimer_0\NNP|NONE (r_compound) chelation_1\NN|produces|learning|.|but (r_nsubj) improves_2\VBZ|NONE (l_conj) produces_16\VBZ|learning|.|but|chelation (l_dobj) impairment_19\NN|in
D004113_D003072 NONE succimer_3\JJ|exposed|of (r_amod) treatment_4\NN|,|In|dysfunction|. (r_nsubj) produced_12\VBD|NONE (l_dobj) dysfunction_19\NN|,|treatment|In|.
D007854_D007859 CID Pb_0\NNP|NONE (r_amod) exposure_1\NN|.|impairments|paralleling (r_nsubj) produced_2\VBD|NONE (l_dobj) impairments_4\NNS|.|paralleling|exposure (l_prep) in_5\IN|lasting (l_pobj) learning_6\NN|NONE (l_conj) attention_8\NN|, (l_conj) control_11\NN|, (l_conj) regulation_15\NN|,|inhibitory|and
D007854_D007859 CID Pb_24\NNP| (r_npadvmod) exposed_26\VBN|NONE (r_amod) children_27\NNS|NONE (r_pobj) in_23\IN|NONE (r_prep) seen_22\VBN|NONE (r_acl) dysfunction_21\NN|NONE (r_pobj) of_20\IN|the (r_prep) areas_19\NNS|NONE (r_dobj) paralleling_17\VBG|.|impairments|exposure (r_advcl) produced_2\VBD|NONE (l_dobj) impairments_4\NNS|.|paralleling|exposure (l_prep) in_5\IN|lasting (l_pobj) learning_6\NN|NONE (l_conj) attention_8\NN|, (l_conj) control_11\NN|, (l_conj) regulation_15\NN|,|inhibitory|and
D007854_D019964 NONE Pb_11\NNP|NONE (r_pobj) to_10\IN|previously|not (r_prep) exposed_9\VBN|succimer|of (r_acl) treatment_4\NN|,|In|dysfunction|. (r_nsubj) produced_12\VBD|NONE (l_dobj) dysfunction_19\NN|,|treatment|In|.
D007854_D019964 NONE Pb_29\NNP|the|exposure|higher (r_compound) regimen_31\NN|NONE (r_pobj) by_26\IN|NONE (r_agent) produced_25\VBN|NONE (r_acl) that_24\DT|NONE (r_pobj) to_23\IN|NONE (r_prep) magnitude_22\NN|NONE (r_pobj) in_21\IN|NONE (r_prep) comparable_20\JJ|affective|cognitive (r_amod) dysfunction_19\NN|,|treatment|In|.
15625689
D007980_D003680 NONE levodopa_6\NN|NONE (r_pobj) for_5\IN|a (r_prep) role_4\NN|.|and|results|confirm (r_dobj) suggest_2\VBP|NONE (l_conj) confirm_14\VB|.|and|role|results (l_ccomp) is_17\VBZ|NONE (l_nsubj) dysphagia_16\NN|that|predictor|not
D007980_D004409 CID levodopa_17\NN| (r_npadvmod) induced_19\VBN|NONE (r_amod) dyskinesia_20\NN|NONE
D007980_D004409 CID levodopa_23\NN|a|greater (r_compound) dose_24\NN|NONE (r_pobj) of_20\IN|the (r_prep) basis_19\NN|NONE (r_pobj) on_17\IN|which|be|could (r_prep) explained_16\VBN|swallowing|, (r_relcl) function_11\NN|NONE (r_pobj) in_9\IN|patients|,|.|In|better (r_prep) performed_7\VBD|NONE (l_nsubj) patients_6\NNS|,|.|In|in|better (l_amod) dyskinetic_5\JJ|NONE
D007980_D010300 NONE levodopa_17\NN| (r_npadvmod) induced_19\VBN|NONE (r_amod) dyskinesia_20\NN|NONE (r_pobj) without_16\IN|and (r_conj) with_14\IN|to|dynamics (r_prep) characterize_7\VB|aim|. (l_dobj) dynamics_10\NNS|to|with (l_prep) in_11\IN|the|oropharyngeal (l_pobj) patients_13\NNS|NONE (l_compound) PD_12\NNP|NONE
D007980_D010300 NONE levodopa_6\NN|NONE (r_pobj) for_5\IN|a (r_prep) role_4\NN|.|and|results|confirm (r_dobj) suggest_2\VBP|NONE (l_conj) confirm_14\VB|.|and|role|results (l_ccomp) is_17\VBZ|NONE (l_attr) predictor_21\NN|that|dysphagia|not (l_prep) of_22\IN|a|good (l_pobj) alterations_24\NNS|NONE (l_prep) in_25\IN|deglutition (l_pobj) PD_26\NNP|NONE
448423
D015119_D020767 CID EACA_27\NNP|NONE (r_pobj) with_26\IN|NONE (r_prep) treated_25\VBN|fibrinolytic (r_acl) syndromes_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) patients_21\NNS|NONE (r_pobj) in_20\IN|thrombi (r_prep) capillary_17\JJ|and (r_conj) arteriolar_15\JJ|, (r_conj) SAH_13\NNP|NONE (r_pobj) with_12\IN|NONE (r_prep) patients_11\NNS|NONE (r_pobj) in_10\IN|thrombosis|and|clinical (r_prep) deterioration_5\NN|complications|.|have (l_conj) thrombosis_9\NN|in|and|clinical
D015119_D013923 NONE EACA_27\NNP|NONE (l_conj) phenomena_32\NNS|or|,
D000614_D007674 NONE acid_6\NN|and|thrombosis|aminocaproic (r_compound) therapy_7\NN|NONE (l_conj) thrombosis_12\NN|acid|and|aminocaproic
D000614_D013345 NONE acid_6\NN|and|thrombosis|aminocaproic (r_compound) therapy_7\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|subarachnoid|Recurrent|. (r_acl) hemorrhage_2\NN|NONE
D015119_D013345 CID acid_2\NN|been|has|.|prevent (r_nsubjpass) used_8\VBN|NONE (l_xcomp) prevent_10\VB|been|has|acid|. (l_dobj) rebleeding_11\NN|to (l_prep) with_14\IN|in (l_pobj) hemorrhage_16\NN|NONE
D015119_D013345 CID acid_2\NN|been|has|.|prevent (r_nsubjpass) used_8\VBN|NONE (l_xcomp) prevent_10\VB|been|has|acid|. (l_dobj) rebleeding_11\NN|to (l_prep) with_14\IN|in (l_pobj) hemorrhage_16\NN|NONE (l_appos) SAH_18\NNP|)|(|subarachnoid
D015119_D013345 CID EACA_4\NNP|aminocaproic|Epsilon (r_appos) acid_2\NN|been|has|.|prevent (r_nsubjpass) used_8\VBN|NONE (l_xcomp) prevent_10\VB|been|has|acid|. (l_dobj) rebleeding_11\NN|to (l_prep) with_14\IN|in (l_pobj) hemorrhage_16\NN|NONE
D015119_D013345 CID EACA_4\NNP|aminocaproic|Epsilon (r_appos) acid_2\NN|been|has|.|prevent (r_nsubjpass) used_8\VBN|NONE (l_xcomp) prevent_10\VB|been|has|acid|. (l_dobj) rebleeding_11\NN|to (l_prep) with_14\IN|in (l_pobj) hemorrhage_16\NN|NONE (l_appos) SAH_18\NNP|)|(|subarachnoid
D015119_D013345 CID EACA_27\NNP|NONE (r_pobj) with_26\IN|NONE (r_prep) treated_25\VBN|fibrinolytic (r_acl) syndromes_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) patients_21\NNS|NONE (r_pobj) in_20\IN|thrombi (r_prep) capillary_17\JJ|and (r_conj) arteriolar_15\JJ|, (r_conj) SAH_13\NNP|NONE
D015119_D013345 CID EACA_4\NNP|in (r_compound) therapy_5\NN|NONE (l_prep) in_6\IN|EACA (l_pobj) patient_8\NN|NONE (l_prep) with_9\IN|a (l_pobj) SAH_10\NNP|documentation
D015119_D013345 CID EACA_4\NNP|in (r_compound) therapy_5\NN|NONE (l_prep) in_6\IN|EACA (l_pobj) patient_8\NN|NONE (l_prep) with_9\IN|a (l_pobj) documentation_13\NN|SAH (l_prep) of_14\IN|histopathological (l_pobj) SAH_16\NNP|NONE
D015119_D013927 CID EACA_17\NNP|NONE (r_compound) therapy_18\NN|NONE (r_pobj) of_16\IN|thrombotic (r_prep) complications_15\NNS|,|have|reports|decrease|. (l_amod) thrombotic_14\JJ|of
D015119_D013927 CID EACA_27\NNP|NONE (r_pobj) with_26\IN|NONE (r_prep) treated_25\VBN|fibrinolytic (r_acl) syndromes_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) patients_21\NNS|NONE (r_pobj) in_20\IN|thrombi (r_prep) capillary_17\JJ|and (l_dobj) thrombi_19\NN|in
D015119_D013927 CID EACA_13\NNP|observed|.|be|,|should|not|in (r_nsubjpass) implicated_17\VBN|NONE (l_advcl) observed_6\VBN|.|EACA|be|,|should|not|in (l_nsubjpass) thrombi_3\NN|are|Since|often|in
D015119_D013927 CID EACA_13\NNP|observed|.|be|,|should|not|in (r_nsubjpass) implicated_17\VBN|NONE (l_prep) in_18\IN|observed|.|EACA|be|,|should|not (l_pobj) pathogenesis_20\NN|NONE (l_prep) of_21\IN|the (l_pobj) thrombi_23\NN|NONE
D015119_D004211 NONE EACA_13\NNP|observed|.|be|,|should|not|in (r_nsubjpass) implicated_17\VBN|NONE (l_prep) in_18\IN|observed|.|EACA|be|,|should|not (l_pobj) pathogenesis_20\NN|NONE (l_prep) of_21\IN|the (l_pobj) thrombi_23\NN|NONE (l_prep) in_24\IN|fibrin (l_pobj) patients_25\NNS|NONE (l_prep) with_26\IN|NONE (l_pobj) coagulation_29\NN|NONE
D015119_D004211 NONE EACA_13\NNP|observed|.|be|,|should|not|in (r_nsubjpass) implicated_17\VBN|NONE (l_prep) in_18\IN|observed|.|EACA|be|,|should|not (l_pobj) pathogenesis_20\NN|NONE (l_prep) of_21\IN|the (l_pobj) thrombi_23\NN|NONE (l_prep) in_24\IN|fibrin (l_pobj) patients_25\NNS|NONE (l_prep) with_26\IN|NONE (l_pobj) coagulation_29\NN|NONE (l_conj) coagulopathies_34\NNS|intravascular|or|disseminated
8755612
D004054_D006470 NONE diethylstilbestrol_3\NN|(|)|DES (r_nmod) treatment_7\NN|NONE (r_pobj) of_2\IN|Ten (r_prep) weeks_1\NNS|.|grow (r_nsubj) caused_8\VBD|NONE (l_ccomp) grow_14\VB|.|weeks (l_conj) become_39\VB|,|pituitaries|versus|to|to|and (l_acomp) hemorrhagic_41\JJ|to
D004054_D006470 NONE DES_5\NNP|diethylstilbestrol|(|) (r_nmod) treatment_7\NN|NONE (r_pobj) of_2\IN|Ten (r_prep) weeks_1\NNS|.|grow (r_nsubj) caused_8\VBD|NONE (l_ccomp) grow_14\VB|.|weeks (l_conj) become_39\VB|,|pituitaries|versus|to|to|and (l_acomp) hemorrhagic_41\JJ|to
D004054_D006470 NONE DES_3\NNP| (r_npadvmod) induced_5\VBN|pituitary (r_amod) growth_7\NN|while|inheritance (r_nsubj) exhibited_8\VBD|However|inheritance|.|,|,|phenotype (r_advcl) exhibited_17\VBD|NONE (l_nsubj) phenotype_16\NN|However|inheritance|.|exhibited|,|, (l_amod) hemorrhagic_15\JJ|the
D004967_D009369 NONE estrogen_10\NN| (r_npadvmod) induced_12\VBN|an (r_amod) tumor_13\NN|NONE (r_pobj) in_8\IN|Genetic|of|. (r_prep) separation_1\NN|NONE (l_prep) of_2\IN|Genetic|.|in (l_pobj) growth_4\NN|NONE (l_compound) tumor_3\NN|and|phenotypes
D004967_D009369 NONE estrogen_10\NN| (r_npadvmod) induced_12\VBN|an (r_amod) tumor_13\NN|NONE
D004967_D006470 NONE estrogen_10\NN| (r_npadvmod) induced_12\VBN|an (r_amod) tumor_13\NN|NONE (r_pobj) in_8\IN|Genetic|of|. (r_prep) separation_1\NN|NONE (l_prep) of_2\IN|Genetic|.|in (l_pobj) growth_4\NN|NONE (l_conj) phenotypes_7\NNS|and|tumor (l_amod) hemorrhagic_6\JJ|NONE
D004967_D006470 NONE estrogen_3\NN|NONE (r_pobj) of_2\IN|Chronic|to (r_prep) administration_1\NN|growth|. (r_nsubj) induces_12\VBZ|NONE (l_dobj) growth_13\NN|administration|. (l_prep) of_14\IN|NONE (l_pobj) tumors_19\NNS|NONE (l_amod) hemorrhagic_17\JJ|pituitary|,|large
D004967_D010911 NONE estrogen_3\NN|NONE (r_pobj) of_2\IN|Chronic|to (r_prep) administration_1\NN|growth|. (r_nsubj) induces_12\VBZ|NONE (l_dobj) growth_13\NN|administration|. (l_prep) of_14\IN|NONE (l_pobj) tumors_19\NNS|NONE
12452552
D008728_D007676 NONE levomepromazine_21\NN|and (r_conj) risperidone_19\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) administration_17\NN|NONE (r_pobj) after_16\IN|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN|.|patient (r_dobj) developed_9\VBD|NONE (l_nsubj) patient_1\NN|.|syndrome (l_prep) with_2\IN|A (l_pobj) failure_5\NN|NONE
D008728_D007676 NONE levomepromazine_21\NN|and (r_conj) risperidone_19\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) administration_17\NN|NONE (r_pobj) after_16\IN|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN|.|patient (r_dobj) developed_9\VBD|NONE (l_nsubj) patient_1\NN|.|syndrome (l_prep) with_2\IN|A (l_pobj) failure_5\NN|NONE (l_appos) CRF_7\NNP|renal|chronic|)|(
D008728_D009459 CID levomepromazine_21\NN|and (r_conj) risperidone_19\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) administration_17\NN|NONE (r_pobj) after_16\IN|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN|.|patient
D008728_D009459 CID levomepromazine_21\NN|and (r_conj) risperidone_19\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) administration_17\NN|NONE (r_pobj) after_16\IN|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN|.|patient (l_appos) NMS_14\NNP|neuroleptic|malignant|after
D018967_D007676 NONE risperidone_19\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) administration_17\NN|NONE (r_pobj) after_16\IN|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN|.|patient (r_dobj) developed_9\VBD|NONE (l_nsubj) patient_1\NN|.|syndrome (l_prep) with_2\IN|A (l_pobj) failure_5\NN|NONE
D018967_D007676 NONE risperidone_19\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) administration_17\NN|NONE (r_pobj) after_16\IN|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN|.|patient (r_dobj) developed_9\VBD|NONE (l_nsubj) patient_1\NN|.|syndrome (l_prep) with_2\IN|A (l_pobj) failure_5\NN|NONE (l_appos) CRF_7\NNP|renal|chronic|)|(
D018967_D009459 CID risperidone_19\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) administration_17\NN|NONE (r_pobj) after_16\IN|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN|.|patient
D018967_D009459 CID risperidone_19\NN|NONE (r_pobj) of_18\IN|NONE (r_prep) administration_17\NN|NONE (r_pobj) after_16\IN|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN|.|patient (l_appos) NMS_14\NNP|neuroleptic|malignant|after
24126708
D007980_D004409 CID Levodopa_0\NNP|therapy|,|but|lead (r_nsubj) is_1\VBZ|NONE (l_conj) lead_17\VB|therapy|,|but|Levodopa (l_prep) to_18\IN|could|.|use (l_pobj) outcomes_21\NNS|NONE (l_prep) as_24\IN|chronic|adverse|, (l_pobj) fluctuations_26\NNS|such (l_conj) dyskinesia_28\JJ|motor|,
D007980_D006212 CID Levodopa_0\NNP|therapy|,|but|lead (r_nsubj) is_1\VBZ|NONE (l_conj) lead_17\VB|therapy|,|but|Levodopa (l_prep) to_18\IN|could|.|use (l_pobj) outcomes_21\NNS|NONE (l_prep) as_24\IN|chronic|adverse|, (l_pobj) fluctuations_26\NNS|such (l_conj) dyskinesia_28\JJ|motor|, (l_conj) hallucinations_31\NNS|and
D007980_D010300 NONE levodopa_9\JJ|adverse|in (r_amod) effects_11\NNS|NONE (l_prep) in_12\IN|adverse|levodopa (l_pobj) patients_16\NNS|NONE (l_compound) disease_15\NN|Parkinson
D007980_D010300 NONE Levodopa_0\NNP|therapy|,|but|lead (r_nsubj) is_1\VBZ|NONE (l_attr) therapy_6\NN|,|but|lead|Levodopa (l_prep) for_7\IN|symptomatic|the|effective (l_pobj) disease_10\NN|NONE
11708428
D011241_D001008 CID Prednisone_0\NNP|.|anxiety (r_nsubj) induces_1\VBZ|NONE (l_dobj) anxiety_2\NN|Prednisone|.
D011241_D001008 CID prednisone_3\NNP|whether|anxiety (r_nsubj) produces_7\VBZ|To|. (l_dobj) anxiety_8\NN|whether|prednisone
D011241_D001008 CID PDN_5\NNP|)|( (r_appos) prednisone_3\NNP|whether|anxiety (r_nsubj) produces_7\VBZ|To|. (l_dobj) anxiety_8\NN|whether|prednisone
D011241_D001008 CID PDN_7\NNP|NONE (r_pobj) of_6\IN|both (r_prep) groups_5\NNS|NONE (r_pobj) in_3\IN|treated|was|.|Anxiety (r_prep) documented_2\VBN|NONE (l_nsubjpass) Anxiety_0\NN|treated|in|was|.
D011241_D001008 CID PDN_3\NNP|NONE (r_pobj) to_2\IN|Subacute (r_prep) exposure_1\NN|anxiety|. (r_nsubj) induced_4\VBD|NONE (l_dobj) anxiety_5\NN|exposure|.
1858969
D004049_D005368 NONE diethylcarbamazine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_dobj) following_4\VBG|Five|of (r_prep) cases_1\NNS|with|.|were|in (r_nsubjpass) observed_12\VBN|NONE (l_prep) with_16\IN|.|were|in|cases (l_pobj) filariasis_19\NN|NONE
D004049_D005368 NONE DEC_9\NNP|NONE (r_appos) diethylcarbamazine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_dobj) following_4\VBG|Five|of (r_prep) cases_1\NNS|with|.|were|in (r_nsubjpass) observed_12\VBN|NONE (l_prep) with_16\IN|.|were|in|cases (l_pobj) filariasis_19\NN|NONE
D004049_D008118 NONE diethylcarbamazine_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) loiasis_7\NN|NONE
D004049_D004660 CID diethylcarbamazine_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) loiasis_7\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) during_4\IN|Five|of|. (r_prep) cases_1\NNS|NONE (l_prep) of_2\IN|Five|.|during (l_pobj) encephalitis_3\NN|NONE
D004049_D004660 CID diethylcarbamazine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_dobj) following_4\VBG|Five|of (r_prep) cases_1\NNS|with|.|were|in (l_prep) of_2\IN|Five|following (l_pobj) encephalitis_3\NN|NONE
D004049_D004660 CID DEC_9\NNP|NONE (r_appos) diethylcarbamazine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_dobj) following_4\VBG|Five|of (r_prep) cases_1\NNS|with|.|were|in (l_prep) of_2\IN|Five|following (l_pobj) encephalitis_3\NN|NONE
6615679
D013999_D007022 CID timolol_6\NN|eye (r_nmod) drops_10\NNS|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|NONE (r_acl) hypotension_3\NN|.|Intraoperative|and
D013999_D007022 CID maleate_16\NN|eye (r_amod) drops_18\NNS|NONE (r_dobj) timolol_15\NN|and|pilocarpine (r_conj) nitrate_13\NN|NONE (r_pobj) with_11\IN|was|who|concurrently|being (r_prep) treated_10\VBN|old|,|A|, (r_relcl) man_4\NN|.|and|became|bradycardia (r_nsubj) developed_20\VBD|NONE (l_conj) became_24\VBD|.|and|bradycardia|man (l_acomp) hypotensive_25\JJ|during
D010862_D007022 CID pilocarpine_8\VB|and (r_conj) timolol_6\NN|eye (r_nmod) drops_10\NNS|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|NONE (r_acl) hypotension_3\NN|.|Intraoperative|and
D010862_D007022 CID nitrate_13\NN|NONE (r_pobj) with_11\IN|was|who|concurrently|being (r_prep) treated_10\VBN|old|,|A|, (r_relcl) man_4\NN|.|and|became|bradycardia (r_nsubj) developed_20\VBD|NONE (l_conj) became_24\VBD|.|and|bradycardia|man (l_acomp) hypotensive_25\JJ|during
D013999_D001919 CID timolol_6\NN|eye (r_nmod) drops_10\NNS|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|NONE (r_acl) hypotension_3\NN|.|Intraoperative|and (r_conj) bradycardia_1\NNP|NONE
D013999_D001919 CID maleate_16\NN|eye (r_amod) drops_18\NNS|NONE (r_dobj) timolol_15\NN|and|pilocarpine (r_conj) nitrate_13\NN|NONE (r_pobj) with_11\IN|was|who|concurrently|being (r_prep) treated_10\VBN|old|,|A|, (r_relcl) man_4\NN|.|and|became|bradycardia (r_nsubj) developed_20\VBD|NONE (l_dobj) bradycardia_22\NN|.|and|became|man
D006221_D001919 NONE halothane_27\NN|NONE (r_compound) anaesthesia_28\NN|NONE (r_pobj) during_26\IN|hypotensive (r_prep) became_24\VBD|.|and|bradycardia|man (r_conj) developed_20\VBD|NONE (l_dobj) bradycardia_22\NN|.|and|became|man
D006221_D001919 NONE halothane_11\NN|with (r_compound) anaesthesia_12\NN|NONE (l_prep) with_13\IN|halothane (l_pobj) bradycardia_15\NN|NONE
D006221_D007022 NONE halothane_27\NN|NONE (r_compound) anaesthesia_28\NN|NONE (r_pobj) during_26\IN|hypotensive (r_prep) became_24\VBD|.|and|bradycardia|man (l_acomp) hypotensive_25\JJ|during
D006221_D007022 NONE halothane_11\NN|with (r_compound) anaesthesia_12\NN|NONE (l_prep) with_13\IN|halothane (l_pobj) bradycardia_15\NN|NONE (l_conj) hypotension_17\NN|and|resultant
D010862_D001919 CID pilocarpine_8\VB|and (r_conj) timolol_6\NN|eye (r_nmod) drops_10\NNS|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|NONE (r_acl) hypotension_3\NN|.|Intraoperative|and (r_conj) bradycardia_1\NNP|NONE
D010862_D001919 CID nitrate_13\NN|NONE (r_pobj) with_11\IN|was|who|concurrently|being (r_prep) treated_10\VBN|old|,|A|, (r_relcl) man_4\NN|.|and|became|bradycardia (r_nsubj) developed_20\VBD|NONE (l_dobj) bradycardia_22\NN|.|and|became|man
24088636
D004977_D054908 NONE ethambutol_22\NN|and (l_prep) for_23\IN|NONE (l_pobj) tuberculosis_28\NN|NONE
D004977_D054908 NONE ethambutol_22\NN|and (l_prep) for_23\IN|NONE (l_pobj) tuberculosis_28\NN|NONE (l_appos) TB_32\NNP|resistant
D004977_D009901 NONE Ethambutol_0\NNP| (r_npadvmod) induced_2\VBN|optic (r_amod) neuropathy_5\NN|withdrawn|and|was
D004977_D009901 NONE ethambutol_10\NN|was|. (r_nsubjpass) withdrawn_12\VBN|neuropathy|and|was (r_conj) suspected_7\VBN|NONE (l_nsubjpass) neuropathy_5\NN|withdrawn|and|was
C098010_D054908 NONE linezolid_20\NN|NONE (l_conj) ethambutol_22\NN|and (l_prep) for_23\IN|NONE (l_pobj) tuberculosis_28\NN|NONE
C098010_D054908 NONE linezolid_20\NN|NONE (l_conj) ethambutol_22\NN|and (l_prep) for_23\IN|NONE (l_pobj) tuberculosis_28\NN|NONE (l_appos) TB_32\NNP|resistant
D004977_D015354 NONE ethambutol_7\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) withdrawal_5\NN|NONE (r_pobj) despite_4\IN|Deterioration|. (r_prep) occurred_3\VBD|NONE (l_nsubj) Deterioration_0\NN|despite|. (l_prep) of_1\IN|NONE (l_pobj) vision_2\NN|NONE
C098010_D009901 CID Linezolid_0\NNP| (r_npadvmod) induced_2\VBN|.|optic (r_amod) neuropathy_4\NN|NONE
D004977_D014786 NONE ethambutol_22\NN|and (r_conj) linezolid_20\NN|NONE (r_pobj) including_19\VBG|line|multiple|tuberculous (r_prep) drugs_18\NNS|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|NONE (r_pobj) on_8\IN|who (r_prep) was_7\VBD|A|male|old (r_relcl) patient_5\NN|to|with|. (r_nsubj) presented_34\VBN|NONE (l_prep) with_37\IN|to|patient|. (l_pobj) loss_40\NN|NONE (l_prep) of_41\IN|in|painless|progressive (l_pobj) vision_42\NN|NONE
C098010_D014786 NONE linezolid_11\NN|NONE (r_amod) therapy_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|NONE (r_acl) vision_8\NN|NONE
C098010_D014786 NONE linezolid_20\NN|NONE (r_pobj) including_19\VBG|line|multiple|tuberculous (r_prep) drugs_18\NNS|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|NONE (r_pobj) on_8\IN|who (r_prep) was_7\VBD|A|male|old (r_relcl) patient_5\NN|to|with|. (r_nsubj) presented_34\VBN|NONE (l_prep) with_37\IN|to|patient|. (l_pobj) loss_40\NN|NONE (l_prep) of_41\IN|in|painless|progressive (l_pobj) vision_42\NN|NONE
24727461
D004317_D066126 NONE doxorubicin_8\NN| (r_npadvmod) induced_10\VBN|in (r_amod) cardiotoxicity_11\NN|NONE
D004317_D066126 NONE Doxorubicin_0\NNP|cardiotoxicity|. (r_nsubj) causes_1\VBZ|NONE (l_dobj) cardiotoxicity_3\NN|.|Doxorubicin
D004317_D066126 NONE doxorubicin_5\RB| (r_npadvmod) associated_7\VBN|chronic|cardiac (r_amod) toxicity_10\NN|whether|can|with|be
C005975_D028361 NONE Hydroxytyrosol_0\NNP|.|stress|in (r_nsubj) ameliorates_1\VBZ|NONE (l_dobj) stress_3\NN|Hydroxytyrosol|.|in (l_conj) dysfunction_6\NN|and|oxidative
D004317_D028361 NONE doxorubicin_8\NN| (r_npadvmod) induced_10\VBN|in (r_amod) cardiotoxicity_11\NN|NONE (r_pobj) in_7\IN|Hydroxytyrosol|.|stress (r_prep) ameliorates_1\VBZ|NONE (l_dobj) stress_3\NN|Hydroxytyrosol|.|in (l_conj) dysfunction_6\NN|and|oxidative
D004317_D028361 NONE Doxorubicin_0\NNP|cardiotoxicity|. (r_nsubj) causes_1\VBZ|NONE (l_dobj) cardiotoxicity_3\NN|.|Doxorubicin (l_acl) characterized_4\VBN|significant (l_agent) by_5\IN|NONE (l_pobj) increases_7\NNS|NONE (l_prep) in_8\IN|marked (l_pobj) stress_10\NN|NONE (l_conj) dysfunction_13\NN|oxidative|and
C005975_D006331 NONE Hydroxytyrosol_0\NNP|.|disturbances (r_nsubj) improved_1\VBD|NONE (l_dobj) disturbances_4\NNS|.|Hydroxytyrosol
C005975_D006331 NONE hydroxytyrosol_4\JJ|study|.|decreasing (l_dobj) damage_8\NN|that
C005975_D001943 NONE Hydroxytyrosol_0\NNP|.|stress|in (r_nsubj) ameliorates_1\VBZ|NONE (l_prep) in_7\IN|Hydroxytyrosol|.|stress (l_pobj) cardiotoxicity_11\NN|NONE (l_prep) in_12\IN|induced (l_pobj) rats_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) cancer_16\NN|NONE
C005975_D001943 NONE hydroxytyrosol_17\NN|NONE (l_prep) in_18\IN|antioxidant|the (l_pobj) rats_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) cancer_22\NN|NONE
C005975_D001943 NONE hydroxytyrosol_17\NN|,|week (r_conj) control_15\NN|:|)| (r_appos) groups_13\NNS|NONE (r_pobj) into_11\IN|,|were|.|induced|doxorubicin (r_prep) divided_10\VBN|NONE (l_csubjpass) induced_7\VBD|,|were|.|into|doxorubicin (l_nsubj) rats_3\NNS|chemically (l_acl) bearing_4\VBG|six (l_dobj) tumors_6\NNS|NONE
C005975_D001943 NONE hydroxytyrosol_40\NN|plus (r_conj) doxorubicin_38\NN|week|,|and (r_conj) doxorubicin_28\NN|,|were|.|into|induced (r_appos) divided_10\VBN|NONE (l_csubjpass) induced_7\VBD|,|were|.|into|doxorubicin (l_nsubj) rats_3\NNS|chemically (l_acl) bearing_4\VBG|six (l_dobj) tumors_6\NNS|NONE
D004317_D001943 NONE doxorubicin_8\NN| (r_npadvmod) induced_10\VBN|in (r_amod) cardiotoxicity_11\NN|NONE (l_prep) in_12\IN|induced (l_pobj) rats_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) cancer_16\NN|NONE
D004317_D001943 NONE doxorubicin_5\RB| (r_npadvmod) associated_7\VBN|chronic|cardiac (r_amod) toxicity_10\NN|whether|can|with|be (r_nsubjpass) ameliorated_13\VBN|.|Herein|,|we (l_prep) with_14\IN|toxicity|whether|can|be (l_pobj) hydroxytyrosol_17\NN|NONE (l_prep) in_18\IN|antioxidant|the (l_pobj) rats_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) cancer_22\NN|NONE
D004317_D001943 NONE doxorubicin_28\NN|,|were|.|into|induced (r_appos) divided_10\VBN|NONE (l_csubjpass) induced_7\VBD|,|were|.|into|doxorubicin (l_nsubj) rats_3\NNS|chemically (l_acl) bearing_4\VBG|six (l_dobj) tumors_6\NNS|NONE
D004317_D001943 NONE doxorubicin_38\NN|week|,|and (r_conj) doxorubicin_28\NN|,|were|.|into|induced (r_appos) divided_10\VBN|NONE (l_csubjpass) induced_7\VBD|,|were|.|into|doxorubicin (l_nsubj) rats_3\NNS|chemically (l_acl) bearing_4\VBG|six (l_dobj) tumors_6\NNS|NONE
D004317_D009369 NONE doxorubicin_28\NN|such (r_pobj) as_27\IN|NONE (r_prep) drugs_25\NNS|NONE (r_pobj) of_24\IN|therapeutic|the (r_prep) effect_23\NN|to (r_dobj) potentiate_20\VB|been|has (r_xcomp) shown_18\VBN|,|stress|in|and|.|is (r_conj) involved_3\VBN|NONE (l_prep) in_4\IN|,|stress|and|shown|.|is (l_pobj) processes_6\NNS|NONE (l_prep) including_7\VBG|several (l_pobj) cancer_8\NN|NONE
C005975_D066126 NONE Hydroxytyrosol_0\NNP|.|stress|in (r_nsubj) ameliorates_1\VBZ|NONE (l_prep) in_7\IN|Hydroxytyrosol|.|stress (l_pobj) cardiotoxicity_11\NN|NONE
C005975_D066126 NONE hydroxytyrosol_17\NN|NONE (r_pobj) with_14\IN|toxicity|whether|can|be (r_prep) ameliorated_13\VBN|.|Herein|,|we (l_nsubjpass) toxicity_10\NN|whether|can|with|be
D004317_D006331 CID doxorubicin_7\NN|NONE (r_pobj) by_6\IN|by (r_agent) enhanced_5\VBN|cardiac|the (r_acl) disturbances_4\NNS|.|Hydroxytyrosol
D004317_D006331 CID doxorubicin_11\NN|damage (r_nmod) decreasing_12\VBG|hydroxytyrosol|study|. (r_advcl) demonstrates_2\VBZ|NONE (l_ccomp) hydroxytyrosol_4\JJ|study|.|decreasing (l_dobj) damage_8\NN|that
D004317_D002318 NONE doxorubicin_28\NN|such (r_pobj) as_27\IN|NONE (r_prep) drugs_25\NNS|NONE (r_pobj) of_24\IN|therapeutic|the (r_prep) effect_23\NN|to (r_dobj) potentiate_20\VB|been|has (r_xcomp) shown_18\VBN|,|stress|in|and|.|is (r_conj) involved_3\VBN|NONE (l_prep) in_4\IN|,|stress|and|shown|.|is (l_pobj) processes_6\NNS|NONE (l_prep) including_7\VBG|several (l_pobj) cancer_8\NN|NONE (l_conj) disease_13\NN|,
1424076
D014750_D007177 CID vincristine_9\NN|NONE (r_pobj) after_7\IN|.|of (r_prep) Syndrome_0\NN|NONE (l_prep) of_1\IN|.|after (l_pobj) secretion_3\NN|NONE (l_prep) of_4\IN|inappropriate (l_pobj) hormone_6\NN|NONE
D014750_D007177 CID vincristine_16\NN|the (r_compound) infusion_17\NN|NONE (r_pobj) to_14\IN|was|which (r_prep) attributed_13\VBN|,|antidiuretic (r_relcl) hormone_9\NN|NONE
D014750_D009101 NONE vincristine_18\NN|NONE (r_pobj) of_17\IN|day|continuous|intravenous|doxorubicin|a|and (r_prep) infusion_16\NN|NONE (r_pobj) with_11\IN|woman|.|was (r_prep) treated_10\VBN|NONE (l_nsubjpass) woman_4\NN|.|with|was (l_prep) with_5\IN|A|old (l_pobj) myeloma_8\NN|NONE
D004317_D009101 NONE doxorubicin_20\NN|day|continuous|intravenous|of|a|and (r_conj) infusion_16\NN|NONE (r_pobj) with_11\IN|woman|.|was (r_prep) treated_10\VBN|NONE (l_nsubjpass) woman_4\NN|.|with|was (l_prep) with_5\IN|A|old (l_pobj) myeloma_8\NN|NONE
D003907_D009101 NONE dexamethasone_26\NN|NONE (r_pobj) of_24\IN| (r_prep) days_23\NNS|and (r_conj) doxorubicin_20\NN|day|continuous|intravenous|of|a|and (r_conj) infusion_16\NN|NONE (r_pobj) with_11\IN|woman|.|was (r_prep) treated_10\VBN|NONE (l_nsubjpass) woman_4\NN|.|with|was (l_prep) with_5\IN|A|old (l_pobj) myeloma_8\NN|NONE
24554916
D010758_D017114 CID phosphorus_3\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Poisoning_0\VBG|with|.|classically (r_nsubj) manifests_5\VBZ|NONE (l_prep) with_6\IN|Poisoning|.|classically (l_pobj) hepatitis_8\NN|NONE (l_acl) leading_9\VBG|acute (l_prep) to_10\IN|NONE (l_pobj) failure_13\NN|NONE
D010758_D056486 NONE phosphorus_1\NN|known|. (r_nsubj) is_12\VBZ|NONE (l_acomp) known_14\JJ|.|phosphorus (l_xcomp) cause_16\VB|well (l_dobj) hepatotoxicity_17\NN|to
D010758_D056486 NONE phosphorus_6\NN|yellow|presented (r_compound) poisoning_7\NN|NONE (l_relcl) presented_12\VBN|phosphorus|yellow (l_advcl) highlighting_19\VBG|patient|with|in (l_dobj) fact_21\NN|NONE (l_acl) be_26\VB|the (l_attr) feature_29\NN|rarely|can|that|cholestasis (l_prep) of_30\IN|presenting|a (l_pobj) hepatotoxicity_33\NN|NONE
D010758_D056486 NONE phosphorus_32\NN|NONE (r_compound) hepatotoxicity_33\NN|NONE
D010758_D011041 NONE phosphorus_4\NN|yellow (r_compound) poisoning_5\NN|NONE
D010758_D011041 NONE phosphorus_3\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Poisoning_0\VBG|with|.|classically
D010758_D011041 NONE phosphorus_6\NN|yellow|presented (r_compound) poisoning_7\NN|NONE
D010758_D011041 NONE phosphorus_32\NN|NONE (r_compound) hepatotoxicity_33\NN|NONE (r_pobj) of_30\IN|presenting|a (r_prep) feature_29\NN|rarely|can|that|cholestasis (r_attr) be_26\VB|the (r_acl) fact_21\NN|NONE (r_dobj) highlighting_19\VBG|patient|with|in (r_advcl) presented_12\VBN|phosphorus|yellow (r_relcl) poisoning_7\NN|NONE
D010758_D006505 CID phosphorus_3\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Poisoning_0\VBG|with|.|classically (r_nsubj) manifests_5\VBZ|NONE (l_prep) with_6\IN|Poisoning|.|classically (l_pobj) hepatitis_8\NN|NONE
D010758_D002779 CID phosphorus_4\NN|yellow (r_compound) poisoning_5\NN|NONE (r_pobj) of_2\IN|.|Cholestatic (r_prep) presentation_1\NN|NONE (l_amod) Cholestatic_0\JJ|.|of
D010758_D002779 CID phosphorus_6\NN|yellow|presented (r_compound) poisoning_7\NN|NONE (l_relcl) presented_12\VBN|phosphorus|yellow (l_prep) with_13\IN|patient|highlighting|in (l_pobj) features_16\NNS|NONE (l_prep) of_17\IN|florid|clinical (l_pobj) cholestasis_18\NN|NONE
D010758_D002779 CID phosphorus_6\NN|yellow|presented (r_compound) poisoning_7\NN|NONE (l_relcl) presented_12\VBN|phosphorus|yellow (l_advcl) highlighting_19\VBG|patient|with|in (l_dobj) fact_21\NN|NONE (l_acl) be_26\VB|the (l_nsubj) cholestasis_23\NN|rarely|can|that|feature
D010758_D002779 CID phosphorus_32\NN|NONE (r_compound) hepatotoxicity_33\NN|NONE (r_pobj) of_30\IN|presenting|a (r_prep) feature_29\NN|rarely|can|that|cholestasis (r_attr) be_26\VB|the (r_acl) fact_21\NN|NONE (r_dobj) highlighting_19\VBG|patient|with|in (r_advcl) presented_12\VBN|phosphorus|yellow (l_prep) with_13\IN|patient|highlighting|in (l_pobj) features_16\NNS|NONE (l_prep) of_17\IN|florid|clinical (l_pobj) cholestasis_18\NN|NONE
D010758_D002779 CID phosphorus_32\NN|NONE (r_compound) hepatotoxicity_33\NN|NONE (r_pobj) of_30\IN|presenting|a (r_prep) feature_29\NN|rarely|can|that|cholestasis (r_attr) be_26\VB|the (l_nsubj) cholestasis_23\NN|rarely|can|that|feature
24571687
D020927_D001919 CID dexmedetomidine_7\NN|NONE (r_dobj) following_5\VBG|severe (r_prep) bradycardia_4\NNS|and|Vasovagal|.
D020927_D001919 CID dexmedetomidine_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) following_11\VBG|old|an (r_acl) girl_10\NN|NONE (r_pobj) in_5\IN|NONE (r_prep) bradycardia_4\NN|and
D020927_D019462 CID dexmedetomidine_7\NN|NONE (r_dobj) following_5\VBG|severe (r_prep) bradycardia_4\NNS|and|Vasovagal|. (r_conj) syncope_1\NN|NONE
D020927_D013575 NONE dexmedetomidine_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) following_11\VBG|old|an (r_acl) girl_10\NN|NONE (r_pobj) in_5\IN|NONE (r_prep) bradycardia_4\NN|and (r_conj) syncope_2\NN|.|We
8312983
C036139_D006948 NONE desmethylfluoxetine_22\NN|plus (r_conj) fluoxetine_20\NN|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) connected_12\VBN|hyperkinetic|acute (r_acl) delirium_11\NN|NONE (l_amod) hyperkinetic_10\JJ|connected|acute
D015283_D020820 NONE citalopram_9\NN|NONE (r_pobj) of_8\IN|L|high|a|in|serum (r_prep) concentration_7\NN|,|.|has|In|with|been (r_nsubjpass) associated_22\VBN|NONE (l_prep) with_23\IN|,|concentration|.|has|In|been (l_pobj) somnolence_25\NN|NONE (l_conj) difficulties_28\NNS|and|increased
D005473_D006948 CID fluoxetine_18\NN|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) connected_12\VBN|hyperkinetic|acute (r_acl) delirium_11\NN|NONE (l_amod) hyperkinetic_10\JJ|connected|acute
D005473_D006948 CID fluoxetine_20\NN|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) connected_12\VBN|hyperkinetic|acute (r_acl) delirium_11\NN|NONE (l_amod) hyperkinetic_10\JJ|connected|acute
C036139_D003693 NONE desmethylfluoxetine_22\NN|plus (r_conj) fluoxetine_20\NN|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) connected_12\VBN|hyperkinetic|acute (r_acl) delirium_11\NN|NONE
D005473_D003693 CID fluoxetine_2\NN|NONE (r_amod) treatment_3\NN|NONE (r_pobj) during_1\IN|. (r_prep) Delirium_0\NN|NONE
D005473_D003693 CID fluoxetine_18\NN|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) connected_12\VBN|hyperkinetic|acute (r_acl) delirium_11\NN|NONE
D005473_D003693 CID fluoxetine_20\NN|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) connected_12\VBN|hyperkinetic|acute (r_acl) delirium_11\NN|NONE
D015283_D006970 NONE citalopram_9\NN|NONE (r_pobj) of_8\IN|L|high|a|in|serum (r_prep) concentration_7\NN|,|.|has|In|with|been (r_nsubjpass) associated_22\VBN|NONE (l_prep) with_23\IN|,|concentration|.|has|In|been (l_pobj) somnolence_25\NN|NONE
12372954
C036067_D012170 NONE lysine_10\NN|due (r_dobj) bendazac_9\VB|Before|,|.|had|nicergoline|been|he|and (l_prep) due_11\IN|lysine (l_pobj) occlusion_15\NN|to
D009530_D009395 CID nicergoline_5\NN|to (r_pobj) due_3\IN|Acute|.|interstitial (r_prep) nephritis_2\NN|NONE
D009530_D009395 CID Sermion_7\NN|NONE (r_appos) nicergoline_5\NN|to (r_pobj) due_3\IN|Acute|.|interstitial (r_prep) nephritis_2\NN|NONE
D009530_D009395 CID nicergoline_13\NN|to (r_pobj) due_11\IN|We|.|case (r_prep) report_1\VBP|NONE (l_dobj) case_3\NN|We|.|due (l_prep) of_4\IN|a (l_pobj) nephritis_7\NN|NONE
D009530_D009395 CID nicergoline_13\NN|to (r_pobj) due_11\IN|We|.|case (r_prep) report_1\VBP|NONE (l_dobj) case_3\NN|We|.|due (l_prep) of_4\IN|a (l_pobj) nephritis_7\NN|NONE (l_appos) AIN_9\NNP|acute|)|interstitial|(
D009530_D009395 CID Sermion_15\NN|NONE (r_appos) nicergoline_13\NN|to (r_pobj) due_11\IN|We|.|case (r_prep) report_1\VBP|NONE (l_dobj) case_3\NN|We|.|due (l_prep) of_4\IN|a (l_pobj) nephritis_7\NN|NONE
D009530_D009395 CID Sermion_15\NN|NONE (r_appos) nicergoline_13\NN|to (r_pobj) due_11\IN|We|.|case (r_prep) report_1\VBP|NONE (l_dobj) case_3\NN|We|.|due (l_prep) of_4\IN|a (l_pobj) nephritis_7\NN|NONE (l_appos) AIN_9\NNP|acute|)|interstitial|(
D009530_D009395 CID nicergoline_10\NN| (r_npadvmod) associated_12\VBN|NONE (r_amod) AIN_13\NNP|NONE
D009530_D012170 NONE nicergoline_7\NN|Before|,|bendazac|.|had|been|he|and (r_dobj) taking_6\VBG|NONE (l_conj) bendazac_9\VB|Before|,|.|had|nicergoline|been|he|and (l_prep) due_11\IN|lysine (l_pobj) occlusion_15\NN|to
1564030
D012701_D003866 NONE serotonin_4\NN|a|selective|reuptake (r_compound) inhibitor_6\NN|,|, (r_appos) Fluoxetine_0\NNP|.|is|acceptance (r_nsubj) gaining_9\VBG|NONE (l_dobj) acceptance_11\NN|Fluoxetine|.|is (l_prep) in_12\IN|increased (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) depression_17\NN|NONE
D005473_D001714 CID fluoxetine_3\NN|in (r_amod) treatment_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|. (r_acl) Mania_0\NNP|NONE
D005473_D001714 CID fluoxetine_8\NN|been|induce|has|safe|.|, (r_nsubjpass) reported_11\VBN|NONE (l_xcomp) induce_13\VB|been|fluoxetine|has|safe|.|, (l_dobj) mania_14\NN|to
D005473_D001714 CID fluoxetine_20\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) pharmacotherapy_18\NN|NONE (r_pobj) during_17\IN|who|mania (r_prep) developed_15\VBD|years|,|The|,|of|, (l_dobj) mania_16\NN|during|who
D005473_D001714 CID fluoxetine_11\NN|in (r_amod) pharmacotherapy_12\NN|NONE (r_pobj) during_10\IN|NONE (r_prep) hypomania_9\NN|or|the|of (r_conj) development_5\NN|NONE (l_prep) of_6\IN|or|the|hypomania (l_pobj) mania_7\NN|NONE
D005473_D001714 CID fluoxetine_11\NN|in (r_amod) pharmacotherapy_12\NN|NONE (r_pobj) during_10\IN|NONE (r_prep) hypomania_9\NN|or|the|of
D005473_D001714 CID fluoxetine_11\NN|in (r_amod) pharmacotherapy_12\NN|NONE (r_pobj) during_10\IN|NONE (r_prep) hypomania_9\NN|or|the|of (r_conj) development_5\NN|NONE (r_pobj) for_3\IN|Apparent|depression|risk (r_prep) factors_2\NNS|;|combination|. (l_appos) depression_30\NN|Apparent|risk|for (l_conj) history_37\NN|;|major|with (l_prep) of_38\IN|;|diagnosis|a|and|family (l_pobj) disorder_40\NN|NONE (l_appos) disorder_44\NN|affective|,
D005473_D001714 CID fluoxetine_11\NN|in (r_amod) pharmacotherapy_12\NN|NONE (r_pobj) during_10\IN|NONE (r_prep) hypomania_9\NN|or|the|of (r_conj) development_5\NN|NONE (r_pobj) for_3\IN|Apparent|depression|risk (r_prep) factors_2\NNS|;|combination|. (l_appos) depression_30\NN|Apparent|risk|for (l_conj) history_37\NN|;|major|with (l_conj) diagnosis_48\NN|;|a|of|and|family (l_prep) of_49\IN|a (l_pobj) disorder_51\NN|NONE
D005473_D001714 CID fluoxetine_19\VB|NONE (r_advmod) induced_20\VBN|in (r_amod) mania_21\NN|NONE
D005473_D019964 NONE fluoxetine_11\NN|in (r_amod) pharmacotherapy_12\NN|NONE (r_pobj) during_10\IN|NONE (r_prep) hypomania_9\NN|or|the|of (r_conj) development_5\NN|NONE (r_pobj) for_3\IN|Apparent|depression|risk (r_prep) factors_2\NNS|;|combination|. (l_appos) depression_30\NN|Apparent|risk|for (l_conj) history_37\NN|;|major|with (l_prep) of_38\IN|;|diagnosis|a|and|family (l_pobj) disorder_40\NN|NONE
D005473_D001289 NONE fluoxetine_11\NN|in (r_amod) pharmacotherapy_12\NN|NONE (r_pobj) during_10\IN|NONE (r_prep) hypomania_9\NN|or|the|of (r_conj) development_5\NN|NONE (r_pobj) for_3\IN|Apparent|depression|risk (r_prep) factors_2\NNS|;|combination|. (r_nsubj) were_16\VBD|NONE (l_attr) combination_18\NN|;|factors|. (l_prep) of_19\IN|the (l_pobj) disorder_24\NN|NONE
D005473_D011618 NONE fluoxetine_11\NN|in (r_amod) pharmacotherapy_12\NN|NONE (r_pobj) during_10\IN|NONE (r_prep) hypomania_9\NN|or|the|of (r_conj) development_5\NN|NONE (r_pobj) for_3\IN|Apparent|depression|risk (r_prep) factors_2\NNS|;|combination|. (l_appos) depression_30\NN|Apparent|risk|for (l_prep) with_31\IN|history|;|major (l_pobj) features_33\NNS|NONE (l_amod) psychotic_32\JJ|NONE
D005473_D003866 NONE Fluoxetine_0\NNP|.|is|acceptance (r_nsubj) gaining_9\VBG|NONE (l_dobj) acceptance_11\NN|Fluoxetine|.|is (l_prep) in_12\IN|increased (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) depression_17\NN|NONE
D005473_D003866 NONE fluoxetine_20\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) pharmacotherapy_18\NN|NONE (r_pobj) during_17\IN|who|mania (r_prep) developed_15\VBD|years|,|The|,|of|, (r_relcl) cases_1\NNS|.|are|here (l_prep) of_2\IN|years|,|The|,|,|developed (l_pobj) adolescents_5\NNS|NONE (l_amod) depressed_4\JJ|five
D005473_D003866 NONE fluoxetine_11\NN|in (r_amod) pharmacotherapy_12\NN|NONE (r_pobj) during_10\IN|NONE (r_prep) hypomania_9\NN|or|the|of (r_conj) development_5\NN|NONE (r_pobj) for_3\IN|Apparent|depression|risk (r_prep) factors_2\NNS|;|combination|. (l_appos) depression_30\NN|Apparent|risk|for
19553912
D020123_D000740 CID sirolimus_6\NN|NONE (r_pobj) of_5\IN|the (r_prep) role_4\NN|.|Posttransplant|: (r_appos) anemia_1\NN|NONE
D020123_D000740 CID Sirolimus_0\NNP|.|as|has|been (r_nsubjpass) implicated_11\VBN|NONE (l_prep) as_12\IN|Sirolimus|.|has|been (l_pcomp) playing_13\VBG|NONE (l_dobj) role_16\NN|NONE (l_prep) in_17\IN|a|special (l_pobj) anemia_19\NN|NONE
D020123_D000740 CID rapamycin_6\NNS|NONE (r_compound) inhibitor_7\NN|NONE (r_pobj) of_5\IN|a|mammalian (r_prep) target_4\NN|,|, (r_appos) Sirolimus_0\NNP|.|as|has|been (r_nsubjpass) implicated_11\VBN|NONE (l_prep) as_12\IN|Sirolimus|.|has|been (l_pcomp) playing_13\VBG|NONE (l_dobj) role_16\NN|NONE (l_prep) in_17\IN|a|special (l_pobj) anemia_19\NN|NONE
D020123_D000740 CID sirolimus_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|including|, (r_acl) anemia_3\NN|.|review
17496739
C085143_D007676 NONE tazobactam_54\NN|mental|,|episodes|and|progressive (r_conj) confusion_34\NN|,|bizarre (r_conj) behavior_30\NN|, (r_conj) tremor_27\NN|slurred|, (r_conj) speech_25\NN|who (r_dobj) developed_23\VBD|,|ambulatory|)|continuous|peritoneal|CAPD|( (r_relcl) dialysis_17\NN|NONE (r_dobj) receiving_13\VBG|renal|stage (r_acl) disease_12\NN|NONE
C085143_D012640 NONE tazobactam_2\NN||Piperacillin|/ (r_advmod) induced_4\VBN|NONE (r_amod) seizure_5\NN|in|rapidly|.|by
C085143_D060085 NONE tazobactam_54\NN|mental|,|episodes|and|progressive (r_conj) confusion_34\NN|,|bizarre (r_conj) behavior_30\NN|, (r_conj) tremor_27\NN|slurred|, (r_conj) speech_25\NN|who (r_dobj) developed_23\VBD|,|ambulatory|)|continuous|peritoneal|CAPD|( (r_relcl) dialysis_17\NN|NONE (r_dobj) receiving_13\VBG|renal|stage (r_acl) disease_12\NN|NONE (r_pobj) with_7\IN|a|old (r_prep) woman_6\NN|were|for (r_nsubjpass) given_61\VBN|We|. (l_prep) for_62\IN|were|woman (l_pobj) bronchiectasis_63\NN|NONE (l_prep) with_64\IN|NONE (l_pobj) infection_66\NN|NONE
C085143_D004830 CID tazobactam_54\NN|mental|,|episodes|and|progressive (r_conj) confusion_34\NN|,|bizarre (l_conj) episodes_38\NNS|tazobactam|mental|,|and|progressive (l_prep) of_39\IN|GTCS| (l_pobj) seizure_44\NN|NONE
C085143_D004830 CID tazobactam_54\NN|mental|,|episodes|and|progressive (r_conj) confusion_34\NN|,|bizarre (l_conj) episodes_38\NNS|tazobactam|mental|,|and|progressive (l_parataxis) GTCS_46\NNP|of|
C085143_D004830 CID tazobactam_18\NN|NONE (r_pobj) after_11\IN|Despite|episode|,|. (r_prep) recurred_10\VBD|NONE (l_nsubj) episode_9\NN|Despite|,|after|. (l_amod) GTCS_8\NNP|another
C085143_D014202 CID tazobactam_54\NN|mental|,|episodes|and|progressive (r_conj) confusion_34\NN|,|bizarre (r_conj) behavior_30\NN|, (r_conj) tremor_27\NN|slurred|,
C085143_D001987 NONE tazobactam_54\NN|mental|,|episodes|and|progressive (r_conj) confusion_34\NN|,|bizarre (r_conj) behavior_30\NN|, (r_conj) tremor_27\NN|slurred|, (r_conj) speech_25\NN|who (r_dobj) developed_23\VBD|,|ambulatory|)|continuous|peritoneal|CAPD|( (r_relcl) dialysis_17\NN|NONE (r_dobj) receiving_13\VBG|renal|stage (r_acl) disease_12\NN|NONE (r_pobj) with_7\IN|a|old (r_prep) woman_6\NN|were|for (r_nsubjpass) given_61\VBN|We|. (l_prep) for_62\IN|were|woman (l_pobj) bronchiectasis_63\NN|NONE
D010878_D001927 NONE Piperacillin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) encephalopathy_3\NN|be|.|should|in
D010878_D001927 NONE piperacillin_5\NN|NONE (r_dobj) removing_4\VBG|NONE (r_pcomp) in_3\IN|NONE (r_prep) inefficient_2\JJ|CAPD|terminate|.|, (r_acomp) is_1\VBZ|NONE (l_advcl) terminate_11\VB|inefficient|CAPD|.|, (l_dobj) encephalopathy_16\NN|rapidly|can|hemodialysis|whereas
D010878_D001927 NONE piperacillin_13\NN| (r_npadvmod) induced_15\VBN|the (r_amod) encephalopathy_16\NN|rapidly|can|hemodialysis|whereas
C085143_D003221 CID tazobactam_54\NN|mental|,|episodes|and|progressive (r_conj) confusion_34\NN|,|bizarre
D010878_D006463 NONE Piperacillin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) encephalopathy_3\NN|be|.|should|in (r_nsubjpass) considered_6\VBN|NONE (l_prep) in_7\IN|be|.|should|encephalopathy (l_pobj) patients_10\NNS|NONE (l_amod) uremic_9\JJ|any|with
D010878_D020258 NONE piperacillin_4\NN|NONE (r_pobj) of_3\IN|popular (r_prep) use_2\NN|NONE (r_pobj) Despite_0\IN|,|unrecognized|.|,|still|neurotoxicity|leading (r_prep) goes_13\VBZ|NONE (l_nsubj) neurotoxicity_8\NN|Despite|,|unrecognized|.|,|still|leading
D010878_D020258 NONE piperacillin_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|the|dire (r_acl) neurotoxicity_8\NN|Despite|,|unrecognized|.|,|still|leading
D000641_D007964 NONE ammonia_8\NN|leukocytosis|but|electrolyte (r_compound) levels_9\NNS|data|. (l_conj) leukocytosis_11\NN|ammonia|but|electrolyte
12119460
D005472_D013274 NONE 5-fluorouracil_3\CD|/ (r_punct) folinic_5\JJ|.|in|dose (r_compound) acid_6\NN|NONE (l_prep) in_7\IN|folinic|.|dose (l_pobj) combination_8\NN|NONE (l_prep) with_9\IN|NONE (l_pobj) C_14\NN|NONE (l_prep) in_15\IN|weekly|mitomycin (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) cancer_21\NN|NONE
D005472_D013274 NONE 5-fluorouracil_5\CD|NONE (r_punct) (_6\-LRB-|folinic|)|and (r_punct) 5-FU_7\CD|NONE (l_conj) folinic_10\VB|(|)|and (l_prep) as_15\IN|)|FA (l_pobj) part_16\NN|NONE (l_prep) of_17\IN|NONE (l_pobj) regimens_22\NNS|NONE (l_prep) in_23\IN|chemotherapy|new|several (l_pobj) cancer_26\NN|NONE
D005472_D013274 NONE 5-fluorouracil_5\CD|NONE (r_punct) (_6\-LRB-|folinic|)|and (r_punct) 5-FU_7\CD|NONE (r_pobj) of_4\IN|continuous|The|hour (r_prep) infusion_3\NN|(|be|has|.|AGC (r_nsubj) shown_31\VBN|NONE (l_nsubj) AGC_28\NNP|(|be|has|infusion|.
D005472_D013274 NONE 5-FU_7\CD|NONE (l_conj) folinic_10\VB|(|)|and (l_prep) as_15\IN|)|FA (l_pobj) part_16\NN|NONE (l_prep) of_17\IN|NONE (l_pobj) regimens_22\NNS|NONE (l_prep) in_23\IN|chemotherapy|new|several (l_pobj) cancer_26\NN|NONE
D005472_D013274 NONE 5-FU_7\CD|NONE (r_pobj) of_4\IN|continuous|The|hour (r_prep) infusion_3\NN|(|be|has|.|AGC (r_nsubj) shown_31\VBN|NONE (l_nsubj) AGC_28\NNP|(|be|has|infusion|.
D005472_D013274 NONE 5-FU_18\CD|to (r_dobj) receive_15\VB|with|)|preceded| (r_relcl) patients_11\NNS|we|for|,|From|.|,|followed (l_prep) with_12\IN|)|receive|preceded| (l_pobj) AGC_13\NNP|NONE
D005472_D013274 NONE 5-FU_3\CD|FA|dose|/|/ (r_nmod) MMC_7\NNP|regimen|. (r_nsubj) is_8\VBZ|NONE (l_attr) regimen_16\NN|MMC|. (l_prep) for_17\IN|an|effective|outpatient (l_pobj) AGC_18\NNP|NONE
D016685_D013274 NONE C_14\NN|NONE (l_prep) in_15\IN|weekly|mitomycin (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) cancer_21\NN|NONE
D016685_D013274 NONE MMC_7\NNP|regimen|. (r_nsubj) is_8\VBZ|NONE (l_attr) regimen_16\NN|MMC|. (l_prep) for_17\IN|an|effective|outpatient (l_pobj) AGC_18\NNP|NONE
D005472_D064420 NONE 5-fluorouracil_5\CD|NONE (r_punct) (_6\-LRB-|folinic|)|and (r_punct) 5-FU_7\CD|NONE (r_pobj) of_4\IN|continuous|The|hour (r_prep) infusion_3\NN|(|be|has|.|AGC (r_nsubj) shown_31\VBN|NONE (l_xcomp) be_33\VB|(|has|infusion|.|AGC (l_prep) with_36\IN|effective|to|, (l_pobj) toxicity_38\NN|NONE
D005472_D064420 NONE 5-FU_7\CD|NONE (r_pobj) of_4\IN|continuous|The|hour (r_prep) infusion_3\NN|(|be|has|.|AGC (r_nsubj) shown_31\VBN|NONE (l_xcomp) be_33\VB|(|has|infusion|.|AGC (l_prep) with_36\IN|effective|to|, (l_pobj) toxicity_38\NN|NONE
D002955_D013274 NONE acid_6\NN|NONE (l_prep) in_7\IN|folinic|.|dose (l_pobj) combination_8\NN|NONE (l_prep) with_9\IN|NONE (l_pobj) C_14\NN|NONE (l_prep) in_15\IN|weekly|mitomycin (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) cancer_21\NN|NONE
D002955_D013274 NONE acid_11\NN|( (r_nmod) FA_13\NNP|)|as (r_dobj) folinic_10\VB|(|)|and (l_prep) as_15\IN|)|FA (l_pobj) part_16\NN|NONE (l_prep) of_17\IN|NONE (l_pobj) regimens_22\NNS|NONE (l_prep) in_23\IN|chemotherapy|new|several (l_pobj) cancer_26\NN|NONE
D002955_D013274 NONE acid_11\NN|( (r_nmod) FA_13\NNP|)|as (r_dobj) folinic_10\VB|(|)|and (r_conj) 5-FU_7\CD|NONE (r_pobj) of_4\IN|continuous|The|hour (r_prep) infusion_3\NN|(|be|has|.|AGC (r_nsubj) shown_31\VBN|NONE (l_nsubj) AGC_28\NNP|(|be|has|infusion|.
D002955_D013274 NONE FA_13\NNP|)|as (r_dobj) folinic_10\VB|(|)|and (l_prep) as_15\IN|)|FA (l_pobj) part_16\NN|NONE (l_prep) of_17\IN|NONE (l_pobj) regimens_22\NNS|NONE (l_prep) in_23\IN|chemotherapy|new|several (l_pobj) cancer_26\NN|NONE
D002955_D013274 NONE FA_13\NNP|)|as (r_dobj) folinic_10\VB|(|)|and (r_conj) 5-FU_7\CD|NONE (r_pobj) of_4\IN|continuous|The|hour (r_prep) infusion_3\NN|(|be|has|.|AGC (r_nsubj) shown_31\VBN|NONE (l_nsubj) AGC_28\NNP|(|be|has|infusion|.
D002955_D013274 NONE FA_27\NNP|/|hour||mg (r_nmod) m(2_31\NN|NONE (r_punct) )_32\-RRB-|with|receive|preceded| (r_punct) patients_11\NNS|we|for|,|From|.|,|followed (l_prep) with_12\IN|)|receive|preceded| (l_pobj) AGC_13\NNP|NONE
D002955_D013274 NONE FA_5\NNP|FU|dose|/|/ (r_nmod) MMC_7\NNP|regimen|. (r_nsubj) is_8\VBZ|NONE (l_attr) regimen_16\NN|MMC|. (l_prep) for_17\IN|an|effective|outpatient (l_pobj) AGC_18\NNP|NONE
D002945_D006463 NONE cisplatin_7\NN| (r_advmod) containing_9\VBG|NONE (r_amod) regimens_10\NNS|NONE (r_pobj) to_6\IN|an (r_prep) alternative_5\NN|NONE (r_pobj) as_3\IN|may|It (r_prep) serve_2\VB|,|considered|it|.|however|; (r_ccomp) has_15\VBZ|NONE (l_xcomp) considered_18\VBN|serve|,|it|.|however|; (l_ccomp) occur_23\VB|to|be (l_nsubj) HUS_21\NNP|possibly|may|that
D002955_D064420 NONE acid_11\NN|( (r_nmod) FA_13\NNP|)|as (r_dobj) folinic_10\VB|(|)|and (r_conj) 5-FU_7\CD|NONE (r_pobj) of_4\IN|continuous|The|hour (r_prep) infusion_3\NN|(|be|has|.|AGC (r_nsubj) shown_31\VBN|NONE (l_xcomp) be_33\VB|(|has|infusion|.|AGC (l_prep) with_36\IN|effective|to|, (l_pobj) toxicity_38\NN|NONE
D002955_D064420 NONE FA_13\NNP|)|as (r_dobj) folinic_10\VB|(|)|and (r_conj) 5-FU_7\CD|NONE (r_pobj) of_4\IN|continuous|The|hour (r_prep) infusion_3\NN|(|be|has|.|AGC (r_nsubj) shown_31\VBN|NONE (l_xcomp) be_33\VB|(|has|infusion|.|AGC (l_prep) with_36\IN|effective|to|, (l_pobj) toxicity_38\NN|NONE
12912689
D016190_D005355 CID carboplatin_1\NN|NONE (l_ccomp) associated_4\VBN|Subtenon|. (l_prep) with_5\IN|is|leading|chemotherapy|, (l_pobj) fibrosis_7\NN|NONE
D016190_D064420 NONE carboplatin_2\NN|NONE (l_ccomp) used_7\VBN|.|subtenon (l_prep) as_8\IN|recently|have|been|injections (l_pobj) adjunct_14\NN|NONE (l_amod) free_13\JJ|to|a (l_npadvmod) toxicity_11\NN|presumably|
D016190_D064420 NONE carboplatin_1\NN|restricted|free|,|and|not (r_nsubj) is_2\VBZ|NONE (l_acomp) free_4\JJ|restricted|,|and|carboplatin|not (l_prep) of_5\IN|NONE (l_pobj) toxicity_6\NN|NONE
D016190_D012175 NONE carboplatin_5\VBP|Ocular|motility|. (l_prep) for_7\IN|subtenon|after|chemotherapy (l_pobj) retinoblastoma_8\NN|NONE
D016190_D012175 NONE carboplatin_2\NN|NONE (l_ccomp) used_7\VBN|.|subtenon (l_prep) as_8\IN|recently|have|been|injections (l_pobj) adjunct_14\NN|NONE (l_prep) to_15\IN|free|a (l_pobj) chemotherapy_17\NN|NONE (l_prep) for_18\IN|systemic (l_pobj) retinoblastoma_20\NN|NONE
D016190_D012175 NONE carboplatin_15\NN|We|motility|. (r_ccomp) noted_1\VBD|NONE (l_dobj) motility_4\NN|We|carboplatin|. (l_prep) in_5\IN|ocular|abnormal (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN||consecutive (l_pobj) retinoblastoma_10\NN|NONE
D016190_D012175 NONE carboplatin_24\NN|in|was|Limitation|. (r_advmod) detected_5\VBN|NONE (l_prep) in_6\IN|carboplatin|was|Limitation|. (l_pobj) eyes_9\NNS|NONE (l_prep) of_10\IN|all| (l_pobj) patients_12\NNS|NONE (l_acl) treated_13\VBN| (l_prep) for_14\IN|with (l_pobj) retinoblastoma_16\NN|NONE
D016190_D015835 CID carboplatin_14\NN|NONE (r_amod) chemotherapy_15\NN|with (r_dobj) treated_11\VBN|NONE (r_acl) patients_10\NNS|NONE (r_pobj) in_9\IN|ocular|abnormal (r_prep) motility_8\NN|NONE
D016190_D015835 CID carboplatin_15\NN|We|motility|. (r_ccomp) noted_1\VBD|NONE (l_dobj) motility_4\NN|We|carboplatin|.
9158667
D006493_D013927 NONE heparin_13\NN|NONE (r_dobj) using_9\VBG|NONE (r_pcomp) by_8\IN|.|events|,|however|be|could|, (r_prep) avoided_7\VBN|NONE (l_nsubjpass) events_1\NNS|.|,|however|be|could|by|, (l_amod) Thrombotic_0\JJ|NONE
D014212_D015473 NONE acid_12\NN|retinoic (r_compound) therapy_13\NN|NONE (r_pobj) during_6\IN|in|Thrombotic|. (r_prep) complications_1\NNS|NONE (l_prep) in_2\IN|Thrombotic|during|. (l_pobj) leukemia_5\NN|NONE
D014212_D015473 NONE acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_amod) due_7\IN|A|treated|of|, (l_pobj) occlusion_9\NN|to (l_prep) in_13\IN|of (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) leukemia_19\NN|NONE
D014212_D015473 NONE acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_amod) due_7\IN|A|treated|of|, (l_pobj) occlusion_9\NN|to (l_prep) in_13\IN|of (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) leukemia_19\NN|NONE (l_appos) APL_21\NNP|acute|)|(|promyelocytic
D014212_D015473 NONE ATRA_32\NNP|retinoic|and|acid (r_appos) acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_amod) due_7\IN|A|treated|of|, (l_pobj) occlusion_9\NN|to (l_prep) in_13\IN|of (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) leukemia_19\NN|NONE
D014212_D015473 NONE ATRA_32\NNP|retinoic|and|acid (r_appos) acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_amod) due_7\IN|A|treated|of|, (l_pobj) occlusion_9\NN|to (l_prep) in_13\IN|of (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) leukemia_19\NN|NONE (l_appos) APL_21\NNP|acute|)|(|promyelocytic
D014212_D015473 NONE ATRA_14\NNP|NONE (r_pobj) with_13\IN|alone (r_prep) treated_12\VBN|APL|an (r_acl) patient_11\NN|NONE (l_compound) APL_10\NNP|an|treated
D014212_D015473 NONE ATRA_11\NNP|in (r_compound) therapy_12\NN|NONE (l_prep) in_13\IN|ATRA (l_pobj) patients_15\NNS|NONE (l_compound) APL_14\NNP|NONE
D014212_D015473 NONE ATRA_25\NNP|NONE (r_pobj) with_24\IN|a|treatment (r_prep) protocol_23\NN|NONE (r_pobj) in_20\IN|was (r_prep) included_19\VBN|patients|signs|and|. (r_conj) presented_9\VBD|NONE (l_dobj) signs_12\NNS|patients|and|.|included (l_prep) of_15\IN|all|symptoms|the|and (l_pobj) APL_16\NNP|NONE
D014212_D015473 NONE ATRA_3\NNP|corrected|that|choice|, (r_nsubj) is_4\VBZ|We|. (l_attr) choice_8\NN|ATRA|corrected|that|, (l_prep) for_9\IN|therapeutic|a|valid (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) APL_12\NNP|NONE
D014212_D058186 CID acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_prep) of_2\IN|A|treated|,|due (l_pobj) failure_5\NN|NONE
D014212_D058186 CID ATRA_32\NNP|retinoic|and|acid (r_appos) acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_prep) of_2\IN|A|treated|,|due (l_pobj) failure_5\NN|NONE
D014212_D058186 CID ATRA_14\NNP|NONE (r_pobj) with_13\IN|alone (r_prep) treated_12\VBN|APL|an (r_acl) patient_11\NN|NONE (r_pobj) in_8\IN|acute|renal (r_prep) failure_7\NN|NONE
D014212_D013927 CID acid_12\NN|retinoic (r_compound) therapy_13\NN|NONE (r_pobj) during_6\IN|in|Thrombotic|. (r_prep) complications_1\NNS|NONE (l_amod) Thrombotic_0\JJ|in|during|.
D014148_-1 NONE acid_36\NN|retinoic|and|ATRA (r_conj) acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_amod) due_7\IN|A|treated|of|, (l_pobj) occlusion_9\NN|to (l_prep) of_10\IN|in (l_pobj) vessels_12\NNS|NONE
D014148_D015473 NONE acid_36\NN|retinoic|and|ATRA (r_conj) acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_amod) due_7\IN|A|treated|of|, (l_pobj) occlusion_9\NN|to (l_prep) in_13\IN|of (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) leukemia_19\NN|NONE
D014148_D015473 NONE acid_36\NN|retinoic|and|ATRA (r_conj) acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_amod) due_7\IN|A|treated|of|, (l_pobj) occlusion_9\NN|to (l_prep) in_13\IN|of (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) leukemia_19\NN|NONE (l_appos) APL_21\NNP|acute|)|(|promyelocytic
D014212_D013923 NONE ATRA_11\NNP|in (r_compound) therapy_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|thromboembolic (r_acl) complications_8\NNS|NONE (l_compound) thromboembolic_7\JJ|associated
D014212_-1 NONE acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_amod) due_7\IN|A|treated|of|, (l_pobj) occlusion_9\NN|to (l_prep) of_10\IN|in (l_pobj) vessels_12\NNS|NONE
D014212_-1 NONE ATRA_32\NNP|retinoic|and|acid (r_appos) acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_amod) due_7\IN|A|treated|of|, (l_pobj) occlusion_9\NN|to (l_prep) of_10\IN|in (l_pobj) vessels_12\NNS|NONE
D014148_D058186 NONE acid_36\NN|retinoic|and|ATRA (r_conj) acid_30\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) treated_23\VBN|A|of|,|due (r_acl) case_1\NN|been|recently|.|has (l_prep) of_2\IN|A|treated|,|due (l_pobj) failure_5\NN|NONE
15265979
D000638_D056486 CID Amiodarone_0\NNP|has|cause|.|been (r_nsubjpass) reported_12\VBN|NONE (l_xcomp) cause_14\VB|has|Amiodarone|.|been (l_dobj) hepatotoxicity_15\NN|in|to
D000638_D056486 CID amiodarone_12\NN|NONE (r_pobj) of_11\IN|hepatotoxic|the (r_prep) effects_10\NNS|NONE (l_amod) hepatotoxic_9\JJ|of|the
D000638_D056486 CID amiodarone_12\NN|NONE (r_pobj) of_11\IN|hepatotoxic|the (r_prep) effects_10\NNS|NONE (r_pobj) regarding_7\VBG|important|mechanistic|new (r_prep) information_6\NN|indicate|and|results|. (r_dobj) provide_2\VBP|NONE (l_conj) indicate_14\VBP|and|information|results|. (l_ccomp) protects_17\VBZ|NONE (l_prep) against_18\IN|that|PPARalpha (l_pobj) hepatotoxicity_22\NN|NONE
D000638_D056486 CID amiodarone_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) hepatotoxicity_22\NN|NONE (r_pobj) against_18\IN|that|PPARalpha (r_prep) protects_17\VBZ|NONE (r_ccomp) indicate_14\VBP|and|information|results|. (r_conj) provide_2\VBP|NONE (l_dobj) information_6\NN|indicate|and|results|. (l_prep) regarding_7\VBG|important|mechanistic|new (l_pobj) effects_10\NNS|NONE (l_amod) hepatotoxic_9\JJ|of|the
D000638_D056486 CID amiodarone_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) hepatotoxicity_22\NN|NONE
D014280_D006529 NONE triglycerides_15\NNS|NONE (r_pobj) in_13\IN|a|significant (r_prep) decrease_12\NN|and|Amiodarone|.|accumulation|, (r_conj) induced_1\VBD|NONE (l_dobj) accumulation_7\NN|and|Amiodarone|.|decrease|, (l_amod) hepatomegaly_2\NN|hepatocyte|lipid|microvesicular|,
D000638_D006529 CID Amiodarone_0\NN|and|.|accumulation|decrease|, (r_nsubj) induced_1\VBD|NONE (l_dobj) accumulation_7\NN|and|Amiodarone|.|decrease|, (l_amod) hepatomegaly_2\NN|hepatocyte|lipid|microvesicular|,
D005947_D006529 NONE glucose_17\NN|serum|and (r_conj) triglycerides_15\NNS|NONE (r_pobj) in_13\IN|a|significant (r_prep) decrease_12\NN|and|Amiodarone|.|accumulation|, (r_conj) induced_1\VBD|NONE (l_dobj) accumulation_7\NN|and|Amiodarone|.|decrease|, (l_amod) hepatomegaly_2\NN|hepatocyte|lipid|microvesicular|,
D000638_D006528 NONE amiodarone_3\NN|NONE (r_pobj) of_2\IN|activate|The (r_prep) inability_1\NN|in|transiently (r_nsubj) expressed_13\VBN|.|were (l_prep) in_14\IN|transiently|inability (l_pobj) cells_18\NNS|NONE (l_compound) hepatoma_17\NN|HepG|human
D000638_D006528 NONE amiodarone_24\NN|NONE (r_pobj) of_23\IN|the (r_prep) effects_22\NNS|that|indirect (r_nsubj) were_31\VBD|.|expressed (r_ccomp) indicates_19\VBZ|NONE (l_csubj) expressed_13\VBN|.|were (l_prep) in_14\IN|transiently|inability (l_pobj) cells_18\NNS|NONE (l_compound) hepatoma_17\NN|HepG|human
D000638_D015431 NONE amiodarone_12\NN|NONE (r_pobj) with_11\IN|of (r_prep) treatment_7\NN|type|, (r_appos) mice_5\NNS|NONE (r_pobj) to_1\IN|NONE (r_prep) Compared_0\VBN|in|. (r_prep) resulted_13\VBD|NONE (l_prep) in_14\IN|Compared|. (l_pobj) rate_17\NN|NONE (l_conj) extent_19\NN|and|an|increased (l_prep) of_20\IN|NONE (l_pobj) loss_24\NN|NONE
1117341
D015119_D006030 NONE amino_17\JJ|certain|of (r_amod) derivatives_18\NNS|NONE (r_pobj) of_15\IN|%|small|)|( (r_prep) amounts_5\NNS|NONE (r_pobj) of_3\IN|The|chronic (r_prep) feeding_2\NN|in|. (r_nsubj) resulted_21\VBD|NONE (l_prep) in_22\IN|.|feeding (l_pobj) hyperglycemia_23\NN|NONE (l_appos) curve_29\NN|, (l_conj) glucosuria_34\NN|an|and|elevated|occasionally|,|tolerance|,
D005947_D006030 NONE glucose_27\NN|NONE (r_compound) tolerance_28\NN|an|glucosuria|and|elevated|occasionally|,|, (r_compound) curve_29\NN|, (l_conj) glucosuria_34\NN|an|and|elevated|occasionally|,|tolerance|,
C037652_D006030 NONE caproate_20\NN|NONE (r_pobj) of_19\IN|amino|certain (r_prep) derivatives_18\NNS|NONE (r_pobj) of_15\IN|%|small|)|( (r_prep) amounts_5\NNS|NONE (r_pobj) of_3\IN|The|chronic (r_prep) feeding_2\NN|in|. (r_nsubj) resulted_21\VBD|NONE (l_prep) in_22\IN|.|feeding (l_pobj) hyperglycemia_23\NN|NONE (l_appos) curve_29\NN|, (l_conj) glucosuria_34\NN|an|and|elevated|occasionally|,|tolerance|,
C037652_D006943 NONE caproate_8\NN|effect|.|structurally (r_xcomp) related_6\VBN|NONE (l_nsubj) effect_1\NN|.|caproate|structurally (l_amod) Hyperglycemic_0\JJ|of
C037652_D006943 NONE caproate_20\NN|NONE (r_pobj) of_19\IN|amino|certain (r_prep) derivatives_18\NNS|NONE (r_pobj) of_15\IN|%|small|)|( (r_prep) amounts_5\NNS|NONE (r_pobj) of_3\IN|The|chronic (r_prep) feeding_2\NN|in|. (r_nsubj) resulted_21\VBD|NONE (l_prep) in_22\IN|.|feeding (l_pobj) hyperglycemia_23\NN|NONE
D015119_D006943 CID amino_3\JJ|NONE (r_compound) compounds_4\NNS|NONE (r_pobj) of_2\IN|Hyperglycemic (r_prep) effect_1\NN|.|caproate|structurally (l_amod) Hyperglycemic_0\JJ|of
D015119_D006943 CID amino_17\JJ|certain|of (r_amod) derivatives_18\NNS|NONE (r_pobj) of_15\IN|%|small|)|( (r_prep) amounts_5\NNS|NONE (r_pobj) of_3\IN|The|chronic (r_prep) feeding_2\NN|in|. (r_nsubj) resulted_21\VBD|NONE (l_prep) in_22\IN|.|feeding (l_pobj) hyperglycemia_23\NN|NONE
D005947_D006943 NONE glucose_27\NN|NONE (r_compound) tolerance_28\NN|an|glucosuria|and|elevated|occasionally|,|, (r_compound) curve_29\NN|, (r_appos) hyperglycemia_23\NN|NONE
19108278
D011433_D017180 NONE propranolol_3\NN|NONE (r_pobj) of_2\IN|Both (r_prep) isomers_1\NNS|.|also|capable (r_nsubj) were_4\VBD|NONE (l_acomp) capable_6\JJ|isomers|.|also (l_prep) of_7\IN|NONE (l_pcomp) reversing_8\VBG|NONE (l_dobj) tachycardia_10\NN|NONE
D004837_D001145 CID adrenaline_8\RB| (r_advmod) induced_10\VBN|cardiac|in (r_amod) arrhythmias_12\NNS|NONE
D004837_D001145 CID adrenaline.7_13\NNS|NONE (r_pobj) of_12\IN|the (r_prep) dose_11\NN|NONE (r_dobj) increasing_9\VBG|NONE (r_pcomp) by_8\IN|surmountable|.|Blockade (r_prep) was_6\VBD|NONE (l_nsubj) Blockade_0\NN|by|surmountable|. (l_prep) of_1\IN|NONE (l_pobj) arrhythmias_2\NNS|NONE
D010042_D017180 CID ouabain_13\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) caused_11\VBN|ventricular (r_acl) tachycardia_10\NN|NONE
D006221_D001145 CID halothane_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) anaesthetized_15\VBN|NONE (r_acl) cats_14\NNS|NONE (r_pobj) in_13\IN|cardiac|induced (r_prep) arrhythmias_12\NNS|NONE
D011433_D001145 NONE propranolol_8\NN|NONE (r_pobj) of_7\IN|optical|and|effects|the (r_prep) isomers_6\NNS|NONE (l_conj) effects_11\NNS|optical|and|the|of (l_prep) on_12\IN|their (l_pobj) arrhythmias_14\NNS|NONE
D011433_D001145 NONE propranolol_3\NN|NONE (r_pobj) of_2\IN|Both (r_prep) isomers_1\NNS|but|was|capable|, (r_nsubj) were_4\VBD|NONE (l_acomp) capable_5\JJ|but|isomers|was|, (l_prep) of_6\IN|NONE (l_pcomp) preventing_7\VBG|NONE (l_dobj) arrhythmias_12\NNS|NONE
D011433_D001145 NONE -)-propranolol_25\,|NONE (r_pobj) of_23\IN|mean|the (r_prep) dose_22\NN|.+/.|was|mg/kg|. (r_nsubj) was_26\VBD|but|isomers|capable|, (r_conj) were_4\VBD|NONE (l_acomp) capable_5\JJ|but|isomers|was|, (l_prep) of_6\IN|NONE (l_pcomp) preventing_7\VBG|NONE (l_dobj) arrhythmias_12\NNS|NONE
D011433_D001145 NONE -propranolol_35\,|+|( (r_conj) of_31\IN|NONE (r_prep) that_30\DT|.+/.|whereas|mg/kg (r_nsubj) was_36\VBD|.+/.|dose|mg/kg|. (r_advcl) was_26\VBD|but|isomers|capable|, (r_conj) were_4\VBD|NONE (l_acomp) capable_5\JJ|but|isomers|was|, (l_prep) of_6\IN|NONE (l_pcomp) preventing_7\VBG|NONE (l_dobj) arrhythmias_12\NNS|NONE
1451544
D017275_D005483 CID isradipine_25\NN|with|or (r_pobj) with_24\IN|other (r_prep) studies_23\NNS|NONE (r_pobj) in_21\IN|than (r_prep) reported_20\VBN|more (r_advcl) frequent_18\JJ|not|headache (r_acomp) were_15\VBD|effects|. (l_nsubj) headache_6\NN|not|frequent (l_conj) dizziness_8\NN|, (l_conj) palpitation_10\NN|, (l_conj) flushing_12\NN|and|and|these
D017275_D006261 CID isradipine_25\NN|with|or (r_pobj) with_24\IN|other (r_prep) studies_23\NNS|NONE (r_pobj) in_21\IN|than (r_prep) reported_20\VBN|more (r_advcl) frequent_18\JJ|not|headache (r_acomp) were_15\VBD|effects|. (l_nsubj) headache_6\NN|not|frequent
D017275_D006973 NONE Isradipine_0\NNP|.|for (r_compound) treatment_1\NN|NONE (l_prep) for_2\IN|.|Isradipine (l_pobj) hypertension_3\NN|NONE
D017275_-1 NONE isradipine_25\NN|with|or (r_pobj) with_24\IN|other (r_prep) studies_23\NNS|NONE (r_pobj) in_21\IN|than (r_prep) reported_20\VBN|more (r_advcl) frequent_18\JJ|not|headache (r_acomp) were_15\VBD|effects|. (l_nsubj) headache_6\NN|not|frequent (l_conj) dizziness_8\NN|, (l_conj) palpitation_10\NN|,
D017275_D004244 CID isradipine_25\NN|with|or (r_pobj) with_24\IN|other (r_prep) studies_23\NNS|NONE (r_pobj) in_21\IN|than (r_prep) reported_20\VBN|more (r_advcl) frequent_18\JJ|not|headache (r_acomp) were_15\VBD|effects|. (l_nsubj) headache_6\NN|not|frequent (l_conj) dizziness_8\NN|,
1395192
D001971_D009203 CID bromocriptine_8\NN|NONE (r_dobj) receiving_7\VBG|a|postpartum (r_acl) patient_6\NN|NONE (r_pobj) in_3\IN|.|myocardial|Recurrent (r_prep) infarction_2\NN|NONE
D001971_D009203 CID Bromocriptine_0\NNP|in|been|has|. (r_nsubjpass) implicated_3\VBN|NONE (l_prep) in_4\IN|been|Bromocriptine|has|. (l_pobj) reports_8\NNS|NONE (l_prep) of_9\IN|previous|several|case (l_pobj) infarction_11\NN|NONE
3475563
D001507_D002177 NONE beclomethasone_7\NN|and|oral (r_conj) prednisone_4\NN|NONE (r_pobj) of_2\IN|Concomitant (r_prep) use_1\NN|may|.|risk (r_nsubj) increase_9\VB|NONE (l_dobj) risk_11\NN|may|use|. (l_prep) of_12\IN|the (l_pcomp) developing_13\VBG|NONE (l_dobj) hoarseness_14\NN|NONE (l_conj) candidiasis_16\NN|or
D001507_D006685 CID dipropionate_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) hoarseness_8\NN|or|oral
D001507_D006685 CID beclomethasone_9\NN|NONE (r_pobj) on_7\IN|who|were (r_prep) placed_6\VBN||asthmatic (r_relcl) patients_3\NNS|NONE (r_pobj) Of_0\IN|.|hoarseness (r_prep) developed_16\VBD|NONE (l_dobj) hoarseness_18\NN|.|Of
D001507_D006685 CID beclomethasone_9\NN|NONE (r_pobj) on_7\IN|be|patients|that|indicated|may (r_prep) restarted_6\VBN|We (r_ccomp) conclude_1\VBP|however|should|;|not|,|because (r_ccomp) be_29\VB| (l_prep) because_16\IN|conclude|however|should|;|not|, (l_pobj) rate_21\NN|of (l_appos) patients_23\NNS|the|recurrence|, (l_relcl) develop_25\VBP|NONE (l_dobj) hoarseness_26\NN|who
D001507_D006685 CID beclomethasone_7\NN|and|oral (r_conj) prednisone_4\NN|NONE (r_pobj) of_2\IN|Concomitant (r_prep) use_1\NN|may|.|risk (r_nsubj) increase_9\VB|NONE (l_dobj) risk_11\NN|may|use|. (l_prep) of_12\IN|the (l_pcomp) developing_13\VBG|NONE (l_dobj) hoarseness_14\NN|NONE
D001507_D002180 CID dipropionate_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) hoarseness_8\NN|or|oral (r_conj) candidiasis_6\NN|who
D001507_D002180 CID beclomethasone_9\NN|NONE (r_pobj) on_7\IN|who|were (r_prep) placed_6\VBN||asthmatic (r_relcl) patients_3\NNS|NONE (r_pobj) Of_0\IN|.|hoarseness (r_prep) developed_16\VBD|NONE (l_dobj) hoarseness_18\NN|.|Of (l_appos) 8)_20\CD|(|either (l_appos) thrush_23\NN|,
D001507_D001249 NONE beclomethasone_9\NN|NONE (r_pobj) on_7\IN|who|were (r_prep) placed_6\VBN||asthmatic (r_relcl) patients_3\NNS|NONE (l_amod) asthmatic_2\JJ|placed|
D011241_D006685 NONE prednisone_4\NN|NONE (r_pobj) of_2\IN|Concomitant (r_prep) use_1\NN|may|.|risk (r_nsubj) increase_9\VB|NONE (l_dobj) risk_11\NN|may|use|. (l_prep) of_12\IN|the (l_pcomp) developing_13\VBG|NONE (l_dobj) hoarseness_14\NN|NONE
D011241_D002177 NONE prednisone_4\NN|NONE (r_pobj) of_2\IN|Concomitant (r_prep) use_1\NN|may|.|risk (r_nsubj) increase_9\VB|NONE (l_dobj) risk_11\NN|may|use|. (l_prep) of_12\IN|the (l_pcomp) developing_13\VBG|NONE (l_dobj) hoarseness_14\NN|NONE (l_conj) candidiasis_16\NN|or
11799346
D008795_D001714 CID metronidazole_2\NNP|, (r_conj) Cotrimoxazole_0\NNP|in|were|. (r_nsubjpass) involved_7\VBN|NONE (l_prep) in_8\IN|were|Cotrimoxazole|. (l_pobj) episodes_12\NNS|NONE (l_amod) manic_11\JJ|reported|
D004917_D001714 CID erythromycin_5\NN|,|and (r_conj) metronidazole_2\NNP|, (r_conj) Cotrimoxazole_0\NNP|in|were|. (r_nsubjpass) involved_7\VBN|NONE (l_prep) in_8\IN|were|Cotrimoxazole|. (l_pobj) episodes_12\NNS|NONE (l_amod) manic_11\JJ|reported|
D017291_D001714 CID clarithromycin_6\NN|be|.|Cases (r_dobj) showed_5\VBD|NONE (l_xcomp) be_10\VB|clarithromycin|.|Cases (l_attr) the_11\DT|to (l_acl) associated_14\VBN|NONE (l_prep) with_15\IN|frequently (l_pobj) development_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) mania_19\NN|NONE
D015662_D001714 CID Cotrimoxazole_0\NNP|in|were|. (r_nsubjpass) involved_7\VBN|NONE (l_prep) in_8\IN|were|Cotrimoxazole|. (l_pobj) episodes_12\NNS|NONE (l_amod) manic_11\JJ|reported|
D002939_D001714 CID ciprofloxacin_8\NNS|and (r_conj) clarithromycin_6\NN|be|.|Cases (r_dobj) showed_5\VBD|NONE (l_xcomp) be_10\VB|clarithromycin|.|Cases (l_attr) the_11\DT|to (l_acl) associated_14\VBN|NONE (l_prep) with_15\IN|frequently (l_pobj) development_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) mania_19\NN|NONE
10764869
D016559_D015354 NONE tacrolimus_8\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) discontinuation_5\NN|NONE (r_pobj) despite_4\IN|.|Deterioration (r_prep) occurred_3\VBD|NONE (l_nsubj) Deterioration_0\NN|.|despite (l_prep) of_1\IN|NONE (l_pobj) vision_2\NN|NONE
D016559_D009901 CID tacrolimus_10\NN|NONE (r_pobj) on_9\IN|a (r_prep) patient_8\NN|NONE (r_pobj) in_6\IN|of|A|.|after (r_prep) case_1\NN|NONE (l_prep) of_2\IN|in|A|.|after (l_pobj) neuropathy_5\NN|NONE
D016559_D009901 CID FK506_12\NNP|(|therapy|) (r_appos) tacrolimus_10\NN|NONE (r_pobj) on_9\IN|a (r_prep) patient_8\NN|NONE (r_pobj) in_6\IN|of|A|.|after (r_prep) case_1\NN|NONE (l_prep) of_2\IN|in|A|.|after (l_pobj) neuropathy_5\NN|NONE
D016559_D009901 CID tacrolimus_12\NN|NONE (r_dobj) receiving_11\NN|a (r_acl) patient_10\NN|NONE (r_pobj) in_8\IN|of|a|)|for (r_prep) case_3\NN|.|To (l_prep) of_4\IN|in|a|)|for (l_pobj) neuropathy_7\NN|NONE
D016559_D009901 CID 506_15\CD|,|Prograf (r_nummod) FK_14\NNP|(|;|USA (r_appos) tacrolimus_12\NN|NONE (r_dobj) receiving_11\NN|a (r_acl) patient_10\NN|NONE (r_pobj) in_8\IN|of|a|)|for (r_prep) case_3\NN|.|To (l_prep) of_4\IN|in|a|)|for (l_pobj) neuropathy_7\NN|NONE
D016559_D009901 CID Tacrolimus_0\NNP|may|be|.|with (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|may|be|Tacrolimus|. (l_pobj) toxicity_11\NN|NONE
24595967
D018817_D008569 CID ecstasy_5\NN|NONE (r_compound) users_6\NNS|NONE (r_pobj) in_4\IN|overnight|Dysfunctional|.|memory (r_prep) consolidation_3\NN|NONE (l_compound) memory_2\NN|overnight|Dysfunctional|.|in
D018817_D008569 CID Ecstasy_0\NNP|NONE (r_compound) users_1\NNS|consolidation|. (r_nsubj) demonstrated_2\VBD|NONE (l_dobj) consolidation_6\NN|users|. (l_compound) memory_5\NN|finding|,|impaired|overnight
D018817_D008569 CID ecstasy_3\NN| (r_npadvmod) associated_5\VBN|that|in (r_amod) dysfunction_6\NN|may|impairments (r_nsubj) underlie_13\VB|We|. (l_dobj) impairments_17\NNS|dysfunction|may
D018817_D008569 CID ecstasy_20\NN|regular (r_compound) users_21\NNS|NONE (r_pobj) in_18\IN|overnight|memory (r_prep) impairments_17\NNS|dysfunction|may
D018817_D012893 CID ecstasy_4\NN|NONE (r_compound) users_5\NNS|impairments|that|have|and (r_nsubj) marked_7\VBN|.|studies (l_conj) impairments_15\NNS|users|that|have|and
48835
D011433_D007003 NONE propranolol_2\NN|NONE (l_prep) of_3\IN|NONE (l_pobj) effects_5\NNS|NONE (l_prep) of_6\IN|cardiovascular (l_pobj) hypoglycaemia_8\NN|NONE
17572393
D008550_D054220 NONE melatonin_3\NN|NONE (r_pobj) of_2\IN|.|Neuroprotective|upon (r_prep) effects_1\NNS|NONE (l_prep) upon_4\IN|.|of|Neuroprotective (l_pobj) cortex_8\NN|NONE (l_prep) in_9\IN|offspring|the|cerebellar (l_pobj) model_12\NN|NONE (l_prep) of_13\IN|rat|the (l_pobj) dysplasia_18\NN|NONE
D008550_D054220 NONE melatonin_10\NN|NONE (l_prep) upon_11\IN|exogenous (l_pobj) dysplasia_17\NN|NONE
D002330_D054220 CID BCNU_14\NNP| (r_npadvmod) induced_16\VBN|cortical (r_amod) dysplasia_18\NN|NONE
D002330_D054220 CID BCNU_1\NNP|NONE (l_conj) investigate_5\VB|)|.|(|and (l_dobj) effects_7\NNS|using|,|to (l_prep) of_8\IN|the (l_pobj) melatonin_10\NN|NONE (l_prep) upon_11\IN|exogenous (l_pobj) dysplasia_17\NN|NONE
D002330_D054220 CID BCNU_13\NNP| (r_npadvmod) induced_15\VBN|cerebellar|cortical (r_amod) dysplasia_17\NN|NONE
D002330_D054220 CID BCNU_25\NNP| (r_npadvmod) exposed_27\VBN|cortical|dysplasia (r_amod) group_30\NN|NONE (l_compound) dysplasia_29\NN|cortical|exposed
12677626
D002045_D066126 NONE bupivacaine_11\NN|NONE (r_pobj) than_9\IN|a|safer|toxicity (r_prep) profile_8\NN|Although|levobupivacaine|may (l_compound) toxicity_7\NN|than|a|safer
C476513_D066126 NONE levobupivacaine_1\PRP|Although|profile|may (r_nsubj) have_3\VB|.|,|in|will|,|reach|it (l_dobj) profile_8\NN|Although|levobupivacaine|may (l_compound) toxicity_7\NN|than|a|safer
C476513_D066126 NONE levobupivacaine_17\NN|NONE (r_pobj) of_16\IN|adequate (r_prep) amounts_15\NNS|circulation|if (r_nsubj) reach_18\VBP|.|,|in|have|will|,|it (r_advcl) result_24\VB|NONE (l_advcl) have_3\VB|.|,|in|will|,|reach|it (l_dobj) profile_8\NN|Although|levobupivacaine|may (l_compound) toxicity_7\NN|than|a|safer
C476513_D012640 NONE levobupivacaine_1\PRP|Although|profile|may (r_nsubj) have_3\VB|.|,|in|will|,|reach|it (r_advcl) result_24\VB|NONE (l_prep) in_25\IN|.|,|have|will|,|reach|it (l_pobj) convulsions_26\NNS|NONE
C476513_D012640 NONE levobupivacaine_17\NN|NONE (r_pobj) of_16\IN|adequate (r_prep) amounts_15\NNS|circulation|if (r_nsubj) reach_18\VBP|.|,|in|have|will|,|it (r_advcl) result_24\VB|NONE (l_prep) in_25\IN|.|,|have|will|,|reach|it (l_pobj) convulsions_26\NNS|NONE
C476513_D020258 NONE levobupivacaine_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) administration_6\NN|NONE (r_dobj) following_4\VBG|system|Central|.|:|report (r_prep) toxicity_3\NN|NONE
D013390_D012640 NONE succinylcholine_11\NN|NONE (r_pobj) to_10\IN|NONE (r_prep) addition_9\NN|NONE (r_pobj) in_8\IN|.|with|seizures|were|successfully (r_prep) treated_4\VBN|NONE (l_nsubjpass) seizures_1\NNS|.|with|in|were|successfully
D002045_D012640 NONE bupivacaine_11\NN|NONE (r_pobj) than_9\IN|a|safer|toxicity (r_prep) profile_8\NN|Although|levobupivacaine|may (r_dobj) have_3\VB|.|,|in|will|,|reach|it (r_advcl) result_24\VB|NONE (l_prep) in_25\IN|.|,|have|will|,|reach|it (l_pobj) convulsions_26\NNS|NONE
C476513_D004830 CID levobupivacaine_13\NN|NONE (r_pobj) of_12\IN|intravascular|accidental (r_prep) injection_11\NN|NONE (r_pobj) following_8\VBG|We|.|cases (r_prep) describe_1\VBP|NONE (l_dobj) cases_3\NNS|We|.|following (l_prep) of_4\IN| (l_pobj) seizures_7\NNS|NONE
C476513_D004830 CID levobupivacaine_5\NN|NONE (r_pobj) of_4\IN|%|the (r_prep) administration_3\NN|NONE (r_pobj) after_1\IN|seizures|Immediately|despite|patients|,|.|, (r_prep) developed_17\VBD|NONE (l_dobj) seizures_20\NNS|Immediately|after|despite|patients|,|.|,
D013874_D012640 NONE thiopental_7\VBN|NONE (r_pobj) with_5\IN|.|seizures|in|were|successfully (r_prep) treated_4\VBN|NONE (l_nsubjpass) seizures_1\NNS|.|with|in|were|successfully
D004837_D004830 NONE epinephrine_9\NN|/|microgram (r_nmod) mL_13\NNP|NONE (r_pobj) with_8\IN|. (r_prep) %_7\NN|of|the (r_appos) administration_3\NN|NONE (r_pobj) after_1\IN|seizures|Immediately|despite|patients|,|.|, (r_prep) developed_17\VBD|NONE (l_dobj) seizures_20\NNS|Immediately|after|despite|patients|,|.|,
D004837_D004830 NONE epinephrine_33\NN|intravenous (r_compound) administration_34\NN|NONE (r_pobj) of_31\IN|clinical|no (r_prep) signs_30\NNS|negative|for|and (r_conj) aspiration_24\NN|NONE (r_pobj) despite_22\IN|seizures|Immediately|after|patients|,|.|, (r_prep) developed_17\VBD|NONE (l_dobj) seizures_20\NNS|Immediately|after|despite|patients|,|.|,
7727612
D008140_D009207 CID lorazepam_3\NN|NONE (r_amod) therapy_4\NN|NONE (r_pobj) with_2\IN|in (r_prep) associated_1\VBN|. (r_acl) Myoclonus_0\NNP|NONE
D008140_D009207 CID lorazepam_19\NN|NONE (r_pobj) of_18\IN|intravenous|the (r_prep) administration_17\NN|NONE (r_pobj) following_14\VBG|NONE (r_prep) myoclonus_13\NN|infants|.
17543491
19293073
D001241_D002318 NONE aspirin_24\NN|NONE (r_pobj) of_23\IN|for|systematic (r_prep) reviews_22\NNS|;|meta|and| (l_prep) for_27\IN|systematic|of (l_pobj) prevention_30\NN|NONE (l_prep) of_31\IN|primary|the (l_pobj) disease_33\NN|NONE
D001241_D002318 NONE aspirin_24\NN|NONE (r_pobj) of_23\IN|for|systematic (r_prep) reviews_22\NNS|;|meta|and| (l_prep) for_27\IN|systematic|of (l_pobj) prevention_30\NN|NONE (l_prep) of_31\IN|primary|the (l_pobj) disease_33\NN|NONE (l_appos) CVD_35\NN|cardiovascular
D001241_D002318 NONE aspirin_24\NN|NONE (r_pobj) of_23\IN|for|systematic (r_prep) reviews_22\NNS|;|meta|and| (r_conj) analyses_18\NNS|;|control (r_conj) studies_14\NNS|;|)|controlled|(|RCTs|,|language|randomized (r_conj) trials_6\NNS|answer|were (r_nsubjpass) selected_38\VBN|aspirin|:|events|?|Does (r_ccomp) decrease_47\NN|NONE (l_dobj) events_50\NNS|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS|coronary|heart|, (l_conj) death_54\NN|, (l_conj) mortality_66\NN|from|,|or (l_prep) in_67\IN|cause (l_pobj) adults_68\NNS|NONE (l_prep) without_69\IN|NONE (l_pobj) CVD_71\NN|NONE
D001241_D002318 NONE aspirin_46\NN|:|events|selected|?|Does (r_nsubj) decrease_47\NN|NONE (l_ccomp) selected_38\VBN|aspirin|:|events|?|Does (l_nsubjpass) trials_6\NNS|answer|were (l_conj) studies_14\NNS|;|)|controlled|(|RCTs|,|language|randomized (l_conj) analyses_18\NNS|;|control (l_conj) reviews_22\NNS|;|meta|and| (l_prep) for_27\IN|systematic|of (l_pobj) prevention_30\NN|NONE (l_prep) of_31\IN|primary|the (l_pobj) disease_33\NN|NONE
D001241_D002318 NONE aspirin_46\NN|:|events|selected|?|Does (r_nsubj) decrease_47\NN|NONE (l_ccomp) selected_38\VBN|aspirin|:|events|?|Does (l_nsubjpass) trials_6\NNS|answer|were (l_conj) studies_14\NNS|;|)|controlled|(|RCTs|,|language|randomized (l_conj) analyses_18\NNS|;|control (l_conj) reviews_22\NNS|;|meta|and| (l_prep) for_27\IN|systematic|of (l_pobj) prevention_30\NN|NONE (l_prep) of_31\IN|primary|the (l_pobj) disease_33\NN|NONE (l_appos) CVD_35\NN|cardiovascular
D001241_D002318 NONE aspirin_46\NN|:|events|selected|?|Does (r_nsubj) decrease_47\NN|NONE (l_dobj) events_50\NNS|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS|coronary|heart|, (l_conj) death_54\NN|, (l_conj) mortality_66\NN|from|,|or (l_prep) in_67\IN|cause (l_pobj) adults_68\NNS|NONE (l_prep) without_69\IN|NONE (l_pobj) CVD_71\NN|NONE
D001241_D002318 NONE aspirin_27\JJ|NONE (r_compound) use_28\NN|that|number (r_nsubj) reduces_29\VBZ|.|evidence (l_dobj) number_31\NN|use|that (l_prep) of_32\IN|the (l_pobj) events_34\NNS|NONE (l_compound) CVD_33\NN|in
D001241_D002318 NONE aspirin_27\JJ|NONE (r_compound) use_28\NN|that|number (r_nsubj) reduces_29\VBZ|.|evidence (l_dobj) number_31\NN|use|that (l_prep) of_32\IN|the (l_pobj) events_34\NNS|NONE (l_prep) in_35\IN|CVD (l_pobj) patients_36\NNS|NONE (l_prep) without_37\IN|NONE (l_pobj) CVD_39\NNP|NONE
D001241_D002318 NONE Aspirin_0\NNP|.|affect|does|not (r_nsubj) seem_3\VB|NONE (l_xcomp) affect_5\VB|.|Aspirin|does|not (l_dobj) mortality_7\NN|to (l_compound) CVD_6\NN|mortality|or
D001241_D002318 NONE aspirin_3\NN|NONE (l_prep) for_4\IN|NONE (l_pobj) prevention_7\NN|NONE (l_prep) of_8\IN|the|primary (l_pobj) CVD_9\NNP|NONE
D001241_D020300 CID aspirin_1\NN|strokes|?|Does (r_nsubj) increase_2\VB|NONE (l_dobj) strokes_7\NNS|aspirin|?|Does
D001241_D020300 CID aspirin_9\JJ|NONE (r_compound) use_10\NN|NONE (r_pobj) with_8\IN|hemorrhagic (r_prep) strokes_7\NNS|NONE
D001241_D020521 CID aspirin_8\NN|for (r_dobj) taking_7\VBG|NONE (l_prep) for_9\IN|aspirin (l_pobj) prevention_12\NN|NONE (l_prep) of_13\IN|the|primary (l_pobj) infarctions_15\NNS|NONE (l_conj) strokes_17\NNS|myocardial|,
D001241_D020521 CID aspirin_24\NN|NONE (r_pobj) of_23\IN|for|systematic (r_prep) reviews_22\NNS|;|meta|and| (r_conj) analyses_18\NNS|;|control (r_conj) studies_14\NNS|;|)|controlled|(|RCTs|,|language|randomized (r_conj) trials_6\NNS|answer|were (r_nsubjpass) selected_38\VBN|aspirin|:|events|?|Does (r_ccomp) decrease_47\NN|NONE (l_dobj) events_50\NNS|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS|coronary|heart|,
D001241_D020521 CID aspirin_24\NN|NONE (r_pobj) of_23\IN|for|systematic (r_prep) reviews_22\NNS|;|meta|and| (r_conj) analyses_18\NNS|;|control (r_conj) studies_14\NNS|;|)|controlled|(|RCTs|,|language|randomized (r_conj) trials_6\NNS|answer|were (r_nsubjpass) selected_38\VBN|aspirin|:|events|?|Does (r_ccomp) decrease_47\NN|NONE (l_dobj) events_50\NNS|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS|coronary|heart|, (l_conj) death_54\NN|, (l_prep) from_55\IN|mortality|,|or (l_pobj) events_58\NNS|NONE (l_conj) stroke_60\NN|coronary|or|heart
D001241_D020521 CID aspirin_46\NN|:|events|selected|?|Does (r_nsubj) decrease_47\NN|NONE (l_dobj) events_50\NNS|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS|coronary|heart|,
D001241_D020521 CID aspirin_46\NN|:|events|selected|?|Does (r_nsubj) decrease_47\NN|NONE (l_dobj) events_50\NNS|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS|coronary|heart|, (l_conj) death_54\NN|, (l_prep) from_55\IN|mortality|,|or (l_pobj) events_58\NNS|NONE (l_conj) stroke_60\NN|coronary|or|heart
D001241_D020521 CID aspirin_1\NN|strokes|?|Does (r_nsubj) increase_2\VB|NONE (l_dobj) strokes_7\NNS|aspirin|?|Does
D001241_D020521 CID aspirin_9\JJ|NONE (r_compound) use_10\NN|NONE (r_pobj) with_8\IN|hemorrhagic (r_prep) strokes_7\NNS|NONE
D001241_D020521 CID Aspirin_0\NNP|risk|. (r_nsubj) reduces_1\VBZ|NONE (l_dobj) risk_3\NN|Aspirin|. (l_prep) for_4\IN|the (l_pobj) infarction_6\NN|NONE (l_prep) in_7\IN|myocardial (l_pobj) men_8\NNS|NONE (l_conj) strokes_10\NNS|and|in
D001241_D003327 NONE aspirin_17\NN|clinicians|that|with (r_dobj) discuss_16\VB|.|strongly|In|,|USPSTF (l_prep) with_18\IN|clinicians|aspirin|that (l_pobj) adults_19\NNS|NONE (l_relcl) are_21\VBP|NONE (l_prep) at_22\IN|who (l_pobj) risk_24\NN|NONE (l_prep) for_25\IN|increased (l_pobj) disease_28\NN|NONE
D001241_D006471 CID aspirin_1\NN|strokes|?|Does (r_nsubj) increase_2\VB|NONE (l_dobj) strokes_7\NNS|aspirin|?|Does (l_nmod) bleeding_4\NN|NONE
D001241_D006471 CID aspirin_3\NN|NONE (r_pobj) of_2\IN|The|for (r_prep) use_1\NN|.|risk (r_nsubj) increases_7\VBZ|NONE (l_dobj) risk_9\NN|.|use (l_prep) for_10\IN|the (l_pobj) events_13\NNS|NONE (l_appos) events_18\NNS|in|bleeding|major|,|, (l_compound) bleeding_17\NN|gastrointestinal
D001241_D009203 NONE aspirin_8\NN|for (r_dobj) taking_7\VBG|NONE (l_prep) for_9\IN|aspirin (l_pobj) prevention_12\NN|NONE (l_prep) of_13\IN|the|primary (l_pobj) infarctions_15\NNS|NONE
D001241_D009203 NONE Aspirin_0\NNP|risk|. (r_nsubj) reduces_1\VBZ|NONE (l_dobj) risk_3\NN|Aspirin|. (l_prep) for_4\IN|the (l_pobj) infarction_6\NN|NONE
D001241_D006470 NONE aspirin_3\NN|NONE (r_pobj) of_2\IN|The|for (r_prep) use_1\NN|.|risk (r_nsubj) increases_7\VBZ|NONE (l_dobj) risk_9\NN|.|use (l_prep) for_10\IN|the (l_pobj) events_13\NNS|NONE (l_compound) bleeding_12\NN|events|in|major|,|,
D001241_D006470 NONE Aspirin_0\NNP|NONE (r_compound) use_1\NN|.|risk (r_nsubj) increases_2\VBZ|NONE (l_dobj) risk_4\NN|.|use (l_prep) for_5\IN|the (l_pobj) events_8\NNS|NONE (l_compound) bleeding_7\NN|serious
3125850
D015760_D005207 NONE alfentanil_15\NN|NONE (r_pobj) by_14\IN|NONE (r_prep) inhibition_13\NN|:|in|muscle|induced (r_appos) fasciculations_9\NNS|NONE
D015760_D005207 NONE alfentanil_19\NN|the (r_compound) group_20\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) than_16\IN|in|significantly (r_prep) greater_12\JJR|.|incidence (r_acomp) were_10\VBD|NONE (l_nsubj) incidence_1\NN|.|greater (l_conj) intensity_3\NN|and|The (l_prep) of_4\IN|NONE (l_pobj) fasciculations_6\NNS|NONE
D015760_D005207 NONE alfentanil_26\NN|the (r_compound) group_27\NN|NONE (r_pobj) in_24\IN|NONE (r_prep) than_23\IN|in|pressure|higher (r_prep) was_6\VBD|NONE (l_nsubj) pressure_2\NN|in|than|higher (l_prep) during_3\IN|intragastric|The (l_pobj) fasciculations_5\NNS|NONE
D015760_D005207 NONE Alfentanil_0\NNP|kg|effectively|incidence (r_dep) inhibits_5\VBZ|moreover|at|,|;|pressure|. (l_dobj) incidence_7\NN|kg|effectively|Alfentanil (l_prep) of_10\IN|intensity|and|the (l_pobj) fasciculations_15\NNS|NONE
D013390_D005207 CID suxamethonium_5\NN|NONE (r_npadvmod) induced_7\VBN|inhibition|:|in|muscle (r_amod) fasciculations_9\NNS|NONE
D013390_D005207 CID suxamethonium_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) caused_7\VBN|muscle (r_acl) fasciculations_6\NNS|NONE
D013390_D005207 CID suxamethonium_13\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) caused_11\VBN|muscle (r_acl) fasciculations_10\NNS|NONE
D013390_D005207 CID suxamethonium_11\NN| (r_npadvmod) induced_13\VBN|muscle (r_amod) fasciculations_15\NNS|NONE
D014867_D005207 NONE H2O_21\NNP|(|the|)|control (r_appos) group_12\NN|NONE (r_pobj) in_9\IN|pressure|than|higher (r_prep) was_6\VBD|NONE (l_nsubj) pressure_2\NN|in|than|higher (l_prep) during_3\IN|intragastric|The (l_pobj) fasciculations_5\NNS|NONE
19655282
D003042_D007511 NONE cocaine_12\NN| (r_npadvmod) associated_14\VBN|chest (r_amod) pain_16\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) efficacious_10\JJ|strategy|account|would|whether|, (r_acomp) be_9\VB|.|unclear|It (l_advcl) account_22\VB|strategy|efficacious|would|whether|, (l_prep) for_23\IN|as|may|vasospasm (l_pobj) some_24\DT|NONE (l_prep) of_25\IN|NONE (l_pobj) ischemia_27\NN|NONE
D003042_D007511 NONE cocaine_1\NN| (r_npadvmod) associated_3\VBN|myocardial (r_amod) ischemia_5\NN|from|.|Although|can (r_nsubj) result_7\VB|NONE (l_prep) from_8\IN|.|Although|can|ischemia (l_pobj) vasoconstriction_10\NN|NONE (l_acl) discharged_35\VBN|coronary|, (l_nsubjpass) patients_12\NNS|with|be|from|safely|may|after (l_prep) with_13\IN|NONE (l_pobj) cocaine_14\NN|NONE (l_acl) associated_15\VBN|NONE (l_dobj) pain_17\NN|NONE (l_conj) ECG_23\NNP|chest|, (l_amod) ischemic_22\JJ|,|a|and|
D003042_D007511 NONE cocaine_14\NN|NONE (l_acl) associated_15\VBN|NONE (l_dobj) pain_17\NN|NONE (l_conj) ECG_23\NNP|chest|, (l_amod) ischemic_22\JJ|,|a|and|
D003042_D002637 CID cocaine_13\NN| (r_npadvmod) associated_15\VBN|chest (r_amod) pain_17\NN|NONE
D003042_D002637 CID cocaine_10\NN| (r_npadvmod) associated_12\VBN|chest (r_amod) pain_14\NN|NONE
D003042_D002637 CID cocaine_12\NN| (r_npadvmod) associated_14\VBN|chest (r_amod) pain_16\NN|NONE
D003042_D002637 CID cocaine_10\NN| (r_npadvmod) associated_12\VBN|chest (r_amod) pain_14\NN|NONE
D003042_D002637 CID cocaine_6\NN| (r_npadvmod) associated_8\VBN|chest (r_amod) pain_10\NN|NONE
D003042_D002637 CID cocaine_1\NN| (r_npadvmod) associated_3\VBN|myocardial (r_amod) ischemia_5\NN|from|.|Although|can (r_nsubj) result_7\VB|NONE (l_prep) from_8\IN|.|Although|can|ischemia (l_pobj) vasoconstriction_10\NN|NONE (l_acl) discharged_35\VBN|coronary|, (l_nsubjpass) patients_12\NNS|with|be|from|safely|may|after (l_prep) with_13\IN|NONE (l_pobj) cocaine_14\NN|NONE (l_acl) associated_15\VBN|NONE (l_dobj) pain_17\NN|NONE
D003042_D002637 CID cocaine_14\NN|NONE (l_acl) associated_15\VBN|NONE (l_dobj) pain_17\NN|NONE
D003042_D054058 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|chest (r_amod) pain_14\NN|NONE (r_pobj) with_9\IN|to (r_prep) presenting_2\VBG|Most (r_acl) patients_1\NNS|and|are|receive|for|. (r_nsubjpass) admitted_16\VBN|NONE (l_conj) receive_23\VB|and|patients|are|for|. (l_dobj) protocol_32\NN|prior (l_nmod) syndrome_30\NN|a|"|with|acute|,|rule|"
D003042_D003329 NONE cocaine_12\NN| (r_npadvmod) associated_14\VBN|chest (r_amod) pain_16\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) efficacious_10\JJ|strategy|account|would|whether|, (r_acomp) be_9\VB|.|unclear|It (l_advcl) account_22\VB|strategy|efficacious|would|whether|, (l_nsubj) vasospasm_20\NN|as|may|for
D003042_D017202 CID cocaine_1\NN| (r_npadvmod) associated_3\VBN|myocardial (r_amod) ischemia_5\NN|from|.|Although|can
D003042_D017202 CID cocaine_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) patients_12\NNS|with|be|from|safely|may|after (r_nsubjpass) discharged_35\VBN|coronary|, (r_acl) vasoconstriction_10\NN|NONE (r_pobj) from_8\IN|.|Although|can|ischemia (r_prep) result_7\VB|NONE (l_nsubj) ischemia_5\NN|from|.|Although|can
24284476
D047310_D000647 NONE apigenin_2\NN|not|.|)|amnesia|,|Furthermore|did (r_nsubj) prevent_5\VB|NONE (l_dobj) amnesia_7\NN|not|.|)|apigenin|,|Furthermore|did
D012601_D000647 CID scopolamine_10\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) induced_8\VBN|the (r_acl) amnesia_7\NN|not|.|)|apigenin|,|Furthermore|did
10985896
D004317_D013280 CID doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) being_41\VBG|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN|NONE (l_appos) syndrome_49\NN|severe (l_conj) stomatitis_53\NN|)|foot|"|"|(|and
D004317_D013280 CID Doxil_7\NNS|liposomal (r_appos) doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) being_41\VBG|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN|NONE (l_appos) syndrome_49\NN|severe (l_conj) stomatitis_53\NN|)|foot|"|"|(|and
D004317_D013280 CID doxorubicin_3\NN|NONE (r_compound) regimen_4\NN|modified|.|in|than|This|liposomal (r_compound) results_5\VBZ|NONE (l_prep) in_6\IN|modified|.|than|This|liposomal|regimen (l_pobj) toxicity_8\NN|NONE (l_appos) stomatitis_10\NN|)|less|(
D010984_D013280 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|ovarian (r_amod) cancer_20\NN|NONE (r_pobj) in_15\IN|active|antineoplastic|an (r_prep) agent_14\NN|to|with|q|, (r_attr) be_10\VB|studies|.|doxorubicin|being|have (r_advcl) demonstrated_3\VBN|NONE (l_advcl) being_41\VBG|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN|NONE (l_appos) syndrome_49\NN|severe (l_conj) stomatitis_53\NN|)|foot|"|"|(|and
D010984_D060831 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|ovarian (r_amod) cancer_20\NN|NONE (r_pobj) in_15\IN|active|antineoplastic|an (r_prep) agent_14\NN|to|with|q|, (r_attr) be_10\VB|studies|.|doxorubicin|being|have (r_advcl) demonstrated_3\VBN|NONE (l_advcl) being_41\VBG|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN|NONE
D010984_D060831 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|ovarian (r_amod) cancer_20\NN|NONE (r_pobj) in_15\IN|active|antineoplastic|an (r_prep) agent_14\NN|to|with|q|, (r_attr) be_10\VB|studies|.|doxorubicin|being|have (r_advcl) demonstrated_3\VBN|NONE (l_advcl) being_41\VBG|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN|NONE (l_appos) syndrome_49\NN|severe
D017239_D010051 NONE paclitaxel_16\NN|/|platinum| (r_compound) refractory_18\JJ|and|ovarian|carcinoma (r_amod) cancers_23\NNS|NONE
D017239_D010051 NONE paclitaxel_14\NN| (r_compound) refractory_16\JJ|)|platinum|(|months|disease|/ (r_amod) disease_17\NN|NONE (r_pobj) with_11\IN|peritoneal|primary (r_prep) carcinoma_10\NN|or|ovarian|tube (r_conj) cancers_6\NNS|NONE
D017239_D010051 NONE paclitaxel_17\NN|refractory|and (r_conj) platinum-_15\NN|defined|ovarian (r_nmod) cancer_21\NN|NONE
D004317_D060831 CID doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) being_41\VBG|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN|NONE
D004317_D060831 CID doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) being_41\VBG|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN|NONE (l_appos) syndrome_49\NN|severe
D004317_D060831 CID Doxil_7\NNS|liposomal (r_appos) doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) being_41\VBG|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN|NONE
D004317_D060831 CID Doxil_7\NNS|liposomal (r_appos) doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) being_41\VBG|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN|NONE (l_appos) syndrome_49\NN|severe
D004317_D060831 CID doxorubicin_3\NN|NONE (r_compound) regimen_4\NN|modified|.|in|than|This|liposomal (r_compound) results_5\VBZ|NONE (l_prep) in_6\IN|modified|.|than|This|liposomal|regimen (l_pobj) toxicity_8\NN|NONE (l_appos) stomatitis_10\NN|)|less|( (l_appos) syndrome_15\NN|,
D010984_D005185 NONE platinum_14\NN|/||paclitaxel (r_nmod) refractory_18\JJ|and|ovarian|carcinoma (r_amod) cancers_23\NNS|NONE
D010984_D005185 NONE platinum_12\NN|)|(|months|disease|refractory|/ (r_nmod) disease_17\NN|NONE (r_pobj) with_11\IN|peritoneal|primary (r_prep) carcinoma_10\NN|or|ovarian|tube (r_conj) cancers_6\NNS|NONE
D010984_D010051 NONE platinum_14\NN|/||paclitaxel (r_nmod) refractory_18\JJ|and|ovarian|carcinoma (r_amod) cancers_23\NNS|NONE
D010984_D010051 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|ovarian (r_amod) cancer_20\NN|NONE
D010984_D010051 NONE platinum_12\NN|)|(|months|disease|refractory|/ (r_nmod) disease_17\NN|NONE (r_pobj) with_11\IN|peritoneal|primary (r_prep) carcinoma_10\NN|or|ovarian|tube (r_conj) cancers_6\NNS|NONE
D010984_D010051 NONE platinum-_15\NN|defined|ovarian (r_nmod) cancer_21\NN|NONE
D010984_D064420 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|ovarian (r_amod) cancer_20\NN|NONE (r_pobj) in_15\IN|active|antineoplastic|an (r_prep) agent_14\NN|to|with|q|, (r_attr) be_10\VB|studies|.|doxorubicin|being|have (l_prep) with_22\IN|to|agent|q|, (l_pobj) toxicity_25\NN|NONE
D004317_D010534 NONE doxorubicin_5\NN|NONE (r_pobj) of_3\IN|.|in|Phase (r_prep) trial_2\NN|NONE (l_prep) in_13\IN|.|of|Phase (l_pobj) cancers_23\NNS|NONE (l_conj) carcinoma_26\NN|and|ovarian|refractory (l_prep) of_27\IN|primary (l_pobj) peritoneum_29\NN|NONE
D004317_D010534 NONE doxorubicin_41\NN|NONE (r_pobj) with_39\IN|were|Patients|.|weeks|at (r_prep) treated_38\VBN|NONE (l_nsubjpass) Patients_0\NNS|were|.|weeks|at|with (l_prep) with_1\IN|NONE (l_pobj) cancers_6\NNS|NONE (l_conj) carcinoma_10\NN|or|ovarian|tube
D004317_D005185 NONE doxorubicin_5\NN|NONE (r_pobj) of_3\IN|.|in|Phase (r_prep) trial_2\NN|NONE (l_prep) in_13\IN|.|of|Phase (l_pobj) cancers_23\NNS|NONE
D004317_D005185 NONE doxorubicin_41\NN|NONE (r_pobj) with_39\IN|were|Patients|.|weeks|at (r_prep) treated_38\VBN|NONE (l_nsubjpass) Patients_0\NNS|were|.|weeks|at|with (l_prep) with_1\IN|NONE (l_pobj) cancers_6\NNS|NONE
D004317_D064420 NONE doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) be_10\VB|studies|.|doxorubicin|being|have (l_prep) with_22\IN|to|agent|q|, (l_pobj) toxicity_25\NN|NONE
D004317_D064420 NONE Doxil_7\NNS|liposomal (r_appos) doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) be_10\VB|studies|.|doxorubicin|being|have (l_prep) with_22\IN|to|agent|q|, (l_pobj) toxicity_25\NN|NONE
D004317_D064420 NONE doxorubicin_3\NN|NONE (r_compound) regimen_4\NN|modified|.|in|than|This|liposomal (r_compound) results_5\VBZ|NONE (l_prep) in_6\IN|modified|.|than|This|liposomal|regimen (l_pobj) toxicity_8\NN|NONE
D017239_D005185 NONE paclitaxel_16\NN|/|platinum| (r_compound) refractory_18\JJ|and|ovarian|carcinoma (r_amod) cancers_23\NNS|NONE
D017239_D005185 NONE paclitaxel_14\NN| (r_compound) refractory_16\JJ|)|platinum|(|months|disease|/ (r_amod) disease_17\NN|NONE (r_pobj) with_11\IN|peritoneal|primary (r_prep) carcinoma_10\NN|or|ovarian|tube (r_conj) cancers_6\NNS|NONE
D004317_D010051 NONE doxorubicin_5\NN|NONE (r_pobj) of_3\IN|.|in|Phase (r_prep) trial_2\NN|NONE (l_prep) in_13\IN|.|of|Phase (l_pobj) cancers_23\NNS|NONE
D004317_D010051 NONE doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) be_10\VB|studies|.|doxorubicin|being|have (l_attr) agent_14\NN|to|with|q|, (l_prep) in_15\IN|active|antineoplastic|an (l_pobj) cancer_20\NN|NONE
D004317_D010051 NONE Doxil_7\NNS|liposomal (r_appos) doxorubicin_5\NN|studies|be|.|being|have (r_dobj) demonstrated_3\VBN|NONE (l_advcl) be_10\VB|studies|.|doxorubicin|being|have (l_attr) agent_14\NN|to|with|q|, (l_prep) in_15\IN|active|antineoplastic|an (l_pobj) cancer_20\NN|NONE
D004317_D010051 NONE doxorubicin_41\NN|NONE (r_pobj) with_39\IN|were|Patients|.|weeks|at (r_prep) treated_38\VBN|NONE (l_nsubjpass) Patients_0\NNS|were|.|weeks|at|with (l_prep) with_1\IN|NONE (l_pobj) cancers_6\NNS|NONE
D010984_D010534 NONE platinum_14\NN|/||paclitaxel (r_nmod) refractory_18\JJ|and|ovarian|carcinoma (r_amod) cancers_23\NNS|NONE (l_conj) carcinoma_26\NN|and|ovarian|refractory (l_prep) of_27\IN|primary (l_pobj) peritoneum_29\NN|NONE
D010984_D010534 NONE platinum_12\NN|)|(|months|disease|refractory|/ (r_nmod) disease_17\NN|NONE (r_pobj) with_11\IN|peritoneal|primary (r_prep) carcinoma_10\NN|or|ovarian|tube
D017239_D010534 NONE paclitaxel_16\NN|/|platinum| (r_compound) refractory_18\JJ|and|ovarian|carcinoma (r_amod) cancers_23\NNS|NONE (l_conj) carcinoma_26\NN|and|ovarian|refractory (l_prep) of_27\IN|primary (l_pobj) peritoneum_29\NN|NONE
D017239_D010534 NONE paclitaxel_14\NN| (r_compound) refractory_16\JJ|)|platinum|(|months|disease|/ (r_amod) disease_17\NN|NONE (r_pobj) with_11\IN|peritoneal|primary (r_prep) carcinoma_10\NN|or|ovarian|tube
10939760
D013411_D014123 NONE Sulfadiazine_0\NN|acute (r_nmod) nephrotoxicity_2\NN|is|.|because (r_nsubj) reviving_4\VBG|NONE (l_prep) because_6\IN|is|nephrotoxicity|. (l_pobj) use_9\NN|specially|of (l_prep) in_10\IN|in|its (l_pobj) toxoplasmosis_11\NN|NONE
D013411_D058186 CID sulfadiazine_2\NN|acute (r_nmod) nephrotoxicity_4\NN|NONE
D013411_D058186 CID Sulfadiazine_0\NN|acute (r_nmod) nephrotoxicity_2\NN|is|.|because
14748761
C056507_D066126 NONE gemcitabine_22\NN|other|cardiotoxic|leader|anthracyclines (r_appos) drugs_16\NNS|and|risk|similar|. (l_amod) cardiotoxic_15\JJ|other|gemcitabine|leader|anthracyclines
C056507_D066126 NONE GEM_24\NNP|NONE (r_appos) gemcitabine_22\NN|other|cardiotoxic|leader|anthracyclines (r_appos) drugs_16\NNS|and|risk|similar|. (l_amod) cardiotoxic_15\JJ|other|gemcitabine|leader|anthracyclines
C030852_D009369 NONE VNR_21\VBN|with (r_dobj) comparing_20\VBG|clinical (l_prep) with_22\IN|VNR (l_pobj) agents_25\NNS|NONE (l_prep) in_26\IN|chemotherapeutic|other (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) malignancies_31\NNS|NONE
C030852_D009369 NONE VNR_4\VBN|in|with (r_dobj) comparing_3\VBG|Randomized|clinical (l_prep) in_8\IN|VNR|with (l_pobj) treatment_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) cancer_12\NN|NONE
D014751_D066126 NONE vindesine_9\NN|NONE (r_xcomp) similar_7\JJ|and|risk|drugs|. (r_acomp) was_6\VBD|NONE (l_conj) drugs_16\NNS|and|risk|similar|. (l_amod) cardiotoxic_15\JJ|other|gemcitabine|leader|anthracyclines
D014751_D066126 NONE VDS_11\NNP|)|to|( (r_appos) vindesine_9\NN|NONE (r_xcomp) similar_7\JJ|and|risk|drugs|. (r_acomp) was_6\VBD|NONE (l_conj) drugs_16\NNS|and|risk|similar|. (l_amod) cardiotoxic_15\JJ|other|gemcitabine|leader|anthracyclines
D005472_D066126 NONE fluorouracil_18\NN|, (r_nmod) anthracyclines_20\NNS|other|gemcitabine|cardiotoxic|leader (r_appos) drugs_16\NNS|and|risk|similar|. (l_amod) cardiotoxic_15\JJ|other|gemcitabine|leader|anthracyclines
D018943_D066126 NONE anthracyclines_20\NNS|other|gemcitabine|cardiotoxic|leader (r_appos) drugs_16\NNS|and|risk|similar|. (l_amod) cardiotoxic_15\JJ|other|gemcitabine|leader|anthracyclines
C030852_D066126 CID VNR_3\VBN|cardiac (r_nmod) events_5\NNS|NONE (r_pobj) of_2\IN|The (r_prep) risk_1\NN|and|drugs|similar|. (r_nsubj) was_6\VBD|NONE (l_conj) drugs_16\NNS|and|risk|similar|. (l_amod) cardiotoxic_15\JJ|other|gemcitabine|leader|anthracyclines
3423103
D015116_D001919 NONE 5,7-dihydroxytryptamine_16\CD|NONE (r_pobj) of_15\IN|bilateral|spinal (r_prep) injection_14\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) produced_10\VBN|spinal|,|HT|, (r_acl) nerves_8\NNS|NONE (r_pobj) of_4\IN|selective (r_prep) destruction_3\NN|,|.|clonidine|magnitude|Furthermore (r_nsubj) reduced_18\VBD|NONE (l_dobj) magnitude_20\NN|,|.|clonidine|destruction|Furthermore (l_prep) of_21\IN|the (l_pobj) vasodepressor_23\NN|NONE (l_conj) responses_27\NNS|or|the (l_compound) bradycardiac_26\NN|the
D003000_D001919 CID clonidine_11\NN| (r_npadvmod) induced_13\VBN|and|bradycardia (r_amod) hypotension_14\NN|NONE (l_conj) bradycardia_16\NN|and|induced
D003000_D001919 CID clonidine_6\NN| (r_npadvmod) induced_8\VBN|the (r_amod) bradycardia_9\NN|,|transection|,|but|On|was|by|.
D003000_D001919 CID clonidine_29\NN|,|.|destruction|magnitude|Furthermore (r_advcl) reduced_18\VBD|NONE (l_dobj) magnitude_20\NN|,|.|clonidine|destruction|Furthermore (l_prep) of_21\IN|the (l_pobj) vasodepressor_23\NN|NONE (l_conj) responses_27\NNS|or|the (l_compound) bradycardiac_26\NN|the
D003000_D001919 CID clonidine_13\NN| (r_npadvmod) induced_15\VBN|and|bradycardia (r_amod) hypotension_16\NN|NONE (l_conj) bradycardia_18\NN|induced|and
D003000_D007022 CID clonidine_11\NN| (r_npadvmod) induced_13\VBN|and|bradycardia (r_amod) hypotension_14\NN|NONE
D003000_D007022 CID clonidine_1\NN| (r_npadvmod) induced_3\VBN|The (r_amod) hypotension_4\NN|by|was|.
D003000_D007022 CID clonidine_13\NN| (r_npadvmod) induced_15\VBN|and|bradycardia (r_amod) hypotension_16\NN|NONE
D012701_D001919 NONE 5-HT_7\CD|spinal|,|,|produced (r_nummod) nerves_8\NNS|NONE (r_pobj) of_4\IN|selective (r_prep) destruction_3\NN|,|.|clonidine|magnitude|Furthermore (r_nsubj) reduced_18\VBD|NONE (l_dobj) magnitude_20\NN|,|.|clonidine|destruction|Furthermore (l_prep) of_21\IN|the (l_pobj) vasodepressor_23\NN|NONE (l_conj) responses_27\NNS|or|the (l_compound) bradycardiac_26\NN|the
15094729
D020888_D014786 CID Vigabatrin_4\NNP|NONE (r_pobj) of_3\IN|natural|The (r_prep) history_2\NN|.|defects (r_nsubj) associated_5\VBD|NONE (l_dobj) defects_8\NNS|history|.
D020888_D014786 CID Vigabatrin_17\NN| (r_npadvmod) associated_19\VBN|elected (r_amod) changes_20\NNS|to (r_dobj) have_16\VB|NONE (r_xcomp) known_14\VBN|NONE (r_acl) patients_13\NNS|NONE (r_pobj) of_12\IN|a (r_prep) group_11\NN|NONE (r_pobj) in_9\IN|visual|field (r_prep) defects_8\NNS|NONE
D020888_D014786 CID Vigabatrin_9\NNP|NONE (r_compound) therapy_10\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) due_7\JJ|to (r_acomp) be_6\VB|defects (r_xcomp) presumed_4\VBN|did|usually|not|.|in (l_nsubj) defects_3\NNS|be
D020888_D014786 CID Vigabatrin_11\NNP| (r_npadvmod) associated_13\VBN|field|visual (r_amod) defects_16\NNS|NONE
D020888_D064420 NONE Vigabatrin_11\NNP| (r_npadvmod) associated_13\VBN|field|visual (r_amod) defects_16\NNS|NONE (r_pobj) of_10\IN|the (r_prep) pathogenesis_9\NN|that|reaction|may (r_nsubj) be_18\VB|the (l_attr) reaction_23\NN|that|may|pathogenesis (l_cc) than_25\IN|an|idiosyncratic|adverse|drug (l_pobj) toxicity_29\NN|rather
D020888_D012640 NONE Vigabatrin_17\NN| (r_npadvmod) associated_19\VBN|elected (r_amod) changes_20\NNS|to (l_relcl) elected_22\VBD|associated (l_xcomp) continue_24\VB|who (l_prep) because_27\IN|to|medication (l_pobj) control_31\NN|of (l_compound) seizure_30\NN|good
1280707
D011374_D001145 CID progesterone_32\NN|NONE (r_compound) HCl_33\NN|hour|on (r_compound) exposure_34\NN|NONE (r_pobj) of_30\IN|the (r_prep) effect_29\NN|,|we|After|(|. (r_dobj) determined_27\VBD|NONE (l_punct) (_5\-LRB-|,|we|effect|After|. (l_preconj) concentration_7\NN|NONE (l_relcl) caused_11\VBD|of|the|) (l_dobj) %_13\NN|that (l_prep) of_14\IN| (l_pcomp) beating_16\VBG|all (l_advcl) become_22\VB|cultures (l_acomp) arrhythmic_23\JJ|to
D002045_D001145 CID bupivacaine_3\NN|AD (r_dobj) determining_1\VBG|NONE (r_pcomp) After_0\IN|,|we|effect|(|. (r_prep) determined_27\VBD|NONE (l_punct) (_5\-LRB-|,|we|effect|After|. (l_preconj) concentration_7\NN|NONE (l_relcl) caused_11\VBD|of|the|) (l_dobj) %_13\NN|that (l_prep) of_14\IN| (l_pcomp) beating_16\VBG|all (l_advcl) become_22\VB|cultures (l_acomp) arrhythmic_23\JJ|to
D002045_D001145 CID bupivacaine_9\NN|NONE (r_pobj) of_8\IN|the|caused|) (r_prep) concentration_7\NN|NONE (l_relcl) caused_11\VBD|of|the|) (l_dobj) %_13\NN|that (l_prep) of_14\IN| (l_pcomp) beating_16\VBG|all (l_advcl) become_22\VB|cultures (l_acomp) arrhythmic_23\JJ|to
D002045_D001145 CID bupivacaine_2\NN|NONE (r_compound) arrhythmia_3\NN|NONE
D006851_D001145 NONE HCl_33\NN|hour|on (r_compound) exposure_34\NN|NONE (r_pobj) of_30\IN|the (r_prep) effect_29\NN|,|we|After|(|. (r_dobj) determined_27\VBD|NONE (l_punct) (_5\-LRB-|,|we|effect|After|. (l_preconj) concentration_7\NN|NONE (l_relcl) caused_11\VBD|of|the|) (l_dobj) %_13\NN|that (l_prep) of_14\IN| (l_pcomp) beating_16\VBG|all (l_advcl) become_22\VB|cultures (l_acomp) arrhythmic_23\JJ|to
7477981
D001058_D010300 NONE apomorphine_29\NN|dopamine|,|the (r_appos) agonist_27\NN|NONE (r_pobj) with_23\IN|an|acute (r_prep) challenge_22\NN|NONE (r_pobj) after_19\IN|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD|NONE (l_dobj) severity_3\NN|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS|the|of|and (l_prep) in_9\IN|NONE (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|seven|responsive (l_pobj) disease_18\NN|NONE
D001058_D010300 NONE apomorphine_17\NN|NONE (r_pobj) of_16\IN|)|significant|(|%|.|a (r_prep) improvement_10\NN|there|After|,|induced|. (r_attr) was_5\VBD|NONE (l_advcl) induced_19\VBN|there|After|,|.|improvement (l_prep) without_21\IN||dyskinesias (l_pobj) modification_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) disability_26\NN|NONE (l_amod) parkinsonian_24\JJ|motor
D005473_D004409 CID fluoxetine_7\NN|NONE (r_pobj) by_6\IN|.|dyskinesias|are (r_agent) improved_5\VBN|NONE (l_nsubjpass) dyskinesias_3\NNS|.|by|are
D005473_D004409 CID fluoxetine_37\NN|NONE (r_pobj) of_36\IN|the (r_prep) administration_35\NN|twice (r_pobj) after_33\IN|and (r_conj) before_31\RB|.|severity|for|)|after|We|, (r_prep) evaluated_1\VBD|NONE (l_dobj) severity_3\NN|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS|the|of|and
D005473_D004409 CID fluoxetine_1\NN|NONE (r_amod) treatment_2\NN|NONE (r_pobj) After_0\IN|there|,|induced|.|improvement (r_prep) was_5\VBD|NONE (l_advcl) induced_19\VBN|there|After|,|.|improvement (l_dobj) dyskinesias_20\NNS||without
D005473_D004409 CID fluoxetine_9\NN|NONE (r_pobj) with_8\IN|serotoninergic|increased (r_prep) transmission_7\NN|may|that|without|dyskinesias (r_nsubj) reduce_11\VB|.|results (l_dobj) dyskinesias_18\NNS|may|that|transmission|without
D005473_D010300 NONE fluoxetine_37\NN|NONE (r_pobj) of_36\IN|the (r_prep) administration_35\NN|twice (r_pobj) after_33\IN|and (r_conj) before_31\RB|.|severity|for|)|after|We|, (r_prep) evaluated_1\VBD|NONE (l_dobj) severity_3\NN|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS|the|of|and (l_prep) in_9\IN|NONE (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|seven|responsive (l_pobj) disease_18\NN|NONE
D005473_D010300 NONE fluoxetine_1\NN|NONE (r_amod) treatment_2\NN|NONE (r_pobj) After_0\IN|there|,|induced|.|improvement (r_prep) was_5\VBD|NONE (l_advcl) induced_19\VBN|there|After|,|.|improvement (l_prep) without_21\IN||dyskinesias (l_pobj) modification_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) disability_26\NN|NONE (l_amod) parkinsonian_24\JJ|motor
D005473_D010300 NONE fluoxetine_9\NN|NONE (r_pobj) with_8\IN|serotoninergic|increased (r_prep) transmission_7\NN|may|that|without|dyskinesias (r_nsubj) reduce_11\VB|.|results (l_prep) without_19\IN|may|that|transmission|dyskinesias (l_pobj) disability_23\NN|NONE (l_amod) parkinsonian_21\JJ|aggravating|motor
D004298_D004409 NONE dopamine_26\NN|,|apomorphine|the (r_compound) agonist_27\NN|NONE (r_pobj) with_23\IN|an|acute (r_prep) challenge_22\NN|NONE (r_pobj) after_19\IN|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD|NONE (l_dobj) severity_3\NN|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS|the|of|and
D004298_D004409 NONE dopamine_14\NN|or (r_conj) levodopa-_12\JJ|induced (r_nmod) dyskinesias_18\NNS|may|that|transmission|without
D001058_D004409 CID apomorphine_29\NN|dopamine|,|the (r_appos) agonist_27\NN|NONE (r_pobj) with_23\IN|an|acute (r_prep) challenge_22\NN|NONE (r_pobj) after_19\IN|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD|NONE (l_dobj) severity_3\NN|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS|the|of|and
D001058_D004409 CID apomorphine_17\NN|NONE (r_pobj) of_16\IN|)|significant|(|%|.|a (r_prep) improvement_10\NN|there|After|,|induced|. (r_attr) was_5\VBD|NONE (l_advcl) induced_19\VBN|there|After|,|.|improvement (l_dobj) dyskinesias_20\NNS||without
D007980_D010300 NONE levodopa_11\JJ| (r_npadvmod) responsive_13\JJ|with|seven (r_amod) patients_14\NNS|NONE (l_prep) with_15\IN|seven|responsive (l_pobj) disease_18\NN|NONE
D007980_D010300 NONE levodopa-_12\JJ|induced (r_nmod) dyskinesias_18\NNS|may|that|transmission|without (r_dobj) reduce_11\VB|.|results (l_prep) without_19\IN|may|that|transmission|dyskinesias (l_pobj) disability_23\NN|NONE (l_amod) parkinsonian_21\JJ|aggravating|motor
D004298_D009069 NONE dopamine_26\NN|,|apomorphine|the (r_compound) agonist_27\NN|NONE (r_pobj) with_23\IN|an|acute (r_prep) challenge_22\NN|NONE (r_pobj) after_19\IN|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD|NONE (l_dobj) severity_3\NN|.|before|for|)|after|We|, (l_prep) of_4\IN|the|dyskinesias|and (l_pobj) disability_6\NN|NONE
D004298_D009069 NONE dopamine_14\NN|or (r_conj) levodopa-_12\JJ|induced (r_nmod) dyskinesias_18\NNS|may|that|transmission|without (r_dobj) reduce_11\VB|.|results (l_prep) without_19\IN|may|that|transmission|dyskinesias (l_pobj) disability_23\NN|NONE
D007980_D004409 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) dyskinesias_3\NNS|.|by|are
D007980_D004409 NONE levodopa_11\JJ| (r_npadvmod) responsive_13\JJ|with|seven (r_amod) patients_14\NNS|NONE (r_pobj) in_9\IN|NONE (r_prep) dyskinesias_8\NNS|the|of|and
D007980_D004409 NONE levodopa-_12\JJ|induced (r_nmod) dyskinesias_18\NNS|may|that|transmission|without
D007980_D009069 NONE levodopa_11\JJ| (r_npadvmod) responsive_13\JJ|with|seven (r_amod) patients_14\NNS|NONE (r_pobj) in_9\IN|NONE (r_prep) dyskinesias_8\NNS|the|of|and (r_conj) severity_3\NN|.|before|for|)|after|We|, (l_prep) of_4\IN|the|dyskinesias|and (l_pobj) disability_6\NN|NONE
D007980_D009069 NONE levodopa-_12\JJ|induced (r_nmod) dyskinesias_18\NNS|may|that|transmission|without (r_dobj) reduce_11\VB|.|results (l_prep) without_19\IN|may|that|transmission|dyskinesias (l_pobj) disability_23\NN|NONE
D005473_D009069 NONE fluoxetine_37\NN|NONE (r_pobj) of_36\IN|the (r_prep) administration_35\NN|twice (r_pobj) after_33\IN|and (r_conj) before_31\RB|.|severity|for|)|after|We|, (r_prep) evaluated_1\VBD|NONE (l_dobj) severity_3\NN|.|before|for|)|after|We|, (l_prep) of_4\IN|the|dyskinesias|and (l_pobj) disability_6\NN|NONE
D005473_D009069 NONE fluoxetine_1\NN|NONE (r_amod) treatment_2\NN|NONE (r_pobj) After_0\IN|there|,|induced|.|improvement (r_prep) was_5\VBD|NONE (l_advcl) induced_19\VBN|there|After|,|.|improvement (l_prep) without_21\IN||dyskinesias (l_pobj) modification_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) disability_26\NN|NONE
D005473_D009069 NONE fluoxetine_9\NN|NONE (r_pobj) with_8\IN|serotoninergic|increased (r_prep) transmission_7\NN|may|that|without|dyskinesias (r_nsubj) reduce_11\VB|.|results (l_prep) without_19\IN|may|that|transmission|dyskinesias (l_pobj) disability_23\NN|NONE
D001058_D009069 NONE apomorphine_29\NN|dopamine|,|the (r_appos) agonist_27\NN|NONE (r_pobj) with_23\IN|an|acute (r_prep) challenge_22\NN|NONE (r_pobj) after_19\IN|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD|NONE (l_dobj) severity_3\NN|.|before|for|)|after|We|, (l_prep) of_4\IN|the|dyskinesias|and (l_pobj) disability_6\NN|NONE
D001058_D009069 NONE apomorphine_17\NN|NONE (r_pobj) of_16\IN|)|significant|(|%|.|a (r_prep) improvement_10\NN|there|After|,|induced|. (r_attr) was_5\VBD|NONE (l_advcl) induced_19\VBN|there|After|,|.|improvement (l_prep) without_21\IN||dyskinesias (l_pobj) modification_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) disability_26\NN|NONE
D004298_D010300 NONE dopamine_26\NN|,|apomorphine|the (r_compound) agonist_27\NN|NONE (r_pobj) with_23\IN|an|acute (r_prep) challenge_22\NN|NONE (r_pobj) after_19\IN|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD|NONE (l_dobj) severity_3\NN|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS|the|of|and (l_prep) in_9\IN|NONE (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|seven|responsive (l_pobj) disease_18\NN|NONE
D004298_D010300 NONE dopamine_14\NN|or (r_conj) levodopa-_12\JJ|induced (r_nmod) dyskinesias_18\NNS|may|that|transmission|without (r_dobj) reduce_11\VB|.|results (l_prep) without_19\IN|may|that|transmission|dyskinesias (l_pobj) disability_23\NN|NONE (l_amod) parkinsonian_21\JJ|aggravating|motor
18165598
D015232_D010146 NONE E2_9\NNP|prostaglandin|in|,|expression (r_compound) release_10\NN|NONE (l_conj) expression_14\NN|prostaglandin|E|in|, (l_conj) pain_16\NN|cyclooxygenase|and|gene
D015232_D010146 NONE E2_9\NNP|prostaglandin|in|,|expression (r_compound) release_10\NN|NONE (l_prep) in_17\IN|prostaglandin|E|,|expression (l_pobj) model_21\NN|NONE (l_compound) pain_20\NN|clinical|a
D015232_D010146 NONE PGE2_15\NNP|and (r_conj) h_13\NN| (r_nmod) levels_16\NNS|NONE (r_pobj) at_11\IN|However|pain|group|were|,|.|during (r_prep) reported_7\VBD|NONE (l_dobj) pain_10\NN|However|group|were|,|.|at|during
D015232_D010146 NONE PGE2_18\NNP|pain|higher|and (r_compound) production_19\NN|NONE (l_conj) pain_21\NN|higher|PGE|and
D015232_D017695 NONE PGE2_18\NNP|pain|higher|and (r_compound) production_19\NN|NONE (r_pobj) with_16\IN|which|is (r_prep) associated_15\VBN|tissue|, (r_relcl) injury_11\NN|NONE
D002045_D017695 NONE bupivacaine_4\NN|dissipates|expression|after (r_nsubj) stimulates_5\VBZ|.|results (l_prep) after_9\IN|dissipates|bupivacaine|expression (l_pobj) injury_11\NN|NONE
D015232_D010149 NONE E2_15\NNP|and|local|prostaglandin|cyclooxygenase (r_nmod) production_19\NN|COX|(|increases|gene|) (r_nmod) expression_26\NN|NONE (l_relcl) increases_28\VBZ|COX|(|gene|production|) (l_dobj) pain_30\NN|that
D015232_D010149 NONE PGE2_17\NNP|( (r_appos) E2_15\NNP|and|local|prostaglandin|cyclooxygenase (r_nmod) production_19\NN|COX|(|increases|gene|) (r_nmod) expression_26\NN|NONE (l_relcl) increases_28\VBZ|COX|(|gene|production|) (l_dobj) pain_30\NN|that
D008012_D010146 NONE lidocaine_6\NN|.|The|differential|of|and (l_prep) on_7\IN|NONE (l_pobj) release_10\NN|NONE (l_conj) expression_14\NN|prostaglandin|E|in|, (l_conj) pain_16\NN|cyclooxygenase|and|gene
D008012_D010146 NONE lidocaine_6\NN|.|The|differential|of|and (l_prep) on_7\IN|NONE (l_pobj) release_10\NN|NONE (l_prep) in_17\IN|prostaglandin|E|,|expression (l_pobj) model_21\NN|NONE (l_compound) pain_20\NN|clinical|a
D002045_D010149 CID bupivacaine_11\NN|NONE (l_prep) on_12\IN|NONE (l_pobj) expression_26\NN|NONE (l_relcl) increases_28\VBZ|COX|(|gene|production|) (l_dobj) pain_30\NN|that
C116926_D010146 NONE rofecoxib_3\NN|The (r_compound) group_4\NN|pain|,|assessed|compared|, (r_nsubj) reported_5\VBD|NONE (l_dobj) pain_8\NN|group|,|assessed|compared|,
D002045_D010146 NONE bupivacaine_4\NN|NONE (r_pobj) of_3\IN|.|The|differential|lidocaine|and (r_prep) effects_2\NNS|NONE (l_conj) lidocaine_6\NN|.|The|differential|of|and (l_prep) on_7\IN|NONE (l_pobj) release_10\NN|NONE (l_conj) expression_14\NN|prostaglandin|E|in|, (l_conj) pain_16\NN|cyclooxygenase|and|gene
D002045_D010146 NONE bupivacaine_4\NN|NONE (r_pobj) of_3\IN|.|The|differential|lidocaine|and (r_prep) effects_2\NNS|NONE (l_conj) lidocaine_6\NN|.|The|differential|of|and (l_prep) on_7\IN|NONE (l_pobj) release_10\NN|NONE (l_prep) in_17\IN|prostaglandin|E|,|expression (l_pobj) model_21\NN|NONE (l_compound) pain_20\NN|clinical|a
D002045_D010146 NONE bupivacaine_1\NN|/ (r_nmod) rofecoxib_3\NN|The (r_compound) group_4\NN|pain|,|assessed|compared|, (r_nsubj) reported_5\VBD|NONE (l_dobj) pain_8\NN|group|,|assessed|compared|,
D002045_D010146 NONE bupivacaine_3\NN|/ (r_nmod) placebo_5\NN|the (r_compound) group_6\NN|However|pain|were|,|.|at|during (r_nsubj) reported_7\VBD|NONE (l_dobj) pain_10\NN|However|group|were|,|.|at|during
D002045_D010146 NONE bupivacaine_4\NN|dissipates|expression|after (r_nsubj) stimulates_5\VBZ|.|results (l_prep) after_9\IN|dissipates|bupivacaine|expression (l_pobj) injury_11\NN|NONE (l_relcl) associated_15\VBN|tissue|, (l_prep) with_16\IN|which|is (l_pobj) production_19\NN|NONE (l_conj) pain_21\NN|higher|PGE|and
